<SEC-DOCUMENT>0000950170-24-038868.txt : 20240401
<SEC-HEADER>0000950170-24-038868.hdr.sgml : 20240401
<ACCEPTANCE-DATETIME>20240401073036
ACCESSION NUMBER:		0000950170-24-038868
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240401
DATE AS OF CHANGE:		20240401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alaunos Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001107421
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				841475642
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33038
		FILM NUMBER:		24805539

	BUSINESS ADDRESS:	
		STREET 1:		2617 BISSONNET ST
		STREET 2:		SUITE 225
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77005
		BUSINESS PHONE:		(346) 355-4099

	MAIL ADDRESS:	
		STREET 1:		2617 BISSONNET ST
		STREET 2:		SUITE 225
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZIOPHARM ONCOLOGY INC
		DATE OF NAME CHANGE:	20050919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EASYWEB INC
		DATE OF NAME CHANGE:	20010213
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tcrt-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-04-01T07:06:09.1856+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:tcrt="http://alaunos.com/20231231" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_4bf44b7f-9ed1-4682-9e9b-9ebfcef178ea" name="dei:DocumentFiscalPeriodFocus" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3">FY</ix:nonNumeric><ix:nonNumeric id="F_01232f89-8180-4996-b75a-96eddc1fbf4c" name="dei:EntityCentralIndexKey" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3">0001107421</ix:nonNumeric><ix:nonNumeric id="F_a16a1e16-840b-432d-809a-bb4535f4b98d" name="dei:AmendmentFlag" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonFraction id="F_15b0f2c7-17af-4d93-a8cb-5eeec14ce40e" name="us-gaap:CommitmentsAndContingencies" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_51f9a637-4669-4919-8023-57118471f122" name="us-gaap:CommitmentsAndContingencies" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" unitRef="U_USD" xsi:nil="true"/><ix:nonNumeric id="F_fa18b81e-dc37-4248-8153-57693071a98f" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" contextRef="C_53b2cce5-dd6d-4584-81a2-934fca6f36e1">http://fasb.org/us-gaap/2023#UsefulLifeTermOfLeaseMember</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tcrt-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_e0870a39-743c-4197-a2bf-d7b68c1a75eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_37060ce3-beaa-4b5d-8b6b-3b25f9e47087"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:ClassOfWarrantOrRightAxisAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31df6cae-3411-4d1e-afda-0b2df9d5828c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:MaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b0fea0c-fa5c-4f28-a5af-abd1ad3285a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5a914c9-36ee-47c1-b8f0-1cd50fd2cc9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1be53cd-8ca0-4fbc-8225-e0b9cea77dc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-14</xbrli:startDate><xbrli:endDate>2023-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb295f58-cf1f-496d-99a4-62856a01fdf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc7acd0c-a196-474b-904e-2422719555e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EmployeeStockOptionAndRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d86720e4-1c24-43a1-bbdc-09b83278c5c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:PerformanceBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4e43b9c-1c1a-4ee7-8310-f49b0b04362e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">tcrt:ZiopharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">tcrt:EdenBioCellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86d41d2a-3fa1-4e8f-a00d-faeb00c9cc56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bcbf392a-4dba-4a84-ab43-3ee5a35cd906"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:DueDateAxis">tcrt:PostMarketingApprovalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:PerformanceBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0517427-ae4d-43a0-9947-ed007458a817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c34e2ea2-6bfb-4c2d-919a-3fb69b17bab3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ee1d3ea-fecf-43a4-b0be-9cca9bc302be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4bade1a4-e2fe-4751-93c1-f31838539841"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3feb1b1-0ac3-4b26-ba91-a5e0df500c8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c598769-068f-4e4c-b4a0-a1504cfbdf40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonAgreementAndWorldwideLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-13</xbrli:startDate><xbrli:endDate>2015-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12319f01-0ffd-4415-8d9c-445e79250b84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_03dd637f-957e-4172-9001-e07d902c6e28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:AgreementTypeAxis">tcrt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-11</xbrli:startDate><xbrli:endDate>2018-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d3c500a-8039-4aa4-9783-2c2376933de5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:AgreementTypeAxisAxis">tcrt:CantorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-29</xbrli:startDate><xbrli:endDate>2022-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d71e8ff-49c9-42da-a181-17cbc8b8e234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c575269-28b3-45c2-9022-f2fac466229a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61083e15-726c-43c1-8169-eca505a1dd5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-08-17</xbrli:startDate><xbrli:endDate>2015-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11127a99-f933-4bcc-a852-9e3580fee74e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_698ba229-d584-4d13-99e6-5cd10624b1c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1270a725-670c-4033-b553-4b1ffa03336d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2285624-3869-463c-86d8-22c65f4a4ba3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f040735-cf7c-45e8-b576-fbda049ff33e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e81976f-0dda-4005-94a7-17763001d331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a9aab26-46d9-488c-b695-2646b51f35c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tcrt:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d8ef632-f188-499c-855f-f56d87eeb09c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01c537c5-d7da-43b7-9828-3dd4fac7a6b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:EdenBiocellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-18</xbrli:startDate><xbrli:endDate>2018-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c56bef7f-3b74-416e-b3f9-37e431049ea5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tcrt:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_759b438f-e084-415a-bd3e-33a77795c829"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-19</xbrli:startDate><xbrli:endDate>2023-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db1f1c30-f159-463f-bb42-52af80ab87ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc9a8a39-bf1f-4865-b472-106ea73fc8f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0e9f476-c0cc-4b3e-b34e-81e4371b4b81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d5825d4-3830-441a-87c7-7eaf314a9d2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d601659b-5678-4e9a-8c2e-09453abc5b8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9a17b33-5bfe-4087-a30f-e86addf030a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3fc31a6-03ef-43cc-97ab-fa4366fe7871"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59b1d649-d101-49bf-a3c7-bd6b2abc3d7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffb8b599-3fe6-43c2-9fb2-30c91dd8802b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-14</xbrli:startDate><xbrli:endDate>2023-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6b3f307-9aef-450c-9206-261565a5306c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-14</xbrli:startDate><xbrli:endDate>2023-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95d872d4-ff79-4993-afa4-1fc260f3a843"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tcrt:OtherIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_112e62be-1071-454a-9093-81a7c718e165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9fc04f3c-c57e-4e06-b36c-5fbfcaec5cd3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5e88f0f-cfd7-41a4-bf45-de43957559af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4e17587-5901-4339-8423-005a5407feac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c513888a-3b48-4024-a189-900f74620507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8437c692-33c1-493a-b928-11fb26d089fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5f0ce97-7e26-409e-8300-d1a1644a54a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df6734c9-10ba-4183-bed0-db726b38f022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EmployeeStockOptionAndRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae07e329-a5b4-4996-9101-5c81cefa338b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:OfficeAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_220d9373-ebbf-48e2-9ada-0496f791e56e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:NewWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e105059-91f4-41fa-bb01-cb0f4ed0fb32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4120da5-aa3b-4ae8-8a1f-b0df2ff0da10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-12</xbrli:startDate><xbrli:endDate>2019-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9bfa8341-1726-4852-8e7d-295f0376fd93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8baad0c4-09aa-4617-9aa3-03a23b56ba42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d722990-44ad-48ec-bab6-e38f76af3769"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_82b0d417-0325-416b-9745-26ad2cfd0d65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d276298c-740b-42ff-98cb-ed95e869f300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:AgreementTypeAxisAxis">tcrt:CantorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a5a10cc-553a-4c9b-9781-bb8cb6a5dd9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-28</xbrli:startDate><xbrli:endDate>2021-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1da526c-ca16-481e-9bc7-b20e2797d243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5192514c-c4a7-4570-99f5-e8a967b213de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-15</xbrli:startDate><xbrli:endDate>2023-11-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_178ac7cd-5b14-4544-b80c-336bc2dd52d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-12</xbrli:startDate><xbrli:endDate>2022-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42fcfea8-a421-4581-aa9a-f10b12c3fff7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4d53f28-56a7-404b-af45-6335e67f7941"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97c705ca-f124-47df-ba05-d7327601d771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-20</xbrli:startDate><xbrli:endDate>2023-10-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a62dc996-32ea-430d-9357-c8af5aff9a7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5b52643-6d79-400f-8b1d-031a3c875379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9eeb8156-fd64-4f9c-a68b-13acb840c000"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9eb8bb51-2ecf-42fc-9df9-3543c2498b7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e377f39-2755-46fa-ab15-461adb70dd68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:OneTimeBenchmarkPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcrt:LicensedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-28</xbrli:startDate><xbrli:endDate>2019-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f261627-186d-4c4c-9a00-ee68ecc9a86c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3c26aba-b1fb-4834-9c5e-b8e01a5ecc3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fec7df81-6165-4556-94da-9ce5e0afffd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:DuneLakeCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_941cd6f3-5783-415e-b2da-d758935f04dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00381981-d3cd-44fe-a13f-32128dadfda9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36cd6252-28b4-4775-b0f9-58a9b230b1c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4b60ecf-6d80-4fa1-b071-1864dd9c10b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9372d727-0118-429b-87d8-c76963744d6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd40fe04-39eb-4618-9e08-4ccfc8585a11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4ef7ff5-bba3-4349-98dd-d7df9d126723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47de4d35-3a62-44ad-a1e3-078eb736401e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a4b610b-874a-4c4c-a87e-050473791707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-22</xbrli:startDate><xbrli:endDate>2024-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c08c022b-51fd-407b-9baa-ebc8ead77d26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c30dcdbc-ca80-4f40-8509-a02802f4927d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_018d6e8c-001c-45fa-97e4-4efe0b2a752b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-14</xbrli:startDate><xbrli:endDate>2023-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6eff864f-3158-4523-99bb-a0cf8c94ad47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-12</xbrli:startDate><xbrli:endDate>2019-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_61732725-ae5b-416f-8f67-a2ab46a40cc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4764432d-361f-42c3-b4d4-131225ea696e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53b2cce5-dd6d-4584-81a2-934fca6f36e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6240eae2-8099-486d-9b0b-6163532f0ff8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:NewWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-12</xbrli:startDate><xbrli:endDate>2019-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7dad8626-c247-4cc6-80b0-0ea99635780c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a51d51e-d3d6-455b-ac86-ce8e857d2093"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2dfc65a-f1b4-4bd3-ae8f-235fa879ba0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1eb9814e-4de9-413f-980e-56701e4ada9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed3ce84b-d7e9-4796-87f3-b1cbfed8bb7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66a9005c-fc69-4b3a-83be-3826cef87dcb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e64be0f6-91d9-4db7-86b4-e80514f8c958"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d63de51f-7fcb-4cee-816b-0f40bc587e2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_271f0dcf-64b5-4fbf-a9a4-9481a9d78720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63da8372-4842-42f7-846e-29d35b96baad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d19272f-497c-47f6-a99d-591f9130da04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c03e3f83-0461-4bff-a6ec-c8e8f6eae256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:OfficeAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec1d55bd-1201-4107-bcad-9c39a5fd6ee6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-28</xbrli:startDate><xbrli:endDate>2021-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8995cf5-f0d5-4e4e-99fc-41441a44780e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4a1c311-3a9e-4881-9787-deb17fe41e97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0982ca17-65ec-46e2-b808-c94e4aa0b3df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d22c7a01-1ee3-4ae9-b8e5-5302459c17aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2c1287b-cb3c-456e-a570-1593261f684d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:AgreementTypeAxisAxis">tcrt:CantorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-29</xbrli:startDate><xbrli:endDate>2022-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d20f89b1-a277-46ad-a886-0783d93e0131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d7a6c39-7681-4ca3-99fb-8b12b128396b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_919b08ce-ab39-4642-b52f-67c2d4317819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:OneTimeBenchmarkPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9251b0d7-fe5b-457f-a984-b77be81cbbed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e982006-943b-4fee-97ab-42236865abf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-22</xbrli:startDate><xbrli:endDate>2019-10-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4104f83e-9d9d-42d3-ba02-e04dc9b2ed5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tcrt:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab6d30fd-d037-4c8b-a225-3af57f8a921c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d0c8320-b169-4c12-9015-18779c3f403e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tcrt:HogueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-21</xbrli:startDate><xbrli:endDate>2024-01-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70ef5a8d-4cca-4f80-ae99-5f24fedd40fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38467bd2-81f8-405d-9362-d3b8371c7945"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45a84280-5929-4306-93d7-0db1814fb46c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a40112e-a10a-439d-a924-dded53c33f05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25fd3671-b6ec-42c5-a84d-f3bb943d4679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tcrt:FederalAndStateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c44e0959-6f71-4672-bea1-d6bc634b6ad9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60aa9216-7e7f-400b-9d0d-65567c8ce942"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b40d2d6-501d-4e7d-8b78-1a53bdaa393a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-17</xbrli:startDate><xbrli:endDate>2023-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5399d8c-4124-42b7-a6a2-756bfbee1738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-22</xbrli:startDate><xbrli:endDate>2024-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_532e995e-0f74-4893-864c-58c3f779b2e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-11</xbrli:startDate><xbrli:endDate>2018-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10887a30-fe67-4725-98ec-6def6ef0869d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b07e679c-ee37-4ba5-b372-9bfc376e0ba0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcrt:TcellReceptorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f58e5ef7-a8c3-4cae-b017-bebbe49b3b1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_614aa634-42cc-4d32-8a9a-8b4df7e3a7b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5434f85-d96c-496b-8794-5fd3bbc24ce8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tcrt:FederalAndStateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1dfdf14-86ec-4861-a350-a0829f3f94bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-09</xbrli:startDate><xbrli:endDate>2023-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3bcbadbe-09aa-42ba-8a38-e52fd3a5ad82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:OneTimeBenchmarkPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a75d2a0-9d24-4504-a3dc-2dac5fdd0e65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f6ea145-3408-4127-8187-484ad479069b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tcrt:OtherIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c63ac11-1fe7-4822-9cb9-1e975eedf1b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-31</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e188d5a-6779-4f0e-aeb1-22f1285c7349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tcrt:FederalAndStateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80b02891-b4a1-429e-ab36-34271657c7e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b52611a-b9c3-4f92-b8bb-c439f1b299fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tcrt:AgreementTypeAxisAxis">tcrt:CantorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-05</xbrli:startDate><xbrli:endDate>2023-01-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e1408a8-5e0e-4b89-8b8c-917a420bac4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_82f28128-caf0-440d-b3fe-b4abba328cf5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06432621-89ab-472f-911c-5458e9f57386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6dbf0481-cdd5-4b3c-8af0-560dbff890e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b32ddd3-7ce4-4f74-9808-a45ab5d03ffd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:MdAndersonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41ccee47-b234-4941-b8eb-978d9f5b2e42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11b50a8f-e3f7-4d6b-85de-985e603d9114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f95291d4-e96b-46f8-b36c-1c199e1f5e39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tcrt:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c4cb663-e0ce-4562-a60a-f57ab1bd16cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d7932fa-9451-44de-93c6-0aeabfb182de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6804cc66-48f9-4973-9521-76cf1de8e41d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcrt:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-29</xbrli:startDate><xbrli:endDate>2022-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db650e42-fee8-4d18-8c55-3c11a3ece9bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9081085f-fcee-4652-b4bf-4c50be103e98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c83e3ba4-ff7f-49bc-b367-c3a48773a81c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:EdenBiocellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dada01c2-0448-4544-80b7-17e67bdfc890"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9bebd57d-5315-4cfa-aa91-69cf64124596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-08-17</xbrli:startDate><xbrli:endDate>2015-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56dcfc15-8dde-431d-a7db-bbfed94629e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a00674d-0901-4260-8a18-828129c14592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46848514-696b-4f06-9e6b-d4096db50827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0fb6425a-bd51-4ef2-a4fc-01fe4f515d0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c84cbaaa-b7b5-4569-80f5-59327bf2d4e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-28</xbrli:startDate><xbrli:endDate>2019-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aec61900-53b4-4857-87b4-484cc2b801ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-14</xbrli:startDate><xbrli:endDate>2023-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae242319-1a7e-447c-b3ec-f37cbc585f56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tcrt:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7076c57a-eac4-4967-be0d-548e7041b7f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa3c307b-d3f5-4b67-b1f6-1018ba02f672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f075a278-5164-4d2a-9bd2-198370833aca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bef1fda7-f827-43a9-a2e5-5a8bc3c58ab2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2004-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63369074-a4f7-4fe2-8674-f1c4a1a3245e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_05605a3c-4399-47be-99a9-52abcb18dab3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_afef85da-f505-4cb3-8378-c367deebf43d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Washington, DC 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:14.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ad5ce14-f747-4cf5-bff0-a5dee5721dca" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_7f599f6b-8e34-4ff7-9b2e-5f44eb8610cd" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:DocumentAnnualReport" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c5b6da5-3072-4041-a87a-4ca38632f90d" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e759e77-b9b6-48ab-adaa-08586db20fb2" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f261cfc8-2694-43c4-bd29-cb066d991134" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_06fb3557-1b97-42f6-a7ac-6dc2cbc3d4b1" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:DocumentTransitionReport" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from _______ to _______</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3dd913b-c0d3-4109-8f52-38292ded97ae" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">001-33038</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b6d9e610-1b15-403b-9c27-6749404bf63b" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact Name of Registrant as Specified in Its Charter)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.5%;"/>
    <td style="width:1.02%;"/>
    <td style="width:48.48%;"/>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_8d5096bf-08c2-4db2-a512-2425347bda2e" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_286ded9c-a1d2-4800-99b9-4555a349817f" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">84-1475642</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="height:3.6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:5.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:5.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_6af8c6b8-f505-4c70-9f6a-712c707a5c85" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2617 Bissonnet Street,</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;min-width:fit-content;"> </span><span style="font-size:7.5pt;"><ix:nonNumeric id="F_d03bce70-7343-4e0c-994d-7f112da278de" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 225</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_9a37ae7c-8eef-49da-b371-11b3f05f6987" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Houston</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;min-width:fit-content;">, </span><span style="font-size:7.5pt;"><ix:nonNumeric id="F_69282c88-0487-46be-b0c7-73e2b519a6d4" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TX</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_c5aaca85-6848-459e-ae6e-bde8035eae25" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">77005</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_381474df-d9aa-4b38-a034-188cdf505993" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">346</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c8138210-29ca-4083-a8da-156375c27747" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">355-4099</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">(Registrant&#8217;s Telephone Number, Including Area Code)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32%;"/>
    <td style="width:1%;"/>
    <td style="width:35%;"/>
    <td style="width:1%;"/>
    <td style="width:31%;"/>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which<br/>registered</span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_212b8c1b-51c8-47c9-98d3-9dd87c8d0177" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_e15797ff-0af5-4953-a1a9-7f600142b734" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TCRT</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_7bcbed53-51b3-4d20-aba9-c2c9c5c9b731" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">The Nasdaq</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;min-width:fit-content;">&#160;Capital Market</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80715f7e-4f92-4fa2-b90d-05b2d9f08f27" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9745;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes &#9744; </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7df54698-575c-4176-b3c8-bda0701e67bd" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9745;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5703de69-5af1-4772-9502-36ff0bf6351f" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9745; No &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf091147-2ba6-467c-82be-58dda0f79c4b" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9745; No &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerate filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:16.983%;"/>
    <td style="width:1%;"/>
    <td style="width:58.012%;"/>
    <td style="width:1%;"/>
    <td style="width:20.004%;"/>
    <td style="width:1%;"/>
    <td style="width:2%;"/>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large Accelerated Filer</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated Filer</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:3.6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:5.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:5.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:5.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:5.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_744305d5-efe7-4ad0-9194-eee0754de725" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non- Accelerated Filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9745;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller Reporting Company</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_9881cfb7-1692-4ab0-af85-130c020acf79" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9745;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:3.6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:5.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:5.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:5.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:5.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging Growth Company</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_5e5ebd22-2778-4ffa-a088-3c9a4c9dcca8" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">If an emerging</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_496a5465-960a-4e37-8922-01eb97c2524f" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_96432cc7-bec9-4ed0-aac8-012a85c8da69" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &#9744; No </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b76a4a7-be47-4c8a-b4ea-76e3e98d4155" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9745;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates was $</span><span style="font-size:7.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_917114b1-77cd-408c-b85e-03e464948e69" contextRef="C_cc9a8a39-bf1f-4865-b472-106ea73fc8f0" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">94,764,946</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> as of June 30, 2023 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter), based on a total of 16,041,804 shares of common stock held by non-affiliates and a closing price of $7.65 as reported on the Nasdaq Capital Market on June 30, 2023. For purposes of this computation, all officers, directors, and 10% beneficial owners of the registrant are deemed to be affiliates. Such determination should not be deemed to be an admission that such officers, directors or 10% beneficial owners are, in fact, affiliates of the registrant.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">As of March 27, 2024, there were </span><span style="font-size:7.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19e057d1-8587-4ea7-be3f-2b9dee18afc8" contextRef="C_9bfa8341-1726-4852-8e7d-295f0376fd93" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,012,479</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> shares of the registrant&#8217;s common stock, $0.001 par value per share, outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Portions of the Proxy Statement for the Registrant's 2024 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> Alaunos Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ANNUAL REPORT ON FORM 10-K</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="toc_page"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">TAB</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">LE OF CO</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NTENTS</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.002%;"/>
    <td style="width:1%;"/>
    <td style="width:78.216%;"/>
    <td style="width:1.8%;"/>
    <td style="width:1%;"/>
    <td style="width:6.181%;"/>
    <td style="width:1.8%;"/>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.017in;padding-right:0.003in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.017in;padding-right:0.003in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.017in;padding-right:0.003in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.017in;padding-right:0.003in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Page</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.017in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART I</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item IC.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART II</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_management_discussion_and_analys"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosures</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9C</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART III</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accountant"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART IV</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:10pt;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are all statements contained in this Annual Report that are not historical fact, and in some cases can be identified by terms such as: &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; "potential," &#8220;will&#8221; and other words and terms of similar meaning.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These statements are based on management&#8217;s current beliefs and assumptions and on information currently available to management. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this Annual Report include, but are not limited to, statements about:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to successfully implement our strategic reprioritization or realize any or all of the anticipated benefits once implemented;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to raise substantial additional capital to continue as a going concern and fund our planned operations in the near term and our strategic reprioritization in the longer term;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to successfully consummate any strategic transactions, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">estimates regarding our expenses, use of cash, timing of future cash needs and anticipated capital requirements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to license additional intellectual property to support our strategic reprioritization or out-license our intellectual property and to comply with our existing license agreements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to enter into partnerships or strategic collaboration agreements and our ability to achieve the results and potential benefits contemplated from relationships with collaborators; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to maintain collaborations and licenses; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectation of developments and projections relating to competition from other pharmaceutical and biotechnology companies or our industry; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the anticipated amount, timing and accounting of contract liabilities, milestones and other payments under licensing, collaboration or acquisition agreements, research and development costs and other expenses; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to remain listed on the Nasdaq Capital Market; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our intellectual property position, including the strength and enforceability of our intellectual property rights.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any forward-looking statements in this Annual Report on Form 10-K reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievements to be materially different from any future results, level of activity, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results, levels of activity or performance of achievements to differ materially from current expectations include, among other things, those described under Part I, Item 1A, &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless the context requires otherwise, references in this Annual Report to &#8220;Alaunos,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to Alaunos Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We own or have rights to trademarks, service marks and trade names that we use in connection with the operation of our business, including our corporate name, logos and website names. We own the trademarks Alaunos&#174;, hunTR&#174;, and Ziopharm&#174; as well as the graphic trademark found on our website. Other trademarks, service marks and trade names appearing in this Annual Report on Form 10-K are the property of their respective owners. Solely for convenience, some of the trademarks, service marks and trade names referred to in this Annual Report on Form 10-K are listed without the &#174; and &#153; symbols, but we will assert, to the fullest extent under applicable law, our rights to our trademarks, service marks and trade names.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SUMMARY OF SELECTED RISKS ASSOCIATED WITH OUR BUSINESS</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business faces significant risks and uncertainties. If any of the following risks are realized, our business, financial condition, results of operations, cash flows and prospects could be materially and adversely affected. You should carefully review and consider the full discussion of our risk factors in the section titled &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report. Some of the more significant risks include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our strategic reprioritization may not be successful, may not yield the desired results and we may be unsuccessful in identifying and implementing any strategic transaction.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a strategic transaction is not consummated, our Board of Directors may decide to pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may require substantial additional financial resources to continue as a going concern, including through the strategic review process, and if we raise additional funds it may affect the value of your investment in our common stock. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to consummate a strategic transaction depends on our ability to retain our current employees and consultants.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our corporate restructuring and the associated headcount reduction may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could significantly disrupt our business.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may become involved in litigation, including securities class action litigation, that could divert management&#8217;s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We received a Delisting Determination from Nasdaq in 2023 that while we have addressed with our recent reverse stock split and stock price trends, we remain subject to panel monitoring until February 2025, at any time during which we could be delisted again if we again fail to comply with the Minimum Bid Price Rule. Delisting could prevent us from maintaining an active, liquid and orderly trading market for our common stock and may impact our ability to consummate certain strategic transactions.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have approval by our shareholders for a second reverse stock split of our common stock to enable the Board of Directors to respond to a Panel if we fail to comply with the Minimum Bid Price Rule during the monitor period.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we do get approval and effectuate a second reverse stock split, the trading price of our common stock may not meet the Minimum Bid Price Rule.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In light of the recent reverse stock split, or if we implement a second reverse stock split during the monitor period, liquidity of our common stock may be materially and adversely affected.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may identify material weaknesses in the future or otherwise fail to maintain an effective internal controls system, which may result in material misstatements of our financial statements or have a material adverse effect on our business or stock price.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The recent termination of our licenses and research and development agreement with the National Cancer Institute could limit our ability to resume our clinical trial or begin new clinical trials focused on TCR-T.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any termination of our licenses with Precigen or MD Anderson or our research and development agreements with MD Anderson could result in the loss of significant rights and could materially harm our ability to develop and commercialize our product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should we resume development of our product candidates, we may not be able to commercialize them, generate significant revenues, or attain profitability. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We relied and, should we in the future resume development of our product candidates, will rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology or loss of data, including any cybersecurity incidents, could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability which could harm our ability to operate our business effectively and materially and adversely affect our business and reputation.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should we resume development of our product candidates, we may encounter difficulties enrolling patients in our clinical trials, and our clinical development activities could be delayed or otherwise materially and adversely affected.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates are subject to extensive regulation and compliance, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates, should we resume development.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have halted development of our product candidates early in our development efforts. Our most advanced product candidates were only in an early-stage clinical trial, which is very expensive and time-consuming. We cannot be certain if or when we will be able to submit a Biologics License Application, or BLA, to the U.S. Food and Drug Administration, or the FDA, and the delay, or any failure, in completing clinical trials for our product candidates could significantly harm our business. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any potential marketing approval.  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The gene transfer vectors from our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> system used to manufacture our product candidates may incorrectly modify the genetic material of a patient&#8217;s T cells, potentially triggering the development of a new cancer or other adverse events.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should we resume development of our product candidates, any candidate for which we obtain marketing approval could be subject to post-marketing restrictions or withdrawal from the market and we may be subject to significant penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should we resume development of our product candidates, our inability to obtain the necessary U.S. or worldwide regulatory approvals to commercialize any product candidate, our business will suffer materially. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable either to create sales, marketing and distribution capabilities or enter into agreements with third parties to perform these functions, we will be unable to commercialize our product candidates successfully.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If physicians and patients do not accept and use our product candidates, once approved, our ability to generate revenue from sales of our products will be materially and adversely impaired. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to generate product revenues will be diminished if our products do not obtain coverage and adequate reimbursement from payors. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our immuno-oncology product candidates may face competition in the future from biosimilars and/or new technologies and our pending patent applications may not be granted, further limiting our ability to compete with other companies. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or our licensors fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of our intellectual property rights would diminish and our ability to successfully commercialize our products may be materially impaired. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party claims of intellectual property infringement would require us to spend significant time and money and could prevent us from developing or commercializing our products. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our stock price has been, and may continue to be, volatile. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we do not expect to pay dividends, you will not realize any income from an investment in our common stock unless and until you sell your shares at a profit. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to use net operating loss carryforwards and research tax credits to reduce future tax payments may be limited or restricted.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The exercise of outstanding warrants, and issuance of equity awards may have a dilutive effect on our stock, and negatively and materially impact the price of our common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our principal stockholders, executive officers and directors have substantial control over the Company, which may prevent you and other stockholders from influencing significant corporate decisions and may significantly harm the market price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 1. Business</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage oncology-focused cell therapy company that was historically involved in developing adoptive T-cell receptor, or TCR, engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. We leveraged our cancer hotspot mutation TCR library and our proprietary, non-viral </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gene transfer platform to design and manufacture patient-specific cell therapies that target neoantigens arising from common tumor-related mutations in key oncogenic genes, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In collaboration with The University of Texas MD Anderson Cancer Center, or MD Anderson, we were enrolling and treating patients for a Phase 1/2 clinical trial evaluating 12 TCRs reactive to mutated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from our TCR library for the investigational treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers, which we refer to as our TCR-T Library Phase 1/2 Trial.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, the Company announced a strategic reprioritization of its business and wind down of its TCR-T Library Phase 1/2 Trial. In connection with the reprioritization, the Company has reduced its workforce by approximately 95% to date and continues working to reduce costs in order to extend its cash runway. The Company continues to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. The Company has engaged Cantor Fitzgerald &amp; Co., or Cantor, to act as strategic advisor for this process. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology. In addition, on August 14, 2023, we announced that we had provided the requisite notice to the National Cancer Institute, or NCI, to terminate the Cooperative Research and Development Agreement, dated January 9, 2017, by and among us, the NCI and Intrexon Corporation, or Intrexon, as amended (such agreement referred to herein as the CRADA), pursuant to its terms, effective October 13, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eight patients were treated and evaluated in our TCR-T Library Phase 1/2 Trial with three unique TCRs from our library, which targeted KRAS-G12D, TP5304175H, and KRAS-G12V hotspot mutations. Patients with pancreatic (3), colorectal (4) and non-small cell lung cancer (1) were treated, with certain pancreatic and colorectal patients also having lung metastases. Overall, the trial showed our T-cells were generally well-tolerated in all evaluable participants with no dose-limiting toxicities (DLTs) and no immune effector cell-associated neurotoxicity syndrome (ICANS) were observed. All cytokine release syndrome (CRS) events were within grades 1-3 and were self-limiting or resolved with standard clinical management and, in some cases, a single dose of tocilizumab.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One patient with non-small cell lung cancer (NSCLC) achieved an objective partial response with six months progression-free survival. Six other patients achieved a best overall response of stable disease. The total overall response rate was 13% and disease control rate was 87% in evaluable patients with advanced, metastatic, refractory solid tumors (see Figure A). Disease control was measured by objective responses and stable disease. Increased secretion of interferon-gamma relative to baseline was detected in all patients' serum post-cell transfer suggesting recognition of the tumor by the infused TCR-T cells. Persistence of TCR-T cells in peripheral blood was detected in all evaluable patients at their last follow-up, including up to six months in one patient. Infiltration of TCR-T cells into the tumor was also detected in three samples where a fresh biopsy was collected suggesting homing to the tumor microenvironment. All patients have progressed or withdrawn from the trial and long-term follow-up is ongoing for a subset of patients with no further intervention per the treatment protocol. This trial established proof-of-concept that </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> TCR-T cells can result in objective clinical responses and recognize established tumors in vivo.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure A</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img160836378_0.jpg" alt="img160836378_0.jpg" style="width:522px;height:272px;"/>&#160;</p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite the encouraging TCR-T Library Phase 1/2 Trial data, based on the substantial cost to continue development and the current financing environment, we announced in August 2023 that we would not pursue any further development of our clinical programs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, solid tumors represent approximately 90% of new cancer diagnoses. Approximately 2.0 million people are expected to be diagnosed with cancer in the United States in 2023 and approximately 610,000 people are expected to die from cancer in the United States in 2023. Some of the cancers we targeted in our TCR-T Library Phase 1/2 Trial are expected to be among the most prevalent cancers diagnosed in the United States in 2023. In 2023, it was estimated that 238,340 people were expected to be diagnosed with lung and bronchus cancer, 153,020 were expected to be diagnosed with colorectal cancer, 66,200 people were expected to be diagnosed with endometrial cancer, 64,050 people were expected to be diagnosed with pancreatic cancer, 19,710 people were expected be diagnosed with ovarian cancer and approximately 8,000 people were expected to be diagnosed with bile duct cancer. Mutations of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> genes are commonly expressed across a wide variety of cancers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our TCR-T Library Phase 1/2 Trial Approach</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below sets forth our multiple solid tumor pipeline programs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><img src="img160836378_1.jpg" alt="img160836378_1.jpg" style="width:634px;height:241px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our TCR-T program targeting solid tumors consisted of:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TCR Library</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: We built a TCR library that targets shared hotspot mutations known to be one of the key causes of cancer. These are non-inherited mutations. We in-licensed from the NCI multiple TCRs derived from third parties that are reactive to mutated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty Gene Transfer Platform</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Our proprietary non-viral genetic engineering technology utilizes a particular enzyme referred to as a transposase to cut and paste donor DNA referred to as a transposon into chromosomes of a T cell using a process called transposition. </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">hunTR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">man </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">n</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eoantigen </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cell </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">R</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eceptor) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Discovery Engine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Our robust and innovative TCR discovery engine enabled us to rapidly identify new TCRs to add to the TCR library. Using our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">hunTR </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">discovery engine, we were able to analyze thousands of single T cells simultaneously using state-of-the-art bioinformatics and next generation sequencing. We aimed to maximize the breadth of our TCR library by evaluating both helper (CD4) and killer (CD8) T cells.  </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe our TCR-T program has several potential advantages over other cell therapy approaches for solid tumors, including CAR-T and tumor-infiltrating lymphocytes, or TIL. As compared to CAR-T, these potential advantages include that our TCR-T program targeted intracellular and extracellular neoantigens whereas CAR-T primarily targets extracellular antigens. As compared to TIL, these potential advantages include that our TCR-T program defined target specificity from the genetic engineering employed in manufacturing whereas in TIL specificity typically arises from the endogenous TCR rather than an introduced immunoreceptor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Background on TCRs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our strategy was to target the hallmark of genomic instability in cancer with TCRs. Genes in cancer cells can lead to the production of proteins, which are then processed by the cell into protein fragments known as peptides. These peptides are presented to T cells by a specialized set of molecules on the cancer cell surface called the human leukocyte antigen, or HLA, system. When peptide presentation occurs, and it results in T cell activation through the TCR, the peptides are known as antigens.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When these immunogenic peptides are derived from proteins which are in turn expressed from genes that are mutated only in tumor cells (for example, within the cancer genome and not encoded in the germline), they are known as neoantigens. Tumor cells presenting neoantigens via</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HLA are targets for T cells. T cells can recognize and kill neoantigen-presenting cancer cells. This approach is different from traditional CARs, which directly recognize antigens, such as CD19, on the surface of malignant B cells, without presentation by HLA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In general, the immune system avoids targeting the body&#8217;s own healthy cells principally through processes known as immune tolerance by which T cells do not respond to HLA containing peptides from normal proteins. The recognition by the TCR of a peptide presented by the HLA system is a vital immune mechanism that allows the body both to respond against foreign threats, including cancer, as well as to avoid targeting the body&#8217;s own healthy cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tumors utilize a variety of strategies to evade and suppress the host immune system. This often renders T cells residing within the tumor, referred to as TILs, ineffective and, despite expressing tumor-specific TCRs, unable to recycle their effector functions to kill tumors. To overcome immune suppression, healthier T cells are likely needed, such as those found in the peripheral blood. However, these circulating T cells do not typically express tumor-specific TCRs in adequate numbers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Neoantigens are encoded by tumor-specific mutated genes that are often unique to each patient. Targeting these unique neoantigens requires TCRs that are generated on a patient-by-patient basis. During cancer initiation and progression, tumor cells acquire mutations in naturally occurring genes that are responsible for transformation, known as driver mutations. Some of these driver mutations occur in common places called hotspots and are a class of mutations shared between tumor types and between individuals. Since driver mutations can be anticipated, it is possible to prepare TCRs in advance of a patient&#8217;s need and form a library of banked TCRs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Approach to Targeting Neoantigens</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that to be successful in treating solid tumors, genetically modified T cells targeting one or more neoantigens will likely need to address the fact that (1) among a population of patients, not all tumors express the targeted neoantigen, referred to as inter-tumor heterogeneity, and (2) within a single patient, not all tumor cells express the targeted antigen, referred to as intra-tumor heterogeneity. Inter-tumor heterogeneity limits the number of recipients that are eligible to receive a treatment and intra-tumor heterogeneity creates the risk of antigen-escape variants, increasing the likelihood of cancer relapse. As a result, we believe companies developing T cell therapies targeting neoantigens must address both inter- and intra-tumor heterogeneity.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We genetically modified peripheral blood-derived T cells to express TCRs with specificity to tumor-derived antigens, especially neoantigens, and propagated them to sufficient numbers prior to administration. We aimed to overcome the key challenges of targeting neoantigens by using DNA plasmids to reprogram T cells to express introduced TCRs on a patient-by-patient basis. This was designed to help address tumor heterogeneity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our TCR-T cells contained multiple different subsets of T cells, including effector and memory T cells. The effector T cells were associated with immediate anti-tumor activity. Memory T cells have greater growth potential relative to the effector T cells. Some of our TCR-T cells were T memory stem cells, which have been described to have the largest capacity for growth and renewal relative to other T-cell populations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our TCR-T Manufacturing Process</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The diagram below illustrates our manufacturing process for our TCR-T product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img160836378_2.jpg" alt="img160836378_2.jpg" style="width:479px;height:335px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our TCR-T approach focused on what we believed to be the most critical and prevalent tumor-specific targets in cancer. These target mutations, called hotspots, are prevalent in genes including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS, TP53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> which can be found in non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers in several different HLA alleles. These driver genes play a key role in regulating cell division, maturation and death, and mutations in these genes have been observed to play a critical role in the development of certain cancers. The advantage of our Library TCR-T approach was that subsets of patients with solid tumors could potentially be rapidly treated by screening them for targeted neoantigens (e.g., </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">), identifying patient HLA, and matching these results to the TCRs in the library. Patients with a variety of different cancers (e.g., non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers) could be screened for a match to our TCR library through tumor sequencing and identification of the patient&#8217;s tumor mutation and HLA typing. Once a match to our TCR library was confirmed, a portion of the patient&#8217;s white blood cells was collected through a peripheral blood leukapheresis and sent to our in-house current Good Manufacturing Practices, or cGMP, manufacturing facility in Houston, Texas.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once the desired pre-manufactured TCR transposon was selected from our TCR library, we utilized our proprietary non-viral </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> genetic engineering technology to modify the patient&#8217;s T cells (both CD4+ and CD8+). We used T cells from peripheral blood, which have a younger and healthier phenotype relative to tumor-resident T cells, to generate our TCR-T cells. Given initial clinical cellular kinetics of the TCR-T cells in the patients treated to date, we believed these modified TCR-T cells would persist in the recipient following infusion. We observed in preclinical studies that genetic engineering of T cells by our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology resulted in the rapid and stable expression of the introduced neoantigen-specific TCR. The genetically modified T cells expressing high levels of the TCR were expanded to produce the patient-specific, or autologous, TCR-T cell product. The product candidate was then harvested from the manufacturing process, formulated, cryopreserved, transferred to the hospital facility and infused in the patient after thawing.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Benefits of Our Non-Viral Sleeping Beauty Gene Transfer Platform</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gene transfer platform provides several benefits, including those described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Scalability and Reduction in Complexity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology is a straightforward means to manufacture a large number of autologous T-cell products. The technology requires only the synthesis of DNA plasmids as the starting material for genetic engineering of the T cells. In contrast, traditional viral gene transfer is more complex and requires specialized manufacturing of each viral vector(s) of interest. Production of a viral vector starts with the generation of plasmid DNA with the transgene of interest. This plasmid is then introduced into a packaging cell line and viruses are secreted into the media over a couple of days. This process is inherently more complex to scale with the numbers of cells and associated media required relative to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> which only requires the plasmid DNA. Genetic modification of the patient cells using the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology is accomplished through electroporation with the DNA plasmids and subsequent culture, selection and growth of the T cells to large numbers using traditional manufacturing techniques. This simple process can be scaled through the addition of manufacturing lines.</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Customizable Therapies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We believe our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> platform provided us with the ability to manufacture more customizable therapies. The platform enabled a library of TCRs to be assembled and used in cells to recognize diverse mutations within shared </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neoantigens and address a multitude of HLA types. We believe this could enable both our Library TCR-T approach against shared cancer targets as well as personalized TCR therapies against unique, and potentially multiple, personal neoantigens. We believe multiplexing TCR-T cells, which involves infusing a patient with more than one TCR product, would be best enabled by our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> system and through our unique TCRs and expanding TCR library.</span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Potential Clinical Benefits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We believe the anti-tumor activity of our TCR-T cells have the potential to last as long as the TCR-T cells persist and proliferate following the recognition of the neoantigen on the tumor cell surface. This may lead to durable and progressively greater clinical response in patients. In CAR-T cell products generated in human cells, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transposons were observed to integrate in a close-to-random distribution at thymine-adenine, or TA, dinucleotide sites, which increases the likelihood of insertion in a genomic safe harbor, thereby making them less likely to cause off-target effects when compared to other transposons and viral gene delivery methods. We also believe that including membrane-bound interleukin-15, or mbIL-15, in TCR-T cells can provide additional benefits. In particular, we have observed that T cells modified to express mbIL-15 as well as a TCR show increased potential for stemness corresponding with a potential ability to persist longer in the patient after infusion.  </span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accommodation of Large Transgene Size</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Plasmids manufactured using our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> platform have a large enough payload size to allow for genetic engineering of both the TCR as well as insertion of a gene encoding for the expression of cytokines, such as mbIL-15. This facilitates uniformly high co-expression of both the TCR and cytokine on a single integrated gene.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical and Clinical Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical Development of our TCR-T Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We independently evaluated all the TCRs we had licensed from NCI using our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> platform. Candidate TCRs for clinical translation were selected based on conventional </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> immunological measurements. We presented these data at the 2021 American Association for Cancer Research (AACR) and Society for Immunotherapy of Cancer (SITC) annual meetings. We selected the TCRs based, in part, on their ability to express on the T cell surface and then specifically recognize the mutated target without also targeting healthy cells. For those TCRs that are destined for killer T cells, our preclinical data suggested that those TCR-T cells could kill the appropriate tumor cell lines expressing the target neoantigen. In our preclinical studies, we also observed TCR-T cells killed significantly more tumor cells when matched with the corresponding HLA and neoantigen relative to mismatched tumor cells and relative to mismatched T cells not expressing the relevant neoantigen-specific TCR.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selected formerly licensed TCRs were co-expressed with mbIL-15 on T cells. This was accomplished with the transfer of a single transposon to deliver three independent genes (TCRalpha, TCRbeta, mbIL-15) to the T cell. We optimized the orientation order of these three genes and the growth conditions specific for the generation of mbIL-15 TCR-T cells. Using similar standard immunologic readouts described above, the mbIL-15 TCR-T cells were observed to display a similar specificity and potency profile to conventional TCR-T cells; however, we observed increased </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> survival of mbIL-15 TCR-T cells in the absence of all added support relative to TCR-T cells, especially in the T memory stem cell populations. We filed an international patent application around these findings and presented preclinical data from this program at the American Society of Gene &amp; Cell Therapy conference in 2022. We believe mbIL-15 has the potential to increase the survival of TCR-T cells in the harsh tumor microenvironment and deepen clinical responses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TCR-T Library Phase 1/2 Trial</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2021, we received FDA clearance for our company-sponsored IND to initiate a Phase 1/2 open-label, dose-escalation trial which was initially being conducted at MD Anderson. In January 2022, after screening patients, we opened enrollment in our TCR-T Library Phase 1/2 Trial and expected to enroll up to 180 adults during the course of the trial. We only enrolled patients who had a matched HLA and hotspot mutation that was targeted by one of the TCRs from our TCR library, who had progressive or recurrent solid tumors and who had failed at least one prior line of standard therapy. The trial was evaluating the 12 TCRs that were in our library that targeted neoantigens arising from </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mutations in patients across a broad range of solid tumors that include non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers, all in a single trial. We intended to use our hunTR discovery engine in an effort to add new TCRs to the library and clinical program as they were qualified by our laboratory. The patients were enrolled in cohorts according to their cancer at three separate dose levels. The Phase 1 primary endpoint was to define dose limiting toxicity or the recommended maximum tolerated dose for a subsequent clinical trial. The primary endpoints for the Phase 2 portion of the trial was expected to determine the objective response rate and otherwise evaluate safety and tolerability. We were also monitoring TCR-T cell persistence and performing multiple conventional immune monitoring assays in the clinical trial to evaluate their persistence in patients. As of December 31, 2023, we have enrolled and dosed 8 patients.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We presented information on the first two patients treated in September 2022 at the CRI-ENCI-AACR International Cancer Immunotherapy Conference, or CICON. The first patient we treated had lung adenocarcinoma with multiple lines of prior therapy and was refractory to checkpoint inhibitors. The second patient we treated was diagnosed with colon cancer and had received multiple lines of standard prior therapies. We successfully dosed a third patient who was diagnosed with advanced pancreatic cancer refractory to multiple lines of standard therapy in our TCR-T Library Phase 1/2 Trial in December 2022. We performed translational assessments to assess the biological activity of our TCR-T cells in order to guide next generation TCR-T therapy approaches including potential combination and multiplexed TCR-T cell</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">therapies. We believe that these data provided early clinical validation of the potential of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> TCR-T cell therapy in high value indications with significant unmet need.</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All patients treated demonstrated manageable safety profiles with no dose limiting toxicities, or DLTs, or immune effector cell-associated neurotoxicity syndrome;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Persistence of the TCR-T cells has been observed. Patient 1 had persistence at 24 weeks with approximately 30% of the patient's total CD3+ T cells comprising TCR-T cells in peripheral blood after treatment with KRAS-G12D/HLA-A*11:01 mutation-specific TCR-T cells at dose level 1 (9x10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">9 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cells). Patient 2 had persistence at 12 weeks with approximately 20% of the patient's total CD3+ T cells comprising TCR-T cells in peripheral blood after treatment with TP53-R175H/HLA-A*02:01 mutation-specific TCR-T cells at dose level 2 (64x10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cells).</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Demonstrating six month progression-free survival, Patient 1 had a best overall response of objective, partial response with regression of greater than 50% of target lesions at 12 weeks post-cell therapy. Patient 2 had a best overall response of stable disease at six weeks with 12 week progression-free survival. Progressive disease was observed in Patient 1 and Patient 2 at weeks 24 and 12, respectively, and each patient subsequently went off study;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The targeted mutations, KRAS-G12D and TP53-R175H, were detected in respective progressing tumor biopsies suggesting no antigen loss; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tumor homing was observed in Patient 1 with infiltration of both CD4 and CD8 TCR-T cells six months post-TCR-T cell therapy.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To our knowledge, achievement of an objective clinical response resulting from treatment with KRAS-G12D and HLA-A*11:01 specific TCR-T cells had not been reported until Patient 1 in our TCR-T Library Phase 1/2 Trial. Patient 1&#8217;s infusion product was high quality with 97.3% viability, 99.7% CD3+ purity and 95.2% TCR positivity. Patient 1&#8217;s target lesions were reduced compared to baseline by 46% at six weeks, 51% at 12 weeks and 46% at 24 weeks. At six months following treatment, an elective tumor biopsy of non-measurable disease in the right lung showed continued presence of tumor cells, KRAS-G12D mutation and HLA-A*11:01 allele, and progressive disease was corroborated by another elective scan at seven months. Patient 1 is now off trial and is being monitored as part of our long-term follow-up protocol.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patient 2's treatment was the first-in-human </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TCR-T cell therapy targeting TP53 hotspot mutations and was generally well tolerated. The same TCR used by the NCI to treat breast cancer, which resulted in a 6-month confirmed, objective partial response, was used to treat Patient 2. Patient 2 received highly pure TCR-T cells (92.5% viability, 99% CD3+ purity, and 92% TCR positivity). Reduction of target lesions by 15% from baseline was observed at six weeks post-infusion, but we observed 21.8% growth of lesions from the week six measurements and appearance of new liver and lung metastases at week 12 signaled progressive disease in Patient 2, who was removed from the trial as a result of such progression.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the fourth quarter of 2022, we submitted an IND amendment to the FDA to add two new TCRs to our clinical trial targeting frequent mutations and HLAs, with the potential to double the addressable market of our TCR-T Library Phase 1/2 Trial. In over 700 patients screened at MD Anderson Cancer Center with gastrointestinal or lung tumors, we improved our match rate from 5% to over 10%, including roughly one in five patients matching two TCRs in the library. The addition of these new TCRs highlighted our strategy to add both more HLAs to existing mutations (KRAS-G12V and HLA-DRB1*07:01) and new mutations within our targeted gene families (TP53-R273C and HLA-DPB1*04:02). The IND amendment also combined our treatment and screening protocols, streamlining enrollment and potentially making it easier for both patients and physicians. The amended IND also eliminated the requirement for retesting of the tumor mutation if six months had passed between screening and treatment.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2023, Our cGMP facility in Houston, Texas was staffed by Alaunos personnel and was fully operational for manufacturing TCR T-cells genetically modified with our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gene transfer platform for our early-stage clinical trials. We relied on third parties for the production of the DNA plasmids used in manufacturing our product candidates.  We closed our cGMP facility in Houston in November 2023 and laid off all manufacturing personnel by September 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Library TCR-T approach allowed us to streamline the T cell manufacturing process by pre-manufacturing DNA plasmids corresponding to each of our qualified library TCRs. These TCRs were then utilized in the manufacturing for the patient-specific, autologous TCR-T product candidates. Our in-house TCR-T manufacturing facility also allowed us to integrate our research and development capabilities, potentially reducing the time from discovery to treating patients in a clinical trial. This integration was designed to minimize delays and reduce risks that can be encountered in drug development, including the failure of third parties to successfully produce the desired product, long technology transfer periods and long lead times for orders. We doubled our manufacturing capacity in 2022, allowing for production of two products simultaneously. We also filed an IND amendment to move from fresh to cryopreserved product and began implementing this change in the first half of 2023. The use of cryopreserved cell products was expected to reduce manufacturing process time from 30 days to 26 days, a 13% decrease, while increasing flexibility for patient scheduling and treatment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">IL-12 Program</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we announced in May 2021, we are winding down our existing Controlled IL-12 clinical program for the treatment of recurrent glioblastoma multiforme. On April 4, 2023, we returned the IL-12 assets to Precigen, Inc. via the parties' Amended and Restated Exclusive License Agreement.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our goal is to obtain, maintain and enforce patent and trade secret protection for our product candidates, formulations, processes, methods and other proprietary technologies. We strive to preserve our trade secrets and other confidential information and to operate without infringing the proprietary rights of other parties. Our policy is to actively seek the strongest possible intellectual property protection for our technology and product candidates through a combination of license agreements and owned patents, both in the United States and abroad.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Owned Patents</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we have six families of pending patent applications that cover our TCR-T library, products and processes. We do not currently own any granted patents.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patent terms extend for varying periods according to the date of patent filing or grant and the legal patent terms in the various countries where patent protection is obtained. The actual protection offered by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage, the issued claims and the availability of legal remedies in the country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, some of our patents, under certain conditions, may be eligible for limited patent term extension for a period of up to five years as compensation for patent term lost during drug development and the FDA regulatory review process. However, this extension period cannot be extended beyond 14 years from the drug&#8217;s approval date. The patent term restoration period is generally one-half the period of time elapsed between the effective date of an IND application or the issue date of the patent, whichever is later. The submission date of a New Drug Application, or NDA, plus the period of time between the submission date of the NDA or the issue date of the patent, whichever is later, and FDA approval. The United States Patent and Trademark Office, or USPTO, in consultation with the FDA, reviews and approves applications for any patent term extension or restoration. We intend to seek the benefits of this statute, but there can be no assurance that we will be able to obtain any such benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also depended upon the skills, knowledge and experience of our scientific and technical employees, as well as those of our advisors, consultants, and other contractors, none of which may be patentable. To help protect unpatentable proprietary know-how, and for inventions for which patents may be difficult to enforce, we currently rely, and in the future, will continue to rely, on trade secret protection and confidentiality agreements to protect our interests. To this end, we generally require employees, consultants, advisors and other contractors to enter into confidentiality agreements that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our patent position and proprietary rights are subject to certain risks and uncertainties. Please read Item Ia. Risk Factors&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> section for further information about certain risks and uncertainties that may affect our patent position and proprietary rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreements</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusive License Agreement with PGEN Therapeutics</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 5, 2018, we entered into an exclusive license agreement, or License Agreement, with PGEN Therapeutics, or PGEN, a wholly owned subsidiary of Precigen Inc., or Precigen, which was formerly known as Intrexon Corporation. Pursuant to the terms of the License Agreement, we had exclusive, worldwide rights to research, develop and commercialize (i) TCR products designed for neoantigens for the treatment of cancer, (ii) products utilizing Precigen&#8217;s RheoSwitch&#174; gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (iii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the License and Collaboration Agreement effective March 27, 2015 between us, Precigen and ARES TRADING S.A., a subsidiary of Merck KGaA, as assigned by Precigen to PGEN. Under the License Agreement, we also have exclusive, worldwide rights for certain patents relating to the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.  We were  solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer as well as required to use commercially reasonable efforts, as defined in the License Agreement, to develop and commercialize IL-12 products, CD19 products and TCR Products. The License Agreement required us to pay PGEN an annual license fee of $0.1 million and reimburse PGEN for certain historical costs of the licensed programs.  We were required to make milestone payments totaling up to an additional $52.5 million for each exclusively licensed program upon the initiation of later stage clinical trials and upon the approval of exclusively licensed products in various jurisdictions and pay PGEN tiered royalties ranging from low-single digit to high-single digit on the net sales derived from the sales of any approved IL-12 products and CAR products. We were also to pay PGEN royalties ranging from low-single digit to mid-single digit on the net sales derived from the sales of any approved TCR products, up to a maximum royalty amount of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$100.0 million in the aggregate, 0% of any sublicensing income received by us relating to the licensed products, and fund development costs associated with each of the licensed products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PGEN was required to pay us royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of PGEN&#8217;s CAR products, up to a maximum royalty amount of $100.0 million. In October 2020, we entered into an amendment to the License Agreement relating to the transfer of certain materials and PGEN&#8217;s obligations to provide transition assistance relating to the IL-12 products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2023, we amended and restated the License Agreement by entering into the Amended and Restated License Agreement, or A&amp;R License, which replaces in its entirety the License Agreement.  We returned all rights to the CAR-T and IL-12 programs to Precigen.  We were granted, royalty-free, an exclusive, worldwide, sublicensable rights to research, develop and commercialize TCR products designed for neoantigens for the treatment of cancer.  We are required to pay Precigen a $75,000 annual license payment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreement and 2015 Research and Development Agreement-The University of Texas MD Anderson Cancer Center</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 13, 2015, we, together with Precigen, entered into that certain license agreement, or the MD Anderson License, with MD Anderson (which Precigen subsequently assigned to PGEN). Pursuant to the MD Anderson License, we, together with PGEN, hold an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR T-cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells, and TCRs, arising from the laboratory of Laurence Cooper, M.D., Ph.D. Dr. Cooper served as our Chief Executive Officer from May 2015 until February 2021 and was formerly a tenured professor of pediatrics at MD Anderson.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 17, 2015, the Company, Precigen and MD Anderson entered into the Research and Development Agreement, or the 2015 R&amp;D Agreement, to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. The rights and obligations of Precigen under the 2015 R&amp;D Agreement were assigned to us pursuant to the Fourth Amendment to the 2015 R&amp;D Agreement which was entered into on September 19, 2019, or the Fourth Amendment, with an effective date of October 5, 2018. The activities under the 2015 R&amp;D Agreement are directed by a joint steering committee comprised of two members from our company and one member from MD Anderson.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As provided under the MD Anderson License, we provided funding for research and development activities in support of the research programs under the 2015 R&amp;D Agreement for a period of three years and in an amount of no less than $15.0 million and no greater than $20.0 million per year. On November 14, 2017, we entered into an amendment to the 2015 R&amp;D Agreement extending its term until April 15, 2021 and on October 22, 2019, we entered into another amendment to the 2015 R&amp;D Agreement extending its term until December 31, 2026 and to allow cash resources on hand at MD Anderson under the 2015 R&amp;D Agreement to be used for development costs under the 2019 Research and Development Agreement, or the 2019 R&amp;D Agreement, which we entered into on October 22, 2019, with MD Anderson, pursuant to which we agreed to collaborate with respect to the TCR program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term of the MD Anderson License, we, together with Precigen, shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if we and Precigen are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if we and Precigen are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by us and Precigen, if such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both us and Precigen and may be terminated by the mutual written agreement of us, Precigen, and MD Anderson.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Research and Development Agreement-The University of Texas MD Anderson Cancer Center</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the 2019 R&amp;D Agreement, we and MD Anderson will, among other things, collaborate on programs to expand our TCR library and conduct clinical trials. The activities under the 2019 R&amp;D Agreement are directed by a joint steering committee comprised of two members from our company and one member from MD Anderson.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will own all inventions and intellectual property developed under the 2019 R&amp;D Agreement and we will retain all rights to all intellectual property, patentable or not, for oncology products manufactured using non-viral gene transfer technologies under the 2019 R&amp;D Agreement, including our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology. We have granted MD Anderson an exclusive license for such intellectual property to develop and commercialize autologous TCR products manufactured using viral gene transfer technologies, and any products outside the field of oncology and a non-exclusive license for allogenic TCR products manufactured using viral-based technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the 2019 R&amp;D Agreement, we agreed, beginning on January 1, 2021, to reimburse MD Anderson up to a total of $20 million for development costs under the 2019 R&amp;D Agreement, after the funds from the 2015 R&amp;D Agreement are exhausted. In addition, we will pay MD Anderson royalties on net sales of its TCR products at rates in the low single digits. We are required to make performance-based payments upon the successful completion of clinical and regulatory benchmarks relating to its TCR products. The aggregate potential benchmark payments are $36.5 million, of which only $3.0 million will be due prior to the first marketing approval of our TCR products. The royalty rates and benchmark payments owed to MD Anderson may be reduced upon the occurrence of certain events. We also agreed to sell our TCR products to MD Anderson at preferential prices and will sell our TCR products in Texas exclusively to MD Anderson for a limited period of time following the first commercial sale of our TCR products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2019 R&amp;D Agreement will terminate on December 31, 2026 and either party may terminate the 2019 R&amp;D Agreement following written notice of a material breach. The 2019 R&amp;D Agreement also contains customary provisions related to indemnification obligations, confidentiality and other matters.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the execution of the 2019 R&amp;D Agreement, on October 22, 2019, we issued MD Anderson a warrant to purchase 3,333,333 shares of our common stock, which is referred to as the MD Anderson Warrant. The MD Anderson Warrant has an initial exercise price of $0.001 per share, expires on December 31, 2026 and vests in four parts upon the occurrence of certain clinical milestones. As of December 31, 2023, the milestones have not been met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The MD Anderson Warrant and the shares of our common stock to be issued upon exercise of the MD Anderson Warrant have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreement with the NCI</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 28, 2019, we entered into a patent license agreement, or the Patent License, with the NCI. Pursuant to the Patent License, we hold an exclusive, worldwide license to certain intellectual property to develop and commercialize patient-derived (autologous), peripheral blood T-cell therapy products engineered by transposon-mediated gene transfer to express TCRs reactive to mutated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> neoantigens. In addition, pursuant to the Patent License, we hold an exclusive, worldwide license to certain intellectual property for manufacturing technologies to develop and commercialize autologous, peripheral blood T-cell therapy products engineered by non-viral gene transfer to express TCRs, as well as a non-exclusive, worldwide license to certain additional manufacturing technologies. On May 29, 2019, January 8, 2020, September 28, 2020, April 16, 2021, May 4, 2021, and August 13, 2021 we amended the Patent License to expand our TCR library to include additional TCRs reactive to mutated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> neoantigens licensed from the NCI.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The terms of the Patent License required us to pay the NCI minimum annual royalties in the amount of $0.3 million, which amount will be reduced to $0.1 million once the aggregate minimum annual royalties paid by us equals $1.5 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were also required to make performance-based payments upon successful completion of clinical and regulatory benchmarks relating to the licensed products. Of such payments, the aggregate potential benchmark payments were $4.3 million, of which aggregate payments of $3.0 million was due only after marketing approval in the United States or in Europe, Japan, Australia, China or India. The first benchmark payment of $0.1 million was paid in 2022 upon the initiation of our TCR-T Library Phase 1/2 Trial, which was a qualifying Phase 1 clinical trial under the terms of the Patent License.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we were required to pay the NCI one-time benchmark payments following aggregate net sales of licensed products at certain aggregate net sales ranging from $250.0 million to $1.0 billion. The aggregate potential amount of these benchmark payments is $12.0 million. We must also pay the NCI royalties on net sales of products covered by the Patent License at rates in the low to mid-single digits depending upon the technology included in a licensed product. To the extent we enter into a sublicensing agreement relating to a licensed product, we are required to pay the NCI a percentage of all consideration received from a sublicensee, which percentage will decrease based on the stage of development of the licensed product at the time of the sublicense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Patent License was to expire upon expiration of the last patent contained in the licensed patent rights, unless terminated earlier. The NCI could have terminated or modified the Patent License in the event of a material breach, including if we did not meet certain milestones by certain dates, or upon certain insolvency events that remained uncured following the date that was 90 days following written notice of such breach or insolvency event. We could have terminated the Patent License, or any portion thereof, in our sole discretion at any time upon 60 days&#8217; written notice to the NCI. In addition, the NCI had the right to: (i) require us to sublicense the rights to the product candidates covered by the Patent License upon certain conditions, including if we are not reasonably satisfying required health and safety needs and (ii) terminate or modify the Patent License, including if we are not satisfying requirements for public use as specified by federal regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 27, 2023, we provided the requisite 60-days' notice to the NCI of our intention to terminate the Patent License, effective December 26, 2023.  The Patent License subsequently was terminated on that date.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cooperative Research and Development Agreement with the NCI</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 9, 2017, we entered into a Cooperative Research and Development Agreement, or CRADA, with the NCI. The purpose of this collaboration was to advance a personalized TCR-T approach for the treatment of solid tumors. Using our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology, the NCI</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">would analyze a patient&#8217;s own cancer cells, identify their unique neoantigens and TCRs reactive against those neoantigens and then use our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology to transpose one or more TCRs into T cells for re-infusion. Research conducted under the CRADA was at the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI, in collaboration with our researchers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were responsible for providing the NCI with the test materials necessary for them to conduct their studies, and eventually, clinical trials pursuant to the CRADA. Inventions, data and materials discovered or produced in connection with performance of the research plan under the CRADA would have remained the sole property of the party who produced the discovery. The parties would have jointly owned all inventions jointly discovered under the research plan. The owner of any invention under the CRADA would have made the decision to file a patent covering the invention, or in the case of a jointly owned invention, we would have had the first opportunity to file a patent covering the invention. If we failed to provide timely notice of our decision to the NCI or decided not to file a patent covering the joint invention, NCI had the right to make the filing. For any invention solely owned by NCI or jointly made by NCI and us for which a patent application was filed, the U.S. Public Health service would have granted us an exclusive option to elect an exclusive or non-exclusive commercialization license. For inventions owned solely by NCI or jointly owned by NCI and us, which are licensed according to the terms described above, we agreed to grant to the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world. We were also required to grant the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world for any of our solely owned inventions. The agreement could have been terminated by any of the parties upon 60 days prior written consent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The NCI had a cleared IND that would permit them to begin this trial. To our knowledge, the trial has not yet enrolled. The progress and timeline for this trial, including the timeline for dosing patients, were under control of the NCI.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2019, we extended the CRADA with the NCI until January 9, 2022, committing an additional $5.0 million to this program. In March 2022, we entered into an amendment to the CRADA that is retroactive, effective January 9, 2022 to extend the term of the CRADA until January 9, 2023. In June 2022, we entered into the Fourth Amendment to the CRADA, or the CRADA Fourth Amendment, which, among other things, extended the term of the CRADA until January 9, 2025. In connection with the CRADA Fourth Amendment, we agreed to contribute $1.0 million per year, payable on a quarterly basis, beginning in the first quarter of 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, we provided the requisite 60-days' notice of our intention to terminate the CRADA, which did subsequently terminate at that time.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TCR-T Platform Licenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2015, we in-licensed from MD Anderson a technology portfolio that includes intellectual property directed to certain non-viral </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technologies as well as TCR-T cell therapy and bioprocessing technology. Under the terms of the agreement, we have an exclusive license to certain of the intellectual property technology, a co-exclusive license to certain of the intellectual property technology and a non-exclusive license to certain of the intellectual property technology. Our rights to the MD Anderson intellectual property flow to us via our agreement with PGEN.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Governmental Regulation and Product Approval</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a biopharmaceutical company, we are subject to extensive regulation. Our genetically engineered T-cell product candidates are regulated as biologics. With this classification, commercial production of our products will need to occur in registered and licensed facilities in compliance with cGMPs for biologics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human immunotherapy products are a new category of therapeutics. The FDA categorizes human cell- or tissue-based products as either minimally manipulated or more than minimally manipulated and has determined that more than minimally manipulated products require clinical trials to demonstrate product safety and efficacy and the submission of a Biologics License Application, or BLA, for marketing authorization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government authorities in the United States (at the federal, state and local level) and in other countries and jurisdictions extensively regulate, among other things, the research, development, preclinical and clinical testing, manufacturing, quality control, labeling, packaging, storage, record-keeping, promotion, advertising, sale, distribution, post-approval monitoring and reporting, marketing and export and import of biopharmaceutical products such as those we are developing. Our product candidates must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. The process for obtaining regulatory marketing approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Product Development Process</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the FDA regulates biological products under the Public Health Service Act, or PHSA, and the Federal Food, Drug and Cosmetic Act, or FDCA, and implementing regulations. Products are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable United States requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters and similar public notice of alleged non-compliance with laws, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a biological product may be approved for marketing in the United States generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completion of preclinical laboratory tests and animal studies according to Good Laboratory Practices, or GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations; </span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations commonly referred to as Good Clinical Practices, or GCPs, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use; </span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation and submission to the FDA of a BLA for marketing approval that includes substantive evidence of safety, purity and potency from results of nonclinical testing and clinical trials; </span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities where the biological product is produced to assess compliance with cGMP to assure that the facilities, methods and controls used in product manufacture are adequate to preserve the biological product&#8217;s identity, strength, quality and purity and, if applicable, the FDA&#8217;s current Good Tissue Practices, or GTPs, for the use of human cellular and tissue products; </span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; </span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payment of user fees for FDA review of the BLA; and </span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA acceptance, review and approval, or licensure, of the BLA, which might include review by an advisory committee, a panel typically consisting of independent clinicians and other experts who provide recommendations as to whether the application should be approved and under what conditions.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before testing any biological product candidate, including our product candidates, in humans, the product candidate must undergo rigorous preclinical testing. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations as well as </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and animal studies to assess the potential safety and efficacy of the product candidate. The clinical trial sponsor must submit an IND to the FDA before clinical testing can begin in the United States. An IND must contain the results of the preclinical tests, manufacturing information, analytical data, any available clinical data or literature, a proposed clinical protocol, an investigator&#8217;s brochure, a sample informed consent form and other materials. Clinical trial protocols detail, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Some preclinical testing, such as toxicity studies, may continue even after the IND is submitted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials or places the trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Clinical trials involving recombinant or synthetic nucleic acid molecules also must be reviewed by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees basic and clinical research conducted at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials involve the administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients with the target disease or condition. </span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population, generally at geographically dispersed clinical trial sites. These clinical trials are intended to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk to benefit profile of the product and to provide an adequate basis for product labeling.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA, the NIH and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">testing that suggest a significant risk for human patients, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. The FDA or the sponsor or its data safety monitoring board, an independent group of experts that evaluates study data for safety and makes recommendations concerning continuation, modification, or termination of clinical trials, may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product has been associated with unexpected serious harm to patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concurrently with clinical trials, companies usually complete additional nonclinical studies and must also develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA has a fast track designation program that is intended to expedite or facilitate the process for reviewing new drug or biologic products that meet certain criteria. Specifically, new drugs or biologics are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Unique to a fast track product, the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After the completion of clinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual program fee for approved biological products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">is safe, potent, and/or effective for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessary to ensure that the benefits of the product outweigh its risks and to assure the safe use of the biological product, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve a BLA without a REMS, if required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. For immunotherapy products, the FDA also will not approve the product if the manufacturer is not in compliance with the GTPs, to the extent applicable. These are FDA regulations and guidance documents that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues and cellular and tissue-based products, or HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA GTP regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval. If the agency decides not to approve the BLA in its present form, the FDA will issue a Complete Response Letter, which generally outlines the specific deficiencies in the BLA identified by the FDA and may require additional clinical or other data or impose other conditions that must be met in order to secure final approval of the application. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Even with the submission of additional information, the FDA may ultimately decide that the application does not satisfy the regulatory criteria for approval. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may require that certain contraindications, warnings or precautions be included in the product labeling, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a biological product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements and complying with FDA promotion and advertising requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, quality control and manufacturing procedures must continue to conform to applicable manufacturing requirements after approval to ensure the long-term stability of the product. We relied on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. cGMP regulations require, among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA also may require post-marketing testing, known as Phase 4 testing, and surveillance to monitor the effects of an approved product. Discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, with manufacturing processes, or the failure to comply with applicable FDA requirements can have negative consequences, including adverse</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">publicity, judicial or administrative enforcement, complete withdrawal from the market, product recalls, warning letters from the FDA, mandated corrective advertising or communications with doctors, product seizure or detention, injunctions and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, the FDA strictly regulates marketing, labeling, advertising and promotion of products. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label, although physicians, in the practice of medicine, may prescribe approved drugs for unapproved indications. However, companies may share truthful and not misleading information that is otherwise consistent with the labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Marketing Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Biologics Price Competition and Innovation Act, or BPCIA, amended the PHSA to authorize the FDA to approve similar versions of innovative biologics, commonly known as biosimilars. Biosimilars are approved pursuant to an abbreviated pathway whereby applicants need not submit the full slate of preclinical and clinical data, and approval is based in part on the FDA&#8217;s findings of safety, purity, and potency for the original biologic (i.e., the reference product). Reference products are eligible to receive 12 years of exclusivity from the time of first licensure of the product, which prevents the FDA from approving any biosimilars to the reference product through the abbreviated pathway, but does not prevent approval of BLAs that are accompanied by a full data package and that do not rely on the reference product. A biosimilar may be approved if the product is highly similar to the reference product notwithstanding minor differences in clinically inactive components and there are no clinically meaningful differences with the reference product in terms of the safety, purity and potency.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan Drug Designation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a drug or biologic product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting a marketing application. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The designation of such drug also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user fee waivers. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval of the same product as defined by the FDA or if our product candidate is determined to be contained within the competitor&#8217;s product for the same indication or disease. If an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity. Orphan drug status in the European Union, or EU, has similar but not identical benefits in that jurisdiction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage, Pricing and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in significant part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication. In addition, in the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payor. Third-party payors are increasingly challenging the price, examining the medical necessity of and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reimbursement may impact the demand for, and/or the price of, any product candidate that obtains marketing approval. Even if coverage and reimbursement is obtained for a given product candidate by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with those medications. Patients are unlikely to use a product, and physicians may be less likely to prescribe a product, unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of the product. Therefore, coverage and adequate reimbursement is critical to new drug product acceptance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The downward pressure on health care costs in general, particularly prescription drugs and biologics, has become very intense. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. As a result, increasingly high barriers are being erected to the entry of new products. The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide favorable coverage and adequate reimbursement. In addition, emphasis on managed care in the United States has increased, and we expect will continue to increase, the pressure on healthcare pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Health Care Laws Governing Interactions with Healthcare Providers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare providers and third-party payors in the United States play a primary role in the recommendation and prescription of drug products. Arrangements with healthcare providers, third-party payors and customers can expose pharmaceutical manufactures to broadly applicable fraud and abuse and other healthcare laws, including false claims, privacy and security, price reporting and physician sunshine laws or regulations. Some of our pre-commercial activities are subject to some of these laws. The applicable federal, state and foreign healthcare laws and regulations laws that may affect a pharmaceutical manufacture&#8217;s ability to operate include, but are not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal Anti-Kickback Statute, which regulates our business activities, including our marketing practices, educational programs, pricing policies and relationships with healthcare providers or other entities, by prohibiting, among other things, soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual or the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; </span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal civil and criminal false claims laws, including the False Claims Act which permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal civil and criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on entities and individuals subject to the law including certain healthcare providers, health plans and healthcare clearinghouses, known as covered entities, as well as individuals and entities that perform services for them which involve the use, or disclosure of, individually identifiable health information, known as business associates as well as their covered subcontractors; </span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Requirements to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, certain financial arrangements with physicians and teaching hospitals, as defined in the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, and its implementing regulations, including reporting any &#8220;transfer of value&#8221; made or distributed to prescribers and teaching hospitals, and reporting any ownership and investment interests held by physicians and their immediate family members during the preceding calendar year; and </span></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">State and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government that otherwise restricts certain payments that may be made to healthcare providers and entities; state laws that require drug manufacturers to report information related to payments and other transfer of value to physicians and other healthcare providers and entities; state laws that require the reporting of information related to drug pricing; state and local laws that require the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Efforts to ensure that business arrangements comply with applicable healthcare laws involve substantial costs. It is possible that governmental and enforcement authorities will conclude that a pharmaceutical manufacturer&#8217;s business practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against a pharmaceutical manufacturer, and it is not successful in defending itself or asserting its rights, it may be subject to the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of operations, as well as additional reporting obligations and oversight if subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. In addition, the approval and commercialization of drug products outside the United States may also subject a pharmaceutical manufacturer to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare Reform Efforts</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A primary trend in the United States healthcare industry and elsewhere is cost containment. Over the last several years, there have been federal and state proposals and legislation enacted regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products and making changes to healthcare financing and the delivery of care in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2010, President Obama signed into law the ACA, which included measures that have significantly changed the way healthcare is financed by both governmental and private insurers. The ACA, among other things, imposed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations, added a provision to increase the Medicaid rebate for line extensions or reformulated drugs, established annual fees on manufacturers and importers of certain branded prescription drugs and biologic agents, promoted a new Medicare Part D coverage gap discount program, expanded the entities eligible for discounts under the Public Health Service Act pharmaceutical pricing program and imposed a number of substantial new compliance provisions related to pharmaceutical companies&#8217; interactions with healthcare practitioners. The ACA also expanded eligibility for Medicaid programs and introduced a new Patient Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research and a new Center for Medicare &amp; Medicaid Innovation at CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been executive, legal and political challenges to certain aspects of the ACA. For example, President Trump signed several executive orders and other directives designed to delay, circumvent or loosen certain requirements mandated by the ACA. Concurrently, Congress considered legislation to repeal or repeal and replace all or part of the ACA. While Congress has not passed repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or Tax Act, included a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Further, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. The Bipartisan Budget Act of 2018, or the BBA, among other things, amended the ACA, effective January 1, 2019, to increase from 50 percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; Further, President Biden issued an executive order that instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. Further, there have been a number of health reform initiatives by the Biden administration that have impacted the ACA. For example, on August 16, 2022, President Biden signed the Inflation Reduction Act, or IRA, into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the "donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and implementing a newly established manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact ACA and our business. The ultimate content, timing or effect of any healthcare reform measures on the U.S. healthcare industry is unclear.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, other federal health reform measures have been proposed and adopted in the United States since the ACA was enacted. For example, as a result of the Budget Control Act of 2011, providers are subject to Medicare payment reductions of 2% per fiscal year, which went into effect on April 1, 2013. This 2% reduction was temporarily suspended during the COVID-19 pandemic, but has since been reinstated and, unless Congress and/or the Executive Branch take additional action, will begin to increase gradually starting in April 2030, reaching 4% in April 2031, until sequestration ends in October 2031. Further, the American Taxpayer Relief Act of 2012 reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments from providers from three to five years. The Medicare Access and CHIP Reauthorization Act of 2015 also introduced a quality payment program under which certain individual Medicare providers will be subject to certain incentives or penalties based on new program quality standards. In November 2019, CMS issued a final rule finalizing the changes to the Medicare Quality Payment Program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals. The FDA also released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 30, 2020, the U.S. Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The IRA delayed the implementation of the rule to January 1, 2032. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers; the implementation of these provisions has also been delayed by the IRA until January 1, 2032. In addition, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate price cap, currently set at 100% of a drug&#8217;s average manufacturer price for single source and innovator multiple source products, beginning on January 1, 2024. Further, in July 2021, the Biden Administration released an executive order that included multiple provisions aimed at prescription drugs. In response to President Biden's executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug price reform. The plan sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions by HHS. No legislative or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of the budget reconciliation process. Additionally, the IRA, among other things, (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subjects drug manufacturers to civil monetary penalties and a potential excise tax for offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions began to take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be effectuated but is likely to have a significant impact on the pharmaceutical industry.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the state level, legislatures have increasingly enacted legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Foreign Corrupt Practices Act, U.K. Bribery Act and Other Laws</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Foreign Corrupt Practices Act, or the FCPA, prohibits any United States individual or business from paying, offering or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Activities that violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment, disgorgement, oversight, and debarment from government contracts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations are also subject to non-United States anti-corruption laws such as the U.K. Bribery Act 2010, or the Bribery Act. As with the FCPA, these laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering or providing, directly or indirectly, improper or prohibited payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some other business advantage. Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States and authorities in the EU, including applicable export control regulations, economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations, collectively referred to as trade control laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure to comply with the Bribery Act, the FCPA and other anti-corruption laws and trade control laws could subject us to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe our novel hunTR discovery engine demonstrated the ability to identify proprietary TCRs, allowing us to further expand and advance our pipeline with multiple solid tumor programs under development. In addition, our non-viral transposon method of expressing TCRs, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was less complex relative to many of our competitors&#8217; viral approaches. Finally, our TCR-T Phase 1/2 Library Trial was designed to allow us to treat patients quickly and efficiently in many different indications with a tumor mutation and HLA matching one or more of the several TCRs in our library, which we believe gives us a distinct competitive advantage. However, the development and commercialization for new products to treat cancer, including the indications we pursued, is highly competitive and considerable competition exists from major pharmaceutical, biotechnology and specialty cancer companies. Many of these companies have more experience in preclinical and clinical development, manufacturing, regulatory, and global commercialization. Given the rapidly advancing and changing science and technologies in the industry, they may compete with us in hiring personnel, setting up clinical study sites, recruiting patients for clinical trials, and procuring technologies and licenses complementary to, or required for, our programs. We are also competing with academic institutions, governmental agencies and private organizations that are conducting research in the field of cancer.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our TCR-T cell therapies targeting solid tumors face significant competition from multiple companies, and their collaborators, in the TCR and CAR technology space. We face competition from several companies, including 2Seventy Bio, Achilles Therapeutics, Adaptimmune Therapeutics, Affini-T Therapeutics, Annoca, ArsenalBio, Athenex, BioNTech, Bristol-Myers Squibb, Immatics, Iovance Biotherapeutics, Kite (a Gilead company), Lion TCR, Lyell Immunopharma, Medigene, Nurix Therapeutics, Neogene Therapeutics (a member of the AstraZeneca group), NexImmune, PACT Pharma, Precigen, Tactiva Therapeutics, Takara Bio, TCR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Therapeutics, T-Cure BioScience, T-knife Therapeutics, Triumvira Immunologics, TScan Therapeutics, Turnstone Biologics, Zelluna Immunotherapy and others. Many of these companies are either investigating TCR-T cells against germline antigens or are utilizing tumor infiltrating lymphocytes. Some are pursuing CAR-T cells for solid tumors. In contrast, we are focused on developing TCR-T cell products against neoantigens arising from somatic mutations in solid tumors.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Companies in the T-cell therapy segment that have target discovery platforms like ours include Adaptive Biotechnologies, Affini-T Therapeutics, Enara Bio, Immatics, Neogene Therapeutics (a member of the AstraZeneca group), PACT Pharma, T-knife Therapeutics, TScan Therapeutics and 3T Biosciences. Several companies, including Advaxis, Amgen, BioNTech, Geneos Therapeutics, and Gritstone, are pursuing vaccine platforms to target neoantigens for solid tumors. Other companies are developing non-viral gene therapies, including Poseida Therapeutics and several companies developing CRISPR technology, including Captain T Cell and Crispr Therapeutics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Several companies are pursuing the development of allogeneic CAR-T therapies, including Allogene Therapeutics, Atara Biotherapeutics and Precision Biosciences, which may compete with our product candidates. We also face competition from companies developing therapies using cells other than T cells, such as Athenex, Fate Therapeutics, ImmunityBio, IN8bio, Nkarta Therapeutics and Takeda Pharmaceutical. Other competitors are developing T cells with cytokines, such as Fate Therapeutics and Obsidian Therapeutics. Finally, we also face competition from non-cellular treatments offered by other companies, such as Amgen, AstraZeneca, Bristol-Myers Squibb, Immatics, Immunocore, Incyte, Merck, Mirati and Roche.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face competition on a broader spectrum of the oncology market that is more common, cost-effective and reimbursable, such as surgery, radiation and other drug therapies like chemotherapy, hormone therapy, biologic therapy such as monoclonal and bispecific antibodies, or a combination of any of these therapies. If any of our TCR-T therapies are approved, they may not be as competitive as other therapies, to the extent they are used in combinations with these therapies. Insurers and other third-party payors may also encourage use of certain products; thus, gaining market acceptance or market share for any of our TCR-T therapies could pose difficulties. Finally, standard of care could evolve or change throughout the clinical development of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, if our competitors develop and market a drug that is safer, more effective with fewer side effects, easier to administer, or less expensive, we could see a less favorable market opportunity for our TCR-T therapy candidates. Our competition may also receive FDA or other regulatory approval for their products more quickly than we do, which could give them a first mover advantage and a strong market position before we are able to commercialize our products. If approved, key competitive factors that may affect the success of our TCR-T candidates are likely their efficacy, safety, ease of administering, price and reimbursement from insurance or government.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employees and Human Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 1, 2024, we had 1 full-time employee who is engaged in administration and no part-time employees. None of our employees are subject to a collective bargaining agreement and we believe our relations with our employees are good.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our human capital resources objectives include identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We endeavor to recruit the best people for the position regardless of gender, ethnicity or other protected traits and it is our policy to fully comply with all laws applicable to discrimination in the workplace. Our diversity, equity and inclusion principles are also reflected in our employee training and policies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2023 and the first quarter of 2024, we entered into several material consulting agreements to ensure smooth transitions and business continuity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Boyle Separation Agreement and Consulting Agreement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 22, 2023, we entered into a Separation and Release Agreement, effective December 22, 2023, with Kevin S. Boyle, Sr. (the &#8220;Separation Agreement&#8221;), the Company&#8217;s Chief Executive Officer, in connection with Mr. Boyle&#8217;s termination. Pursuant to the terms of his employment agreement, upon his termination Mr. Boyle was deemed to automatically resign from our Board of Directors.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of the Separation Agreement, and subject to customary conditions, we agreed to pay Mr. Boyle a one-time separation payment in an amount equal to six months of Mr. Boyle&#8217;s base salary and the cost of six months of COBRA premiums for Mr. Boyle, or approximately $331,990 less all applicable income and payroll taxes, deductions and withholdings. Mr. Boyle has agreed to make himself reasonably available to us to provide information related to his transition. The Separation Agreement also provides for a customary mutual release of all claims by us and Mr. Boyle against one another.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also entered into a consulting agreement (the &#8220;Boyle Consulting Agreement&#8221;), effective January 1, 2024, with Mr. Boyle pursuant to which he will continue providing strategic and advisory services to us. The Boyle Consulting Agreement will continue for a period of six months. The Boyle Consulting Agreement provides for compensation at a fixed rate of $15,000 per month and reimbursement  for any usual and customary expenses incurred by Mr. Boyle in connection with performing services pursuant to the Boyle Consulting Agreement.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Deniger Separation and Lackey Separation &amp; Consulting Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As previously reported, on November 10, 2023, we terminated the employment of Melinda Lackey, Senior Vice President, Legal and Administration, and Drew Deniger, Vice President, Research and Development, &#8220;Without Cause&#8221; (as defined in their respective employment agreements) and, per their respective retention agreements, not because either failed to perform their duties at an &#8220;Acceptable Level&#8221; (as defined therein), effective November 15, 2023. In connection with their termination, we paid $44,998 to Ms. Lackey pursuant to her retention letter agreement, dated August 14, 2023, and $45,623 to Dr. Deniger pursuant to his retention letter agreement, dated September 1, 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Deniger Separation Agreement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of the separation and release agreement between us and Dr. Deniger (the &#8220;Deniger Separation Agreement&#8221;), Dr. Deniger has agreed to remain reasonably available to the Company, and to reasonably cooperate and assist us, in connection with (i) any investigations, litigation or other proceedings in which he was involved while an employee and (ii) our consideration of strategic alternatives relating to its scientific assets. Subject to customary conditions, we paid Dr. Deniger a one-time separation payment in an amount equal to $182,500, less all applicable income and payroll taxes, deductions and withholdings. The Deniger Separation Agreement also provides for a customary release of all claims against us by Dr. Deniger.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Lackey Separation Agreement and Consulting Agreement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of the separation and release agreement between us and Ms. Lackey (the &#8220;Lackey Separation Agreement&#8221;), Ms. Lackey agreed to remain reasonably available to the Company, and to reasonably cooperate and assist us, in connection with any investigations, litigation or other proceedings in which she was involved while an employee. Subject to customary conditions, we paid Ms. Lackey a one-time separation payment in an amount equal to $180,000, less all applicable income and payroll taxes, deductions and withholdings. The Lackey Separation Agreement also provides for a customary release of all claims against us by Ms. Lackey.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also entered into a consulting agreement (the &#8220;Lackey Consulting Agreement&#8221;), effective November 16, 2023, with Ms. Lackey pursuant to which Ms. Lackey will continue providing legal services to us, including assisting in its ongoing exploration of strategic alternatives. The Lackey Consulting Agreement will continue indefinitely until terminated by the Company or Ms. Lackey upon 30 days prior written notice. The Lackey Consulting Agreement provides for compensation at a fixed rate of $400 per hour and reimbursement by the Company for any usual and customary expenses incurred by Ms. Lackey in connection with performing services pursuant to the Lackey Consulting Agreement.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Mr. Wong's Departure and Mr. Groenewald Engagement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 15, 2024, Michael Wong gave notice of his resignation as Vice President, Finance, of the Company effective February 23, 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 22, 2024, the Company and Ferdinand Groenewald entered into a consulting agreement (the &#8220;Consulting Agreement&#8221;), effective February 22, 2024, pursuant to which Mr. Groenewald will lead accounting and financial reporting activities of the Company. Mr. Groenewald will serve as the Company&#8217;s Vice President, Finance. The Consulting Agreement will continue indefinitely until terminated by either party upon 30 days&#8217; advance notice. The Consulting Agreement provides for compensation at a fixed rate of $15,000 per month and reimbursement by the Company for any usual and customary business expenses incurred by Mr. Groenewald in connection with performing services pursuant to the Consulting Agreement. In addition, the Consulting Agreement provides for the Company to indemnify Mr. Groenewald on terms customary for officers.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since July 2022, Mr. Groenewald, age 39, has served in several capacities at the CFO Squad, which provides outsourced accounting and consulting services. From January 2, 2022 to July 31, 2022, Mr. Groenewald had served as the Chief Accounting Officer of Muscle Maker, Inc., a Nasdaq-listed company. From September 2018 to January 2, 2022, Mr. Groenewald served as the Chief Financial Officer of Muscle Maker,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inc. From January 25, 2018 through May 29, 2018, Mr. Groenewald served as the Vice President of Finance, Principal Financial Officer and Principal Accounting Officer of Muscle Maker, Inc., Muscle Maker Development, LLC and Muscle Maker Corp., LLC. In addition, from October 2017 through May 29, 2018, he served as the controller of Muscle Maker, Inc. Mr. Groenewald is a certified public accountant with significant experience in finance and accounting. From July 2018 through August 2018, he served as senior financial reporting accountant of Wrinkle Gardner &amp; Company, a full-service tax, accounting and business consulting firm. From February 2017 to October 2017, Mr. Groenewald served as Senior Financial Accounting Consultant at Pharos Advisors, Inc. serving a broad range of industries. From November 2013 to February 2017, he served as a Senior Staff Accountant at Financial Consulting Strategies, LLC, where he provided a broad range of accounting, financial reporting, and pre-auditing services to various industries. From August 2015 to December 2015, Mr. Groenewald served as a Financial Reporting Analyst at Valley National Bank. Mr. Groenewald holds a Bachelor of Science in accounting from the University of South Africa. Mr. Groenewald has served as a member of the Board of Directors of (i) HeartCore Enterprises, Inc., a company listed on the Nasdaq Capital Market, since January 24, 2022; (ii) SYLA Technologies Co., Ltd., a publicly reporting company that is listed on the Nasdaq Capital Market, since December 1, 2022; and (iii) Sushi Ginza Onodera, Inc., a company that has publicly filed a registration statement on Form S-1 in connection with its initial public offering, since July 1, 2023.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We originally incorporated in Colorado in September 1998 (under the name Net Escapes, Inc.) and later changed our name to &#8220;EasyWeb, Inc.&#8221; in February 1999. We re-incorporated in Delaware on May 16, 2005 under the same name. On September 13, 2005, we completed a &#8220;reverse&#8221; acquisition of privately held Ziopharm, Inc., a Delaware corporation. To effect this transaction, we caused ZIO Acquisition Corp., our wholly-owned subsidiary, to merge with and into Ziopharm, Inc., with Ziopharm, Inc. surviving as our wholly owned subsidiary. Following the merger, we caused Ziopharm, Inc. to merge with and into us and we changed our name to &#8220;Ziopharm Oncology, Inc.&#8221; As a result, Ziopharm, Inc. became the registrant with the Securities and Exchange Commission, or the SEC, and the historical financial statements of Ziopharm, Inc. became our historical financial statements. On January 25, 2022, we filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation with the Delaware Secretary of State to change our name to Alaunos Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our principal executive offices are located at 2617 Bissonnet Street, Suite 225, Houston, Texas 77005, and our telephone number is (346) 355-4099.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our website address is www.alaunos.com. Our website and information included in or linked to our website are not part of this Annual Report on Form 10-K. We file reports with the SEC, which we make available on our website free of charge. These reports include annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to such reports, each of which is provided on our website as soon as reasonably practicable after we electronically file such materials with or furnish them to the SEC. In addition, the SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers, like us, that file electronically with the SEC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 1A. Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">An investment in our common stock is risky. In addition to the other information in this Annual Report on Form 10-K, you should carefully consider the following risk factors in evaluating us and our business. If any of the events described in the following risk factors were to occur, our business, financial condition, results of operations, cash flows and prospects would likely be materially and adversely affected. In that event, the trading price of our common stock could decline, and you could lose all or a part of your investment in our common stock. Therefore, we urge you to carefully review this entire Annual Report on Form 10-K and consider the risk factors discussed below. Moreover, the risks described below are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business, financial condition, results of operations, cash flows and prospects. Additional risks that we currently do not know about, or that we currently believe to be immaterial, may also impair our business, financial condition, results of operations, cash flows and prospects. Certain statements below are forward-looking statements. See &#8220;Special Note Regarding Forward-Looking Statements&#8221; in this Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO OUR STRATEGIC REPRIORITIZATION</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our strategic reprioritization may not be successful, may not yield the desired results and we may be unsuccessful in identifying and implementing any strategic transaction.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, we announced a strategic reprioritization of our business and wind down of our TCR-T Library Phase 1/2 Trial. In connection with the reprioritization, we have reduced our workforce by approximately 95% to date and we continue working to reduce costs in order to extend our cash runway. We continue to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. We have engaged Cantor Fitzgerald &amp; Co., or Cantor, to act as strategic advisor for this process. In addition, while we are evaluating several potential in-licensing opportunities in obesity, oncology and virology, there is no assurance that any of these potential opportunities will come to fruition.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe there is value in our hunTR&#174; TCR discovery platform. However, the platform is experimental. There can be no assurances that we can succeed in improving the platform&#8217;s appeal and increasing its value. We may be unable to successfully monetize the platform or any TCRs we discovered, either through partnerships or out-licensing.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to devote substantial time and resources to exploring strategic alternatives that our Board of Directors believes will maximize stockholder value. Despite devoting significant efforts to identify and evaluate potential strategic alternatives, there can be no assurance that this strategic review process will result in us pursuing any transaction or that any transaction, if pursued, will be completed on attractive terms or at all. We have not set a timetable for completion of this strategic review process, and our Board of Directors has not approved a definitive course of action. Additionally, there can be no assurances that any particular course of action, business arrangement or transaction, or series of transactions, will be pursued, successfully consummated or lead to increased stockholder value or that we will make any additional cash distributions to our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process of continuing to evaluate these strategic options may be very costly, time-consuming and complex and we have incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal and accounting fees and expenses and other related charges. We may also incur additional unanticipated expenses in connection with this process. A considerable portion of these costs will be incurred regardless of whether any such course of action is implemented or transaction is completed. Any such expenses will decrease the remaining cash available for use in our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, potential counterparties in a strategic transaction involving the Company may place minimal or no value on our assets or our public listing. Further, should we resume the development of our product candidates, the development and any potential commercialization of our product candidates will require substantial additional cash to fund the costs associated with conducting the necessary preclinical and clinical testing and obtaining regulatory approval. Consequently, any potential counterparty in a strategic transaction involving the Company may choose not to spend additional resources and continue development of our product candidates and may attribute little or no value, in such a transaction, to those product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, any strategic business combination or other transactions that we may consummate in the future could have a variety of negative consequences and we may implement a course of action or consummate a transaction that yields unexpected results that adversely affect our business and decreases the remaining cash available for use in our business or the execution of our strategic plan. Any potential transaction would be dependent on a number of factors that may be beyond our control, including, among other things, market conditions, industry trends, the interest of third parties in a potential transaction with us, obtaining stockholder approval and the availability of financing to third parties in a potential transaction with us on reasonable terms. Any failure of such potential transaction to achieve the anticipated results could significantly impair our ability to enter into any future strategic transactions and may significantly diminish or delay any future distributions to our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are not successful in setting forth a new strategic path for the Company, or if our plans are not executed in a timely fashion, this may cause reputational harm with our stockholders and the value of our securities may be adversely impacted. In addition, speculation regarding any developments related to the review of strategic alternatives and perceived uncertainties related to the future of the Company could cause our stock price to fluctuate significantly.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we successfully consummate a transaction from our strategic assessment, we may fail to realize all of the anticipated benefits of the transaction, those benefits may take longer to realize than expected, or we may encounter integration difficulties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to realize the anticipated benefits of any potential business combination or any other result from our strategic assessment is highly uncertain. Any anticipated benefits will depend on a number of factors, including our ability to integrate with any future business partner, the success of any future business we may engage in following the transaction and our ability to obtain value for our product candidates or technologies, if divested. The process may be disruptive to our business and the expected benefits may not be achieved within the anticipated timeframe, or at all. The failure to meet the challenges involved and to realize the anticipated benefits of any potential transaction could adversely affect our business and financial condition. Furthermore, our stockholders may experience substantial dilution as a result of the transaction without receiving the expected commensurate benefit, or only receiving part of the commensurate benefit to the extent we are able to realize only part of the expected strategic and financial benefits currently anticipated from a transaction.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may require substantial additional financial resources to continue as a going concern, including through the strategic review process, and if we raise additional funds, this may materially and negatively affect the value of your investment in our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not generated significant revenue and have incurred significant net losses in each year since our inception. For the year ended December 31, 2023, we had a net loss of $35.1 million, and, as of December 31, 2023, our accumulated deficit since inception in 2003 was $915.8 million. Although we are in the process of implementing a restructuring plan, or the Plan, whereby we are winding down our TCR-T Library Phase 1/2 Trial, other development programs and implemented a reduction in force, in order to reduce operating expenditures and net losses, as discussed above, there can be no assurances we will be successful at all, or in the amount we anticipate. In connection with our strategic reprioritization, we unilaterally terminated the CRADA with the NCI in August 2023 and the Patent License with the NCI in October 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we have approximately $6.1&#8239;million of cash and cash equivalents.&#8239;Following implementation of the Plan, we anticipate our cash resources will be sufficient to fund our operations into the third quarter of 2024. We have not set a timetable for completion of the strategic review process and the timing of consummating a strategic transaction, if any, is not entirely within our control. We have no committed sources of additional capital at this time. Accordingly, we could exhaust our current cash resources prior to the identification or consummation of a suitable strategic alternative, requiring the Company to raise additional capital.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that our exploration of strategic alternatives will make it more difficult to raise additional capital. To the extent that we raise additional capital by issuing equity securities, our existing stockholders&#8217; ownership will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, creating liens, making capital expenditures or declaring dividends, which may further constrain our ability to execute on strategic alternatives.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We follow the guidance of Accounting Standards Codification, or ASC, Topic 205-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Presentation of Financial Statements - Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, in order to determine whether there is substantial doubt about our ability to continue as a going concern for one year after the date our financial statements are issued. Based on the current cash forecast, management has determined that our present capital resources will not be sufficient to fund our planned operations for at least one year from the issuance date of the financial statements, which raises substantial doubt as to our ability to continue as a going concern.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The forecast of cash resources is forward-looking information that involves risks and uncertainties, and our actual cash requirements may vary materially from our current expectations for a number of other factors that may include, but are not limited to, the progress of our strategic review and the pursuit of and progress on one or more options identified in such review. Global political and economic events, including the war in Ukraine and increased inflation, have already resulted in a significant disruption of global financial markets. If the disruption persists and deepens, we could experience an inability to access additional capital or make the terms of any available financing less attractive, which could in the future negatively affect our operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are successful in completing a strategic transaction, we may be exposed to other operational and financial risks.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although there can be no assurance that a strategic transaction will result from the process we have undertaken to identify and evaluate strategic alternatives, the negotiation and consummation of any such transaction will require significant time on the part of our management, and the diversion of management&#8217;s attention may disrupt our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The negotiation and consummation of any such transaction may also require more time or greater cash resources than we anticipate and expose us to other operational and financial risks, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased near-term and long-term expenditures;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unknown liabilities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">higher than expected acquisition or integration costs;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">incurrence of substantial debt or dilutive issuances of equity securities to fund future operations;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">write-downs of assets or incurrence of non-recurring, impairment or other charges;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased amortization expenses;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty and cost in combining the operations and personnel of any counterparty business with our operations and personnel;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impairment of relationships with key suppliers or customers of any acquired business due to changes in management and ownership;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to retain key employees of our company or any acquired business; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">possibility of future litigation.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of the foregoing risks could have a material adverse effect on our business, financial condition, results of operations, cash flows and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If a strategic transaction is not consummated, our Board of Directors may decide to pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There can be no assurance that a strategic transaction will be completed. If a strategic transaction is not completed, our Board of Directors may decide to pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such decision and, with the passage of time the amount of cash available for distribution will be reduced as we continue to fund our operations and exploration of strategic alternatives. In addition, if our Board of Directors were to approve and recommend, and our stockholders were to approve, a dissolution and liquidation, we would be required under Delaware corporate law to pay our outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to our stockholders. As a result of this requirement, a portion of our assets may need to be reserved pending the resolution of such obligations and the timing of any such resolution is uncertain. In addition, we may be subject to litigation or other claims related to a dissolution and liquidation. If a dissolution and liquidation were pursued, our Board of Directors, in consultation with our advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, holders of our common stock could lose all or a significant portion of their investment in the event of a liquidation, dissolution or winding up.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to consummate a strategic transaction depends on our ability to retain our remaining employees and consultants.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to consummate a strategic transaction depends upon our ability to retain our remaining employees and consultants, the loss of whose services may adversely impact our ability to consummate such transaction. In connection with the evaluation of strategic alternatives and in order to extend our resources, on August 14, 2023, we implemented the Plan that included reducing our workforce. The reduction in force has impacted approximately 95%</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of our workforce to date, including key members of our management team. Our cash conservation activities may yield unintended consequences, such as attrition beyond our planned reduction in workforce and reduced employee morale, which may cause remaining employees and consultants to seek alternative opportunities. If we are unable to successfully retain our remaining personnel, we are at risk of a disruption to our exploration and consummation of a strategic alternative as well as business operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our corporate restructuring and the associated headcount reduction may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could significantly disrupt our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, in connection with the evaluation of strategic alternatives and in order to extend our resources, our Board of Directors approved the Plan that included reducing our workforce, which has impacted approximately 95%</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of our workforce to date. In addition, the Plan included a discontinuation of our clinical development programs and further prioritization of our resources as we assess strategic alternatives. We incurred approximately $1.5 million for retention, severance and other employee termination-related costs starting in the third quarter of 2023 through to the fourth quarter of 2023. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from the restructuring, our operating results and financial condition would be adversely affected. Furthermore, the Plan may be disruptive to our operations. For example, our headcount reductions could yield unanticipated consequences, such as increased difficulties in implementing our business strategy, including retention of our remaining employees and consultants. Any employee litigation related to the headcount reduction could be costly and prevent management from fully concentrating on the business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees. Due to our limited resources, we may not be able to effectively manage our operations or recruit and retain qualified personnel, which may result in weaknesses in our infrastructure and operations, risks that we may not be able to comply with legal and regulatory requirements, and loss of employees and reduced productivity among remaining employees. For example, the workforce reduction may negatively impact our clinical, regulatory, technical operations, and commercial functions, should we choose to continue to pursue them, which would have a negative impact on our ability to successfully develop, and ultimately, commercialize our product candidates. Our future financial performance and our ability to develop our product candidates or additional assets will depend, in part, on our ability to effectively manage any future growth or restructuring, as the case may be.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may become involved in litigation, including securities class action litigation, that could divert management&#8217;s attention and harm the Company&#8217;s business, and insurance coverage may not be sufficient to cover all costs and damages.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the past, litigation, including securities class action litigation, has often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic transaction, or the announcement of negative events, such as negative results from clinical trials. These events may also result in investigations by the SEC or other governmental agencies. We may be exposed to such litigation even if no wrongdoing occurred. Litigation is usually expensive and diverts management&#8217;s attention and resources, which could adversely affect our business and cash resources and our ability to consummate a potential strategic transaction or the ultimate value our stockholders receive in any such transaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO OUR BUSINESS</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We received a Delisting Determination from Nasdaq. Delisting could prevent us from maintaining an active, liquid and orderly trading market for our common stock and may materially and adversely impact our ability to consummate certain strategic transactions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if we are delisted from the Nasdaq Capital Market or if we are unable to transfer our listing to another stock market. On January 4, 2023, we were notified by The Nasdaq Stock Market LLC, or Nasdaq, that we were in breach of Listing Rule 5450(a)(1), or the Minimum Bid Price Rule, for continued listing on the Nasdaq Global Select Market because the minimum bid price of our listed securities for 30 consecutive business days had been less than $1 per share. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), or the Compliance Period Rule, we were provided a period of 180 calendar days, or until July 3, 2023, or the Compliance Date, to regain compliance with the Bid Price Requirement. On June 22, 2023, we applied to transfer our listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, or the Transfer. On July 5, 2023, Nasdaq notified us that the Transfer was approved, and that, in connection with the Transfer, we were eligible for an additional 180 calendar day period, or until January 2, 2024, or the Extended Compliance Date, to regain compliance with the Minimum Bid Price Rule.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 8, 2023, we received the Delisting Determination notifying us that, because the closing bid price for our common stock was below $0.10 per share for 10 consecutive trading days during the Extended Compliance Period, the Staff has determined to suspend trading of our common stock on Nasdaq, effective November 17, 2023, and file a Form 25-NSE with the SEC to remove our common stock from listing and registration under the Securities Exchange Act of 1934, as amended, unless we timely request an appeal of the Delisting Determination to the Panel. On November 14, 2023, we timely filed a notice requesting a hearing before the Panel to appeal the Delisting Determination.  A hearing was initially scheduled for February 15, 2024 and subsequently rescheduled to January 25, 2024. Our common stock continued to trade on the Nasdaq Capital Market Exchange, or the Exchange, under the symbol "TCRT" during this time. Following the hearing, on February 5, 2024, the Panel granted our request to continue listing on the Exchange subject to certain conditions until February 15, 2024. These conditions included the completion of the already shareholder approved 1-for-15 reverse stock split and compliance with the Minimum Bid Price Rule for ten consecutive trading days. We were required to provide prompt notification to the Panel of any "significant" events during the exception period.  We executed this reverse stock split on January 31, 2024. On February 16, 2024, we were notified by Nasdaq that we had regained compliance with the Minimum Bid Price Rule. While we are now in compliance, we are now subject to a Mandatory Panel Monitor until February 16, 2025. If we fail to comply with the Minimum Bid Price Rule during this period, we will not be permitted to provide the Staff with a compliance plan and Staff will not be permitted to grant extra time to us to regain compliance. In addition, we would be issued a Delist Determination Letter with the opportunity to request a new hearing with the initial Panel, or a newly convened Hearings Panel if the initial Panel is not available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our common stock is delisted by Nasdaq, it could lead to a number of negative implications, including an adverse effect on the price of our common stock, deterring broker-dealers from making a market in or otherwise seeking or generating interest in our common stock, increased volatility in our common stock, reduced liquidity in our common stock, the loss of federal preemption of state securities laws and greater difficulty in obtaining financing. Delisting could also cause a loss of confidence of our customers, collaborators, vendors, suppliers and employees, which could harm our business and future prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our common stock is delisted by Nasdaq, the price of our common stock may decline, and although our common stock may be eligible to trade on the OTC Bulletin Board, another over-the-counter quotation system, or on the pink sheets, an investor may find it more difficult to dispose of their common stock or obtain accurate quotations as to the market value of our common stock. If our common stock is delisted from Nasdaq, trading in our securities may be subject to the SEC&#8217;s &#8220;penny stock&#8221; rules. These &#8220;penny stock&#8221; rules will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our common stock. The additional burdens imposed upon broker-dealers by these requirements may discourage broker-dealers from recommending transactions in our securities, which could severely limit the liquidity of our securities and consequently adversely affect the market price for our securities. Furthermore, if our common stock is delisted, we would expect it to have an adverse impact on our ability to consummate certain strategic alternatives.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, if our common stock is delisted, we would incur additional costs under state blue sky laws in connection with any sales of our securities. These requirements could severely limit the market liquidity of our common stock and the ability of our stockholders to sell our common stock in the secondary market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not have approval by our shareholders for a second reverse stock split of our common stock to enable the Board of Directors to respond to a Panel if we fail to comply with the Minimum Bid Price Rule during the monitor period.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While our stockholders approved a reverse stock split of the issued and outstanding shares of our common stock, our treasury stock, and a proportionate reduction in the shares of our authorized common stock, if needed in the discretion of our Board of Directors to regain compliance with the Minimum Bid Price Rule, at a ratio between the range of 1-for-5 and 1-for-15, inclusive, at any time on or before June 6, 2024, we have already executed this approved stock split to achieve compliance to the November delisting notice.  If we receive a second delisting notice during the monitor period, we have to convene a special shareholder meeting to obtain approval for another reverse stock split.  There is no guarantee that the Panel will grant us an exception to convene such a meeting.  There is no guarantee that the shareholders would approve another reserve stock split.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shareholders may not approve another reverse stock split.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we are able to convene a shareholders meeting within the time allowed by the Panel should we fail to comply with the Minimum Bid Price Rule during the monitor period, there is no guarantee that the shareholders would approve a reverse stock split.  Failure to acquire shareholder approval of a second reverse stock split would negatively effect our ability to regain compliance with the Minimum Bid Price Rule, which would result in our common stock being delisted from the Exchange.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we do get approval and effectuate a second reverse stock split, the trading price of our common stock may not meet the Minimum Bid Price Rule</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we do effect a second reverse stock split, there can be no assurance that the market price per new share of our common stock after the reverse stock split will remain unchanged or increase in proportion to the reduction in the number of old shares of our common stock outstanding before the reverse stock split. Other factors, such as our financial results, market conditions and the market perception of our business may adversely affect the market price of our common stock and there can be no assurance that a reverse stock split, if completed, will result in the intended benefits, that the market price of our common stock will increase in proportion to the reduction in the number of shares of our common stock outstanding before the reverse stock split or that the market price of our common stock will not decrease in the future. If the market price of our common stock does not increase the price per share of our common stock above Nasdaq&#8217;s minimum bid price threshold of $1.00 per share or if the market price of our common stock does not remain above Nasdaq&#8217;s minimum bid price threshold of $1.00 per share, our common stock may still be delisted from Nasdaq. There is also no guarantee that the Panel agrees that implementing a reverse stock split warrants reversing the Staff's delisting determination, regardless of the price at which our common stock would trade following the split.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In light of the recent reverse stock split, or if we implement a second reverse stock split during the monitor period, liquidity of our common stock may be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In light of our recent reverse stock split, or if we have to effect a second reverse stock split to avoid a delisting pursuant to a new Delisting Determination during the monitor period, the liquidity of the shares of our common stock may be affected materially and adversely by any such reverse stock split given the reduced number of shares of common stock that will be outstanding following the reverse stock split, especially if the market price of our common stock does not increase as a result of the reverse stock split.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following any reverse stock split, the resulting market price of our common stock may not attract new investors and may not satisfy the investing requirements of those investors. Although we believe a higher market price of our common stock may help generate greater or broader investor interest, there can be no assurance that the reverse stock split will result in a share price that will attract new investors, including institutional investors. In addition, there can be no assurance that the market price of our common stock will satisfy the investing requirements of those investors. As a result, the trading liquidity of our common stock may not necessarily improve.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may identify material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, which may result in material misstatements of our financial statements or could have a material adverse effect on our business and trading price of our securities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and the rules and regulations of the Nasdaq Capital Market. Pursuant to Section 404 of the Sarbanes-Oxley Act, we are required to perform system and process evaluation and testing of our internal control over financial reporting to allow our management to report on the effectiveness of our internal control over financial reporting. We may also be required to have our independent registered public accounting firm issue an opinion on the effectiveness of our internal control over financial reporting on an annual basis.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have identified material weaknesses in our internal control over financial reporting in the past. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although the material weaknesses identified in the past have been remediated, we cannot assure you that any measures we have taken or may take in the future will be sufficient to avoid potential future material weaknesses. If we are unable to successfully remediate any future material weakness and maintain effective internal controls, we may not have adequate, accurate or timely financial information, and we may be unable to meet our reporting obligations as a public company, including the requirements of the Sarbanes-Oxley Act, we may be unable to accurately</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">report our financial results in future periods, or report them within the timeframes required by the requirements of the SEC, Nasdaq or the Sarbanes-Oxley Act. Failure to comply with the Sarbanes-Oxley Act, when and as applicable, could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in the identification of additional material weaknesses or significant deficiencies, cause us to fail to meet our reporting obligations or result in material misstatements in our financial statements. Furthermore, if we cannot provide reliable financial reports or prevent fraud, our business, financial condition, results of operations, cash flows and prospects could be materially harmed and investors could lose confidence in our reported financial information.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The development and commercialization of non-viral adoptive TCR-T cell therapies could be considered a new approach to cancer treatment, the successful development of which is subject to significant challenges.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have employed technologies such as the technology licensed from MD Anderson pursuant to the MD Anderson License, described above, from Precigen, pursuant to the A&amp;R License Agreement, and from the NCI, pursuant to the Patent License described above, to pursue the development and commercialization of non-viral cellular therapies based on T-cells and TCRs, targeting solid tumor malignancy. Because this is a new approach to cancer immunotherapy and cancer treatment generally, developing and commercializing product candidates is subject to a number of challenges, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining regulatory approval from the FDA and other regulatory authorities that have very limited experience with the commercial development of genetically modified T-cell therapies for cancer; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">designing and conducting our clinical trials using this new approach or selecting the appropriate TCRs in a way that may lead to optimal results; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identifying and manufacturing appropriate TCRs from either the patient or third parties that can be administered to the patient; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developing and deploying consistent and reliable processes for engineering a patient&#8217;s and/or donor&#8217;s T-cells ex vivo and infusing the T cells back into the patient; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conditioning patients with chemotherapy in conjunction with delivery of the potential products, which may increase the risk of adverse side effects of the chemotherapy itself or of the potential products; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">educating medical personnel regarding the potential side effect profile of each of the potential products, such as the potential adverse side effects related to cytokine release; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">addressing any competing technological and market developments; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developing processes for the safe administration of these potential products, including long-term follow-up for all patients who receive the potential products; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sourcing additional clinical and, if approved, commercial supplies for the materials used to manufacture and process the potential products; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developing a manufacturing process with a cost of goods that allows for an attractive return on investment; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing sales and marketing capabilities after obtaining any regulatory approval to gain market acceptance; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developing therapies for types of cancers beyond those addressed by the current potential products; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining and defending the intellectual property rights relating to any products we develop;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not infringing the intellectual property rights, in particular, the patent rights, of third parties, including competitors, such as those developing T-cell therapies; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unless we revoke the notice to terminate the Patent License or subsequently acquire substantially similar rights, our inability to use the technology currently licensed to us pursuant to the Patent License. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should we resume our clinical programs, we cannot assure you that we will be able to successfully address these challenges, which could prevent us from achieving our research, development and commercialization goals. In addition, these challenges may diminish the value of our assets in the execution of any strategic alternative.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Should we resume development of our product candidates, we will need to recruit, hire and retain qualified personnel.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following our strategic reprioritization in August 2023, we have reduced our workforce by approximately 95</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to date. Our cash conservation activities may yield unintended consequences, such as attrition beyond our planned reduction in workforce and reduced employee morale, which may cause remaining employees and consultants to seek alternative opportunities. The reductions in force included employees responsible for key aspects of our clinical and other development programs.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should we, in the future, resume development of our product candidates, we may not be able to attract or retain qualified management and commercial, scientific, manufacturing and clinical personnel due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. If we are not able to attract and retain necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The recent termination of our licenses and research and development agreement with the National Cancer Institute could significantly limit our ability to resume our clinical trial or begin new ones focused on TCR-T.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have terminated our TCR license with the National Cancer Institute. This will affect our ability to quickly resume TCR-T-based clinical trials as we will need to renegotiate this license or obtain approval from FDA to use TCRs that we validate internally. We may not obtain such approval or be able to validate TCRs internally quickly or at all, significantly hindering our ability to resume our clinical trial.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any termination of our licenses with Precigen or MD Anderson or our research and development agreements with MD Anderson could result in the loss of significant rights and could significantly harm our ability to develop and commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our clinical programs, if resumed, depend on patents, know-how, and proprietary technology that are licensed from others, particularly MD Anderson and Precigen, as well as the contributions by MD Anderson under our research and development agreements. Any termination of these licenses or research and development agreements could result in the loss of significant rights and could harm our ability to develop or monetize our product candidates. Disputes may also arise between us and these licensors regarding intellectual property subject to a license agreement, including those relating to:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of rights granted under the applicable license agreement and other interpretation-related issues; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether and the extent to which our technology and processes, and the technology and processes of Precigen, MD Anderson and our other licensors, infringe intellectual property of the licensor that is not subject to the applicable license agreement;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our right to sublicense patent and other rights to third parties pursuant to our relationships with our licensors and partners; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether we are complying with our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our potential products under the MD Anderson License and the A&amp;R License Agreement; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether or not our partners are complying with all of their obligations to support our programs under licenses and research and development agreements; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the allocation of ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and by us. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements, particularly with MD Anderson and Precigen, on acceptable terms, we may be unable to successfully monetize the affected potential products. On October 27, 2023, we provided the NCI the requisite notice of our intent to terminate the Patent License, effective 60 days from such notice, which is now terminated. If we are unable to acquire the rights from the NCI that we currently have under the Patent License following its termination, on terms acceptable to us or at all, our clinical development programs will be negatively impacted. We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own. If we or our licensors fail to adequately protect this intellectual property, our ability to monetize potential products under our applicable licenses could suffer. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, and reexamination proceedings before the United States Patent and Trademark Office, or USPTO, or oppositions and other comparable proceedings in foreign jurisdictions. Recently, due to changes in U.S. law referred to as patent reform, new procedures including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review and post-grant review have been implemented, which adds uncertainty to the possibility of challenge to our or our licensors&#8217; patents in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to retain the rights licensed to us and Precigen by MD Anderson to technologies relating to TCR-T cell therapies and other related technologies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the MD Anderson License, we, together with Precigen, received an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel TCR-T cell therapies as well as either co-exclusive or non-exclusive licenses under certain related technologies. These proprietary methods and technologies, along with others within Precigen's technology suite and licensed to us by Precigen, may help realize the promise of genetically modified TCR-T cell therapies by controlling cell expansion and activation in the body, minimizing off-target and unwanted on-target effects and toxicity while maximizing therapeutic efficacy. The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term, we and Precigen shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After 10 years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if we and Precigen are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if we and Precigen are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by us or Precigen, if such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both us or Precigen and may be terminated by the mutual written agreement of us, Precigen and MD Anderson.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should we in the future resume development of our product candidates, there can be no assurance that we will be able to successfully perform under the MD Anderson License or regain our terminated rights under the Patent License and if the MD Anderson License is terminated, we may be prevented from achieving our business objectives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Should we resume development of our product candidates, we may not be able to commercialize them, generate significant revenues, or attain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, none of our product candidates have been approved for commercial sale in any country. The process to develop, obtain regulatory approval for, and commercialize potential product candidates is long, complex and costly. Should we resume clinical development, unless and until we receive approval from the FDA and/or other foreign regulatory authorities for our product candidates, we cannot sell our products and will not have product revenues. Even if we should in the future resume development of our product candidates and obtain regulatory approval for one or more of our product candidates, if we are unable to successfully commercialize our products, we may not be able to generate sufficient revenues to achieve or maintain profitability or to continue our business without raising significant additional capital, which may not be available. Our failure to achieve or maintain profitability could negatively impact the trading price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operating history makes it difficult to evaluate our business and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not previously completed any pivotal clinical trials, submitted a BLA or demonstrated an ability to perform the functions necessary for the successful commercialization of any product candidates. If we resume development of our product candidates, successful commercialization of any product candidates will require us to perform a variety of functions, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Continuing to undertake preclinical development and clinical trials; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Participating in regulatory approval processes; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Formulating and manufacturing products; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Conducting sales and marketing activities. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations have been limited to organizing and staffing our company, acquiring, developing and securing our proprietary product candidates and undertaking preclinical and clinical trials of our product candidates. These operations provide a limited basis for you to assess our ability to commercialize our product candidates and the advisability of investing in our securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business subjects us to the risk of liability claims associated with the use of hazardous materials and chemicals.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our contract research and development activities have involved and may in the future involve the controlled use of hazardous materials and chemicals. Although we believe that our safety procedures for using, storing, handling and disposing of these materials complied with federal, state and local laws and regulations, we cannot completely eliminate the risk of accidental injury or contamination from these materials. In the event of such an accident, we could be held liable for any resulting damages, and any liability could have a materially adverse effect on our business, financial condition, results of operations, cash flows and prospects. In addition, the federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous or radioactive materials and waste products may require our contractors to incur substantial compliance costs that could materially adversely affect our business, financial condition, results of operations, cash flows and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The testing and marketing of medical products entail an inherent risk of product liability, and we will face an even greater risk if we commercially sell any medicines that we may develop. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products, if approved. Even a successful defense would require significant financial and management resources. Regardless of the merit or eventual outcome, liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Decreased demand for our product candidates; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Injury to our reputation; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Withdrawal of clinical trial participants; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Initiation of investigations by regulators;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Withdrawal of prior governmental approvals; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs of related litigation; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substantial monetary awards to patients; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product recalls; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Loss of revenue; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The inability to commercialize our product candidates; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A decline in our share price. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we currently carry clinical trial insurance and product liability insurance which we believe to be reasonable, it may not be adequate to cover all liability that we may incur. An inability to renew our policies or to obtain sufficient insurance at an acceptable cost could prevent or inhibit the commercialization of pharmaceutical products that we develop, alone or with collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations, and those of our clinical investigators, contractors and consultants, are based primarily in Houston, Texas. These operations could be subject to power shortages, telecommunications failures, water shortages, hurricanes, floods, earthquakes, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we maintain customary insurance policies that we believe are appropriate. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We relied and, should we in the future resume development of our product candidates, will rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology or loss of data, including any cybersecurity incidents, could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability which could significantly harm our ability to operate our business effectively and adversely affect our business and reputation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of our business, we, our CROs and other third parties on which we rely collected and stored sensitive data, including legally protected patient health information, personally identifiable information about our employees, intellectual property, and proprietary business information. We manage and maintain our applications and data utilizing on-site systems. These applications and data encompass a wide variety of business-critical information including research and development information and business and financial information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy. Despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from cyber-attacks, computer viruses, breaches, unauthorized access, interruptions due to employee error or malfeasance or other disruptions, or damage from natural disasters, terrorism, war and telecommunication and electrical failures. Any such event could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Although we have measures in place that are designed to detect and respond to such security incidents and breaches of privacy and security mandates, we cannot guarantee that those measures will be successful in preventing any such security incident. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, government enforcement actions and regulatory penalties. Such legal claims or proceedings, liability or government enforcement actions may make it more difficult to consummate opportunities presented to us during our search for a strategic alternative. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to resume research, development and commercialization activities, process and prepare Company financial information, manage various general and administrative aspects of our business and damage our reputation, in addition to possibly requiring substantial expenditures of resources to remedy, any of which could adversely affect our business. In addition, there can be no assurance that we will promptly detect any such disruption or security breach, if at all. If the technology supporting our hunTR discovery engine were to experience a cyber-incident resulting in the disclosure or theft of our proprietary screening software or library of TCRs, its value may decrease and our business, or ability to consummate a strategic transaction, may be materially and negatively impacted. While we are not aware of any such material system failure, accident or security breach to date, to the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our search for a strategic alternative negatively impacted.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO THE CLINICAL TESTING, GOVERNMENT REGULATION AND MANUFACTURING OF OUR PRODUCT CANDIDATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Should we resume development of our product candidates, we may encounter difficulties enrolling patients in our clinical trials, and our clinical development activities could be delayed or otherwise materially and adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have experienced, and may in the future experience, difficulties in patient enrollment in our TCR-T Library Phase 1/2 Trial and any future clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to enroll a sufficient number of patients who remain in the clinical trial until its conclusion. The enrollment of patients depends on many factors, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our reputation as a result of halting our ongoing clinical development;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patient eligibility criteria defined in the clinical trial protocol;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The size of the patient population required for analysis of the clinical trial&#8217;s primary endpoints;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The proximity of patients to clinical trial sites;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The number of clinical trial sites;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The design of the clinical trial;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to recruit and retain clinical trial investigators with the appropriate competencies and experience;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to obtain and maintain patient consents;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reporting of the preliminary results of any of our clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patient insurance approvals of trial participation; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk that patients enrolled in clinical trials will drop out of the clinical trials before the manufacturing and infusion of our product candidates or clinical trial completion.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should we resume clinical development, our clinical trials would compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition could reduce the number and types of patients available to us because some of our potential patients may instead opt to enroll in a clinical trial being conducted by one of our competitors. In addition, patients may be unwilling to participate in our studies because of negative publicity from adverse events in the biotechnology industry or for other reasons. Since the number of qualified clinical investigators is limited, we would expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use if we resume development of our product candidates, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and hematopoietic stem cell transplantation, rather than enroll patients in any future clinical trial. Additionally, because our product candidates address patients with relapsed/refractory cancer, the patients are typically in the late stages of their disease and may experience disease progression independent from our product candidates, making them unevaluable for purposes of the clinical trial, which would require additional patient enrollment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delays in completing patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing and planned clinical trials, which could prevent completion or commencement of these clinical trials and adversely affect our ability to advance the development of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates are subject to extensive regulation and compliance, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates, should we resume development.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical development, manufacturing, labeling, packaging, storage, record-keeping, advertising, promotion, import, export, marketing, distribution and adverse event reporting, including the submission of safety and other information, of our product candidates are subject to extensive regulation by the FDA in the United States and by comparable foreign regulatory authorities in foreign markets. The process of obtaining regulatory approval is expensive and often takes many years following the commencement of clinical trials. Approval policies or regulations may change, and the FDA has substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Regulatory approval is never guaranteed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective, or with respect to a biological product candidate, safe, pure and potent, for their intended uses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such authorities may disagree with the design or implementation of our or our collaborators&#8217; clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs or biologics similar to our therapeutic product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We, or any of our collaborators, may be unable to demonstrate that a product candidate is safe and effective, and that the therapeutic product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be unable to demonstrate to the satisfaction of such authorities that our companion diagnostics are suitable to identify appropriate patient populations;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of a BLA, New Drug Application, premarket approval, or PMA, or other submission or to obtain regulatory approval in the United States or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such authorities may disagree regarding the formulation, labeling and/or the specifications of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such authorities may find deficiencies in the manufacturing processes, test procedures and specifications or facilities of our third-party manufacturers with which we or any of our current or future collaborators contract for clinical and commercial supplies;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulations and approval policies of such authorities may significantly change in a manner rendering our or any of our potential future collaborators&#8217; clinical data insufficient for approval; or</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates should we resume clinical development, which would significantly harm our business, financial condition, results of operations, cash flows and prospects. In addition, even if we obtain regulatory approval of our product candidates, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request and may impose significant limitations in the form of narrow indications, warnings, or a Risk Evaluation and Mitigation Strategy, or REMS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Events raising questions about the safety of certain marketed biopharmaceuticals may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new drugs or biologics based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our potential future collaborators from commercializing our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have halted development of our product candidates very early in our development efforts. Our most advanced product candidates were only in an early-stage clinical trial, which is very expensive and time-consuming. We cannot be certain if or when we will be able to submit a BLA to the FDA and the delay, or any failure, in completing clinical trials for our product candidates could significantly harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our most advanced product candidates were in a Phase 1/2 trial when we ceased development activity and will require extensive clinical testing should we resume development. Human clinical trials are very expensive and difficult to design, initiate and implement, in part because they are subject to rigorous regulatory requirements. Failure can occur at any stage of a clinical trial, and we can encounter problems that cause us to delay the start of, abandon or repeat clinical trials. Some factors which may lead to a delay in the commencement or completion of our clinical trials, if resumed, include: requests for additional nonclinical data from regulators, unforeseen safety issues, dosing issues, lack of effectiveness during clinical trials, difficulty recruiting or monitoring patients, or difficulty manufacturing clinical products, among other factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As they enter later stages of development, product candidates generally will become subject to more stringent regulatory requirements, including the FDA&#8217;s requirements for chemistry, manufacturing and controls for product candidates entering Phase 3 clinical trials. There is no guarantee the FDA will allow us or any potential licensee to commence Phase 3 clinical trials for product candidates studied in earlier clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA does not allow our product candidates to enter later stage clinical trials or requires changes to the formulation or manufacture of our product candidates before commencing Phase 3 clinical trials, the ability to further develop, or seek approval for, such product candidates may be materially impacted. As such, if we resume clinical development of our product candidates, we cannot predict with any certainty if or when we might submit a BLA for regulatory approval of our product candidates or whether such a BLA will be accepted. Because we do not anticipate generating significant revenues unless and until we submit one or more BLAs and thereafter obtain requisite FDA approvals, the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">timing of our BLA submissions and FDA determinations regarding approval thereof will directly affect if and when we are able to generate significant revenues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we have halted development of our product candidates. There is an additive degree of risk to any development program that is paused because the time to restart the program and the associated expense may be longer and more costly than previously anticipated. It may also not be possible to restart the program altogether.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any potential marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As with many pharmaceutical and biological products, treatment with our product candidates, if resumed, may produce undesirable side effects or adverse reactions or events, including potential adverse side effects related to cytokine release. If our product candidates or similar products or product candidates under development by third parties demonstrate unacceptable adverse events, we may be required to halt or delay further clinical development of our product candidates, should we resume it. The FDA or foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. If a serious adverse event were to occur in a trial, the FDA may place a hold on the clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The product-related side effects could affect patient recruitment or the ability of enrolled patients to resume and complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately or timely recognized or managed by the treating medical staff, particularly outside of the institutions that collaborate with us, as toxicities resulting from our novel technologies may not be normally encountered in the general patient population and by medical personnel. Should we resume product development or begin commercialization, we expect to have to train medical personnel using our product candidates to understand their side effect profiles. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in adverse effects to patients, including death. Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, including during any long-term follow-up observation period recommended or required for patients who receive treatment using our product candidates, a number of potentially significant negative consequences could result, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may withdraw approvals of such product; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require additional warnings on the product&#8217;s label; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to create a risk evaluation and mitigation strategy plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could be sued and held liable for harm caused to patients; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of the foregoing could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved. Furthermore, any of these occurrences may harm our business, financial condition and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our cellular therapy immuno-oncology product candidates relied on the availability of reagents, specialized equipment and other specialty materials and infrastructure, which may not be available to us on acceptable terms or at all if we resume our clinical trial. For some of these reagents, equipment and materials, we relied or may rely on sole source vendors or a limited number of vendors, which could significantly impair our ability to manufacture and supply our products, should we resume these activities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing our product candidates required many reagents, which are substances used in our manufacturing processes to bring about chemical or biological reactions, and other specialty materials and equipment, some of which are manufactured or supplied by small companies with limited resources and experience to support commercial biologics production. We have depended on a limited number of vendors for certain materials and equipment used in the manufacture of our product candidates, including DNA plasmids, which we used as the vector to insert our TCRs into human T cells. Should we resume product manufacturing, some or all of these suppliers may not have the capacity to support commercial products manufactured under current good manufacturing practices by biopharmaceutical firms or may otherwise be ill-equipped to support our needs, should we resume manufacturing. We also do not have supply contracts with some of these suppliers and may not be able to obtain supply contracts with them on acceptable terms or at all. Accordingly, we may experience significant delays in receiving key materials and equipment to support clinical or commercial manufacturing, should we resume those activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For some of these reagents, equipment, infrastructure, and materials, we may rely on sole source vendors or a limited number of vendors. An inability to source product from any of these suppliers, or source product on commercially reasonable terms, which could be due to, among other things, regulatory actions or requirements affecting the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands, supply chain issues or quality issues, could materially and adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our ability to conduct clinical trials, should we resume them, which could significantly harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, some of the reagents and products used by us may be stored at a single vendor. The loss of materials located at a single vendor, or the failure of such a vendor to manufacture clinical product in accordance with our specifications, would impact our ability to conduct clinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trials and continue the development of our products, should we resume it. Further, manufacturing replacement material may be expensive and require a significant amount of time, which may further impact our clinical programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we resume developing and scaling our manufacturing process, we expect that we will need to obtain additional rights to and supplies of certain materials and equipment to be used as part of that process. We may not be able to maintain rights to such materials on commercially reasonable terms, or at all, and if we are unable to alter our process in a commercially viable manner to avoid the use of such materials or find a suitable substitute, it would have a material adverse effect on our business. Even if we are able to alter our process so as to use other materials or equipment, such a change may lead to a delay in clinical development and/or commercialization plans. If such a change occurs for a product candidate that is already in clinical trials, the change may require us to perform both ex vivo comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have limited experience producing and supplying our product candidates. We may be unable to consistently manufacture our product candidates to the necessary specifications or in quantities necessary to treat patients in clinical trials, should we resume the activities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited experience in biopharmaceutical manufacturing. In 2021, we began manufacturing our product candidates at our in-house current good manufacturing practices, or cGMP, manufacturing facility at our leased headquarters in Houston, Texas. In connection with our exploration of strategic alternatives, we have halted manufacturing of our product candidates and eliminated positions relating to the same. Accordingly, should we elect to in the future, our ability to resume manufacturing our product candidates will depend on our hiring and retaining personnel with the appropriate background and training to staff and operate the facility on a daily basis. Should we be unable to hire or retain these individuals, we may need to train additional personnel to fill the needed roles or engage with external contractors. There are a small number of individuals with experience in cell therapy and the competition for these individuals is high.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Specifically, the operation of a cell-therapy manufacturing facility is a complex endeavor requiring knowledgeable individuals who have successful previous experience in cleanroom environments. Cell therapy facilities, like other biological agent manufacturing facilities, require appropriate commissioning and validation activities to demonstrate that they operate as designed. Additionally, each manufacturing process must be proven through the performance of process validation runs to guarantee that the facility, personnel, equipment, and process work as designed. Although we have developed our own manufacturing processes using an in-house team, there is timing risk associated with increased in-house product manufacture, including as a result of implementing the Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The manufacture of our product candidates is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial production and ensuring the absence of contamination. These include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. It is possible that stability or other issues relating to the manufacture of our product candidates could occur in the future. Before we halted clinical development, we had amended our clinical trial IND to use cryopreservation-based storage of clinical products. This process is new and should we resume clinical development and in-house manufacturing, we may experience manufacturing failures or difficulties producing sufficient quantities of our clinical products as a result of this change.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates have been manufactured on a patient-by-patient basis. Delays in manufacturing could adversely impact the treatment of each patient and may discourage participation in clinical trials should clinical development be resumed. We have not manufactured our clinical trial product candidates on a large scale and may not be able to achieve large scale clinical trial or commercial manufacturing and processing on our own to satisfy expected clinical trial or commercial demands for any of our product candidates, should development resume in the future. The manufacturing processes employed by us may not result in product candidates that will be safe and effective. If we are unable to manufacture sufficient number of TCR-T cells for our product candidates, development efforts would be delayed, which would adversely affect our business and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing operations are subject to review and oversight by the FDA. If we resume manufacturing operations, we will be subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with cGMP and other government regulations. Our license to manufacture product candidates is subject to continued regulatory review.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not yet have sufficient information to reliably estimate the cost of commercial manufacturing and processing of our product candidates. The actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also may fail to manage the logistics of collecting and shipping patient material to our manufacturing site and shipping the product candidate back to the patient. Logistical and shipment delays and problems, whether or not caused by us or our vendors, could prevent or delay the delivery of product candidates to patients, should we resume the trial.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may have difficulty validating our manufacturing process as we manufacture our product candidates from an increasingly diverse patient population for our clinical trials, should we resume these activities.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During our development of the manufacturing process, our TCR-T cell product candidates have demonstrated consistency from lot to lot and from donor to donor. However, our sample size is small and the starting material used during our preclinical development work came from healthy donors. If our development work is continued, we may encounter unforeseen difficulties due to starting with material from donors who are not healthy, including challenges inherent in harvesting white blood cells from unhealthy patients.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we believe our manufacturing process is scalable for clinical development and commercialization, if any of our product candidates are approved or commercialized, we may encounter challenges in validating our process due to the heterogeneity of the product starting material. We cannot guarantee that any other issues relating to the heterogeneity of the starting material will not impact our ability to commercially manufacture our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The gene transfer vectors from our </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> system used to manufacture our product candidates may incorrectly modify the genetic material of a patient&#8217;s T cells, potentially triggering the development of a new cancer or other adverse events.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our TCR-T cells were manufactured using our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> system, a non-viral vector to insert genetic information encoding the TCR construct into the patient&#8217;s T cells. The TCR construct was then primarily integrated at thymine-adenine, or TA, dinucleotide sites throughout the patient&#8217;s genome and, once expressed as protein, is transported to the surface of the patient&#8217;s T cells. Because the gene transfer vector modifies the genetic information of the T cell, there is a theoretical risk that modification will occur in the wrong place in the T cell&#8217;s genetic code, leading to vector-related insertional oncogenesis, and causing the T cell to become cancerous. If the cancerous T cell is then administered to the patient, the cancerous T cell could trigger the development of a new cancer in the patient. We used non-viral vectors to insert genetic information into T cells, which we believe have a lower risk of insertional oncogenesis as opposed to viral vectors. However, the risk of insertional oncogenesis remains a concern for gene therapy, and we cannot assure you that it will not occur in any clinical trials of our product candidates. There is also the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of the vectors used to carry the genetic material. Although our product candidates use non-viral vectors, the FDA has stated that lentiviral vectors possess characteristics that may pose high risks of delayed adverse events. If any such adverse events occur from our non-viral vector, preclinical studies or clinical trials could be halted or delayed, which would have a material adverse effect on our business and operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Should we resume development of our product candidates, any product candidate for which we obtain marketing approval could be subject to post-marketing restrictions or withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include, among other things, submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a REMS, which could include requirements for a restricted distribution system. If any of our product candidates receives marketing approval, the accompanying label may limit the approved uses, which could limit sales of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of our approved products. The FDA closely regulates the post-approval marketing and promotion of products to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. However, companies may share truthful and not misleading information that is otherwise consistent with the labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we market our products outside of their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug and Cosmetic Act relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, later discovery of previously unknown adverse events or other problems with our product candidates, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Litigation involving patients taking our product; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restrictions on such products, manufacturers or manufacturing processes; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restrictions on the labeling or marketing of a product; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restrictions on product distribution or use; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Requirements to conduct post-marketing studies or clinical trials; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warning letters; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Withdrawal of the products from the market; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refusal to approve pending applications or supplements to approved applications that we submit; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recall of products; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fines, restitution or disgorgement of profits or revenues; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Suspension or withdrawal of marketing approvals; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Damage to relationships with existing and potential collaborators; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unfavorable press coverage and damage to our reputation; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refusal to permit the import or export of our products; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product seizure; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Noncompliance with requirements regarding safety monitoring or pharmacovigilance can also result in significant financial penalties. Similarly, failure to comply with U.S. and foreign regulatory requirements regarding the development of products for pediatric populations and the protection of personal health information can also lead to significant penalties and sanctions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO OUR ABILITY TO COMMERCIALIZE OUR PRODUCT CANDIDATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Should we resume development of our product candidates, our inability to obtain the necessary U.S. or worldwide regulatory approvals to commercialize any product candidate would cause our business to suffer significantly.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we resume clinical development, we may not be able to obtain the approvals necessary to commercialize our product candidates, or any product candidate that we may acquire or develop in the future for commercial sale. We will need FDA approval to commercialize our product candidates in the United States and approvals from regulatory authorities in foreign jurisdictions equivalent to the FDA to commercialize our product candidates in those jurisdictions. In order to obtain FDA approval of any product candidate, we must submit to the FDA a BLA demonstrating that the product candidate is safe for humans and effective for its intended use. This demonstration requires significant research and animal tests, which are referred to as preclinical studies, as well as human tests, which are referred to as clinical trials. Satisfaction of the FDA&#8217;s regulatory requirements typically takes many years, depending upon the type, complexity and novelty of the product candidate, and will require substantial resources for research, development and testing. We cannot predict whether our research, development, and clinical approaches will result in products that the FDA will consider safe for humans and effective for their intended uses. The FDA has substantial discretion in the approval process and may require us to conduct additional preclinical studies and clinical trials or to perform post-marketing studies. The approval process may also be delayed by changes in government regulation, future legislation or administrative action or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delay commercialization of, and our ability to derive product revenues from, our product candidates; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Impose costly procedures on us; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diminish any competitive advantages that we may otherwise enjoy. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we comply with all FDA requests, the FDA may ultimately reject one or more of our BLAs. We cannot be sure that we will ever obtain regulatory approval for any of our product candidates even if we should resume development in the future. Failure to obtain FDA approval for our product candidates will severely undermine our business by leaving us without a marketable product, and therefore without any potential revenue source, until another product candidate can be developed. There is no guarantee that we will ever be able to develop or acquire another product candidate or that we will obtain FDA approval if we are able to do so.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In foreign jurisdictions, we similarly must receive approval from applicable regulatory authorities before we can commercialize any of our product candidates. Foreign regulatory approval processes generally include all of the risks associated with the FDA approval procedures described above.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable either to create sales, marketing and distribution capabilities or enter into agreements with third parties to perform these functions, we will be unable to commercialize our product candidates successfully.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently have no marketing, sales, or distribution capabilities. If, and when we become reasonably certain that we will be able to commercialize our product candidates, we anticipate allocating resources to the marketing, sales and distribution of our proposed products in North America and in certain other geographies; however, we cannot assure that we will be able to market, sell, and distribute our products successfully. Our future success also may depend, in part, on our ability to enter into and maintain collaborative relationships for such capabilities and to encourage the collaborator&#8217;s strategic interest in the product candidates under development, and such collaborator&#8217;s ability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to successfully market and sell any such products. Although we intend to pursue certain collaborative arrangements regarding the sale and marketing of certain of our product candidates, there are no assurances that we will be able to establish or maintain collaborative arrangements or, if we are able to do so, whether we would be able to conduct our own sales efforts. There can also be no assurance that we will be able to establish or maintain relationships with third-party collaborators or develop in-house sales and distribution capabilities. To the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the efforts of such third parties, and there can be no assurance that such efforts will be successful. In addition, there can also be no assurance that we will be able to market and sell our product candidates in the United States or overseas.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are not able to partner with a third party and are not successful in recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty commercializing our product candidates, which would harm our business. If we rely on pharmaceutical or biotechnology companies with established distribution systems to market our products, we will need to establish and maintain partnership arrangements, and we may not be able to enter into these arrangements on acceptable terms or at all. To the extent that we enter into co-promotion or other arrangements, any revenues we receive will depend upon the efforts of third parties that may not be successful and that will be only partially in our control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If physicians and patients do not accept and use our product candidates, once approved, our ability to generate revenue from sales of our products will be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if the FDA and/or foreign equivalents thereof approve our product candidates, physicians and patients may not accept and use them. The use of engineered T cells as potential cancer treatments is a relatively recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers, third-party payors and others in the medical community. Acceptance and use of our products will depend upon a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical indications for which our product candidates are approved;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our products; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The prevalence and severity of any side effects;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pharmacological benefit and cost-effectiveness of our products relative to competing products; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Availability of coverage and adequate reimbursement for our products from government or other third-party payors; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effectiveness of marketing and distribution efforts by us and our licensees and distributors, if any; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The price at which we sell our products. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to generate product revenues will be diminished if our products do not obtain coverage and adequate reimbursement from payors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to commercialize our product candidates, if approved, alone or with collaborators, will depend in part on the extent to which coverage and reimbursement will be available from third-party payors, including government and health administration authorities, private health maintenance organizations and health insurers and other payors. Patients who are prescribed medicine for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Sufficient coverage and adequate reimbursement from third-party payors are critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. It is difficult to predict the coverage and reimbursement decisions that will be made by third-party payors for novel gene and cell therapy products such as ours. Even if we obtain coverage for our product candidates, the resulting reimbursement payment rates might not be adequate or may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the market for our product candidates for which we may receive regulatory approval will depend significantly on access to third-party payors&#8217; drug formularies or lists of medications for which third-party payors provide coverage and reimbursement, which might not include all of the FDA-approved drugs for a particular indication. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payors may refuse to include a particular branded drug in their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In addition, in the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">coverage determination process is often a time-consuming and costly process that would require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that approval will be obtained. If we are unable to obtain coverage of and adequate payment levels for our product candidates, if approved, from third-party payors, physicians may limit how much or under what circumstances they will prescribe or administer our products and patients may decline to purchase them. This in turn could affect our ability to successfully commercialize our products and materially and adversely impact our business, financial condition, results of operations, cash flows and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in many foreign countries, particularly the countries of the European Union, or EU, the pricing of prescription drugs is subject to government control. In some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. We may face competition for our product candidates from lower-priced products in foreign countries that have placed price controls on pharmaceutical products. In addition, there may be importation of foreign products that compete with our own products, which could negatively impact our profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cancer therapies are sometimes characterized as first line, second line or third line, and the FDA often approves new therapies initially only for third line use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapy, usually chemotherapy, hormone therapy, surgery, or a combination of these, proves unsuccessful, second line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor targeted small molecules, or a combination of these. Third line therapies can include bone marrow transplantation, antibody and small molecule targeted therapies, more invasive forms of surgery and new technologies. We expect to initially seek approval of our product candidates as a third line therapy for patients who have failed other approved treatments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsequently, for those product candidates that prove to be sufficiently beneficial, if any, we would expect to seek approval as a second line therapy and potentially as a first line therapy, but there is no guarantee that our product candidates, even if approved, would be approved for second line or first line therapy. In addition, we may have to conduct additional clinical trials prior to gaining approval for second line or first line therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our projections of both the number of people who have the cancers we targeted, as well as the subset of people with these cancers in a position to receive therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Our market opportunities may also be limited by competitor treatments that may enter the market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare legislative reform measures may have a material adverse effect on our business, financial condition, results of operations, cash flows and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory enactments in recent years that change the healthcare system in ways that could impact our future ability to sell our product candidates profitably.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, there have been and continue to be a number of initiatives at the federal and state level that seek to reduce healthcare costs. Most significantly, in March 2010, President Obama signed into law the ACA, which included measures that have significantly changed the way healthcare is financed by both governmental and private insurers. The ACA, among other things, imposed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations, added a provision to increase the Medicaid rebate for line extensions or reformulated drugs, established annual fees on manufacturers and importers of certain branded prescription drugs and biologic agents, promoted a new Medicare Part D coverage gap discount program, expanded the entities eligible for discounts under the Public Health Service Act pharmaceutical pricing program and imposed a number of substantial new compliance provisions related to pharmaceutical companies&#8217; interactions with healthcare practitioners. The ACA also expanded eligibility for Medicaid programs and introduced a new Patient Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research and a new Center for Medicare &amp; Medicaid Innovation at CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been executive, legal and political challenges to certain aspects of the ACA. For example, President Trump signed several executive orders and other directives designed to delay, circumvent or loosen certain requirements mandated by the ACA. Concurrently,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Congress considered legislation to repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. In December 2017, Congress repealed the tax penalty, effective January 1, 2019, for an individual&#8217;s failure to maintain ACA-mandated health insurance as part of the Tax Act. Further, President Biden issued an executive order that instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. Further, there have been a number of health reform initiatives by the Biden administration that have impacted the ACA. For example, on August 16, 2022, President Biden signed the IRA into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the "donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and implementing a newly established manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact ACA and our business. The ultimate content, timing or effect of any healthcare reform measures on the U.S. healthcare industry is unclear.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. As a result, there have been several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA also released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 30, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The IRA delayed the implementation of the rule to January 1, 2032. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January 1, 2032. In addition, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate price cap, currently set at 100% of a drug's average manufacturer price for single source and innovator multiple source products, beginning on January 1, 2024. Further, in July 2021, the Biden Administration released an executive order that included multiple provisions aimed at prescription drugs. In response to President Biden's executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug price reform. The plan sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions by HHS. No legislative or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of the budget reconciliation process. Additionally, the IRA, among other things, (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions began to take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be effectuated but is likely to have a significant impact on the pharmaceutical industry. Individual states in the United States also have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or, if we receive regulatory approval, commercialize our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, we could face substantial penalties and our business, financial condition, results of operations, cash flows and prospects could be materially and adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a pharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our business. For example, we could be subject to healthcare fraud and abuse and patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include, among others:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal Anti-Kickback Statute, which regulates our business activities, including our clinical research and relationships with healthcare providers or other entities as well as our future marketing practices, educational programs and pricing policies, and by prohibiting, among other things, soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual or the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal civil and criminal false claims laws, including the False Claims Act, which permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, which created new federal civil and criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HITECH, and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on entities and individuals subject to the law including certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as individuals and entities that perform services for them which involve the use, or disclosure of, individually identifiable health information, known as business associates and their subcontractors that use, disclose or otherwise process individually identifiable health information; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Requirements under the Physician Payments Sunshine Act to report annually to CMS certain financial arrangements with prescribers and teaching hospitals, as defined in the ACA and its implementing regulations, including reporting any &#8220;transfer of value&#8221; made or distributed to teaching hospitals, and physicians, as defined by such law and reporting any ownership and investment interests held by physicians and their immediate family members during the preceding calendar year; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">State and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government that otherwise restricts certain payments that may be made to healthcare providers and entities; state laws that require drug manufacturers to report information related to payments and other transfer of value to physicians and other healthcare providers and entities; state laws that require the reporting of information related to drug pricing; state and local laws that require the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities, including any consulting agreements with physicians who may receive stock or stock options as compensation for their services, could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has further strengthened these laws. For example, the ACA, among other things, amended the intent requirement of the federal Anti-Kickback Statute and certain criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that any of our product candidates is ultimately sold in a foreign country, we may be subject to similar foreign laws and regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Efforts to ensure that our business arrangements comply with applicable healthcare laws involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, exclusion from participation in United States federal or state health care programs, such as Medicare and Medicaid, disgorgement, imprisonment, integrity oversight and reporting obligations, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate our business and our financial results. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security and fraud laws may prove costly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our immuno-oncology product candidates may face competition in the future from biosimilars and/or new technologies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, provides an abbreviated pathway for the approval of follow-on biological products. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product was approved under a BLA. However, there is a risk that the U.S. Congress could amend the BPCIA to significantly shorten</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">this exclusivity period, potentially creating the opportunity for generic competition sooner than anticipated. Further, this data exclusivity does not prevent another company from developing a product that is highly similar to the original branded product, generating its own data and seeking approval. Data exclusivity only assures that another company cannot rely upon the data within the innovator&#8217;s application to support the biosimilar product&#8217;s approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO OUR INTELLECTUAL PROPERTY</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we or our licensors fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of our intellectual property rights would diminish and our ability to successfully develop our product candidates may be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success, competitive position and future revenues will depend in part on our ability and the abilities of our licensors to obtain and maintain patent protection for our products, methods, processes and other technologies, to preserve confidential information, including trade secrets, to prevent third parties from infringing our proprietary rights, and to operate without infringing the proprietary rights of third parties. Our ability to consummate certain strategic transactions, including strategic partnerships or out-licensing opportunities, among others, may also be impaired if we are unable to adequately protect our intellectual property or if we infringe on the proprietary rights of others.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have exclusive rights in the field of cancer treatment to certain U.S. and foreign intellectual property with respect to certain cell therapy and related technologies from MD Anderson as well as with respect to the Precigen technology, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Under the MD Anderson License, future patent applications require the agreement of each of MD Anderson, Precigen and us, and MD Anderson has the right to control the preparation, filing, and prosecution of such patent applications unless the parties agree that we or Precigen instead may control such activities. Although under the License Agreement MD Anderson has agreed to review and incorporate any reasonable comments that we or Precigen may have regarding licensed patents and patent applications, we cannot guarantee that our comments will be solicited or implemented. Under the Patent License with the NCI for certain TCRs, the NCI is responsible for the preparation, filing, prosecution, and maintenance of patent applications and patents licensed to us. Although under the Patent License, the NCI is required to consult with us in the preparation, filing, prosecution, and maintenance of all its patent applications and patents licensed to us, we cannot guarantee that our comments will be solicited or implemented. On October 27, 2023, we provided the NCI the requisite notice of our intent to terminate the Patent License, effective 60 days from such notice. We no longer have any rights to the technology licensed pursuant to the Patent License upon the effectiveness of the termination notice. Under our A&amp;R License Agreement Precigen has the right, but not the obligation, to prepare, file, prosecute, and maintain the patents and patent applications licensed to us and shall bear all related costs incurred by it in regard to those actions. Precigen is required to consult with us and keep us reasonably informed of the status of the patents and patent applications licensed to us, and to confer with us prior to submitting any related filings and correspondence. Although under the A&amp;R License Agreement Precigen has agreed to consider in good faith and consult with us regarding any comments we may have regarding these patents and patent applications, we cannot guarantee that our comments will be solicited or followed. Without direct control of the in-licensed patents and patent applications, we are dependent on MD Anderson or Precigen, as applicable, to keep us advised of prosecution, particularly in foreign jurisdictions where prosecution information may not be publicly available. We anticipate that we and Precigen will file additional patent applications both in the United States and in other jurisdictions. However, we cannot predict or guarantee for either our in-licensed patent portfolios or for Alaunos&#8217; patent portfolio:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When, if at all, any patents will be granted on such applications;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The scope of protection that any patents, if obtained, will afford us against competitors; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">That third parties will not find ways to invalidate and/or circumvent our patents, if obtained; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">That others will not obtain patents claiming subject matter related to or relevant to our product candidates; or </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">That we will not need to initiate litigation and/or administrative proceedings that may be costly whether we win or lose. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost, in a timely manner or at all. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. We may also require the cooperation of our licensors in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of other jurisdictions may not protect our rights to the same extent as the laws of the United States. For example, methods of therapeutic treatment, which are patent-eligible in the United States, may not be claimed in many other jurisdictions; some patent offices (such as the European Patent Office) may permit the redrafting of method of treatment claims into a "medical use" format that is patent-eligible, while other patent offices (such as the Indian Patent Office) may not accept any redrafted claiming format for such claims.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in patent laws or in interpretations of patent laws in the United States and other jurisdictions may diminish the value of our intellectual property or narrow the scope of our patent protection. In September 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">signed into law, resulting in a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. In addition, the United States Supreme Court has ruled on several patent cases in recent years, narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the value of patents, once obtained, and with regard to our ability to obtain patents in the future. As the USPTO continues to implement the Leahy-Smith Act, and as the federal courts have the opportunity to interpret the Leahy-Smith Act, the laws and regulations governing patents, and the rules regarding patent procurement could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain technologies utilized in our research and development programs are already in the public domain. Moreover, a number of our competitors have developed technologies, or filed patent applications or obtained patents on technologies, compositions and methods of use that are relevant to our business and may cover or conflict with our owned or licensed patent applications, technologies or product candidates. Such conflicts could limit the scope of the patents, if any, that we may be able to obtain. Because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases at all, and because publications of discoveries in the scientific literature lag behind actual discoveries per se, neither we nor our licensors can be certain that others have not filed patent applications for technology used by us or covered by our pending patent applications. We cannot know with certainty whether we were the first to make and file for the inventions claimed in our owned patent portfolio, or whether our licensors were the first to make and file for the inventions claimed in our in-licensed patent portfolio. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in the issuance of patents that protect our technology or products, in whole or in part, or that effectively prevent others from commercializing competitive technologies and products. In addition, our own earlier filed patents and applications or those of MD Anderson or Precigen, to the extent not then terminated, may limit the scope of later patents we obtain, if any. If third parties file or have filed patent applications or obtained patents on technologies, compositions and methods of use that are relevant to our business and that cover or conflict with our owned or licensed patent applications, technologies or product candidates, we may be required to challenge such protection, terminate or modify our programs impacted by such protection, or obtain licenses from such third parties, which might not be available on acceptable terms, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if our owned and licensed patent applications were to be issued as patents, they may not issue in a form that would provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity due to our patents being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or even after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our confidential information, our business and competitive position would be significantly harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success also depends upon the skills, knowledge and experience of our scientific and technical personnel, our consultants and advisors, as well as our licensors and contractors. To help protect our proprietary know-how and our inventions for which patents may be unobtainable or difficult to obtain, and to maintain our competitive position, we rely on trade secret protection and confidentiality agreements. To this end, it is our general policy to require our employees, consultants, advisors and contractors to enter into agreements that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business. These agreements may not provide adequate protection for our trade secrets, know-how, confidential information or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such information. Moreover, we may not be able to obtain adequate remedies for any breaches of these agreements. Our trade secrets or other confidential information may also be obtained by third parties by other means, such as breaches of our physical or computer security systems. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret or other confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets or other confidential information were to be lawfully obtained or independently developed by competitors, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets, know-how or other proprietary information is disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly impaired and our business and competitive position would suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third-party claims of intellectual property infringement would require us to spend significant time and money and could prevent us from developing or commercializing our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to protect or enforce patent rights, we may initiate patent infringement litigation against third parties. Similarly, we may be sued by others for patent infringement. We also may become subject to pre- and post-grant proceedings conducted in the USPTO, including interferences, derivations, post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, or reexamination. In other jurisdictions, our patent estate may be subject to pre- and post-grant opposition, nullity, revocation proceedings and the like. Asserting and defending against intellectual property actions are costly and divert technical and management personnel away from their normal responsibilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should we resume development in the future, our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our product candidates without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. While no such litigation has been brought against us and we have not been held by any court to have infringed a third party&#8217;s intellectual property rights, we cannot guarantee that our products or use of our products do not infringe or will not be asserted to infringe third-party patents. It is also possible that we have failed to identify relevant third-party patents or applications, or that as-yet unpublished third-party patent applications will later result in the grant of patents relevant to our business. Another possibility is for a third-party patent or patent application to first contain claims not relevant to our business but then to be reissued or amended in such a way that it does become relevant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research, development and commercialization activities, as well as any product candidates or products resulting from these activities, may infringe or be asserted to infringe patents or patent applications under which we do not hold licenses or other rights. Owning a patent does not confer on the patentee the right to practice the claimed invention and does not protect the patentee from being sued for infringement of another owner&#8217;s patent. Our patent position cannot and does not provide any assurance that we are not infringing or will not be asserted to infringe the patent rights of another.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent landscape in the field of immuno-oncology is particularly complex. We are aware of numerous United States and foreign patents and pending patent applications of third parties directed to compositions, methods of use and methods of manufacture of immuno-oncology products. In addition, there may be patents and patent applications in the field of which we are not aware. The technology we currently license from MD Anderson and Precigen is early-stage technology, and we were in the process of designing and developing products using this technology. Although we sought and, should we resume development activities, will seek to avoid pursuing the development of products that may infringe any third-party patent claims that we believe to be valid and enforceable, we may fail to do so. Moreover, given the breadth and number of claims in patents and pending patent applications in the field of immuno-oncology and the complexities and uncertainties associated with them, third parties may allege that we are infringing patent claims even if we do not believe such claims have merit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a claim for patent infringement is asserted, there can be no assurance that the resolution of the claim would permit us to continue marketing the relevant product on commercially reasonable terms, if at all. We may not have sufficient resources to bring these actions to a successful conclusion. If we do not successfully defend any infringement actions to which we become a party or if we are unable to have any asserted third-party patents declared invalid or unenforceable, we may have to pay substantial monetary damages, which can be tripled if the infringement is deemed willful, and/or we may be required to discontinue or significantly delay commercialization and development of the affected products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any legal action against us or our collaborators claiming damages and seeking to enjoin developmental or marketing activities relating to affected products could, in addition to subjecting us to potential liability for damages, require us or our collaborators to obtain licenses to continue to develop, manufacture or market the affected products. Such licenses may not be available to us on commercially reasonable terms, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An adverse determination in a proceeding involving our owned or licensed intellectual property may allow entry in the market of substitutes, including biosimilar or generic substitutes, for our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Annuities and other similar fees must be paid to the respective patent authority to maintain patents (or patents and patent applications) in most jurisdictions worldwide. Further, patent authorities in jurisdictions worldwide require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to submit documents with the necessary formal requirements, such as notarization and legalization. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We license rights to products and technology that are important to our business, and we expect to enter into additional licenses in the future. For instance, we have in-licensed patents and patent applications under the MD Anderson License and the License Agreement. Under these agreements, we are subject to a range of obligations pertaining to commercialization and development, sublicensing, royalty, patent prosecution and maintenance, and insurance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any failure by us to obtain a needed license, comply with any of these obligations or any other breach by us of our license agreements could give the licensor the right to terminate the license in whole, terminate the exclusive nature of the license or bring a claim against us for damages. Any such termination or claim could have a material adverse effect on our business, financial condition, results of operations, cash flows and prospects. Even if we contest any such termination or claim and are ultimately successful, such dispute could lead to delays in the development or commercialization of potential products and result in time-consuming and expensive litigation or arbitration. On termination we may be required to license to the licensor any related intellectual property that we developed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in certain cases, the rights licensed to us are rights of a third party licensed to our licensor. In such instances, if our licensors do not comply with their obligations under such licenses, our rights under our license agreements with our licensor may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the licensing or acquisition of third-party intellectual property rights is a highly competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, cash flows and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property or claiming ownership of what we regard as our own intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our employees were previously employed at universities or at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OTHER RISKS RELATED TO OUR COMPANY</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our stock price has been, and may continue to be, volatile.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market price for our common stock is volatile and may fluctuate significantly in response to a number of factors, most of which we cannot control, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our decision to pursue a strategic reprioritization;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Price and volume fluctuations in the overall stock market; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in operating results and performance and stock market valuations of other biopharmaceutical companies generally, or those that develop and commercialize cancer drugs in particular; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market conditions or trends in our industry or the economy as a whole; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical studies or clinical trial results, should we resume clinical development; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The commencement, enrollment or results of clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Public statements by third parties like trial participants and clinical investigators regarding clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Public concern as to the safety of drugs developed by us or others; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The financial or operational projections we may provide to the public, any changes in these projections or our failure to meet these projections; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comments by securities analysts or changes in financial estimates or ratings by any securities analysts who follow our common stock, our failure to meet these estimates or failure of those analysts to initiate or maintain coverage of our common stock;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The public&#8217;s response to press releases or other public announcements by us or third parties, including our filings with the SEC, as well as announcements of the status of development of our products, announcements of technological innovations or new therapeutic products by us or our competitors, announcements regarding collaborative agreements and other announcements relating to product development, litigation and intellectual property impacting us or our business;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government regulation;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA determinations on the approval of a product candidate BLA submission; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The sustainability of an active trading market for our common stock; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future sales of our common stock by us, our executive officers, directors and significant stockholders; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Announcements of mergers or acquisition transactions; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our inclusion or removal from certain stock indices; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our delisting from Nasdaq;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Developments in patent or other proprietary rights; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in reimbursement policies; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Announcements of medical innovations or new products by our competitors; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Announcements of changes in our senior management or directors; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General economic, industry, political and market conditions, including, but not limited to, the ongoing impact of global economic conditions; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other events or factors, including those resulting from war, incidents of terrorism, natural disasters, pandemics or responses to these events; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in accounting principles.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the stock market in general and our stock in particular from time to time experiences significant price and volume fluctuations unrelated to the operating performance of particular companies, which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. Public debt and equity markets, and in particular the Nasdaq Capital Market, have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many biopharmaceutical companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock prices of many biopharmaceutical companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the past, stockholders have instituted securities class action litigation following periods of market volatility. If we were involved in securities litigation, we could incur substantial costs and our resources, and the attention of management could be diverted from our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Public statements made by third parties such as trial participants and clinical investigators about clinical trials without our consent may adversely impact our stock price. We may not be aware of these third-party statements when made, may not be able to respond to these third-party statements and may not be able to defend our business or the public&#8217;s legitimate interests due to restrictions on what we may say about our product candidates, which may cause the price of our stock to fluctuate. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other significant harm to our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions of our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even if doing so would benefit our stockholders. These provisions authorize the issuance of &#8220;blank check&#8221; preferred stock that could be issued by our Board of Directors to increase the number of outstanding shares and hinder a takeover attempt, and limit who may call a special meeting of stockholders. In addition, Section 203 of the Delaware General Corporation Law, or Section 203, generally prohibits a publicly held Delaware corporation from engaging in a business combination with a party that owns at least 15% of its common stock unless the business combination is approved by our Board of Directors before the person acquires the 15% ownership stake or later by its Board of Directors and two-thirds of its stockholders. Section 203 could have the effect of delaying, deferring or preventing a change in control that our stockholders might consider to be in their best interests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have begun exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. If we are approached by a third-party in connection with such process, and our Board of Directors does not believe that a transaction with such party is in the best interest of our stockholders, we may rely on the provisions described above to prevent an acquisition by such party in order to maximize stockholder value. There is no guarantee that we will be able to find a transaction that delivers superior value to our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the exclusive forum for (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders; (iii) any action asserting a claim against us or any of our directors, officers or other employees arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; (iv) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the amended and restated certificate of incorporation or our bylaws; (v) any claim or cause of action as to which the Delaware General Corporation Law confers jurisdiction on the Court of Chancery of the State of Delaware; or (vi) any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because we do not expect to pay dividends, you will not realize any income from an investment in our common stock unless and until you sell your shares at a profit.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never paid dividends on our common stock, and we do not anticipate that we will pay any dividends for the foreseeable future. Accordingly, any return on an investment in us will be realized, if at all, only when you sell shares of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to use net operating loss carryforwards and research tax credits to reduce future tax payments may be limited or restricted.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have generated significant net operating loss carryforwards, or NOLs, and research and development tax credits, or R&amp;D credits, as a result of our incurrence of losses and our conduct of research activities since inception. We generally are able to carry NOLs and R&amp;D credits forward to reduce our tax liability in future years. However, our ability to utilize the NOLs and R&amp;D credits is subject to the rules of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, respectively. Those sections generally restrict the use of NOLs and R&amp;D credits after an &#8220;ownership change.&#8221; An ownership change occurs if, among other things, the stockholders (or specified groups of stockholders) who own or have owned, directly or indirectly, 5% or more of a corporation&#8217;s common stock or are otherwise treated as 5% stockholders under Section 382 of the Code and the U.S. Treasury Department regulations promulgated thereunder increase their aggregate percentage ownership of that corporation&#8217;s stock by more than 50 percentage points over the lowest percentage of the stock owned by these stockholders over the applicable testing period. In the event of an ownership change, Section 382 of the Code imposes an annual limitation on the amount of taxable income a corporation may offset with NOL carry forwards and Section 383 of the Code imposes an annual limitation on the amount of tax a corporation may offset with business credit (including R&amp;D credits) carryforwards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may have experienced an &#8220;ownership change&#8221; within the meaning of Section 382 of the Code in the past and there can be no assurance that we will not experience additional ownership changes in the future. As a result, our NOLs and business credits (including R&amp;D credits) may be subject to limitations, and we may be required to pay taxes earlier and in larger amounts than would be the case if our NOLs or R&amp;D credits were freely usable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities and/or industry analysts fail to continue publishing research about our business, if they change their recommendations adversely or if our business, financial condition, results of operations, cash flows or prospects do not meet their expectations, our stock price and trading volume could significantly decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of these analysts cease coverage of our Company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. In addition, it is likely that in some future period our operating results will be below the expectations of securities analysts or investors. If one or more of the analysts who cover us downgrade our stock, or if our business, financial condition, results of operations, cash flows or prospects do not meet their expectations, our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">stock price could significantly decline. If our common stock is delisted by Nasdaq, the impact of analysts ceasing to cover our securities may negatively impact the price of our common stock more dramatically.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business could be materially and negatively affected as a result of the actions of activist stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2021, we were engaged in a consent solicitation led by WaterMill Asset Management Corp., or WaterMill, where three new directors were added to our Board of Directors. We could experience other stockholder activism in the future, including another consent solicitation or a proxy contest. Activist stockholders may advocate for certain governance and strategic changes at our company. In the event of stockholder activism, particularly with respect to matters which our Board of Directors, in exercising their fiduciary duties, disagree with or have determined not to pursue, our business could be adversely affected because responding to actions by activist stockholders can be costly and time-consuming, disrupting our operations and diverting the attention of management, and perceived uncertainties as to our future direction may result in the loss of potential business opportunities and may make it more difficult to attract and retain qualified personnel, business partners, and customers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if faced with a consent solicitation or proxy contest, we may not be able to respond successfully to the contest or dispute, which would be disruptive to our business. If individuals are elected to our Board of Directors with a differing agenda, our ability to effectively and timely implement our strategic plan and create additional value for our stockholders may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our Board of Directors elects to pursue a strategic alternative requiring a stockholder vote, activists may pursue a campaign against the transaction and as a result may make consummating the transaction more difficult, or impossible, despite the Board of Directors' conclusions that such transaction is in the best interest of our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The exercise of outstanding warrants, and issuance of equity awards may have a dilutive effect on our stock, and materially and negatively impact the price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had warrants for 1,452,394 shares of our common stock outstanding at a weighted average exercise price of $86.33 per share. We are able to grant stock options, restricted stock, restricted stock units, stock appreciation rights, bonus stocks, and performance awards under our 2020 Equity Incentive Plan. As of December 31, 2023, under the 2020 Equity Incentive Plan and the 2012 Equity Incentive Plan, 465,895 shares were issuable upon the exercise of outstanding options at a weighted average exercise price of $25.31 per share.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our principal stockholders, executive officers and directors have substantial control over the Company, which may prevent you and other stockholders from influencing significant corporate decisions and may significantly harm the market price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our executive officers, directors and holders of five percent or more of our outstanding common stock beneficially owned, in the aggregate, 14.0% of our outstanding common stock. These stockholders may have interests that conflict with our other stockholders and, if acting together, have the ability to influence the outcome of matters submitted to our stockholders for approval, including the election and removal of directors and any merger, consolidation or sale of all or substantially all of our assets. Accordingly, this concentration of ownership may harm the market price of our common stock by:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delaying, deferring or preventing a change in control; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Impeding a merger, consolidation, takeover or other business combination involving us; or </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, this significant concentration of stock ownership may adversely affect the trading price of our common stock should investors perceive disadvantages in owning shares of common stock in a company that has such concentrated ownership.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are considered a &#8220;smaller reporting company&#8221; under Rule 12b-2 of the Exchange Act. We are therefore entitled to rely on certain reduced disclosure requirements, such as an exemption from providing selected financial data and executive compensation information. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company also mean our auditors are not required to review our internal control over financial reporting and may make it harder for investors to analyze our business, financial condition, results of operations, cash flows and prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our common stock prices may be more volatile. We will remain a smaller reporting company until our public float exceeds $250 million as of the last business day of our most recently completed second quarter if our annual revenues are $100 million or more as of our most recently completed fiscal year, or until our public float exceeds $700 million as of the last business day of our most recently completed second quarter if our annual revenues are less than $100 million as of our most recently completed fiscal year.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 1B. Unresolved Staff Comments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 1C. Cyber</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">security</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cybersecurity Program</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have implemented a cybersecurity program to support both the effectiveness of our systems and our preparedness for information security risks. This program includes a number of safeguards, such as: password protection; multi-factor authentication; monitoring and alerting systems for internal and external threats; and regular evaluations of our cybersecurity program.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use a risk-based approach with respect to our use and oversight of third-party service providers, tailoring processes according to the nature and sensitivity of the data accessed, processed, or stored by such third-party service provider. We also seek to include appropriate security terms in our contracts, where applicable as part of our oversight of third-party providers.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Process for Assessing, Identifying and Managing Material Risks from Cybersecurity Threats</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain an incident response program. In the event of a cybersecurity incident, designated personnel are responsible for assessing the severity of an incident and associated threat, containing the threat, remediating the threat, including recovery of data and access to systems, analyzing any reporting obligations associated with the incident, and performing post-incident analysis and program enhancements. We maintain an Incident Response Plan, which includes an Incident Response Process in the event of a significant cybersecurity incident. In the event of a significant cybersecurity incident, our head of administration will chair an incident response team to handle the incident. Such incident response team will include members of IT, finance (if applicable), legal, communications, human resources and any affected unit or department.  IT, along with a designated forensic team, will use the Incident Response Process to guide the response.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Governance</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management Oversight</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The controls and processes employed to assess, identify and manage material risks from cybersecurity threats are implemented and overseen by head of administration and our managed service provider. Our head of administration has over four years of experience addressing cybersecurity risks. Our head of administration is responsible for the day-to-day management of the cybersecurity program, including the prevention, detection, investigation, response to, and recovery from cybersecurity threats and incidents, and is regularly engaged to help ensure the cybersecurity program functions effectively in the face of evolving cybersecurity threats. Our head of administration oversees the Incident Response Plan and briefs our board of directors on cybersecurity matters, including the nature and design of our cybersecurity program, and threats, events, and program enhancements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board Oversight</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In its oversight role, our Board of Directors is expected to specifically consider risks, including with respect to privacy, information technology and cybersecurity and threats to technology infrastructure.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On a regular basis, the head of administration reports to our Board of Directors on cybersecurity matters, including key risks, the potential impact of those exposures on our business, financial condition, results of operations, cash flows and prospects, and the programs and steps implemented by our management team to monitor and mitigate risks.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cybersecurity Risks</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our cybersecurity risk management processes are integrated into our overall approach to risk management. Given our nature and size, we do not have a dedicated enterprise risk function, but our management team regularly considers and evaluates risks. As part of that risk management process, our management team identifies, assesses and evaluates risks impacting our operations, including those risks related to cybersecurity, and raise them for internal discussion, and where it is determined to be appropriate, issues are also raised to our Board of Directors for consideration.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the date of this Annual Report on Form 10-K, we are not aware of any previous cybersecurity incidents that have materially affected our business, financial condition, results of operations, cash flows and prospects or that are reasonably likely to have such a material effect. While we have implemented a cybersecurity program, the techniques used to infiltrate information technology systems continue to evolve. Accordingly, we may not be able to timely detect threats or anticipate and implement adequate security measures. For additional information regarding risks relating to privacy and cybersecurity, see "Item IA&#8212;Risk Factors&#8212;Risks Related to Our Business."</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 2. Properties</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our corporate office is located at 2617 Bissonnet Street, Suite 225, Houston, Texas 77005. We believe that our existing facilities are adequate to meet our current needs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 3. Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, we may periodically become subject to legal proceedings and claims arising in connection with ongoing business activities. The results of litigation and claims cannot be predicted with certainty, and unfavorable resolutions are possible and could materially affect our business, financial condition, results of operations, cash flows and prospects. In addition, regardless of the outcome, litigation could have a material and adverse impact on us because of defense costs, diversion of management resources and other factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have any pending litigation that, separately or in the aggregate, would, in the opinion of management, be reasonably likely to have a material adverse effect on our business, financial condition, results of operations, cash flows or prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KBI Biopharma Litigation</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 17, 2023, KBI Biopharma, Inc., or KBI, filed a complaint against us in the District Court of Harris County, Texas, 165th Judicial District, asserting breach of an Amended and Restated Master Services Agreement between us and KBI relating to the development of an autologous gene modified T-cell therapy product, or the KBI Agreement. KBI was primarily seeking unspecified monetary damages in excess of $3.2 million. On May 1, 2023, we filed an answer generally denying all of KBI&#8217;s allegations and asserting affirmative and other defenses as well as counterclaims for breach of the KBI Agreement and conversion. On October 20, 2023, we entered into an agreement with KBI to settle all claims asserted by KBI against us and our counterclaims against KBI at issue in the litigation for $1.0 million. All claims have been dismissed in their entirety with prejudice.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 4. Mine Safety Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="bkmk_106"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Equity, Related Stockholders Matters and Issuer Purchases of Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market for Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock trades on the Nasdaq Capital Market under the symbol &#8220;TCRT.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Record Holders</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 18, 2024, we had approximately 167 holders of record of our common stock, one of which was Cede &amp; Co., a nominee for Depository Trust Company, or DTC. Shares of common stock that are held by financial institutions as nominees for beneficial owners or in &#8220;street name&#8221; are deposited into participant accounts at DTC and are considered to be held of record by Cede &amp; Co. as one stockholder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividends</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid a cash dividend on our common stock and do not anticipate paying any cash dividends in the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unregistered Sales of Securities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We did not sell or issue any equity securities during the three months ended December 31, 2023 that were not registered under the Securities Act.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Repurchases</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no repurchases of our common stock by the Company during the fiscal quarter ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 6. [Reserved]</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="bkmk_19"><span id="item_7_management_discussion_and_analys"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 7. Management's Discussion and Analysis</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> of Financial Condition and Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results, levels of activity, performance or achievements could differ materially from those contained in or implied by any forward-looking statements. Factors that could cause or contribute to these differences include those under &#8220;Risk Factors&#8221; included in Part I, Item 1A and under &#8220;Special Note Regarding Forward-Looking Statements&#8221; or in other parts of this Annual Report on Form 10-K. All share amounts presented in this Item 7 give effect to the 1-for-15 reverse stock split of our outstanding shares of common stock that occurred on January 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have operated as a clinical-stage oncology-focused cell therapy company developing adoptive TCR-T cell therapy, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. We were working to leverage our cancer hotspot mutation TCR library and our proprietary, non-viral Sleeping Beauty gene transfer platform to design and manufacture patient-specific cell therapies that target neoantigens arising from shared tumor-specific mutations in key oncogenic genes, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In collaboration with the MD Anderson Cancer Center, or MD Anderson, we were enrolling and treating patients for a Phase 1/2 clinical trial which was evaluating 12 TCRs reactive to mutated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">from our TCR library for the investigational treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers, which we refer to as our TCR-T Library Phase 1/2 Trial.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not generated any product revenue and have incurred significant net losses in each year since our inception. For the year ended December 31, 2023, we had a net loss of $35.1 million, and as of December 31, 2023, we have incurred approximately $915.8 million of accumulated deficit since our inception in 2003. We expect to continue to incur significant operating expenditures and net losses for the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, we announced a strategic reprioritization of our business and wind down of our TCR-T Library Phase 1/2 Trial. In connection with the reprioritization, we have reduced our workforce during the third and fourth quarters of 2023, and we continue working to reduce costs in order to extend our cash runway. We continue to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. We have engaged Cantor Fitzgerald &amp; Co., or Cantor, to act as strategic advisor for this process. In addition, on August 14, 2023, we announced that we had provided the requisite notice to the National Cancer Institute, or the NCI, to terminate the Cooperative Research and Development Agreement, dated January 9, 2017, by and among us, the NCI and Intrexon Corporation, or Intrexon, as amended (such agreement referred to herein as the CRADA), pursuant to its terms, effective October 13, 2023. In addition, on October 27, 2023, we provided notice of termination of the Patent License with the NCI, effective December 26, 2023.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 Developments</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TCR-T Library Phase 1/2 Trial</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eight patients were treated and evaluated in our TCR-T Library Phase 1/2 Trial. Patients with pancreatic (3), colorectal (4) and non-small cell lung cancer (1) were treated, with certain pancreatic and colorectal patients also having lung metastases. Overall, the trial showed our T-cells were generally well-tolerated in all evaluable participants with no dose-limiting toxicities (DLTs) and no immune effector cell-associated neurotoxicity syndrome (ICANS) were observed. All cytokine release syndrome (CRS) events were within grades 1-3 and were self-limiting or resolved with standard clinical management and, in some cases, a single dose of tocilizumab.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One patient with non-small cell lung cancer (NSCLC) achieved an objective partial response with six months progression-free survival. Six other patients achieved a best overall response of stable disease. The total overall response rate was 13% and disease control rate was 87% in evaluable patients with advanced, metastatic, refractory solid tumors (see Figure A). Disease control was measured by objective responses and stable disease. Increased secretion of interferon-gamma relative to baseline was detected in all patients' serum post-cell transfer suggesting recognition of the tumor by the infused TCR-T cells. Persistence of TCR-T cells in peripheral blood was detected in all evaluable patients at their last follow-up, including up to six months in one patient. Infiltration of TCR-T cells into the tumor was also detected in three samples where a fresh biopsy was collected suggesting homing to the tumor microenvironment. All patients have progressed or withdrawn from the trial and long-term follow-up is ongoing for a subset of patients with no further intervention per the treatment protocol. This trial established proof-of-concept that Sleeping Beauty TCR-T cells can result in objective clinical responses and recognize established tumors in vivo.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite the encouraging TCR-T Library Phase 1/2 Trial data, based on the substantial cost to continue development and the current financing environment, we announced in August 2023 that we would not pursue any further development of our clinical programs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">hunTR&#174; Platform</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have discovered multiple proprietary TCRs targeting driver mutations through our hunTR TCR discovery platform. In addition to TCRs that recognize KRAS and TP53 mutations similar to those licensed from the NCI, we identified additional TCRs that bind to other driver</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mutations and TCRs that are restricted to additional HLAs. We believe that the hunTR library has the potential to allow for the treatment of a large patient population.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Strategic Alternatives</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We continue to explore strategic alternatives, which may include but are not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. In connection with the strategic reprioritization, we reduced our workforce by approximately 95% to date in order to streamline the organization and to maximize our cash runway.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nasdaq Delisting Determination</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As previously disclosed on January 4, 2023, we were notified by the Listing Qualifications Department, or the Staff, of The Nasdaq Stock Market LLC, or Nasdaq, that we were in breach of Listing Rule 5450(a)(1), or the Minimum Bid Price Rule, for continued listing on the Nasdaq Global Select Market because the minimum bid price of our listed securities for 30 consecutive business days had been less than $1 per share. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), or the Compliance Period Rule, we were provided a period of 180 calendar days, or until July 3, 2023, or the Compliance Date, to regain compliance with the Bid Price Requirement. On June 22, 2023, we applied to transfer our listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, or the Transfer. On July 5, 2023, Nasdaq notified us that the Transfer was approved, and that, in connection with the Transfer, we were eligible for an additional 180 calendar day period, or until January 2, 2024, or the Extended Compliance Date, to regain compliance with the Minimum Bid Price Rule. On November 8, 2023, we received a Staff Delisting Determination letter, or the Delisting Determination, from the Staff notifying us that, because the closing bid price for our common stock was below $0.10 per share for 10 consecutive trading days during the Extended Compliance Period, the Staff has determined to suspend trading of our common stock on Nasdaq pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii), effective November 17, 2023, and file a Form 25-NSE with the SEC to remove our common stock from listing and registration under the Securities Exchange Act of 1934, as amended, unless we timely request an appeal of the Delisting Determination to a Nasdaq Hearings Panel, or the Panel. We timely requested a hearing before the Panel to appeal the Delisting Determination and were granted a hearing before the Panel on January 25, 2024.  This timely request for a hearing stayed the suspension or delisting of our common stock so our common stock continued to trade on the Nasdaq Capital Market under the symbol &#8220;TCRT&#8221; while the appeal process was pending.  By letter dated February 16, 2024, we were notified by The Nasdaq Stock Market LLC that we regained compliance with the minimum $1.00 bid price requirement, and otherwise satisfied all applicable criteria for continued listing on The Nasdaq Capital Market. As such, the listing matter was closed. Pursuant to Nasdaq Listing Rule 5815(d)(4)(B), we will be subject to a mandatory panel monitor for the one-year period through February 16, 2025.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Overview</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Revenue</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize research and development funding revenue over the estimated period of performance. To date we have not generated product revenue. Unless and until we receive approval from the FDA and/or other regulatory authorities for our product candidates, we cannot sell our products and will not have product revenue.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research and development expenses have historically consisted primarily of salaries and related expenses for personnel, costs of contract manufacturing services, costs of facilities, reagents, and equipment, fees paid to professional service providers in conjunction with our clinical trials, fees paid to contract research organizations, or CROs, in conjunction with clinical trials, fees paid to CROs in conjunction with costs of materials used in research and development, consulting, license and milestone payments, sponsored research fees paid to third parties and impairment charges to prepaid expenses and other current assets.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist primarily of salaries, benefits and stock-based compensation, consulting and professional fees, including patent related costs, general corporate costs and facility costs not otherwise included in research and development expenses or cost of product revenue.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restructuring Costs</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restructuring costs consists of severance provided to terminated employees.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income (Expense)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income (expense) consists primarily of interest expense associated with our amended Loan and Security Agreement (as defined below), interest income on our cash balances and sublease income.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations for the Fiscal Years ended December 31, 2023 and 2022</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.72%;"/>
    <td style="width:1.72%;"/>
    <td style="width:1%;"/>
    <td style="width:12.92%;"/>
    <td style="width:1%;"/>
    <td style="width:1.72%;"/>
    <td style="width:1%;"/>
    <td style="width:12.92%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,922</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,279</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,018</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,219</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,142</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gain on lease modification and termination</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(298</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(133</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restructuring costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,269</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment and right-of-use assets impairment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,803</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,272</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,027</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(34,267</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(35,105</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,921</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,154</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,048</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">529</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(873</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,625</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(35,140</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(37,730</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Revenue</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration revenue during the years ended December 31, 2023 and 2022 were as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.38%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.184000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.184000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:8.944%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.645%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,922</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,917</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration revenue during the year ended December 31, 2023 was $5 thousand compared to $2.9 million during the year ended December 31, 2022. The decrease was primarily due to $2.9 million milestone revenue earned under the Solasia License and Collaboration Agreement for the first commercial sale of darinaparsin, which did not recur in the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses during the years ended December 31, 2023 and 2022 were as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.37%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:8.942%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.662%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,279</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,018</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(8,739</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(35</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses for the year ended December 31, 2023 decreased by $8.7 million when compared to the year ended December 31, 2022 primarily due to lower program expenses of $1.1 million as a result of the wind down of our clinical activities, a $3.0 million decrease in employee-related expenses due to our reduced headcount, an accrual adjustment related to our de-prioritized clinical programs of $1.0 million, a $0.9 million decrease in facilities costs following the termination of our leases, a one-time $2.5 million milestone payment to MD Anderson in 2022 under the terms of our patent and technology license agreement that did not recur in 2023 and a $0.2 million decrease in consulting costs due to the reduced scope of activities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our clinical stage projects included our TCR-T Library Phase 1/2 Trial evaluating TCRs from our library for the investigational treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers, which we are currently in the process of winding down.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses during the years ended December 31, 2023 and 2022 were as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.37%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:8.942%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.662%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,219</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,142</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(923</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(7</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses for the year ended December 31, 2023 decreased by $0.9 million as compared to the year ended December 31, 2022, primarily due to a $1.1 million decrease in employee-related expenses as a result of our reduced headcount and a $0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million decrease in insurance fees, partially offset by a $0.6 million increase in consulting and professional services expenses related to higher legal costs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Gain on lease modification and termination</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gain on lease modification and termination during the years ended December 31, 2023 and 2022 was as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.38%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.184000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.184000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:8.944%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.645%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gain on lease modification and termination</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(298</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(133</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(165</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gain on lease modification and termination during the year ended December 31, 2023 was $0.3 million as compared to $0.1 million during the year ended December 31, 2022. As a result of real estate lease terminations during 2023, the associated lease liabilities and right-of-use assets were remeasured based on the revised lease payments, resulting in a gain of $0.3 million. As a result of a real estate lease modification during 2022, the associated lease liability and right-of-use asset were remeasured based on the revised lease payments, resulting in a gain of $0.1 million.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restructuring costs</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restructuring costs during the years ended December 31, 2023 and 2022 were as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.38%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.184000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.184000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:8.944%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.645%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restructuring costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,269</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,269</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restructuring costs during the year ended December 31, 2023 were $1.3 million as compared to $0 during the year ended December 31, 2022, due to severance expenses for terminated employees related to our strategic reprioritization announced in August 2023.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairments</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Impairments during the years ended December 31, 2023 and 2022 were as follows:</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.04%;"/>
    <td style="width:1.259%;"/>
    <td style="width:1%;"/>
    <td style="width:9.236%;"/>
    <td style="width:1%;"/>
    <td style="width:1.259%;"/>
    <td style="width:1%;"/>
    <td style="width:9.236%;"/>
    <td style="width:1%;"/>
    <td style="width:1.259%;"/>
    <td style="width:1%;"/>
    <td style="width:8.996%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.715%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ccecff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment and right-of-use assets impairment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,803</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,803</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment and right-of-use asset impairments of $4.8 million were recorded during the year ended December 31, 2023, compared to $0 during the year ended December 31, 2022, following the announcement of our strategic reprioritization in August 2023.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income (Expense)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income (expense) during the years ended December 31, 2023 and 2022 was as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.37%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:8.942%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.662%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,921</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,154</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,233</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(39</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,048</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">529</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">519</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(873</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,625</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,752</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(67</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total other expense, net for the year ended December 31, 2023 decreased by $1.8 million as compared to the year ended December 31, 2022 due to lower interest expense associated with our amended Loan and Security Agreement, as defined below, of $1.2 million and increased interest income of $0.5 million recognized during the year ended December 31, 2023 as a result of higher interest rates earned on our cash balances.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sources of Liquidity</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not generated any revenue from product sales. Since inception, we have incurred net losses and negative cash flows from our operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have financed our operations primarily through public offerings of our common stock, private placements of our convertible equity securities, term debt and collaborations. Through December 31, 2023, we have received an aggregate of $729.2 million from issuances of equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, we announced a strategic reprioritization of our business and wind down of our TCR-T Library Phase 1/2 Trial. In connection with the reprioritization, we have reduced our workforce, and we continue working to reduce costs in order to extend our cash runway. We continue to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. We have engaged Cantor to act as strategic advisor for this process.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We follow the guidance of Accounting Standards Codification, or ASC, Topic 205-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Presentation of Financial Statements - Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, in order to determine whether there is substantial doubt about our ability to continue as a going concern for one year after the date our financial statements are issued. Given our current development plans and cash management efforts, we anticipate that our cash resources will be sufficient to fund operations into the third quarter of 2024. Our ability to continue operations after our current cash resources are exhausted depends on our ability to obtain additional financing, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in our focus and direction of our research and development programs, competitive and technical advances, patent developments, regulatory changes or other developments. If adequate additional funds are not available when required, management may need to curtail its development efforts and planned operations to conserve cash.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the current cash forecast, management has determined that our present capital resources will not be sufficient to fund our planned operations for at least one year from the issuance date of the financial statements, which raises substantial doubt as to our ability to continue as a going concern. This forecast of cash resources and planned operations is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 Public Offering</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 29, 2022, we entered into an underwriting agreement, or the Underwriting Agreement, with Cantor Fitzgerald &amp; Co., or the Underwriter, as the sole underwriter, relating to the issuance and sale in an underwritten offering, or the Offering, of 1,615,247 shares of our common stock, or the Firm Shares, to the Underwriter at a price of $9.2865 per share.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our net proceeds from the Offering were $14.7 million (before accounting for the partial exercise of the Underwriter's option as described below) after deducting underwriting discounts and commissions and offering expenses payable by us.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Underwriting Agreement, we granted the Underwriter an option, exercisable for 30 days, to purchase up to an additional 242,287 shares of common stock, or, together with the Firm Shares, the Shares, at the same price per share as the Firm Shares. On January 5, 2023, the Underwriter partially exercised its option to purchase 14,420 shares of common stock.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 Equity Distribution Agreement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 12, 2022, we entered into an Equity Distribution Agreement, or the Equity Distribution Agreement, with Piper Sandler &amp; Co., or Piper Sandler, pursuant to which we can offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $50 million through Piper Sandler as our sales agent in an &#8220;at the market offering.&#8221; Piper Sandler will receive a commission of 3.0% of the gross proceeds of any common stock sold under the Equity Distribution Agreement. During the years ended December 31, 2023 and 2022, there were no sales of our common stock under the Equity Distribution Agreement.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 Loan and Security Agreement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 6, 2021, we entered into a Loan and Security Agreement, or the Loan and Security Agreement, with Silicon Valley Bank, or SVB. The Loan and Security Agreement provided for an initial term loan of $25.0 million funded at the closing, or the Term A Tranche, with an additional tranche of $25.0 million available if certain funding and clinical milestones were met by August 31, 2022. The SVB Facility and related obligations under the Loan and Security Agreement were secured by substantially all of our properties, rights and assets, except for our intellectual property (which was subject to a negative pledge under the Loan and Security Agreement). In addition, the Loan and Security Agreement contained customary representations, warranties, events of default and covenants.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective December 28, 2021, we entered into the First Amendment to the Loan and Security Agreement. Under the terms of the First Amendment, the additional tranche, which remained unfunded, was eliminated, leaving only the Term A Tranche, which is referred to as the SVB Facility. The SVB Facility bore interest at a floating rate per annum on the outstanding loans, payable monthly, at the greater of (a) 7.75% and (b) the current published U.S. prime rate, plus a margin of 4.5%. Commencing on September 1, 2022, aggregate outstanding borrowings became repayable in twelve consecutive, equal monthly installments of principal plus accrued interest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All outstanding obligations under the amended Loan and Security Agreement were due and payable on August 1, 2023. We also owed SVB $1.4 million as a final payment, or the Final Payment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective March 30, 2023, we entered into a Third Amendment to the Loan and Security Agreement, or the Third Amendment. Under the terms of the Third Amendment, we were no longer required to maintain all of our operating accounts, depository accounts and excess cash with SVB, and were instead only required to maintain a single operating or depository account at SVB. The Third Amendment also modified the cash collateralization requirement, such that we were required to cash collateralize the entire sum of the outstanding principal amount of the SVB Facility plus an amount equal to the Final Payment, which amount was to be reduced commensurate with each regularly scheduled monthly payment of principal and interest on the SVB Facility.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 1, 2023, we paid SVB all amounts outstanding under the amended Loan and Security Agreement, comprised of the entire outstanding principal amount under the SVB Facility, all accrued and unpaid interest and the Final Payment. The payment was subject to a prepayment premium of 2.00%.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with our entry into the Loan and Security Agreement in August 2021, we issued to SVB warrants to purchase (i) up to 28,856 shares of our common stock, in the aggregate, and (ii) up to an additional 28,856 shares of Common Stock, in the aggregate, in the event we achieved certain clinical milestones, in each case at an exercise price per share of $33.30. In connection with our entry into the First Amendment in December 2021, we amended and restated the warrants issued to SVB. As amended and restated, the warrants are for up to 43,307 shares of our common stock, in the aggregate, with an exercise price of $17.40 per share, or the SVB Warrants. The SVB Warrants expire on August 6, 2031.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our net increase (decrease) in cash and cash equivalents for the years ended December 31, 2023 and 2022:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by (used in):</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(30,142</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(29,232</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,346</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(193</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(18,138</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,367</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(46,934</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(23,058</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Operating cash flow is derived by adjusting our net loss for:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-cash operating items such as depreciation, amortization, impairment charges, stock-based compensation and reduction in right-of-use assets; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities for the year ended December 31, 2023 was $30.1 million, as compared to $29.2 million for the year ended December 31, 2022. The net cash used in operating activities for the year ended December 31, 2023 was primarily a result of our net loss of $35.1 million, adjusted for $11.3 million of non-cash items such as depreciation, property and equipment and right-of-use assets impairment, stock-based compensation and a decrease in the carrying amount of right-of-use assets, an increase in prepaid expenses of $1.4 million and decreases in accounts payable of $0.8 million, accrued expenses of $4.0 million and lease liabilities of $0.6 million, offset by a decrease in non-current assets of $0.5 million. The net cash used in operating activities for the year ended December 31, 2022 was primarily a result of our net loss of $37.7 million, adjusted for $7.6 million of non-cash items such as depreciation, stock-based compensation and a decrease in the carrying amount of right-of-use assets, a decrease in accounts receivable of $1.1 million and a decrease in prepaid expenses and other assets of $1.0 million, partially offset by a decrease in accrued expenses of $0.7 million and a decrease in lease liabilities of $0.5 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by investing activities was $1.3 million for the year ended December 31, 2023 as compared to net cash used in investing activities of $0.2 million for the year ended December 31, 2022. The increase in net cash provided by investing activities for the year ended December 31, 2023 compared to the year ended December 31, 2022 was primarily due to proceeds from the disposal of property and equipment of $1.5 million, partially offset by purchases of property and equipment of $0.2 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in financing activities was $18.1 million for the year ended December 31, 2023 compared to $6.4 million of net cash provided by financing activities for the year ended December 31, 2022. The increase in net cash used in financing activities for the year ended December 31, 2023 compared to the year ended December 31, 2022 was primarily due to the repayment of long-term debt of $18.1 million and debt extinguishment costs of $0.1 million, partially offset by proceeds from the issuance of common stock of $0.1 million.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The $6.4 million provided by financing activities during the year ended December 31, 2022 related primarily to $14.7 million in net proceeds from the issuance of common stock (before accounting for the partial exercise of the Underwriter's option), offset by $8.3 million of repayments of long-term debt.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating Capital and Capital Expenditure Requirements</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that losses will continue for the foreseeable future. As of December 31, 2023, our accumulated deficit was approximately $915.8 million. Our actual cash requirements may vary materially from those planned because of a number of factors, including changes in the focus, direction and pace of our development programs, including those resulting from the recently announced exploration of strategic alternatives and related workforce reduction.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had approximately $6.1&#8239;million of cash and cash equivalents. In light of our announced strategic reprioritization and concurrent exploration of strategic alternatives, including our decision to halt work on our TCR-T Library Phase 1/2 Trial, our development programs and reducing our workforce, we anticipate our cash resources will be sufficient to fund our operations into the third quarter of 2024. In order to continue our operations beyond our forecasted runway, including, if necessary, to continue to explore strategic alternatives, we will need to raise additional capital, and we have no committed sources of additional capital at this time. The forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of our expenses could vary materially and adversely as a result of a number of factors. We have based our estimates on assumptions that may prove to be wrong, and our expenses could prove to be significantly higher than we currently anticipate. Management does not know whether additional financing will be on terms favorable or acceptable to us when needed, if at all. If adequate additional funds are not available when required, we may be unable to persist as a going concern for sufficient time to identify or execute on any strategic alternatives.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Working capital as of December 31, 2023 was $6.3 million, consisting of $8.3 million in current assets and $2.0 million in current liabilities. Working capital as of December 31, 2022 was $15.7 million, consisting of $39.9 million in current assets and $24.2 million in current liabilities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Leases</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 12, 2019, we entered into a lease agreement for office space in Houston, Texas at MD Anderson through April 2021. On October 15, 2019, we entered into another lease agreement for additional office and laboratory space in Houston through February 2027. On April 7, 2020, we entered into amendments to our existing lease to lease additional office and laboratory space in Houston through February 2027. On December 15, 2020, we entered into another lease in Houston with MD Anderson which provided us additional office and laboratory space through April 2028.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2022, we modified our real estate lease agreement executed on December 15, 2020 with MD Anderson. The modification reduced our leased space from 18,111 square feet to 3,228 square feet. As a result, the associated lease liability and right-of-use asset were remeasured to $0.4 million based on revised lease payments.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2023, we executed an agreement to terminate the lease for our remaining office space in Boston, Massachusetts. Under the terms of the lease termination, we were required to pay a $0.2 million termination fee. Additionally, we have been released from a sub-sublease of certain of our office space in Boston signed in June 2022 as it has been assigned to the Boston office space's landlord in conjunction with the agreement to terminate the lease for the remaining office space.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2023, in accordance with the lease agreement executed on December 15, 2020, we provided notification to the landlord to terminate office space of 3,228 square feet in Houston, Texas. As a result, the associated lease liability and right-of-use asset were remeasured to $19 thousand, reflecting the revised lease payments and term end date of November 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 1, 2023, we and MD Anderson, as landlord, agreed to mutually terminate the leases dated October 15, 2019 and April 7, 2020, which represent office space totaling 14,037 square feet, effective November 15, 2023. As a result, we agreed to make a final payment of $0.1 million to the landlord.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had terminated all operating leases and therefore have no remaining lease commitments, other than a short-term lease.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Royalty and License Fees</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 28, 2019, we entered into the Patent License with the NCI. The terms of the Patent License required us to pay the NCI minimum annual royalties in the amount of $0.3 million, which would be reduced to $0.1 million once the aggregate minimum annual royalties paid by us equaled $1.5 million. For the year ended December 31, 2023, we recognized $0.3 million in royalty payments under the Patent License, and we recognized $0.3 million in royalty payments for the year ended December 31, 2022. As of December 31, 2023, we paid a total of $0.8 million in minimum annual royalty payments under the Patent License.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Patent License, we were also required to make performance-based payments contingent upon the successful completion of clinical and regulatory benchmarks relating to the licensed products. Of such payments, the aggregate potential benchmark payments were $4.3 million, of which aggregate payments of $3.0 million were due only after marketing approval in the United States or in Europe, Japan, Australia, China or India. The first benchmark payment of $0.1 million was due upon the initiation of our TCR-T Library Phase 1/2 Trial. In addition, we were required to pay the NCI one-time benchmark payments following aggregate net sales of licensed products at certain aggregate net sales ranging from $250.0 million to $1.0 billion. The aggregate potential amount of these benchmark payments was $12.0 million. No payments were made during the year ended December 31, 2023, compared to payments of $0.1 million during the year ended December 31, 2022. On October 27, 2023, we provided notice of termination of the Patent License with the NCI, effective December 26, 2023.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 5, 2018, we entered into the License Agreement with PGEN. Under the License Agreement, we are obligated to pay PGEN an annual licensing fee of $0.1 million expected to be paid through the term of the agreement and we have also agreed to reimburse certain historical costs of PGEN up to $1.0 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of the License Agreement, we were responsible for contingent milestone payments totaling up to an additional $52.5 million for each exclusively licensed program upon the initiation of later stage clinical trials and upon the approval of exclusively licensed products in various jurisdictions. In addition, we were also required to pay Precigen tiered royalties ranging from low-single digits to high-single digits on the net sales derived from the sale of any approved IL-12 products and CAR products as well as royalties ranging from low-single digits to mid-single digits on the net sales derived from the sales of any approved TCR products, up to a maximum royalty amount of $100.0 million in the aggregate. We were also required to pay Precigen 20% of any sublicensing income received by us relating to the licensed products. We were also responsible for all development costs associated with each of the licensed products. Precigen was required to pay us royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of Precigen's CAR products, up to a maximum royalty amount of $100.0 million. Pursuant to the A&amp;R License Agreement, all royalty and milestone obligations between us and Precigen have been removed, and annual license payments due to Precigen have been reduced from $100 thousand to $75 thousand. For the years ended December 31, 2023 and 2022, we made licensing fee payments in accordance with the terms of the agreement. We have discovered multiple proprietary TCRs targeting driver mutations through its hunTR TCR discovery platform, including many of the same KRAS and TP53 mutations as were licensed from the NCI.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, Solasia Pharma K. K., or Solasia, announced that darinaparsin had been approved from relapsed or refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare in Japan. During the year ended December 31, 2023, we recorded collaboration revenue of $5 thousand for royalties on sales under the License and Collaboration Agreement, dated March 7, 2011, as amended on July 31, 2014 between Solasia and us, compared to $2.9 million in milestone revenue related to Solasia's achievement of certain sales-based milestones in Japan for the year ended December 31, 2022.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Significant Estimates</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported expenses during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. Actual results may differ materially from these estimates under different assumptions or conditions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe the following are our more significant estimates and judgments used in the preparation of our financial statements:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trial expenses and other research and development expenses;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration agreements;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value measurements of stock-based compensation; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs / Clinical Trial Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel and third-party vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us in arrears for services performed, on a predetermined schedule or when contractual milestones are met; however, a few require advanced payments. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include fees paid to:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CROs in connection with performing research services on our behalf and clinical trials;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">investigative sites or other providers in connection with clinical trials;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">vendors in connection with preclinical and clinical development activities; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">vendors related to product manufacturing, development, and distribution of preclinical and clinical supplies.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CROs that conduct and manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the completion of clinical trial milestones. In accruing service fees, we estimate the time period over</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which services will be performed, enrollment of patients, number of sites activated and the level of effort to be expended in each period. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in changes to our previous estimates, which we considered reasonably reliable at the time. During the year ended December 31, 2023, we recorded an accrual adjustment related to our de-prioritized clinical programs of $1.0 million.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition from Collaboration Agreements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We primarily generate revenue through collaboration arrangements with strategic partners for the development and commercialization of product candidates. Commencing January 1, 2018, we recognized revenue in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASC 606&#8221;). The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods and/or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and/or services. To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize collaboration revenue under certain of our license or collaboration agreements that are within the scope of ASC 606. Our contracts with customers typically include promises related to licenses to intellectual property, research and development services and options to purchase additional goods and/or services. If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. Contracts that include an option to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer&#8217;s election.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The terms of our arrangements with customers typically include the payment of one or more of the following: (i) non-refundable, up-front payment, (ii) development, regulatory and commercial milestone payments, (iii) future options and (iv) royalties on net sales of licensed products. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. We measure the transaction price based on the amount of consideration to which we expect to be entitled in exchange for transferring the promised goods and/or services to the customer. We utilize the most likely amount method to estimate the amount of variable consideration, to predict the amount of consideration to which we will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, we evaluate whether the associated event is considered probable of achievement and estimate the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of us or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, we reevaluate the probability of achievement of each milestone and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, we recognize revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We allocate the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contract to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. We develop assumptions that require the use of judgment to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenue, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, we recognize revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting for Stock-Based Compensation</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation cost is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense over the employee&#8217;s requisite service period. Stock-based compensation expense is based on the number of awards ultimately expected to vest and is reduced for forfeitures as they occur. Consistent with prior years, the Company uses the Black-Scholes option pricing model, which requires estimates of the expected term option holders will retain their options before exercising them and the estimated volatility of the Company&#8217;s common stock price over the expected term.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We review our valuation assumptions periodically and, as a result, we may change our valuation assumptions used to value share-based awards granted in future periods. Such changes may lead to a significant change in the expense we recognize in connection with share-based payments.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our assumptions are estimated as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the fair market value of our common stock is considered the quoted market price on Nasdaq;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the expected volatility is based on the historical stock volatility of our common stock over a sufficient period of time equal to the expected term of the option;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the expected term represents the period that our stock options are expected to be outstanding;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the risk-free interest rate is based on the yields of U.S. Treasury securities with maturities commensurate with the expected term of the award; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we have not paid dividends on our common stock nor do we expect to pay dividends in the foreseeable future.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In preparing our financial statements, we estimate our income tax liability in each of the jurisdictions in which we operate by estimating our actual current tax expense together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred tax assets and liabilities, which, prior to the consideration for the need for a valuation allowance, are included on our balance sheet. Significant management judgment is required in assessing the realizability of our deferred tax assets. In performing this assessment, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial accounting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and the effects of tax planning strategies. Our estimates of future taxable income include, among other items, our estimates of future income tax deductions related to the exercise of stock options. In the event that actual results differ from our estimates, we adjust our estimates in future periods and we may need to establish a valuation allowance, which could materially impact our business, financial condition, results of operations, cash flows and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. We evaluate uncertain tax positions on an annual basis and adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Our liabilities for uncertain tax positions can be relieved only if the contingency becomes legally extinguished through either payment to the taxing authority or the expiration of the statute of limitations, the recognition of the benefits associated with the position meet the &#8220;more-likely-than-not&#8221; threshold or the liability becomes effectively settled through the examination process. We consider matters to be effectively settled once the taxing authority has completed all of its required or expected examination procedures, including all appeals and administrative reviews; we have no plans to appeal or litigate any aspect of the tax position; and we believe that it is highly unlikely that the taxing authority would examine or re-examine the related tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a discussion of new accounting standards, please read Note 3 to the accompanying financial statements, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">included in this report.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="bkmk_20"><span id="item_7a_quantitative_and_qualitative"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 7A. Quantitative and Qualitative</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Disclosures About Market Risk</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, we are not required to provide the information under this Item 7A.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 8. Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> and Supplementary Data</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 8 is contained on pages F-1 through F-25 of this Annual Report and is incorporated herein by reference. All share numbers and share prices presented in this Item 8 have been adjusted to reflect the 1&#8209;for&#8209;15 reverse stock split of the Company&#8217;s common stock effected on January 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_and_disagreements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 9. Changes in and Disagreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> with Accountants on Accounting and Financial Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 9A. Controls and Procedures</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer and our principal accounting officer, we have evaluated the effectiveness of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) or 15d-15(e) promulgated under the Exchange Act, as of December 31, 2023. Based on that evaluation, our principal executive officer and principal financial officer has concluded that as of December 31, 2023, our disclosure controls and procedures were effective.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We note that the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving the stated goals under all potential future conditions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management&#8217;s Report on Internal Control over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive officer and principal financial officer and our principal accounting officer and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the supervision and with the participation of management, including our principal executive officer and principal financial officer and our principal accounting officer, we assessed our internal control over financial reporting as of December 31, 2023, based on criteria for effective internal control over financial reporting established in Internal Control - Integrated Framework (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Our management&#8217;s assessment of the effectiveness of our internal control over financial reporting included testing and evaluating the design and operating effectiveness of our internal controls. In management&#8217;s opinion, we have maintained effective internal control over financial reporting as of December 31, 2023, based on the criteria discussed above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inherent Limitations on Internal Controls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management, including our principal executive officer and principal financial officer, and our principal accounting officer, do not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Controls over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and Rule 15d-15(f) of the Exchange Act) that occurred during the fiscal quarter ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 9B. Other Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Trading Plans</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended December 31, 2023, no director or Section 16 officer of the Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f3947dd5-f476-4cb7-bdd2-1f9ba0596998" contextRef="C_10887a30-fe67-4725-98ec-6def6ef0869d" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_befdf3f8-3000-48b7-9e2d-e7fe761d4ae7" contextRef="C_10887a30-fe67-4725-98ec-6def6ef0869d" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc224997-9be5-457a-8f4f-2518f487b083" contextRef="C_10887a30-fe67-4725-98ec-6def6ef0869d" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_f1364332-7b85-4dd5-80f0-ff67e0ee898e" contextRef="C_10887a30-fe67-4725-98ec-6def6ef0869d" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" as each term is defined in Item 408(a) of Regulation S-K.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 9C. Disclosure Regarding</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Foreign Jurisdictions that Prevent Inspections</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="bkmk_134"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART III</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="bkmk_25"><span id="item_10_directors_executive"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 10. Directors, Executive</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Officers and Corporate Governance</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 10 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2024 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span id="bkmk_26"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 11. Executive Compensation</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 11 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2024 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="bkmk_27"><span id="item_12_security_ownership"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 12. Security Ownership</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> of Certain Beneficial Owners and Management and Related Stockholder Matters</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 12 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2024 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="bkmk_28"><span id="item_13_certain_relationships"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 13. Certain Relationships</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> and Related Transactions, and Director Independence</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 13 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2024 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="bkmk_29"><span id="item_14_principal_accountant"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 14. Principal Accountant</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Fees and Services</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 14 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2024 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:center;" id="bkmk_140"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART IV</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits"><span id="bkmk_30"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 15. Exhibits, Financial Statement Schedules</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(1) Financial Statements:</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Financial Statements required to be filed by Item 8 of this Annual Report, and filed in this Item 15, are as follows:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:87.317%;"/>
    <td style="width:2.02%;"/>
    <td style="width:1.1%;"/>
    <td style="width:8.462%;"/>
    <td style="width:1.1%;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.875pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.025in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.875pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:9pt;vertical-align:top;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="#report_of_independent"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:9pt;vertical-align:top;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Balance Sheets as of December 31, 2023 and 2022</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:9pt;vertical-align:top;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="#statements_of_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Statements of Operations for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:9pt;vertical-align:top;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="#stockholders_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Statements of Changes in Stockholders&#8217; Equity for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:9pt;vertical-align:top;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="#cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Statements of Cash Flows for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:9pt;vertical-align:top;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="#notes_to_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(2) Financial Statement Schedules:</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="bkmk_147"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Schedules are omitted because they are not applicable, or are not required, or because the information is included in the financial statements and notes thereto.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(3) Exhibits:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.269%;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8%;"/>
    <td style="width:2%;"/>
    <td style="width:90%;"/>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Description of Document</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;2.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000112178105000194/exhibit10one.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Agreement and Plan of Merger among the Registrant (formerly &#8220;EasyWeb, Inc.&#8221;), ZIO Acquisition Corp. and ZIOPHARM, Inc., dated August 3, 2005 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Form 8-K, SEC File No. 000-32353, filed August 9, 2005).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017023042486/tcrt-ex3_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Certificate of Incorporation, and all amendments thereto (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Annual Report on Form 10-Q, SEC File No. 001-33038, filed August 14, 2023).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;3.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000114420405029250/v025882_ex3-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Merger dated September 13, 2005, relating to the merger of ZIO Acquisition Corp. with and into ZIOPHARM, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Form 8-K, SEC File No. 000-32353, filed September 19, 2005).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;3.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000114420405029250/ex3-2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Ownership of the Registrant (formerly &#8220;EasyWeb, Inc.&#8221;) dated as of September 14, 2005, relating the merger of ZIOPHARM, Inc. with and into the Registrant, and changing the Registrant&#8217;s corporate name from EasyWeb, Inc. to ZIOPHARM Oncology, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Form 8-K, SEC File No. 000-32353, filed September 19, 2005).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;3.4</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312516640603/d220092dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, as filed with the Delaware Secretary of State on July 1, 2016 (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K/A, SEC File No. 001-33038, filed July 1, 2016).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;3.5</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520250711/d42031dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws of the Registrant, dated as of September 21, 2020 (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, SEC File No. 001-33038, filed September 22, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;4.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000114420405031725/v026661_ex4-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Specimen common stock certificate (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form SB-2, SEC File No. 333-129020, filed October 14, 2005).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;4.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000114420406010771/v038061_ex4-6.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Option for the Purchase of Shares of common stock dated August 30, 2004 and issued to The University of Texas M. D. Anderson Cancer Center (incorporated by reference to Exhibit 4.6 to the Registrant&#8217;s Annual Report on Form 10-KSB, SEC File No. 000-32353, filed March 20, 2006).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;4.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000114420406010771/v038061_ex4-7.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Schedule identifying Material Terms of Options for the Purchase of Shares of Common Stock (incorporated by reference to Exhibit 4.7 to the Registrant&#8217;s Annual Report on Form 10-KSB, SEC File No. 000-32353, filed March 20, 2006).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;4.4</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312518324941/d601714dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K SEC File No. 001-33038 filed November 13, 2018).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;4.5#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520058863/d861766dex47.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Warrant to Purchase Common Stock issued to The University of Texas M. D. Anderson Cancer Center (incorporated by reference to Exhibit 4.7 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 2, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;4.6</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex4_6.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Warrant to Purchase Shares of Common Stock issued to SVB and certain of its Affiliates, dated December 28, 2021 (incorporated by reference to Exhibit 4.6 to the Registrant's Annual Report on Form 10-K, SEC File No. 001-33038, filed March 30, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;4.7</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex4_7.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (incorporated by reference to Exhibit 4.7 to the Registrant's Annual Report on Form 10-K, SEC File No. 001-33038, filed March 30, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.3+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312518281213/d627352dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ZIOPHARM Oncology, Inc. 2012 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K SEC File No. 001-33038 filed September 24, 2018).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8%;"/>
    <td style="width:2%;"/>
    <td style="width:90%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.4+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000114420412036511/v316803_ex10-2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Restricted Stock Agreement Granted Under the ZIOPHARM Oncology, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K SEC File No. 001-33038 filed June 26, 2012).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.5+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000114420412036511/v316803_ex10-3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Option Agreement Granted Under the ZIOPHARM Oncology, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K SEC File No. 001-33038 filed June 26, 2012).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.7+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520136509/d926789dex993.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Inducement Award Grant Notice and Inducement Award Grant Agreement (incorporated by reference to Exhibit 99.3 to the Registrant&#8217;s Registration Statement on Form S-8, SEC File No. 333-238090, filed May 8, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.8+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520184639/d862521dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ZIOPHARM Oncology, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K SEC File No. 001-33038 filed July 1, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.9+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446dex109.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Restricted Stock Agreement Granted Under the ZIOPHARM Oncology, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.9 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 1, 2021 ).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.10+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446dex1010.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Stock Option Agreement Granted Under the ZIOPHARM Oncology, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.10 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 1, 2021 ).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.11+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000114420413005124/v333304_ex99-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnity Agreement for directors and executive officers (incorporated by reference to Exhibit 99.1 to the Registrant&#8217;s Current Report on Form 8-K, SEC File No. 001-33038, filed January 31, 2013).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.16+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521260859/d11000dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated August 24, 2021, by and between the Registrant and Kevin S. Boyle Sr. (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, SEC File No. 001-33038, filed August 30, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.23#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446dex1020.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Retention Bonus Agreement (incorporated by reference to Exhibit 10.20 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 1, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.24#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312515023826/d862579dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">License Agreement by and among the Registrant, Intrexon Corporation and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center dated as of January 13, 2015 (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Current Report on Form 8-K, SEC File No. 001-33038, filed January 28, 2015).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.25&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312518323155/d623821dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exclusive License Agreement by and between the Registrant, Precigen, Inc. and Intrexon Corporation, dated October 5, 2018 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, SEC File No. 001-33038, filed November 9, 2018).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.26#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520286807/d82436dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 1 to the Exclusive License Agreement by and between the Registrant and PGEN Therapeutics, Inc. (formerly known as Precigen, Inc.), dated October 15, 2020 (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q SEC File No. 001-33038, filed November 5, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.27</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017023020088/tcrt-ex10_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Exclusive License Agreement, dated, April 3, 2023, by and between the Registrant and Precigen, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q SEC File No. 001-33038, filed May 10, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.28&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312515117648/d902541dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">License and Collaboration Agreement by and among the Registrant, Intrexon Corporation and Ares Trading S.A. dated as of March 27, 2015 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, SEC File No. 001-33038, filed April 2, 2015).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.29#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312515298126/d40873dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Research and Development Agreement by and among the Registrant, Intrexon Corporation and The University of Texas M.D. Anderson Cancer Center dated as of August 17, 2015 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, SEC File No. 001-33038, filed August 21, 2015).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.30</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312519063978/d678734dex1021.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to the Research and Development Agreement by and among the Registrant, Intrexon Corporation and The University of Texas M.D. Anderson Cancer Center dated as of August 30, 2016 (incorporated by reference to Exhibit 10.21 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 5, 2019).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.31</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312519063978/d678734dex1022.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amendment to the Research and Development Agreement by and among the Registrant, Intrexon Corporation and The University of Texas M.D. Anderson Cancer Center dated as of January 17, 2017 (incorporated by reference to Exhibit 10.21 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 5, 2019).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.32</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312519063978/d678734dex1023.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Amendment to the Research and Development Agreement by and among the Registrant, Intrexon Corporation and The University of Texas M.D. Anderson Cancer Center dated as of November 14, 2017 (incorporated by reference to Exhibit 10.23 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 5, 2019).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.33</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312519287259/d786918dex107.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Fourth Amendment to Research and Development Agreement, dated September 19, 2019 by and among the Registrant, The University of Texas MD Anderson Cancer Center and Precigen, Inc. (incorporated by reference to Exhibit 10.7 to the Registrant&#8217;s Quarterly Report on Form 10-Q, SEC File No. 001-33038, filed November 7, 2019).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.34#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520058863/d861766dex1020.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Fifth Amendment to Research and Development Agreement, dated October 22, 2019 by and among the Registrant and The University of Texas MD Anderson Cancer Center (incorporated by reference to Exhibit 10.20 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 2, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.35#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520058863/d861766dex1021.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2019 Research and Development Agreement, dated October 22, 2019, by and between the Registrant and The University of Texas MD Anderson Cancer Center (incorporated by reference to Exhibit 10.21 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 2, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.36#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312519216056/d777738dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Patent License Agreement, dated as of May 28, 2019, by and between the Registrant and the National Cancer Institute (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Quarterly Report on Form 10-Q, SEC File No. 001-33038, filed August 8, 2019).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8%;"/>
    <td style="width:2%;"/>
    <td style="width:90%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.37#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520058863/d861766dex1023.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to Patent License Agreement, dated as of January 8, 2020, by and between the Registrant and the National Cancer Institute (incorporated by reference to Exhibit 10.23 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 2, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.38#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520286807/d82436dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amendment to Patent License Agreement, dated as of September 28, 2020, by and between the Registrant and the National Cancer Institute (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, SEC File No. 000-33038, filed November 5, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.39#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex10_38.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Amendment to Patent License Agreement, dated as of April 16, 2021, by and between the Registrant and the National Cancer Institute (incorporated by reference to Exhibit 10.38 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 30, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.40#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex10_39.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Fourth Amendment to Patent License Agreement, dated as of May 4, 2021, by and between the Registrant and the National Cancer Institute  (incorporated by reference to Exhibit 10.39 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 30, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.41#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex10_40.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Fifth Amendment to Patent License Agreement, dated as of August 13, 2021, by and between the Registrant and the National Cancer Institute  (incorporated by reference to Exhibit 10.40 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 30, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.42#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312519255309/d608895dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cooperative Research and Development Agreement, dated January 9, 2017, by and among the Registrant, the National Cancer Institute, and Intrexon Corporation (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K SEC File No. 001-33038, filed September 26, 2019).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.43</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312519255309/d608895dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to the Cooperative Research and Development Agreement, dated March 23, 2018, by and among the Registrant, National Cancer Institute, Intrexon Corporation and Precigen, Inc. (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K SEC File No. 001-33038, filed September 26, 2019).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.44#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312519255309/d608895dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amendment to the Cooperative Research and Development Agreement, dated February 1, 2019, by and among the National Cancer Institute, the Registrant and Precigen, Inc. (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K SEC File No. 001-33038, filed September 26, 2019).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.45</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex10_44.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Amendment to the Cooperative Research and Development Agreement, dated March 15, 2022, by and among the National Cancer Institute and the Registrant (incorporated by reference to Exhibit 10.44 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 30, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.46</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017022017225/tcrt-ex10_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Fourth Amendment to the Cooperative Research and Development Agreement, dated June 24, 2022, by and between the National Cancer Institute and the Registrant (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q, SEC File No. 001-33038, filed August 15, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.47</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446dex1039.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease Agreement, dated as of October 15, 2019, by and between the Registrant and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center (incorporated by reference to Exhibit 10.39 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 1, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.48</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446dex1040.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment, dated as of April 7, 2020, to the Lease Agreement, dated as of October 15, 2019, by and between the Registrant and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center (incorporated by reference to Exhibit 10.40 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 1, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.49</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446dex1041.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amendment, dated as of April 7, 2020, to the Lease Agreement, dated as of October 15, 2019, by and between the Registrant and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center (incorporated by reference to Exhibit 10.41 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 1, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.50</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446dex1042.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Amendment, dated as of December 15, 2020, to the Lease Agreement, dated as of October 15, 2019, by and between the Registrant and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center (incorporated by reference to Exhibit 10.42 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 1, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.51</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446dex1043.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease Agreement dated as of December 15, 2020, by and between the Registrant and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center (incorporated by reference to Exhibit 10.43 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 1, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.52</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312521030026/d122203dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Agreement dated February 4, 2021, by and among the Registrant, WaterMill Asset Management Corp. and Robert W. Postma (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, SEC File No. 001-33038, filed February 5, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.53</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017021003463/ziop-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Loan and Security Agreement by and among the Registrant, the lenders party thereto and Silicon Valley Bank, as administrative agent and collateral agent, dated August 6, 2021 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, SEC File No. 001-33038, filed November 8, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.54</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex10_52.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to the Loan and Security Agreement by and among the Registrant, the lenders party thereto and Silicon Valley Bank, as administrative agent and collateral agent, dated December 28, 2021 (incorporated by reference to Exhibit 10.52 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed March 30, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8%;"/>
    <td style="width:2%;"/>
    <td style="width:90%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.55</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017022017225/tcrt-ex10_2.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Equity Distribution Agreement, dated August 12, 2022, by and between Piper Sandler &amp; Co. and the Registrant (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q, SEC File No. 001-33038, filed August 15, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.56</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312522295491/d424988dex11.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Underwriting Agreement, dated as of November 29, 2022, by and between Cantor Fitzgerald &amp; Co. and the Registrant (incorporated by reference to Exhibit 1.1 to the Registrant&#8217;s Current Report on Form 8-K, SEC File No. 001-33038, filed November 30, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.57+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017023063354/tcrt-ex10_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Retention Agreement, dated as of August 14, 2023, between the Registrant and Melinda Lackey (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q, SEC File No. 001-33038, filed November 14, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.58+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000095017023063354/tcrt-ex10_2.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Retention Agreement, dated as of August 14, 2023, between the Registrant and Drew Deniger (incorporated by reference to Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q, SEC File No. 001-33038, filed November 14, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.59+*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="tcrt-ex10_59.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consulting Agreement, dated as of November 14, 2023, between the Registrant and Melinda Lackey.</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.60+*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="tcrt-ex10_60.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Separation Agreement, dated as of December 22, 2023, between the Registrant and Kevin S. Boyle, Sr.</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.61+*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="tcrt-ex10_61.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consulting Agreement, dated as of December 22, 2023, between the Registrant and Kevin S. Boyle, Sr.</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.62+*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="tcrt-ex10_62.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consulting Agreement, dated as of February 21, 2024, between the Registrant and Ferdinand Groenewald.</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;23.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="tcrt-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;31.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="tcrt-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Exchange Act Rule 13a-14(a) or 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;32.1**</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="tcrt-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;97.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="tcrt-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Alaunos Therapeutics, Inc. Clawback Policy.</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File-the cover page interactive data is embedded within the Inline XBRL document or included within the Exhibit 101 attachments</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Filed herewith.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">**</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furnished herewith.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Indicates management contract or compensatory plan.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Confidential treatment has been granted by the Securities and Exchange Commission as to certain portions of this document.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Portions of this document (indicated by &#8220;[***]&#8221;) have been omitted because such information is not material and is the type of information that the Registrant treats as private or confidential.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 16. Form 10-K Summary</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGN</span><span id="power_of_attorney"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATURES</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44%;"/>
    <td style="width:1%;"/>
    <td style="width:3%;"/>
    <td style="width:52%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ALAUNOS THERAPEUTICS, INC.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: April 1, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Dale Curtis Hogue, Jr.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dale Curtis Hogue, Jr.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interim Chief Executive Officer and Director</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Executive Officer and Principal Financial Officer)</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: April 1, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ferdinand Groenewald</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ferdinand Groenewald</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vice President, Finance</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44%;"/>
    <td style="width:1%;"/>
    <td style="width:34%;"/>
    <td style="width:1%;"/>
    <td style="width:20%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Signature</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Dale Curtis Hogue, Jr.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dale Curtis Hogue, Jr.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interim Chief Executive Officer and Director </span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Executive Officer and Principal Financial Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 1, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ferdinand Groenewald</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Ferdinand Groenewald</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vice President, Finance </span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Accounting Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 1, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Robert Hofmeister</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Robert Hofmeister</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 1, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Robert W. Postma</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Robert W. Postma</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 1, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Jaime Vieser</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jaime Vieser</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 1, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Holger Weis</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Holger Weis</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 1, 2024</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:2.32%;font-size:10pt;margin-top:15.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p>
  <p style="margin-left:2.32%;font-size:10pt;margin-top:10.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:center;" id="financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">INDEX TO FINANCIAL STATEMENTS</span></p>
  <p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:2.315%;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:89.144%;"/>
    <td style="width:2.021%;"/>
    <td style="width:1.104%;"/>
    <td style="width:6.626%;"/>
    <td style="width:1.104%;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.875pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.025in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.875pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:9pt;vertical-align:top;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="#report_of_independent"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:9pt;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (</span><span style="font-size:9pt;"><ix:nonNumeric id="F_f9129d74-68fd-41de-8bb6-520fac83be5b" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:AuditorName"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">RSM US LLP</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:9pt;min-width:fit-content;">; </span><span style="font-size:9pt;"><ix:nonNumeric id="F_1505f51a-d1c3-4fbc-a592-db28b0008a49" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:AuditorLocation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Boston, MA</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:9pt;min-width:fit-content;">; PCAOB ID: </span><span style="font-size:9pt;"><ix:nonNumeric id="F_3b406227-7260-4f1e-ab21-16d4379396b8" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">49</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:9pt;min-width:fit-content;">)</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:9pt;vertical-align:top;"><p style="text-indent:-9pt;padding-left:9pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Balance Sheets as of December 31, 2023 and 2022</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:9pt;vertical-align:top;"><p style="text-indent:-9pt;padding-left:9pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="#statements_of_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Statements of Operations for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:9pt;vertical-align:top;"><p style="text-indent:-9pt;padding-left:9pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="#stockholders_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Statements of Changes in Stockholders&#8217; Equity for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:9pt;vertical-align:top;"><p style="text-indent:-9pt;padding-left:9pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="#cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Statements of Cash Flows for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:9pt;vertical-align:top;"><p style="text-indent:-9pt;padding-left:9pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><a href="#notes_to_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;" id="bkmk_180">&#160;</p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:center;" id="bkmk_141"><span id="report_of_independent"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">REPORT OF INDEPENDENT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> REGISTERED PUBLIC ACCOUNTING FIRM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and the Board of Directors of Alaunos Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying balance sheets of Alaunos Therapeutics, Inc.  (the Company) as of December 31, 2023 and 2022, the related statements of operations, stockholders' equity and cash flows for the years then ended, and the related notes to the financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Ability to Continue as a Going Concern</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations since inception and will be required to raise additional capital to fund operations. This raises substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters also are described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Critical Audit Matters</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of this critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accruals for Clinical Trials and Other Research and Development Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">As discussed in Note 3 to the financial statements, the Company accrues costs for clinical trials and other research and development expenses based on estimates of costs incurred through the balance sheet date that have not been invoiced by the clinical research organizations, clinical study sites, consultants, or other vendors. This process involves reviewing open contracts and purchase orders, communicating with vendors and internal personnel to identify services that have been performed, and estimating the level of service performed and the associated costs incurred for the services when the Company has not yet been invoiced or otherwise notified of the actual costs. The Company's accrual for clinical trial expenses totaled $0.6 million at December 31, 2023, as disclosed in Note 6.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We identified the accruals for clinical trials and other research and development expenses to be a critical audit matter because auditing the Company&#8217;s accruals is complex as the information necessary to make an estimate is accumulated from multiple sources and there may be delays in invoicing from clinical study sites and other vendors, or payments may depend on factors such as the completion of clinical trial milestones. Additionally, in certain circumstances, it requires judgment, as the timing and pattern of vendor invoicing may not correspond to the level of services provided.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">How We Addressed the Matter in our Audit</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our audit procedures to test the accruals for clinical trials and preclinical studies expenses included, among others:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We tested the accuracy and completeness of the underlying data used in the estimates and evaluated the reasonableness of assumptions used by management.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We inspected certain contracts with third parties and related information received by the Company to test proper recording of costs incurred to date.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We corroborated the progress of research and development activities through confirmations with certain third parties.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We performed analytical procedures over fluctuations in accrued expenses by department level throughout the year.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We tested subsequent invoices received from third parties and cash disbursements to assess completeness of recorded accruals.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">/s/ RSM US LLP</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company's auditor since 2010.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Boston, Massachusetts</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">April 1, 2024</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="bkmk_188"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">launos Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="bkmk_142"><span id="balance_sheets"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">BALANCE SHEETS</span></p>
  <p style="font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share data)</span></p>
  <p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ASSETS:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba5d5e08-085b-4a40-aa26-a5f55d9a7e4a" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,062</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00977ef4-8f4d-4488-8883-a9732574babe" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,058</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28305217-72c0-411b-96ec-73e754a34a43" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f26b0e5-a3a2-44c5-bea6-f48a314e1f37" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,938</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Receivables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e45513e-d34b-47ae-937d-6d8f0e15c419" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:ReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10ddb40f-2f35-46d7-a7d8-d1375d38a721" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:ReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b400a21-76a1-494c-b186-49c6671e5b07" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,198</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8edd913-0cce-4cae-a783-8da304d55831" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">799</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cef09b50-2028-4bfe-95bf-8d323da28afe" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,261</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa8dd556-7d16-4a9e-a32a-e44eb1ef7f23" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,799</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7a53a3a-df64-4806-97cd-b7ae426b4711" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_490aded0-787d-49c2-b764-8028b336682c" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,460</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8ca5726-846d-496e-b7bd-db4f1fc1552c" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5588d3f3-1c66-4d94-a415-64d76fa0b89d" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,136</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deposits</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_449221ac-b90f-4e65-bb47-3d132b2fbc0e" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:DepositsAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fae5ab64-1176-4998-a4f2-89a68413d64f" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:DepositsAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7691098-840c-4998-b24a-94ae814dc22d" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_252b46d7-cc97-42ba-a80a-b1da7ab2857a" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:50pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:50pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_483c5d77-5ce1-4b07-883b-f38132d5883b" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,263</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dacb71c3-a771-4aae-a37f-71f7bd07ed59" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,937</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">LIABILITIES AND STOCKHOLDERS' EQUITY</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4837e603-55d5-45c8-8faa-74416154601f" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">616</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_813bb7d3-554d-484c-bbfa-014645421a92" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,389</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of long-term debt</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a0d02a2-370d-43b5-a1a5-e52d3b8ddc5f" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0aa0bf11-d508-4345-940b-405a49966a21" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,765</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ae5422d-2117-4492-bc9f-8e5e0950ef44" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,340</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a224fe9-a276-4d28-8a3a-396eab0ef326" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,454</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities, current</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c92552e-5f1c-4f90-97b0-568ad0d5b326" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d303e93-b1d1-49bc-8446-94a2ea56d85b" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">558</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04d8a268-f2e0-4e6e-8936-1492974cf25e" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,956</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85e18570-fd73-4fc7-8daa-ddbd9ef2bfad" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities, non-current</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2351335d-1fe3-4e11-a6c3-d4f6f5c21f97" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5012be5-d125-4a4a-a865-94550e881191" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,188</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e58290ae-af3e-4f60-9897-6b8251d74bdb" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f6e08e6-2a32-414b-a5f4-81e67ff548db" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_757ec81b-cd85-4810-9435-c0c69b1f33c1" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,956</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87f16a0b-9857-4090-82ba-38ad519ec158" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,382</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_15b0f2c7-17af-4d93-a8cb-5eeec14ce40e;"><span style="-sec-ix-hidden:F_51f9a637-4669-4919-8023-57118471f122;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (Note 9)</span></span></span></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders' equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07858731-3d09-4dbf-91e3-d03fb8137b60" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bfe21680-2949-44b3-b695-331d9f356f92" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_301c8352-8566-46a2-82c4-ac73f2dbaec4" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">34,666,667</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_690111d0-0bce-42f9-80d3-df593d986214" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a0ee96ee-86dd-473d-8a05-83d4f96fe581" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,012,522</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2023 and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a40347f9-f198-4ee9-a9db-410f1978cfbf" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">28,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_128dd82e-2c6b-4b78-b7d2-1e3903706b67" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8ef15a32-88af-4b02-86b5-91e5cdb34103" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,027,384</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97a5556f-a03f-4935-bb8f-7fecf921aa52" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94b82d4a-5547-4b90-8e2b-b738c880af96" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c87ba1f0-b136-4c29-8092-27fed7d9a03c" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">922,058</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3f066e8-f6b9-407f-b673-7eb4ae3e3d7d" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">919,166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec3f0a8b-874d-42a7-86df-b5c9435edd63" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">915,767</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8783138b-d369-4978-8863-d14685a9e8ce" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">880,627</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7171e49a-155a-4cfd-b7cb-a957ae1ffd73" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,307</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ce1cb40-a052-40cb-a995-2483806cea80" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,555</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:40pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c14da8e-c9db-486d-8a4f-2e7ac5ddddab" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,263</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3114bb7a-6bd0-40be-9012-94b55aea0513" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,937</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="bkmk_191"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">launos Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="bkmk_143"><span id="statements_of_operations"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">STATEMENTS OF OPERATIONS</span></p>
  <p style="font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share data)</span></p>
  <p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ccaa974d-88d4-4e4e-a025-10e5956cb892" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f5182a2-42f2-4477-93d9-92a28fa0ebbe" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,922</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bd6bb73-c6cc-448e-9406-3fee63ba6774" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,279</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56f7bd13-dfbd-41be-b238-da8225ff7c48" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,018</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e607b17d-d27b-4307-96e5-2e949d44e365" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,219</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_592cf4e0-1265-4599-8eff-2e668b2f7390" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,142</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gain on lease modification and termination</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfe8f009-e07b-4c13-9027-8757da0ea741" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="tcrt:GainLossOnOperatingLeaseModificationAndTermination" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">298</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2689ec2-5222-4347-8cd0-3d9526c24d04" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="tcrt:GainLossOnOperatingLeaseModificationAndTermination" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restructuring costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b6f9d14-b31e-4c71-8f57-a08852729d80" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,269</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6172cb06-2e03-43d5-9da5-efb9c8e5318c" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment and right-of-use assets impairment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_864217d5-ea23-462b-92fb-e4d0dc2d1b3a" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="tcrt:PropertyAndEquipmentAndRightOfUseAssetsImpairment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,803</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe73eb30-6ec8-489c-be41-389739af9e65" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="tcrt:PropertyAndEquipmentAndRightOfUseAssetsImpairment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e02db245-b81c-491f-96ad-53a8dfb3ab3a" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,272</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a51bafb1-2927-4953-8cfb-1b8e44bb94d8" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,027</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c5b1493-026c-4979-8352-c0fe4c98bb90" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">34,267</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_604a6880-314d-4ba1-aecb-c1001720d7e1" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,105</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4c5d1df-6488-4cc7-957a-4aebfa103b8a" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,921</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18f631f6-2ef9-4a2d-b516-b21263f97616" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,154</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4d1d627-790e-4a0b-9b8e-e6d70ca9eace" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,048</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eae22e88-bdc1-4269-913d-3695fa22ce55" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">529</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48a432fa-2f91-49d0-a7ae-3980852c283c" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">873</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c546660-9613-4a7f-9dcf-d1828f7b9af5" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,625</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_826da2a3-f208-482b-9edd-3f5f79cbb596" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,140</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ad9b430-0928-453b-8053-25fd7365ae34" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">37,730</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic and diluted net loss per share</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25dd968d-64cf-4849-9ce0-c6c8a4022dc6" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_85287abe-c784-452a-9e66-443f3defd027" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.20</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c85ddfd4-4604-460a-b678-bf66622b06cf" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8b9f4203-60b7-4808-b221-ba254285ea3c" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.61</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average common shares outstanding, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c4a4ec4-92ae-4302-a61f-9e09c0715e8c" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f0e875eb-3a5b-40f1-9c42-13132d1bbaab" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">15,995,323</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f605a62-ec01-4743-9089-dff614ebddfd" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_eea3525b-1df9-40f4-8680-59266fc124a6" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,475,354</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="bkmk_193"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">launos Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="bkmk_144"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">STATEMENTS OF CHANGES IN </span><span id="stockholders_equity"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">STOCKHOLDERS&#8217; EQUITY</span></p>
  <p style="font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share data)</span></p>
  <p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.42%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.42%;"/>
    <td style="width:1%;"/>
    <td style="width:1.08%;"/>
    <td style="width:1%;"/>
    <td style="width:7.960000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.08%;"/>
    <td style="width:1%;"/>
    <td style="width:7.960000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.08%;"/>
    <td style="width:1%;"/>
    <td style="width:7.960000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.08%;"/>
    <td style="width:1%;"/>
    <td style="width:7.960000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional Paid in Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Stockholders' Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2dae33c0-e428-401a-9b97-44eb15d652ec" contextRef="C_11127a99-f933-4bcc-a852-9e3580fee74e" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,408,496</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11199501-8636-42f1-b468-1807760d6d2c" contextRef="C_11127a99-f933-4bcc-a852-9e3580fee74e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a1c240a-5582-49d3-b0e4-fc04cf8de98b" contextRef="C_2d71e8ff-49c9-42da-a181-17cbc8b8e234" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">900,895</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2689c65-10c3-4c55-8d75-05f6207c2333" contextRef="C_e4e17587-5901-4339-8423-005a5407feac" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">842,852</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4f75342-07c8-45b3-b271-3ee6334c979b" contextRef="C_9e81976f-0dda-4005-94a7-17763001d331" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,057</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f91f1c8c-bee3-4b49-b367-ec9e36d5f50a" contextRef="C_9081085f-fcee-4652-b4bf-4c50be103e98" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,528</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cf698fa-b9c0-4fee-83f6-bee81f239894" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,528</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock awards</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5d50adb-f6c6-40d1-9a6c-f8b4a10ad4f3" contextRef="C_f58e5ef7-a8c3-4cae-b017-bebbe49b3b1d" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,667</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled restricted common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d01c5f2-bf63-4d2f-a0da-2f75778a16dc" contextRef="C_f58e5ef7-a8c3-4cae-b017-bebbe49b3b1d" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,527</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of employee stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93f8ef12-24fc-46a0-9ef9-04f65f72f7ac" contextRef="C_f58e5ef7-a8c3-4cae-b017-bebbe49b3b1d" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,750</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46f65749-08f0-49c4-b6fe-02bada2fc0ff" contextRef="C_9081085f-fcee-4652-b4bf-4c50be103e98" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ba4ceab-5c7a-442d-a8da-587a6799e11b" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchase of common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3f70d09-0ec3-42ba-8614-910883470569" contextRef="C_f58e5ef7-a8c3-4cae-b017-bebbe49b3b1d" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,250</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87adacb3-53b1-4cd7-80cd-dac38a99c042" contextRef="C_9fc04f3c-c57e-4e06-b36c-5fbfcaec5cd3" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e81bfe72-4ba7-43e0-8142-c775bc38f817" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock, net of expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bb77925-e5dd-4e8e-aebd-c93d94543f90" contextRef="C_f58e5ef7-a8c3-4cae-b017-bebbe49b3b1d" name="tcrt:IssuanceOfCommonStockNetOfExpensesInShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,615,248</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d86b8c22-f74c-4e30-9ed4-da788ef1d26e" contextRef="C_f58e5ef7-a8c3-4cae-b017-bebbe49b3b1d" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_447b1517-e010-4a67-ba9c-2ac1359d2d1c" contextRef="C_9081085f-fcee-4652-b4bf-4c50be103e98" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,722</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3304f86-775e-4b3a-9a1c-dd4683691c87" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,724</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ba1e1d5-c34a-4292-a4b9-91ca5effea5b" contextRef="C_9fc04f3c-c57e-4e06-b36c-5fbfcaec5cd3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">37,730</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b86f4fa-54fb-4404-8aa9-b04351eb5750" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">37,730</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4509710-7324-47b4-a9de-729680a65071" contextRef="C_45a84280-5929-4306-93d7-0db1814fb46c" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,027,384</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc421cdb-0ca6-4858-b7ef-ac2b0b64d587" contextRef="C_45a84280-5929-4306-93d7-0db1814fb46c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd1d68b3-96d0-4c50-b701-0d961d837e3b" contextRef="C_698ba229-d584-4d13-99e6-5cd10624b1c9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">919,166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dab0cff6-8eb4-44b7-b50e-ef81ed329a77" contextRef="C_f9a17b33-5bfe-4087-a30f-e86addf030a5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">880,627</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d45bfe97-24ef-4a9a-ad86-f43f0910e4a9" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,555</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af1b4513-8ca3-4be9-b5e4-a4634881f6c4" contextRef="C_8baad0c4-09aa-4617-9aa3-03a23b56ba42" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,800</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbc22a5f-9ee4-4623-8b04-bf20dded6b0c" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,800</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock, net of expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72c73620-b8d1-4f8c-9e57-615e64501246" contextRef="C_82f28128-caf0-440d-b3fe-b4abba328cf5" name="tcrt:IssuanceOfCommonStockNetOfExpensesInShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,420</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24d33993-fed4-44bf-ad85-6f75d9e153f3" contextRef="C_8baad0c4-09aa-4617-9aa3-03a23b56ba42" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98897b9e-8555-4176-953d-74c9663561a6" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled restricted common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_069c53e2-f548-4e8d-8218-dbef1bd3ad44" contextRef="C_82f28128-caf0-440d-b3fe-b4abba328cf5" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">29,282</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a02ed2a0-7bb6-4456-bb3e-33d669b7a73a" contextRef="C_80b02891-b4a1-429e-ab36-34271657c7e4" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,140</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2096364-5e07-48fc-97cb-d8f901620803" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,140</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66a1b560-970f-4b8d-86fe-7eb371d8f978" contextRef="C_0fb6425a-bd51-4ef2-a4fc-01fe4f515d0b" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,012,522</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3e2366e-820e-40ed-a46a-e7201baf2363" contextRef="C_0fb6425a-bd51-4ef2-a4fc-01fe4f515d0b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5ec8c26-c663-4147-b560-e36ed85da9b9" contextRef="C_06432621-89ab-472f-911c-5458e9f57386" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">922,058</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e225e36-bea9-4372-99f6-28f590116a51" contextRef="C_00381981-d3cd-44fe-a13f-32128dadfda9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">915,767</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7dc774eb-c4df-4f63-af50-60052111bd4b" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,307</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:center;" id="bkmk_198"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="bkmk_200"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">launos Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="bkmk_145"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">STATEMENTS OF </span><span id="cash_flows"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">CASH FLOWS</span></p>
  <p style="font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">For the Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41b2bdb9-99ac-40c5-8a38-93e5002d45a1" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,140</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce361cdb-72d1-4dd5-aa31-da5d23f7303d" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">37,730</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07b23bb8-aeb6-4d45-8b11-57374e825039" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,315</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4133daf0-0f9d-4ae7-b5ea-ae945ede5e27" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,759</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment and right-of-use assets impairment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5b4fa56-21b8-47b9-98f1-d90046eba7b7" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,803</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85481f74-b801-40d5-bf3a-c01d85c03e4a" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of financing costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58d59f32-4134-488b-855f-3f490d4fac13" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,339</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c65c42d-ef88-4ab6-91ca-e972013b9116" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">981</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8dbd8d8-c51e-4e5e-9967-a987a55481d4" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,800</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac76f685-5dcb-4942-9478-df35ed868dc4" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,528</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decrease in the carrying amount of right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea170a2e-ff4b-483a-8d91-8ea3058d1cab" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="tcrt:IncreaseDecreaseInRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">286</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a2e9a98-0408-46b9-9b09-ceb2a8f867ef" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="tcrt:IncreaseDecreaseInRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">486</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gain on lease modification and termination</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b50096d2-35cf-421a-ba53-2011b5ae6c49" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:GainLossOnTerminationOfLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">298</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae03b776-ef15-4616-9779-c05e4ae46709" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:GainLossOnTerminationOfLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on sale of equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc892caa-165e-49f2-83a4-e3512d382246" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef066c3e-d675-4331-b1af-2d0e40cc7dd6" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Increase) decrease in:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Receivables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30af23b6-6d67-481a-a083-820b2bda66dd" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:IncreaseDecreaseInReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c035baf-0961-4492-b475-7ed995fb6a58" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:IncreaseDecreaseInReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,107</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_633fc122-820e-435b-8911-5ba776feeb05" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,399</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8e27881-0a32-47cf-9cd9-91b0b6d9b7ac" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">867</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deposits</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8565d9a-d8b8-48f4-aa40-035b6b802560" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="tcrt:IncreaseDecreaseInOperatingDeposits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c29e0d3-f8b6-437e-9ba0-1a6330b5ac46" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="tcrt:IncreaseDecreaseInOperatingDeposits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5390603f-b3b9-4b00-a07b-11cc1e929004" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77770c7f-ab7c-42c8-b736-ddb4ea1c2d71" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">131</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase (decrease) in:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de21a915-01b6-4e4d-8d93-26644ef34100" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">773</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84aa0b19-24b1-42f5-81e2-2fcd45f33d27" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ddb3592-f1a4-4f38-aae4-83e16aaa0414" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,989</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99d58e8f-0949-4af9-8e4f-4bd6b36ccfe7" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">668</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0dce7925-635e-4b44-8a30-4d4d1a4b92a4" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="tcrt:IncreaseDecreaseInLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">610</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af727150-f285-42e7-b041-10f91b153003" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="tcrt:IncreaseDecreaseInLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">570</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6175a2d2-fd17-4995-a7b1-e7e423e91c35" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d577a245-ec6f-4154-8154-e5e5c5ca6283" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:40pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f2604be-9c41-409b-9c96-84a367197acb" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">30,142</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b934134-e3e6-4f56-a260-19d8288c8249" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,232</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82ed1822-5f93-46c5-8fdb-0b92fc63f710" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">197</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0dea074-87b1-4014-8b39-43f0bde22e90" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">216</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from the disposal of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b07be922-b088-4885-9558-4e57d8e7ed56" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,543</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e17ddb73-2ac7-4cb2-a6f0-70147ee23c02" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:40pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fd05f90-882a-42d1-b911-72a2f6b1d83b" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,346</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_288e84b3-7fc6-481e-b918-e9933f9c5ae6" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">193</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from the issuance of common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16637ba1-22fc-4aa0-84a0-b5ab2798702a" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aad7f459-9536-4a7c-a8c3-418532b61ba3" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,724</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from the exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce706446-2c8e-41a4-8933-5bb892c95b96" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad725eb2-3d54-4ad9-a05b-aef619a25831" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchase of common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ab5fa21-45cc-4d3c-864c-cdad193ddb16" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20a2079c-2bb0-4382-963a-bc71278d0487" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repayment of long-term debt</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aff94808-33d3-4325-82b3-33f6cb4454a8" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,105</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aff920d9-951c-44a1-8a0a-25d3435a7f09" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,333</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Debt extinguishment costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf92f3b1-cf1b-49b2-8a6a-dce503d0569a" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ef40dc7-b137-497d-90d1-5b9d4a488eaf" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by (used in) financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41a4fa94-6430-43fd-9454-6e0820525cb8" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,138</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6f5b409-d552-4138-8dfe-fcc371242772" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,367</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61df6c7e-395c-488e-a9ae-0798fa3c177a" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">46,934</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7d7a346-46e1-416c-83aa-12b22f237174" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23,058</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash, beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6248aa83-66cb-4941-84db-9b16b89f9121" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,996</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81351239-3623-4377-9440-d616bcbaf985" contextRef="C_9e81976f-0dda-4005-94a7-17763001d331" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,054</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents, end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_221e9209-e738-4157-bd8c-bc401a78ba1b" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,062</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7af67d65-eb83-46d1-9ec8-c3de2d4acc73" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,996</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplementary disclosure of cash flow information:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf4a75f9-d17d-45ac-9c93-bdb8a470237f" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,063</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4781dc10-6c36-467c-9d4f-20bf0f8e4110" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,171</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reduction in right-of-use assets for modification and termination</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f738340f-d051-414a-b003-790001ada227" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="tcrt:ReductionInRightOfUseAssetsForModificationAndTermination" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,839</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81435723-cc7d-459a-85c1-b794762cd832" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="tcrt:ReductionInRightOfUseAssetsForModificationAndTermination" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,790</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amounts included in accrued expenses and accounts payable related to property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf9e86c7-edba-4daa-8ee7-d7cc2bd6a4b8" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_154e892b-6320-46de-a6df-fdb61536ed95" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="bkmk_202"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p>
  <p style="margin-left:2.32%;font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:center;" id="bkmk_146"><span id="notes_to_financial_statements"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a0f95e0-c307-42f5-9c8b-cec4e85557a7" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Organization</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc., which is referred to herein as &#8220;Alaunos,&#8221; or the &#8220;Company,&#8221; is a clinical-stage oncology-focused cell therapy company that was historically involved in the development of adoptive TCR therapies, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. On January 25, 2022, the Company changed its corporate name from ZIOPHARM Oncology, Inc. to Alaunos Therapeutics, Inc. The Company was working to leverage its proprietary, non-viral </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gene transfer platform and its novel cancer mutation hotspot TCR library to design and manufacture personalized cell therapies that target neoantigens arising from common tumor-related mutations in key oncogenic genes, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s operations to date have consisted primarily of conducting research and development and raising capital to fund those efforts.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e4b43ad-9841-4ef6-b0d6-e6d912c601cd" contextRef="C_0fb6425a-bd51-4ef2-a4fc-01fe4f515d0b" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,012,522</ix:nonFraction></span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares of common stock outstanding and an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92b14dea-f4ac-46ac-93b5-df01a01cabb1" contextRef="C_0fb6425a-bd51-4ef2-a4fc-01fe4f515d0b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,918,297</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock reserved for issuance pursuant to outstanding stock options and warrants.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, the Company announced a strategic reprioritization of its business and wind down of its TCR-T Library Phase 1/2 Trial. In connection with the reprioritization, the Company has significantly reduced its workforce and continues working to reduce costs in order to extend its cash runway. The Company continues to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. The Company has engaged Cantor Fitzgerald &amp; Co., or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3cbb77a9-e6f1-47b6-a57b-ec142d7b2591" contextRef="C_018d6e8c-001c-45fa-97e4-4efe0b2a752b" name="tcrt:StrategicAdvisorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cantor</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to act as strategic advisor for this process.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company follows the guidance of Accounting Standards Codification, or ASC, Topic 205-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Presentation of Financial Statements - Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has operated at a loss since its inception in 2003 and has no recurring revenue from operations.&#8239;The Company anticipates that losses will continue for the foreseeable future. As of December 31, 2023, the Company had approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8aac8710-c1b9-4938-9437-78497cf0313c" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8239;million of cash and cash equivalents. The Company&#8217;s accumulated deficit at December 31, 2023 was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_155dd0a0-71d7-4a96-91f5-bb402b7356b6" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">915.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8239;million.&#8239;Given its current development plans and cash management efforts, the Company anticipates cash resources will be sufficient to fund operations into the third quarter of 2024.&#8239;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company continues to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. The Company&#8217;s ability to continue operations after its current cash resources are exhausted depends on future events, including its ability to obtain additional financing or to achieve profitable operations, as to which no assurances can be given, nor are within the Company's control. If adequate additional funds are not available when required, or if the Company is unsuccessful in entering into partnership agreements for further development of its product candidates, management may need to curtail its development efforts and planned operations to conserve cash until sufficient additional capital is raised. There can be no assurances that such a plan would be successful.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements, and substantial doubt as to the Company's ability to continue as a going concern exists. This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has elected to make a reclassification in the presentation of the cash flow to show non-cash changes in right-of-use assets and lease liabilities related to modifications and terminations as non-cash for the year ended December 31, 2022 in order to conform presentation to the December 31, 2023 disclosures.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5fe9a89f-dc70-495e-91b0-44789b36a77a" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="tcrt:FinancingArrangementsDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financings</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 Loan and Security Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 6, 2021, the Company entered into a Loan and Security Agreement, or the Loan and Security Agreement, with Silicon Valley Bank and affiliates of Silicon Valley Bank, or collectively, SVB. The Loan and Security Agreement provided for an initial term loan of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7cc6f69-3473-4476-8db2-180b283f34d3" contextRef="C_c513888a-3b48-4024-a189-900f74620507" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million funded at the closing, or the Term A Tranche, with an additional tranche of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_630365e8-46d8-4e3a-b466-3147a6ddec5c" contextRef="C_d63de51f-7fcb-4cee-816b-0f40bc587e2e" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million available if certain funding and clinical milestones were met by August 31, 2022, or the Term B Tranche.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective December 28, 2021, the Company, entered into an amendment to the Loan and Security Agreement, or the First Amendment. The First Amendment extended the interest-only period through August 31, 2022. The First Amendment also eliminated the Term B Tranche, which remained unfunded, leaving only the Term A Tranche, or the SVB Facility. Under the amended Loan and Security Agreement, the SVB Facility was to mature on August 1, 2023. On May 1, 2023, the Company repaid its outstanding debt obligations under the amended Loan and Security Agreement in their entirety.</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to Note 4, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for further discussion of the Loan and Security Agreement and the First Amendment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 Equity Distribution Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 12, 2022, the Company entered into an Equity Distribution Agreement, or the Equity Distribution Agreement, with Piper Sandler &amp; Co., or Piper Sandler, pursuant to which the Company can offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26e4348f-80fb-4235-95a3-88904579417a" contextRef="C_178ac7cd-5b14-4544-b80c-336bc2dd52d9" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million through Piper Sandler as its sales agent in an "at the market offering." Piper Sandler will receive a commission of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89ff1fde-529c-4255-ac57-dbe8c3990b6e" contextRef="C_178ac7cd-5b14-4544-b80c-336bc2dd52d9" name="tcrt:PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the gross proceeds of any common stock sold under the Equity Distribution Agreement. During the years ended December 31, 2023 and 2022, there have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d85b550-41b8-446c-acde-35bff44bac7b" contextRef="C_c34e2ea2-6bfb-4c2d-919a-3fb69b17bab3" name="tcrt:StockOfferedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8512b420-fde3-4d98-8625-57db33ed72a6" contextRef="C_a0e9f476-c0cc-4b3e-b34e-81e4371b4b81" name="tcrt:StockOfferedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> sales of the Company's common stock under the Equity Distribution Agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 Public Offering</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 29, 2022, the Company entered into an underwriting agreement, or the Underwriting Agreement, with Cantor Fitzgerald &amp; Co., or the Underwriter, as the sole underwriter, relating to the issuance and sale in an underwritten offering, or the Offering, of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c986885-1988-4d7d-bb9e-0e5bc44f50b5" contextRef="C_b2c1287b-cb3c-456e-a570-1593261f684d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,615,248</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, or the Firm Shares, of the Company&#8217;s common stock to the Underwriter at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97c92761-a7d7-4366-ba9f-7d4c06045013" contextRef="C_d276298c-740b-42ff-98cb-ed95e869f300" name="tcrt:UnderwriterParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:num-dot-decimal">9.2865</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The net proceeds to the Company from the Offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e9d988e-322d-4024-9a8b-e204bd25620e" contextRef="C_8d3c500a-8039-4aa4-9783-2c2376933de5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (before accounting for the partial exercise of the Underwriter's option as described below) after deducting underwriting discounts and commissions and offering expenses payable by the Company.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Underwriting Agreement, the Company granted the Underwriter an option, exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a3ba876-063b-4f13-a319-0bedaf38a879" contextRef="C_b2c1287b-cb3c-456e-a570-1593261f684d" name="tcrt:ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30 days</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to purchase up to an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86cd6d04-d2b4-49e9-a964-85a498c2cf10" contextRef="C_6804cc66-48f9-4973-9521-76cf1de8e41d" name="tcrt:NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">242,287</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, which we refer to, together with the Firm Shares, as the Shares, at the same price per share as the Firm Shares. On January 5, 2023, the Underwriter partially exercised its option to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28183e36-4a0a-47c4-8b6e-a7f26f6455b9" contextRef="C_9b52611a-b9c3-4f92-b8bb-c439f1b299fc" name="tcrt:StockOfferedDuringPeriodShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,420</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_d0c11f10-1c9c-4037-91da-3c9bc2c84437" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Significant Accounting Policies </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55f57150-f25e-407f-9a5b-764c21f3c24d" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3410640-f30e-45b9-802e-138cb2f17035" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s most significant estimates and judgments used in the preparation of the financial statements are:</span></p><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trial expenses and other research and development expenses;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration agreements;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value measurements of stock-based compensation; and</span></div></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></div></ix:exclude><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes.</span></div></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e9a4da4-ff16-4852-8111-6b4bba64fde3" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents consist primarily of demand deposit accounts, certificates of deposit and deposits in short-term U.S. treasury money market mutual funds. Cash equivalents are stated at cost, which approximates fair market value.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe6fabe2-74ee-4be9-8c24-6ede6eed4e52" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9626ccae-6e52-4e9f-9082-b5426b851e40" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to expense while the costs of significant improvements are capitalized. Depreciation and amortization is calculated on a straight-line basis using the following periods, which represent the estimated useful lives of the assets:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:54.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.44%;"/>
        <td style="width:3.88%;"/>
        <td style="width:26.68%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office and computer equipment</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#65279;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_9bdcb5de-fc56-40d7-bf5c-033b1ef8f2cc" contextRef="C_ae07e329-a5b4-4996-9101-5c81cefa338b" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#65279;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_f036f18f-7662-42c3-bdad-7c12c67ef643" contextRef="C_59b1d649-d101-49bf-a3c7-bd6b2abc3d7d" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#65279;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_1b9190a4-fc10-4738-884a-d9b58d14f9c1" contextRef="C_0d7a6c39-7681-4ca3-99fb-8b12b128396b" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#65279;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_fa18b81e-dc37-4248-8153-57693071a98f;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Life of the lease</span></span></span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs, including certain design, construction and installation costs related to assets that are under construction and are in the process of being readied for their intended use, are recorded as construction in progress and are not depreciated until such time as the subject asset is placed in service. Repairs and maintenance that do not extend the useful life of the asset are expensed as incurred. Upon sale, retirement or other disposition of these assets, the costs and related accumulated depreciation are removed from the respective accounts and any gain or loss on the disposition is included in the statements of operations.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_05e7bddb-cf01-43a9-95b3-c481b4685c0c" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-Lived Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assessments of long-lived assets and the remaining useful lives of such long-lived assets are reviewed for impairment whenever a triggering event occurs or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An asset, or group of assets, is considered to be impaired when the undiscounted estimated net cash flows expected to be generated by the asset, or group of assets, are less than its carrying amount. The impairment recognized is the amount by which the carrying amount exceeds the fair market value of the impaired asset, or group of assets, based on the present value of the expected future cash flows associated with the use of the asset.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c19be71-7a9d-4032-bbb4-70be8e322455" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Segments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the Company&#8217;s chief operating decision maker, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_690fffcd-4e61-41d5-8d53-63dbe6d93c4a" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="tcrt:WarrantsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrants</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assesses whether warrants issued require accounting as derivatives. The Company determined that the warrants were (1) indexed to the Company&#8217;s own stock and (2) classified in stockholders&#8217; equity in accordance with Financial Accounting Standards Board, or FASB, ASC Topic 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As such, the Company has concluded the warrants meet the scope exception for determining whether the instruments require accounting as derivatives and should be classified in stockholders&#8217; equity.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8414510a-5d8a-4ac8-855c-b21209234e6d" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></p><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></div></ix:exclude><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d7dfef4-7428-4c62-8e8d-a6d2bf7d63b2" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of December 31, 2023 and 2022 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;"/>
          <td style="width:1.22%;"/>
          <td style="width:1%;"/>
          <td style="width:9.184000000000001%;"/>
          <td style="width:1%;"/>
          <td style="width:1.22%;"/>
          <td style="width:1%;"/>
          <td style="width:9.184000000000001%;"/>
          <td style="width:1%;"/>
          <td style="width:1.22%;"/>
          <td style="width:1%;"/>
          <td style="width:9.184000000000001%;"/>
          <td style="width:1%;"/>
          <td style="width:1.22%;"/>
          <td style="width:1%;"/>
          <td style="width:9.184000000000001%;"/>
          <td style="width:1%;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of<br/>December 31,<br/>2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94d5cd61-b6f8-485c-87d5-d1ff7c9d1609" contextRef="C_d20f89b1-a277-46ad-a886-0783d93e0131" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,744</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bce979fc-cef6-4236-ad85-273f0baad847" contextRef="C_6ee1d3ea-fecf-43a4-b0be-9cca9bc302be" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,744</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;"/>
          <td style="width:1.22%;"/>
          <td style="width:1%;"/>
          <td style="width:9.184000000000001%;"/>
          <td style="width:1%;"/>
          <td style="width:1.22%;"/>
          <td style="width:1%;"/>
          <td style="width:9.184000000000001%;"/>
          <td style="width:1%;"/>
          <td style="width:1.22%;"/>
          <td style="width:1%;"/>
          <td style="width:9.184000000000001%;"/>
          <td style="width:1%;"/>
          <td style="width:1.22%;"/>
          <td style="width:1%;"/>
          <td style="width:9.184000000000001%;"/>
          <td style="width:1%;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of<br/>December 31,<br/>2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0eaad22e-bca5-4bf0-81ee-458f5e2c7638" contextRef="C_d5b52643-6d79-400f-8b1d-031a3c875379" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,058</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f6643f4-b025-46c9-88f7-78ba54497f56" contextRef="C_b4d53f28-56a7-404b-af45-6335e67f7941" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,058</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cash equivalents represent demand deposit accounts and deposits in a short-term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset. There have been no changes to the valuation methods during the years ended December 31, 2023 and 2022. The Company had no financial assets or liabilities that were classified as Level 2 or Level 3 during the years ended December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair value of non-financial instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates assets for impairment whenever events or changes in circumstances indicate that indicators of impairment exist. In those evaluations, the Company compares estimated future undiscounted cash flows generated by each asset (or asset group) to the carrying value of the asset (or asset group) to determine if an impairment charge is required. If the undiscounted cash flows test fails, the Company estimates the fair value of the asset (or asset group) to determine the impairment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following the Company&#8217;s announced strategic reprioritization on August 14, 2023, the Company determined that changes in the intended use of certain property and equipment represented an indicator of impairment, resulting in an impairment charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75864bf6-fbe7-4373-9d92-5f229f8a7a8e" contextRef="C_018d6e8c-001c-45fa-97e4-4efe0b2a752b" name="us-gaap:TangibleAssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which was primarily related to leasehold improvements of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de2f47b1-b8e8-4c6b-82e2-03affc0def88" contextRef="C_f1be53cd-8ca0-4fbc-8225-e0b9cea77dc9" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and lab equipment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf0f34fd-3bcf-4924-8b7d-c3ba0777ed98" contextRef="C_aec61900-53b4-4857-87b4-484cc2b801ce" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Company determined certain prepaid expense balances to be impaired given the Company&#8217;s strategic reprioritization, and therefore, has recorded an impairment charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c62849a-d5a0-4004-b4c4-941db49c4eca" contextRef="C_ffb8b599-3fe6-43c2-9fb2-30c91dd8802b" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to prepaid expenses and other current assets, which is recorded in research and development expenses within the statement of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 9, 2023, the Company executed an agreement to sell laboratory equipment for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3cfdbac-fffa-42ad-991c-e6ef93fb803a" contextRef="C_b1dfdf14-86ec-4861-a350-a0829f3f94bb" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and recognized a gain on disposal of equipment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e104cd13-9496-45d8-b527-c6b206978d50" contextRef="C_b1dfdf14-86ec-4861-a350-a0829f3f94bb" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand, which is recorded in other income in the statement of operations</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_275979c4-bf1b-410b-934c-6d3da77c35eb" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition from Collaboration Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue for the year ended December 31, 2023 consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f5f01fc-1a36-40b9-8786-ba66a246d6f2" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand and for the year ended December 31, 2022 consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5415a93c-6936-461d-afb1-96edeeda9c92" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. For the years ended December 31, 2023 and 2022, the Company recognized revenue through its Collaboration Agreement with Solasia Pharma K.K. primarily due to the achievement of milestones, as further described in Note 9, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commitments and Contingencies.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company primarily generates revenue through collaboration arrangements with strategic partners for the development and commercialization of product candidates. The Company recognizes revenue in accordance with ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers, or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASC 606. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods and/or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and/or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes collaboration revenue under certain of the Company&#8217;s license or collaboration agreements that are within the scope of ASC 606. The Company&#8217;s contracts with customers typically include promises related to licenses to intellectual property, research and development services and options to purchase additional goods and/or services. If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contracts that include an option to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer&#8217;s election.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The terms of the Company&#8217;s arrangements with customers typically include the payment of one or more of the following:(i) non-refundable, up-front payment, (ii) development, regulatory and commercial milestone payments, (iii) future options and (iv) royalties on net sales of licensed products. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the most likely amount method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company reevaluates the probability of achievement of each milestone and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company allocates the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contract to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require the use of judgment to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenue, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54a0fc6c-4d20-42af-b89a-7adb2982d152" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the process of preparing the Company's financial statements, the Company is required to estimate its accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with its personnel and third-party vendors to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the services when the Company has not yet been invoiced or otherwise notified of the actual costs. The majority of the Company's service providers invoice the Company in arrears for services performed, on a predetermined schedule or when contractual milestones are met; however, a few require advanced payments. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known to it at that time. Examples of estimated accrued research and development expenses include fees paid to:</span></p><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical research organizations, or CROs, in connection with performing research services on its behalf and clinical trials;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">investigative sites or other providers in connection with clinical trials;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">vendors in connection with preclinical and clinical development activities; and</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">vendors related to product manufacturing, development, and distribution of preclinical and clinical supplies.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company bases its expenses related to preclinical studies and clinical trials on its estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct and manage clinical trials on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company's vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed, enrollment of patients, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low in any particular period.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a5b3b18c-6a30-4139-ad06-319520af78e4" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. The Company evaluates the realizability of its deferred tax assets and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates this tax position on an annual basis. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense (Refer to Note 12, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">).</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_18e7c8e5-08d8-4a79-94b6-29da4f31e53b" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting for Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation cost is measured at the grant date based on the estimated fair value of the award and is recognized as expense over the employee&#8217;s requisite service period. Stock-based compensation expense is based on the number of awards ultimately expected to vest and is reduced for forfeitures as they occur. Consistent with prior years, the Company uses the Black-Scholes option pricing model, which requires estimates of the expected term option holders will retain their options before exercising them and the estimated volatility of the Company&#8217;s common stock price over the expected term.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized the full impact of its share-based employee payment plans in the statements of operations for each of the years ended December 31, 2023 and 2022 and did not capitalize any such costs on the balance sheets. The Company recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5c625fa-adad-4eb6-b3ff-606286977591" contextRef="C_47de4d35-3a62-44ad-a1e3-078eb736401e" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of compensation expense related to stock options </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the year ended December 31, 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_767c8412-f591-44f9-bd3d-880702f54ed2" contextRef="C_66a9005c-fc69-4b3a-83be-3826cef87dcb" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of compensation expense related to stock options </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the year ended December 31, 2022. The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c428618-1b98-435e-8644-d8b43f2c8f4b" contextRef="C_b3feb1b1-0ac3-4b26-ba91-a5e0df500c8d" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of compensation expense related to restricted stock for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the year ended December 31, 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d31c007-98d3-49ce-aa79-fc4fc96be661" contextRef="C_d601659b-5678-4e9a-8c2e-09453abc5b8d" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the year ended December 31, 2022 (refer to Note 13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Option Plan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). The total compensation expense relating to vesting of stock options and restricted stock awards for the year ended December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91b43b6a-783a-4334-9f3c-3fceaa100b20" contextRef="C_df6734c9-10ba-4183-bed0-db726b38f022" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d44fc3d-7c90-48fa-879d-ee833de489f7" contextRef="C_cc7acd0c-a196-474b-904e-2422719555e7" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2022. </span><span><ix:nonNumeric id="F_87fdc4d5-9852-4981-be5d-e0b87b27fb31" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true" continuedAt="F_87fdc4d5-9852-4981-be5d-e0b87b27fb31_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents share-based compensation expense included in the Company&#8217;s statements of operations:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_87fdc4d5-9852-4981-be5d-e0b87b27fb31_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:64.713%;"/>
          <td style="width:1.56%;"/>
          <td style="width:1%;"/>
          <td style="width:12.643%;"/>
          <td style="width:1%;"/>
          <td style="width:1.56%;"/>
          <td style="width:1%;"/>
          <td style="width:15.523%;"/>
          <td style="width:1%;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_515dc6da-4b0b-4691-a8d8-1a4972a875f3" contextRef="C_2d8ef632-f188-499c-855f-f56d87eeb09c" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">439</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fe670f6-0d14-4d8b-a404-94032e8f388a" contextRef="C_60aa9216-7e7f-400b-9d0d-65567c8ce942" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">868</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb825339-34b4-490c-9bfc-e4e4a8b0b339" contextRef="C_a0517427-ae4d-43a0-9947-ed007458a817" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,361</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5049425-8859-433e-b210-3f0a2075599b" contextRef="C_86d41d2a-3fa1-4e8f-a00d-faeb00c9cc56" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,660</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02c2006c-bfd5-4eb7-bb25-06c49e9347b2" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,800</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b903f96f-ebc0-4c37-aa6e-875bab5948c2" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,528</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. The estimated weighted-average fair value of stock options granted to employees in the year ended December 31, 2023 was approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_531babb8-9499-4898-a051-b01e929f582d" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.58</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">per share and was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_820ce1a7-0715-42c7-b7e0-3903dfcd4193" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.54</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2022. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company&#8217;s historical experience. The risk-free interest rate is based on a U.S. treasury note with a maturity similar to the option award&#8217;s expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The Company calculated expected term using the simplified method described in SEC Staff Accounting Bulletin, or SAB, No. 107 and No. 110 as it continues to meet the requirements promulgated in SAB No. 110.</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_614c2781-2006-402a-9e08-98e2874f6993" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" escape="true" continuedAt="F_614c2781-2006-402a-9e08-98e2874f6993_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The assumptions for volatility, expected life, dividend yield and risk-free interest rate are presented in the table below:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_614c2781-2006-402a-9e08-98e2874f6993_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.173%;"/>
          <td style="width:1.62%;"/>
          <td style="width:13.443%;"/>
          <td style="width:1.62%;"/>
          <td style="width:16.143%;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_639eed61-d510-42e1-a42a-517b7b31e8a6" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.51</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b508de13-8792-4c8a-a32b-5049edcf89e2" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c6d0a2a-fc1e-4182-bc05-7e0557fbad26" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.63</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae222a16-b882-4b36-b104-fb73d63aea68" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.21</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected life in years</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_ed1eef18-91b0-47bf-8d52-ccb0e6779c50" contextRef="C_c08c022b-51fd-407b-9baa-ebc8ead77d26" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.06</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><ix:nonNumeric id="F_ce566634-79a8-405d-96d2-624379010254" contextRef="C_d22c7a01-1ee3-4ae9-b8e5-5302459c17aa" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></ix:nonNumeric></span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_ed004503-5340-4e50-bd8b-0074139c4412" contextRef="C_614aa634-42cc-4d32-8a9a-8b4df7e3a7b4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.27</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><ix:nonNumeric id="F_065fe0c4-7c48-41d8-a5b3-9bb6062ea924" contextRef="C_38467bd2-81f8-405d-9362-d3b8371c7945" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2f29327-1d3e-4de4-b75a-967f40e8aacc" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">89.69</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9b60cce-a0d6-4cbd-99bf-1dc30d9275a3" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">112.12</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10e0dcba-5c4d-46c4-a9ad-3b3b385183f1" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">74.49</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd62d006-94b4-4671-8398-1f2609b1b7de" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">88.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;%</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;%</span></p></td>
         </tr>
        </table></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Stock Split</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 31, 2024, the Company filed a Second Amended and Restated Certificate of Incorporation (the &#8220;Charter Amendment&#8221;) with the Secretary of State of the State of Delaware in order to effect a reverse stock split of the Company&#8217;s common stock at a ratio of 1-for-15 (the &#8220;Reverse Split&#8221;). The Charter Amendment decreased the number of authorized shares of common stock from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92c59b7f-df53-44b3-9c87-1d4591792963" contextRef="C_1a75d2a0-9d24-4504-a3dc-2dac5fdd0e65" name="tcrt:PreStockSplitSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">520,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a4a0905-e911-4214-ba70-710c3c6e3cc4" contextRef="C_1a75d2a0-9d24-4504-a3dc-2dac5fdd0e65" name="tcrt:PostStockSplitSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">34,666,667</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Charter Amendment does not affect the par value of the Company&#8217;s common stock or change the number of authorized shares or par value of the Company&#8217;s preferred stock. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b48bafbd-aeea-4a83-b97e-302cd621f330" contextRef="C_8c63ac11-1fe7-4822-9cb9-1e975eedf1b6" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Charter Amendment became effective on January 31, 2024 at 5:00 p.m. Eastern Time, at which time every 15 shares of the Company&#8217;s issued and outstanding common stock automatically combined and converted into 1 share of common stock.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No fractional shares were issued in connection with the Reverse Split. Stockholders of record who would otherwise have been entitled to receive fractional shares as a result of the Reverse Split received a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing sales price per share of the common stock (as adjusted for the Reverse Split) on The Nasdaq Capital Market on January 31, 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="bkmk_220"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All share and per share amounts of common stock, options, warrants, and restricted stock in the accompanying financial statements and notes thereto have been retroactively adjusted for all periods presented to reflect the Reverse Split as if it had occurred at the beginning of the earliest period presented.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cddaa5f4-aead-4071-8da5-f3ba53177542" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Share</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ff8e5c82-8933-4923-aac2-dc31ff7558b8" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company&#8217;s common stock during the applicable period, unless their effect on net loss per share is antidilutive. The effect of computing diluted net loss per common share was antidilutive for any potentially issuable shares of common stock from the conversion of stock options, unvested restricted stock and warrants and, as such, have been excluded from the calculation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
         <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The computation of basic and diluted net loss per share consists of the following:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.72%;"/>
          <td style="width:1.72%;"/>
          <td style="width:1%;"/>
          <td style="width:12.92%;"/>
          <td style="width:1%;"/>
          <td style="width:1.72%;"/>
          <td style="width:1%;"/>
          <td style="width:12.92%;"/>
          <td style="width:1%;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3ee0ee7-23f4-447b-ba42-5951d3813488" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,140</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9338b24d-9519-4c11-8163-b2ef35a9286c" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">37,730</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab06097a-e952-47fe-a7e9-e1f2e492400e" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a6bb691b-a1cf-426e-847a-fd08787bf53c" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">15,995,323</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae86b235-2c64-4b71-a99c-3d8403738e04" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bf01d427-02d8-46c9-ad36-898c407dfdab" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,475,354</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_915291ca-64e7-4b63-8e92-38edc57f4cd6" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bc65e511-b865-48d7-97fa-218411eb8354" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.20</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f1d5f48-8cf1-4087-88b2-f65796d7d40a" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2055e1eb-8227-4cf1-87ef-f1df171b4268" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.61</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain shares related to some of the Company&#8217;s outstanding common stock options, unvested restricted stock and warrants have not been included in the computation of diluted net loss per share for the years ended December 31, 2023 and 2022 as the result would be antidilutive. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e88792c3-3c40-4cc4-abac-7b2bba9d15e8" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_e88792c3-3c40-4cc4-abac-7b2bba9d15e8_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such potential common shares on December 31, 2023 and 2022 consist of the following:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e88792c3-3c40-4cc4-abac-7b2bba9d15e8_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.967%;"/>
          <td style="width:1.16%;"/>
          <td style="width:1%;"/>
          <td style="width:13.357%;"/>
          <td style="width:1%;"/>
          <td style="width:1.16%;"/>
          <td style="width:1%;"/>
          <td style="width:13.357%;"/>
          <td style="width:1%;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8dc406dc-3393-4605-bcf0-2cba12847668" contextRef="C_4104f83e-9d9d-42d3-ba02-e04dc9b2ed5f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">465,898</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7f9b236-b4e2-4968-8b1c-514ee6a7c9ea" contextRef="C_0a9aab26-46d9-488c-b695-2646b51f35c2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">693,909</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0df0f2db-0b54-4ae4-9e32-11ce324bc3b2" contextRef="C_5a00674d-0901-4260-8a18-828129c14592" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f92dad80-186c-422b-8619-d509597908f9" contextRef="C_9251b0d7-fe5b-457f-a984-b77be81cbbed" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">62,604</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8212927-696f-4c30-a764-a80b79af487f" contextRef="C_ab6d30fd-d037-4c8b-a225-3af57f8a921c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,452,399</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab5ff1f9-166b-4c34-bea7-a4ff049f5759" contextRef="C_9372d727-0118-429b-87d8-c76963744d6d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,528,156</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68087b1e-f3e2-4928-8e00-894ee07d6408" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,918,297</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8efe0f17-f224-4043-96e9-93f55e9a29e4" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,284,669</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e0827b2-d323-49d0-b81e-ca03dca1b2c4" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued Accounting Standards Update, or ASU, 2016-13, Financial Instruments: Credit Losses (Topic 326) as clarified in ASU 2019-04, ASU 2019-05 and ASU 2020-02. The objective of this standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than-temporary impairments on investment securities are recorded. The Company adopted ASU 2016-13 effective January 1, 2023, with no material impact upon adoption.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances the disclosures required for operating segments in the Company's annual and interim financial statements. ASU 2023-07 is effective retrospectively for fiscal years beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this standard.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for the Company prospectively to all annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this standard.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f433ffa9-4880-4bab-b9e2-55e72e40aca6" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Debt</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ea9db2c3-1969-44fd-ba72-4e4b2d4744f4" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ScheduleOfDebtTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8ce865e-2a59-4efd-9635-db723186bf11" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> debt obligations outstanding at December 31, 2023. The carrying values of the Company's debt obligation at December 31, 2022 were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:15.823%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loan and Security Agreement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66aeae9f-93bf-4e4e-adf3-fe0a36d11045" contextRef="C_e64be0f6-91d9-4db7-86b4-e80514f8c958" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,395</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unamortized discount on Loan and Security Agreement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67606748-0aa0-452a-bdbd-42c445461b97" contextRef="C_e64be0f6-91d9-4db7-86b4-e80514f8c958" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">630</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe8a2cab-4833-4574-bcb6-3eb3f19f27fe" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,765</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: long-term debt, current</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5450736-e7ab-474e-b750-61f78ffcb68e" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,765</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9754e075-fb64-4200-95ce-751e89b9345d" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 6, 2021, the Company entered into the Loan and Security Agreement with SVB. The Loan and Security Agreement provided for the funding of the Term A Tranche at the closing, with the Term B Tranche available if certain funding and clinical milestones were met by August 31, 2022. The SVB Facility and related obligations under the Loan and Security Agreement were secured by substantially all of the Company's</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">properties, rights and assets, except for its intellectual property (which was subject to a negative pledge under the Loan and Security Agreement). In addition, the Loan and Security Agreement contained customary representations, warranties, events of default and covenants.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 28, 2021, the Company entered into the First Amendment to the Loan and Security Agreement. The First Amendment eliminated the unfunded Term B Tranche, among other things. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00915b95-be63-48ce-b1df-d5cbd594744d" contextRef="C_b4ef7ff5-bba3-4349-98dd-d7df9d126723" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The SVB Facility bore interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38847a84-ff57-4b52-a69d-1be25a17ab5f" contextRef="C_36cd6252-28b4-4775-b0f9-58a9b230b1c3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">7.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and (b) the current published U.S. prime rate, plus a margin of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33312005-1ea7-4236-b610-d39888ad6a02" contextRef="C_70ef5a8d-4cca-4f80-ae99-5f24fedd40fc" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All outstanding obligations under the amended Loan and Security Agreement were due and payable on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80515573-ae88-4ff7-abf9-47b76caefbad" contextRef="C_b4ef7ff5-bba3-4349-98dd-d7df9d126723" name="us-gaap:DebtInstrumentMaturityDateRangeStart1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 1, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In connection with the payment of all of the Company's outstanding obligations, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_088be771-7077-4a5e-9de1-897069dfb287" contextRef="C_5d7932fa-9451-44de-93c6-0aeabfb182de" name="us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" continuedAt="F_088be771-7077-4a5e-9de1-897069dfb287_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company also owed SVB </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b36667f-ffad-4f1a-95fb-0c04b8408c2f" contextRef="C_36cd6252-28b4-4775-b0f9-58a9b230b1c3" name="tcrt:PercentageOfOriginalPrincipalDueAsAFinalPayment" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the original principal amounts borrowed as a final payment, or the Final Payment. Effective March 30, 2023, the Company entered into a Third Amendment to the Loan and Security Agreement, or the Third Amendment. Under the terms of the Third Amendment, the Company was no longer required to maintain all of its operating accounts, depository accounts and excess cash with SVB or one of its affiliates, and was instead only required to maintain a single operating or depository account at Silicon Valley Bank. The Third Amendment also modified the cash collateralization requirement, such that the Company was required to cash collateralize the entire sum of the outstanding principal amount of the SVB Facility, plus an amount equal to the Final Payment, which amount was to be reduced commensurate with each regularly scheduled monthly payment of principal and interest on the SVB Facility.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_088be771-7077-4a5e-9de1-897069dfb287_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 1, 2023, the Company paid SVB an amount equal to the entire outstanding principal amount under the SVB Facility, all accrued and unpaid interest and the Final Payment. In accordance with the First Amendment, the payment was subject to a prepayment premium of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41026c6e-4956-4500-a440-b8be322bea70" contextRef="C_f075a278-5164-4d2a-9bd2-198370833aca" name="tcrt:PercentageOfPrepaymentsPremium" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> During the year ended December 31, 2023, the Company recorded the remaining amounts associated with the Final Payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44edd090-c163-4346-9e98-4358479f0e57" contextRef="C_b4ef7ff5-bba3-4349-98dd-d7df9d126723" name="us-gaap:ExtinguishmentOfDebtAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and the prepayment premium of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc477a7a-a61a-476e-a5c2-2de4d686cd9d" contextRef="C_b4ef7ff5-bba3-4349-98dd-d7df9d126723" name="tcrt:AmountOfPrepaymentsPremium" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as interest expense within the statement of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with its entry into the Loan and Security Agreement in August 2021, the Company issued to SVB warrants to purchase (i) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7843618-781d-4771-bd89-53b39a50ff98" contextRef="C_7076c57a-eac4-4967-be0d-548e7041b7f8" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">28,856</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock, in the aggregate, and (ii) up to an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f01ad276-45ba-475a-9ba2-0be6438b3bd5" contextRef="C_7076c57a-eac4-4967-be0d-548e7041b7f8" name="tcrt:AdditionalNumberOfWarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">28,856</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, in the aggregate, in the event the Company achieved certain clinical milestones, in each case at an exercise price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_197d6a5b-e21c-4531-bd43-f103fdfcbf07" contextRef="C_7076c57a-eac4-4967-be0d-548e7041b7f8" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">33.30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with its entry into the First Amendment in December 2021, the Company amended and restated the warrants issued to SVB. As amended and restated, the warrants are for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_469b306c-168b-4ee7-9cd5-59fbe65eb1ba" contextRef="C_0a5a10cc-553a-4c9b-9781-bb8cb6a5dd9b" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,308</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, in the aggregate, with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cc81055-b5ac-4ac3-8947-6cd33b78a0be" contextRef="C_42fcfea8-a421-4581-aa9a-f10b12c3fff7" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, or the SVB Warrants. The SVB Warrants expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_16529a74-6784-463a-8385-2dd23bbc0e49" contextRef="C_0a5a10cc-553a-4c9b-9781-bb8cb6a5dd9b" name="tcrt:WarrantsExpirationDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 6, 2031</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The issuance costs for the Loan and Security Agreement, including the First Amendment, were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_949723f6-f74c-437c-b15b-333ea4c2d86f" contextRef="C_bb295f58-cf1f-496d-99a4-62856a01fdf4" name="us-gaap:DeferredFinanceCostsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and primarily related to the SVB Warrants, which were amortized into interest expense over the term of the loan. Interest expense, including the amortization of issuance costs, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbbea518-0261-409e-b6e4-a51e67edaf56" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f1602b7-fe87-4c1e-9705-5ae80271d020" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54d01e53-53e4-4165-924c-e55ccc1684e8" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and Equipment, net</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9fae5cd-acec-4d10-b87c-5934a25b20b2" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net, consists of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.213%;"/>
        <td style="width:1.66%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
        <td style="width:2.44%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office and computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5bda8718-96a8-4b22-8c4a-891fb99d147c" contextRef="C_ae07e329-a5b4-4996-9101-5c81cefa338b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f8e6492-5846-4a98-b424-b5fb0b617fb8" contextRef="C_c03e3f83-0461-4bff-a6ec-c8e8f6eae256" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,183</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cfb3842-1ad3-43ca-a160-7b465674bef1" contextRef="C_59b1d649-d101-49bf-a3c7-bd6b2abc3d7d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6e71f24-458b-4150-b0ea-57a3b6d67d01" contextRef="C_63da8372-4842-42f7-846e-29d35b96baad" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,291</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_accd9a7f-6749-41b1-8a48-42e54f1a585d" contextRef="C_53b2cce5-dd6d-4584-81a2-934fca6f36e1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0df60c81-1541-4b81-9be6-9197e79589a6" contextRef="C_1eb9814e-4de9-413f-980e-56701e4ada9c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,561</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c74a7d9c-e457-4754-bfc7-80c15555ca9f" contextRef="C_0d7a6c39-7681-4ca3-99fb-8b12b128396b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2967a6c4-7637-494d-94d0-972562ede83b" contextRef="C_8437c692-33c1-493a-b928-11fb26d089fe" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,232</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b02084f4-0a4c-4200-a4a6-93b2903c9a18" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f988f6b1-5574-43a1-8ab1-b9bb8eb509db" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,267</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7279ba97-269e-48ae-b1af-1ebe45701193" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20ad6d81-e7b2-42b7-86f6-87c78ec56175" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,807</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89ea558e-7391-4b4a-91ed-8a2fabceea74" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa9746c6-89f4-4d8a-b567-3ee470c6ded3" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,460</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense for the year ended December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_036c76db-c852-42b0-9d76-0bad20cbd1a3" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_847a1955-9a6e-425e-8f74-e474a79dbc62" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2022. During the year ended December 31, 2023, the Company impaired property and equipment by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12be8c6f-e92a-4493-a4fb-75dca9ecd834" contextRef="C_61732725-ae5b-416f-8f67-a2ab46a40cc5" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Refer to Note 3, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, for further details.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee0bf0c7-33aa-4d64-ba1e-d9fb87b3ade7" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cdec8af5-273f-45b0-95d3-6639fea597ea" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consist of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"/>
        <td style="width:1.68%;"/>
        <td style="width:1%;"/>
        <td style="width:12.96%;"/>
        <td style="width:1%;"/>
        <td style="width:1.68%;"/>
        <td style="width:1%;"/>
        <td style="width:12.96%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25f409bf-4d25-44f0-a827-ffbab1cba529" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="tcrt:AccruedClinicalExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">568</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1daf1ca7-40be-4d97-8670-6586899af628" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="tcrt:AccruedClinicalExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,200</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ae5374b-9f32-4218-bbb3-30fc8fca5821" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:AccruedBonusesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5c11288-efdb-40bf-96be-c01ae9bf8f01" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:AccruedBonusesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,160</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1aae791b-c060-402c-a7db-efa5d59801ee" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">717</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4839e19d-a568-4b8e-8300-84f448446e6c" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">534</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preclinical services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e930e229-12e8-4797-b135-0fd23c980a7b" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="tcrt:AccruedPreclinicalServicesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bae8d8a1-cdf8-47a9-9f72-6d3334c12338" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="tcrt:AccruedPreclinicalServicesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Manufacturing services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5ea0a61-c9e9-43e8-b342-31bbda1ab403" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="tcrt:AccruedManufacturingCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29594e79-d3e3-4692-be71-7e9cd274091a" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="tcrt:AccruedManufacturingCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,177</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other consulting services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_421987d2-9311-4712-b303-78178fcc47bd" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="tcrt:AccruedConsultingFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42475661-4d8f-4c12-b14e-a919ad850903" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="tcrt:AccruedConsultingFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_335ff904-2ac2-4c04-9078-fe29f2686d1f" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e31ae0da-0c2b-4bd3-8157-3d3bf2ac8a4d" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f01a9d9-e35e-4f72-9338-b6ff28de548f" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,340</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18c88f8d-d1dc-4dd9-9562-e611fee0016f" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,454</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78a79fea-8202-4ef2-abb5-da32b097d0f4" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Related Party Transactions</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Joint Venture with TriArm Therapeutics/Eden BioCell</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 18, 2018, the Company and TriArm Therapeutics, Ltd., or TriArm, launched Eden BioCell, Ltd., or Eden BioCell, as a joint venture to lead commercialization of the Company&#8217;s </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-generated CAR-T therapies in the People&#8217;s Republic of China (including Macau and Hong Kong), Taiwan and Korea. The Company licensed to Eden BioCell the rights in Greater China for its third-generation Sleeping Beauty-generated CAR-T therapies targeting the CD19 antigen. Eden BioCell is owned equally by the Company and TriArm and the parties share decision-making authority. TriArm contributed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f96dd304-45b0-490c-939d-4a7598d90d32" contextRef="C_01c537c5-d7da-43b7-9828-3dd4fac7a6b1" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Eden BioCell and has committed up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ee63367-801f-492b-8489-cbe0f023fb66" contextRef="C_c83e3ba4-ff7f-49bc-b367-c3a48773a81c" name="tcrt:AdditionalLoansCommitted" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to this joint venture. TriArm also managed all clinical development in the territory pursuant to a master services agreement between TriArm and Eden BioCell. James Huang was the founder and serves as managing partner of Panacea Venture, which is an investor in TriArm. Mr. Huang was the Chair of the Company's board of directors until September 22, 2023 and had been a director since July 2020. He also serves as a member of Eden BioCell&#8217;s board of directors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, TriArm and Alaunos mutually agreed to dissolve the Eden BioCell joint venture. The joint venture agreement has been terminated and the Eden BioCell entity has been dissolved as of July 2023. Refer to Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Joint Venture</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, for further details.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration with Dune Lake Capital</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, the Company entered into a consulting agreement with Dune Lake Capital, LLC, or Dune Lake Capital, which was founded by Dale Curtis Hogue, Jr., the Company's interim Chief Executive Officer. During the year ended December 31, 2023, the Company recorded expenses of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c24c4aa-136a-43a8-9f8c-8d94f2a8a816" contextRef="C_fec7df81-6165-4556-94da-9ce5e0afffd4" name="us-gaap:ProfessionalAndContractServicesExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand for consulting services performed by Dune Lake Capital with respect to the period from January 2023 to August 2023.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f73cc1d-8706-47b6-9812-6fbd987857ed" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2022, the Company modified its real estate lease agreement executed on December 15, 2020 with MD Anderson for office space in Houston, Texas, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which reduced the Company's leased space from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1444f76-8f2a-46b4-8333-927d82ff0cb8" contextRef="C_41ccee47-b234-4941-b8eb-978d9f5b2e42" name="tcrt:OperatingLeaseArea" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">18,111</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aaf2d64f-0e4f-433f-a8cd-d195e8926385" contextRef="C_aa3c307b-d3f5-4b67-b1f6-1018ba02f672" name="tcrt:OperatingLeaseArea" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">3,228</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet. As a result, the associated lease liability and right-of-use asset were remeasured to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8fc9c35-f964-4356-9882-76b51a7dc4b1" contextRef="C_aa3c307b-d3f5-4b67-b1f6-1018ba02f672" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million based on revised lease payments. A gain of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ca563f9-02ec-4473-ac24-627e0702085d" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="tcrt:GainLossOnModificationOfLease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recorded on the lease modification during the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, the Company executed an agreement to sub-sublease </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11fc1bec-4b64-4bcf-b24e-14c34b5e0c57" contextRef="C_112e62be-1071-454a-9093-81a7c718e165" name="tcrt:SubleaseArea" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">4,772</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of subleased office space in Boston. For the year ended December 31, 2023, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7bcaf91-342b-4c0c-b2e1-3bb352a8761e" contextRef="C_9f6ea145-3408-4127-8187-484ad479069b" name="us-gaap:LeaseIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand in lease income, and for the year ended December 31, 2022, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f390000-62e7-4bdf-8082-49990cc5aa8c" contextRef="C_95d872d4-ff79-4993-afa4-1fc260f3a843" name="us-gaap:LeaseIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in lease income. Lease income is classified within other income on the statement of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f52ebf41-a794-49ad-a782-5faf5565adca" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="tcrt:LeaseTerminationDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 19, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company terminated its office lease in Boston, Massachusetts, which was set to expire on August 31, 2026. In connection with the termination, the Company also assigned to the landlord its sub-sublease of the Boston office space, which had </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d3b063b6-47eb-43df-ae72-c96c7c502a34" contextRef="C_759b438f-e084-415a-bd3e-33a77795c829" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a term expiring on June 30, 2025 with an option to extend through </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1812c93-2671-4598-a2a5-1546d7e70253" contextRef="C_759b438f-e084-415a-bd3e-33a77795c829" name="tcrt:SubleaseTermCommencedEndDateAmendment" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">July 31, 2026</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Termination costs for the Boston office lease were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78bc9ea9-c3fb-49c4-a9b7-dabae183b80f" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="tcrt:TerminationCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. A gain of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7a1992e-9b70-4f21-a414-bae29c51d087" contextRef="C_31df6cae-3411-4d1e-afda-0b2df9d5828c" name="us-gaap:GainLossOnTerminationOfLease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recorded on the lease termination during the year ended December 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2023, in accordance with the lease agreement executed on December 15, 2020, the Company notified MD Anderson, as landlord, of its intention to terminate office space of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cdfba2a6-11c1-48fc-8056-0e6277427878" contextRef="C_a5f0ce97-7e26-409e-8300-d1a1644a54a8" name="tcrt:OperatingLeaseArea" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">3,228</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet in Houston, Texas. As a result, the associated lease liability and right-of-use asset were remeasured to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bec7e99a-4d97-4916-bdf5-61b3bb0e544e" contextRef="C_a5f0ce97-7e26-409e-8300-d1a1644a54a8" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand, reflecting the revised lease payments and term end date of November 2023.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 1, 2023, the Company and MD Anderson, as landlord, agreed to mutually terminate the leases dated October 15, 2019 and April 7, 2020, which represented office space totaling </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51052de3-21bd-4175-9752-c556394c0ecc" contextRef="C_c30dcdbc-ca80-4f40-8509-a02802f4927d" name="tcrt:OperatingLeaseArea" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">14,037</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet, effective November 15, 2023. As a result, the Company agreed to make a final payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3837987a-77dc-4921-b7bf-cb46fb23280c" contextRef="C_5192514c-c4a7-4570-99f5-e8a967b213de" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to the landlord. A gain of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43074f09-eba4-4df8-8a49-68c9831897d6" contextRef="C_0b32ddd3-7ce4-4f74-9808-a45ab5d03ffd" name="us-gaap:GainLossOnTerminationOfLease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recorded on the lease termination during the year ended December 31, 2023.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae71dfb2-212e-473d-a067-e1829a5b9d9b" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="bkmk_231"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of lease expense were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.493%;"/>
        <td style="width:1.839%;"/>
        <td style="width:1%;"/>
        <td style="width:12.915%;"/>
        <td style="width:1%;"/>
        <td style="width:1.839%;"/>
        <td style="width:1%;"/>
        <td style="width:12.914%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38427c69-5b8d-43e8-84bf-9ca32bb39bc1" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">428</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5043313-85a5-4f9b-b7ca-eda5d95a5e0b" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">756</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09a2b4f7-4c22-46a8-be53-adafd97a0158" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">428</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce7efc7d-23a1-4a71-a787-6d3cd5305c24" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">756</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average remaining lease term (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_edc1ca29-d7a0-4ab2-bad2-aa458d85c900" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.13</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff822e01-f4d4-4514-8121-284e13c2a51b" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fa335db-0c51-42db-b34a-1df63193cc63" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.26</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17d7c030-e17e-4764-a268-188b1efd83ad" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in operating lease costs for the year-ended December 31, 2023. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a0a7b2b-28ab-4d2b-951c-e1fb26fa1c31" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize new operating lease assets obtained in exchange for operating lease liabilities for the year-ended December 31, 2023. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9eeec2c1-3e84-4b4d-9309-bb7f4e0d9f2a" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have any leases, other than a short-term lease, as of December 31, 2023.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d279e3a-cef3-49b2-b120-09a04de48714" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commitments and Contingencies</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusive License Agreement with Precigen</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 5, 2018, the Company entered into an exclusive license agreement, or License Agreement, with PGEN Therapeutics, or PGEN, a wholly owned subsidiary of Precigen Inc., or Precigen, which was formerly known as Intrexon Corporation. Except where the context otherwise requires, the Company refers to PGEN and Precigen together as Precigen. Pursuant to the terms of the License Agreement, the Company had exclusive, worldwide rights to research, develop and commercialize (i) TCR products designed for neoantigens for the treatment of cancer, (ii) products utilizing Precigen&#8217;s RheoSwitch&#174; gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (iii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the License and Collaboration Agreement effective March 27, 2015 between the Company, Precigen and ARES TRADING S.A., a subsidiary of Merck KGaA, as assigned by Precigen to PGEN. Under the License Agreement, the Company also had exclusive, worldwide rights for certain patents relating to the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company was responsible for all aspects of the research, development and commercialization and was required to use commercially reasonable efforts to develop certain products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In consideration of the licenses and other rights granted by Precigen, the Company was required to pay Precigen an annual license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e2c512f-579a-4a77-bec8-bbc1a72b21c9" contextRef="C_56dcfc15-8dde-431d-a7db-bbfed94629e4" name="tcrt:AnnualLicenseFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, reimburse Precigen for certain historical costs, pay Precigen milestones up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e7c9cce-f7fd-40cc-9136-8fcce3c00971" contextRef="C_56dcfc15-8dde-431d-a7db-bbfed94629e4" name="tcrt:MaximumAmountOfAdditionalMilestonesPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">52.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for each exclusively licensed program upon the achievement of certain milestones, and pay Precigen tiered royalties up to a maximum royalty amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3d5aef3-7616-48c0-89b8-1a434256c162" contextRef="C_b07e679c-ee37-4ba5-b372-9bfc376e0ba0" name="tcrt:MaximumAmountOfRoyaltyPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the aggregate. The Company was also obligated to pay Precigen </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75d6462d-e4b0-4f6d-9512-45d77a859483" contextRef="C_b07e679c-ee37-4ba5-b372-9bfc376e0ba0" name="tcrt:PercentageOfSubLicensingIncomePayableToRelatedParty" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of any sublicensing income received relating to the licensed products. The Company was responsible for all development costs associated with each of the licensed products. For the years ended December 31, 2023 and 2022, the Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a60ae98-d676-4b6b-9404-4b611e826ec1" contextRef="C_5f261627-186d-4c4c-9a00-ee68ecc9a86c" name="tcrt:AnnualLicenseFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_44306530-9eb6-4e2e-959f-17d04835ca61" contextRef="C_8a40112e-a10a-439d-a924-dded53c33f05" name="tcrt:AnnualLicenseFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in annual license fees under this agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Precigen was obligated to pay the Company royalties up to a maximum royalty amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98bb3a2f-7c9b-4142-9c55-2ab1b5250eff" contextRef="C_9eeb8156-fd64-4f9c-a68b-13acb840c000" name="tcrt:MaximumRoyaltyAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89687c62-2515-4501-9aec-e33a96ab40fa" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_078c23b6-e159-4a59-8a52-5c05a43f652c" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> royalty amounts were incurred during the years ended December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 3, 2023, the Company entered into the Amended and Restated Exclusive License Agreement with Precigen, or the A&amp;R License Agreement, which restated and amended the License Agreement in full. Under the A&amp;R License Agreement, the Company still has exclusive, worldwide rights to research, develop and commercialize TCR products designed for neoantigens or driver mutations for the treatment of cancer and non-exclusive rights to use non-driver mutation TCRs. The Company further maintains its exclusive, worldwide rights for certain patents relating to the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company remains solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. The (i) products utilizing Precigen&#8217;s RheoSwitch&#174; gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (ii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the License and Collaboration Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">effective </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 27, 2015 between the Company, Precigen and ARES TRADING S.A., a subsidiary of Merck KGaA, as assigned by Precigen to PGEN are no longer exclusively licensed to the Company. The Company is no longer obligated to use commercially reasonable efforts for the exclusively licensed products. The A&amp;R License Agreement further eliminates any royalty or milestone obligations to Precigen, with an annual license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8401a7a4-2fee-4464-9e95-fd5011493c5c" contextRef="C_dada01c2-0448-4544-80b7-17e67bdfc890" name="tcrt:AnnualLicenseFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand due on the anniversary of the A&amp;R License Agreement effective date. Precigen is no longer obligated to pay the Company royalties on the net sales derived from the sale of Precigen's CAR products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreement and 2015 Research and Development Agreement &#8212;The University of Texas MD Anderson Cancer Center</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1cca0ac-cd39-4525-9274-c0f11a1812bd" contextRef="C_4c598769-068f-4e4c-b4a0-a1504cfbdf40" name="tcrt:LicenseAgreementCommencingDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 13, 2015</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company, together with Precigen, entered into a license agreement, or the MD Anderson License with MD Anderson (which Precigen subsequently assigned to PGEN). Pursuant to the MD Anderson License, the Company, together with Precigen, holds an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR T-cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells, and TCRs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 17, 2015, the Company, Precigen and MD Anderson entered into the 2015 R&amp;D Agreement to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. The rights and obligations of Precigen under the 2015 R&amp;D Agreement were assigned to the Company pursuant to the Fourth Amendment to 2015 R&amp;D Agreement which was entered into on September 19, 2019 (the &#8220;Fourth Amendment&#8221;) with an effective date of October 5, 2018. The activities under the 2015 R&amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As provided under the MD Anderson License, the Company provided funding for research and development activities in support of the research programs under the 2015 R&amp;D Agreement for a period of three years and in an amount of no less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfdefe25-8674-46bd-9a0f-734147dacddd" contextRef="C_61083e15-726c-43c1-8169-eca505a1dd5c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and no greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e1a55eb-6dc9-43b7-a6da-117224b10df2" contextRef="C_9bebd57d-5315-4cfa-aa91-69cf64124596" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million per year. On November 14, 2017, the Company entered into an amendment to the 2015 R&amp;D Agreement, extending its term until April 15, 2021. In connection with the execution of the 2019 R&amp;D Agreement described below, on October 22, 2019, the Company amended the 2015 R&amp;D Agreement to extend the term of the 2015 R&amp;D Agreement until December 31, 2026 and to allow cash resources on hand at MD Anderson under the 2015 R&amp;D Agreement to be used for development costs under the 2019 Research and Development Agreement, or the 2019 R&amp;D Agreement, which the Company entered into on October 22, 2019, with MD Anderson, pursuant to which the Company agreed to collaborate with respect to the TCR program. For the year ended December 31, 2023 the Company incurred clinical expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4efc3e77-8f89-49d3-9263-657f13a7529c" contextRef="C_7dad8626-c247-4cc6-80b0-0ea99635780c" name="tcrt:ClinicalExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from MD Anderson related to the 2015 R&amp;D Agreement, and did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c35b29ea-d9d2-4733-a253-fec6056ab122" contextRef="C_82b0d417-0325-416b-9745-26ad2cfd0d65" name="tcrt:ClinicalExpenses" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t incur clinical costs from MD Anderson related to the 2015 R&amp;D Agreement for the year ended December 31, 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term of the MD Anderson License, the Company, together with Precigen, shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if the Company and Precigen are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if the Company and Precigen are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by the Company and Precigen, if such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both the Company and Precigen and may be terminated by the mutual written agreement of the Company, Precigen, and MD Anderson.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Research and Development Agreement&#8212;The University of Texas MD Anderson Cancer Center</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the 2019 R&amp;D Agreement, the Company and MD Anderson will, among other things, collaborate on programs to expand the Company's TCR library and conduct clinical trials. The activities under the 2019 R&amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will own all inventions and intellectual property developed under the 2019 R&amp;D Agreement and the Company will retain all rights to all intellectual property, patentable or not, for oncology products manufactured using non-viral gene transfer technologies under the 2019 R&amp;D Agreement, including the Company's</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology. The Company has granted MD Anderson an exclusive license for such intellectual property to develop and commercialize autologous TCR products manufactured using viral gene transfer technologies and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any products outside the field of oncology and a non-exclusive license for allogenic TCR products manufactured using viral-based technologies.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the 2019 R&amp;D Agreement, the Company agreed, beginning on January 1, 2021, to reimburse MD Anderson up to a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9661da2-601d-4f19-84d1-c5f4fde2a99c" contextRef="C_46848514-696b-4f06-9e6b-d4096db50827" name="tcrt:AggregateAmountPotentiallyReimburseableAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for development costs under the 2019 R&amp;D Agreement, after the funds from the 2015 R&amp;D Agreement are exhausted. In addition, the Company will pay MD Anderson royalties on net sales of its TCR products. The Company is required to make performance-based payments upon the successful completion of clinical and regulatory benchmarks relating to its TCR products. The aggregate potential benchmark payments are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_866cfc9a-8360-4935-85e0-bc61767bd17d" contextRef="C_46848514-696b-4f06-9e6b-d4096db50827" name="tcrt:AggregatePotentialBenchmarkPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">36.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, of which only $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b6a34d7-e2f9-444b-9a73-e6148510a33d" contextRef="C_46848514-696b-4f06-9e6b-d4096db50827" name="tcrt:AccrualsPriorToFirstMarketingApproval" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will be due prior to the first marketing approval of the Company's TCR products. The royalty rates and benchmark payments owed to MD Anderson may be reduced upon the occurrence of certain events. The Company also agreed to sell its TCR products to MD Anderson at preferential prices and will sell the Company's TCR products in Texas exclusively to MD Anderson for a limited period of time following the first commercial sale of the Company's TCR products. For the years ended December 31, 2023 and 2022, the Company incurred clinical expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_396d8b43-5ec5-42ef-80fa-500a8e6eec0a" contextRef="C_db1f1c30-f159-463f-bb42-52af80ab87ba" name="tcrt:ClinicalExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9c4d1d5b-3610-42b3-aeba-703167aee121" contextRef="C_afef85da-f505-4cb3-8378-c367deebf43d" name="tcrt:ClinicalExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from MD Anderson related to the 2019 R&amp;D Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2019 R&amp;D Agreement will terminate on December 31, 2026 and either party may terminate the 2019 R&amp;D Agreement following written notice of a material breach. The 2019 R&amp;D Agreement also contains customary provisions related to indemnification obligations, confidentiality and other matters.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the execution of the 2019 R&amp;D Agreement, on October 22, 2019, the Company issued MD Anderson a warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ce16746-bb97-4e60-83df-1fd518672e1a" contextRef="C_37060ce3-beaa-4b5d-8b6b-3b25f9e47087" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">222,222</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, which is referred to as the MD Anderson Warrant. The MD Anderson Warrant has an initial exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9f91e8a-3dc8-45d6-96d7-fe6f61b1ea68" contextRef="C_37060ce3-beaa-4b5d-8b6b-3b25f9e47087" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" decimals="INF" format="ixt:num-dot-decimal">0.015</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c9a4053-38c1-48a5-842b-3d55fb07f31f" contextRef="C_37060ce3-beaa-4b5d-8b6b-3b25f9e47087" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and vests upon the occurrence of certain clinical milestones. As of December 31, 2023, the milestones have not been met.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreement with the NCI</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 28, 2019, the Company entered into a patent license agreement, or the Patent License, with the NCI. Pursuant to the Patent License, the Company held an exclusive, worldwide license to certain intellectual property to develop and commercialize patient-derived (autologous), peripheral blood T-cell therapy products engineered by transposon-mediated gene transfer to express TCRs reactive to mutated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS, TP53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neoantigens. In addition, pursuant to the Patent License, the Company held an exclusive, worldwide license to certain intellectual property for manufacturing technologies to develop and commercialize autologous, peripheral blood T-cell therapy products engineered by non-viral gene transfer to express TCRs, as well as a non-exclusive, worldwide license to certain additional manufacturing technologies. On May 29, 2019, January 8, 2020, September 28, 2020, April 16, 2021, May 4, 2021 and August 13, 2021 the Company amended the Patent License to expand its TCR library to include additional TCRs reactive to mutated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neoantigens licensed from the NCI.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The terms of the Patent License required the Company to pay the NCI minimum annual royalties in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aeb4016a-0b15-40a3-ac34-95ff98b7ca22" contextRef="C_d4b60ecf-6d80-4fa1-b071-1864dd9c10b1" name="tcrt:MinimumRoyaltiesAmountPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which amount would be reduced to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e48108f-09ef-4a01-9a7c-840b7806448f" contextRef="C_d4b60ecf-6d80-4fa1-b071-1864dd9c10b1" name="tcrt:RoyaltiesAmountPayableThereafter" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million once the aggregate minimum annual royalties paid by the Company equaled $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_656b94bc-894d-4854-82aa-1e512c2bc3e6" contextRef="C_d4b60ecf-6d80-4fa1-b071-1864dd9c10b1" name="tcrt:AggregateMinimumAnnualRoyaltiesPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company was also required to make performance-based payments upon successful completion of clinical and regulatory benchmarks relating to the licensed products. Of such payments, the aggregate potential benchmark payments were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9059c92f-88c0-4da3-b908-98793ac7128f" contextRef="C_d86720e4-1c24-43a1-bbdc-09b83278c5c5" name="tcrt:AggregateBenchmarkPaymentsPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, of which aggregate payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90b582b7-647d-4fc4-9ef7-db742e934aa5" contextRef="C_bcbf392a-4dba-4a84-ab43-3ee5a35cd906" name="tcrt:AggregateBenchmarkPaymentsPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million would be due only after marketing approval in the United States or in Europe, Japan, Australia, China or India. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_35b2dd21-b98a-4226-bfff-b7d4c4c99212" contextRef="C_c84cbaaa-b7b5-4569-80f5-59327bf2d4e3" name="tcrt:DescriptionOfFirstBenchmarkPayable"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The first benchmark payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5d084c2-51e0-4afb-9cf4-97f0c1e98d67" contextRef="C_919b08ce-ab39-4642-b52f-67c2d4317819" name="tcrt:InitialBenchmarkPaymentDue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was paid during the year ended December 31, 2022 upon the initiation of the Company's TCR-T Library Phase 1/2 Trial, which was a qualifying Phase 1 clinical trial under the terms of the Patent License.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Company was required to pay the NCI one-time benchmark payments following aggregate net sales of licensed products at certain aggregate net sales ranging from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb9b104b-d154-452d-87f5-ec9b68f0ba7c" contextRef="C_8e377f39-2755-46fa-ab15-461adb70dd68" name="tcrt:MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">250.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aed05913-549e-401a-8c61-ad56ebdfd6bd" contextRef="C_8e377f39-2755-46fa-ab15-461adb70dd68" name="tcrt:MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion. The aggregate potential amount of these benchmark payments was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eaec5b49-4802-4911-916a-125b732425ff" contextRef="C_3bcbadbe-09aa-42ba-8a38-e52fd3a5ad82" name="tcrt:PotentialBenchmarkPaymentsPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company was also required to pay the NCI royalties on net sales of products covered by the Patent License at rates in the low to mid-single digits depending upon the technology included in a licensed product. To the extent the Company entered into a sublicensing agreement relating to a licensed product, the Company would be required to pay the NCI a percentage of all consideration received from a sublicensee, which percentage would decrease based on the stage of development of the licensed product at the time of the sublicense.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Patent License was to expire upon expiration of the last patent contained in the licensed patent rights, unless terminated earlier. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b1d81f66-90f1-42a2-a99d-ab7880eed21d" contextRef="C_c84cbaaa-b7b5-4569-80f5-59327bf2d4e3" name="tcrt:DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The NCI could terminate or modify the Patent License in the event of a material breach, including if the Company did not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company could terminate the Patent License, or any portion thereof, in the Company's sole discretion at any time upon </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d817de8-2e78-457f-896d-eae0a828e873" contextRef="C_c84cbaaa-b7b5-4569-80f5-59327bf2d4e3" name="tcrt:AgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days&#8217; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">written notice to the NCI. In addition, the NCI had the right to: (i) require the Company to sublicense the rights to the product candidates covered by the Patent License upon certain conditions, including if the Company was not reasonably satisfying required health and safety needs and (ii) terminate or modify the Patent License, including if the Company was not satisfying requirements for public use as specified by federal regulations. On October 27, 2023, the Company provided the NCI the requisite notice of its intent to terminate the Patent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">effective December 26, 2023. The Company discovered multiple proprietary TCRs targeting driver mutations through its hunTR TCR discovery platform, including many of the same </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mutations licensed from the NCI.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023 the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcfc080a-cc5d-4f87-b058-2475a6a83658" contextRef="C_271f0dcf-64b5-4fbf-a9a4-9481a9d78720" name="tcrt:LicenseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of expenses and incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6aea52ee-122d-4b90-aed5-85b157417ece" contextRef="C_9e105059-91f4-41fa-bb01-cb0f4ed0fb32" name="tcrt:LicenseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of expenses for the year ended December 31, 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cooperative Research and Development Agreement (CRADA) with the NCI</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 9, 2017, the Company entered into a Cooperative Research and Development Agreement, or the CRADA, with the NCI. The purpose of this collaboration was to advance a personalized TCR-T approach for the treatment of solid tumors. Using the Company's </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology, the NCI would analyze a patient&#8217;s own cancer cells, identify their unique neoantigens and TCRs reactive against those neoantigens and then use the Company's </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology to transpose one or more TCRs into T cells for re-infusion. Research conducted under the CRADA was under the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI, in collaboration with the Company's researchers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company was responsible for providing the NCI with the test materials necessary for them to conduct their studies, and eventually, clinical trials pursuant to the CRADA. Inventions, data and materials discovered or produced in connection with performance of the research plan under the CRADA would have remained the sole property of the party who produced the discovery. The parties would have jointly owned all inventions jointly discovered under the research plan. The owner of any invention under the CRADA would have made the decision to file a patent covering the invention, or in the case of a jointly owned invention, the Company would have the first opportunity to file a patent covering the invention. If the Company failed to provide timely notice of its decision to the NCI or decided not to file a patent covering the joint invention, the NCI had the right to make the filing. For any invention solely owned by the NCI or jointly made by the NCI and the Company for which a patent application was filed, the U.S. Public Health service granted the Company an exclusive option to elect an exclusive or non-exclusive commercialization license. For inventions owned solely by the NCI or jointly owned by the NCI and the Company, which were licensed according to the terms described above, the Company agreed to grant to the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world. The Company was also required to grant the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world for any of the Company's solely owned inventions. The agreement could be terminated by any of the parties upon 60 days' prior written consent.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2019, the Company extended the CRADA with the NCI until January 9, 2022, committing an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68da5da6-aede-47f4-96d0-bae64412a102" contextRef="C_c2285624-3869-463c-86d8-22c65f4a4ba3" name="tcrt:ObligationsDueUnderContract" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to this program; however, for the third and fourth quarters of 2021, the Company was not required to make payments toward the program as agreed with the NCI. In March 2022, the Company entered into an amendment to the CRADA that is retroactive, effective January 9, 2022 to extend the term of the CRADA until January 9, 2023. In June 2022, the Company entered into the Fourth Amendment to the CRADA, or the CRADA Fourth Amendment, which, among other things, extended the term of the CRADA until January 9, 2025. In connection with the CRADA Fourth Amendment, the Company agreed to contribute $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18244394-58ca-4c17-9005-f716efb12d3b" contextRef="C_1b0fea0c-fa5c-4f28-a5af-abd1ad3285a6" name="tcrt:ContributionPayableOnPerAnnumBasis" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million per year, payable on a quarterly basis, beginning in the first quarter of 2023. The Company recorded expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41af8d00-9e29-4f5e-87ff-d905054b2940" contextRef="C_1b0fea0c-fa5c-4f28-a5af-abd1ad3285a6" name="tcrt:AnnualExpenseIncurred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023, compared to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1cbb805-c18c-4079-965d-2a63e2bf18d1" contextRef="C_ed3ce84b-d7e9-4796-87f3-b1cbfed8bb7c" name="tcrt:AnnualExpenseIncurred" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the year ended December 31, 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, the Company announced that it had provided the requisite notice to terminate the CRADA, pursuant to its terms, effective </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8fd0d596-094a-4b8c-8347-00aa4077e45a" contextRef="C_c6b3f307-9aef-450c-9206-261565a5306c" name="tcrt:AgreementTerminationDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 13, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, in light of the Company&#8217;s exploration of strategic alternatives.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent and Technology License Agreement&#8212;The University of Texas MD Anderson Cancer Center and the Texas A&amp;M University System</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 24, 2004, the Company entered into a patent and technology license agreement with MD Anderson and the Texas A&amp;M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes darinaparsin.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the agreement, the Company may be required to make additional payments to the Licensors upon achievement of certain milestones in varying amounts which, on a cumulative basis could total up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_174b5644-71c5-4f4d-acba-6338ae77dd17" contextRef="C_bef1fda7-f827-43a9-a2e5-5a8bc3c58ab2" name="tcrt:MilestonePaymentsMaximumAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In addition, the Licensors are entitled to receive royalty payments on sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances. During the year ended December 31, 2023, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2ff508c-2489-4b95-89ba-dc00e68b47a7" contextRef="C_d5a914c9-36ee-47c1-b8f0-1cd50fd2cc9e" name="tcrt:PaymentUnderLicenseAgreement" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t incur any milestone expenses under this agreement, and the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75db513a-219b-429b-91d5-5475e9d21e76" contextRef="C_d5a914c9-36ee-47c1-b8f0-1cd50fd2cc9e" name="tcrt:PaymentUnderLicenseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand in royalty expenses on sales under this agreement during the year ended December 31, 2023. During the year ended December 31, 2022, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_057850b7-a43d-4de1-a745-7c7334200f4a" contextRef="C_4e1408a8-5e0e-4b89-8b8c-917a420bac4c" name="tcrt:MilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">was incurred as a one-time milestone payment under</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terms of the agreement, and the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9955d8c-f5ea-4b27-aeb5-16c98978037b" contextRef="C_c3c26aba-b1fb-4834-9c5e-b8e01a5ecc3e" name="tcrt:PaymentUnderLicenseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand in royalty expenses on sales under this agreement during the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Agreement with Solasia Pharma K.K.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia Pharma K. K., or Solasia, which was amended on July 31, 2014 to include an exclusive worldwide license and amended on October 14, 2021 to revise certain payment schedule details, or, as so amended, the Solasia License and Collaboration Agreement. Pursuant to the Solasia License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms and related organic arsenic molecules, in all indications for human use.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As consideration for the license, the Company is eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenue generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company&#8217;s licensors, as defined in the Solasia License and Collaboration Agreement, will receive a portion of all milestone and royalty payments made by Solasia to the Company in accordance with the terms of the Solasia License and Collaboration Agreement with the licensors, as described above.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, Solasia announced that darinaparsin had been approved from relapsed or refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare in Japan. During the year ended December 31, 2023, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7657f58-d203-46f5-8a18-c3e684075d91" contextRef="C_a62dc996-32ea-430d-9357-c8af5aff9a7c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t earn collaboration revenue and earned $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84beb26d-4f37-4fd5-87ca-75feac7901be" contextRef="C_8d19272f-497c-47f6-a99d-591f9130da04" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand in royalty revenues on net sales under the Solasia License and Collaboration Agreement. During the year ended December 31, 2022, the Company earned $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98b6e073-c47f-4b46-85b5-16ab7ad5d6a4" contextRef="C_1270a725-670c-4033-b553-4b1ffa03336d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of collaboration revenue under the Solasia License and Collaboration Agreement primarily related to Solasia's achievement of certain sales-based milestones in Japan, and did not earn royalty revenues on net sales under the agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KBI Biopharma Litigation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 17, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b88dc6b-3942-4b0c-999d-ff04a7634a60" contextRef="C_5b40d2d6-501d-4e7d-8b78-1a53bdaa393a" name="us-gaap:LossContingencyNameOfPlaintiff"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KBI Biopharma</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Inc., or KBI, filed a complaint against the Company in the District Court of Harris County, Texas, 165th Judicial District, asserting breach of an Amended and Restated Master Services Agreement between the Company and KBI relating to the development of an autologous gene modified T-cell therapy product, or the KBI Agreement. KBI was primarily seeking unspecified monetary damages in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_224165f3-c2c3-4be0-8bf6-bd624b694b4c" contextRef="C_5b40d2d6-501d-4e7d-8b78-1a53bdaa393a" name="us-gaap:LossContingencyDamagesSoughtValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. On May 1, 2023, the Company filed an answer generally denying all of KBI&#8217;s allegations and asserting affirmative and other defenses as well as counterclaims for breach of the KBI Agreement and conversion. On October 20, 2023, the Company entered into an agreement with KBI to settle all claims asserted by KBI against the Company and the Company's counterclaims against KBI at issue in the litigation for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4c39402-b05c-4b67-b885-1ac0903c5a9e" contextRef="C_97c705ca-f124-47df-ba05-d7327601d771" name="us-gaap:LitigationSettlementExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_97d9cf1c-7a6e-4b81-8766-4e5e2c792fe4" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="tcrt:WarrantTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrants</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Company&#8217;s November 2018 private placement that provided net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc1ddb5d-5c61-4077-be67-e20657464987" contextRef="C_03dd637f-957e-4172-9001-e07d902c6e28" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">47.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, the Company issued warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f51c5fd3-a66c-4ac6-b3d4-f7a8c2f96e3c" contextRef="C_4bade1a4-e2fe-4751-93c1-f31838539841" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,262,626</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, which became exercisable six months after the closing of the private placement, or the November 2018 Warrants. The November 2018 Warrants had an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b50a59c9-8a8f-4ad9-ac5d-b32184fc8e97" contextRef="C_4bade1a4-e2fe-4751-93c1-f31838539841" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">45.15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and have a five-year term. The fair value of the November 2018 Warrants was estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44300fa8-499f-43d8-bdb3-e54d1cc93413" contextRef="C_532e995e-0f74-4893-864c-58c3f779b2e8" name="tcrt:FairValueOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">18.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million using a Black-Scholes model with the following assumptions: expected volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_861bfd46-fa44-4f57-b5d6-853bc27b4b9f" contextRef="C_532e995e-0f74-4893-864c-58c3f779b2e8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">71</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e569f53-6a73-4c1a-932d-7ff2cef5fb60" contextRef="C_532e995e-0f74-4893-864c-58c3f779b2e8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, expected life of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40fbedc4-c435-49b0-b813-42a7393873fe" contextRef="C_532e995e-0f74-4893-864c-58c3f779b2e8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c491cef-b9f1-4db3-ad23-93fb4c2283cc" contextRef="C_532e995e-0f74-4893-864c-58c3f779b2e8" name="us-gaap:Dividends" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 26, 2019 and September 12, 2019, the Company entered into agreements with existing investors whereby the investors exercised the November 2018 Warrants for an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc8f971f-2089-428f-920d-dbcdc1d908a5" contextRef="C_f2dfc65a-f1b4-4bd3-ae8f-235fa879ba0d" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,186,869</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3dea688b-26ad-48f7-a22a-219c0d4c2566" contextRef="C_f2dfc65a-f1b4-4bd3-ae8f-235fa879ba0d" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">45.15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. Proceeds from the warrant exercise after deducting placement agent fees and other related expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e3a253c-ab9d-4fee-b696-adefcee10117" contextRef="C_6eff864f-3158-4523-99bb-a0cf8c94ad47" name="tcrt:PlacementAgentFeesAndOtherRelatedExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04f05df7-6c6d-40fe-8435-7cdea016ac25" contextRef="C_c4120da5-aa3b-4ae8-8a1f-b0df2ff0da10" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">52.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company issued participating investors new warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17cbe2d8-9841-486d-903b-e93364d75ea6" contextRef="C_220d9373-ebbf-48e2-9ada-0496f791e56e" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,186,869</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional shares of common stock (the "2019 Warrants") as consideration for the warrant holders to exercise their November 2018 Warrants. The 2019 Warrants will expire on the fifth anniversary of the initial exercise date and have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fba17ff-1ccd-4fdc-a0fb-cb7b4944da40" contextRef="C_220d9373-ebbf-48e2-9ada-0496f791e56e" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">105.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The 2019 Warrants were valued using a Black-Scholes valuation model and resulted in a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abbe0462-2b2f-471b-8dc5-ba242f390447" contextRef="C_6240eae2-8099-486d-9b0b-6163532f0ff8" name="tcrt:NonOperatingIncomeExpenseInducementOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">60.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million non-cash charge in the Company&#8217;s statement of operations in 2019.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 22, 2019, the Company entered into the 2019 R&amp;D Agreement with MD Anderson. In connection with the execution of the 2019 R&amp;D Agreement, the Company issued the MD Anderson Warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9ab38b0-3bd4-4a89-97b9-6a3c4c94dff1" contextRef="C_c3fc31a6-03ef-43cc-97ab-fa4366fe7871" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">222,222</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The MD Anderson Warrant has an initial exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbe09c5c-2a46-4949-a822-aa5b699d20c5" contextRef="C_c3fc31a6-03ef-43cc-97ab-fa4366fe7871" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.015</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0603f136-4afc-4d91-aab0-40ccb35eebf4" contextRef="C_6e982006-943b-4fee-97ab-42236865abf4" name="tcrt:FairValueOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The MD Anderson Warrant expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f044e3c-a6e8-40b3-bc6b-b86c07b9399f" contextRef="C_c3fc31a6-03ef-43cc-97ab-fa4366fe7871" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and vests upon the occurrence of certain clinical milestones. The Company will recognize expense on the MD Anderson Warrant in the same manner as if the Company paid cash for services to be rendered. For the years ended December 31, 2023 and 2022, the Company did not recognize any expense related to the MD Anderson Warrant as the clinical milestones have not been achieved.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 6, 2021, the Company entered into the Loan and Security Agreement with SVB. Refer to Note 4, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In connection with the Loan and Security Agreement, the Company issued SVB warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96f52267-5558-4422-a49b-02124f7f5c3b" contextRef="C_db650e42-fee8-4d18-8c55-3c11a3ece9bc" name="us-gaap:CommonStockSharesSubscribedButUnissued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">28,856</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8274197e-35af-482d-9c46-8cedb5db661e" contextRef="C_c1da526c-ca16-481e-9bc7-b20e2797d243" name="us-gaap:CommonStockCallOrExerciseFeatures"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33.30</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The warrants have a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0242dfeb-4a26-400f-8f61-8fd44696656c" contextRef="C_db650e42-fee8-4d18-8c55-3c11a3ece9bc" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> life and were fully vested upon issuance. The fair value of the warrants was estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7eb98951-941d-4234-89ec-93fed6c44ab0" contextRef="C_5d722990-44ad-48ec-bab6-e38f76af3769" name="tcrt:FairValueOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million using a Black-Scholes model with the following assumptions: expected volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23318e7b-f660-47df-aa71-d8baab14cf5a" contextRef="C_5d722990-44ad-48ec-bab6-e38f76af3769" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22bede1d-bd95-43ce-96bd-3a01ecbac9ac" contextRef="C_5d722990-44ad-48ec-bab6-e38f76af3769" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.31</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, expected life of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6746e362-644c-4065-8326-d13915d8fb77" contextRef="C_5d722990-44ad-48ec-bab6-e38f76af3769" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4faf58a-9b21-4848-bb66-6aa911207ff7" contextRef="C_5d722990-44ad-48ec-bab6-e38f76af3769" name="us-gaap:Dividends" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends. On December 28, 2021, the Company entered into the First Amendment, as described in Note 4, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in connection with which, the original warrants issued to SVB were amended and restated. As amended and restated, the SVB Warrants are for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4d02a07-ad43-4c36-8159-4784d59147e2" contextRef="C_9eb8bb51-2ecf-42fc-9df9-3543c2498b7b" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">43,308</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, in the aggregate, with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_64c85b7f-9c38-49d2-b4c4-15227b7726bd" contextRef="C_ec1d55bd-1201-4107-bcad-9c39a5fd6ee6" name="us-gaap:CommonStockCallOrExerciseFeatures"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17.40</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The SVB Warrants expire on August 6, 2031 and were fully vested upon issuance. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_840fc5b9-5afa-43b5-944f-60757acac016" contextRef="C_7c575269-28b3-45c2-9022-f2fac466229a" name="tcrt:ClassOfWarrantOrRightWarrantsExercised" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">none</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the SVB Warrants have been exercised.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a5085f8d-a2d3-4678-85a0-4f2658f6d4a7" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restructuring</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, the Company announced a strategic reprioritization of its business and wind down of its TCR-T Library Phase 1/2 Trial. In connection with the reprioritization, the Company reduced its workforce during the third and fourth quarters of 2023. Concurrently, the Company began considering certain strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. During the year ended December 31, 2023, the Company recorded termination benefits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bb52f69-28ac-4d7d-bb24-d9e80ddd5f03" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:SeveranceCosts1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, recorded in restructuring costs within the statement of operations. The termination benefits were fully paid as of December 31, 2023.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_8fa5c478-4d5a-4f5a-98f3-4beb59eac23c" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no provision for income taxes because the Company has incurred operating losses since inception. The reported amounts of income tax expense for the years ended December 31, 2023 and 2022 differ from the amounts that would result from applying domestic federal statutory tax rates to pretax losses primarily because of the changes in the valuation allowance. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ff4cdb3-cc97-413a-ab56-4dcf28a782ed" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_1ff4cdb3-cc97-413a-ab56-4dcf28a782ed_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets at December 31, 2023 and 2022 are as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_1ff4cdb3-cc97-413a-ab56-4dcf28a782ed_1"><p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:12.923%;"/>
        <td style="width:1%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:12.923%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa962916-6cb2-4999-a20e-f437893b37c2" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148,009</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_080ffe87-7077-4552-846c-37129cc3dbb7" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">171,070</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Start-up and pre-clinical studies</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bfae520-1289-4095-9e01-ba02de9e3798" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="tcrt:DeferredTaxAssetsStartUpAndPreClinicalStudies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,754</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1054c29f-e158-413f-ba75-fa3f6fb4412c" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="tcrt:DeferredTaxAssetsStartUpAndPreClinicalStudies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,204</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8703552e-5e00-46dd-bf77-5a68ffd9b302" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,838</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c41166c2-b506-49ed-98fc-d20004c02667" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,116</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6c31848-7325-485a-b8c5-91d8394d8b6e" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">681</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8c85ef9-6077-43ee-8798-e863c5792ea0" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">698</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized acquisition costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c3ec787-e090-4c8c-881a-2890bccb687b" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="tcrt:DeferredTaxAssetsCapitalizedAcquisitionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,570</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9091cb0f-6334-408f-8503-21d86d25d836" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="tcrt:DeferredTaxAssetsCapitalizedAcquisitionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,180</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f328c3da-22a6-4e3e-a6c6-b138629c6c42" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="tcrt:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80fa05dc-2854-4ce5-8343-d1b6ebc435ad" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="tcrt:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">618</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af20ce3a-5501-46aa-95c7-b9f92dc874a1" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="tcrt:DeferredTaxAssetsDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b215203-9e68-4970-ae18-8306f95842f0" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="tcrt:DeferredTaxAssetsDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6489c932-9cfa-4752-9107-c3055926b4e3" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="tcrt:DeferredTaxAssetsResearchExpensesCapitalized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,176</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc9defed-f50f-483d-9b49-35152244b3e9" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="tcrt:DeferredTaxAssetsResearchExpensesCapitalized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,156</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68431c4c-0720-48de-bf4c-ff81406303b4" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0d70218-9baf-4e7b-bc6a-13d667dd3710" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c855339-db1a-4488-9b92-d2c219d272e9" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">211,031</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b55cc2c-b99e-453b-a9b9-abdb24f7700c" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">237,308</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d91eb4d-bb11-4bbb-af34-af0599823267" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">211,031</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff6ee13f-520c-48b6-8adc-30b97bc5b653" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236,827</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90786b30-7cb1-4cad-ae09-575a420b60e1" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cdad5b20-84ae-42e6-8b9a-f780307db7d5" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">481</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6eff5e4c-8f9b-436d-a704-f5daa5c364a0" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="tcrt:DeferredTaxLiabilityRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01d97356-10d0-48a0-985d-c34dd2d6747b" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="tcrt:DeferredTaxLiabilityRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">481</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05006676-09ca-4584-a3b1-375ac5c6466e" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aeeb343b-bc21-4012-a072-e512a06cf9b8" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">481</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_818b1f1e-f3ce-4544-b618-1f4a01f15662" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ed6d1cf-9e89-4e01-aa35-6ddf18a2fcd3" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. At December 31, 2023, the Company has aggregate net operating loss carryforwards for federal tax purposes of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e535fa6-da43-41fe-8b7d-a5aba6affe0d" contextRef="C_941cd6f3-5783-415e-b2da-d758935f04dc" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">704.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, of which approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05dd8a38-4104-4c72-bfa9-af3f446c0ac3" contextRef="C_d5434f85-d96c-496b-8794-5fd3bbc24ce8" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">341.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million expire at various dates through December 31, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f761efe8-7d38-4b8d-b20b-920b9eb84e4f" contextRef="C_c44e0959-6f71-4672-bea1-d6bc634b6ad9" name="tcrt:OperatingLossCarryforwardsExpirationDatesState"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2037 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4784b88a-c464-4e84-97a9-82347ad84c00" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">363.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million can be carried forward indefinitely. The Company is reducing its approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84caa237-019b-42f3-9c26-54d76bb428be" contextRef="C_5f040735-cf7c-45e8-b576-fbda049ff33e" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">497.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of state net operating loss carryforwards to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e97b2ab-f345-4901-9716-b8a84dbae578" contextRef="C_e0870a39-743c-4197-a2bf-d7b68c1a75eb" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as these state net operating loss carryforwards all related to Massachusetts filings and, as of December 31, 2023 the Company no longer had any employees or property in Massachusetts and, as a result, the Company will no longer have income tax nexus in Massachusetts or an income tax filing obligation after the year ended December 31, 2023. Additionally, the Company has approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0cb3cab-acd6-4aee-87f6-b0d4adff88cf" contextRef="C_25fd3671-b6ec-42c5-a84d-f3bb943d4679" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">39.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of federal and state research and development credits at December 31, 2023, expiring in varying amounts through </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b991c6cb-3309-44f0-a5d1-894155fa1a38" contextRef="C_2e188d5a-6779-4f0e-aeb1-22f1285c7349" name="tcrt:OperatingLossCarryforwardsResearchExpirationDates"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2043</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which may be available to reduce future taxes. The Company has reduced its Massachusetts credits carryforward to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3fb2508-894b-4dee-ad07-e5523a67bd11" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has provided a valuation allowance for the full amount of its net deferred tax assets since it is more likely than not that these future benefits will not be realized. However, these deferred tax assets may be available to offset future income tax liabilities and expenses. The valuation allowance decreased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0887cc76-ee99-4a49-ad5b-3ae5f18477ad" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">25.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in 2023 due primarily to the reduction of Massachusetts net operating loss carryforwards and Massachusetts research and development credits.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes using the federal statutory income tax rate differ from the Company&#8217;s effective tax rate primarily due to non-deductible expenses related to the Company&#8217;s issuance of warrants along with the change in the valuation allowance on deferred tax assets.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de951ad6-4258-4753-807b-8ce68311ba8a" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of income tax expense (benefit) at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.360000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.34%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal income tax at statutory rates</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbfe4132-186a-4e5d-9f42-7ca900035f7e" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e9265f6-29e1-499f-a893-c69486044239" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income tax, net of federal tax benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e4df151-9158-4030-bcba-f309e2c45d8b" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_216a2cc0-6687-4f46-b133-afc2d23b03e3" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a00034d-b644-45ce-9b15-2a5d7e170801" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ab3e13b-a6f9-41db-89a0-5b7be1811aa9" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development true-up</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_029faeaf-5370-48f8-84bf-80eb8ce79692" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_293822d0-8f7a-49e4-8f60-14d3777520fc" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1bb0a67-95a9-4437-9639-dfab9758a6b9" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8dd75218-bd78-4950-a218-2241504d8412" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal/state rate change</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f026270-2100-4bb0-99e8-8646d5b23357" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21721ae4-c555-493e-a1aa-f43738fe42d3" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ede46d50-be0b-4ffd-bd78-de621d1eafc7" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">73</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d5730a0-9dc1-45e7-9250-998ece1e9fd6" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f517ead0-9a47-4427-b773-04397e8f0ac7" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2690e5d-fb5b-43c3-a7b6-9efa67276f39" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company adopted ASC 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting for Uncertain Tax Positions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on January 1, 2007. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements in accordance with FASB Statement No. 109, &#8220;Accounting for Income Taxes.&#8221; ASC 740 prescribes a recognition threshold and measurement of a tax position taken or expected to be taken in a tax return. The Company did not establish any additional reserves for uncertain tax liabilities upon adoption of ASC 740. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4068645-0b51-4a1d-b7c2-fd6db7653e59" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4ee307a0-4b24-4928-aaba-acafbc239c54" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> adjustments to its uncertain tax positions in the years ended December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has not recognized any interest and penalties in the statements of operations because of the Company&#8217;s net operating losses and tax credits that are available to be carried forward. When necessary, the Company will account for interest and penalties related to uncertain tax positions as part of its provision for federal and state income taxes. The Company does not expect the amounts of unrecognized benefits will change significantly within the next twelve months.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is currently open to audit under the statute of limitations by the Internal Revenue Service and state jurisdictions for the years ended December 31, 1999 through 2023 to the extent net operating losses continue to be carried forward to 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Beginning in 2022, the Tax Cuts and Jobs Act of 2017, or the Tax Act, eliminated the option to deduct research and development expenditures immediately in the year incurred and requires taxpayers to capitalize and amortize them over five years pursuant to IRC Section 174. The mandatory capitalization requirement had no impact to the overall deferred tax assets due to the Company's loss position and full valuation allowance.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_033b2a15-9955-4192-9e4a-f643df1f3580" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock Option Plan</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company adopted the 2012 Equity Incentive Plan, or the 2012 Plan, in May 2012. Including subsequent increases, the Company had reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1eac0463-3094-4de2-83ef-2784f320e26e" contextRef="C_0982ca17-65ec-46e2-b808-c94e4aa0b3df" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">933,333</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares for issuance. On December 31, 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b58997cc-fa95-4894-a68f-4c93265cc177" contextRef="C_1a51d51e-d3d6-455b-ac86-ce8e857d2093" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,728</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares reserved for issuance and no shares available for future grant.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company adopted the 2020 Equity Incentive Plan, or the 2020 Plan, in June 2020. The Company reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c55faf3d-1795-4e07-8cc9-25a6d233fe88" contextRef="C_12319f01-0ffd-4415-8d9c-445e79250b84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,400,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares for issuance plus a carryover of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92a0b922-84b0-45b0-91f4-94e17ae84219" contextRef="C_d4a1c311-3a9e-4881-9787-deb17fe41e97" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">71,085</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares from the 2012 Plan for a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_342d803c-bcca-478b-9f59-c637f3d0f6c3" contextRef="C_12319f01-0ffd-4415-8d9c-445e79250b84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,471,085</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, returning shares from the 2012 Plan are available for issuance under the 2020 Plan. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a2dbb44-5063-4e1e-bf3d-bdee6de4a3c8" contextRef="C_c5e88f0f-cfd7-41a4-bf45-de43957559af" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">400,167</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares reserved for issuance and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88e12f30-26f1-4004-9f54-b3402b39c2fd" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,302,411</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for future grant.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock options generally vest ratably in either quarterly or annual installments over three or four years, commencing on the first anniversary of the grant date and have contractual terms of ten years. Stock options to directors generally vest ratably over one or two years and have contractual terms of ten years. Stock options are valued using the Black-Scholes option pricing model and compensation is recognized based on such fair value over the period of vesting on a straight-line basis.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b90791b1-2d16-4918-b7b3-4aa8e51b6a18" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> proceeds from option exercises during the year ended December 31, 2023 as compared to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3033177d-6aea-4b14-946c-e2c7da0ddbd3" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand during the year ended December 31, 2022. The intrinsic value of these options amounted to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_372ecb99-2389-49ba-9421-cf15d25da45c" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand for the year ended December 31, 2022.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b88c21a1-b584-4f92-9a09-0ed4a047244e" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity under the Company's stock options plans for the years ending December 31, 2023 and 2022 were as follows:</span></p><p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:8.942%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted- Average Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted- Average Contractual Term (Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_508b5950-0a0b-490a-9406-4bf4e6c0292d" contextRef="C_9e81976f-0dda-4005-94a7-17763001d331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">711,058</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fde087f-930c-47d8-9783-400fc31af37f" contextRef="C_9e81976f-0dda-4005-94a7-17763001d331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">43.05</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b13e483-fc0f-4618-a5cd-51e27b32c068" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">313,167</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fcdf489-cea2-4000-a864-bc29e48ee603" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a6e4df7-fd32-4916-a85d-61fd9c9652f3" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,750</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52878e53-6fca-4700-a5e4-a4701fcf0e38" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5832b686-1ee7-430a-8ef1-5850b80a9d2d" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">328,566</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_281ac761-fecc-4627-9226-61eebbbd63fd" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">50.10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96384b31-bcff-4c6a-afb1-a15c5929d742" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">693,909</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58a16e8e-3b4b-40f4-89be-2e2d4f3d31ed" contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">27.60</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e56e3da1-4f72-498f-8c8a-37a022198ba7" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">259,122</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9845eca-6190-4a01-8289-be5342c478c6" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.35</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_441608b5-fb44-46db-bd22-b5e27c5abc8c" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">487,133</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_253504ff-7ed5-4158-99bb-174075692a3d" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.70</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0fd2b02-290e-490b-bde0-08db40a0f33e" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">465,898</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbf8ee5e-4ad4-44e7-8181-26207371b3f7" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">26.85</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_3a6ed2db-e851-44d0-8114-9aae8af99eab" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.81</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75c2ec62-aa58-42d8-92f1-07bb23defd7c" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercisable, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ee13ece-e2a6-491b-b3d0-de6ad743944b" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">415,376</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8e4ad67-2c86-4960-b6de-bf06d747985c" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">28.80</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_46475b01-6a45-4e51-a4d6-eaa9521aff08" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.64</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_315eee6d-5b35-4f06-97c7-862f62ba8c69" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options available for future grant, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5517e9eb-f60a-4b9d-b4f6-b010cb3d4d85" contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,302,411</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 31, 2023, total unrecognized compensation costs related to non-vested stock options outstanding amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36ec86d5-a02b-406f-abfb-a1570098deeb" contextRef="C_5d5825d4-3830-441a-87c7-7eaf314a9d2c" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6997428-43f5-4f23-9bfd-67a5c8d38733" contextRef="C_11b50a8f-e3f7-4d6b-85de-985e603d9114" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.53</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023 the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ac736cb-dca7-47d5-beef-3f21033d0efc" contextRef="C_ae242319-1a7e-447c-b3ec-f37cbc585f56" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t issue</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares of restricted stock and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6606cdb-00b2-4624-b6fe-dc1d412ff82e" contextRef="C_c56bef7f-3b74-416e-b3f9-37e431049ea5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">18,667</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the year ended December 31, 2022 to directors. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a945c44d-d016-4a2b-bb29-b127da843c15" contextRef="C_ae242319-1a7e-447c-b3ec-f37cbc585f56" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> repurchases by the Company for the year ended December 31, 2023. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2022, the Company repurchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c68331d-897c-4a03-ad07-01fe19f562ba" contextRef="C_c56bef7f-3b74-416e-b3f9-37e431049ea5" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,250</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75a9e43a-205e-4edf-906e-e9f702b0dc5a" contextRef="C_f95291d4-e96b-46f8-b36c-1c199e1f5e39" name="us-gaap:SharePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">36.15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share to cover payroll taxes for one employee exercise, which is in accordance with the original terms of the award.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce0c1c0f-756d-4d71-9dc5-b65c1fa65b4a" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the status of restricted stock as of December 31, 2023 and 2022 is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.36%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.88%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested, December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ccc935f-7170-4e98-923d-38012d904a80" contextRef="C_cd40fe04-39eb-4618-9e08-4ccfc8585a11" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">79,905</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7862f059-966f-412f-99b5-076963a0d55e" contextRef="C_cd40fe04-39eb-4618-9e08-4ccfc8585a11" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">31.54</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b83d9da5-bf25-452a-af00-a9d5fd549c55" contextRef="C_63369074-a4f7-4fe2-8674-f1c4a1a3245e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">18,667</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f88d1f70-64ec-494c-9fe3-1734d53d5465" contextRef="C_63369074-a4f7-4fe2-8674-f1c4a1a3245e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.30</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05f9aa35-ad77-4786-91ce-5013f1f1c86f" contextRef="C_63369074-a4f7-4fe2-8674-f1c4a1a3245e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">20,441</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4df8c41-17ea-4809-9b4a-6170839111ef" contextRef="C_63369074-a4f7-4fe2-8674-f1c4a1a3245e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">34.21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c6cae1a-3fa6-4038-b905-c4d031fb9236" contextRef="C_63369074-a4f7-4fe2-8674-f1c4a1a3245e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">15,527</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4df4c0f4-ae5c-46a5-b59e-d6752d77fae3" contextRef="C_63369074-a4f7-4fe2-8674-f1c4a1a3245e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">47.23</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested, December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a36c485-cda8-42eb-863d-5fcba97875bb" contextRef="C_3c4cb663-e0ce-4562-a60a-f57ab1bd16cb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">62,604</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f24d15c5-bdb0-497a-beff-285b0c120e0e" contextRef="C_3c4cb663-e0ce-4562-a60a-f57ab1bd16cb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">21.04</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6ec5998-98c7-4e67-b095-6bb1b31953d8" contextRef="C_6dbf0481-cdd5-4b3c-8af0-560dbff890e7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">33,322</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ada6e08-e1ff-4e8a-9bda-04fb70ac7da1" contextRef="C_6dbf0481-cdd5-4b3c-8af0-560dbff890e7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.94</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_474944b5-66cc-4e8f-a5eb-56876ce4f6ca" contextRef="C_6dbf0481-cdd5-4b3c-8af0-560dbff890e7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">29,282</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07f285cc-1a33-405f-8df1-45699afc1ded" contextRef="C_6dbf0481-cdd5-4b3c-8af0-560dbff890e7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">24.60</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4258ea1-8c89-45f7-9946-b57653e31a09" contextRef="C_f8995cf5-f0d5-4e4e-99fc-41441a44780e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f1e9f89-8a10-4392-a357-41564271b235" contextRef="C_f8995cf5-f0d5-4e4e-99fc-41441a44780e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1e602d6-193c-4f9c-806c-2861940507a1" contextRef="C_f8995cf5-f0d5-4e4e-99fc-41441a44780e" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unrecognized stock-based compensation expense related to non-vested restricted stock arrangements.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d4c77a7-baea-4752-8bb5-5dc27d43a222" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employee Benefit Plan</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company sponsors a qualified 401(k) retirement plan under which employees are allowed to contribute certain percentages of their pay, up to the maximum allowed under Section 401(k) of the IRC, or the 401(k) Plan. The Company may make contributions to the 401(k) Plan at its discretion. The Company contributed approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d403e80e-4d28-497e-b174-3cffd94b9916" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to the 401(k) Plan during the year ended December 31, 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bd64422-4f18-4595-b947-a3191bbf03ef" contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the year ended December 31, 2022.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d64042ff-ef4a-4b62-8191-ae24d08a2335" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">15.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Joint Venture</span></div></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 18, 2018, the Company entered into a Framework Agreement with TriArm whereby the parties agreed to launch Eden BioCell, to lead clinical development and commercialization of certain </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-generated CAR-T therapies as set forth in a separate license agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 3, 2019, Eden BioCell was incorporated in Hong Kong as a private company. Eden BioCell, the Company and TriArm entered into a Share Subscription Agreement on January 23, 2019, where the Company and TriArm agreed to contribute certain intellectual property, services and cash (only with respect to TriArm) to Eden BioCell to subscribe for a certain number of newly issued ordinary shares in the share capital of Eden BioCell.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The closing of the transaction occurred on July 5, 2019. The Framework Agreement and Share Subscription Agreements were each respectively amended to be effective as of this date. Upon consummation of the joint venture, Eden BioCell and the Company also entered into a license agreement, pursuant to which the Company licensed the rights to Eden BioCell for third generation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-generated CAR-T therapies targeting the CD19 antigen for the territory of China (including Macau and Hong Kong), Taiwan and Korea. TriArm and the Company each received a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e211d675-3d39-4990-88bf-16f137825b28" contextRef="C_c4e43b9c-1c1a-4ee7-8310-f49b0b04362e" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% equity interest in the joint venture in exchange for their contributions to Eden BioCell.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that Eden BioCell was considered a variable interest entity, or VIE, and concluded that it was not the primary beneficiary of the VIE as it did not have the power to direct the activities of the VIE. As a result, the Company accounted for the equity interest in Eden BioCell under the equity method of accounting as it had the ability to exercise significant influence.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, TriArm and the Company mutually agreed to dissolve the joint venture, which has now been terminated. The Eden BioCell entity has been dissolved as of July 2023.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe504b48-a48b-4de5-8e4e-48c731286d1f" contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3" name="us-gaap:SubsequentEventsTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">16.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsequent Events</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluated all events and transactions that occurred after the balance sheet date through the date of this Annual Report on Form 10-K. Other than as described in the notes to the financial statements, the Company did not have any material subsequent events that impacted its financial statements or disclosures aside from the following.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 20, 2024, the Board of Directors appointed Dale Curtis Hogue, Jr. as Interim Chief Executive Officer of the Company, effective immediately. On January 21, 2024, the Company entered into an employment agreement with Mr. Hogue, under which he will receive an annual base salary of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cda8272-277f-478d-8f5c-400d1ddfed59" contextRef="C_8d0c8320-b169-4c12-9015-18779c3f403e" name="us-gaap:SalariesWagesAndOfficersCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">250</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand. Mr. Hogue was awarded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82ab4648-0d23-40a8-9f7e-ba97dbae7b8b" contextRef="C_8d0c8320-b169-4c12-9015-18779c3f403e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">40,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock of the Company with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0801d18-2e7b-4383-8b1f-8a767e82f0c6" contextRef="C_8d0c8320-b169-4c12-9015-18779c3f403e" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 15, 2024, Michael Wong gave notice of his resignation as Vice President, Finance, effective February 23, 2024. On February 22, 2024, the Company and Ferdinand Groenewald entered into a consulting agreement, or the Consulting Agreement, effective February 22, 2024, pursuant to which Mr. Groenewald will lead accounting and financial reporting activities of the Company. Mr. Groenewald will serve as the Company&#8217;s Vice President, Finance. The Consulting Agreement will continue indefinitely until terminated by either party upon </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a598809-9f7a-4e27-a9d4-3a9770bb20b2" contextRef="C_2a4b610b-874a-4c4c-a87e-050473791707" name="tcrt:AdvanceNoticePeriodForTerminationAgreement" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30 days</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217; advance notice. The Consulting Agreement provides for compensation at a fixed rate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc9b5349-f125-4b7f-b674-49009cfd1ebf" contextRef="C_c5399d8c-4124-42b7-a6a2-756bfbee1738" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand per month and reimbursement by the Company for any usual and customary business expenses incurred by Mr. Groenewald in connection with performing services pursuant to the Consulting Agreement. In addition, the Consulting Agreement provides for the Company to indemnify Mr. Groenewald on terms customary for officers.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.59
<SEQUENCE>2
<FILENAME>tcrt-ex10_59.htm
<DESCRIPTION>EX-10.59
<TEXT>
<html>
 <head>
  <title>EX-10.59</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.59</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CONSULTING AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Consulting Agreement (this &#x201c;Agreement&#x201d;), dated as of November 14, 2023, is made by and between Alaunos Therapeutics, Inc. (the &#x201c;Company&#x201d;) and Melinda Lackey (&#x201c;Consultant&#x201d;), (together the &#x201c;Parties&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">I</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">T</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">N</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">E</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">S</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">S</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">E</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">T</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">H</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> :</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, the Company desires to engage Consultant to provide services pursuant to the terms and conditions contained in this Agreement; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, Consultant desires to accept such engagement pursuant to the terms and conditions contained in this Agreement;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE, in consideration of the premises, and of the mutual covenants and agreements hereinafter contained, the parties agree as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  Consultant&#x2019;s services relationship with the Company will commence on November 16, 2023 (the &#x201c;Start Date&#x201d;) and will continue indefinitely until terminated in accordance with this Section 1.  Either party may terminate this Agreement by providing the other party with at least thirty (30) days of advance written notice of such decision.  The period of Consultant&#x2019;s services relationship with the Company, beginning on the Start Date, is referred to as the &#x201c;Term.&#x201d;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Services</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  During the Term, Consultant will be responsible for providing the Company with the services set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereto and such other services as the Parties may agree to from time to time (the &#x201c;Services&#x201d;).  Consultant may not subcontract or otherwise delegate Consultant&#x2019;s obligations under this Agreement without the Company&#x2019;s prior written consent.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compensation</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Service Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  As sole compensation for the performance of the Services, the Company will pay to Consultant the amount(s) and on the schedule specified in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereto.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Withholdings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Consultant acknowledges that the Company does not intend to make withholdings from any payments hereunder.  Consultant will have the exclusive responsibility for paying any taxes (including income taxes, social security contributions, and similar obligations) on such payments. At the appropriate time, the Company will provide Consultant with a Form 1099 for Consultant&#x2019;s tax purposes.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company will not provide Consultant with any benefits except as provided in this Agreement, nor will Consultant be entitled to participate in any benefit plan or arrangement of the Company or any affiliated entity of the Company, including without limitation any vacation benefit or insurance arrangement (the &#x201c;Company Benefit Plans&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Independent Contractor Status</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  Consultant acknowledges that, during the Term, Consultant&#x2019;s relationship with the Company will be that of an independent contractor, and not that of an employee of the Company.  Nothing herein will be deemed to establish a partnership, joint venture, or employment relationship between the parties. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Existing Obligations</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> This Agreement supplements and does not amend the responsibilities of the Parties with respect to agreements regarding confidential information, trade secrets, or invention or intellectual property assignment, including that certain Invention, Non-Disclosure, and Non-Solicitation Agreement dated November 17, 2021. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All notices and other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given (a) when delivered and received by the other party, or (b) two (2) business days after being sent when sent by recognized overnight courier to the following addresses:</font></div></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">if to the Company:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2617 Bissonnet St., Suite 225</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Houston TX 77005</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Attention:  legalteam@alaunos.com;</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">if to Consultant:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Melinda Lackey</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">mlackey@alaunos.com;</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">or to such other address as either party will have furnished to the other in writing in accordance with this Section 6, except that such notice of change of address shall be effective only upon receipt.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">D&amp;O Insurance</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  The Company has obtained and shall cause to be maintained in effect during the Term of this Agreement, with financially sound insurers, a policy of directors&#x2019; and officers&#x2019; liability insurance (the &#x201c;D&amp;O Policy&#x201d;). The Company and Consultant acknowledge and agree that, in providing the Services, Consultant will act as an officer of the Company, and the Company and Consultant expect and intend that Consultant shall be covered by the D&amp;O policy under no less favorable terms than any other individual covered by the D&amp;O policy. The provisions in this Section 7 shall survive the termination of this Agreement. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company shall defend and indemnify Consultant, to the fullest extent permitted by law against any and all threatened, pending, or completed action, suit, proceeding, or alternative dispute resolution mechanism, whether civil, criminal, administrative, arbitrative, investigative, or other, and whether made pursuant to federal, state, or other law (each, a &#x201c;Claim&#x201d;) against Consultant as a result of the Consultant&#x2019;s performance of the Services or as result of the Consultant&#x2019;s prior work as an employee and officer of the Company, including without limitation Claims brought by or in </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the right of the Company, Claims brought by third parties, and Claims in which Consultant is solely a witness.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Consultant shall have the right to advancement by the Company, prior to the final disposition of any Claim by final adjudication to which there are no further rights of appeal, of any and all Expenses (as that term is defined below) actually and reasonably paid or incurred by Consultant in connection with any Claim. Consultant&#x2019;s right to such advancement is not subject to the satisfaction of any standard of conduct. Without limiting the generality or effect of the foregoing, within ten (10) days after any written request by Consultant, the Company shall, in accordance with such request, (a) pay such Expenses on behalf of Consultant, (b) advance to Consultant funds in an amount sufficient to pay such Expenses, or (c) reimburse Consultant for such Expenses. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any and all expenses, including attorneys&#x2019; and experts&#x2019; fees, court costs, transcript costs, travel expenses, duplicating, printing, and binding costs, telephone charges, and all other costs and expenses incurred in connection with investigating, defending, being a witness in, or participating in (including on appeal), or preparing to defend, be a witness in, or participate in, any Claim.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Without limiting the generality or effect of the foregoing, Consultants right to indemnification and advancement of Expenses shall be no less favorable than that of any officer of the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The provisions in this Section 8 shall survive the termination of this Agreement. </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Miscellaneous</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	In the event that any of the provisions of this Agreement, or the application of any such provisions to Consultant or the Company with respect to obligations hereunder, is held to be unlawful or unenforceable by any court, then the remaining portions of this Agreement shall remain in full force and effect and shall not be invalidated or impaired in any manner.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	No waiver by any party of the breach of any term or covenant contained in this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such breach, or a waiver of any other term or covenant contained in this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	This Agreement (including all Exhibits hereto) contains the entire agreement between Consultant and the Company with respect to the subject matter of this Agreement (including all Exhibits hereto), and supersedes any and all prior agreements and understandings, whether verbal or written, between Consultant and the Company with respect to the subject matter of this Agreement (including all Exhibits hereto).  This Agreement may be amended only by an agreement in writing signed by Consultant and the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)	This Agreement may not be assigned by Consultant or the Company without the other party&#x2019;s consent, and any such attempted assignment shall be void and of no effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(e)	The terms and language of this Agreement are the result of arm&#x2019;s length negotiations between the parties.  Consequently, there shall be no presumption that any ambiguity in this Agreement should be resolved in favor of one party and against another.  Any controversy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">concerning the construction of this Agreement shall be decided neutrally without regard to authorship.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(f)	The titles and headings of sections and subsections contained in this Agreement are included solely for convenience of reference and will not control the meaning or interpretation of any of the provisions of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(g)	This Agreement may be executed in any number of counterparts, each of which so executed shall be deemed to be an original, and such counterparts shall together constitute but one agreement.  Each party may execute this Agreement in Adobe Portable Document Format or in a similar format (&#x201c;PDF&#x201d;) sent by electronic mail.  In addition, PDF signatures of authorized signatories of any party will be deemed to be original signatures and will be valid and binding, and delivery of a PDF signature by any party will constitute due execution and delivery of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(h)	This Agreement shall be governed by, and construed in accordance with, the laws of Texas, without giving effect to its conflict of laws principles.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, the parties have executed this Agreement effective as of the date first written above.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ALAUNOS THERAPEUTICS, INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">			</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CONSULTANT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_/s/ Michael Wong</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">__________			_</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_/s/ Melinda Lackey___</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">______</font></p>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">    Name:  	Michael Wong					Name:  Melinda Lackey</font></p>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">    Title:  	Vice President, Finance</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Description of Services</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Consultant shall provide legal, corporate and administrative services to the Company and other services as may be requested by the Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT B</font></p>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Service Fee</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a) 	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Service Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">: $ 400 per hourly rate paid in U.S. dollars by the Company to Consultant for the entire Term of this Agreement, unless otherwise agreed by the Company and Consultant in writing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">: The Company will reimburse Consultant for any usual and customary business expenses as may be reasonably required to provide the services to the Company for the term of this Agreement (e.g. office supplies, travel time and mileage).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c) 	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Payments to Consultant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">: Consultant will provide the Company a Statement of Services rendered, including hourly fees and expenses, every bi-weekly period during the Term of this Agreement. The payments for Statement of Services rendered will be delivered to Consultant within ten (10) business days upon receipt of the Statement of Services by the Company during the term of this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.60
<SEQUENCE>3
<FILENAME>tcrt-ex10_60.htm
<DESCRIPTION>EX-10.60
<TEXT>
<html>
 <head>
  <title>EX-10.60</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.60</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">December 20, 2023</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Dear Kevin,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Separation and Release Agreement (&#x201c;Agreement&#x201d;) follows up on our recent discussions concerning the termination of your employment with Alaunos Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  To assist you in your transition, the Company is offering you certain transitional benefits in exchange for a mutual, general release of claims and other terms set forth below.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The specific terms of the Agreement are as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination of Employment.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  Effective December 22, 2023, you will be relieved of all duties and not required to perform any additional services, you will be paid through and including December 22, 2023, which shall be your last day of employment with the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Separation Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  The Company will pay you all wages earned and any accrued and unused PTO in accordance with the Company&#x2019;s policies through your Separation Date.  You will receive these amounts regardless of whether you sign this Agreement.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Separation Pay</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In consideration for your execution of and compliance with this Agreement, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">provided that you execute, return, and do not revoke this Agreement pursuant to Section 11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, you shall receive a one-time lump sum separation payment representing six (6) months of your base salary and six (6) months of COBRA eligibility reflecting the same coverage as you currently hold with the Company (the &#x201c;Separation Payment&#x201d;), less all applicable income and payroll taxes, deductions and withholdings. The Separation Payment shall be paid to you on the next regularly scheduled pay day following the Effective Date (as that term is defined below) of this Agreement.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company reserves the right to withhold from any payments (including but not limited to the Separation Payment) to you all sums that it is required or allowed to withhold pursuant to applicable tax withholding laws or regulations.  You shall remain solely responsible for any and all income or other taxes due by you or assessed against you on payments made to you.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Benefits.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Healthcare Continuation Coverage</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If applicable, your healthcare coverage will cease as of the last day of the month in which the employment separation occurs.  However, you may be eligible to continue health insurance coverage at your own expense pursuant to the Consolidated Omnibus Budget Reconciliation Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">COBRA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Pursuant to COBRA, if you are eligible, you will be notified of the procedures to access health care continuation coverage by separate correspondence. All other employee benefits will terminate effective on your Separation Date.    </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Unemployment Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company agrees that if you decide to seek unemployment compensation benefits, it will not contest your application for </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">unemployment compensation.  The Company, however, will not provide any false information to any state agency.  The Company makes no representations concerning your eligibility for unemployment compensation.  You acknowledge and understand that any determination as to your eligibility for unemployment compensation is made solely by the state agency to which you apply for such benefits.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Other Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except as specifically set forth in this Agreement, and except as to any vested benefits, your right to, and participation in, all employee benefit plans of the Company shall terminate as of your Separation Date in accordance with the specific terms of each plan.  To the extent you have any vested assets in any employee benefit plan of the Company, the status and treatment of any such assets shall be governed by the applicable terms of such plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Acknowledgements.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  You acknowledge and agree that:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">this Agreement and the Separation Payment are neither intended to nor shall constitute a severance plan and shall confer no benefit on anyone other than the Company and you; and</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">except for (i) any unpaid regular wages (including accrued but unused vacation time) earned through (and including) the Separation Date, which shall be paid by the Company and (ii) any vested monies due to you pursuant to any retirement programs in which you participate, you have been paid and provided (or will be paid and provided by December 31, 2023) all wages, vacation pay, holiday pay, earned paid sick time, PTO, family and medical leave, bonuses, commissions and any other form of compensation or benefit that may be due to you now or which would have become due in the future in connection with your employment with or separation of employment from the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Return of Company Property.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  Except as agreed to for fulfillment of services under any consulting agreement entered into by you and the Company, you agree to relinquish access to or return to the Company, and agree that you will knowingly retain no copies of:  (a) all originals and copies of any proprietary or confidential information and trade secrets of the Company, whether in print, electronic or other form; (b) all originals and copies of Company and customer files, written materials, records and other documents, whether in print, electronic or other form, whether made by you or coming into your possession during the course of your employment with the Company; (c) all identification cards, keys, security passes or other means of access to Company facilities; and (d) any credit cards, or telephone cards.  All such property must be returned on or before your Separation Date or the expiration of any consulting agreement, whichever is later. In addition, on the Separation Date or the expiration of any consulting agreement, whichever is later, you will factory-reset your company laptop and company iPhone and ensure all data is deleted. After such deletion, you are permitted to retain this laptop and iPhone.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Confidentiality.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">You understand that nothing in this Agreement shall limit the rights of any government agency or entity or any party&#x2019;s right of access to, participation or cooperation </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	- </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> -	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">with any government agency or entity including, but not limited to, the Department of Justice, the Securities and Exchange Commission, Congress, and any agency Inspector General, nor shall anything in this Agreement limit your ability to make any other disclosures that are protected under the whistleblower provisions of federal law or regulation.  You understand that you do not need the prior authorization of the Company to make any such reports or disclosures and that you are not required to notify the Company that you have made such reports or disclosures.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">You agree to abide by any applicable common law and/or statutory obligations relating to the protection and non-disclosure of the Company&#x2019;s trade secrets and/or confidential and proprietary documents and information, and you specifically agree that you will not disclose any confidential or proprietary information that you acquired as an employee of the Company to any other person or entity, or use such information in any manner that is detrimental to the interests of the Company. </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Defend Trade Secrets Act Notice</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  Notwithstanding your confidentiality and nondisclosure obligations, you are hereby advised as follows pursuant to the Defend Trade Secrets Act: &#x201c;An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.&#x201d;</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Transition and Cooperation.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  Following the Separation Date, you agree to make yourself reasonably available to the Company to provide any information related to the transition of your duties.  You further agree to reasonably cooperate with and assist the Company as reasonably requested by the Company, with respect to any investigation, litigation, proceeding, arbitration or other formal or informal dispute resolution effort in which you are or have had involvement, is in regard to events that occurred during your tenure with the Company, or with respect to which you have relevant information by being reasonably available (i) to consult with the Company&#x2019;s counsel, and (ii) for interviews, depositions and/or testimony in regard to any such matters, except with respect to any such matter to which you are or may become a party.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Non-Filing of Complaint or Charges</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  You represent that you have not filed or asserted any cause of action, claim, charge or other action or proceeding against the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Knowledge of Misconduct</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. You represent that during the term of your employment with the Company, you have at all times conducted yourself in a lawful manner and that you are unaware of any act or omission on your part or the part of the Company that may constitute a violation of any law, regulation, or order, nor do you know of any basis on which any third party or governmental entity could assert such a claim.  This expressly includes any and all conduct that potentially could give rise to claims under the Sarbanes-Oxley Act of 2002.  You </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	- </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> -	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">further represent that you have disclosed any misconduct of which you are aware, including potential violations of Company policies.  You further affirm that you have no information concerning any conduct involving the Company that involves any false claims to the United States.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Release of All Claims. </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">You hereby acknowledge and agree that by signing this Agreement and accepting the Severance Payment, you are waiving your right to assert any form of legal claim against the Company of any kind whatsoever from the beginning of time through and including the date you sign this Agreement, except for claims related to the Company&#x2019;s failure to perform its obligations under this Agreement.  Your waiver and release is intended to bar any form of legal claim, charge, complaint or any other form of action (jointly referred to as &#x201c;Claims&#x201d;) (specifically including any claims of breach of contract whether express or implied, and claims sounding in intentional or unintentional torts such as negligence and fraud, and any statutory or regulatory claims)  against the Company seeking any form of relief including, without limitation, equitable relief (whether declaratory, injunctive or otherwise), the recovery of any damages or any other form of monetary recovery whatsoever (including, without limitation, back pay, front pay, compensatory damages, emotional distress damages, punitive damages, attorneys&#x2019; fees and any other costs) against the Company up through and including the date you sign this Agreement.  You understand that there could be unknown or unanticipated Claims resulting from your employment with the Company and the termination thereof and agree that such Claims are intended to be, and are, included in this waiver and release.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company herby acknowledges and agrees that by signing this Agreement and accepting the consideration herein, the Company is waiving its right to assert any form of legal claim against you, Kevin S. Boyle, Sr., of any kind whatsoever from the beginning of time through and including the Separation Date, except for claims related to any failure to perform your obligations under this Agreement.  The Company&#x2019;s waiver and release is intended to bar any Claims against you seeking any form of relief including, without limitation, equitable relief (whether declaratory, injunctive or otherwise), the recovery of any damages or any other form of monetary recovery whatsoever (including, without limitation, compensatory damages, emotional distress damages, punitive damages, attorneys&#x2019; fees and any other costs) against you up through and including the Separation Date.  The Company understands that there could be unknown or unanticipated Claims resulting from your employment with the Company and the termination thereof and agree that such Claims are intended to be, and are, included in this waiver and release.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Without limiting the foregoing general waiver and release, you specifically waive and release the Company from any Claims arising from or related to your employment relationship with the Company or the termination thereof, and the Company specifically waives and releases you from any Claims arising from or related to your employment relationship with the Company, including without limitation: </font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">i.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Claims under any local, state or federal discrimination, harassment, fair employment practices or other employment related statute, regulation or </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	- </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> -	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">executive order, including, without limitation, the Age Discrimination in Employment Act, the Older Workers Benefits Protection Act (&#x201c;OWBPA&#x201d;), the Americans with Disabilities Act, the Genetic Information Nondiscrimination Act, the Pregnancy Discrimination Act, the Worker Adjustment and Retraining Notification Act, the National Labor Relations Act, the Civil Rights Act of 1991, and Title VII of the Civil Rights Act of 1964, each as they may have been amended through the date you sign this Agreement;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">ii.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Claims under any local, state or federal employment related statute, regulation or executive order relating to wages, hours, whistleblowing, leaves of absence or any other terms and conditions of employment, including, without limitation, the Fair Labor Standards Act, the Equal Pay Act of 1963, and the Family and Medical Leave Act, in its entirety (including, without limitation, the sections concerning payment of wages, minimum wage and overtime), each as they may have been amended through the date you sign this Agreement; </font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">iii.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Claims under any local, state or federal common law theory; and </font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">iv.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">any other Claim arising under other local, state or federal law.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The general release in this Section 10 is not affected or limited by the recitation of the specific releases in this Section 10.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Consistent with federal and state discrimination laws, nothing in this release shall be deemed to prohibit you from challenging the validity of this release under federal or state discrimination laws or from filing a charge or complaint of age or other employment related discrimination with the Equal Employment Opportunity Commission (&#x201c;EEOC&#x201d;) or similar state agency, or from participating in any investigation or proceeding conducted by the EEOC or similar state agency.  Further, nothing in this release or Agreement shall be deemed to limit the Company&#x2019;s right to seek immediate dismissal of such charge or complaint on the basis that your signing of this Agreement constitutes a full release of any individual rights under federal or state discrimination laws, or the Company&#x2019;s right to seek restitution or other legal remedies to the extent permitted by law of the economic benefits provided to you under this Agreement in the event that you successfully challenge the validity of this release and prevail in any claim under federal or state discrimination laws.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The general release in this Section 10 shall not limit any right you may have to receive a whistleblower award or bounty for information provided to the Securities and Exchange Commission. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Important Notice Regarding Release of Claims of Age Discrimination.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">You acknowledge that you knowingly and voluntarily enter into this Agreement with the purpose of waiving and releasing any age discrimination claims you may have under the Age Discrimination in Employment Act (&#x201c;ADEA&#x201d;), including the Older Workers Benefit Protection Act (&#x201c;OWBPA&#x201d;), and you acknowledge and agree that:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">this Agreement is written in a manner in which you fully understand;</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	- </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> -	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">you specifically waive any rights or claims arising under the ADEA;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">your agreement to all of the terms set forth in this Agreement is knowing and voluntary;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">you are not waiving rights or claims under the ADEA that may arise after the date this Agreement is executed;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the rights and claims waived in this Agreement are in exchange for consideration over and above anything to which you are already entitled; </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">you have been and are hereby advised in writing to consult with an attorney prior to executing this Agreement, and has, in fact, had an opportunity to do so; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">as required pursuant to the OWBPA, you are being provided with information in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> to this Agreement which employees are eligible for Severance Payment.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Time for Acceptance; Effective Date.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">You have been given a period of up to forty-five (45) calendar days, if desired, within which to consider this Agreement and, in the event you decide to execute this Agreement in fewer than forty-five (45) calendar days, you acknowledge that you have done so with the express understanding that you have been given and declined the opportunity to consider this Agreement for a full forty-five (45) calendar days.  You further acknowledge that your decision to sign the Agreement in fewer than forty-five (45) calendar days was not induced by the Company through fraud, misrepresentation, or a threat to withdraw or alter the offer prior to the expiration of the forty-five (45) day time period.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">You have the right to revoke this waiver and release of any claims under the ADEA covered by this Agreement within seven (7) calendar days from the date you execute this Agreement (the &#x201c;Revocation Period&#x201d;).  This Agreement shall not be effective until such Revocation Period has expired without you having exercised your revocation rights.  Thus, this Agreement will become final, binding and enforceable on the eighth (8</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">) calendar day after you execute and deliver this Agreement to the Company (&#x201c;the Effective Date&#x201d;), provided it has not been duly revoked in accordance with the terms herein.  Notice of revocation must be made in writing and received by the Company prior to the conclusion of the Revocation Period.   In order to constitute notice of acceptance and/or revocation hereunder, such notice must be delivered to Michael Wong, Vice President, Finance at info@alaunos.com.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Agreement will be null and void and no Separation Payment or other benefit offered to you pursuant to Paragraph 6 above will be paid if: (i) you do not sign it within the forty-five (45) day period, or (iii) you revoke your execution within the Revocation Period.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	- </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> -	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Miscellaneous.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Non-Admission</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement does not constitute an allegation, admission or acknowledgment by any party of any unlawful or improper act or conduct, all of which is expressly denied.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement constitutes the full understanding and entire Agreement between you and the Company and supersedes any other agreements of any kind, whether oral or written, formal or informal; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, that you shall remain bound by your continuing obligations to preserve the Company&#x2019;s trade secrets, intellectual property, and confidential information, and you and the Company expressly agree that except for the non-competition obligation set forth in Section 3, which the Company hereby waives, the Invention, Non-Disclosure, Non-Solicitation and Non-Competition Agreement that you signed with the Company (a copy of which is provided in your packet) shall remain in full force and effect.  The parties represent and acknowledge that in signing this Agreement, each has not relied upon any representation or statement made by the other not set forth in this Agreement. </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The parties agree that the failure of a party at any time to require performance of any provision of this Agreement shall not affect, diminish, obviate or void in any way the party&#x2019;s full right or ability to require performance of the same or any other provision of this Agreement at any time thereafter.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Successor and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The rights and benefits of the Company under this Agreement shall be assignable to any successor, related or affiliated entity. All rights and obligations under this Agreement shall inure to the benefit of and be binding upon your successors but shall be personal and non-assignable by you.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Governing Law; Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement shall be construed in accordance with and governed by the laws of the state of Texas without regard to the conflict of law principles thereof. Both parties agree that any action, demand, claim or counterclaim relating to (i) your employment and separation of your employment, and (ii) the terms and provisions of this Agreement or to its breach, shall be commenced solely and exclusively in the state of Texas in a court of competent jurisdiction.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">JURY WAIVER</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  BOTH PARTIES FURTHER AGREE THAT ANY DISPUTE REGARDING THE COMPLIANCE WITH OR ENFORCEABILITY OF THIS AGREEMENT SHALL BE TRIED BY A JUDGE ALONE, AND BOTH PARTIES HEREBY WAIVE AND FOREVER RENOUNCE THE RIGHT TO A TRIAL BEFORE A CIVIL JURY IN ANY SUCH DISPUTE.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement is intended to be severable.  Should any portion, term or provision of this Agreement be declared or determined by any court to be illegal, invalid or unenforceable, the validity of the remaining portions, terms and provisions, and the application of such portion, term or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	- </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> -	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">thereby, and the illegal, invalid or unenforceable portion, term or provision shall be valid and enforceable to the fullest extent permitted by applicable law.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Construction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The headings of the paragraphs of this Agreement are for convenience only and are not binding on any interpretation of this Agreement.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Modifications</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. No variations or modifications hereof shall be deemed valid unless reduced to writing and signed by the Company and you. </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">It is the Company&#x2019;s desire and intent to make certain that you fully understand the provisions and effects of this Agreement.  To that end, you have been encouraged and given an opportunity to consult with legal counsel.  By executing this Agreement, you are acknowledging that (a) you have been afforded sufficient time to understand the provisions and effects of this Agreement and to consult with legal counsel; (b) your agreements and obligations under this Agreement are made voluntarily, knowingly and without duress; and (c) neither the Company nor its agents or representatives have made any representations inconsistent with the provisions of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If you wish to accept this Agreement, please sign and date the Agreement below and return it to me within the time period specified in Section 12.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">We wish you every success for the future.</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sincerely,</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_/s/ Michael Wong_______</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Michael Wong</font></p>
  <p style="margin-left:40%;text-indent:11.111%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vice President, Finance</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">By signing this Agreement, I state that I have read it, I understand it, I agree with everything in it and I have signed it knowingly and voluntarily under seal.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_/s/ Kevin S. Boyle, Sr.___</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Kevin S. Boyle, Sr.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	- </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> -	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ADEA WAIVER INFORMATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The applicable business unit is all personnel employed by Alaunos Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), in its Research &amp; Development, General &amp; Admin, and Technical Operations groups.</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The job titles listed below were selected or not selected for the elimination of their position and offered severance pay.  All individuals who are being offered payment of severance, such offer is contingent upon and subject to entering into a Separation and Release Agreement and General Release (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Separation Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All persons who are being offered severance subject to a Separation Agreement must sign the Separation Agreement and return it to the Company.</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The following is a list of the job title and ages of individuals employed by the Company in the applicable Research &amp; Development, General &amp; Admin, and Technical Operations groups who were and were not selected for the offer of severance in exchange for entering into a Separation Agreement:</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">JOB TITLES AND AGES OF EMPLOYEES SELECTED</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">FOR TERMINATION AND ELIGIBLE FOR SEVERANCE PAYMENT OFFER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:63.14%;"></td>
    <td style="width:36.86%;"></td>
   </tr>
   <tr style="height:20.9pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">JOB TITLE</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">AGES</font></p></td>
   </tr>
   <tr style="height:15.85pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">JOB TITLES AND AGES OF EMPLOYEES </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NOT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> SELECTED</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">FOR TERMINATION AND ARE INELIGIBLE FOR SEVERANCE PAYMENT OFFER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:75.38%;"></td>
    <td style="width:24.62%;"></td>
   </tr>
   <tr style="height:20.9pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">JOB TITLE</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">AGES</font></p></td>
   </tr>
   <tr style="height:12.95pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vice President</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	- </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> -	</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.61
<SEQUENCE>4
<FILENAME>tcrt-ex10_61.htm
<DESCRIPTION>EX-10.61
<TEXT>
<html>
 <head>
  <title>EX-10.61</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.61</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CONSULTING AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Consulting Agreement (this &#x201c;Agreement&#x201d;), dated as of December 22, 2023, is made by and between Alaunos Therapeutics, Inc. (the &#x201c;Company&#x201d;) and Kevin S. Boyle Sr. (&#x201c;Consultant&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">I</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">T</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">N</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">E</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">S</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">S</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">E</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">T</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">H</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> :</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, the Company desires to engage Consultant to provide services pursuant to the terms and conditions contained in this Agreement; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, Consultant desires to accept such engagement pursuant to the terms and conditions contained in this Agreement;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE, in consideration of the premises, and of the mutual covenants and agreements hereinafter contained, the parties agree as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  Consultant&#x2019;s services relationship with the Company will commence on January 1, 2024 (the &#x201c;Start Date&#x201d;) and will continue for a period of six (6) months. The period of Consultant&#x2019;s services relationship with the Company, beginning on the Start Date, is referred to as the &#x201c;Term.&#x201d;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Services</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  During the term, Consultant will be responsible for providing the Company with the services set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereto and such other services as the parties may agree to from time to time (the &#x201c;Services&#x201d;).  Consultant may not subcontract or otherwise delegate Consultant&#x2019;s obligations under this Agreement without the Company&#x2019;s prior written consent. While providing the Services, the Consultant will not have specified hours but will be required to make himself reasonably available. The Company shall provide electronic access to Company systems and facilities to facilitate Consultant&#x2019;s services, including email.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Non-Exclusivity</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Nothing in this Agreement shall prevent Contractor from seeking or accepting other employment, consulting engagements, or board positions with other companies or organizations, provided that such activities do not (i) create a conflict of interest with the Company&#x2019;s business or the Services; or (ii) violate any confidentiality obligations owed by the Contractor to the Company under this or any other agreement. </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compensation</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Service Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  As sole compensation for the performance of the Services, the Company will pay to Consultant the amount(s) and on the schedule specified in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereto.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Withholdings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Consultant acknowledges that the Company does not intend to make withholdings from any payments hereunder.  Consultant will have the exclusive</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">responsibility for paying any taxes (including income taxes, social security contributions, and similar obligations) on such payments. At the appropriate time, the Company will provide Consultant with a Form 1099 for Consultant&#x2019;s tax purposes.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company will not provide Consultant with any benefits except as provided in this Agreement, nor will Consultant be entitled to participate in any benefit plan or arrangement of the Company or any affiliated entity of the Company, including without limitation any vacation benefit or insurance arrangement (the &#x201c;Company Benefit Plans&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Independent Contractor Status</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  Consultant acknowledges that, during the Term, Consultant&#x2019;s relationship with the Company will be that of an independent contractor, and not that of an employee of the Company.  Nothing herein will be deemed to establish a partnership, joint venture, or employment relationship between the parties. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Existing Obligations</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> This Agreement supplements and does not amend the responsibilities of the Parties with respect to agreements regarding confidential information, trade secrets, or invention or intellectual property assignment. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All notices and other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given (a) when delivered and received by the other party, or (b) two (2) business days after being sent when sent by recognized overnight courier to the following addresses:</font></div></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">if to the Company:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2617 Bissonnet, Suite 225</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Houston TX 77054<br>Attention:  Legal Team</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Email: legalteam@alaunos.com;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">if to Consultant:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Kevin S. Boyle, Sr.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">or to such other address as either party will have furnished to the other in writing in accordance with this Section 7, except that such notice of change of address shall be effective only upon receipt.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">D&amp;O Insurance</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  The Company has obtained and shall cause to be maintained in effect during the Term of this Agreement, with financially sound insurers, a policy of directors&#x2019; and officers&#x2019; liability insurance (the &#x201c;D&amp;O Policy&#x201d;). The Company and Consultant acknowledge and agree that, in providing the Services, Consultant will act as an officer of the Company, and the Company and Consultant expect and intend that Consultant shall be covered by the D&amp;O policy </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">under no less favorable terms than any other individual covered by the D&amp;O policy. The provisions in this Section 8 shall survive the termination of this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company shall defend and indemnify Consultant, to the fullest extent permitted by law against any and all threatened, pending, or completed action, suit, proceeding, or alternative dispute resolution mechanism, whether civil, criminal, administrative, arbitrative, investigative, or other, and whether made pursuant to federal, state, or other law (each, a &#x201c;Claim&#x201d;) against Consultant as a result of the Consultant&#x2019;s performance of the Services or as result of the Consultant&#x2019;s prior work as an employee and officer of the Company, including without limitation Claims brought by or in the right of the Company, Claims brought by third parties, and Claims in which Consultant is solely a witness. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Consultant shall have the right to advancement by the Company, prior to the final disposition of any Claim by final adjudication to which there are no further rights of appeal, of any and all Expenses (as that term is defined below) actually and reasonably paid or incurred by Consultant in connection with any Claim. Consultant&#x2019;s right to such advancement is not subject to the satisfaction of any standard of conduct. Without limiting the generality or effect of the foregoing, within ten (10) days after any written request by Consultant, the Company shall, in accordance with such request, (i) pay such Expenses on behalf of Consultant, (ii) advance to Consultant funds in an amount sufficient to pay such Expenses, or (iii) reimburse Consultant for such Expenses. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any and all expenses, including attorneys&#x2019; and experts&#x2019; fees, court costs, transcript costs, travel expenses, duplicating, printing, and binding costs, telephone charges, and all other costs and expenses incurred in connection with investigating, defending, being a witness in, or participating in (including on appeal), or preparing to defend, be a witness in, or participate in, any Claim.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Without limiting the generality or effect of the foregoing, Consultants right to indemnification and advancement of Expenses shall be no less favorable than that of any officer of the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The provisions in this Section 9 shall survive the termination of this Agreement. </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Miscellaneous</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	In the event that any of the provisions of this Agreement, or the application of any such provisions to Consultant or the Company with respect to obligations hereunder, is held to be unlawful or unenforceable by any court, then the remaining portions of this Agreement shall remain in full force and effect and shall not be invalidated or impaired in any manner.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	No waiver by any party of the breach of any term or covenant contained in this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such breach, or a waiver of any other term or covenant contained in this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	This Agreement (including all Exhibits hereto) contains the entire agreement between Consultant and the Company with respect to the subject matter of this Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(including all Exhibits hereto), and supersedes any and all prior agreements and understandings, whether verbal or written, between Consultant and the Company with respect to the subject matter of this Agreement (including all Exhibits hereto).  This Agreement may be amended only by an agreement in writing signed by Consultant and the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)	This Agreement may not be assigned by Consultant or the Company without the other party&#x2019;s consent, and any such attempted assignment shall be void and of no effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(e)	The terms and language of this Agreement are the result of arm&#x2019;s length negotiations between the parties.  Consequently, there shall be no presumption that any ambiguity in this Agreement should be resolved in favor of one party and against another.  Any controversy concerning the construction of this Agreement shall be decided neutrally without regard to authorship.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(f)	The titles and headings of sections and subsections contained in this Agreement are included solely for convenience of reference and will not control the meaning or interpretation of any of the provisions of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(g)	This Agreement may be executed in any number of counterparts, each of which so executed shall be deemed to be an original, and such counterparts shall together constitute but one agreement.  Each party may execute this Agreement in Adobe Portable Document Format or in a similar format (&#x201c;PDF&#x201d;) sent by electronic mail.  In addition, PDF signatures of authorized signatories of any party will be deemed to be original signatures and will be valid and binding, and delivery of a PDF signature by any party will constitute due execution and delivery of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(h)	This Agreement shall be governed by, and construed in accordance with, the laws of Texas, without giving effect to its conflict of laws principles.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, the parties have executed this Agreement effective as of the date first written above.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ALAUNOS THERAPEUTICS, INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">			</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CONSULTANT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By: _/s/ Michael Wong__________			__/s/ Kevin S. Boyle Sr._____</font></p>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">    Name:  	Michael Wong					Name:  Kevin S. Boyle Sr.</font></p>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">    Title:  	Vice President, Finance</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Description of Services</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Consultant, in their capacity as a former CEO, will provide the following Services:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a) </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Strategic Advisory:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> The Consultant will provide strategic advice and insights based on their experience and knowledge of the Company&#x2019;s operations, industry trends, and competitive landscape.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b) </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Other Services:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> The Consultant will perform other services as mutually agreed upon between the Company and the Consultant from time to time.</font></p>
  <p style="text-indent:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Consultant agrees to provide the Services in a professional and diligent manner, consistent with industry standards and in compliance with the Company&#x2019;s policies and procedures. The Consultant may not subcontract or otherwise delegate their obligations under this Agreement without the Company&#x2019;s prior written consent. While providing the Services, the Consultant will not have specified hours but will be required to make themselves reasonably available.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT B</font></p>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Service Fee</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a) 	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Service Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">: $15,000.00 per month paid in U.S. dollars by the Company to Consultant for the entire Term of this Agreement, unless otherwise agreed by the Company and Consultant in writing, payable at the beginning of each month with no invoice required from Consultant.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">: The Company will reimburse Consultant for any usual and customary business expenses as may be reasonably required to provide the services to the Company for the term of this Agreement (e.g. office supplies, travel time and mileage).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.62
<SEQUENCE>5
<FILENAME>tcrt-ex10_62.htm
<DESCRIPTION>EX-10.62
<TEXT>
<html>
 <head>
  <title>EX-10.62</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.62</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CONSULTING AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Consulting Agreement (this &#x201c;Agreement&#x201d;), dated as of February 22, 2024, is made by and between Alaunos Therapeutics, Inc. (the &#x201c;Company&#x201d;) and Ferdinand Groenewald (&#x201c;Consultant&#x201d;), (together the &#x201c;Parties&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">I</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">T</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">N</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">E</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">S</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">S</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">E</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">T</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">H</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> :</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, the Company desires to engage Consultant to provide services pursuant to the terms and conditions contained in this Agreement; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, Consultant desires to accept such engagement pursuant to the terms and conditions contained in this Agreement;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE, in consideration of the premises, and of the mutual covenants and agreements hereinafter contained, the parties agree as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  Consultant&#x2019;s services relationship with the Company will commence on Thursday, February 22, 2023 (the &#x201c;Start Date&#x201d;) and will continue indefinitely until terminated in accordance with this Section 1.  Either party may terminate this Agreement by providing the other party with at least thirty (30) days of advance written notice of such decision.  The period of Consultant&#x2019;s services relationship with the Company, beginning on the Start Date, is referred to as the &#x201c;Term.&#x201d;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Services</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  During the Term, Consultant will be responsible for providing the Company with the services set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereto and such other services as the Parties may agree to from time to time (the &#x201c;Services&#x201d;).  Consultant may not subcontract or otherwise delegate Consultant&#x2019;s obligations under this Agreement without the Company&#x2019;s prior written consent.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compensation</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Service Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  As sole compensation for the performance of the Services, the Company will pay to Consultant the amount(s) and on the schedule specified in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereto.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Withholdings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Consultant acknowledges that the Company does not intend to make withholdings from any payments hereunder.  Consultant will have the exclusive responsibility for paying any taxes (including income taxes, social security contributions, and similar obligations) on such payments. At the appropriate time, the Company will provide Consultant with a Form 1099 for Consultant&#x2019;s tax purposes.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company will not provide Consultant with any benefits except as provided in this Agreement, nor will Consultant be entitled to participate in any benefit plan or arrangement of the Company or any affiliated entity of the Company, including without limitation any vacation benefit or insurance arrangement (the &#x201c;Company Benefit Plans&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Independent Contractor Status</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  Consultant acknowledges that, during the Term, Consultant&#x2019;s relationship with the Company will be that of an independent contractor, and not that of an employee of the Company.  Nothing herein will be deemed to establish a partnership, joint venture, or employment relationship between the parties. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Confidentiality</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Consultant </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">acknowledges</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> and agrees that this Agreement creates a relationship of confidence and trust on the part of Consultant as Consultant provides Services for the benefit  of the Company. In the performance of Consultant&#x2019;s obligations under this Agreement, Consultant and its principals, agents, employees and contractors may receive, create for the Company and/or have access to, among other things, technical, customer, personnel and business information in written, graphic, oral or other tangible forms such as specifications, records, data, computer programs, drawings, models, reports and samples (collectively referred to as &#x201c;Confidential Information&#x201d;) owned or controlled by the Company. Such Confidential Information contains material that is proprietary or confidential, or material that is protected by applicable laws regarding secrecy of communications or trade secrets. Accordingly: </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Consultant recognizes and agrees that nothing in this Agreement will be construed as granting any rights, by license or otherwise, to any Confidential Information or to any inventions or patents, trade secrets, copyrights, trademarks, or other intellectual property right that has issued or that may issue based on such Confidential Information. All Confidential Information (including all copies thereof) will at all times remain the property of the Company and will be immediately returned to the Company after Consultant&#x2019;s need for it has expired, or upon request of the Company, and in any event, upon completion or termination of the Services to be provided by Consultant. At such time, Consultant shall also erase, delete, or destroy any notes, documents, magnetic media or other computer storage, including system backups, which contain any Confidential Information. </font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Consultant will advise its principals, employees, agents and contractors who might have access to Confidential Information of the confidential nature thereof and agrees that its employees will be bound by the terms of this Agreement. Consultant will not disclose any Confidential Information to any employee except for those persons who have a need for such information in connection with Consultant rendering the Services and who agree in writing to bound by the provision of this Agreement, nor will it disclose any Confidential Information to any third party without first obtaining the Company&#x2019;s express written consent, which may be withheld in the sole discretion of the Company. For the purposes of this Sub- section (b), the term &#x201c;employee&#x201d; will include, in addition to employees, directors, officers, members, owners, independent contractors, consultants, collaborators and other agents of the Consultant.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The term &#x201c;Confidential Information&#x201d; will not include information that Consultant can establish (i) was publicly known and made generally available in the public domain prior to the time of disclosure to Consultant; (ii) becomes publicly known and made generally available after disclosure to Consultant through no action or inaction of Consultant; (iii) is in the possession of Consultant, without confidentiality restrictions, at the time of disclosure by the Company, as shown by Consultant&#x2019;s files and records immediately prior to the time of disclosure; or (iv) is approved for release by the Company in writing. Moreover, this confidentiality restriction shall not apply to information that is required by law or regulation or required pursuant to a valid order of a court or regulatory agency to be disclosed by Consultant, but only to the limit and extent of such required disclosure, provided that, prior to such disclosure, Consultant provides the Company with prompt written notice of such requirement and the facts and circumstances concerning such requirement and assists the Company in obtaining an order or orders protecting the information from any disclosure or limiting the extent of information to be disclosed.</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Intellectual</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Property</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">. </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a) </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">It is the intention of the parties that the Company should own the rights in any materials and work product resulting from the Services. To that end, Consultant shall on the Company&#x2019;s written request from time to time sign an unconditional assignment with full title guarantee of all rights in any such materials as are owned by Consultant and capable of assignment. Consultant shall also waive any moral rights it may have in the any materials created by Consultant for Company when providing Services. </font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In addition, any information, know-how, data, results, and inventions, and any associated intellectual property, that is made, discovered, created, invented or generated by Consultant in any activities or work under this Agreement shall be owned by the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Consultant acknowledges that the Company does not desire to acquire any trade secrets, know-how, confidential information, or other intellectual property that Consultant may have acquired from or developed for any third parties. In the course of providing the Services, Consultant shall not use or disclose any third party intellectual property, including without limitation any intellectual property of (i) any former or current employer, (ii) any person for whom Consultant has performed or currently performs consulting services, or (iii) any other person to whom Consultant has a legal obligation regarding the use or disclosure of such intellectual property.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Consultant agrees to assist in any logistics of future intellectual property that is generated from this Agreement as needed and determined by Consultant, with no compensation solely for such participation, including but not limited signing assignment forms, inventor forms, and advising on substantive matters as needed by and when requested by the Company. Company agrees to pay for any associated expenses, fees, and further patent prosecution.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All notices and other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given (a) when delivered and received by the other party, or (b) two (2) business days after being sent when sent by recognized overnight courier to the following addresses:</font></div></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">if to the Company:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2617 Bissonnet St., Suite 225</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Houston TX 77005</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Attention:  legalteam@alaunos.com;</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">if to Consultant:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Ferdinand Groenewald</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">or to such other address as either party will have furnished to the other in writing in accordance with this Section 6, except that such notice of change of address shall be effective only upon receipt.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">D&amp;O Insurance</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  The Company has obtained and shall cause to be maintained in effect during the Term of this Agreement, with financially sound insurers, a policy of directors&#x2019; and officers&#x2019; liability insurance (the &#x201c;D&amp;O Policy&#x201d;). The Company and Consultant acknowledge and agree that, in providing the Services, Consultant will act as an officer of the Company, and the Company and Consultant expect and intend that Consultant shall be covered by the D&amp;O policy under no less favorable terms than any other individual covered</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">by the D&amp;O policy. The provisions in this Section 7 shall survive the termination of this Agreement.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company shall defend and indemnify Consultant, to the fullest extent permitted by law against any and all threatened, pending, or completed action, suit, proceeding, or alternative dispute resolution mechanism, whether civil, criminal, administrative, arbitrative, investigative, or other, and whether made pursuant to federal, state, or other law (each, a &#x201c;Claim&#x201d;) against Consultant as a result of the Consultant&#x2019;s performance of the Services or as result of the Consultant&#x2019;s prior work as an employee and officer of the Company, including without limitation Claims brought by or in the right of the Company, Claims brought by third parties, and Claims in which Consultant is solely a witness. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Consultant shall have the right to advancement by the Company, prior to the final disposition of any Claim by final adjudication to which there are no further rights of appeal, of any and all Expenses (as that term is defined below) actually and reasonably paid or incurred by Consultant in connection with any Claim. Consultant&#x2019;s right to such advancement is not subject to the satisfaction of any standard of conduct. Without limiting the generality or effect of the foregoing, within ten (10) days after any written request by Consultant, the Company shall, in accordance with such request, (a) pay such Expenses on behalf of Consultant, (b) advance to Consultant funds in an amount sufficient to pay such Expenses, or (c) reimburse Consultant for such Expenses. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any and all expenses, including attorneys&#x2019; and experts&#x2019; fees, court costs, transcript costs, travel expenses, duplicating, printing, and binding costs, telephone charges, and all other costs and expenses incurred in connection with investigating, defending, being a witness in, or participating in (including on appeal), or preparing to defend, be a witness in, or participate in, any Claim.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Without limiting the generality or effect of the foregoing, Consultants right to indemnification and advancement of Expenses shall be no less favorable than that of any officer of the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The provisions in this Section 8 shall survive the termination of this Agreement. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Miscellaneous</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	In the event that any of the provisions of this Agreement, or the application of any such provisions to Consultant or the Company with respect to obligations hereunder, is held to be unlawful or unenforceable by any court, then the remaining portions of this Agreement shall remain in full force and effect and shall not be invalidated or impaired in any manner.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	No waiver by any party of the breach of any term or covenant contained in this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such breach, or a waiver of any other term or covenant contained in this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	This Agreement (including all Exhibits hereto) contains the entire agreement between Consultant and the Company with respect to the subject matter of this Agreement (including all Exhibits hereto), and supersedes any and all prior agreements and understandings, whether verbal or written, between Consultant and the Company with respect to the subject matter</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of this Agreement (including all Exhibits hereto).  This Agreement may be amended only by an agreement in writing signed by Consultant and the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)	This Agreement may not be assigned by Consultant or the Company without the other party&#x2019;s consent, and any such attempted assignment shall be void and of no effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(e)	The terms and language of this Agreement are the result of arm&#x2019;s length negotiations between the parties.  Consequently, there shall be no presumption that any ambiguity in this Agreement should be resolved in favor of one party and against another.  Any controversy concerning the construction of this Agreement shall be decided neutrally without regard to authorship.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(f)	The titles and headings of sections and subsections contained in this Agreement are included solely for convenience of reference and will not control the meaning or interpretation of any of the provisions of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(g)	This Agreement may be executed in any number of counterparts, each of which so executed shall be deemed to be an original, and such counterparts shall together constitute but one agreement.  Each party may execute this Agreement in Adobe Portable Document Format or in a similar format (&#x201c;PDF&#x201d;) sent by electronic mail.  In addition, PDF signatures of authorized signatories of any party will be deemed to be original signatures and will be valid and binding, and delivery of a PDF signature by any party will constitute due execution and delivery of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(h)	This Agreement shall be governed by, and construed in accordance with, the laws of Texas, without giving effect to its conflict of laws principles.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, the parties have executed this Agreement effective as of the date first written above.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ALAUNOS THERAPEUTICS, INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">			</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CONSULTANT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_/s/ Dale Curtis Hogue, Jr.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">			__</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">/s/ Ferdinand Groenewald</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">___</font></p>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">    Name:  	Dale Curtis Hogue, Jr.				Name:  Ferdinand Groenewald</font></p>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">    Title:  	CEO (interim)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Description of Services</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Consultant shall lead the accounting and financial reporting function of the Company. Consultant will work directly with the Board of Directors, Company employees and other consultants to ensure proper and complete monthly / quarterly close processes. Consultant will partner with the business in making decisions and promoting continuous improvement. This is a hands-on role that reports directly to the CEO and Board Chair. Further specific responsibilities will include, but not be limited to the following:</font></p>
  <p style="text-indent:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Lead accounting and financial reporting activities of the Company in accordance with U.S. GAAP and SEC requirements</font></div></div>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Ensure effective financial close process and timely SEC filings (10-Q, 10-K, 8-K, registration statements, etc.)</font></div></div>
  <p style="text-indent:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Serve as Principal Accounting Officer for the Company</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Prepare or review general ledger account reconciliations, including journal entries and supporting documentation, to validate accuracy of reported balances</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Responsible for maintaining a strong public company internal control environment in accordance with the provisions of the Sarbanes-Oxley Act within the accounting and reporting function</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Serve as U.S. GAAP technical resource, including literature research and application to transactions or processes</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Liaise with external tax consultants to ensure compliance with all tax jurisdictions</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Review and update accounting policies and procedures to ensure compliance with U.S. GAAP, including the adoption of new accounting pronouncements</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Serve as key contact with internal and external auditors</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Prepare and present Audit Committee / Board of Directors materials and communications</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Manage the treasury function</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Equity management with transfer agent and awards in Certent (equity management tool)</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Motivated in taking on tasks beyond formal job responsibilities and ability to work in a dynamic and changing environment</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Approve and pay invoices and payroll; ability to execute accounts payable function</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Drive the timing for monthly billing and other cash management and expense management techniques</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Ongoing financial planning and analysis and financial forecasting processes</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Evaluate and present period end analytical reviews of financial information</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Provide ad-hoc reporting and analysis</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT B</font></p>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Service Fee</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a) 	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Service Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">: $15,000 per month rate paid in U.S. dollars by the Company to Consultant for the entire Term of this Agreement, unless otherwise agreed by the Company and Consultant in writing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">: The Company will reimburse Consultant for any usual and customary business expenses as may be reasonably required to provide the services to the Company for the term of this Agreement (e.g. office supplies, travel time and mileage).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c) 	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Payments to Consultant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">: Consultant will be paid monthly on the first day of the month for services rendered the previous month (or fraction of month for first payment).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.9in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>tcrt-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:2in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We consent to the incorporation by reference in the Registration Statements (Nos. 333-129884, 333 134280, 333-142701, 333-160496, 333-167925, 333-185433, 333-199304, 333-220804, 333 228291, 333-238090, 333-241698 and 333-263983) on Form S-8 and Registration Statements (Nos. 333-134279, 333-141014, 333-161453, 333-162160, 333-163517, 333-166444, 333-174292, 333 177793, 333-201826, 333-229555, 333-232283 and 333-266841) on Form S-3 of Alaunos Therapeutics, Inc. of our report dated April 1, 2024, relating to the financial statements  of Alaunos Therapeutics, Inc., appearing in this Annual Report on Form 10-K of Alaunos Therapeutics, Inc. for the year ended December 31, 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">/s/ RSM US LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Boston, Massachusetts</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">April 1, 2024</font></p>
  <div style="flex-direction:column;display:flex;min-height:1.25in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>tcrt-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Dale Curtis Hogue, Jr.., certify that:</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Alaunos Therapeutics, Inc.&#x37e;</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#x37e;</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#x37e;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#x37e;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#x37e; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting&#x37e; and</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information&#x37e; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:35.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: April 1, 2024</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Dale Curtis Hogue, Jr.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dale Curtis Hogue, Jr.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interim Chief Executive Officer and Director</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Principal Executive Officer and</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Principal Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>tcrt-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report of Alaunos Therapeutics, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Dale Curtis Hogue, Jr.,, Interim Chief Executive Officer and Director (and Principal Executive Officer and Principal Financial Officer) of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#x37e; and</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:30.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:73.333%;"></td>
    <td style="width:26.667%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Dale Curtis Hogue, Jr.</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dale Curtis Hogue, Jr.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interim Chief Executive Officer and Director</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Principal Executive Officer and</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Principal Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 1, 2024</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>9
<FILENAME>tcrt-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.8in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Compensation Clawback Policy</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Adopted October 3, 2023<br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Purpose</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Board of Directors (the &#x201c;Board&#x201d;) of Alaunos Therapeutics, Inc. (the &#x201c;Corporation&#x201d;) has adopted this compensation clawback policy (the &#x201c;Policy&#x201d;) which provides for the recoupment of incentive-based compensation in the event of an accounting restatement.  This Policy is intended to comply with Section 10D of the Securities Exchange Act of 1934 (the &#x201c;Act&#x201d;), the rules promulgated thereunder by the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), and the listing standards of The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d; and such rules and listing standards the &#x201c;Applicable Rules&#x201d;), and will be interpreted consistent therewith.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Applicability and Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This Policy is effective October 2, 2023 (the &#x201c;Effective Date&#x201d;) and is applicable to all Incentive-Based Compensation (as defined below) received by Executive Officers (as defined below) after the Effective Date.  The Policy will be administered by the Board or, if so designated by the Board, the Compensation Committee of the Board (the &#x201c;Committee&#x201d;), in which case references to the Board will be deemed to be references to the Committee.  Any determination made by the Board under this Policy will be final and binding on all affected individuals.  Each Executive Officer shall be required to execute the acknowledgement in Appendix A of this Policy as soon as practicable after the later of (i) the Effective Date and (ii) the date on which the employee is designated as an Executive Officer; provided, however, that failure to execute such acknowledgement shall have no impact on the enforceability of this Policy.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Restatement Clawback</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In the event the Corporation is required to prepare an Accounting Restatement (as defined below), any Executive Officer who received Excess Compensation (as defined below) during the three (3) completed fiscal years preceding the date the Corporation is required to prepare an Accounting Restatement (the &#x201c;Look-Back Period&#x201d;) shall be required to repay or forfeit such Excess Compensation reasonably promptly.  For purposes of this Policy, the date the Corporation is required to prepare an Accounting Restatement is deemed to be the earlier of the date (i) the Board concludes, or reasonably should have concluded, that the Corporation is required to prepare an Accounting Restatement, or (ii) a court, regulator, or other legally authorized body directs the Corporation to prepare an Accounting Restatement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Method of Repayment, Conditions for Non-Recovery</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Board shall have discretion to determine the appropriate means of recovery of Excess Compensation, which may include, without limitation, direct payment in a lump sum from the Executive Officer, recovery over time, cancellation of outstanding awards, the reduction of future pay and/or awards, and/or any other method which the Board determines is advisable to achieve reasonably prompt recovery of Excess Compensation.  At the direction of the Board, the Corporation shall take all actions reasonable and appropriate to recover Excess Compensation from any applicable Executive Officer, and such Executive Officer shall be required to reimburse the Corporation for any and all expenses reasonably incurred (including legal fees) by the Corporation in recovering such Excess Compensation in accordance with this Policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Committee, or in the absence of the Committee, a majority of the independent directors on the Board, may determine that repayment of Excess Compensation (or a portion thereof) is not required only where</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">it determines that recovery would be impracticable and one of the following circumstances exists: (i) the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered, provided the Corporation has (A) made a reasonable attempt to recover such Excess Compensation, (B) documented such reasonable attempt, and (C) provided such documentation to Nasdaq; or (ii) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Corporation, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and the regulations thereunder.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.8in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">No Fault Application, No Indemnification</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Recovery of Excess Compensation under this Policy is on a &#x201c;no fault&#x201d; basis, meaning that it will occur regardless of whether the Executive Officer engaged in misconduct or was otherwise directly or indirectly responsible, in whole or in part, for the Accounting Restatement.  No Executive Officer may be indemnified by the Corporation, or any of its affiliates, from losses arising from the application of this Policy.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Definitions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">For purposes of this Policy, the following definitions will apply:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;Accounting Restatement&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> means an accounting restatement due to the material noncompliance of the Corporation with any financial reporting requirement under securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that corrects an error that is not material to previously issued financial statements but would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Changes to financial statements that do not constitute an Accounting Restatement include retroactive: (i) application of a change from one generally accepted accounting principle to another generally accepted accounting principle; (ii) revisions to reportable segment information due to a change in internal organization; (iii) reclassification due to a discontinued operation; (iv) application of a change in reporting entity, such as from a reorganization of entities under common control; and (v) revisions for stock splits, reverse stock splits, stock dividends, or other changes in capital structure.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;Excess Compensation&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">means any amount of Incentive-Based Compensation received by an Executive Officer after commencement of service as an Executive Officer that exceeds the amount of Incentive-Based Compensation that otherwise would have been received had it been determined based on the Accounting Restatement, computed without regard to any taxes paid.  For Incentive Compensation based on stock price or total shareholder return, where the amount to be recovered is not subject to mathematical recalculation directly from information in the Accounting Restatement, the amount to be recovered shall be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return, as applicable, and the Corporation shall retain documentation of the determination of such estimate and provide such documentation to Nasdaq if so required by the Applicable Rules.  Incentive-Based Compensation is deemed received during the fiscal year during which the applicable financial reporting measure, stock price and/or total shareholder return measure, upon which the payment is based, is achieved, even if the grant or payment occurs after the end of such period.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;Executive Officer&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> means an individual who is, or was during the Look-Back Period, an executive officer of the Corporation within the meaning of Rule 10D-1(d) under the Act.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;Incentive-Based Compensation&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> means any compensation that is granted, earned or vested based wholly or in part on stock price, total shareholder return, and/or the attainment of (i) any financial reporting measure(s) that are  determined and presented in accordance with the accounting principles used in preparing the Corporation&#x2019;s financial statements and/or (ii) any other measures that are derived in whole or in part from such measures.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Compensation that does not constitute &#x201c;Incentive-Based Compensation&#x201d; includes equity incentive awards for which the grant is not contingent upon achieving any financial reporting measure performance goal for an individual to receive such award and that vest exclusively upon completion of a specified employment period, without any performance condition, and bonus awards that are discretionary or based on subjective goals or goals unrelated to financial reporting measures.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Administration, Amendment, and Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">	- </font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> -</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.8in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This Policy will be enforced and, if applicable, appropriate proxy disclosures and exhibit filings will be made in accordance with the Applicable Rules and any other applicable rules and regulations of the SEC.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Board shall have authority to (i) exercise all of the powers granted to it under the policy, (ii) construe, interpret, and implement this Policy, and (iii) make all determinations necessary or advisable in administering this Policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In addition, the Board may amend this Policy, from time to time in its discretion, and shall amend this Policy, as it deems necessary, including to reflect changes in applicable law, rule or regulation.  The Board may terminate this Policy at any time.  Any such amendment (or provision thereof) or termination shall not be effective if such amendment or termination would (after taking into account any actions taken by the Corporation contemporaneously with such amendment or termination) cause the Corporation to violate the Applicable Rules.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In the event of any conflict or inconsistency between this Policy and any other policies, plans, or other materials of the Corporation (including any agreement between the Corporation and any Executive Officer subject to this Policy), this Policy will govern.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This Policy will be deemed to be automatically updated to incorporate any requirement of law, rule or regulation applicable to the Corporation, including those promulgated by the SEC and the Applicable Rules.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">   </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">	- </font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> -</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.8in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Appendix A:</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Alaunos Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Compensation Clawback Policy</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ACKNOWLEDGMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The undersigned acknowledges and agrees that the undersigned (i) is, and will be, subject to the Compensation Clawback Policy to which this acknowledgement is appended, as may be amended from time to time (the &#x201c;Policy&#x201d;) and (ii) will abide by the terms of the Policy, including by returning Excess Compensation pursuant to whatever method the Board determines is advisable to achieve reasonably prompt recovery of such Excess Compensation, as prescribed under the Policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Capitalized terms used but not defined have the meanings set forth in the Policy.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:40%;border-spacing:0;table-layout:fixed;width:52.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:80.376%;"></td>
    <td style="width:19.624%;"></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td colspan="2" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td colspan="2" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td colspan="2" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td colspan="2" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Print Name</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td colspan="2" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td colspan="2" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td rowspan="2" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Signature</font></p></td>
   </tr>
   <tr style="height:16.55pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td colspan="2" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td colspan="2" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dated:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Cambria',serif;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Cambria',serif;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">	- </font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> -</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img160836378_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img160836378_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $0 @H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/;G&/SK,MOACI-KJFNRQ7$PTO6XRMWI> (=Q_C3'*G.2,=,^PQV]% '&>'?
M5QX>EM8T\6ZW<Z?: +#92O'L"CHK$+D@<<#'3'3BJFJ?#!;^?45M_%&N65AJ
M3,;JQCF5XR&X8)N!*@Y/'3G'3 KOJ* /%_%W@V/_ (6!X#T73UO[;3K2UEB6
MZMF.^ JI*MOP0#D \\'TKN/#WP\T_1KG5+V^O+K6-0U2/R+JYOB"6BQC8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVZ?0HH;T2N9M:<>2ICV84*2,D[^O08]Q6IX2O8[W1R8;W1;N**4QHVCL#"@
M!V\$X;G./0B@#=HHHH 1CM4M@G S@=:YR/Q:L-UY.K:;<Z6'LY;Z-IW1\QQ[
M?,#;"=K*'4XY'/!.*Z*1_+C9]K-M!.U1R?85Y]'87WBBSUA]4L;VUU34=-GL
MH%EAVPV4;J?D#9.YB=I9N^T   <@'3Z%XD36;B2VELI[*Z6WBNEAF96+0R;M
MC94D9RC CL1[@U)XL_Y$W7/^P?<?^BVK,\.P:C=Z_)JM[I\MA&FFP68BFV[V
ME#.TA&TD;1E0#WY[8KF?$?@[Q;#X<U:>7XA7LT*6DSO ;"(!U"$E<]1D<9H
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M6M>(=86*:*SO;B);<31E#((XE4R!2 <$Y )ZA0>A%=10 45D>)QJQ\.W?]B
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M\DM9EC,CQ#/*%'9#R,8W9&1G&16S>ZI::=I,FIW<ACM8X_,8[23@]  ,DDY
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MZF'E*3:/0I8N$(*+3.MHKDO^$"^+'_0Y:5_X#+_\:H_X0+XL?]#EI7_@,O\
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MQGXQO-"D\:W5JMO:&Y$RVD3EB&08Q@?W_P!*;BUN"DGL?1E%>?\ _"$>,O\
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M=>,_=S^-9WQ,;QOX \.6^JQ>/+R]::[6V\MK*)  4=LYP?[GZU!1[G17D/\
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M7>I0SQ6ZVZK:R(JE0S-D[D8YRY[^E=Y63XFNM2LO#MW<:3 TUXFW:B)O8*6
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M;;-"U_>7I9R_F7;AF' & 0!QQ^IJ[10 4444 %%%% !6/XL_Y$W7/^P?<?\
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MMJ3&(N%V8)XSMS[9S4Q\4ZW/_P )!-8Z582V^CW+P,);QHY)=D:2''R$#(?
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7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img160836378_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img160836378_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %3 WP# 2(  A$! Q$!_\0
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MF\PC(3RSDCZ4?6:_\S#ZCA/Y$=/_ ,+$U?\ Y]['_OA__BJ/^%B:O_S[V/\
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MS;>5-HW'<A&!TS491PBN58*V=K$<''7%'UFM_,P6!PKV@CK/^%B:O_S[V/\
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MC*DC&1[4?6:W\S#ZAA?Y$=9_PL35_P#GWL?^^'_^*H_X6)J__/O8_P#?#_\
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MZ$]#C.*XNBM'B;WT[F2P-E;F[?K^#OL=3I]GJ$>HQW6MR2)#9HTP^T.6VG(
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M_P!._P#X_P#_ %JQX?\ 41_[H_E3Z[5E.#M\'XO_ #.-YYC[_P 3\%_D:O\
M;/\ T[_^/_\ UJ/[9_Z=_P#Q_P#^M6511_9.#_D_%_YA_;F/_P"?GX1_R-7^
MV?\ IW_\?_\ K4?VS_T[_P#C_P#]:LJBC^R<'_)^+_S#^W,?_P _/PC_ )&K
M_;/_ $[_ /C_ /\ 6H_MG_IW_P#'_P#ZU95%']DX/^3\7_F']N8__GY^$?\
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MFNX^%G_(SW/_ %YM_P"AI45,LPL(.48:^K_S*AG.-G)1E/3T7^1T_P#PK_\
MZB?_ )+_ /V5'_"O_P#J)_\ DO\ _95VM107,-R91#('\J0QOC^%AU'ZUYWU
M*A_+^+._^U<7_/\ @O\ (X__ (5__P!1/_R7_P#LJ/\ A7__ %$__)?_ .RK
MM:*/J5#^7\6']JXO^?\ !?Y'%?\ "O\ _J)_^2__ -E1_P *_P#^HG_Y+_\
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M_P#^HG_Y+_\ V5<S_P +FN/^@)%_X$'_ .)H_P"%S7'_ $!(O_ @_P#Q-/\
ML^C_ "_B_P#,/[7Q7\_X+_(Z;_A7_P#U$_\ R7_^RH_X5_\ ]1/_ ,E__LJY
MG_A<UQ_T!(O_  (/_P 31_PN:X_Z D7_ ($'_P")H_L^C_+^+_S#^U\5_/\
M@O\ (Z;_ (5__P!1/_R7_P#LJ/\ A7__ %$__)?_ .RKF?\ A<UQ_P! 2+_P
M(/\ \31_PN:X_P"@)%_X$'_XFC^SZ/\ +^+_ ,P_M?%?S_@O\CIO^%?_ /43
M_P#)?_[*C_A7_P#U$_\ R7_^RKF?^%S7'_0$B_\  @__ !-'_"YKC_H"1?\
M@0?_ (FC^SZ/\OXO_,/[7Q7\_P""_P CIO\ A7__ %$__)?_ .RH_P"%?_\
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MO_ @_P#Q-'_"YKC_ * D7_@0?_B:/[/H_P OXO\ S#^U\5_/^"_R.F_X5_\
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M$'_XFC^SZ/\ +^+_ ,P_M?%?S_@O\CIO^%?_ /43_P#)?_[*C_A7_P#U$_\
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M_P#R7_\ LJW];^_I?_7]'_)JUJ?U&A_+^+#^U<7_ #_@O\CBO^%?_P#43_\
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M .OZ/^35K5DZW]_2_P#K^C_DU:U !1110 4444 %%%% !1110 4444 %%%%
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M<G^-/V3[BYSZE\M/[B_E1Y:?W%_*OEK_ (2;7_\ H.:E_P"!<G^-'_"3:_\
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M#RT_N+^5'EI_<7\J=14E#?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q?RIU%
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M1'_NC^5/ID/^HC_W1_*GUZ$=C@>X4444Q!1110 4444 %%%% !1110 4444
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MHU $U%0_:4]&H^TIZ-0!-14/VE/1J/M*>C4 345$+A&8 !N3BI: /G'XH_\
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M ,^FI_\ ?I/_ (NC_A;_ (?_ .?34_\ OTG_ ,77B=%'(@YV>V?\+?\ #_\
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M_P#SZ:G_ -^D_P#BZ/\ A;_A_P#Y]-3_ ._2?_%UXG11R(.=GMG_  M_P_\
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M_(NKDPN2R<#RI'X^7KE!^M7?^%/:'_S_ &H_]]I_\37<:S#&-1T'Y>M^>_\
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M>1'_ '?UH\B/^[^M%P*=%7/(C_N_K1Y$?]W]:+@4Z*N>1'_=_6CR(_[OZT7
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MPO7%*F@W;6R3226L!D3?'%/.J.Z^H!/0]LXSVK0B$.G:3J"O=6DRSP(()8I
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M- U'_P#"6^)/^@_JG_@9)_C1_P );XD_Z#^J?^!DG^-,_P"$9U__ * >I?\
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M)_["$?\ Z"U;%8^O??TG_L(1_P#H+5L4P"BBBD 4444 %%%% !1110 4444
M%%%% !1110!\X_%'_DHVJ_\ ;'_T2E<A77_%'_DHVJ_]L?\ T2E<A73'9&+W
M"BBBJ$%%%% !1110 4444 %%%% !1110 4444 %%%% &M#_J(_\ ='\J?3(?
M]1'_ +H_E3Z]".QP/<****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "N\^$SJGBJZ+' ^Q/_ .AI7!UW'PL_Y&>Y_P"O-O\ T-*RK_PV:4?C
M1[1Y\?\ >_2CSX_[WZ53HKR;'IESSX_[WZ4>?'_>_2J=%%@+GGQ_WOTH\^/^
M]^E4Z*+ 7//C_O?I1Y\?][]*IT46 N>?'_>_2CSX_P"]^E4Z*+ 7//C_ +WZ
M4>?'_>_2J=%%@+GGQ_WOTH\^/^]^E4Z*+ 5-7FC.KZ!\W2]?M_T[S5K^?'_>
M_2N-\8ZQ;Z NDZG=I*\,-X=RQ %CF&11C) ZGUK%_P"%O^'_ /GTU/\ [])_
M\75<K>PKI'IGGQ_WOTH\^/\ O?I7F?\ PM_P_P#\^FI_]^D_^+H_X6_X?_Y]
M-3_[])_\71R,.9'IGGQ_WOTH\^/^]^E>9_\ "W_#_P#SZ:G_ -^D_P#BZ/\
MA;_A_P#Y]-3_ ._2?_%T<C#F1Z9Y\?\ >_2CSX_[WZ5YG_PM_P /_P#/IJ?_
M 'Z3_P"+H_X6_P"'_P#GTU/_ +])_P#%T<C#F1Z9Y\?][]*//C_O?I7F?_"W
M_#__ #Z:G_WZ3_XNC_A;_A__ )]-3_[])_\ %T<C#F1Z9Y\?][]*//C_ +WZ
M5YG_ ,+?\/\ _/IJ?_?I/_BZ/^%O^'_^?34_^_2?_%T<C#F1Z9Y\?][]*//C
M_O?I7F?_  M_P_\ \^FI_P#?I/\ XNC_ (6_X?\ ^?34_P#OTG_Q='(PYD=K
MK,T9U'0?FZ7Y[?\ 3O-6OY\?][]*\FO_ (IZ'=76FRI:Z@%MKDS/NC3)'E2)
MQ\_7+C]:N_\ "W_#_P#SZ:G_ -^D_P#BZ.1BYD>F>?'_ 'OTH\^/^]^E>9_\
M+?\ #_\ SZ:G_P!^D_\ BZ/^%O\ A_\ Y]-3_P"_2?\ Q='(Q\R/3//C_O?I
M1Y\?][]*\S_X6_X?_P"?34_^_2?_ !='_"W_  __ ,^FI_\ ?I/_ (NCD8<R
M/3//C_O?I1Y\?][]*\S_ .%O^'_^?34_^_2?_%T?\+?\/_\ /IJ?_?I/_BZ.
M1AS(],\^/^]^E'GQ_P![]*\S_P"%O^'_ /GTU/\ [])_\71_PM_P_P#\^FI_
M]^D_^+HY&',CTSSX_P"]^E'GQ_WOTKS/_A;_ (?_ .?34_\ OTG_ ,71_P +
M?\/_ //IJ?\ WZ3_ .+HY&',CTSSX_[WZ4>?'_>_2O,_^%O^'_\ GTU/_OTG
M_P 71_PM_P /_P#/IJ?_ 'Z3_P"+HY&',CM=;FC-UHN&Z7X[?],I*U_/C_O?
MI7DVH?%/0[N:P>.UU "WN1,^Z-.1L9>/GZY85=_X6_X?_P"?34_^_2?_ !='
M(Q<R/3//C_O?I1Y\?][]*\S_ .%O^'_^?34_^_2?_%T?\+?\/_\ /IJ?_?I/
M_BZ.1CYD>F>?'_>_2CSX_P"]^E<'HOQ)T'6]22QB^TV\LG$9N4558_W00QYK
ML*3C8:=RYY\?][]*//C_ +WZ53HI6 N>?'_>_2CSX_[WZ53HHL!<\^/^]^E'
MGQ_WOTJG118"YY\?][]*//C_ +WZ53HHL!4UV:,OI6&_Y?X^WLU:_GQ_WOTK
MG=;^_I?_ %_1_P FK6IV N>?'_>_2CSX_P"]^E4Z*5@+GGQ_WOTH\^/^]^E4
MZ*+ 7//C_O?I1Y\?][]*IT46 N>?'_>_2CSX_P"]^E4Z*+ 7//C_ +WZ4>?'
M_>_2J=%%@+GGQ_WOTH\^/^]^E4Z*+ 71-&2 &Y/M3ZHQ_P"L7ZBKU(#YQ^*/
M_)1M5_[8_P#HE*Y"NO\ BC_R4;5?^V/_ *)2N0KICLC%[A1115""BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#6A_U$?^Z/Y4^F0_ZB/_ '1_*GUZ$=C@
M>X4444Q!1110 4444 .CC>618XT9W8X"J,D_A4L]C=VJ![BUGA4G ,D94$_C
M6_X C5_&5D[_ '(0\K'T"H36OHTT-]KT\HU2ZU=;6TENX8KJ,JOG#[H"EFSC
M.:SG4Y7;RO\ U]Q<8<R^=CAY+6XAC626"5$?[K,A /T-2OIM_'&9'LKE4 R6
M:)@/SQ73Q3:WKNARW-QKK7$$EU%%-:/N)!9OEQD8'KP:T_$LRW?C'['!KES)
MYEY% ]@%=8U P#SG!Z>G>E[1\RC_ %T_S'R*SE_77_(X*>RN[90T]K-$IX!D
MC*@_G4%>H>*[MK?2]=N?MTE_;WMS]E2'!\NT=#DYR>O'&!BO+Z=*HYJX5(<C
ML%%%%:&84444 %%%% !7<?"S_D9[G_KS;_T-*X>NX^%G_(SW/_7FW_H:5E7_
M (;-*/QH]<KE+>WLM175;K59W6YM[B5"QF9#;(#\A7!&WY<-GOFNKJI<:7I]
MW.D]S8VLTR?=DDA5F7Z$C(KRCTSF].\0ZFMI9VEU'&;^ZCA:V+(1O4_?+#/5
M0"QQCJ*6[\575NURT*PS0_9IYH',+("8R.,EOF'/4 =.,UU300O-',T2-+&"
M$<J"R@]<'MFJXTG30TC#3[0&4$2'R5^?/7/'.>]-M-W$D8UUK6IZ:RP7:6LL
M]U$/LGE(RJ9MV-C98Y&&4YXX#5TB[MHW$%L<D# S5:>QBN+NUN)"V;8LT:<;
M=Q&,_4#('U-6J 04444AA1110 4444 %%%% 'GOQ@_Y%:T_Z_5_] >O%:^A?
M&>C0>($TG3+F22.&:\.YHB PQ#(PQD'TK#_X4]H?_/\ :C_WVG_Q-:1DDM3.
M46V>+45[3_PI[0_^?[4?^^T_^)H_X4]H?_/]J/\ WVG_ ,35<Z%R,\6HKVG_
M (4]H?\ S_:C_P!]I_\ $T?\*>T/_G^U'_OM/_B:.=!R,\6HKVG_ (4]H?\
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M?LR>K4?9D]6K/O/$ND6<#2MJ%LX25(G"3(2K,VWGGC')/L#6HCI+&LD;*Z,
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M^/\ O?I1Y\?][]*/:/L'(?+G_",Z_P#] /4O_ 23_"C_ (1G7_\ H!ZE_P"
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MZE_X"2?X5]1^?'_>_2CSX_[WZ4>T?8.0^7/^$9U__H!ZE_X"2?X4?\(SK_\
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M !1110 4444 %%%% !1110 4444 %>@?"#_D;+K_ *\7_P#1D=>?UZ!\(/\
MD;+K_KQ?_P!&1U%7X&:4_C1[51117GG<%%%% !1110 4444 %%%% !1110 4
M444 9.J_\A70O^OQ_P#TGEK6K)U7_D*Z%_U^/_Z3RUK4 %%%% !1110 4444
M %%%% !1110 4444 9.K_P#(0T/_ *_C_P"B)JUJR=7_ .0AH?\ U_'_ -$3
M5K4 %%%% !1110 4444 %%%% !1110 4444 9.L_\?6C_P#7\/\ T7)6M63K
M/_'UH_\ U_#_ -%R5K4 %%%% !1110 4444 %%%% !1110 4444 9.M_?TO_
M *_H_P"35K5DZW]_2_\ K^C_ )-6M0 4444 %%%% !1110 4444 %%%% !11
M10 Z/_6+]15ZJ,?^L7ZBKU)@?,OQ8_Y*9J__ &Q_]$I7&5V?Q8_Y*9J__;'_
M -$I7&5LMC)[A1113 *M:9?RZ5JEKJ$"HTMM*LJ!P2I*G(S@CBF65R+.]AN&
MMX;@1MN,,ZDH_LP!''XUZ%KMW8+X7T":V\-Z)%<ZS'*LCB!AY1#;04^;@\YY
MS1JK6#1[G)3>*KZ:RN[5HK<)=7_]H.0K9$G/ Y^[S]?>M*3XA:A.UY]JTS2K
MF.[NA=R130NRAPH48^;@8'^1Q6CX@N=!\):O)X?C\-VE^ELJI<W-S(XEE<J"
M2I!P@Y]*UM T(77@_0KJR\-:?J#7-S,M[)< YCB#\'=N&,#///2I5K76W_#?
MY(;O?7^M_P#@G%W?C+5+^VUB&Y$$G]JO$\[;""GEG*A,' '0<@\58UGQQ/KL
M$JWFAZ-]HDC$?VI8'\U0!@$$N1G ]*@UC06?6=5G\/65S>:-:S,%GCC:2-5'
M)RP[#U/;FNHCU;3F\ 2Z\?"N@_:DU 6H3[.^PJ4W9QOSG/O2TY;^G^0[/FL>
M?6%TME>QW#VL%TJ9S#< E&XQS@@_K6]J7C:?5-8BU.XT;1S.BE'7R&9)5VA0
M&#,>@'!&#3_!VDV.JWNJ:AJ4)>RTZU>\>VB8KYA'1,]0.:#<P^+[JUTC3?#F
MGV-]-,%BFMW=0%P<A@20?7/MTJMVD3W9F:SXBNM9AMK9H+6TL[;=Y-K:QE(U
M+=3R223ZDUD5Z-IO@!],\1Z+/<NE]82WZVTR2VLD7S8)QMD4;E.#R..*S?%>
MGV=KX4TJ>"UABFDOKU'=$ +*L@"@GT Z4KI;?U_5QV;_ *]?\CBZ***H0444
M4 :,?^J3_=%.IL?^J3_=%.KL6QQO<****8@KJ? .F0:IXBDCN;>.>**UEE,<
MA 4D+@9)X')%<M6OHFM_V-%J:BW\U[VT>U#[]OEAL9/0YZ=.*4DW%I%1MS*Y
MU*:%8Z9K6B^&)K..?4+B>*6^N'7("DY\N/VQU8=:D\6Z99VFBW[7FCVFFW?V
MS9I@M_E>:+)W%EW'(QCG YK)L?' MY-$N+K3?M-WI(9$G\_:9(R"%4C:?ND\
M&HK'QA%'8V%MJ6F?;C8W;7,#F?9@'DH?E.1NP?PK)QE?^NY:E&W]=F:VH^'M
M/M/!MU9+;J=;T^.&[NI?X@)"08_^ @J32#2K:/P;!>Z5I>G:I']E+:A(\K&X
MMY.>=H885>.@YK/C^(6KRMJ":F[WMK>021& N$5"W0C@]/2H#XJLK?3[F/3-
M"AL;RZM_LT]PMP[@H<;MJ'[I..N31:=G<=X71-X&T9-3FU&9[&*Z>"W/V9;@
MD0M,2-JL<C)(S@9K)UZVD\\7PT@Z9!*QB\G>2!(F ^ >0,GH>F>M3Z-XBAL-
M*N-+O;#[99RS+.H2<PNDBC (8 ]NV*L>*?%H\406HFL3!/;95)%G+!D/9@1R
MW'WL\^E4^;GOT(7+RV-7PY>6/_"'ZM>7.@:5.^FI$L4DD3%I&=\?.=W/'IBM
M+2M.^V>'=/U"U\+65Y-?W\GG 0,8X81@8!S\@Z\DUQ-MK?V;PO>Z,MODW<\<
MK3;^@3HNW'KWS3M0\027FA:7I4<301V*2*Q$N1*7;.2,#'ZT.+NVN_Z?YC4E
M9+^OZZG86.EZ(FIZQ!I8T:[N'OA!96^HR,5V $G;@Y)+$ $GM6#HBPS:[=VD
MNC6+ZI+/LBAN'\NV@P3O&-V2>P&3^-4]'UW3M(2"?^Q%FU*W<O%<M<L%W?PE
MH\8./8BG:?XCLHH6_M/18;^X^TFZ6X$OE/N/4,0#N7/..*2BT^_]?U<'),K^
M++>RM?%.H6^GPM#;1R[5C8$;2 ,X!YQG.,]JQJMZIJ,^KZI<ZA<[?.N)"[;1
M@#/8>U5*N":BDR9-.3:"BBBJ)"O0/A!_R-EU_P!>+_\ HR.O/Z] ^$'_ "-E
MU_UXO_Z,CJ*OP,TI_&CVJBBL*TUR6YUBYMF>RACMW97ADD(GV@?ZS'0J?Y=^
MU>>=QNT5AWOB2V72[FXLFWS11"5$EB= ZD@;AD#<.>HJ<:W;Q23I<3*SBX:*
M-((9';Y5!.0 2<9Y(XY% &K16+;ZC?WWAJVU&V%LDSQ>:ZR*Q7&#P,'-+I&J
M3SV5C-J+VZ27ZJUND*-U*%B"3GL#Z=*=M_(5S9HK+D\1Z5$,M<MC#L2(7. K
M;6)P. ".2>*<NO::T4D@G8"-E4J8G#$M]W"D9;/; .:5AFE166_B+2T$6ZX?
M=*S(L8@<ON7&05VY!&0<$=.>E6K/4;;4-QMFD=5_C,3JK<X^5B &Z=LT6 M4
M444 %%%% '/>*-3L]'FT:^OYO)MHKQM[[2V,PR@< $]2*J_\+)\)?]!;_P E
MI?\ XFLCXP?\BM:?]?J_^@/7BM:1BFB)2:9] _\ "R?"7_06_P#):7_XFC_A
M9/A+_H+?^2TO_P 37S]13]FA<[/H'_A9/A+_ *"W_DM+_P#$T?\ "R?"7_06
M_P#):7_XFOGZBCV:#G9] _\ "R?"7_06_P#):7_XFC_A9/A+_H+?^2TO_P 3
M7S]11[-!SL^@?^%D^$O^@M_Y+2__ !-'_"R?"7_06_\ ):7_ .)KY^HH]F@Y
MV?0/_"R?"7_06_\ ):7_ .)H_P"%D^$O^@M_Y+2__$U\_44>S0<[/H'_ (63
MX2_Z"W_DM+_\31_PLGPE_P!!;_R6E_\ B:^?J*/9H.=GN.I?$#PO<7FE21:G
MN6"[,DA^SRC:ODR+G[O/+ ?C6A_PLGPE_P!!;_R6E_\ B:^?J*?(A<[/H'_A
M9/A+_H+?^2TO_P 31_PLGPE_T%O_ "6E_P#B:^?J*7LT/G9].Z3K6G:[:&ZT
MVZ6XA#%20""#Z$$ C\:OU\X^$-9U72->@.DHT\LS!&MATF'H?3Z]OIFOHQ"S
M1J67:Q )7.<'TJ)1L5%W'4445)04444 %%%% !1110!DZS_Q]:/_ -?P_P#1
M<E:U9.L_\?6C_P#7\/\ T7)6M0 4444 %%%% !1110 4444 %%%% !1110!D
MZW]_2_\ K^C_ )-6M63K?W]+_P"OZ/\ DU:U !1110 4444 %%%% !1110 4
M444 %%%% #H_]8OU%7JHQ_ZQ?J*O4F!\R_%C_DIFK_\ ;'_T2E<979_%C_DI
MFK_]L?\ T2E<96RV,GN%%%%, K;U3Q"=2T+1=-%L8CIB2*)1)GS-S;LXP,8^
MIK$J]I*Z4UX1K$EXEKM/-HBL^[MPQ QUH Z2X\::9JC17>M>&(+[5$0(;H73
MQK+@8!= /F/XC-5H/&]S9:=HEO96PMYM*N)9UD$A*R!SDIMQP,<=3FMG4_!_
MABR\0:=HD5[J[W=X\!!:.,($D(SSG.X ^F,USNO^$=5T2[EWZ?=BS-RT-O*Z
M?ZSDA>G<CGW[5*L/4IZOJT=]J=U<Z?;R:?;7#;S:K,64$]<<#CVQQ4R:_L\&
MR>'OLV=]Z+OS_,Z83;MVX_'.?PI+KPEK]E+:QW.E7,3W3B.$.N-SGHOL?8U,
MO@GQ,UPD T6[\QD\P*4Q\N<9/ISZ]:>EK?UH%W>Y7\.^(+CPYJ+74,4<\4L;
M0SV\HRDT;=5-:J>+=,TV\M;S0?#D-A<P3B4RRW3SD@ @H,XPI!.>IK+MO"NO
M7EQ<V]OI5R\ULXCG0)S&QSC([=#STJ.Z\.:Q8QW;W6GS1+9LJW&X8\LM]W/L
M>QZ476XK/8W!XRL(-9L-2L]$EB>VNA<.LFH/('Z_*N1A1SZ$^]9NL^)?[7T:
MST_[)Y7V:XGG\SS-V[S6W8Q@8QZ]_:LJ]TZ[T\PB[@:$SQ+-&&ZLC=#^-5J+
M(=W_ %_7F%%%%,04444 :,?^J3_=%.IL?^J3_=%.KL6QQO<****8@HHHH U_
M"VGV^J^*-.L;I6:">8(X4X)'UK:O/!8'C.+3K64_V7<#[1'<D\+ .6)/JN"/
MKCUK"\-ZE#H_B.PU&X61H;>4.ZQ@%B/;)%:+>,KM=!O-(CC7RYY7*3M_K(XF
M;<T8]B0,_C42YKIQ+CRV:D6?%7A6.SU;5FTA<:=8102-YCDMB0#&/7DTND>!
M9KN:9+ZZM[<#3?MT?[X#(8':3D=,CGTJU<>+](OKW6([F&^6QU&UMXMT:IYB
M-$!S@G!!(/>G'QCH[:LK?9[Y;%M&_LQN$,J_[0Y /;TJ/?4;?UM_F5[C=_ZZ
M?\$PK?PCJ%Y#+);3V$S)O*Q1W:&254SN95SDC@_6M6V\'0C3= U![FWG-]/M
MDMOM(4NI=5"IQG/)W>E7=%\8>'M$BM!;65XC1+(DNVWA)FSD!RY^;."/E! ]
M_7.L/$FE1Z5H$5U'>"ZTBZ,H\I5*2(T@8]2"#@''\ZJ\K^6GZ_\  %:-BN_@
M^^N[V\:W2VL[5+M[:$75TJ[W!^XI.-Q'K4%KX-U6XBN))#:VBVUQ]FF-U.L>
MQ\9QSU_"M:?Q1HFJIY.IPZ@D=O?S75LUL$)=9&W%7!/!]P35?6O%\&LZ5J4+
MV\D=S=ZDMVH&"BH$V@$YSGIVI1<]$_ZV_P""-J%W_7?_ (!23P9JWG7D=Q]E
MM!:2B&1[FX6-"Y&0H)/)(YK ="CLAQE20<$$?F.M>@CQQI+^(=0U"0ZF+6Y>
M,FT\J)XYE5 I#JQ.#D'D9XK@;F1)KN:6*(11N[,L8.0@)X'X54')_$3)1MH1
M44459 4444 %>@?"#_D;+K_KQ?\ ]&1UY_7H'P@_Y&RZ_P"O%_\ T9'45?@9
MI3^-'M58=]H$VJ7"_;[U);:-G:-$M]D@W*5P7W<@!CT4=LUN45YYW'/3>&Y[
MJV:*YU!'86OV6)D@V[5)4DL-QW'Y%Z8'M4@\/S1:D]_;7J).TLK?/#N7:X0%
M<;AR"@.?TK=HIW"W0H6.F?8M#BTWSM^R'RO,VXSQUQFJQT21-/TJ""Z59].V
M[)'BW*^$*'*AAU!]:V**5PL<Y'X69+>>-K[<TUM/ 6\G&#*Y?=C/;.,5/-X>
M,ER;E+O9,OD&(F/(5HMPR1GD$.>./K6Y11<+&-::$\&I)?RW0DGWRR2;8MJL
M75%X&3@ (/7-/TO1VTZ\N)_.CVS #R8(C&@.22Q7<1N.>HQ6M11< HHHH **
M** .3\>:*?$5II>EBX^SF:\/[S9NQMBD;ID>E<G_ ,*8?_H/+_X"?_9UZ%JO
M_(5T+_K\?_TGEK6JE)I:$V3/)_\ A3#_ /0>7_P$_P#LZ/\ A3#_ /0>7_P$
M_P#LZ]8HHYY!RH\G_P"%,/\ ]!Y?_ 3_ .SH_P"%,/\ ]!Y?_ 3_ .SKUBBC
MGD'*CR?_ (4P_P#T'E_\!/\ [.C_ (4P_P#T'E_\!/\ [.O6**.>0<J/)_\
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M6_\ <;\J/+?^XWY4 -HIWEO_ '&_*CRW_N-^5 #:*=Y;_P!QORH\M_[C?E0
MVBG>6_\ <;\J/+?^XWY4 -HIWEO_ '&_*CRW_N-^5 &/J_\ R$-#_P"OX_\
MHB:M:LO6$?\ M#0OE;_C_/;_ *=YJUO+?^XWY4 -HIWEO_<;\J/+?^XWY4 -
MHIWEO_<;\J/+?^XWY4 -HIWEO_<;\J/+?^XWY4 -HIWEO_<;\J/+?^XWY4 -
MHIWEO_<;\J/+?^XWY4 -HIWEO_<;\J/+?^XWY4 8^L_\?6C_ /7\/_1<E:U9
M>M(_VK1_E;_C_';_ *925K>6_P#<;\J &T4[RW_N-^5'EO\ W&_*@!M%.\M_
M[C?E1Y;_ -QORH ;13O+?^XWY4>6_P#<;\J &T4[RW_N-^5'EO\ W&_*@!M%
M.\M_[C?E1Y;_ -QORH ;13O+?^XWY4>6_P#<;\J ,?6_OZ7_ -?T?\FK6K+U
MQ'WZ7\K?\?\ 'V]FK6\M_P"XWY4 -HIWEO\ W&_*CRW_ +C?E0 VBG>6_P#<
M;\J/+?\ N-^5 #:*=Y;_ -QORH\M_P"XWY4 -HIWEO\ W&_*CRW_ +C?E0 V
MBG>6_P#<;\J/+?\ N-^5 #:*=Y;_ -QORH\M_P"XWY4 $?\ K%^HJ]5-$<2*
M2K=1VJY28'R!\;?^2O:[_P!N_P#Z(CK@*[_XV_\ )7M=_P"W?_T1'7 4@"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH [BP_Y!UM_P!<D_D*L57L
M/^0=;?\ 7)/Y"K%=BV,&%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %>C_  5_Y'*\_P"P>_\ Z,CKSBO1_@K_ ,CE>?\ 8/?_ -&1U,_A
M8X[GN]%%%<IL%%%% !1110 4444 %%%% !1110 4444 8^K_ /(7\/\ _7Z_
M_I/-6Q6/J_\ R%_#_P#U^O\ ^D\U;%, HHHI %%%% !1110 4444 %%%% !1
M110!CZU_R$M _P"P@?\ TGFK8K'UK_D):!_V$#_Z3S5L4P"BBBD 4444 %%%
M% !1110 4444 %%%% &/KG_'UHO_ &$!_P"BI*V*Q]<_X^M%_P"P@/\ T5)6
MQ3 ****0!1110 4444 %%%% !1110 4444 8^O??TG_L(1_^@M6Q6/KWW])_
M["$?_H+5L4P"BBBD 4444 %%%% !1110 4444 %%%% !1110!\@?&W_DKVN_
M]N__ *(CK@*[_P"-O_)7M=_[=_\ T1'7 4 >@_"C3M"U#4=;;Q%:I/86^F/(
MS$<Q?.HWK[@$UO>!_AO:V'CF[7Q/$D^FVETEG;*P^6\EE_U9'JH0[S^%>>>'
M?$7]@VVM0_9?/_M.P>RSYFWR]Q!W=#GITX^M:UE\2-8CO/#;WY%Y:Z#('@@#
M;#)CIN;!Y   ..!5)KF3_K=_I_6@NC7];$EYX$>2_P!&>&ZBCBUS4I[2% A_
M<;)0F3SR.?TKJ=-\$:1-IOA[2K\P)*WB.XLI[I8COG5, )D<@'G'/&:P-.^)
M5K;PV O_  ZM[-INH2WMC)]L:/RS(X<JP"_-R.#Q]#4;_$N02:?)%I:J]GK<
MNK M/N#;SGR\;1T_O?I4PT23_K6/_!*EJVUY_K_P#0?PMIJZ?XOM]+DL+R&V
MN[:%+F6WD$MN7F9=B$GMC!/.:I:I\,VTS^UUM]=LK^\T9U:]M(XY%98RP&X%
MA@GD9 /'K38?'6G^?K%O:Z.UG;ZS=VL\C/>>9Y)CE+L?N#(.?;&.]:OC7Q]I
M2:SXFA\/Z;&9-5E"7&I"Z:031 @X1",+G R<G\*(Z6O_ %9+\-_,;LVRUXD^
M&C:MXV\0S6*QZ;H]E-%"!;V<DQWM&K;5CB4G'.2>@S6&/A-J\M[?:=;W5O-J
M5C<Q1SVP!7$,@!6<$_P<C/ ([U-=?%--1O\ 6?M^B/+INI3QW MHKYHI(940
M)N64+R"!R"M5=+^) \/S7-QH>C):W-U<H\TDMRT^ZW4#]Q\XSACRQSSZ "B*
MV_KM_P 'Y>9+_K^OZU\CGHKFU\->)9S##I^N6\#-$INH6,,O;<%# _3FO1/&
M4.G3ZQX?\-:=X<T2Q.MVEG*]W% PEA>5N=AW8QQT(/&>:\MU>ZM+[5KJZL+(
MV-K+(7CMC+YGE _PAL#(]..E;'B3QA-KNJ:1J%O;FRFTVS@MHV$N\EHNC]!C
MGMS]:([1YNZ^[4'N[?UL=!XFUCPSH.L:CX<M/!UA/:6;/;?:IY91<O(O!DWA
ML ;N=N,5VVG^%+&33?"K3>%=*DT&YTI)]6U.;,;PG!RPD##!Z'H:X#4O'FAZ
MS++J.H^"K2;6YDQ)="\D2%WQC>81W[_>ZTL'Q.N+74-!N(=.7R=-TT:;<V[S
M;DO(N=P;Y?ESGWP1WH5[6>_X;/\ 6W](;M?3;_ACGET2_C:;6;#2+J\T6UN"
M1<R6[M"R*W =AQ@C&>1UKO\ 4]9TJ#X::7X@C\&>&Q>7UW-;2+]F?8JJ."OS
MYS]2:\QO+X23W"V0GM;&21F2U,Y<(I/"DX&['KBM.\\3_:_ VF^&OL>S[%=2
MW'VCS<[]_;;CC'KDTOL6]/TN'VK^O_ .?HHHIB.XL/\ D'6W_7)/Y"K%5[#_
M )!UM_UR3^0JQ78MC!CX0&GC!&06 (_&O1O&7@RWNM?MQX=MUCCDG%G<0H.(
M9<!MWLI4Y_ UYQ&VR17QG:0<5T]UXZU)M6UB]L +1-44)+$6W[<+C(.!SC/.
M.]*5]+>?Z?\ !&C?\2^%-+N_L2Z&8X8(-,GN7E*Y-QY3;23[G'6J/A3PS")M
M/O;P0W,-_97<BPO'G88P0#SWSS5&Q\;?9$TZ)].$L%M8RV,R&8CSDD))(('R
MG\ZGB\=P6QT]+71O*@LK>X@2/[46)$O<DKU'Z^U0U*S2\_U_X!2:NGZ?I_P2
MTOAK2;>V\*3PW4,UW?2+NAEBD*3YD Y[ +T([U7N?!L4L\MY<ZI9:=#-J,UI
M'&(G(#JV % SA>>_2J5OXMACLM#CFTPR7.D2AXIEN"H=-^\J5VGGMG/X5M2^
M*M'D\.V\]Y8+=W)U6>[%H+DH8MQ!!) ^8=N@_"J=[_-_FOT)6W]=F1-X/G/A
MU-*6V@.K_P!N-:>=CJHCS][KM[UC^(/!MSH6GI??://M_.\AR;>2$J^,\!P-
MP.#R*MCX@WP*SBV3[6-3.H>9N^4Y39Y>W'3'?-9>N:W8ZI$%M-,DM&,AD=GO
M'F'T4$  <^Y]Z2YOZ]%_P1^[_7J_^ :4WAW24\#Z;J?]HI'>W,[KEXWPV-HV
M<<#;R2<<TQO!)D33YK+5(+JVNKQ;-I5B=/+D;H<,!N7'<5%I_BN"TT:PL+G2
MDNGL+HW$$C387D@E67!W9QZ]ZU+OXC&Y:#&G3;(=1COQYU\TIRN<H"5X7GC
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M0 4444 %%%% 'R!\;?\ DKVN_P#;O_Z(CK@*[_XV$'XNZ[C_ *8?^B(ZX"@
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M54_M.R_Y^$H_M.R_Y^$HN@LRW153^T[+_GX2C^T[+_GX2BZ"S+=%5/[3LO\
MGX2C^T[+_GX2BZ"S+=%5/[3LO^?A*/[3LO\ GX2BZ"S+=>C_  5_Y'*\_P"P
M>_\ Z,CKRW^T[+_GX2N[^$_BC1-(\4W5QJ&HQ6\363H&?."V]#CIZ U,VN5E
M16I]'45RG_"RO!O_ $,%K_X]_A1_PLKP;_T,%K_X]_A7,:G5T5RG_"RO!O\
MT,%K_P"/?X4?\+*\&_\ 0P6O_CW^% '5T5RG_"RO!O\ T,%K_P"/?X4?\+*\
M&_\ 0P6O_CW^% '5T5RG_"RO!O\ T,%K_P"/?X4?\+*\&_\ 0P6O_CW^% '5
MT5RG_"RO!O\ T,%K_P"/?X4?\+*\&_\ 0P6O_CW^% '5T5RG_"RO!O\ T,%K
M_P"/?X4?\+*\&_\ 0P6O_CW^% '5T5RG_"RO!O\ T,%K_P"/?X4?\+*\&_\
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M65X-_P"A@M?_ ![_  I@=717*?\ "RO!O_0P6O\ X]_A1_PLKP;_ -#!:_\
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M_P +*\&_]#!:_P#CW^%'_"RO!O\ T,%K_P"/?X4 =717*?\ "RO!O_0P6O\
MX]_A1_PLKP;_ -#!:_\ CW^% &GKWW])_P"PA'_Z"U;%<#K/Q#\)3OIIBUVV
M;R[U'?&[A0&YZ>]:?_"RO!O_ $,%K_X]_A3 ZNBN4_X65X-_Z&"U_P#'O\*/
M^%E>#?\ H8+7_P >_P *0'5T5RG_  LKP;_T,%K_ ./?X4?\+*\&_P#0P6O_
M (]_A0!U=%<I_P +*\&_]#!:_P#CW^%'_"RO!O\ T,%K_P"/?X4 =717*?\
M"RO!O_0P6O\ X]_A1_PLKP;_ -#!:_\ CW^% '5T5RG_  LKP;_T,%K_ ./?
MX4?\+*\&_P#0P6O_ (]_A0!U=%<I_P +*\&_]#!:_P#CW^%'_"RO!O\ T,%K
M_P"/?X4 =717/Z;XY\,ZO?Q6.GZQ;W%U+G9$F<M@$GMZ UT% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img160836378_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img160836378_2.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" :H"88# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*/OD?W4]""RFG&,INT4$I**NSZ0\5^+M%\#:'<:SX@U2UT?2[<9DNKN0(@]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "OD3]LC]M&V^%=K<^#_!5W#=^,95,=U>QD.FEKT(]#-Z*?N]
M3V!^NZ_$;XV?"7Q1\&_'E_HOBJ"3[4TCS0WQ):.^C+'$R-W#=3GD$D$ \5U8
M>$9R]XPK2<5H3?"?X2>+_P!HCQ\=-TA)KZ\N)?/U#5;HLT=NK$EIII.>2<^[
M'@9-?K?\#_@;X<^ O@R#0= @WRMA[W495'G7DN.7<]AZ+T4?B3\S_P#!.OXW
M>#)/"J_#P6%KX?\ %:.\_F*>-7ZDON)SYBKP4S]T97C(7[<IXBI)RY=D31BD
MN;J%?(O[9G[&</Q7M;GQGX,MH[?QG"FZYLTPJ:HH'Y"8 <-_%T/8CZZHKGC)
MP=T;RBI*S/Q0^#/QF\4_L[^/AJVDF2*2-_L^HZ3=;D2Y16^:*1>JL#G!QE3^
M(/ZY_!GXS>'/CGX+MO$7AVYWQMA+FSD(\ZTEQDQR#L?0]",$5X#^V9^QG#\5
M[6Y\9^#+:.W\9PINN;-,*FJ*!^0F '#?Q=#V(^"O@S\9O%/[._CX:MI)DBDC
M?[/J.DW6Y$N45OFBD7JK YP<94_B#WRC'$1YH[G(FZ+L]C]KZ*X/X,_&;PY\
M<_!=MXB\.W.^-L)<V<A'G6DN,F.0=CZ'H1@BN\KSFFG9G8G?5%'6='L/$6E7
M>F:I9PZAIUW&T,]K<('CE0C!5E/!%?D+^V%\$=/^ WQDGT31Y7;1K^TCU.RA
ME8L\$;NZ&(L>6PT;X)YVE<Y.2?U3^+?Q;\._!7P7=^)/$EWY%K%\D,"8,UU*
M0=L4:]V./H "20 37X__ !D^+'B#]H+XEW/B'482]Y=LMK8Z?:J7\F(,1'"@
M'+'+'W9F)QSBNW"J5V^ARUW&UNI^FG["?B^^\7_LU^&WU"1II]/>;3EE8Y+1
MQN1'G_=0JO\ P&OH&O)/V5_A7=?!WX&^&_#NH#;JWEM=WR<?NYI6+E/J@*IG
MN5S7K=<E1IS=CHA?E5PHHHJ"PHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HKPW]LKXN:M\&?@=J&L:"_D:Q=W,6GVUUM#?9VDW$R
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MSL82IS]W8^PJ***X3J"OD7]LS]C.'XKVMSXS\&6T=OXSA3=<V:85-44#\A,
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MK_V+6F?^DL==_7F2^)G='9!1114E!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M4A(4$DX% "U\H_\ !0CXL>*/A[\*=-M_"T\EG!K%[)8W^J6K?/ H0GR0P^XS
M_-R""!&P[UY+^V9^W"-46]\!_#B_9;7+0ZGK]NV/-[-#;L/X>S2#[W1>.3\W
M_ *SU;5)-<L)&F?PI?0>5J%L['R+B0,K1\=W4C<".1ZC-=#BJ%-UZFRZ&N#P
M]3,<3#!T-Y:7[>?IW/-/#.FVFL:]965]?+IUK-(%>Y<9"C_Z_3)X&<FOK[P_
MX?L?#.DP:?IT(AMHQQW+'NQ/<GUKYE^)OPRNO >H>9'NN=(F;]S<8Y4_W']_
M?O\ F!U_P?\ C!_9_DZ%KLW^B\);7DA_U7HCG^[Z'MTZ=./,:<\91C6H2O%=
M/ZZ^1]OPOBJ.0XZI@<QI\E26BD_R]'NFOGY>^UZM\%?C5/X!NDTO5'>?P_,W
MN6M6)Y9?5?5?Q'.0?*,UY?\ $+XD#$NEZ3)S]V:Z4_FJ'^9_+UKXY5WAWSIG
M[A+)XYY!X2<;Q>[[>?J?JY97MOJ5I#=6D\=S;3()(YHF#*ZD9!!'458K\U?V
M5OVJ;KX.ZA%X?\02RW?@RXD]W?3W8\R(.I0GED'^\.<AOT@TW4;76-/M[ZQN
M([RRN8UEAN(7#I(C#(92.""*^FP>,ABX<T='U1^"<3<,XOAK%>QK>]3E\,^C
M7Z-=5^A:HHHKO/C@KGO'WC[0OAGX4O\ Q'XCOX].TJR3=)*_5CV1!U9B> HY
M)KH:_*__ (*#?%/Q-XE^-6I>$+Z22T\.Z$8OL5BN525GA5C.W]YCO(!_A' Y
M+$[4J?M)6,ZD^17//?VFOVE-:_:*\7"ZG5M/\.V+,NF:7NSY:GK)(1]Z1L#)
MZ#H.Y/U3^Q/^Q7%I-OI_Q"\?V(DU%PMQI.BW*<6PZK/,IZR="JG[O!/S8VY_
M[#_[&2>78?$;Q[8$N2)]&T:Y3@#JMS*I[]T4^S'MC[YKHK55%>SIF%.FV^>8
M4445PG6%%%% !1110 4444 %%%% !7#_ !L^(R?"7X3^)_%K(LLFF6;20QN<
M*\S$)$I]B[(#[&NXKQ;]LKPU=^+/V9O'=A8QM+<K:QW81<DE8)XYGX[_ "QM
M5P2<DF3*]G8_)G3[7Q%\9/B-:VKW4FJ^)?$-^D/VBZ<DR32,%#.W91GGC  ]
M!7W]H7_!+WP1#HR)K/BOQ!=ZMM^>>Q,$$ ;':-HW;&<_Q\CTK\\_!?B[4? /
MBW2/$>DND>I:7=1W<!D7<FY&! 8=P>A'H37Z8_"K_@HI\./&=K;P>*#<>#-7
M8 2"Y1IK1F_V)4!('?YU4#U->E7]HK<FQPTN1WY]SYP^)G_!-OX@>'M>A3P;
M<VOBS1[B3:)II4M)[4$]95=L,H&/F0DG!^0=*_0CX._#/3_@_P##;0O"6G8:
M+3X LDW>:9B6ED/^\Y8^P(':N@\/^)M'\7::FHZ'JMEK.GN<+=:?<)/$3W&Y
M21GFM.N"=6<TE(ZXTXQ=T%%?(7[6W[<B?"#59_!_@N"WU+Q3$!]LO;D%[>Q)
M (0*"-\F"#UVKD9R<@?"^O?M1?%SQ)>&ZN_B+XAAE.?EL+Y[./DY^Y"47]/:
MM(8>4U?8F5:,78_:6BOR-^%O[='Q5^'.HVYO==E\7:4N%EL-;?SF=<]1.?WB
MMR<')'3(.,5^FFG^/!X\^";^+;"VOM(&H:-+>P0W2F.>$F)BIX^F0PZC!'6H
MJ494]RH5%/8[ZBOQM^&?[3WQ#\-_$/PWJ>J^/_$E]I5MJ$+WEM?:K<7$,EOO
M E5XV8A@4+=L]QR!73_'#]N#XA_$WQ+=-H&NZAX0\-QR$6=EI<YMYB@/#RRI
MAF8X!(SM'0#J3K]5E>US/V\;7/UKHKY+_84^)FIS?L\>)/%GC[Q1>W]I8:K<
M9U#6+IYVBMT@A8_.Y+$;F? YYX'I7SK\</\ @HAXV\8ZK/9^!)/^$1\/QOB.
M<1J][< '[SLP(C!X.U!D<@L16:HRE)Q70MU8J*;ZGZ?45^/,GCK]HWP_8KXD
MN=6^)%KIB?O?MUX]\;/!SR2_[LCKUXXKZ+_96_;^U76O$FG^$?B7+#="^E6W
ML_$"1K$R2L0$2=5 7:3QO &#][()(J6'DE=.Y,:R;L]#[[HHKX5_:E_X*!7?
MA77K_P )?#06SW=FYAN_$$R+,J2#AD@0Y5BIX+L",@@*>&K&%.51VB:RDH*[
M/NJBOQXL_B)^T5\0H)=:TK6?B)JMF!A[G1GO/LZXSG_4X0=#GZ&N\^#?[?WQ
M$^'>OQ6?C6XF\6:$LGE7,-Y&J7MO@X9DDP"S#GY9,YQC*]:W>&E;1W,5775'
MZET5E>%_$VF^,_#NFZ[H]TMYI>HVZ7-O.O1D89''8^H/(((-?C_XP_:$^)^B
M?$;6VL_B'XGCCL]5G,,#:O</" DS;5,9<J5X VD8QQC%9TZ3J-KL:3J*%F?L
MK17Y,_&G]NSXC?$[4G31-3N?!6AI@16ND3M%.^"#NDG7#Y)'12 !Q@\D\'X9
M_:H^+?A34X[ZU^(.O7;J1F'4[U[V)@#G!28L.?89]ZU6%G:]S/V\;G[15\S?
MMN?LR:K^T!X;T:^\-RP_\)%HC2B.UN)/+2ZBDV[D#'A7!12,X'+9(XKK?V4O
MVB[?]HKX?R:A/!'8^(M-D6WU.TASL#$925,\A' ; )R"K#G )\W_ ."C7C;Q
M#X'^&/AF[\.:]J>@74VL>5)-I=Y);.Z>1(=I9&!(R <>U94XRC426C-)N,H7
MZ'G'['O[$7C'P/\ $RR\:>/+:'18](WO9Z='<QSRS3,I4,QC9E5%#$_>R2!Q
MC-??=?FM^P+\6/&_C+X_1Z=K_C+Q!KFG_P!EW,GV74M4GN(MPV8;8[D9&3SC
MO7M7_!1[QQXD\#>!?"%QX;\0:IX?GGU*6.672[V2V:11%D*Q1@2,]C6M2,IU
M5&3,Z<HQA=(^OZ*_)7X6_MS?$3X:^$_$FG3:I=^*=3U!XFL+[7KI[K^SR PD
M9=Y);(V84G:"N<'D-YUJ7[2?Q7U:^FNY_B/XH264Y9;;5IX(QQCY8XV55_ "
MFL+*^X?6(VV/VOHK\SOV8_V\O%?A_P 7:;H/Q!U1M>\-7LJVYU&[ -S8LQ"K
M(7'+H#][=DXY!XP?THU#4+;2=/N;Z\F2WM+:)IIII#A4102S$^@ )KGJ4Y4W
M9FL)J:NBS17YA?';_@H7XU\7ZY=V/@.Y_P"$6\-Q2%8;F.)6O+I0>'9F!\L'
M .U0".A8UYO-XU_:/\.V*^(KK5?B5::9&/.^W7KWWV3:>A)?]V5^O%;+#2MJ
M[&;K+HKG["T5^3NE_P#!0OXRZ=I\-M)JVFW[QKM^T76GQF1_0MMV@GMT[<\\
MU]@?L._';Q]\=M/\67_C*&$6-FUJFG7-O9&".4MYWG -T?;LCSCIGWJ)T)07
M,RHU8R=D?45%%%<YL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 ?*7_!2C_DW>V_[#EM_Z+FK\MJ_4G_@I1_R;O;?]ARV_
M]%S5^6U>KA?X9Y]?XS]M_P!GW_D@GPU_[%K3/_26.N_KSGX$WEOIW[//P\NK
MN>.VM8?"VG22S3.$2-1:1DLS'@ #N:I>&_VH/A5XM\21:!I/CC2[O599/)BA
MWL@E?. J.P"N2>@4G/;->:TVW9':FDE<]3HHHJ"PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHJ&ZNH;&VFN;F:.WMX4,DLTK!410,EF)X  Y)- $CNL:,[L%51DLQP
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MV]>R?\%0O^22^$_^PW_[0EK67^\(SC_!9\\_\$X?^3CX_P#L$77_ +)7O/\
MP5'_ .2>^"?^PI+_ .BJ\&_X)P_\G'Q_]@BZ_P#9*]Y_X*C_ /)/?!/_ &%)
M?_155+_>$*/\%GS?^P;\-/#GQ0^.;6/B?38]6L+'3)K]+2?F)Y5DB1=Z_P 2
M@2$[3P2!G(XK]2/$GP_\.^+/"-QX8U/2+2?0YHC#]C\E0D8((!08^4C)P1R#
MTK\W_P#@F=_R<%J?_8O7'_H^WK]0JPQ+?M#6BER'X+:YIXTG6M0L5<NMK<20
M!CU.UB,_I7ZZ>-(]7\9_L6W1LR\VKZAX,CE*H?FE+6JLZCU+#<,=\U^2_C3_
M )''7?\ K_G_ /1C5^TWP/8+\$_ !)P/^$>T_P#])HZWQ+LHLQHK5H_(+]GG
M6-"\/_&_P5J/B4PIHEMJ<4ES)<*#'& ?E=L_PJVUC["OV7U[Q9X=TGPK/K6K
M:KI\/A_R2\EY/,AMWC(.><X8$9X&<^]?DA\=O^$-^*G[03Z=\+=*&FVNJ:A'
M8))).%M;JZDE">=&N/W,;,W3)&.0%^[7K%G_ ,$P?B2]W&MUXD\*PVQ;YY(9
M[F1P/4*8%!/MN'UHK1C.TI.P4Y2C=15SY:DMF\1>.G@\-6LBM?:B4TVUCX<;
MY<1(/?E17[K0JZQH)&WR  ,V,9/<U\U?LX_L-^%_@;J4/B#4KUO%/BJ-?W-S
M-"(K>T)ZF*/).[G&]B3QP%YKZ8KGKU%4:4>AM1@X)WZA1117*= 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"X2<M6-:BHKGAL:4JC;Y9;GU11117$=04444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWJ'A97./M=O,+Z%/=\(C@?[JM7C^E_\ !,#X@7%JSW_B?PY9S;<K%"T\O..
MQ\M<>^,_C7C_ ,;OV1_B'\"+0ZCK5C!J.A;@IU;2I#+ A)P!("JLF20,LN"3
M@$T<E"6B%S58ZL_7GPSXHTCQEHEKK&A:E;:MIETN^&ZM9 Z,/J.XZ$'D'@UJ
MU^/O[)_[2VI_L_\ CJW6YN)I_!VH2K'J=@6+*@) ^T1KV=1@\?> VGL1^OMM
M<Q7EO%<02+-!*@DCDC;*NI&00>X(KCJTW3=NATTZBJ(EHHHK$U"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HJI-JME;WT-E+>6\=Y,-T=N\JB1Q
MZJN<D?2K= !7!6OQX^'M]XBO-"M?&.D7.LVH8RV4-TK297[RJ ?F8=U7)&#Q
MQ7R1^VM^VM]C^W_#WX>W_P#I'S0:MKEL_P#J^S00,/XNH9QTZ#G)'RQ^S7\-
MM9\9?$32M5LU:WTO1[N*ZNKQLA?D8,(AZLV,$=@23VSWT<*ZFLCDJU^38^QO
MVJ/AC8_M#*;^WAATW7;*,QV-V5 ,B D^7,1R5))Q_=)XZD'\^V77/AKXJ>.1
M)M+UFPDV/&XY!]#V92/P(.:_3NO*OCM\"=/^+FC^?!Y=EXCM4(M;PC D'7RI
M,=5)Z'JI.1W!]F="/)RI:'ETL34IU%44K-.]^S/D_6/B1=>/A&9MMLD('^BQ
MD[0V.6]_Z=/KF5R6K:3J?@_7;C3]0MY+#4K1]DL,@Y!_J".AZ$'-=!I>J1ZE
M#D?+*OWD]/<>U?EF<95/"R=>GK!_A_P.Q_9'A_QM0SFC'+<7:&(BM.BFNZ_O
M=UUW6ETKM%%%?+G[4%%%5[/4+*\UBVTY[N*T$\RPM=3DK#%N(&YV .%&<D@'
M@5T4</5Q#<:46[=CRLPS3!95353'5HTTW9<SM=F)K6NF0F"V;"]&D7O[#VK[
M:_X)?:-JDLWCG4[G3EDT66*"UCOYX06,H+%XD<\E=I4NO3(2L7PG_P $Q/$3
M>,H!XA\4:6WA-"LDD^FM(;N9?[BJR!4)QC<6. 00#R!^@7A/PGI'@?P[8:%H
M5A#IFDV,8B@MH1A57^9).22>22222:_3*=##86BJ5%7\^OJ?PYF^?9EGF-GB
M\94:OIRIOE2[)=OS>K-5$6-%1%"JHP%48 'I3J**1X@4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV7S/::*\0;]K+P_""]SX0\<6D(^]-/H$@1?J036MX<_:H^%GB:;R8?%]G8W
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MJXB%+1ZL^^Z*_,236+^20N]]<NS')9I6)/ZTG]JWO_/Y<?\ ?UO\:[_[+?\
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MZQ:B]L'2:1X&8J&*QLRYP0<9 _*OOW3=+M-'L8;.PM8;*TA&V."W0(B#T '
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF_MW-J.#E\%[R_PK5_?MZL^2O$.O:IXX\37NK:A*]]JVI7#2RL 2SNQZ ?D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/EE9RZC>06L"[YYY%BC7U9B !^9KY;.ZC]RDO7_+]3^AO";!Q3Q>/GTM%/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KYZ_;0_P"1#T/_ +"7_M)Z^A:^>OVT/^1#T/\
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M-LPI*M1H^Z]FVE?TOK\]CZ_HKP+X=_M=^'_%5]#I^NV;>';J9@B3M*);<D]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?/7[:'_ "(>A_\ 82_]I/7T+7SU^VA_R(>A_P#82_\ :3UV8/\ WB!S
MXC^%(^/J***^Q/G@HHHH **** /T=^%?_)+_  ?_ -@>S_\ 1"5\/?';_DK_
M (K_ .OUOY"ON'X5_P#)+_!__8'L_P#T0E?#WQV_Y*_XK_Z_6_D*^?R_^//^
MNIZN*_A1.#HHHKZ \H**** "NI^%?_)4/!__ &&+/_T>E<M74_"O_DJ'@_\
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MK5S%I&HW.C:!&Y6WAM',4DJC@/(PP23UVYP.G.,GS'_A*];_ .@QJ'_@4_\
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MZ\R_(****^%/UX]B\-ZU>1_LQ^+K%92+?^V+=<>S!2P^F8U_7UKQVO5/#O\
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M(1%*KGV)<_\ ?-?+\0X>E4P;K3=I0V?K;0_0."L=B*&9QPM)7A5TDGV2;O\
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M %%%% !1110 4444 %%%% !7SU^VA_R(>A_]A+_VD]?0M?/7[:'_ "(>A_\
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M=1R+M*3*BE@/4'((/H?7(KN:X#X*_#"/X4>"(-+,@GOYG^TWLRGY3,0 0O\
ML@  >N">,XKOZ_=L'[;ZO#V_QVU/Y S+ZM]=J_4W>G=\OI_6WD%%%%=AYI^9
MWQ"_Y'[Q+_V$[G_T:U8%;_Q"_P"1^\2_]A.Y_P#1K5@5^!5OXLO5G]DX7_=Z
M?HOR"O5/@)_S4;_L3=2_]IUY77JGP$_YJ-_V)NI?^TZZ\O\ ]YA\_P F>=G/
M^X5/E_Z4CRNBBBO./;"OKW]B3_D5O$O_ %^1_P#HNOD*OKW]B3_D5O$O_7Y'
M_P"BZ^DX=_Y&,/1_D?"<;?\ (DJ^L?\ TI'TG1117Z^?S.%>%?MA>(7TGX6Q
M6$3[6U.^CAD&<$QJ&D/_ (\J?G7NM?.G[:UC)+X'T*[ S'#J)C;V+QL1_P"@
M'\Z\;.92CE]9Q[?\/^!]1PQ"%3.<,JFW-^*3:_&Q\=4445^*G]5A7J_[//CZ
M?P+K?B.2-N)M$NI$C[&:)#)&?_'6'_ C7E%=5\.]!FU[4]4$*LQM=(OKI@HS
MPMNX_FP_.NW!U)TL1"=/>YY6:4:.(P56G7^%K7^O4Y>21I'9W8N[')9CDD^I
MIM%%<1Z@5N^!?$4GA/QEHNL1L4-G=QS-CNH8;A]"N1^-856+"SDU*^M[2$;I
M9Y%B0?[3$ ?SJZ<I1FI1W1E6A"I3E"I\+33].I^I%%%%?T ?QD<K\6/^26^,
M?^P->?\ HAZ_-FOTF^+'_)+?&/\ V!KS_P!$/7YLU^;<5_QJ7H_S/W?PZ_W7
M$?XE^04445\*?KAZIX=_Y-S\7?\ 89M/_037E=>J>'?^3<_%W_89M/\ T$UY
M77H8KX*/^'_VZ1XF7?Q,5_U\_P#;(!1117GGMGZ#?LX_\D3\+?\ 7&3_ -'/
M7I5>:_LX_P#)$_"W_7&3_P!'/7I5?NN _P!TH_X8_DC^0\X_Y&6)_P <_P#T
MIA1117<>0?F=\0O^1^\2_P#83N?_ $:U8%;_ ,0O^1^\2_\ 83N?_1K5@5^!
M5OXLO5G]DX7_ '>GZ+\@HHHK$Z@HHHH *]?_ &4?^2UZ1_UQN/\ T2U>05Z_
M^RC_ ,EKTC_KC<?^B6KTLL_WZC_B7YG@Y]_R*<5_@E^3/O&BBBOW$_DH****
M &LP12S$!0,DG@5^=WB_7-5^./Q5DEME::XU*Z%M8PMP(XLX0'T 'S,?7<:^
M_P#Q-*T/AO59(SM=+25E/H0A(KX4_9EA6?XX^&%;D;KAOQ%O*1^HKXGB&]:M
MAL)?W9RU^]+]6?JW!7+A<-CLQ2O.G#3[I-_?9'W!X&\(VO@3PCI>@V?,-E"(
MR^,%VZNY]V8D_C6_117V<(1IQ4(JR6A^75:DZU256H[RD[M^;W"BBBK,CY"_
M;9TV&'Q1X;OU7$]Q:20N?4(X*_\ HPUV7P_\075C^Q_>W2N3-!8WL$3YY4&1
MU!^HW<?05R_[<'_(4\)?]<;G_P!"CK5\'?\ )E^J?]<;K_T>:_/K\F;8SET]
MQ_E$_:.55N',M537][%?+FFOR/-OV1]!AUKXO13S -_9ME->(K=VRL8_+S<_
MA7W/7Q9^Q;_R5+5/^P-+_P"CX*^TZ];AF*C@+KJV?.<>3E+..5O11C;\6%%%
M%?5GYT4-<T>V\0Z+?Z7>+OM;V![>51UVNI4X]\&OSW5M:^!/Q4/5=0T>ZQZ+
M/$?_ &5T/_CU?HO7PY^U]"T/Q@=F((EL('&/3YEY_(U\9Q-24:-/%1TG!Z/^
MO-'ZCP'B'+%5LOJ*].I%MI^6GXINY]KZ/JD&N:39:C:MOM;R!+B)O5'4,I_(
MU<KB/@G?-J'PD\(RO&8BNFPP[3GD(H0'\0N?QKMZ^MH5/:THU.Z3^]'YQBJ/
MU?$5*/\ +)K[G8****V.4**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^?_P!I;7K'
M2?'WPC.J3_9M+M-8EU.ZFP6\L0Q@(2J@L<L^./?BOH"OG;X@>&8/BK^U!9>'
M;J>Y@T[1?#)OI9K.7RY4FDN-H0-@XRN"<=0/:O.Q_M/8\M&W,VK7VWN?5<-J
MG'&RK5FU"$)MVWLXN.GG>2MYGHUO\?/ U\NJ"SUQ+F;3HGEFC\F5.%SG:64!
MN1V)KBOV;_"Y\1_VC\2]<1;G6M9N9?LK/R+>)6*'9GIR"OLJ@=S70:M\"].T
M_0/%K:;?ZY=7^J65PBQ7&IRLAD9'VY (W\MT<MG//6D_9?URWU?X.Z3!$P\Z
MP>6UG3NK>87'YJZG\:]'!O$+"SE7MS-VT[:^NY\_F"P7UF,<$Y.%K^]:]].R
M1ZS7+>)M#L]3@N;"]MX[FQNDVR0R#*L#V_STKJ:Q=:<-<*H_A7FJBVGH<IX=
M\$_$D7PL\6^+/ FKW^W2[$_;]/FFR=L;8++QZAT.!W#'O7<3?M(?#*\LRDOB
M)9+>XW0E6LKG#<#(/[OIAA^=<'X5TV+Q[^T9XJECFN8[#3M-%G)<V5Q)"XE)
M08#HP(((D]ODZ5VB_LU^'5MX8!K7B3RXI3,J_P!IL!N(49QCC[HY'/O7+FKQ
MOM4\,HZI7O??[T>QD\<J]E+Z_*::>G+;;7NF;W@7X.^'? GB+4==TI)!-?1"
M&.,L/*MH<AO+C4#H2 23DY'USWM,5=JJHS@#'))/YFGU5&C3H1Y*<;+R.'$X
MFMBZGM*\W)[7?9;'S-X2UR_N_P!HM8CKWG6C:[J\1L_WF6\NUC7;RN,+M4=<
M?N^.V?IFN7L_AKX9T_Q NN6^DPPZJMQ/="X5FSYLRA97QG&6 ].Y]3745Q8'
M#5,-&:J._-)OKV7<]3-\=0QTZ4J$6E&"B[I+5-OIY->9XE\6OV>=#\2_\)+K
M\*M'=W.E7"M9*/W;7(A(BF7'W77 Z @]QR<]+^SCK USX$^!+D'=MTF"W)]3
M$OE']4KT9E#*589!X(->(?LAM_9OPUU7PNQ ?PQX@U#2"F<D!9C)^(_>'FG"
MA2P^(O3C;G3OZZ?\$]!XJOC\EJ0K3<G1G3M?I%J:?X\J_P"&1[C1117I'R)\
MT_\ !0"S^U? F&39N^SZQ;RY/\.4E3/_ (_C\:^2OV,[S['^TEX/8LP21KJ(
MA>^ZUF !]LX_*OM7]MG33?\ [./B60+N:UDM9P-N3_Q\1J2/3 8_AFO@C]F[
M4O[+^/7@2;=MW:M!!G)'^L;R\<?[U?(YA[F/IR_P_F?TQP5_M7!F-H+?]['[
MX)_J?K;1117UQ_,X4444 %%%% !1110 5\T?\% O^2$V_P#V&;?_ -%RU]+U
M\T?\% O^2$V__89M_P#T7+7#CO\ =JGH?7\(?\C_  ?^-'R=^Q;_ ,G,>#O^
MWS_TBGK]2*_+?]BW_DYCP=_V^?\ I%/7ZD5YV2_[O+_%^B/N/%;_ )'='_KU
M'_TN84445[Y^,!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45G:E
MX@TW1P?MM]!;G^X[C=_WSUK!C^*OAY[H1?:954G'G-$P3_']*M0E+5(ER2W9
MU]%1PS)<1K)&RR1N RLIR"#T(->+_$GQ=>WVN7-A%,\-E;-Y?EH2N]AU+>O-
M53INH[(F<U!7/6[[Q!IFEY%W?V\##^%Y &_+K7/7WQ8\/VF?+EFNSZ0Q$?JV
M*\.HKL6&CU9S.O+HCU*\^-8Y%II9/HTTO] /ZUAW?Q>UVXSY?V:U';RXLG_Q
MXFN)HK94::Z&;J3?4WKKQUK]YGS-5N%S_P \F\O_ -!Q7DWQROKF]T*P-Q<2
MSG[3UD<M_ WK7>JK2,%52Q] ,UQGQFT&^;PA'>&TG6&WN49Y&C(4 @KUQZE?
MSKJHJ,:D3&IS2BSPVBBBO</-"BBB@ HHHH **** "BBB@ HHHH *ZCX6L$^)
MWA!F. -8LR?^_P E<O79?!O3'U;XH^&H44L4O$N#CL(_WA/_ ([6=72$K]BX
M:R2/L+XH>-;JVNH],T^=H$\L/-+$2&.2<*#V&!^M>>P:]J5JVZ'4+J)O5)F'
M]:[?QUX5N-3F2^LU\R15V21=R!T(KA)])O;7_76<\7^_&P_I7S='DY$D>O4Y
MN8V;7XB^(K7&W4Y''I*JO_,9K:M/C)J\.!/;6MPOJ%9&_/./TK@:*T=.#W1"
MG)=3UNR^-5G)@7>G30^IA</_ #VUOV/Q,\/7V!]M^SN?X;A"OZXQ^M>"T5D\
M/![&BK2/IJSU&TU!=UK<PW"]<PR!OY&K-?+T<C1.'1F1P<AE."*W=/\ 'FO:
M;@1:E,ZC^&8^8/I\V:Q>%?1FBKKJCZ$HKR/3?C1>1[5OK"*=>[0L4/UP<Y_2
MO3=%UFUU_3HKVT??"_8C!4CJ".QKFG3E3^(WC.,MB_1116184444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[VS@U*SGM;J%+
MBVG1HY89%W*ZD8*D'J"#5BBDU?1C3<7='Q5^U!\%M-^'<VEZOX?M8K#1;A1;
M/;^=)(_V@%VW?.2<%<#KQMZ<UX)7V5^VK"Q^'NBR 91=452<]"89"/Y&OF_X
M(>$=/\>?%#1="U59'L+KSO,$3[&^6"1Q@_517Y%F^#C',OJ]!)<UK+97?Z']
M*\-9I.60_7,9)RY%)M[MJ-WUW=CA:^@?V,='NKGXB:EJ21M]CM=/:.27'&]W
M3:OU(5C^%>T1_LD?#R.16:SOI #RK7C8/Y8->G^&?">D>#-)33=$T^'3K)#N
M$<(ZM_>8GECP.22>!7NY;P]B,/B8UZ\E:.NG7\#Y+/N-L'C<!4PF$A)RFK7:
M2277J[L^%/VC/"][X;^+FO-=1.L%_.;RWE(^61'Y.#['*GW%>95^G7B+PKH_
MBVR^R:UIEKJ=N#E4NH@^T^JDC@^XYKB9_P!GOX;VL<EPWA6W(B!D($LIZ<]-
M^/PJ,9PS5J5I5*,URMMZWT_!EY7Q[AJ&%IT,32ESQ27NV:=M+ZM6/S\K[V_9
MZ^%MAX'\"Z;=21VUYJEZ/MHO?LRK+&DJ+B,-R<!>O.,DU\$5^F'P^_Y$'PU_
MV#+;_P!%+7-PM2A/$5)R5W%*QZ'B%B*M+!T:4)6C)N_G9?\ !.@HHHK]-/P,
M**** /S.^(7_ "/WB7_L)W/_ *-:L"M_XA?\C]XE_P"PG<_^C6K K\"K?Q9>
MK/[)PO\ N]/T7Y!7JGP$_P":C?\ 8FZE_P"TZ\KKU3X"?\U&_P"Q-U+_ -IU
MUY?_ +S#Y_DSSLY_W"I\O_2D>5T445YQ[85]>_L2?\BMXE_Z_(__ $77R%7U
M[^Q)_P BMXE_Z_(__1=?2<._\C&'H_R/A.-O^1)5]8_^E(^DZ***_7S^9PKB
M_C!X%_X6-\/=6T1-HNY(_-M68XQ,AW(,]@2-I]F-=I1656G&M3E3GLU9G1AZ
M]3"UH5Z3M*+37JC\M;RSFT^ZFMKF)X+B%S')%(,,C X(([$&H:^Y/C7^S5IW
MQ,N'UC2IX](\0$8D9E_<7/H9 .0W^T,^X/&/DOQM\)_$?P_UVSTG5[6-+J]/
M^C&&9767YMN0<\<G^("OQS,,HQ. D[QO#HU^O9G]/9+Q+@<XIQ49J-2VL7OI
MO;NO3IO8X^OKG]C[X9O8Z'J?BC4K? U2,V=K'(/O6^<R,1Z,P '^X3W%9'PQ
M_8[N1?0WWC2YB6VC8-_9=HY9I/:20< >H7.?45]46MK%96\5O;Q)!;Q((XXH
MU"JB@8"@#H .U?3Y%DM6E56*Q,;6V77U9\#Q?Q5A\1AWE^ GS<WQ26UEK9/K
M?J]K:==/SC^*G@&Y^&OCC4=%G5O(C<R6LK#_ %L!)V-]<<'W!%<C7Z+?%?X1
M:-\6M%6TU$-;7L&3:W\0!DA)ZC'\2G RI].QYKXX^)W[/?B?X76<NHWIM;W2
M%D6,7EO*!RWW<HV&!^F1[UXF:Y+6P=252E&]/>ZZ>OIW/J^'>*L+F=&%#$3Y
M:^BL_M/NO7MO<\PKV3]EWX<R^-/B-;:G-$3I6BLMW+(1\K2@YB3Z[AN^BGU%
M3?"_]EWQ!\0+*PU>\NK?2=#NAYBR[O,FD3/54' SC^(C'H:^Q_!/@G2?A_X?
MM]&T:V^SVD7)9L%Y7/5W/=C_ ( 8  KKR7):U:K'$5XV@M5?KV^1YW%7%6&P
MV'J8+!SYJLKQ=MH]'KWZ66V[\]^BBBOU$_GTY7XL?\DM\8_]@:\_]$/7YLU^
MDWQ45I/AAXP15+,VCW@  R2?(?BOS9K\VXK_ (U+T?YG[MX=?[KB/\2_(***
M*^%/UT]4\._\FY^+O^PS:?\ H)KRNO5/#W_)N?BT]O[9M/\ T$UY77H8KX*/
M^'_VZ1XF6_Q,5_U\_P#;(!1117GGMGZ#?LX_\D3\+?\ 7&3_ -'/7I5>:_LX
M_P#)$_"W_7&3_P!'/7I5?NN _P!TH_X8_DC^0\X_Y&6)_P <_P#TIA1117<>
M0?F=\0O^1^\2_P#83N?_ $:U8%;_ ,0O^1^\2_\ 83N?_1K5@5^!5OXLO5G]
MDX7_ '>GZ+\@HHHK$Z@HHHH *]?_ &4?^2UZ1_UQN/\ T2U>05Z_^RC_ ,EK
MTC_KC<?^B6KTLL_WZC_B7YG@Y]_R*<5_@E^3/O&BBBOW$_DH**** ,'QW,T'
M@?Q%*APZ:=<,I]Q$QKXH_96A67XW:&QSF..Y9?KY#C^1-?:OQ!_Y$'Q+_P!@
MRY_]%-7Q=^RC_P EKTC_ *XW'_HEJ^)SG_D98/U_5'ZMPOID69M?RO\ ])D?
M>-%%%?;'Y2%%%% 'R'^VT['Q-X97<=@LY2%SP"7&3^@_*NAT-Q:?L2SR(HW2
M6\X;/?-ZRY_+^5<[^VY_R-/AK_KRD_\ 0ZW],_Y,??\ ZXS?^E[5^=R_Y&>-
M_P"O<ORB?MD?^1#E2_Z?0_.9R/[%<(;XC:S-GE=)9,?6:(_^RU]F5\;_ +$_
M_(_:[_V#/_:J5]D5[G#?_(OCZO\ ,^2XY=\ZG_AC^04445]0? !7G_Q$^!_A
M7XGZG9ZAK5M-]KMU\OS;:4QF2,$D(_J,D],'GK7H%?)_[9/B[6=,\2Z%I=EJ
M-Q967V,W+1V\K1[Y"[+EL'G 48],GUKR,UK4</A95*\.>.FA]+P[A<5C<PA1
MPE7V<VG[ROHK:['U18V,&EV-O9VD*V]K;QK#%$@PJ(H 51[  "K%<%\"=:O?
M$'PE\-7^HW$EY>26[+)/*<N^UV4$GN<*.>IZUWM>A0J*M2A4BK)I/[T>+BZ,
ML-B*E";NXR:;[M.P4445N<@4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "$A023@5^2OQ._;
M=^)OB#XF7^L:!XJN]'T:WNW&FZ?:A1"( V$\Q2,2$@ G?GDG&!@#]0_BE?2Z
M7\,O%UY =L]OH]Y-&<GAEA<CI[BOPQKNPL5*[:.2O)JR1^Y/PF\6W7C[X8>%
M/$E];K:WFK:7;WLL* A5:2-6.W/.TYR/8BO.?@=_Q5'QE^,7BTC?"-3@T&V;
MJ%%K%B4 ^[,IKUE8[?P3X-$<$?\ HFD6&U(U&/DBCX _!:\Q_9!TW[)\!]#O
MI'\V]U>6YU.[EX^>629^>.^T*/PKQZOO5X172[_3]3Z_ _N,JQ=?K+DI_>W-
M_P#IM+YG=_$CXC:?\,]!74;V*:[FFF6WMK.V&99I&R0H]. 3D^GK@5\_^'KO
MQ-X-UB^\>>"]._M_PSJ3>9JFG6:L(EE+,66#JSB/.#(%QDM@8X'H_C;X$WWB
MGXC#6XM:=-,OH_L^J0S2,9/LP _T:$  *CX.XDY!.1W!]6T/0[#PUI-MIFEV
ML=E86R;(H8APH_J>Y)Y)))K/"UL7]:FZBM26EN_G_6WWG/C*670P%.-&3E7E
MJWMR^5OZNM7T/+=/_:L\ 7ECYES?76F7/1K6ZM)"RGORBL/UKC]?^.>H^/)I
MM'^'.DWFK:E,"KZB\6R* '^(;NA]"^ #C@]*F_:8U.;0M<MGLO#FGZD9=*G,
MDTUH)&!,\"[L^J\ ?[Y]:^@-*M(;+3X(X+2*QCV ^1"@14)'(P*[J..PTZU2
ME"#YH6W>FORU/.Q&6XBAA:.)G-<M2]K;Z6WUTW/!_@'X@\.?#^[B\(33-/KV
MJR--+J2J2DLX'S6TF[#1RH=PV,.X;(+[:^A*\2^,'P%/B2:YU+PS#;07>I2*
MNK6DAV)=(&!$B-@^7*K#=N&-W.<Y(;U#PA8MH.AV6BW6LG6K^SBV27,Q FD
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M1\#].3;N\[78(\YZ8AG;/_COZU]/5\K?\%%)T7X-Z%"3^\;7HG QV%O< _\
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M7Z]G+\MP=3"4ISI1;<5T\CYC.L\S2CF6(I4\1-14Y))-Z*[/%O\ AD7X>_\
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M3UK.GE5%3E*--7>]_P#@CEQ5FW*DL3)+IRZ?E8^IE_8M^#>/^1.R?^PG>?\
MQZII/V-O@Z\"0GP;'M4Y!%_=AOQ82Y/XFOB]_P#@IY\4"[%?#_A%4SP&M+HD
M#Z_::DM_^"GOQ,63,_AWPG+'C[L=M<H<_4SG^5=7]F4_^?<?N1A_K5G#WQM7
M_P &3_S/L?\ X8M^#7_0F_\ E4O/_CU)_P ,=_#B,#[-;ZQ92+]R2WUBY#)]
M,N>W%?)EK_P5&\9(K?:?!NA2MG@Q2S(!^;-6]9_\%4KQ-WVKX;03<<>3K1C_
M )P-4_V93_Y]+[D5_K5F_7&U'ZSD_P V?2O_  R;X<CR+3Q7XVT]#U2VUZ0
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M#_A8'A?_ *&32/\ P.B_^*H_X6!X7_Z&32/_  .B_P#BJ.278.:/<WZ*P/\
MA8'A?_H9-(_\#HO_ (JC_A8'A?\ Z&32/_ Z+_XJCDEV#FCW-^BL#_A8'A?_
M *&32/\ P.B_^*K6LM0M=2A\ZTN8;J$\"2%PZ_F#2<6MT/F3V+-%%%2,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD/B1XJG\,Z/$+0[;NY8H
MDA&=@ Y/UY'YUTUQ?PV_#-EO[J\FN'^(6FS>*=.B%NJB:W8NBD_>!'(S^ _*
MM::7.N;8B=^5V/)+R]N-0G::YFDN)6ZO(Q8_K4%:4?AO599O*73[C?\ [49
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M'+&T4B]5<8(_"F54J<)[HF,Y1V/I32];L=<@\ZQNH[E.^P\K]1U'XU?KYO\
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MR_\ ;35HHHK]&/P\**** "OBS]M+_DJ6E_\ 8&B_]'SU]IU\6?MI?\E2TO\
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MG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3/[)U5H%N1;_ &B*;]VQ(5MT;,O53QG/%>Y? O\ Y/\ 8O\ L9M4_E<5H?\
M!2C_ ).(MO\ L!VW_HR:O14WSJ/D<7*N5R\QC?\ !-SXJM90W-M>^&KU)HA*
MJPWTJGD9"_/"O/Z>]86H?\$_/C99;O)\.6=_C&/L^J6XS]-[KTK]6?#_ /R
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MA8'RV)[D;67_ ("#WKY['X2-->UIK3J>MA<0Y/DF>U4445XAZ04444 %%%%
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M^KT,G_Y%]'T/$XG_ .1SB?\ $%?G'\:O^2M^+O\ L)S_ /H9K]'*_./XU?\
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M_<H?XE^4C]/\/?\ D:U/^O;_ /2H'T[^RC_R1/2/^NUQ_P"CFKU^O(/V4?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K/\0?\@'4O^O:7_P! -:%5-4M7OM+N[:,@230O&I;IDJ0,TP/P
M4K]UOA]_R(/AK_L&6W_HI:_$N?X=>)K?QL?"#Z'>_P#"3"Y^R?V8(B9C)G&
M.X]^F.<XYK]O_"NFRZ+X8T?3IRIFM+.&WD*G(W(@4X]LBN_%-6B<>'W9JT44
M5YYV'Y3? O\ Y/\ 8O\ L9M4_E<5H?\ !2C_ ).(MO\ L!VW_HR:N%\-_$73
M?A-^V#J/BW6(+JYTW3/$6I23162*TS!GF0;0S*#RPZD57_:Z^-NA_'SXJQ>)
MO#]IJ%G8IIL-F8]2CC27>CR$G".XQAQW]>*]=1?M$^ECSKKD:\S]>_#_ /R
M=-_Z]HO_ $ 5H5G^'_\ D Z;_P!>T7_H K0KR#T0HHHH **** "N2^+FD?\
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M444 %%%% !1110 5[Q^QQ?2P?$V^ME;]S<:9(77ME9(R#_/\S7@]>X?L?_\
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M:GB#6[GQ)KNH:M>$&ZOIWN)=O3<S$D#VYKZL_;,\??V?H.G>$[:3$U^WVN[
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M4C(\Z0S(I([@$J3[+7MO[77_ "1NY_Z_8/YFOEOPA=+;_!GXB1L&)GNM*C7
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M_P #KYV&,Q']I>R<WR]K^1^^8C),L_U#680P\?;<L?>LN;^(D]?2Z/N( *
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M6</RE++H<WG;TN?G'&D:<<[K>S_NW]>5!1117T9\.%1S2I!$\LCK'&@+,S'
M '4FI*9)&LL;1N-RL-I![@TGY#5KZGYP_%?QP_Q$\?:MKA+?9YI=ELK<;85^
M5!CMP,GW)JEI_P .?%.K:6^I67AW4[JP0;C<16CLA'J#CG\*^^?#OP9\$^$[
MDW&F>&K&&XW;A+*AF=3_ +)<DK^&*[6O@8\,3K3E5Q57WG=Z+KZO_(_9*G'U
M'"TX8?+\/[D4DN9VT7DK_??Y'Y=6-]=:)JEO=V[-;WMI,LL;8PR2(P(/U!%?
MI1X'\56_C;PCI.NVW$5] LNW/W&Z,OX,"/PJGXN^&'A7QTI_MS0[2^DQCSRN
MR8#T$BX8?G6OX?\ #^G^%=&M=)TJV%II]JNR&%69MHR2>223R3U/>O6RC*JV
M659IS4H27SOZ?\$^:XDXBPN?X>DXTG"K!OLU9^>^]NG<^1?VQ/'AUKQI:>&K
M=\VND1[Y@#PT\@!_':FW\685XIX>\&Z]XLD*:-H][J97[QM8&=5^I P/QK]!
M=2^#_@S6/$LNOWWAZTO=5EQYDUP"ZM@  F,G83@#G&>*ZRUM8;&W2"VAC@@C
M&%BB4*JCT '2N"OP]5QN*G7Q%6R;TMVZ;[:>I[.#XUH97E]+!X*@VXK5R=ES
M;MZ7O=^A^8&J:3?:'>/::C9W%A=I]Z"YB:-U^JD9K[9_9.\<_P#"5?#--,GD
MWWVB2?96R>3"<F(_3&Y!_P!<Z]8U[PSI'BFS-KK&F6NIV_\ SSNHED ]QD<'
MW%9?@CX:^&_AS'>IX>TU=/6\<//B5Y"Q&=OWV. ,G@>M=&79)6RW%^UIU$X-
M-/H_+RW.//.*\-GN6_5ZM%QJIIIIIKS[/:^EGT.HHHHK[ _,@KRG]J"UFNO@
MCXA$1/R&WD91_$HGCS^77\*]6K/U[1;7Q)HE_I5ZGF6EY ]O*HZ[64@X]#SU
MKEQ5%XBA4HK[2:^]'H9?B5@\91Q+5U"47]S3/R_KZ+_8HMY6\<:].,^2FG;&
M/;<TJ$?HK5Q/BO\ 9K\<^'O$$EA::-/K%JSD6][: %)%[%N?D/J&]^2.:^I?
MV>?A#)\*/"<JWY1M;U%UEN_+(81A0=D8/?;ELGU8XXK\TR7+<3''QE4@XJ&]
MS]XXJSW 2R><*%53E5LDD[]4VVNEEWZZ'JU?,W[;MO(^A>%IPN8DN9T9O=D4
M@?\ CI_*OIFN)^,'PYB^*7@6]T1I%@NLB>TF?I',N=I/L02I]F-?H.:8>6*P
M=2C#=K3Y:GXOP_C:>79I0Q-7X8O7R335_E>Y^<M?9W[%MK+%\-]6F?B.75'V
M#Z11@G^GX5\^V_[./Q"N-=&EGP[/"V_:;J1E%N!_>\S."._&3[9XK[>^'/@>
MV^'7@S3- M6\T6L?[R;&/-D))=\>[$\=A@5\1P[@*\,4ZU2#BHIK56U9^K\<
M9Q@ZF7QPM"HIRFT]&G9+6^GRL=-1117Z6?A 4444 ?-'[;>E7$WA[PSJ"!C:
MVUS-#+CH&D52I/\ W[;\Z^1J_3?Q9X4TWQMX?O-%U:#[18W2;74'#*<Y#*>S
M @$'VKY$\6?L=^+M+U!QH<UKK5BQ_=LTHAE4>C*W&?<$_A7YQG^4XBIB7B:$
M7)2M>VZ:TV/W'@WB/!4,"L!BYJ$H-V;T33=]]KIOKY6/ Z_0;]G'39])^"OA
M>"Y39(T,DX!_NR3/(I_%7%>*_#']CW4/[4@OO&<\$5E$P<Z;:R;WFQ_"[#A5
M]<$D\].M?6$<:0QI'&BQQH JJHP% Z #TKMX=RROA9RQ%=<MU9+KNG?\#R^-
M\_PF84J>"PDN>SYFUMLTDGUW=_D>??M":5<ZU\&O%%M:!C,+=9L)U*QR)(P_
M[Y5J_/2OU-95D5E90RD8*L,@CTKY3^*?[']Y)JEQJ/@N:W-K,Q<Z7</L,1/4
M1N>"OH&QCU-/B++*^*E'$4%S65FNO?\ 4G@C/\)E\*F"Q<N12?,F]KV2:;Z;
M*W3<^7J^L_V(=,GATGQ9J+(1;7$UM!&^."T:R,P_ 2K^=<-X5_8\\8:I?H-:
MEL]$LE;]X_FB>4C_ &%7C/U(KZZ\&^$--\"^&[/1-)A\JSM5PNXY9V/+.Q[L
M3DFN#(,IQ-/$K$UHN*C>U]VVK;'L<9<1X&O@)8#"S4Y3:NUJDDT]]KW2-RBB
MBOT@_# HHHH **** /$?VOIQ#\(&3&3+?P(/;[S?TKY@\+PE?@KXZFR-KW^F
M(!WX,Y_]F%?3/[8W_))(?^PG#_Z!)7CGP(^'DWQ0^%OCG0[:Z2SNVN;.:&28
M'R]Z^8<-@9P1D9'3K@]*_.<VISKYK[."NW!V_P# 9'[?P[7IX3AU5JKM%58M
MORYX'7_L-_\ ,Z_]N7_MQ7U17D'[._P5OO@_INL'5+ZWN[_4I(]RVFXQ(D>_
M;@L 23O;/'85Z_7UF34*F'P-.E55I*^GJVS\YXHQ=''9O7Q&'ES0?+9^D4G^
M*"BBBO:/E@HHHH ^&/VNO^2Q7'_7G!_Z":Y_XX?\?'@C_L4]-_\ 19K<_:TF
M67XS7R@',=K;HV?79GC\"*Q?CD!'J/A" D&2#POIL3XZ!A$3_(BOQ['_ ,7%
M_P")?FS^F\G_ -VRU?\ 3M_^DQ/M#X*_\DE\(_\ 8,@_] %=K7&?!F-H?A/X
M05Q@G2[=OP,8(_0BNSK]7PO^[T_1?D?SIF'^^UO\4OS84445U'GA1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?$_P#P4CTEFA\"
M:FN=BM>6S^F2(F7^3UQ/_!/'6A9?%S6M-=@JWVD.RCCYGCEC( _X"SG\*^A/
MV[_"C>(O@+<WL:;Y-&OH+T[1SL.8F_#]Z"?]VOB']FCQHG@+XY>$M5GD\NU-
MW]DG8]!',#$6/L-X;_@-?(8K]QF4:CV=O\C^F^'(_P!L<"5\'#64%45O-/G7
MYH_6BBBBOKS^9 HHHH **** "N:^)7B >$_A[XFUHMM-AIMQ<*<X^98V*CZD
M@#\:Z6OFS]O+X@)X5^#/]AQ2!;[Q#<K;*O0^3&1)*WTR(U/_ %TKFQ-3V-&5
M1]$>[D6 EFF:8?!Q5^>23]+W;^2NS\X(87N)DBC4O)(P15'4DG %?M!X;TE=
M \/:7I:X*V5K%;#;TPB!?Z5^57[-/@L^//CEX1TTQ^9;QWJWEP,9'E0_O6!]
MCL"_\"K]9Z\+)*=HSJ=[(_8_%K&*6(PN"3UBI2?_ &\TE_Z2PHHHKZ8_G\**
M** "BBB@ K\_/VNOV=/'FM?&75/$FB:)=^(=,U@0O')9+YKPLD21E' Y'W,@
M],$<Y!K] Z*X\5A88NG[.;MU/J>'>(<3PWC'C,-%2;BXM/:S:?3S2/'?V4?A
MCJ?PG^#FGZ1K42V^K3SRWMS K!O*9R J$C@D*JYQQG(YZU[%116]*FJ4%3CL
MCQ<?C:N98NKC*WQ5&Y.VVO;R"OCW]M#_ )'S0_\ L&_^U7K["KX]_;0_Y'S0
M_P#L&_\ M5Z]?+_]X7S/$Q?\)GSW1117U9X04444 %%%% 'I?[/?P\'Q$^(U
MG!<1^9IEB/MEV".&52-J?\"8@?3=Z5]C?&'QXGPY^'^IZP'5;P)Y%FK?Q3OP
MO'?'+'V4UR_[,WPZ_P"$%^'L-U<Q[-4UC;=SY'*QX_=)^"G/U8BO$OVN?B#_
M ,)!XQ@\.6LNZRTA<S;3PUPPY_[Y7 ]B6KYZ?^V8I1^S'^OQ/6C_ +/0OU9X
M++*\\CR2,7D<EF9CDDGJ33:**^A/)"BBB@ KW#]C_P#Y*Q+_ -@V;_T..O#Z
M]P_8_P#^2L2_]@V;_P!#CKEQ7\"?H;T/XL3[6HHI.E?&'T0M<AXT^(5IX85K
M>#;=:B1Q$#\L?H7_ ,.OTK#\<_% 6WF6&C2!Y?NR7:\A?9/4^_Y5Y3)(TCL[
ML7=CDLQR2?4UVTL/S>],YJE6VD2UJNK7>M7CW5[,T\S=VZ >@'853IRJTC!5
M4LS' 51DFN]\+^ 0NRZU1=QZK;=A_O?X?GZ5VRE&FM3FC%S9@^&_!MUKK"63
M-O9]Y".6]E']>E>I6=K%8VL5O"NR*-=JCVJ55"J%4  #  IW->?4J.IN=T(*
M&P<T<T<T<UD:!S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '
M-'-'-'- !S1S1S1S0 <T<U!>7MOI]N]Q=7$=M @RTLSA%7ZD\"O,?%/[27@[
MPZ7CMKB76KE<C98IE,^\APN/=<UK"G.H[05S.52,/B9ZKS3)94@C:21UCC49
M9F. ![FOE#Q-^U5XEU3>FD6EKHL1Z28\^4?BPV_^.UY7KWB_6_%$OF:MJMWJ
M!SD+/*65?HO0?@*]&GEU27QNQQSQD%\*N?4OQD\9?#GQ#X=N-)U?6X)KA<O;
MO8@W$D,H& 05X^H)&>E?(C *Q"G<,\''6DHKV</06'CRIW/-JU76=V@HHHKI
M, HKK? _PK\2?$)LZ38$VBMM>\G/EPK_ ,"/4^R@GVKWCP?^REI&G[)_$5])
MJLW4VUOF*$>Q/WF^HVURU<52HZ2>IO3H5*FRT/F72M'OM<O$M=.LY[ZY;I#;
MQEV^N!VKV'P=^RSX@UCRY]<N8M$MCR8AB:<CZ [1^)R/2OJ#0_#NE^&;,6NE
M:?;Z?!W2WC"Y]SCJ?<UH\UY%7,)RTIJQZ-/!Q6LW<X7P3\%_"O@-HY[&Q^T7
MZ?\ +Y>'S),^H_A7\ *[KFCFCFO+E.4W>3NSOC%05HH.:.:.:.:@H.:.:.:.
M: #FCFCFCF@ YKY$^(7P/\<ZMXRUW4[?13<VMU?3312)<0Y*,Y*_+OSTQVKZ
M[YHYKIH8B6';<5N85:,:R2D?!MY\*/&5B"9?#&J$#J8[5I /^^0:Y^^TF^TQ
MMMY97%H>F)XF3^8K]$N::RAU*L-RG@@C(->C',I?:B<;P,>DC\Y**^_]2\!^
M&]9W?;M TVZ9NKR6J%O^^L9%<CJO[.?@35,E=)>Q<Y^>UN'7]"2OZ5O',J;^
M*+1D\%/HSXO5BC!E)5@<@@X(]ZZ?1?BEXM\/X^P^(=0C0=(Y)C*@_P" OD?I
M7NNL?LBZ9+DZ7K]W:^BW<*S?JNS^5<+K7[+/B_3U9K*2PU5>RQ3&-S^#@#]:
MZ%BL/4T;^\P="M3U2^XDT/\ :J\6:>574+:QU6/NS1F*0_BIV_\ CM>B>'_V
ML/#M]M35=-O-*D/5X\3QCZD8;_QVOG;7?ASXG\,[CJ6A7UM&O64PEH_^^URO
MZUSM$L)AZJNE]PUB*U/1O[S[W\._$KPMXJV#2]<L[F5ONPF3RY3_ , ;#?I7
M3<U^<5=9X;^*WBWPGL&G:Y=)"O MYF\V+'H$?('X5Q5,M_Y]R^\ZHXW^='WC
MS1S7S-X7_:VNX2L?B#1H[A.AN-/8HP]]C$@G_@0KU_PK\;/!WB[9'::O';7+
M?\NU[^Y?/H-W#'Z$UYM3"UJ?Q1.R%>G4V9W7-'-)]ZEYKE.@.:.:.:.: #FC
MFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFC
MF@ #%2""0?6O&O$7B*[\1Z@]Q<RLZ D11D\(O8 ?SKV7FO+O%W@^?2YY;NW7
MS;)F+';UCSV/M[UU4&E+4YZR;6A6\*^-+_PK<#R6\ZT)^>V=CM/N/0^_\Z]M
M\/>)K'Q-9BXLY,D??B;AXSZ$5\Y5=TG6+O0[Y+NRF:&9>XZ$>A'<5M5HJIJM
MS"%1QTZ'TM7&?&?_ ))/XM_[!L__ * :L^#/'EKXJA$3;;;4%'S0$\-[KZCV
MZC]:K?&?_DD_BW_L&S_^@&N&$7&K%/NCKDU*#:/SLHHHK[8^:"BBB@ HHKI?
MA[\/=6^)7B.'2-)BRY^>:=_]7!'G!=CZ<].YXJ9244Y2V&DY.R'_  Y^'>K?
M$SQ%%I.E1>C3W+#]W!'GEV/\AU)XK[R\.Z%H7P?\"):I,MGI.G1&2>ZF/+GJ
MTC8ZL3V'L .@JMX)\$^'O@QX-D@@DCMK6!/.O=0N"%:5@.7<]AZ#MT'O\D?'
M?XZW?Q2U(V%B7M?#5L^88>C7##CS'_HO;ZUX$I3S"IRQT@CU(J.$AS2UDS#^
M-7Q2G^*WC"2_P\.F6X\FQMVZI'GEC_M,>3^ [5P-%%>]"$:<5&.R/,E)R?,P
MHHHJR0HHHH _1WX5_P#)+_!__8'L_P#T0E=37+?"O_DE_@__ + ]G_Z(2NIK
MX:I\;]3Z:'PH****S+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "OG?XQ?LICQQXEGUWP_J,&F7-XV^[MKI&\MG[R*5!()ZD8Y))S7T11
M7%B\'0QU/V=>-T>KEN:8O*:WM\)/EE:SZIKS1Y3\#?@39_""SN9Y;E=1UN[4
M)-=*FU4C!SY: \XSR3WP.!BO5J**UP^'I86FJ-%6BCGQF-KYA7EB<3+FG+=D
M4\,=S#)#*BRQ2*4='&0RD8(([BOEGQ5^Q9<7&O2RZ!K=M;:3*^X07B.9( 3]
MT$9W@=B<'U]:^JZ*YL9E^'QZ2KQO;8[LKSK'9/*4L'/EYMU9-/MH^QR'PP^&
MNF_"SPM#HVG%ICN\VXNI!AIY2 "Q'8<  =@!UY)Z^BBNRG3A1@J=-62V/+KU
MZN*JRK5I<TI.[84445J8!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!X-^V7<>3\*;)",^;JT*?3]U*W]*\V_9L\>:?\ "[X<>,/$6I++/#]LMK>.
MW@ +R2%7( R<#@DY/93UX%>B?MI_\DMTO_L,Q?\ HB>OG;2O^3>]?_[#]K_Z
M)DK\ZS*M/#YM*K#>,';[F?MV0X6GC.'(8:K\,ZJ3].:)]E_"7XNZ5\7='NKW
M3H)[.:UE$4]M<8++D94@C@@C/Y&N\KYB_8A5O[(\6-M.TSVX#8X)"R9'ZC\Z
M^G:^PRO$5,7@Z=:K\3O^;1^9\0X&CEV:5L+A_@BU;KND_P!0HHHKU3YT****
M /@[]J[_ )+7J_\ UQM__1*UD_'G_D9M#_[ &G_^B!6E^U5,LGQNUQ5ZQQVR
MM]?(0_R(JC\?H6M_%FC1.,.F@Z>K#W$(%?CF._B8M_W_ -9']/93_!RU/_GT
M_P H'VS\)_\ DEO@[_L#6?\ Z(2NJKE?A/\ \DM\'?\ 8&L__1"5U5?K>&_@
M0]%^1_-V._WJK_BE^;"BBBN@X@HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD-O&7;ZX':O7IX&E3UEKZGG3Q52>D="WX@\6:SXKN//U?4[G4)!ROG2$JO\
MNKT'X"LFO:?"/[+7B36@DVLW$&A6YY\L_OIO^^0=H_%L^U>S^%?V=_!GAD(\
ME@VL72\F;4&\P?\ ? PN/J#]:J>,H4E:.OH*.&JU-7IZGR-X?\'ZWXJF\K2-
M*NM0;."88B57_>;H/Q->K^&OV4_$>I;7UB^M=&C/6-?W\H_!2%_\>KZKM[>*
MUA2&&-(8D&U8XU"JH] !TJ3FO-J9C4E\"L=L,'!?$[GC^A_LS^"_#\)N-1%Q
MJS1J7=[N;9&,#D[4QQ]2:^6/%FI6FL>)-1N["UCLK"29OL]O"FU4C'"C [X
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M "BBB@ HHHH **** /G?]M5C_P *_P!$7)VG4P2/4^5)_P#7KQWPAXF7PO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !534M-M-:T^YL+^VBO+*YC:*:WF0,DB$8*L#U!%6Z*-QQD
MXM2B[-'YQ_M*?L=ZO\-[Z[U_PC:S:OX2<F1H(@9+C3QU(8=6C'9^< ?-TW'P
M;P3\0?$GPYU7^T?#6LW6CW? 9K=\+(!T#J?E<>S BOV5KQKXD?LD_#7XF3RW
M=WHQT?4I3E[[1W%N[$\DLN#&Q/<E2?>OFL3E+YO:89V?;_)G[WD7B5#ZNL#G
MU+VD;6YDD[K^_%Z/U6_9O4^4/#G_  4(^(.EPI#JFFZ+K6WK,\+P2M]2C;?R
M6MJ;_@HYXG:-A%X1TE).S//*P'X9'\ZZ/6O^";L+3,VD^.I(XL\17NG!V _W
MUD&>W\(K/C_X)MWY=1)X\ME3/S%=+8D#Z>:,_G7-R9K'1-_>CW7B_#BN_:RC
M%/MRU%^"5ON/,_%'[='Q5\11M';:A8:!&W!&EV8!Q_O2EV'U!%>'Z]XEU?Q9
MJ+7VM:G>:O?/P9[V=IG/MEB3CVK[J\._\$Y_"MFR-K7BG5M4VX)6SBCM5;ZY
M\PX_'\:]P^'_ .SK\//AG)'/H?AFTCO4QB^NLW$X/JKR$E3_ +N*7]G8W$/]
M_.R\W?\ #8I\<\*Y'%K*,-S2_NQ4+^LG[WX,^%_@A^QCXO\ B=<6]_KD$WA;
MPV2':XNH]MS.OI%$>>1_$P YR-W2OT,^'_P\T#X7^&;;0?#EBMC80_,<<O*Y
MZR.W5F.!S[ #  %=+17OX7 TL(O=U?<_&N(N+<QXDFEB'RTUM!;>K[OS?R2"
MBBBO0/B0HHHH **** "BBB@ HHHH **** "OCW]M#_D?-#_[!O\ [5>OL*OC
MW]M#_D?-#_[!O_M5Z]++_P#>%\SCQ?\ "9\]T445]6>$%%%% !]WD<&NG_X6
MEXTV[?\ A+M>VXQM_M*;'T^]7,45+BI;H:;6PZ21YI&DD9GD8EF9CDDGJ2:;
M115""BBB@ HHHH *]&^!L,TWB75!$"VW379PO]T2Q$_EU_"O.:]B_968K\3)
MP.C:=,I]QN3BN?$/EI29M15ZB1Z#6WX;\,7'B&X^7]U:H?WDV/T'J:[V;P'H
MTTQD^SL@)R41R%_^M6Y:VL5G;I#!&L42#"JHP!7SDJZM[I[$:+O[Q%INFV^D
MVJ6]M&(XU_,GU)[FK?-'-'-<9U;!S1S1S1S2&'-'-'-'- !S1S1S1S0 <T<T
M<T<T '-'-'-'- !S1S1S1S0 <TGW:X;XA?&3PY\.XVCO+G[7J6/ET^U(:3VW
M=D'U_ &OF#XA?'3Q)\0/-MWF_LS2F./L-JQ 8>CMU?\ 0>U=U'"5*VNR[G+5
MQ$*>F[/H/X@?M$>&_!OFVMB_]N:HO'DVS?ND/^W)T_!<GZ5\W>.OC%XG\?L\
M=]?&WL&Z6-IF.+'OSEO^!$UQ-==X'^%7B3X@R Z58L+3=M:]N/D@7U^;N?90
M3[5[=/#T<,N9_>SRYUJE9\J^XY&NE\'_  W\1>.Y@FCZ;+/%G:URXV0I]7/&
M?8<^U?2G@7]F7P[X=6*XUDG7K]?FVR#;;J?0)_%_P(D'T%>P001VL*10QK%$
M@VK'&H55 Z  =!7+6S&*TI*YO3P;>LW8\&\%_LHZ;8[+CQ-?MJ4W4VEH3'"/
M8M]YOPVU[7H?AW2_#-F+72K"WL+<8REO&%W8[D]2?<Y-:7-'->/4KU*OQL]*
M%*%/X4'-'-'-'-8&H<T<T<T<T 9][X?TW4M2L[^ZLH;B\LPPMYI4#&+=C)7/
M0\#GK6AS1S1S3NQ!S1S1S1S2&'-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'
M- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S
M1S1S1S0 <T<T<T<T '-'-'-'- !S7+^+OAGX:\<1M_:^E0S3$8%T@V3#T^<<
M_@>/:NHYHYJHR<7>+L2XJ2LSY@\:_LHW]EYEQX9OUU"(<BSO"$E^@<?*Q^NV
MO$-;\/ZEX;OFL]4L9["Y7K'.A4GW'J/<5^AW-9NO>'-,\46+6>K6$%_;'_EG
M,@;!]0>H/N.:]2EF$XZ5-4<-3!QEK#0_/6.1H75T8HZG*LIP01W%>N> _P!I
M3Q'X5\NVU4_V_IZ\?Z0V)T'M)W_X%GZBNU\>_LIQR>9=^$[SRFZ_V?>,2OT2
M3J/HV?K7@/B+POJWA._-EJ]A/I]P.BS+@,/53T8>X)%>K&=#%QMO^9Y[C5P[
MOL?;/@7XK>'/B%"O]EWRB\V[GL;CY)U]?E_B ]5)%=AS7YRP3R6LR2PR-%*A
MW+)&Q5E([@CH:]M^'?[3VK:%Y=GXDC;6;+( NEP+E![]G_'!]Z\VME\HZTM?
M([J6,3TJ:'U;S1S6+X5\8Z-XTTX7NC7\5[#T8(<.A]&4\J?J*VN:\AIQ=F>B
MFFKH.:.:.:.:D8<T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** *FK73V&EWES&%,D,+R*&Z9"DC/Y5^:
M'_#SOXI?] #PA_X!W7_R37Z4^)/^1=U3_KUE_P#0#7X-5W8:$9WYD<M:3C:S
M/W)^$GBR[\>?"[PEXDU".&&^U;2[:^GCME*QK))&K,%#$D#).,DGWKK:\X_9
MN_Y-]^''_8O6/_HA*]'KCE\3.F.R"BBBI&%-=UC1G=@BJ,EF. !ZTZO#OVU_
M$EYX5_9D\;W=C(T5Q-!#9;U."$FGCBD'XH[C\:J*YFD*3LFSQ+XS?\%+-+\-
MZO=:3\/]#C\0M;LT;:Q?RE+5V (!BC7YI%SCYBRYP< @AJS/V=OV^?'/Q6^+
M_A_PEKFA>'HK/5)'B,^GQ3Q21[49\_/*X/W<8P.O6OCGX!?#6#XP?&#PQX0N
MKF2TM-2N&6>:'&]8TC:1]N01N*H0"0>2.*_5?X;_ +)?PK^%'B"RU[P[X8^S
MZY:1M'%?W%Y/.XW+M9@KN4#$$C(4=3C&:[JD:5)<MM3D@ZE1WOH>P4445YYV
M!1110 4444 %%%% 'YM?M&?M[?$#3_BIK6B>![^WT'1=%O)+'?\ 9(IY+MXV
M*N[&16PI8' 4 XQDYKZV_9'_ &@)_P!H3X8OJ^I6L5GKFGW)L;Y( 1%(P566
M1 2<!@W3/!![8KP+]H#_ ()UZMXZ^)&I>)?!6N:78V>K7#7=W8ZJ9(_(E<YD
M,;1H^X%B6VD+C.,U]+_LW_ 33OV>?AW'X=M+HZC?3S&[O[YDV>=,0%^5<G"@
M* !GL3WKKJ.E[-<NYS053G?-L>JT445R'2%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!Y=\8/@'HOQ5C^UE_P"S-=1-J7\:
MY#@=%D7^(>_4>N.*^5_%7[.'CWPK,X_L635K<?=N-+_?AO\ @(^<?BM??-%=
M]#&U:*Y5JCEJ8:%1WV9^;#?#WQ4C%&\-:PK X*FPE!'M]VD_X0#Q1_T+FK?^
M $O_ ,37Z445V?VI+^4YOJ,?YC\U_P#A /%'_0N:M_X 2_\ Q-'_  @'BC_H
M7-6_\ )?_B:_2BBG_:DOY1_4E_,?FO\ \(!XH_Z%S5O_   E_P#B:/\ A /%
M'_0N:M_X 2__ !-?I111_:DOY0^I+^8_-?\ X0#Q1_T+FK_^ ,O_ ,35#_A'
M]5_Z!MW_ -^'_P *^Z?BAXY\I9-%L),.>+F53T']P?U_+UKRJNNGC)R5W&QS
M3P\8NR9\V?\ "/ZI_P! V\_[\/\ X5TWA/X->+?&,Q6STM[>)3A[B\/DHGUS
MR?P!KZ T#0Y]?OEMXOE0<R28X1?7ZUZ[IVGP:79QVUNFR)!^9[D^]9UL?*"M
M%:FE/"J6K>AYM\*/@/I?PYD74+J0:IK>W N&7$<.1R(U]>VX\_3FO4^:.:.:
M\6I4E4ES3=V>I"$::Y8H.:.:.:.:S+#FCFCFCF@ YHYHYHYH .:.:.:.: #F
MCFCFCF@ YJKJ>J6FBV$U[?7,=I:0KNDFF8*JCZU@^/OB+HWPZTDWNJS_ #MD
M06L>#+,WHH]/4G@?E7Q_\2OBQK7Q+O\ ?>R?9M/C;,%A$Q\M/<_WF]S[XQ7=
MA\+.N[[(Y*V(C2TZGH'Q8_:2N]>\[2_"S26&G'*R7V"LTP_V>Z+_ ./?3I7A
M1)8DDY)ZFGPPR7$R111M+*[!51 2S$]  .IKZ&^%'[,S3"'5?&"%(S\\>E*Q
M#'WE(Z?[HY]2.17NWHX.';\V>4O:8F1Y?\-_@_KOQ*N0UI']DTQ6Q+J$ZGRQ
MZA1_&WL/Q(KZQ^'OPGT'X;VN-.@\Z^9<2W]QAI7]0#_"OL/QSUKK;6T@L;:*
MWMH8[>WB4*D42A54#H !T%3<UX6(Q<Z^FR['JT</&EKNPYHYHYHYKA.L.:.:
M.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.:
M #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FC
MFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFC
MF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:\?^*'[.ND>,1+?Z-Y>
MC:P<L=JX@F/^TH^Z?]I??(->P<T<UK3J3I2YH.Q$X1J*TD?GSXH\(ZOX,U1]
M/UBRDL[A>1N&5<?WE8<,/<54T?6;[0-0AO\ 3KJ6SO(3E)H6PP_Q'MWK[W\6
M>#](\;:6^GZQ9I=P-G:QX>-O[R-U4U\G?%;X"ZM\/6EO[/?JFA9S]H5?WD ]
M) .W^T./ITKZ##XR%;W)Z/\ ,\:MAI4O>CJCUSX2_M'67B;R-*\2-'IVJG"1
MW>=L%P??^XQ_(]L9 KV_FOSBKVCX0_M#7OA$PZ5X@:74-%&$CF^]-;#MC^\H
M]#R.WI7/B<#]NC]W^1O1Q7V:GWGUKS1S5/2=7L]=TZ"_T^YCN[.==T<T395A
M_C[=L8K"^*&O_P#",?#W7]1#;)([1TB;TD?Y$_\ 'F%>+&+E)1ZGIN22YC8T
M'7]/\3Z5#J6EW*WEC-N\N9 0#@E3P0#U!K1YKYP_9/\ &?\ R$_"]Q)_T^6@
M8_19%'_CIQ_O&OH_FM:]+V-1P,Z-3VD%(.:.:.:.:YS8.:.:.:.: #FCFCFC
MF@ YKS'QY^S[X8\;W$EXL;Z1J,A+-<68 5V/=T/!/N,$^M>G<T<UI"I.F[P=
MB)0C-6DKGR[??LBZS'(19Z]8SQ]FGB>(_D-W\ZX_4/@-K>EWDEM<7=HDJ'!Y
M?!]Q\O2OM+FL+Q5X9C\06?RX2[C'[J3_ -E/M_*O0ACZM[29QSPD+>ZCY!_X
M4OJG_/\ 6?\ X_\ X5M>%_V<=6\47;VL.M:;;W &Y4F,@WCOC"]1Z5Z7<6\E
MK,\,R-'(AVLK=0:6VN9;.XCG@D:*:-@R.IP01WKL>(J-:,Y%1@GJCF_^&+_%
M'_0<TC\Y?_B*/^&+_%'_ $'-(_.7_P"(KZ<\#^,(O%>FY?;'?P@">,=_]H>Q
M_3I735YTL?B(NS?X':L+1DKI'Q[_ ,,7^*/^@YI'YR__ !%'_#%_BC_H.:1^
M<O\ \17V%14_VAB._P" _JE+L?'O_#%_BC_H.:1^<O\ \15K3_V*];DF OO$
M>GV\.>6MX7E;\CM_G7UQ11_:&([_ (!]4I=CRCX<_LW^$_A[<17QBDUG58SN
M6ZO@"L;>J(.%/N<D=C7J]%%<,ZDZCYIN[.F,(P5HJP4445F6%%%% !1110 5
M#>6<.H6D]K<QK-;S(T4D;#(=6&"#[$$U-10!^/'[3/[+OB/X!^*KQQ97%]X/
MGE9K#5XT+QJA;Y8IF'W)!D#G&[&1W \F\,^+M<\%ZDNH>']8OM$OEX%QI]R\
M+X],J1D>U?NY<6\5U!)!/&DT,BE'CD4,K*1@@@\$$5X7\1?V(_A'\1A++)X:
M3P_?2<_;-!;[*1QC_5@&(]CDIG(Z]<^A#%*UIHXY4-;Q9\<_!_\ X*-^//"%
MY;VOC6*+QCHWRH\NQ(+V)>F5=0%? YPXRV!\XY-?HYX \?:)\3O"6G>)/#MX
MM]I5\F^*0##*0<,C#^%E((([$5^0?[2WP OOV=_B&?#]Q>KJEA=0"\L+X)L:
M2(LRX=><.K*0<$YX/? ^L?\ @EGXCO+C0_'^A22,UC:7%G>0)V1Y5E23\Q#'
M^1HK4X.'M(!3G)2Y)'EG_!0SXZ7WC7XH3>!K*Z9/#OAUE66)#Q/>%<N[>NP-
ML [$.>]=3^QE^Q/X=^)W@F+QQX[2XO;"]D=-/TJ&9H$>-'*M)(RX;EE8 *1P
M,Y.1CY;^/C3-\<OB(9RQF_X2+4-V[KG[3)7KOPY^$O[4&M>!]'OO!U]XFC\,
M3P![!;/Q7';1"/)^[$;E=@SGC K9QY::C%V,D^:;;5SV?]KK]AOP=X/^&>H^
M,? -K/H]QHZB>[TY[F2>*:#(#LID+,KKG=][! 88SBO//^"<7Q>O?"_Q8?P-
M/,SZ-XCCD:.%C\L5U$C.''IN174^I">@JKJG[/?[7.N:=<:?J,WBB_L+E#%/
M:W7C"&6*5",%65KHA@?0BMG]F?\ 8W^+7@?XY^$O$'B'PRND:/IURT]Q=-J-
MK+@!& 4+'*S$DD#IWYJ+KV;C*29>O.G&-C7_ ."I7_(X^ _^O"Y_]&)6A_P2
MM_Y"'Q)_ZY:?_P"A7-9__!4K_D<? ?\ UX7/_HQ*T/\ @E;_ ,A#XD_]<M/_
M /0KFI_YAOZ[C_Y?#O\ @I1\=+Z+4K#X8Z3=-!9>0E]K'EG!E9CF&$G^Z -Y
M'?<GI7G?[$_[(VF?':'4O%'BR2X'AJQN/L<-G;.8VNYPH9]SXR$4,GW>23U&
M#GB?VZFE;]JCQQYV<AK,+G^[]C@QC\*F^"_PS_:'\4>"(K_X:WGB"'PRT\B(
MNF^)$L8O-!&_]T9T(/3G;S6BCRTDD[7(;YJCNKGU=\?/^"?O@";X>ZMJ/@/3
MI_#_ (@T^V>ZAB%Y-<0W6P%C&PE9B"P! ((P<9R,U\G?L2_%Z]^%GQUT.V$S
M?V-XAGCTF^M\_*WF,%BDQZHY4Y_NEQWKO9/@;^V'-&T<E_XN>-@59&\9Q$$'
MJ"/M72L'X??L,_&G3_'GAR[O_"2Z?8V^HV\T]T^J6;B*-9%9FVI,6. .@!-*
M-E!QG-,<K\R<8V/M;]M[XU7?P9^#$[:1<-;:_K<W]FV<T9P\"E2TLJGL548!
MZAG4]J_,/X/_  KUKXX?$73O"VCLJWEZS2374^2D$:C=)*_T'YD@=Z^P_P#@
MJE)-O^&D?(M\:BWL6_T;^G\ZY+_@E[';-\6O%<CA3=KHF(_789XM^/Q"5-/]
MW1<UN54]^KRL]<C_ ."7O@1=%6*3Q9XB?5]F#=+Y"VY;/7R?++8QV\S\:J_L
M\?\ !/W4?A3\7X?%/B/Q!9:KINDL9=+CT\RQ2RR]%>92 $ &3M5FR<9. 0?M
MBBN3VU2S5SH]E"]['Q%^WA^SS\/?"_PL\0^/-*\.K9^*[O4H99K]+J<AVEE_
M>'RR_E@MDYPO4U\>_LJ^!]$^)'Q]\)^&_$=E_:.BWTEPMQ:^:\6\+;RNOS(R
ML,,JG@CI7Z$?\%#O^39=6_Z_[/\ ]&BOA7]AW_DZ?P)_UUNO_22:NRC)^Q;O
MW.:HE[1(_0/_ (8.^!?_ $(__E7OO_C]?)_[?7[/W@'X*:-X-G\&:#_8TNH7
M%RERWVRXG\Q46,J/WLC8QN/3'6OTNKX4_P""IW_(O?#S_KZO/_0(:YZ,Y.HD
MV;58Q4&TCSG_ ()@_P#):O$O_8O2?^E-O7N?_!13XY7WP]\!Z=X/T2ZDM-3\
M2>9]JGB)#QV:8#*#V,C,%X_A5QWKPS_@F#_R6KQ+_P!B])_Z4V]5/^"F\DS?
M'K1$?/DKX=@,8[<W%QD_G_*MW%2Q&IDG:CH>/_LU_L]ZG^T7X\;1;6[73--L
MXOM.H:@R;S%'D*%5<C<['@ D#@GM@_8_B#_@E[X,DT%TT/Q9KMMK03Y)M0\F
M:V9]IZHD:, 3C^(X'K6-_P $L8;<:'\1)5 ^U-<V2OZ[ LQ7]2U?=U9UJTXS
MLGL72IQ<+L_"_4+/Q%\'OB%<6QEETCQ+X?OF3SH&PT4T;?>4]P<9!Z$'T-?L
M7^SY\5$^-'PA\.^+"L<=W=PE+R&+[L=PC%) !U +*6 /\+#KUK\S/V\((+?]
MJCQH+<*H;[&[A>F\VD)/XGK^-?9'_!-.::3]GJ]64L4CUZY6+/9?*@)Q_P "
M+5=?WJ:GU(H^[-Q/S;^(W_)0O$__ &%+K_T:U?7G[.__  3OL_B%X'TKQ7XT
M\0W=I;:M;)=V>GZ-L$BQ.NY&>5U89((.T+QZYX'R'\1O^2A>)_\ L*77_HUJ
M_8W]F[_DWWX<?]B]8_\ HA*TKSE""Y2:,5*3N?FM^U_^RQ'^SAK6CS:5J5QJ
MOAW5Q(()+P+Y\,B$;D<J &X92& &>>..?:O^"7?CJ[_M3QCX-EF:2Q,$>K6\
M1)Q&X812D?[P:+/^X*Z3_@J5_P B=X#_ .O^Y_\ 1:5YA_P3!_Y+5XE_[%Z3
M_P!*;>HNYT+R';EJV1^F-%%%>:=Q^8O_  41^.5]XP^)DG@*PNI(_#_A_;]H
MA0D+<7C*&9F]0@8(,]#O/>LC]DO]BI_C]H]QXG\0:K<:-X8CG-O EDJFYNW7
M&\JS JBC.-Q#9.>..?%_C])--\=?B(UQGSO^$BU -GMBYD&*_4G]B>&"']EW
MP&+8#8;:9FQ_?-S*7_\ 'LUZ=1NE27*<,%[2H^8^9OCY_P $X].\'^!=2\0^
M ];U2_N-,MVN9],U;RY'GC4%G,;QHF&"C(4J<X//(KY>_9X^-6I_ GXG:7XA
MLYG_ +/:18-3M 3MN;8D;U(_O ?,I[,!VR#^TUQ#'<0213*KPNI5U<9!4C!!
M]L5^"-PJ+<2B(YC#D*?;/%%";J1<9ZA6BJ;3B?MA\3O@_P" _C)HL=QXFT"Q
MU]8[9C:W9++(J,-WR2H0P!P#P:_$NOV[^%$TT_P-\'27!9KA_#EFTA;J6-JA
M.?QS7XB4L+?WD.OT9^LOAG]AKX(ZAX;TF[N/!/F7$]I#+(_]JWPW,R DX$^.
MIKZ1K&\%_P#(G:%_UX0?^BUK9K@E*4MV=<8I;(****@H_,[_ (*??\EJ\-?]
MB]'_ .E-Q6[_ ,$M?^1Q\>?]>%M_Z,>L+_@I]_R6KPU_V+T?_I3<5N_\$M?^
M1Q\>?]>%M_Z,>O2?^[G#_P OC]%*_-G_ (*AZA+)\5/"-B<^3#HIF7TW//(#
M^D:U^DU?GU_P5)\(SKJ7@;Q0D9:V>*?39I.RLK"2,?B&E_[Y-<V'_B(WK? S
ME/\ @F%I<%S\8_$M](%:>UT-DB!QQOGBRP]\+C_@1K],*_);]@?XD6WP\_:$
MTZ&_F6"RUZVDTAY)#A5D=E>+\Y(U7_@=?K358E/G%0^ ****Y#H/+_VH/^3=
M_B+_ -@2Z_\ 19K\6:_:;]J#_DW?XB_]@2Z_]%FOQ9KT\+\+.'$;H_3>3_@I
MY\,!&QC\/^+FDP=JM:6H!/8$_:#C\J^1/VI_VLM5_:/O[*TCT\:)X8TZ1I;:
MP,GF222$;?-E; &<9 4#"[CR<YKTWXN?\$W=:^'O@+5/$6B>+5\4W&G1&XET
MW^RS;2/$O+E")7W,!D[<#(!P<X!^7OACXRL_ /CC2]<O] T_Q/96LH:;3-2C
MWQ3+GGCIN]"01GJ".*JG"E\4-29RG\,]#[#_ ."<_P"SOJ7_  D/_"T=<M'M
M-/MX9(=%25<-<2."CS@'^ (64'^(N<?=Y_0NL#P)XNT?Q[X-TCQ!H$RS:/J%
MNLULR@+M7IM('W64@J5[$$=JWZ\^I-SE=G9"*C&R"N!^*WP7\$?%G3B?%OAR
MTUF6V@D6">7<DL0/)"R(0P&0.AKOJK:E_P @^Z_ZY-_(UFFT[HMJ^Y^"5?K+
MX9_8:^".H>&])N[CP3YEQ/:0RR/_ &K?#<S("3@3XZFOR:K]W?!?_(G:%_UX
M0?\ HM:]+%2E&UF<5"*E>Z/@#_@J1_R/7@;_ +!L_P#Z-%?)GP[\!>)_BUXB
ML/"7AJUFU*\F=Y4MP^(H<A0\KD\(,*N6/HHY.!7UG_P5(_Y'KP-_V#9__1HJ
M]_P2PLX'USXBW31(;F.WL8DE(^959IBR@^A*)G_=%5&7)0YA2CS5;!\&?^">
M/C_P+\5/"?B76M9\-2:=I.H0WTT-I<W#S'RV#@*&@52<@?Q?GTKC_P#@HC\<
MK[QA\3)/ 5A=21^'_#^W[1"A(6XO&4,S-ZA P09Z'>>]?IU7XC?'Z2:;XZ_$
M1KC/G?\ "1:@&SVQ<R#%949.K/FET+JQ5.-H]3VC]DO]BI_C]H]QXG\0:K<:
M-X8CG-O EDJFYNW7&\JS JBC.-Q#9.>..?2/CY_P3CT[P?X%U+Q#X#UO5+^X
MTRW:YGTS5O+D>>-06<QO&B88*,A2IS@\\BOIG]B>&"']EWP&+8#8;:9FQ_?-
MS*7_ /'LU[9<0QW$$D4RJ\+J5=7&05(P0?;%93KS4W9EQI1<$?BS^SQ\:M3^
M!/Q.TOQ#9S/_ &>TBP:G: G;<VQ(WJ1_> ^93V8#MD']2?VK;B*\_9E\>SP2
M+-!+I+/'(ARK*2I!![@BOQNN%1;B41',8<A3[9XK]8_B=--<?L%SRW!9KA_!
MMFTA;J6,$1.?QS717BN>,C*BWRR1^57ACP_=>+?$NDZ'9&-;W4[N&R@,S%4$
MDCA%W$ X&6&>*_0C3_\ @EWX5_X1417WC#6#XE,?-U;QQ"S1^/\ ED5WL!S_
M ,M 3P>.E?#GP._Y+5\/_P#L8=/_ /2F.OV_I8BI*#2BPHPC).Y^%UZNN_"7
MQWJ]A;WKZ?K>DW%WI<UQ:O@AAO@E"GT(+C/O7U5^RO\ L&:7\8/A[!XP\8ZQ
MJ6GV>HE_[/LM),<<A1'*&61Y$<8)5L*%' !R<XKYW_:1_P"3@OB/_P!C#??^
MCWK]2OV.O^39? '_ %X'_P!&O55IRC!-=2:45*33/S6_:J_9Y/[.?Q"@T>#4
M)-5TB_M1=V5S,H60+N*LC@<;@1U'!##@<BOKK_@F'XZN]:^'OBKPM<RM+!H=
MY%/:AO\ EG'<"0E![;XG;ZN?6O._^"I'_(]>!O\ L&S_ /HT5J?\$K?^0A\2
M?^N6G_\ H5S4S;G0N]RHKEJV1^@E%%%>:=P4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU+Q=J\VI:K=/=W<IY9NBCLJCH /05)X5\(ZKXUUB+3=(M6NKE^3CA(U[LQ[
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MEPJ@EHRQ4?O OS#C# -TP ? O#__  2\\<7-T5UOQ?X?TZVR/WFGK/=OCO\
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M16UO;>3$@Z*JI@#\@*_!FOWPNX3<6LT2D!G1E&>G(Q7YE_\ #L3XI?\ 0?\
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MP0RY).U@RY.<9YKXY\6_\$N?$EO<2MX8\::7?0%\QQZM!);,J\\%HQ)DCCG
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M)6] JY/N<#J17ZP?M36,&E_LO^.;.V016UOHYABC'157: /R%7_@/^S?X/\
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MBY9>UYK:'U'1117"=84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(XR%R:^U/V&?V.]5\$ZQ#\0_'5D;#4XXV&E:1./WL!8$--*/X6VDA5/(W$D
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M%<;CS*O\$OX@8/N#ZBO3^:^.J0=.3A+='T<)*<5)!S1S1S1S698<T<T<T<T
M'-'-'-'- !S1S1S1S0 <TUE612K ,K#!!&013N:.: /)_&/ADZ#>^9$I-E,<
MH?[I_NG^E<[7M^IZ;#JUC+:SC,<@Z]P>Q'O7CNK:7-HM_+:SCYD/#=F'8BO1
MI5.96>YP5(<KNMCO?A3XR^RRKHMX_P"ZD/\ HSL?NL>J?0]O?ZUZS7S)8PSW
M%];Q6P8W#R*L>WKNSQ^M?3=<F(BHR374WHR;5F%%%%<AT!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MREVH\D;E"ZCMN #8Z DCM714HRII-F,*JF[(]8HK\9/'GQZ^)MGXZ\16]O\
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MF6SB@<-(S@@^6J@C"<<9Z\U]AU$XN$N5EQDI*Z"BBBH*"BBB@ HHHH ****
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MZ^BJSE%Q;BRHR4E=!1114E!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>5_%SQ7N9=$MGX7#W)7UZJG]?RKN_%?B"/PSHL]Z^#(!MB0_Q.>@_J
M?8&OGJXN)+RXEGF<R2R,7=FZDDY)KLP]/F?.^AS5IV7*B*NL\ :!_:&H?;I5
M_P!'MFRO^T_;\NOY5SFGV,NIWT-K",R2-M'MZG\!7LVEZ=%I.GPVD(^2-<9[
MD]R?J:Z:T^5674RI0YG=EOFCFCFCFO/.X.:.:.:.: #FCFCFCF@ YHYHYHYH
M .:.:.:.: #FO,/C?\78OAOHWV6R99->O$/D1\'R5Z>:P^N<#N1Z UW/BO6+
MC0?#FH:C:6$NIW-O$7CM(1EI&[#^IQS@' -?!7B/Q!?^*M:N]4U.8SWEP^YV
M/ 'H .P P /:O2P6'5:7-+9'#B:WLURQW91NKJ:]NI;BXD::>5R\DCG+,Q.2
M2?7->I? WX-R_$+4AJ6HHT?A^U?#GH;EQ@^6/;U/X#DY&'\(_A?=_$WQ"(!N
M@TNWP]Y= ?=7LB]MS<X_$]J^U])TFTT'3+;3["!;:SMT$<42=% _G]3UKT<9
MBO9+V<-_R./#4/:/GEL3V]O%:6\<$$:0P1*$2.-=JJHX  '0 5+S1S1S7SA[
M0<T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<
MT<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<
MT '-'-'->-_M"?M*:!\$_!MW=07EGJGB23]Q8Z7',KMYI!^>55.5C7J>F> .
M351BY.R)<E%79TGQ>^.7A'X(Z,M]XFU#RYI0?LVGVX\RYN2/[B9Z?[3$*.YK
MX;^*'_!0CQSXIGFM_"<%OX2TWD+*%6XNV'J78;5^BKD9^\>M?/FN:YXG^,'C
M9[R_FNM?\1:G*%'\3,>RJ.BJ!T P !V%?3/PO_8UTVRMX;[QK.U_=L W]F6L
MA2&/V=Q\SGI]T@=>O6O3I89>IYU3$?(^8/$GCSQ1XZN-VN:_JFN2N>%O+J2;
MGL "3CZ"I=/^&7B_5E5K/PMK-RC='CL)2OY[<5^C?A[P9H/A.$1Z-H]CIBXP
M3:VZHQ^I R?QK8KO5%=SA=;R/SB@^ _Q"N%++X1U0 ''[R'8?UQ5>[^"_CRQ
M5C+X/UG"G!\NRDD_]!!X]Z_26BG[%=R?;/L?ET8]:\(WRR%;_1;U?NMAX)!S
MV/!KU/P+^V!\5O <D:P>*)]8M$ZVNM#[6K#TW-^\ _W6%?=EY8V^H6[075O'
M<PM]Z.9 ZGZ@UY?XR_9B\ >,$D<:0-%NVZ7&E'R<'_<P4/\ WSGWK.5!2\S2
M->WD5_!/_!2C19[:./Q=X4OK.YZ-/H[I-&WOLD92H]MS5Z/8_M]?"*\CW2ZG
MJ5D< [)].D)^GR;AQ]:^6-<_8=U>)W.C>);*Z3/RK?0O"0/0E=^?RKE;G]CK
MXA0-A%TNX']Z.[P/_'E%<DL(NQUK%/N?=/\ PV]\%O\ H=/_ "E7O_QFC_AM
M[X+?]#I_Y2KW_P",U\#_ /#)OQ*_Z ]O_P"!T/\ \57GGC;P/J_P]UQ](UN!
M;:_6-9#&DBR#:PX.5)%9O"I;W+6);VL?I5-^WA\'HHV9==O)BO18]-G!;Z94
M#\Z]-^%/QG\)_&C1[C4?"NI?;4MG$=S#)&T4L#$$J&5AT(!P1D'!YX-?DW\/
M_@[XT^*5QY?A;PY?:LH;8UQ&FR!&]&E8A%/U-?H3^QK^S7K7P(TW7;_Q'=6[
MZMK'DI]CM&WI;QQ[S\SX&6)<\#@!1R<\85*<(+1ZF].I.3U6A])\T<T<T<UR
M'4'-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-
M'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T ,DC2:-
MHY%62-AM96&00>H(KP_XB?LXP7%U_;?@R8:1JT+B=;7=MB9P<@QG_EFV?PZ?
M=KW/FCFMJ=6=)WBS.=.-16D<WX#\27/B308WU*T?3]9M_P!S?6DB[2D@[@=U
M;[P(XP>O%=)S2;<'..?6EYK.33=TK%Q32LPYHYHYHYJ1AS1S1S1S0 <T<T<T
M<T '-'-'-'- !S1S1S1S0 <T@)4Y!P<TO-'- '06-U]J@#'[XX:K-<+JWB^'
MPC&LKJ9I),A8%.-V.^>PK)TWXT"2[5+_ $\16['!DA<L5]R".::I3DKI&;J1
MB[-GJ%%1PRI/&DL;!XW 964Y!!Y!%25B:!1110 4444 %%%% !1110!^&_Q?
M_P"2M>-O^PW??^CWK]2OV#O^34? _P#V_?\ I=<5^6OQ?_Y*UXV_[#=]_P"C
MWK]2OV#O^34? _\ V_?^EUQ7I8C^&CAH_&SWZBBBO-.X_/CXB_LB_ S5OB%?
MWMG\;/#_ (5L6NG:[T)[ZT=X'W'?'&[3+Y8!R-K(Q7I[5]M_"OPWX9\)?#W0
MM)\&R6\_AJWMP+.>UG69)E)),GF*<.68EBPX))K\8_B__P E:\;?]AN^_P#1
M[U^N'[*/_)N'P\_[!$/]:[:\6H)MW.6E).3LC\@_B-_R4+Q/_P!A2Z_]&M7[
M"_L]WUMIO[.GP[N;NXBM;>/P]8;YIW"(N84')/ Y(K\>OB-_R4+Q/_V%+K_T
M:U>IZ;H_QI_:ET#1='T32K[5_#?ANS@TZUMH72VL8O*C"[B\C*C2D#)))89P
M,# KIK4^>*N[&%.7*WI<_5/0?B[X$\5Z@MCHGC7P[K%ZPR+:PU6">0\@?=5R
M>I _&NNK\-?B)\+/%WPAUN/3?%FB76AWS+YD7F[660 XW)(A*L >ZDU]\_\
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M( ^S2*"?3YG7]*QOVU/^3H/'O_7U%_Z3Q5<:7)4Y8RZ$RJ<T+M'Z>?LZ^ _
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME%60<T<T<T<U(PYHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.:
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M2Y*,BJC?[.Z0,1W"X/!KZ?\ ^"H__)/?!/\ V%)?_15>+_\ !,[_ )."U/\
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M[H'A73P/LVE6B0;P,>8_620^[.68^[45?W5)4UU"G^\J.9U-%%%>>=A^??\
MP52_Y"'PV_ZY:A_Z%;5G_P#!+7_D<?'G_7A;?^C'K0_X*I?\A#X;?]<M0_\
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MX&_[!L__ *-%=KM]87H<R_@LYC_@G3\'= ^)'Q"U[7/$%I%J4?AR&"2ULKA
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MZG==6N=77XW?MB_\G->/_P#K_'_HI*_8]6$BAE(92,@CO7XX?MB_\G->/_\
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M7XZ_MJ?\G0>/?^OJ+_TGBK'"_&_0TQ'PH^\_^">/_)LND_\ 7_>?^C37Q_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !115+5+G[/;[0<,
M_ ^G>@#,U"Y^TW!(/R+P/\:K<T<T<UJ <T<T<T<T '-'-'-'- !S1S1S1S0
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MPU:X@ACW,6;:B.%&6))P.22:_<BBN[ZTK6<3D]AK>Y^)'_#07Q2_Z*5XO_\
M!]=?_'*^_/\ @G'XX\1^./A]XLN?$>OZIX@N(=42.*;5+R2Y=%\I3M4NQ(&>
M<"OKNBLZE93C91L:0I.+O<_#?XO_ /)6O&W_ &&[[_T>]?KA^RC_ ,FX?#S_
M +!$/]:]8HI5*WM(J-MAPI\C;N?A=X^MY;KXD>(X((WFFDU:Y1(XU+,S&9@
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M"$/^X@1/JI]:]KJ*T^>;9=*/+$****P-3\^_^"J7_(0^&W_7+4/_ $*VK/\
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MH0<@\BO$?A9^P[\,_A+XVC\4Z9%J>H:C;N9+./5+E98K1B",HJHN2 >"Y8C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %5[ZPMM5LYK.]MHKRTF0QRP
M3H'CD4]593P1[&K%% 'S;XT_X)]_![Q=<2SP:5?>&YI<%FT6\**#G.0D@=%R
M.,!0/8'FL#2?^":?PGTZ\6:>^\3:I&!C[/=WT2H??,<*-^M?6-%:^UGM<S]G
M#L<I\/?A7X2^%&DG3?"6@V>B6C8,GV=29)2!@&21B6<X[L2:ZNBBLVV]6:;;
M!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KQ+XKZ]_:GB+[)&V8+(>7QT+GEC_(?A7KGB'5TT+1;N
M^?!\F,E0>[=%'XDBOG":9[B9Y9&+R.Q9F/4DG)-=N&C=N1S5Y:<HRO4_ &D?
MV=HHG=<371WG_=_A'\S^->=Z#IC:QJUM:C.UV^<CLHY)_*O:441HJJ-JJ, #
MH!6U>6G*11CKS#N:.:.:.:X3L#FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFN
M/^*'Q'L?AKX;DO[C;+>292TM<\S28_\ 01P2?ZD5<8N;48[LF4E%79S/QV^+
MR?#W2/[/T^16U^\3]WT/V>/IYA'KU"CU!/;GC/V2]%>9?$7B"<M)++(MHDK'
M))^_)D]R<QU\]:]KU[XFUBZU349VN;RY??)(WZ >@ P .P %?9OP'\/GP]\+
M=$C==LUU&;R3W\P[E_\ '=H_"O8KTUA<-R+=[GF4INO6YNB/0>:.:.:.:\0]
M4.:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.
M:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.
M: #FCFCFCF@#\[O^"E#L?BEX73<=HT;(7/ )GDR?T'Y5M?L2HH^%NK-M&XZS
M*"V.2!!!@?J?SK$_X*3?\E5\,?\ 8%'_ */EK<_8G_Y)7JO_ &&I?_1$%>WA
M=D>-BMV?0-%%?*OQ_P#VHM8T#Q5/X>\'SPVHL6\N[OVB65FE'WHU# J O0G&
M<@],<^A*2BKLX(Q<G9'T!\1?B9H7POT-M2UJZ$><B"VCP9KAO[J+W[9/09Y-
M?&>M_M5>/=4\4'4[34%L+-9/W6EK&KP;,_<?(RY(ZGKZ8XQY[>:AXE^*'B:,
MSR7WB'6[MO+C0 RR-W"JHZ <\ 8%?9O[-_[(L'@F2V\2^,XHKS7EQ):Z=D/%
M9MU#,>CR#_OE>HR<$>9B<7&DKO[CT*&&<W9'IO@7]GWP#X;UFT\5Z?X7CTW6
M9(UF6-I9'2U=E^8(C-M4C)'3CMBO4^:.:.:^/E*4W>3N?1QBHJR0<T<T<T<U
M)0<T<T<T<T '-'-'-'- !S45Q"MU;RPL2%D4H2IP<$8XJ7FCF@#\G_B5X%U+
MX3>/]1T*Y9TN+&;=;W*Y7S(_O1R*?<8/L<CM7W'\!?BM#\5O ]O=22*-9LP(
M-0B'!\P#AP/[KCGZY':E_:N^ +_%KPW%J^BPJWBC2T(BCX'VN'.3$3_>!R5]
MR1_%D?"7A/QEXB^%_B)[S2;F;2M2AW0SQ2)U /S1R(PYY'0C(([&OKL'B54C
M?KU/G<3A^5V^X^@OVO?@T89CXZTB#,<A5-4BC7[K<!9L>_"M[X/<UE_L7_M&
M'X/^,/\ A'];NMGA'6I561Y&^6RN#PLWH%/"O[ '^'GWSX-?%"Q^-_@.:6\M
M8%O$!M-3L,;HR6'4 _P.,X!SW&3C)^.OCS\(YOA+XR>UB#2:+>;IK"9LGY,\
MQD_WER ?4%3WKKK4U)7Z,YZ-1Q=GNC]@P0P!!R*7FOE+]@OX\R?$#P;+X+UB
M<R:WH$2FVE=LM<6>0J_4QG"GV9/>OJWFO#E%Q=F>W&2DKH.:.:.:.:@H.:.:
M.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.:
M #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FC
MFCFCF@#BOBY\/X_B)X-NM/ 47\7[^SD/\,H'3/HPRI^N>U?#4\$EK-)#*C1R
MQL4=&&"K X(/O7Z-<U\H_M/_  ]_L+Q%%XDM(]MEJ;;9PHX2X R3_P " S]5
M:O9R^OROV4NNQYF,I77M$:_[+'Q#-O=3^$;V7,<VZXL=QZ,!F1!]0-P^C>M?
M2_-?G9I>IW&BZE:W]I(8KJVE6:)QV93D&OO3P+XMM_''A33M:M\*+F/,D8.?
M+D'#K^# _A@U&84>27M%L_S*P=7FCR/H;_-'-'-'->2>B'-'-'-'- !S1S1S
M1S0 <T<T<T<T '-'-'-0WGF?9)_)_P!=L;9_O8X_6F!0G^*&F:&[6C)-=R1L
M03"!A?49)'-=)X;\6:?XI@:2RD8.GWX9!AU^H]/<5\[MG)SU[UO>!M<_X1_Q
M+:7#-MA<^5-Z;&XS^!P?PKKGAX\NFYQQK/FUV/H2BBBO..P**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@#XD_P""FFFF31_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBWP8''"RQ/D'W&0/J*X,53]I!Q[G=AJG*T^Q^N/-'-<W\.O'%E\1_!.D>([
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MHYHYHYH .:.:.:.: #FCFCFCF@ YKSOX\^#_ /A,/ASJ"1)OO+'_ $V#CG*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(SSY289O_'M@_$U\DUZQ^TQXG_M[XDS6<;[K?2XEMEQTWGYG/URP7_@-<?\
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MF[MU=PO19,8=?P8$?A6[S7A'[)_B;[=X7U/0Y'S)83B:)3_SSD'0?1E8_P#
MJ]WYKP:]/V524#U:,_:04@YHYHYHYK V#FCFCFCF@ YHYHYHYH .:.:.:.:
M/*/'MA]C\12N!A)U$H^O0_J#^=<Y7M&M:#::];K%<J<J<I(APR_2J?AGX9Z7
M%?\ FW,DMV8\,D;X"]>X'6NV->*CKT..5*3EH=KX;:9O#VF&?B8VT>_/7.T=
M?>M*DZ<4M><]7<ZUH@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "OB_]
MMC]LV^^&6H2> _ UPD7B+RPVI:K@.;(,,B*,'CS"I!+'[H(Q\QROU[XEUVW\
M+^'-5UF[S]ETZTEO)L==D:%V_0&OPP\3>(;_ ,9>)M3UO49&N-2U.ZDNIV_O
M2.Q8X'U/ KKP]-3=WLCGK3<59#-4U75O%NL/=ZA=WFLZG<M\TUQ(\\TK>Y))
M)K67X6^-&M3<KX0UYK<=9AIDQ3\]N*_6G]F7]G;0O@3X!TR"/3H&\4W%NLNJ
M:FR!IFF906C5\9$:GY0HP.,D9)->S5M+%6=HHR5"ZNV?@IJ.CW^CR"._L;FR
MDSC;<0M&?R(]Q7Z&?\$P5\4KX0\7?;A<CPF9X#IOVC=Y?G_O//\ *SQC'E[L
M=\=\U]N2PI/&T<B+)&PPRL,@CT(HCC2&-8XU5(U 5548  Z "L:F(]I'EL:0
MH\DKW/@[_@J1X-GEL? _BN&-FMX9+C3;A^RLX62(?CLE_*O)?^">OQEL/AG\
M6+W0]8N%L],\3PQVJW$C81+I&)AW'L&WR+GU9>@S7Z0?%;X9Z3\7_ .K^$]:
M4_8]0BVB90"\$@Y25,_Q*P!]\8Z$U^.'QB^#7B3X(^,[GP[XBLVCD5B;6[13
MY-Y%G DC/<'TZ@\'!K:C)5*;ILSJ)PGSH_;VBO)_V5/^$F_X9[\%?\)?]I_M
M_P"R-YOVW/G>5YK^1OSSGR?*Z\^O.:]8KSY+E;1V)W5SY:_;*_9!D^/4=KXD
M\-306GC"QA^SM%<'9%?0@DJA;^%U).UCP0<'@ C\Z_%/P#^(_@N\>VUGP1KE
MHR-M\Q;%Y8F.<?+(@*-^!-?MS1733Q$J:Y=T8SHJ3N?A';^"/$5XSK;Z!JDS
M(VUA'9R,5/H<+P:ZW0_V;?BIXC8?8?A[XB96Z23:=)!&>O1Y J]CWK]KZ*T>
M*?1&?U==6?C-X@_9'^,'AG37O[_P%JGV6-2[M:^7<LJCJ2L3,P'X>]<;\-_B
M=XG^$/BJ'7?#&I3:7J,)VNHYCF7/,<J'AE/H?J,$ U^Y=?GW_P %(/@%INCV
M]C\3-#LUM)KFY%EK$4"821V4F.X('0DJ58]R4[Y)TIXCVCY9K<B='D7-%GU?
M^S?\>=-_:"^'-MK]JBVFIP,+;4[ '_CWN  3MYY1OO*?0X/(->JU^5G_  3K
M^(<_A/X^0Z"9673_ !):R6LD9/R^;&C2Q,?<;74?]=#7ZIUR5H>SG9'33ESQ
MNPHHHK U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=S\K?2-QQ_WV:]Y^)G[._@;XK2-<:QI7D:DPQ_:5@WDS_B<%7_X$#7@.O?\
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M670]VC'EC=]0YHYHYHYKF.@.:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-_LL ?:NIRJTM]3-1IU-C\XO#_[ ?Q;UB=$O=.TW0HV/S27VH1N%Y](2^?\
MZ]?4/P3_ &#_  E\-[R#5_$MP/%^LQ$/''/"$LX6]1$2=Y'JYQWV@U]/\T<U
ME*M.6AK&C&.H<T<T<T<U@;!S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0
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M[<:3*?\ EE?V$H/_ 'TBLOZU^8=%>C3S;$PW:?JO\K'PV,\-.'\4VZ<94O\
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MAF_[VD_M67,OR4EZZ^?0^6?V9OVVI5GM?"_Q'O-\38CM?$,I.Y3T"W![@_\
M/3M_%GEA]O(XD565@RL,A@>"/6OR-^-7P5UWX'^+GT?6$\ZUEW/8ZC&I$5U&
M#]X>C#(W+U!/<$$_2O[$_P"TTZS6GPY\4W6Z)L1Z+>S'E3VMF/<'^#/3[O\
M= QP./G3G]6Q.^R;_)GJ<8<'83%X3^WLALX-<THQV:ZRBNEOM1_)II_<%%%%
M?3G\_!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%17-Q':6\L\K;(HE+NV"<*!DGBO!O\
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M+KUKFO,Q<N:O)G=AX\M*(<T<T<T<UQG2'-'-'-'- !S1S1S1S0 <T<T<T<T
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MZG8YPK@>AP?]XU\S^'?$VL^"]634-$U2[TC4(C@7%E.T;]>F5/(XZ=#7U?\
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MKQ0R,]O#YWFP7@4$L(V(!#@ G:1T!()P<$J$XJ[01JQD[(^G**P?'FNS^%_
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M\&0?:O$EB!\RJWF9'L":]@YKY6_9J^)4>EZ\OA[4\,EX/+L[ICS&_P#SR/\
MLMV]\#OQ]4\UX&+A*G4Y6>QAI*4+H.:.:.:.:X3J#FCFCFCF@ YHYHYHYH .
M:.:.:.: /&/VJM4^Q_#FVM%/S7E]&A&?X55F/ZA:^2:^B_VOM1S-X:L ?NK/
M.P^I15_DWYU\^Z;9-J6I6MHF=]Q*D0^K$#^M?48%<M!,\+%.]5H^[?ACI?\
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MHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH
M.:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:
M.:.: /"?VMM+\_PAHVH 9:VO3%] Z$G]8Q7RQ7VI^T-IO]I?"76L#+V_E3K_
M ,!D7/\ XZ6KXKKZ;+Y7HV[,\3&1M4OW/T%\&ZI_;GA+1=0)W&ZLH9F/NR G
M\<YK8YKSOX :E_:7PET%B<O$DD#>VV1@/_'=M>B<U\]4CRSE'LSV*;YH)AS1
MS1S1S618<T<T<T<T '-'-'-'- !S5;4(/M6GW,.,^9$R?F"*QO$'Q"\->%7:
M/5=;L[.8<F%I09/^^!EOTKFY/VAOA]&Y4^(5)']VTG(_,1UM&E4EK&+?R,I5
M(+1M'%UTWPWN?LOC33CV=FC/XJ0/UQ7FMS\3O"WVF7R]4S'O.T_9Y1D9X_@J
MWH'Q<\+Z;KFGW3ZIMCAN(W<_9Y3\H89_@],UZDJ4Y1:Y6>=&<4T[GUY17EO_
M  TY\-/^AE_\D+G_ .-T?\-.?#3_ *&7_P D+G_XW7D?5ZW\C^YGH^VI_P R
M^\]2HKRW_AISX:?]#+_Y(7/_ ,;H_P"&G/AI_P!#+_Y(7/\ \;H^KUOY']S#
MVU/^9?>>I45Y;_PTY\-/^AE_\D+G_P"-TZ']ICX:S.$7Q*H)_OV=PH_,QXI?
M5ZW\C^YA[:G_ #+[SU"BN;\-_$;PQXP81Z-KUCJ$Q&?(CF'FX]=A^;]*Z2LI
M1<7:2L:)IZH****D84444 %%%% !1110 5ROQ4L?[4^%_B^RQN^T:/>0XSC.
MZ!QU_&NJK.\11I/X?U..1=T;VLJLI[@H<BHFKQ:.G#3=.O3FNC3_ !/Q:KZS
M_P""=6D6UU\2O$FH2)ON+32Q'"Q_AWRKN(]\)CZ$U\F5[G^QW\5K3X5_&"V?
M5)A;Z/J\)TZYF8X6)F96CD/L&4 GL&)K\]P,XPQ,)3VN?VYQ;AJ^+R+%T<,K
MS<=EULTVOFDT?J'12 AAD<BEK]%/X:"OQ]^-6AV_AOXO>,],M%"6EKJ]U'"@
M& B>:VU?P&!^%?K!\0/'6E?#7P?J?B/69Q#8V,1D(SAI&_AC7U9C@ >IK\??
M$FNW'BCQ%JNLW>/M>HW<MY-CIOD<NWZDU\OG<XVA#J?T)X2X:NJN*Q-K4[1C
MY.5[_@OS,VBBBOE#^CPK[1_X)MV DU/Q[>D#,4-E"#CGYVF)_P#0!^E?%U?=
MW_!-^V*^&/&UQNR)+RVCVXZ;4<Y_\>_2O5RM7Q</G^1^<^(53V?#6)MUY%_Y
M/$^R****^^/XR"BBB@#\[_\ @H5XD_M+XN:3I".3%I>EH67TEE=F;_QT1UZ%
M_P $X?"XCT;QCXC=,F:XAT^)\=-BF1P#[^9'^0KYX_:ZU<ZS^T5XRE)RL,\=
MLH]/+AC0]_52?QK[2_85T==+_9YTJY50#J-Y=73'U(E,6?RB'Y5\EA?WV93F
M^E_\C^E>(G_9? 6&PT=/:*FGZO\ >/\ %,^@Z***^M/YJ"BBB@ HHHH *HZU
MH]IXBT>^TO4(%N;"]A>WGA;H\;J59?Q!-7J*35]&5&4H24HNS1^-WQ)\$W7P
MW\>:[X9NR6FTVZ> 2,,>8G5'QZ,I5OQK]-OV6?B(WQ+^"/A_49Y?-U"TC.GW
MA)R3+%A0Q]V38Y_WJ^6?^"B'@==)\?Z#XHAC"QZO:-;3E1UFA(^8^Y1T'_ *
MV_\ @G)XT:/5?%GA.63*30QZG;H3T92(Y3^(>+_OFODL'_L>/E0Z/3]4?TQQ
M1;B;@ZCFR7[RG:3^_DFO2^OR/N:BBBOKC^90HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ* 3@ 9]J]0_X)6_\@_XD_\ 773_ .5Q7$_\%0O^2M>$_P#L!_\ MQ+7;?\
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M1DO:S7H>5BJ[3]G$5F+L68EF)R23DGWI***]P\L**** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#Q5I7F7<*%+;5+5_*N[<$YPKX((R3\K!ER<XS6]&K[-V>QC5I\^JW/FCX?\
M_!3[PY_PCMLGC7PSJ\>MQHJS3:*D,L$S#JX621"F>#M^;J>:^8OVK/VIK[]I
M#7-.$6GMHWAW2U;[)9/)OD>1\;Y9",#.   .@SR<FOI#5O\ @E?I\UXS:7\1
MKJSM,?+%=Z0MQ(/^!K,@/;^&N\^&/_!.'X>^"[^WO_$5]>^,[J'#"WNE6"S9
MAW,2Y9AG^%G([$&MU*A!\T=S)QJR7*S@O^":OP.OM*CU7XEZM;-;QWL!T_24
MD7!DC+!I9@/0E%53WP_;&>7_ ."I'_(]>!O^P;/_ .C17Z*6]O%:P1P01I##
M&H1(XU"JJ@8  '  %?.W[4G[(/\ PTIKFAZC_P );_PCG]F6TEOY?]F_:O,W
M,&SGS4QC'3!K&%5.KSR-)4[4^6)X1_P2M_Y"'Q)_ZY:?_P"A7-?H)7S[^RM^
MR?\ \,S7'B27_A*?^$D_ME;=<?V=]E\GRC(?^>K[L^9[8QWS7T%6=:2E-M%T
MXN,4F?E1_P %&/\ DY*Z_P"P7:?R:OI+_@F#_P D5\2_]C#)_P"DUO6S^T9^
MPM_PO_XE2^+/^$V_L'S+6*V^Q_V3]IQL!^;?YZ=<],5Z3^R_^SS_ ,,W^"=3
M\/\ ]O\ _"1?;=0:_P#M'V+[+LS'&FS;YCY_U><Y[]*WG4BZ2BGJ9QA)5'+H
M>7?\%,?^3?=,_P"QAM__ $1<5\I_\$\/^3F=)_Z\+S_T4:_07]ICX"_\-%?#
M^V\,?V[_ ,(_Y.H1W_VK[)]ISL21-FSS$Z^9G.>W3FO*OV>/V$?^%"_$VT\7
M?\)Q_;OV>":#['_9/V?=YB[<[_/?&/I2A4BJ3BWJ*4).HI+8^DO'O_(B^(O^
MP;<_^BFK\)Z_>?7M+_MO0]2T[S?)^V6TEOYFW=LWJ5SC(SC/3-?"?_#JK_JJ
M'_EO_P#W53P]2,$^9CK0E*UC[?U318_$W@N\T>9MD6H:>]H[=<*\90G]:_#?
MQ%H&H>#_ !%J.C:E"UIJ>FW+VT\9X*2(Q!_4<&OW?MH?L]O%%G=L0+G&,X&*
M\%_: _8Q\%?'S4#K,\EQX?\ $A4(^IV 4B< 87S8SP^!T(*MP!D@ 5%"JJ;:
M>S'5IN:5CQWPA_P4]\,1^#[5?$GAC6F\2Q1!)AIXA:UF< #?O9U9-QR=NPX]
M37QM^T-\=M4_:&^(3>)]3L;?3%BMELK2SMV+^3 KNZJSG&]MTCDM@=>@Z5]A
M^'/^"6FC6>I))KOC^]U2Q&";>QTQ;1VY_OM+)QC_ &:]-^,7["?A#XA^!_#'
MASPU<Q^"8]!DF:*>&S^U&=90OF>;EU9V)C0[BQQC'3IO&I1IRO$SE&K)6D>;
M_P#!+7_D3O'G_7_;?^BWKP[_ (*/?\G'R?\ 8(M?_9Z^X?V6OV9?^&:='UZP
M_P"$D_X2/^U)XY_,^P_9?*V*1C'F/G.?;I7#_M'?L,_\-!?$AO%?_";?V#NM
M(K7[)_9/VG[F[YM_GIUW=,=JSC4A[9SOH4X2]FHVU,3_ ()@_P#)%?$O_8PR
M?^DUO7YZ_%"QU#3?B3XJM=6#C4XM5NEN3(,,9/-;<3]3S^-?K9^R_P#L\_\
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ME:\)_P#8#_\ ;B6NV_X)6_\ (/\ B3_UUT_^5Q7KW[4/[&O_  TEXNTG6_\
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MHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH
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M(3/?O^"=M\;OX!W46XL+76[B'!'3,<+X_P#'_P!:^H>:^4?^";W_ "0W7/\
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M2OC/]C/_ )*AJG_8'E_]'P5]F5\KF/\ '?R/<P?\)!1117F':%%%% !1110
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M$UC*L<,9[L2N"S=2?H.@%>25^CW@WXF>%_B )/[ UBWU!XQN:$!HY57.,E'
M;&>^.X]:\J_:0^!>G>(/#U_XFT:T2UURS0SSK"N%NXQR^0/XP,D'J<8.<C'9
MA\:H25&<.4YZN&<DZD97/C:BBBO;/-"BBB@ K[F^"O\ R2OPU_UZ#^9KX9K[
MF^"O_)*_#7_7H/YFO(S+^''U/0P7QOT.WYHYHYHYKYX]D.:.:.:.: #FCFCF
MCF@ YHYHYHYH _.[69C<:Q?2L &>>1CCIRQ->_?L?P[KCQ5+GE5M5Q]3*?Z5
M\\3S&XFDE8 ,[%CCIR<U](?L@0A;7Q3+W9[92/H)3_6OJ<9IAY?+\T>!A=:R
M/HKFCFCFCFOECWPYHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.:
M #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FC
MFCFCF@ YHYHYHYH .:.:.:.: #FO#?VDOVJ-)_9X_LRTDTB77]9U!6FCLX[@
M0(D0.-[OM;&3D !3G:>F.?<N:_.W_@I-_P E5\,?]@4?^CY:VI14I69E5DXQ
MNCZW^"_QDTSXZ>"QXETVUFL,7#VUS:3,&:&90K%=PX8;74@X'!Z \5WE?+W_
M  3Q_P"2+:U_V,$W_I-;5]0UU25G9'G[A1114@%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?G_\ \%$_^2H>&_\
ML#C_ -'R5^@%?G__ ,%$_P#DJ'AO_L#C_P!'R5I3^(3/<?\ @F]_R0W7/^QB
MG_\ 2:UKZNYKY1_X)O?\D-US_L8I_P#TFM:^KN:XJOQL]&G\"#FCFCFCFLC4
M.:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:
M.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.:
M #FCFCFCF@ YKX=^.D:P_%KQ&JC ,ZM^)C4G]37W%S7Q/^T,BQ_&+Q %  S
M>/4V\9/ZUZV6_P 5^G^1Y^-_AKU-7]E^1D^*404X#V<RM[C /\P*^P^:^,OV
M:V*_%O3 #@&&<'W_ ';5]F\U.8?QOD/!_P /YAS1S1S1S7EG>'-'-'-'- 'R
M)^U1_P E,B_[!\7_ *$]>.U[%^U1_P E,B_[!\7_ *$]>.U]?A?X,?0^=K_Q
M9!111728!3H89+B9(HD:25V"HB#+,3P !W--KT7X 7F@:7\3M.U#Q)>165C9
M*]Q&\X.TS 80< \@G</=145)<D7*U[%1CS22/=/A3^R9I5CI\&H>,E;4-1D
M?^STD*PP]PK%3EV]>=O;!ZUZ_#\(_!%O D2^$-$95& 7T^)V_%BI)_$UP_QB
M^/VA^'? MS+X;U^PU#6[H"*U6SG29HLXW2, 3MP,XW=\>]?%LNO:E-JIU.34
M+I]2+;S>-,QFW>N_.<_C7@TZ.(Q=YSFT>I.I2P]HQC<^P_B-^RAX9\1:?+-X
M;C&@:JJY15=FMY"!T923MSZKTZD&OCC5=+NM$U*ZT^^A:WO+61HI8FZJRG!'
MYU]__ SQ1?>,?A7H&JZD[27TD;QRRMUD*2,@8^Y"@GWS7RA^U-;P6_QGU?R
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M *^3SOXJ?S_0_I+PD_W?&-]X?E(_;*BBBOK#^;0HHHH **** "BBB@ HHHH
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M(R^UKQG\9;O0M&@MM1\02Z/IT=AIVF:?!).88(U )6-03DGECCJ1V  ^N/\
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M<*F^2)5!)X&3R2!U(KIOB7^T%\//@_-';^+O%5GI-W(NY;0!Y[C:>C&*)6<
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MMYM&OF26-@0RL#!R""01[U\T?#?_ ()M_P#"POA_X;\3_P#"Q?L']L:?!?\
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M3QEX$N/&>E>)K.7PQ;.\<^HW!:W2%EQN5Q*%93\RX! R&4C.17Q#_P %2/\
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M:.:.:^>/9#FCFCFCF@ YHYHYHYH .:.:.:.: /SBKZ7_ &0?^0?XF_ZZP?\
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M^">/_)%M:_[&";_TFMJ^H:Z9[G %%%%0,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *_/_P#X*)_\E0\-_P#8''_H
M^2OT K\__P#@HG_R5#PW_P!@<?\ H^2M*?Q"9[C_ ,$WO^2&ZY_V,4__ *36
MM?5W-?*/_!-[_DANN?\ 8Q3_ /I-:U]7<UQ5?C9Z-/X$'-'-'-'-9&H<T<T<
MT<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T
M'-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-
M'-'- !S7Q3^T1_R6+Q!_V[_^D\5?:W-?$_[0TBR_&'Q"R'(!@7\1!&#^HKU<
MM_BOT_5'GXW^&O4M_LV_\E<TO_KE/_Z*:OLWFOC/]FN-F^+6G$#(6&<GV'EL
M/YD5]F<TLQ_C+T'@OX?S#FCFCFCFO+.\.:.:.:.: /D3]JC_ )*9%_V#XO\
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M[6]AQ=6,UF6_ZY2!P/\ R.?\YJW_ ,$W_$ BUKQKH;-EI[>WO8U]!&SHY_\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<]\1-%?Q+\/\
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MW^,WQO\ $?B73V=M)=TMK NI4F") BM@\C<0SX/(WXK'"Q?.V:5VN6Q]I_\
M!+_4IIOA/XKL7+&&WUKS8\] 7@C! _[X'YU\;?M>_P#)RWQ _P"PD?\ T!:^
M\?\ @G/X$N/"7[/XU.[C,<WB#4);^/<,'R JQ)^9C=A[,*^#OVO?^3EOB!_V
M$C_Z M;4W>M*QE/^'$^[_P#@G5X%TC0?@!:>(K:U0:OKMS</=W3*"Y6*9XHX
MP?[H"$X]78U[9\>-6GT/X(^/]0M6*7-OH-])$X."KB!]I_ X/X5YI^P+_P F
ML>$O^NM[_P"E<U>U^-O#,7C/P;KWA^<A8=6L)[%V/998V0G_ ,>KCJ/]ZV^Y
MU17N)(_"FTG%K=0S-#'<"-U<PS9*/@YVM@@X/?!KZV7_ (*<?%&-0J^'_!ZJ
M!@ 65U@?^3-?+EU::IX!\72VUS"UEK.C7I22*0<QS1/R#]&6OV6^"?QZ\*?'
M+PK9ZIH6I6_V]H@UWI32@7-K)CYE9.N,YPV,$<BO0KR44FXW..DF[I.Q^7OQ
MZ_:U\7?M$:'INE>)-+T*SAT^Y-S#+I=O-')N*E2I+RN-N#V Y YKWW_@EG]L
M7Q%X_*H_V!K2T\Q]OR^8'DVC/K@O7V7\4/CYX"^#MG)+XI\26=C<*/ET^-_-
MNW) (VPKENXY( &1DBM?X9_$[P[\7O"5MXD\+WZW^F3,T>[:5>*1?O(ZGE6&
M1P>Q!'!!KEE5O3Y5&R-XT[3NY79^3O[57P"UWX(_$K5?M%E,WAO4;N6?2]2"
MYBDC9BPC+#@2*#@J<'C(&"*Z#X0_MV?$SX3Z=::2US:^)M$M46**SU="SQ1C
M "I*I#  # #;@!P!7Z;S?$+P#XL\2:AX$N-9T75=81=MWH5Q)'*S  $J8VX8
MC@E><=Q7A/[0'[#OPKUGP;KNNZ791^"=4LK6:[%Y92%+7Y$+8DA8[%3@_<VD
M9SDXQ6D:T9)1J(ATG%\T&=%^SS^VQX/^/.I1Z&]M-X9\4.I:/3KJ021W&!EA
M#* -Q R=I"G ) .#CQ'_ (*H:K.EO\.=,5B+:1[ZY=<\,ZB!5/X!W_[ZKXJ^
M%%U?V7Q0\(S:4[IJ2:O:?9S'G=YGG+M'XGC\:_07_@II\/KCQ!\+= \4VL#3
M'P_>M'<%1_JX+@*I<^WF1Q#_ ('3]G&E6C;J'.ZE-W/AOX$_'O7/V>_$E]KO
MA[3=)O\ 4+NU-F6U:&601QEU8[-DB8)*+G.>E>Y?\/._BE_T /"'_@'=?_)-
M<9^PY\<M*^"?Q:F;Q!-]ET'6K7[#/=$96WDWJT<C=]H(*GTWY[5^KMCX@TO5
M-(&JV>I6=WI90RB]@G1X2@&2V\';C'?-.M*,9>]"XJ47*.DK'X?_ !*\?W_Q
M2\=:QXKU2VM+34-4E$TT-BC)"&VA?E#,Q&<9.2>2:_6'X-_;%_8_\/K?(\=P
MOA0KMD7!""!@G'^X%J?6OVPOA)H?C2R\,2^+[2XU"YE$)GM,RVL#DX DG7Y%
MYX/)VX^;;7I7CW_D1?$7_8-N?_135A4J.22<;&E."BV[W/PGK]S?ACX%TCX;
M^ M%\.Z':I:Z?96R(H50#(V,M(V.K,V6)[DFOPRK][=-_P"0?:_]<E_D*VQ>
MR1GA]V1ZUH]GXAT>_P!*U"%;BQOK>2UN(6Z/&ZE64_4$C\:_$+XA>$=1^$?Q
M.UK0))'BO]#U!HXIUX8[&S'(/JNUA]17[E5^</\ P4V^%ITGQMH/CRUAQ;:O
M#]@O'7_GXB&48^[1\?\ ;*LL+*TN7N:5XWC?L?3WC_\ :$BM_P!C^?XDVDP@
MOM1T9$MMAP8[V4"+ QW20L?^ &OS?_9;^%__  MWXY>%]!EA\[3EN/ME^&&5
M^SQ?.ZGV; 3ZN*KZM\8KG4OV=_#_ ,.#)(4T_7+K46&3M\HQIY2_]]R7)Q[B
MOLC_ ()C?"[^S/"OB+Q[=0@3ZG*--LG8<B",[I2#Z-)M'UBK>WL(29E?VLTC
M[@KPKXM?MH?"[X/W\VFZAJTVLZQ"=LNG:)$+B2,Y (9BRQJ1W4OD8/%0?MO?
M$C5OAE^S[K%]HD\EIJ5_/%IL=W"2'@60G>P/8[%90>H+ CFOS@_97^$^E?&S
MXU:1X8UV\DM=-F2:XF6%@LLXC0OY:D]"<<GKM#8YYKFI4E*+G+9&U2HXM1CN
M?5FJ_P#!5#3H9U&F_#FZNX=N6>ZU=8&#9/ 587R,8YS^%?G]>SK=7D\R1B%)
M)&=8P<[ 3D#\*_8P?L[_  0^%_AR\O[SP3X9L](M(@]Q>:S;)="-%SR9)]Y[
M^N3P.>*_'?5I()=4O'M@HMFF<Q;5VC:6.,#L,8KKH.#OR*QSUE)6YF?N1\-9
M&F^'/A61SEVTJU8GW,*5^*?Q._Y*5XL_["]W_P"CGK]JOAC_ ,DU\)_]@BT_
M]$I7XJ_% %?B7XM!&"-7N_\ T<]987XI&E?9'[$_LW?\F^_#C_L7K'_T0E;/
MQ@_Y)+XV_P"P'??^D[UQO[._C+0;/]G'X;WESK-A:VATJRL!/<7*1H;D1K'Y
M.6(^?>"NWJ2*[+XP?\DE\;?]@.^_])WKC?Q_,Z5\)^(&F_\ (0M?^NJ_S%?K
MM^W%K,VB?LN^-I;=BLDT=O:EA_=DN8D<?BK,/QK\B=-_Y"%K_P!=5_F*_9W]
MISP#<_$SX"^,_#ME$9[ZXLO.MHEZR2PNLR(/=FC"_C7?B&E.#9R4?AE8_)G]
MGOP_;>*OCEX#TJ]19;.XUFU$T;='02!F4^Q (_&OVVK\*OA[XMF^'_C[P[XD
MBC,DND:A!>^5TW^7(&*_B 1^-?M?\/\ XD>'/BEX=MM;\,:M;ZK8S(KYA<%X
ML_PR)U1A@@JV#P:SQ2=TR\.U9H^7?^"GGA^UN_@_X:UED7[;8ZTMM')@9\N6
M&0NN?<Q1G\*^8_\ @GKJ\^F_M.Z);Q,RIJ%G>6TP!(RHA:4 XZ_-$O7T%>L?
M\%(OCGH/BJTT#P'H.I6^JO9W9U+49;2021Q.$9(H]PX+8DD) /'RYZ\<=_P3
M6\ W&O?&J^\3-"WV#0=/D_?8X\^;]VB_4IYQ_#WJX>[0?,1+6LK'2_\ !4C_
M )'KP-_V#9__ $:*U/\ @E;_ ,A#XD_]<M/_ /0KFLO_ (*D?\CUX&_[!L__
M *-%:G_!*W_D(?$G_KEI_P#Z%<TO^8?^NX_^7Q]M_%.-9OACXOC<!T;1[Q64
M]"# _%?AUII*ZE:D'!\U/YBOW(^)W_)-?%G_ &"+O_T2]?AQIO\ R$+7_KJO
M\Q1A=F/$;H_>VBBBO..PRO%7_(KZQ_UYS?\ H!K\SJ_3'Q5_R*^L?]><W_H!
MK\SJ^AROX9_(\K';Q"BBBO</+"BBB@#H_ ?Q"UOX;ZT-3T2Z\F8C9)$XW13+
M_==>X_4=B*^D?#_[:6D26ZC7/#][;3!?F;3W296;CH'*8'7N?QKY+HKEK86E
M7=YK4WIUIT](L^L_$/[:6D1VY&A>'[VYG(X;4'2%5/T0N6'3N*^;_'?Q UOX
MD:T=3URZ\^8#;'$@VQPKG[J+V'ZGN37.444<+2H:P6H5*TZFDF%%%%=1@%%%
M% !7W-\%?^25^&O^O0?S-?#-?<WP5_Y)7X:_Z]!_,UY&9?PX^IZ&"^-^AV_-
M'-'-'-?/'LAS1S1S1S0 <T<T<T<T '-'-'-'- 'YW:U";?6;^(G)CN)%)^C$
M5[[^Q_-MN?%46/O);-NSZ&4?^S?I7B/CFW^R>-O$$&T+Y6H7";1VQ*PQ7K_[
M(UQM\3Z]!EOGLU?';Y7Q_P"S?SKZG%>]AG\OT/!P^E='U'S1S1S1S7RQ[P<T
M<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T
M<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '
M-'-'-'- !S7YX_\ !2BWE7XF^%9RC"%]'*+)C@LLSDCZ@,OYBOT.YKF?'7PU
M\+_$W3HK'Q3H=IK5M"V^);E/FC;N5889<X&<'G%:TY<DKF=2//&Q\S?\$\XW
MC^"FKLRLH?7YV4D8W#[/;C(]>01^%?4%4=%\-Z7X1TZ/2=%L+?3--MLK#:VL
M81$&23@#N3DD]R<U>KJ;YM3SM@HHHI %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %?G__ ,%$_P#DJ'AO_L#C_P!'
MR5^@%?G_ /\ !1/_ )*AX;_[ X_]'R5I3^(3/<?^";W_ "0W7/\ L8I__2:U
MKZNYKY1_X)O?\D-US_L8I_\ TFM:^KN:XJOQL]&G\"#FCFCFCFLC4.:.:.:.
M: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #F
MCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCF
MCF@ YKX<^.<PF^+'B-E! $ZKS[(H/\J^X^:^#OBU<?:OB;XG?=NVZA,F<8^Z
MQ7'Z5Z^6K]Y)^1YV.^!>IV'[+T;2?%*-ATCLYF/T^4?S-?8/-?)?[)]OYOQ$
MOY2#B+3)"#Z$R1#^6:^M.:RS#^-\B\'_  @YHYHYHYKS3N#FCFCFCF@#Y$_:
MH_Y*9%_V#XO_ $)Z\=KV+]JC_DID7_8/B_\ 0GKQVOK\+_!CZ'SM?^+(****
MZ3 *]D_9C\*^$_&?B^\TWQ)9_;+D0B:RC>5EC8J?G! QN.""!GH#UKQNKVAZ
MU>^'-8M-3T^=K:]M9!+%*O9A_,>H[@UE5@ZD'&+LRX249)M7/KG]H#]GNQU[
MPVFH^$=%M+'5K'+-::? L7VJ,]0%4 %QU'<\CTKY%M]#U&[U0:=!874VH%M@
MM4A8R[O3;C.:^R/A[^U=X6\1:?#'K\W]@:JJXD$BLT$A Y*, < ^C8],FO1)
MOBWX(AA:5O%^AE57<0FH1,V/90V2?8"O"IXC$89>SG!O^OQ/3G1I5GSQE8Q?
M@#X#O/AY\-;'3M141ZA-(]U<1 Y\MGQA,^H4+G'?/UKYP_:\UZ'5OBC%9P,&
M_LVQC@EP<XD9F<C\F6O5/B9^UIH6CV,]IX38ZQJ;*46Z:,K;PGIN^8 N?0 8
M/K7R'J.H7.K7]S>WDS7%W<2-++-(<L[L<DGZDUO@Z%1U77JJUS/$58*"I0=R
MO1117MGFA1110![U^QG_ ,E0U3_L#R_^CX*^S*^,_P!C/_DJ&J?]@>7_ -'P
M5]F5\KF/\=^B/<P?\(****\P[0HHHH 0@,"",BOR[_;,_8^U+X7Z_J'C#PGI
M[W?@B[<SS0VR9.ENQ)964=(<_=;HN=IQP6_46FNBR(R.H96&"K#((]*UIU'3
M=T9S@IJS/Q)^$WQV\;_!/4FN_"6MS6$4CAI[&3]Y:W&./GB/!..-PPP[$5]=
M>#_^"I+K9)'XH\"B6[4?-<Z3>[$<_P#7*125_P"^SUKVGXO?L"_#3XFS3WVF
MV\O@W6)/F,^D*HMV;U> _+_WP4)[FOF[7O\ @EYXXM[HKHOB[P_J%OGB2_6>
MU?'^ZJ2CT[UV\]&KK+<Y>6K3^$^JOV<?VPO#'[16J:CI%EIUYH>M6</VD6EV
MZN)H0P4LC+U(++D$#J,9YQXC\1O^"ES>%_B-J>CZ+X0AU+0].NVM7NKF[:.:
MXV,5=T 4A02#MSGC!.,X'=_LA?L7WW[/_B;4/$_B+6K34]8FM#906VFA_(A5
MF5G8NX4L24 'R@ 9/.1CP_\ ;B_9,\/?#/3]5^)&DZM=11ZIJ00Z(T"M&D\Q
M9V99=P*H-K';M;J!D#IE&-%U+=#23J<ESZ,_:(_:[C^%_P %?"WC#PSIT>HW
MOBI8Y-.34%810QF,2,TBJ020"J[01R<YP,'X\O?^"C?QANF/E3Z)9_+MQ#IV
M>?7YV;G]..E;_P"SSXX@_:EAT_X)_$*TC.E6MGYGA_4M*C$%S8201XV9P5=3
M&&R6!)(YR2"/=+/_ ()A?#:,'[3XC\53'/'E3VR#'OF U:5.E[LUJ3[]36+T
M/EG_ (>!_&S_ *&.S_\ !7;_ /Q%:-M_P48^,4#1E[O1[@+U$FG* _UVD?IB
MOJO_ (=K_"7_ )^?$G_@?'_\:KPW]J_]B?P-\"_A'<^*M U3Q!=:A'>06ZQ:
MC<0/#M=B#PD*G/''-5&="3LD2XU8J]SG+7_@IE\5K<,)-+\*W1/0RV4XQ]-L
MXKH+/_@J+XRC8_:_!NA3KD8$,LT9]^K-7BGPB_9.\7?&CX=ZSXTT34=%M=+T
MJ>:WGAU">9)V:*%)6*A(F4C;( ,L.0>G6J7[,WP ?]H[QUJ7AN/7!H#VFER:
MBMPUI]H#E98HQ&5WIC/FYW9.-O0YK1PHZW6Q"E4TUW/IS3_^"J,@PM]\-E8;
MN7M]:(PO^Z8#D_B*Z/3_ /@J1X5D"_;O!&L6QP=WV>YBEQZ8SMS7 :A_P2W\
M41AOL/CC2+DX&W[1:2Q9]<X+8KG-0_X)E?%&UR;;6?"]XF[ "W<Z-CU(:#'Z
MFLN7#LTO61V?Q._X*>7NH:;-9^ _#!TNYD!4:GJ\BRO%[K"HV[O0LQ'JIKXN
M_P")_P#$KQ?_ ,OFO^(]8N?>6>YF<_J2:^L?"G_!,'QS?W2?\)#XHT/1[//S
M&Q\V[F_[Y*QK_P"/5]D? C]ECP-^S_;M-HEH]_KDJ;)M:U##W!4]43  C7V4
M<\9)P*?M*5%>YN')4J/WBE^R3^SW'^S[\,TL;KRY?$NILMUJT\9R X&$A4]U
MC!(SW+,>]>WT45Y\I.3NSL2459'G7[0_A@>,/@?XTTS9YDC:;+/&@&2TD0\U
M /\ @4:U^5G@+Q&?!_CCP]KH8K_9NH079V^B2*Q'X@5^RDT*7$+Q2J'C=2K*
M>A!&"*_&3Q=H3^%_%FM:-)GS-.O9K-MW7,<C(<_E7R>=1Y9TZJ_JQ_1WA3B(
MXC"XW+JFVCM_B3C+\D?LXCB1596#*PR&!X(]:?7"? SQ&?%GP<\&ZJS;Y9]+
MMQ*P[R*@1_\ QY6KNZ^GA)3BI+J?SWBJ$L+7J8>>\&T_D[!1115G,%%%% !1
M110!YK^TC<);_ 7QV[D[3I,Z<>K+M'ZD5^8'PCA>Y^*_@N*-=TDFMV2JO3),
MZ "OTO\ VK[DVO[//C=]N[-FJ8SC[TJ+G\,U^</P#MC=?'#P"@;;C7;*3./[
MLR-C]*^3S;7%4UZ?F?TGX<?N^'L=5\Y?A!?YGZ\4445]8?S8%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!R/Q1^%?AOXQ>$;GPYXHL!
M>V$WS(RG;+!( =LD;?PL,]>AR0002#^<_P 7/^"=/Q"\&WDUQX1,/C/1]Q*+
M$ZP7D:\GYXW(#8X&48D]=HK]1J*VIU94]C.=.,]S\3+K]G/XJV=S+!)\-_%;
M/&Q5C%HUQ(I(]&5"I'N#BN_\ ?L)_%[QQ>0K/X=_X1JQ?!>]UJ580@.#_J@3
M(3@]-O;!(K]=**W>*ET1BL/'JSQO]F_]F+PW^SIX?EAL&.J:_>*!?ZS-&%>4
M#D(BY.R,'G;DDGDDX&/C;]O7X3>./&'[0%SJ.@>#?$&N:>=-MD%WINESW$18
M!LKO1",CTS7Z6T5A"K*,N=ZLUE34H\I\I?\ !.CP;X@\$?"+Q#9^(]"U+0+R
M779)H[?5+.2VD=#;P#<%=02,@C(XR#7U;1142ES2<BXQY58*_(+]N*XT"Y_:
M7\6-H&"JM&E\R?<-XJ 3;?H0 W^T&K]//CW\4K?X,_"7Q%XKF*F>TMREG$W_
M "UN7.R)<=QO()]%!/:OR(^$G@74OCG\8M%T&26:XN=9O_,OKHY9Q'DO/*3Z
MA0Y]SBNO#1M>;V.:N[VBC]$?^">/PF_X0+X*_P#"17<(35?%$HO,D?,MJF5@
M7\<N_P!)!7U/573=-MM'TVTL+.%;>SM8D@AA3[J1J JJ/8  5:KDG+GDY,Z8
MQY4D?.7[5W['^F_M#6L.K:9<PZ+XSM(_*BO)5/DW48R1'-M!(P2<. 2,D$$8
MQ^>OB_\ 9%^+_@N\>"Z\!ZM?J'VK-H\!OHW]&!AW$ _[0'O@\5^R]%;4Z\J:
MMT,YTHS=S\:O!_[(?Q?\:WBPVO@75=/7=M:?6(38HG3)/F[21S_"#[9K]$/V
M4_V1]+_9UT^?4;VYCUGQA?1>5<WT:D101Y!,4((S@D#+'!;:.!C%?0M%%2O*
MHK= A2C!W/F3_@HI_P FTZA_V$K3_P!#-?FI\(_AK>_&#XA:7X1TZZAL[_4A
M,()K@'RPZ0O( V.0#LVYP<9S@XQ7Z5_\%%/^3:=0_P"PE:?^AFOAG]AW_DZ?
MP)_UUNO_ $DFKIH.U%M>9SU5>HDSG?$G[+/Q;\+ZI)8W7P]\074B9_>Z;827
MD+#)&1)$&7MZY]J]E^ /_!/OQCXRUZTU#Q]92>%_#,3AYK660"]N@/X%09\L
M'H6;!'8'J/T^HK%XJ;5D:JA%.Y4TO2[31-,M-.L+>.TL;2)((+>(86.-0 J@
M>@  K\IOVIO@K\0O$/[0GCC4=*\!^)M3T^XOR\-W9Z/<2Q2KL7E75""/<&OU
MDHK&G4=-W1K."FK'A/[$?AW5O"?[-OAC3-;TN]T?4H9+PR6>H6[P3)NNI64L
MC@$9!!&1T(KW:BBLY2YFV7%<J2/DS]K;]B.#XU7TGBSPC/;:5XO*@74%QE;?
M4 HP"6 .R0  ;L8. #C[U?"'B+]E;XN^%[S[-=_#S7IY,D;M.LVO4XQ_'!O7
MOZ\U^T5%;PQ$H*VYC*C&3N?CMX&_8Q^,'CJZ@CA\'7FC6\A.ZZUP?8DB .,L
MK_O#SV5">^,<U^C7[-G[,]M^SOX$U'3+/6KB]U[5 )+S4,?N8Y0I"^5"3MPN
M3R>6[\84>WT4JE>516>PX4HPU/RJ^+O["_Q>\'^)+O5=,BD\<0S7#W(U739,
M71<L6WR1,V\.3D_(7&>^2*XZ\\!_M&^.K./0=3TCXD:GI[8*V>K)>_91L!QD
M3808'3/T%?L-16BQ,K:HCV"Z,^'?V0?V%=5^'_BJT\;?$(6\6I6)WZ=HL,JS
M>3+VEE=25)7G:JDC.#GC%?:>N:'8>)M%O=)U6UCOM-O86M[BVF&5DC8893^!
MJ_17/.<IOF9M&*BK(_,GXZ?\$[/&/A76+F_^'\8\4>'Y&+QV9F5+VU7KM8,0
M) .@*G<>ZCJ?!/\ AG'XJ_;/LO\ PK?Q7YGF>7N_L>XV9SC._9MQ_M9QWSBO
MVQHKHCBII6>IBZ$6]#\OO@K_ ,$[?'7C+5(+KQPG_"'Z K9DC,B27LRCLB*2
M$SR-SG(Z[6K]&-8\/1Z/\,K_ $33(IY8K;29+.VB9WFE8+"51<DEF;@#G)-=
M316,ZLJCNS6--06A^)'_  S[\4O^B:^+_P#P0W7_ ,;K]K]/4K8VRL"K"-00
M>HX%6**=6JZMKK85.FJ=[!7D7[5OPK;XP? OQ)H=M ;C588OM^G(HRYN(OF5
M5'JXW1_\#KUVBL8MQ::-&KJS/Q+M_P!G7XJ75Q%"OPW\6*TCA TFB7**"3C)
M8H ![G@5^P_PG\ VWPM^&_ASPI:;6CTJSC@>1!Q))C,C_P# G+-_P*NMHK>K
M6=1),RITU3U1Y_\ ';X2VGQN^%NM^$;F86KWD8>VNBN?(G0AHWQW&X8([@D5
M^5_B?]E7XR_#7Q JQ^#M<NKF"3-OJ'AZ&2[0E<$.KP@E>HQN"GVX-?LA12IU
MI4]%L$Z:GJ?EIX/_ &7?C_\ 'Z\LH?&NH>(-.T&-M[7?BV]FE:'KG9;R/O+8
MSV4>I%<;\;OV0_'/P[^(VJ:/X<\*>(_$V@Q['LM3L]-EN5EC90?F:)" P;<"
M..F<8(K]?:*T6)DGMH1["-CG?AW:S67P^\,6US#);W$.EVL<D,JE71A$H*D'
MD$'(P:_/_P#; _8I\7K\0]9\9>!]*D\0:+J\KWMQ968#7-K.V6D CZNK-EAM
M!/S;<< G](J*QA4=.7,C64%-69^+OAO]EOXO>)-06WLOA[X@MIL@B34+)[)!
MSUWS;%_6OU,BT?Q@/V:;_2O%2Q:CXQ_X1RYM;C^SF:;[1-Y#JN/E!:1OER ,
M%B<9&*]6HJZE9U+76Q,*:A>S/Q/T_P#9_P#BC'?6[-\-_%RJ)%))T*ZQU'_3
M.OVPHHI5:KJVNMATZ:IWL?#/[4W_  3^N/%VO7WB[X;&U@O;MFGO-!N'$22R
MDY9X'/RJ6)R48A<Y(8<+7QUJW[,_Q9T6\:UN/ASXFDE7DM::9+<Q_@\2LI_.
MOVKHJX8B<59ZD2HQD[GY(?##]A+XK?$*_MOMVB/X2TI\&6^UK]VZ*>>(,^86
MQV( SP2*_3'X*?!G0/@3X&MO#7A^-FB5C-<WDP'FW4Q #2/CO@  =@ *[ZBH
MJ5I5-'L7"G&&Q\$_\%(/AMXN\<^,O!T_AOPMK7B"&WL)DFDTO3IKE8V,@(#%
M%.#CUK2_X)K_  [\5>!;[X@-XE\,ZQX>6ZCL1 =5L);82[3/NV>8HW8W#..F
M17W)11[9^S]G87LUS\YSOQ$M9KWX?>)[:VADN+B;2[J..&)2SNQB8!0!R23@
M8%?CCI_[/_Q1COK=F^&_BY5$BDDZ%=8ZC_IG7[8444JSIWLASIJ=@HHHK U,
MSQ-$\WAS58XUW.]I*JJ.I)0X%?F97ZC5^=GQ@\#R?#WXA:OI)C:.U\TSVAQ@
M- Y)3'KCE3[J:]W*YI.4#S,;%VC(XRBBBOH#R0HHHH **** "BBB@ HHHH *
M*** "ONCX,(T?PL\-!A@_9%//H22*^*?#>@77BG7K'2;)=]S=RK$GH,]6/L!
MDGV!K] -)TV'1]+L]/MQMM[2%((QZ*JA1^@KQ<RFN6,.IZ>"B[N1;YHYHYHY
MKP3U@YHYHYHYH .:.:.:.: #FCFCFCF@#X1^+UK]C^)_B>/&-U]))T_O'=_6
MNV_93NA;_$FZB)XGTZ5 ,XY#QM^/ -8?[15F;/XNZT<$+,(95Z]XD!_4&G?L
MYWOV/XN:,I.%G6:(_P#?IR/U KZF7OX7_MW]#P(^[B/F?:7-'-'-'-?+'OAS
M1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S
M1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0
M<T<T<T<T '-'-'-?,?[7_P"U5J_P&O=%T7PYI]G<ZM?P-=2W&H*SQQ1!BJA5
M5ERQ8-R3@!>ASQ<8N3LB9245=GT#<?\ 'Q+_ +Q_G4=>5?LV_&JX^.WP[;Q!
M>V,.GZC!>265U';[O*:151]R DD K(O!)YSS7JM==K:,\UZNX4444""BBB@
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MG:^8O^"BW_)M=[_V$[3_ -"-8TOC1K4^!G ?L"_\FC_$/_L)ZC_Z06]>0_\
M!,3_ )+WK_\ V+-Q_P"E5K7KW[ O_)H_Q#_[">H_^D%O7D/_  3$_P"2]Z__
M -BS<?\ I5:UV/:H<W6!^G5%%%><=H4444 %%%% !7Y5?M=:"/#_ .T1XQA1
M<1SW$=XI]?-B21C_ -],WY5^JM?G1_P4(TD6/QKTZ[4?+>Z-"['/\:RRH?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH QO%'@W0
M/&UC'9>(M#TW7[..02I;ZI:1W,:N 0&"N" <$C/N:H>&?A?X-\$WLEYX=\):
M%H-W(GEO<:9IL-M(R9SM+(H)&0./:NHHIW>PK+<****0PHHHH **** ,OQ'X
M7T;QAIK:=KVD6.MZ<S!VM-1MDN(BPZ$HX(R/7%86A_!OP!X8U6#4]&\#^&])
MU*W),-Y8Z1;PS1Y!4[75 1D$C@]"178T4[O85D%%%%(84444 %%%% !1110
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MPQ_6OH*>9P:_>*S/)G@I)^XSXAHK[6_X8_\  G_/;5__  *3_P"(H_X8_P#
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MECWPYHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@
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M760K"L<=E&_9F)WN/P 3_OH5]55ROPT\!VGPV\'6&AVA$AA7?//C!FE/+O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3:U9:5+IL^J7DT(N)!%($$498J.2#DDJW''0<\UZ1X?URV\2Z%I^K698VE[
MEQ%O&&VLH(!'KS64J<XQ4VM&:*<9-Q3U1HT445D6%%%% !1110!X+^V9_P D
MOTO_ +#$7_HB>JG[%_\ R(>N?]A+_P!I)5O]LS_DE^E_]AB+_P!$3U4_8O\
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MWWJ0H_[["5]L<UCF$>6M?N:X.5Z5NP<T<T<T<UYIVAS1S1S1S0 <T<T<T<T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ _:>T'P#IL6A>%%BUZ_M85MUN <6D6U0HY!^<\=%X_VNU=5:C.="E2@O/\
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M 4444 %%%% !7Y__ /!1/_DJ'AO_ + X_P#1\E?H!7Y__P#!1/\ Y*AX;_[
MX_\ 1\E:4_B$SW'_ ()O?\D-US_L8I__ $FM:^KN:^4?^";W_)#=<_[&*?\
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MO)=%\WK:Q1117LGY:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAX:_[>?_ $FEKV)?[J_\/Z'GK^/\_P!3LOVT/^1\T/\ [!O_ +5>OH7X#_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTFKAJ=:'M<-\T.G6E3E[.M]Y]A44BL& (.0>012UY!Z 4444 %%%% !1110
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M_P#2:VKZAKY>_P"">/\ R1;6O^Q@F_\ 2:VKZAKIGN< 4445 PHHHH ****
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M^,T\,^(-+U^\OVM4O!)IMO \6QRP R\R'/R'MZ<U[[7Y:?\ !2C_ ).(@_[
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MNQG.,C/K7VQ7XH?LW?\ )P7PX_[&&Q_]'I7[7UOB(1@THHQHR<D[A1117*=
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M$WJK*&'Z&L,=1C&2JP^&1KA:CE%PENB[1117F':%%%% !1110 4444 %%%%
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MCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@
MYHYHYHYH .:.:.:.: #FCFCFCF@ YK\[O^"E$;#XI>%G*D(VC;0V."1/)D9_
M$?F*_1'FN(^*'P8\'_&33[6T\6Z,FIK:L6MYA(\4L)( .UT(.#@9&<' XX%:
MTY*$KLSJ1<HV1\[?\$\1_P 65UG_ +&"?_TFMJ^H:Q_"?@O1/A]HD.A^'M.B
MTO2[<MY=O%D\DY)+$DL3ZDDUL5U2=W<\X****0!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y_\ _!1/_DJ'AO\
M[ X_]'R5^@%?G_\ \%$_^2H>&_\ L#C_ -'R5I3^(3/<?^";W_)#=<_[&*?_
M -)K6OJ[FOE'_@F]_P D-US_ +&*?_TFM:^KN:XJOQL]&G\"#FCFCFCFLC4.
M:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.
M:.: #FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.:
M#FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH @OKM+&SFN9/N1
M(7/X#I7B-S</=7$L\AS)(Q=C[DYKT7XD:I]FTN*S4_/<-EO]U>?YX_(UYK7?
M0C9<W<XJTKNQH>']+;6M:LK%0?WT@5L=EZL?P&:^D(XUAC5$4*BC:%'0 =J\
MG^#6B^=?7>INOR0KY,9_VCR?R&/^^J];KFQ,KRMV-:,;1N%%%%<AT!1110 4
M444 %%%% !1110 5\X?\%!?^37_$/_7U9_\ I0E?1]?.'_!07_DU_P 0_P#7
MU9_^E"5I3^./J14^%GYK_L^_\E[^&O\ V,VF_P#I5'7[;U^%'P^\5?\ "">/
MO#7B7[+]N_L;4[;4?LOF>7YWDRK)LW8.W.W&<'&<X-?;3_\ !51BC!/AB%?'
M!;7\@'W'V:N_$4Y3:Y4<E&<8IIL]&_X*8/8K\!-,6YVF\.NP?91D;LB*;<?I
MMSGZCVKX=_9'69OVE/A\( Q?^TT)V_W=K;O_ !W-0?M ?M(>*?VB=>MKW7?(
MLM/LE9;+2[/<(8-V-S'))9S@98^@P!TKZ7_X)U?LYZHGB!?BCKUH]G80P/%H
ML<R[7G>1=KS@'^ (64'^(N2.!RTO8T6I";]I431]2?M'?M0>&OV<]%@DU&-]
M5U^]5FL='MW"O(!QO=B#Y<>>-V"2>@.#CX)\6?\ !1+XPZ_?/+I>HZ=X9MMY
M*6]CI\4N%[!FG$A)]QCDG@#@>0_'?XF7?Q>^+'B/Q/<S-)%=73+:(S$B*V4[
M8D'IA0,XZDD]Z_0S]E-_@I\%OAAHA/C3P7%XKO;6.YU2]FUFT^T"9UW&+<7R
MJIN*A>.A)Y)-1R1HQ3:NRN:525D[(^9_AW_P4A^)?AS4(!XH33_%VG;_ -]Y
MENEK<;<_P/$%0'ZH>GXU^B?PE^+'A_XT>";/Q/X;N6FL9R4DBD&V6WE &Z*1
M>S#(]B"""00:^./V_(_A+X\\!Q>*?#7B;PO>^,;&ZC1UTG4K:6>\@<[6#I&Q
M9RI*L&.< -ZUQW_!,CQW=Z9\4-?\)O,QTW5-.-XL1.0+B%U (],H[Y]=J^@J
M9PC.GSQ5FBHRE&?*W<]7_;V_:&^(/P5\5^%+/P9X@_L:VOK*6:X3[%;S[V60
M ',L;$<>F*X7P/\ \%%-:\/_  -O+CQ$UOXE^(3:E);6 DA2&,P>6C>;.L04
M85F90%"EN.>&:JG_  5(_P"1Z\#?]@V?_P!&BOG[]F?]GG4OVB_'C:/;W/\
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MA&K!R2LT"E*$U%NZ9]*_M[?M#?$'X*^*_"EGX,\0?V-;7UE+-<)]BMY][+(
M#F6-B./3%<+X'_X**:UX?^!MY<>(FM_$OQ";4I+:P$D*0QF#RT;S9UB"C"LS
M* H4MQSPS54_X*D?\CUX&_[!L_\ Z-%?/W[,_P"SSJ7[1?CQM'M[G^S=)LHQ
M<:EJ&S>8HR<*J#H78Y !/0,><8.D(0=)2DB92FJC43U;X4_ML_&;QM\8O".D
MW7B:W.G:KK-K9S6*:9;+&(Y)51@&\O>, DYW9K[3_:0_:Q\+?LZ6L-K>P3:S
MXENX?/M=(MVV93) >20@A$R".C$D<#J1R/P]_P""?/PZ^&_C/1?$]CJ_B6\U
M#2;A+J&.[NH#"TB\@L%@5L \X#=J[S]HK]F'PS^T=INFQZQ<7.EZEIKL;;4+
M+:7"-C?&P8893@'L01D'D@\\Y4I36FAM&-2,7W/@OQ?_ ,%%_B[X@N7.DW>F
M>%[??N2.QL4F8+S\K-.'!ZC) '(&,<BI_ /_  4:^*OAO4XW\0S6'B_3R_[V
M"YM([67;QD1O"JA3QU96ZGCIC[A^'G[&?PC^'FG+;Q^$;+Q!<;=LE[XAB2]D
MDZ<[778IX_@5>_J:^/?^"B/P+\*_"_5O"VO>%=+@T2+6#<Q7=C:+L@\R/RV5
MT0<)D.P(7 ^4<=:VA*C-\BB92C4BN9L^_?A'\5M#^-'@73_%/A^5GLKH%9(9
M<"6WE'WXG Z,#^!!!&00:^'O^"I7_(X^ _\ KPN?_1B5=_X);>)[M=6\=>'6
ME+6+06^H)$>B2!FC9A_O IG_ '!5+_@J5_R./@/_ *\+G_T8E13AR5^4N4N:
ME<T/^"5O_(0^)/\ URT__P!"N:_02OS[_P""5O\ R$/B3_URT_\ ]"N:_02L
M<1_$9I1^!!7Y:?\ !2C_ ).(@_[ =M_Z,EK]2Z_+3_@I1_R<1!_V [;_ -&2
MU>%_B$U_@/4/^"5?_-4/^X7_ .W=??1(4$DX%?A3X5^(7BGP)]J_X1KQ+K'A
M[[5M^T?V5?RVOG;<[=_EL-V-S8STW'UK0USXQ>/O$^GO8ZQXW\1ZM8O]ZVOM
M6N)HFR".59R#P2/Q-=%3#NI-RN8PK*,;6.^_;/\ &.D^.OVD/%NIZ)/'=V"O
M#:BZA8,DSQ0I&[*1P1N4@$=0 :^S/^":/@W4- ^#6KZQ>PM!!K6IF2T#C!DB
MC14\P>Q?>/\ @-? 'P=U3P!H_C"VN?B)HVK:WHD;!C;Z7<K'DYZ2*0"Z^RNA
MXZFOV/\ A9XR\*^// NE:IX+N;>?P]Y0AMX[9/+$ 0!?**8&PJ,#:1QQVQ4X
MAN,%!(=%<TG)GYL_\%'O^3CY/^P1:_\ L]?1W_!,'_DBOB7_ +&&3_TFMZ^<
M?^"CW_)Q\G_8(M?_ &>OH[_@F#_R17Q+_P!C#)_Z36]$_P" @C_&9]!?&[XY
M>&?@+X1;7?$EPQ,C>7:6%O@SW<G7:BDC@#DL> /<@'\^O'W_  4B^)_B.]G_
M .$<CTWPC8EOW*PVZW<ZKG/S/*"K'MP@X[=ZY/\ ;F^)UU\1/V@]>M6E)TWP
M^YTFTAR=J&,_OFQ_>,N_GT"CM7T%^PA^RAX2\2?#V'Q_XQTB'7[G49Y%T^SO
ME#VT4,;E"YC/#LSJ_P!X$8 P.32C3A2@IS5V-RE4ERQ/#_#?_!0OXSZ)>>=?
M:SI_B&+()M]0TV%%P,Y ,"QMSGU[#WS]Q?LQ_M?^'?VAX9-->W_L'Q;;Q^9-
MIDDF])E'#20OQN [J1D9[CFJ'[07[&O@#Q]\/]5/A[POIOASQ+:VSS:?<:/:
MK;*\B L(W2,!6#'Y22,C(P>,5^6O@/QIJ7P[\9:/XETB9H-1TNY2YB96QNP>
M4/\ LL,J1W!(IJ-.O%\JLQ<TZ4ES.Z/W9KXJ_:*_X*)6/@?5[SPY\/+&UU[4
M;5S%/K%VQ:SC<<,L2J092#GYMP7(XWBO3?VOOC*_@_\ 9AN]?T69K>Y\1Q06
M5C-G#1K<(79@1_%Y0DP0>#@YXK\S/@7\,7^,GQ9\-^$%F>WBU&XQ//& 6CA1
M3)*PSQD(C8SWQ65&E%ISGLC2K4::C$])OOV^OCA=W4DT7BZ&RC8\6\&E6A1.
M.Q>)F_,FO7?A%_P4QURTU:&S^(FCVM_I<C;6U'28C%<09/WFC)*R >@VGZ]#
M]?Z)^RO\)-!T)=)B^'V@W, 389[ZR2XN&RN"3,X+Y]P1@\C%?G=^W%^S[I?P
M*^(UA+X=B>W\.Z[ ]Q;6SL6^SRHP$L:D\E1N1ADDC?CL*UC*E5?+RV,Y*I37
M-<_5;P_X@TWQ7H=CK&D7D6H:9?1+/;W4)RDB$9!'^'4=*\__ &@/V@O#O[//
M@]=9UH->7ERQBT_2X6"RW<@QD D':J@@LQ'&1U) /S)_P3"^)=WJ&D^*? MY
M,\L%@4U*P5FR(U=BLRCT&[8V!QEV/!//SQ^W7\1KGQ]^T1K]L9F?3M!(TJUB
MW':A0?O3CIDRE^?0*.U8QH7J.#V1K*K[G,C7\7?\%$/C#X@U)I]*U.P\,6FY
MMEK8Z?%-\IQ@,TZR$D8ZC&23QT 37/VZ/%GQ ^$'BCP/XUM;?59-3MDCMM6M
M8E@E219$;]XBX1E(4\J%()Z'M[#^P1^ROX5\6>!S\0/&&DP:])=W,D.FV5XF
M^V2.-MK2,AX=BX9<-D +TR>.]_;2_9F^'%G\$]?\5:/X8L?#NMZ/''+!-H\*
MVL;AI41DDC0!&!#'G&00.>H._-24U#E,N6HX\USX/_9N_P"3@OAQ_P!C#8_^
MCTK]KZ_%#]F[_DX+X<?]C#8_^CTK]KZSQ7Q(O#[,****X3J"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#Y7_ &PO%WB*#5-.\.0"6WT"ZMUF
M8QK_ ,?4N\@J3W"X7Y?4@G/RX\I\6?!/5/ WPSL_$VMEK2]O;Z.VBTXCYHXS
M'*Q:3T8E!A>P)SSP/OQE#8R <'(S7G/Q\^'%]\4/ 9TO39(4OH;E+J(7!(5B
MH92N>QPYY_#WKU\/C.10I)675GGUL/S<T[W?0^7/AG\"9?BG\.]4U32[GRM;
MLKPQ1P2G$5PGEHVW/\+9)P>G.#CJ.Q_9=L/''AGXBRZ1/8:A9Z'MD.HPW43+
M$CA#L9<C&\L%''5<]0./8_V=_A9J?PM\)WMKJ\T;7MY<^>88'W)$H4*.<<DX
M)./:O5Z,1C6W.G\47L%+#)*,]F@HHHKR#T HHHH **** /@_]I3Q%+XL^,6I
MP1$RQV)33H$7KE?O#Z^8SU];VZ6OP9^$*@A6CT33MS <"64+D_\ ?<A/_?5?
M&GP_3_A,_CMI4LH\T7FM?:W[[@)#*V>.F :^F/VNM8?3?A+]F1L?VA?0V[ =
MU :3\LQC]*]_$PO*CA^G]?\ !/*HRTJ5CXMU+4+C5M0NKZ[D,UU=2M-+(W5G
M8DD_F35>BBO>V/+"BBB@ HHHH **** "OJ;]C/QN\L>K^$[B3<L8^WVBGL"0
MLJCVR4./=C7RS7IG[-VKOH_QE\/,&VI</);./[P>-@!_WUM/X5R8NFJE&2^9
MT4)<E1,]4_;2\*JLGA_Q)$F&;?83OZXR\?\ [5_2N^_9-\2'7/A1#9R-NETN
MYDM>>NPXD4_3YR/^ U:_:JTM=0^#.J3$9:SG@N%^OF!#^CFO-_V)]283>++
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M3*JL=K8&5*R(>G&<=LUZ179:VAYK"BBB@04444 %%%% !1110 4444 %%%%
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MSI-+O'9/+?NT4@SL)P,Y# XZ9YK7FE.FG3>IG:,9M36A]#?\.JO^JH?^6_\
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M*;MKBUM-6\-,[[V31[T!#UR LRR!1ST7&,#&*^FZ*N,I1^%DN*ENCYB\)_\
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M_L&S_P#HT5]1:C^W#\$])U"ZL;OQIY5U:RM#+'_95ZVUU)5AD0X."#TKS/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC^ [U]?\UMF&(_Y<Q^9E@Z/_ "\?R#FCFCFCFO#/5#FCFCFCF@ YHYHYHYH
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M9]TUQWQBT_6=6^$_C*R\/EAKEQI%U%9>6<.96B8*%/9B> ?4BOG3X:_\%)O
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MC?0*'N-+O4$5W"#CDIDAAR!N0LN3C->GUDTXNS-$TU=!1112&%%%% !1110
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MX5>E^C?9?YGU]3AC&T\N68-;Z\O51LWS/MMMO^)]"4445[I\@%%%% !1110
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M-H8VB96B*@HRG((QP14E8,L****0!1110 4444 %%%% !1110 4444 %%%%
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MZ@?3=>94YN;W]SNAR\ON[!1116984444 %%%% !1110 4444 %%%% !1110
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MA/2Y-1UB_AT^RCX,LS8&?0#J3[#FO O%W[9NEV,KP>'-%FU+!P+J\?R8S[A
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M/$'$BQSE0R^\:4M97WG+35]EI:U[>04445].? !1110 4444 %%%% !1110
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M1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0
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M))QJ*C&-HZLTA[1N\MC@_CE^VCX+^!/CJP\+ZI:WVJ7DD:S7K:>$862,?DW
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC1R(T<BG!5A@@UVX=+5]3DKMZ((XVFD5$4N[$*JJ,DD]A7OW@?PPOA?1(X'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&M33NMM6?0XSBO,\=AYX:M*/++?W5ZA1117O'QX4444 %%%% !1110 4444
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M_$8>6'E9[=SV*-:-576Y;YHYHYHYKD.@.:.:.:.: #FCFCFCF@ YHYHYHYH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/U)ZGFO(Q6+=9\L=(_F>CA\.J:YI;AS1S1S1S7FG:'-'-'-'- !S1S1S1S0
M<T<T<T<T '-'-'-'- !S3)9D@C:21@D:C<S,<  =Z?S7G'COQ5]MD;3K5\VZ
M']ZZG[[#M]!6D(.;LB)R4%<K:YX]OKRZ=;&4VUJIPNT#<WN2?Y5T?PU\;3W>
ML+I^H$3/,"(9\ $$#.#CU ZUYE7;_"OP[-J6O1Z@5*VEF=S/_><@X4?GD_\
MUZ[*D(*#T..$I.9[91117E'>%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5\^_M6:]XN^QZ?X=\/65W)I^H1LU]<6D+,2 <"-G
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M-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'-
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MY'TZ%?*CWRR(R(%8.J*2AR"/F SCBNNHG*G"R.>#2G*Y[U17B/\ PVM\$_\
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MR73_ .KBS^I]J\FN[N6^N9)YY#)+(<LQI^H:A/JEY)<W#[Y7//H/8>U5P"Q
M R:]*G3]FO,\^<W-CHXWFD2.-&>1R%55&22>@ KV_P"'_@=/#-G]INE#:E,O
MS'KY2_W1[^M9_P -_ /]DQIJ>H1_Z<PS%"P_U(]3_M']*]!KCKUN;W8['12I
MV]YA1117&=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM-'J0JPJ*\66^:.:.:.:P-0YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6ETX\LO):'Z^J^_Y^M<-7JJ4:D=-C@:<&>UZ/K-MK=H)[9]PZ,A^\A]"*O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:Y#J#FCFCFCF@ YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.:
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M-'$Y.;*=E93ZA=1VUM$TT\APJ*,DU[3X'^'L'AI5N[O;<:D1]X<K%[+[^_\
MDZ7A/P;9>$[7$0\Z[<8DN&'S-[#T'M70UP5:[E[L=CJITN75[A1117(= 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17A_Q_\
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MU,&\.S6VUCF(:-*0GMDYX_&OGO\ 6##6OR3_ / ?^"?;?ZF8^]O:T_\ P/\
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MZOK$1*332$_9[=O[IP<NP[@$ >N015S]J#XL3> O"\.D:7,T.LZL&43(<-!
M.&<'LQ)V@_[QZ@5\3<YR:]K X-55[6IMT/.Q.(<'R0W.\\0_';QYXEF9[GQ+
M?6Z-QY5C)]F3'IB/&1]<UR]QXJUN\D\RXUB_GDQC=)=.QQ]2:RZ*]^-.$=(I
M(\IRE+=FA_PD&J?]!*\_[_O_ (T^'Q1K-L^^'5[Z)\8W)<N#^AK,HJN5=B;L
MV_\ A./$?_0?U3_P-D_^*H_X3CQ'_P!!_5/_  -D_P#BJQ**.2/8?-+N;?\
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M VK;O.\.6D9//^B[H,?@A%=4<RC]J)SO!2Z2/AROI#]D&Q^3Q/>D=3;PJ?\
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M&_UBZ\F,G;'$HW22M_=1>Y_0=R*T-?URU\-Z+>ZI>OY=K:1-+(1UP!T'J3T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDHQ6K)E)15V?-'[8?BI-6^(%CH\3[DTFU_>#^[+*0Q'_ 'R(_P Z]5L?V?\
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MK4XNZVU9[F+XLS7'8>>%K33C+?W5_D%%%%>\?'A1110 4444 %%%% !1110
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M6**^9?&G_!0WX0^$;][2VN]4\3.C['DT6T5HP?4/*\88>ZDCFKW@7]OKX/\
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M<R!)'RH)VY..01VKT*DTT[,:=U=!1112&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MF'Q5_: \._"F^M["\2?4=1E7>UK9[2T2]BY)&,]AUQSZ9H_'3X^VGPGMXK&R
MCBU#Q#. ZVTA/EPQY^])@@\X( '/?IU^6_%EG;_V</'FH:E97GB#6[R6?_A'
MR07LB[NR2.C,69-H4JI !#IDD<-\KFN;O#\U'"M.:U;[+]7Y'Z'P[PTL8X8G
M,(M4I:12WD_TCY[>??M_C!\([W4-/LO%LMU:CQ1XCN?,7P_81$[U=5*B+:,L
MZCYG8@ EB<@XW<[\.?CUK_PU;^Q]5MI-1TV!O+-K<$I/;8."JDC@#^ZP[<8K
MV3]E7P#K=O#=^+?$BO+->QJFG->DO.D9)+N-W*J^1CU STQGU/QY\'?"GQ&0
MMK&F(;O&%OK<^7.OI\P^]CT;(]J^JRC,)U\)%8N'NO:_Q6[OUW6UD?'9_@*.
M$Q\X82:;6[5E&_9+RV=V[M-G!^&_VBO!6L+&_P#:QTNXX_<WT90K_P "&5_6
MNR_X7OX$BMS)/XGTY2O41S;R?H%R:\5\7?L91VEG>7>C^)Y$2*)Y%AO;4,>%
M)^^K#T_NU\2?LG^$]2^+'Q>7P^=8>T%U:S3RS3 R@E #G;D9/O[FO7='"S]Z
M,G;KY?@?.^TKQTE%7/OWQU^V%H6F0/!X6LY=9NR,+<W*&&W7WP<.WTPOUKP%
M=+\=_'G6K_5OL]WK4ENA:61 !'"HY$<8)"Y]$')SGU-?1GA']C_PIHLL<VLW
MEWK\JG/EM^X@/U526_\ 'J]MTO2;/0["&RT^UALK.$;8X+= B*/8"B6(HX>+
MCAE[SZLJ-*I4DI5]ET[GSA#JFB?!CP78^+/ 6HG4K(HD&JZ+>2_/.^2OG,O)
MAD5CM/&T@@>A/J_P>^,VD_%S1VEMP++5K<?Z5I[/N9.P=3QN4^N.#P>V?#OV
MAO@SXGT_QY-XO\-VMQJ\.H./-M[.W,LD+[ K*T8!WQL <G&.2&ZC/"V^N0?#
M&WTWQ/X U,G6;BT:/7+&6(2)8;FB8(JNN[;O4KNRV,*"V6&?RZIFF+PN,F\0
MO<6Z[_WHW^]J]EKYG[93R#+LSRRFL)*]67PR_E_N5++IJE)I-NR6ED_N^BN!
M^#7Q7M/BUX5_M".$VE];L(;RWY*I)C.5/=2.1W'0^I[ZOM*-:&(IJK3=XO8_
M*\5AJN#K2P]>-I1=F@HHHK8Y0HHK.U_7K#POHMYJVIW"VMA:QF265N<#Z#J2
M< #N2!4RDHIRD[)%PC*I)0@KM[(9XB\1:=X3T6ZU75;I+.PMEWR2OV] !W)/
M  Y)->$7'BVS_:L63P_I]LVCZ)I[+=WU]>HC7 /(C6$ D+G#;F)Z<?7S[Q=\
M4I/VCM8C\.SRV7A3PY:SM=IJ=XQ^0*C*GFDL$&XM@>[ 9/?A_!OA/6?'OBP^
M%/"LSVVFQLRW-Y&YV/&#M:>4K][/\*]!D =68_%5\\JRQ$/JBO"]E;1R?YI>
M?77Y?K&"X3H4<%5>8-1K)7=]8PB^KZ2D]=+Z.VG>DB^(/A1KK:MHUY))8K<2
M6]OJ]O$WV2]"'# %AAQ[<C(X)P#7N7@W]JO1M0ACA\26DNE771KBW4RP-ZG
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M@Q#FCFCFCFN$Z@YHYHYHYH .:.:.:.: #FCFCFCF@ YHYHYHYH .:.:.:.:
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M-Y;I.(..(DW @8SR1U/L!7 ?LH_!H[H_&^L0<<C3(9%_ S8_,+^)]#7N]O\
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M<]__ &&_V2+;QK_PC?Q5U'7O]%T[43-!H\-O\S30290O(6X 94; 4YZ9'?\
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MBUO+N=M3O(RTDD2N?E28*/O8P .E<7^U7^PW\/O"_P )]:\6>"[.X\/:CHL
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M/X5576M%$T]*<F?'?[%^CMKG[3W@. +N\N[DN3D<#RH9),_^.?G7[&5^5_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-'-'-'- !S1S1S1S0 <T<T<T<T '-'-'-'- !S1S1S4<TT=O&9)9%B0=68@
M?B: ).:.:Y?5/B%IMCE8-U[(/^>?"_\ ?1_H#7'ZKXZU34@4206D1_AAX/\
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M8VS6,DKR&^D= 0P4#&U&_NGK7Q?XL\,W/@WQ)J&B7LD,MU8RF*1[<DH2/0D
MXY]*]#+ZD714$]5_F<F+C)5')K0R:***]0X@HHHH [WX#_\ )8/"O_7X/Y&O
MT)K\]O@/_P E@\*_]?@_D:_0FOF\T_B1]#V,#\#]0HHHKQCT0HHHH @O+R#3
M[.>ZNIH[>U@1I99I6"I&BC)8D\   G-?".H_\%.!9_%BXMH/#MO>_#R.8P+=
M1[UU"10<>>N6V;3R1&5!QC+ U]TZMI-GKFFW6G:C:PWMA=1M#/;7"!XY4889
M64]017P?\9O^"9LL^H3ZC\-=9MX;:0L_]BZP[#R^^V*8!LCL X&.[FNBC[/5
M5#&IS_8/J;0/VJ/A)XBT1-4@^(.@VL)7<8;^]2UN%X!(,4A#YY[ Y/3-?GO^
MW9^T%HGQQ^(&E6WAJ0W>A:#!)#'?%2HN99&4R,H.#L 1 "1S@GIBLMOV!?C@
MM\8!X1B:(2[/M0U6S\LKG&_'F[MO?[N<=L\5[S\#_P#@FI)9ZI;:K\3-3MKF
M"%UD70]+=F67'.V:4@8'JJ#G/WA73&-*B^;FN8-U*BY;'6_\$T_A/=>%_A]K
M?C34;<PR^(I$BLA(,-]FBW?./0.['ZB,'O7Q'^T]K0\0?M#?$*\!W*-:N8%;
M.<B)S$#^2"OVAL[.WT^S@M+2".VM8$6**&% B1HHPJJHX     K\H/$_[$OQ
MTU_Q+JVI_P#"#-_IMW-<_-J]CGYW+<_O_>E1J*4Y3D[#J0:BHQ/M_P#9U\#M
MJ7[%.B^&XOW4NKZ!=QJ3Q\UR9F!_\BU^4-I/>^$_$<,S1&#4=,NU<Q3+]R6-
M\[6'LR\U^WWPQ\-R>#?AOX4T&5!'-I>E6ME(H(.&CA5&Y'!Y!YKY@_:H_8+C
M^*VNWOC#P1>6VE>(KK]Y>Z;=Y6VO).\BNH)20]\@JQY)4Y)FC5C&4N;9E5*;
M<5;H>R>!/VM?A5XX\,VFK?\ ":Z+HLLL:M-8:O?Q6L\#X^9"LA7=@Y&Y<@]C
M7DGQ1_X*2>!_!NN0:?X8TJX\:Q*V+J^AG^RP1C_IF61C*1SV5>F&/;Y,_P"&
M!/C?_:'V;_A$H?)\WR_M?]JVGE;<X\S'F[]N.?N[L=L\5]!? ?\ X)M)H^J6
MNL_$S4;;4EA*RIH.G,S0NW7$\A + =U48)'WB.".G0CJW<7-5EHE8]Z^.5Q:
M?'S]DKQ+?>%GDO;75=)^WV8V%9'\IUEV;3_%F(KCUK\K/@_X\'PQ^*/A?Q4T
M+7$6E7\5Q+"F-SQ XD5<]RI;'OBOW"M;6&QM8;:VAC@MX4$<<42A410,!5 X
M  P !7PG^T5_P3HN-?\ $-WXB^&EW9VJWDIEN-!O28HXF8_,8' ("Y.=C  <
MX/10J%2,;PELQU82=I+<^GM+_:D^$FK:&FJQ?$/P_#;M'YGDW5_'#< 8S@PN
M1)GVVYKPWQ-_P4P\#Z3XXMM+TK0[[6O#OF".ZUX2>1L!."\4#(6D4#GYBA//
M'3/RGI_[ GQOO;R.&;PE#81MG-Q<:K:%$P">0DK-STX!Z_C7U3^SI_P3STGX
M=ZM;>(?'MY:^)M8MV#V^FVZ$V,+CD.V\ RD'H" H[@\8'"C#5NX*566B5BU_
MP4<\66UQ^SCHC6,PGMM:U:U>*100'A\F64-S]$_.OC[]B?QMX8^'OQ\TO6_%
M>I1Z3I\%K<)%=3*Q19738 2H. 0S<GBOI#_@J;K@CT?X?:.IR9I[R[=?38L2
M+^?F-^5?,/[.?[,NI_M'6?BY-(U*'3M1T6&"6 72GR9FD9QL9@"5X0D, >F,
M<Y&U*RH^]HF95+^UT/T2^,7[9WPW^&?A&ZO],\2Z5XKUIHV%EIND7B77F28^
M7S&C)$: ]23G'0$X%?E;96?B+XT?$A8(5?5/$OB+4"Q_VYI7+,Q]%&22>@ )
MZ"O9;'_@GW\:[S6/L<OAZSL;;>5_M"?5+<P8!QNPCM)@]?N9]A7W%^RY^Q_H
M?[/-N^J7=PFO>,+B/RY=1,>V.W0]8X%/(![L>6QT4<5*E3H1?*[LJTZK]Y61
MWL?AVT^"7[/MSI=B_P#H_ASP_-B;[I=HH&9I/8LP+?C7XNZ/I[ZQJUE819\R
MZG2!<=<LP4?SK]JOV@- UOQ5\%?&6B^';0WVLZEILMG;VZR)'O,@V,-SLJCY
M2W4BOSR^$O[#_P 7]'^*7A#4-=\'_9-%M-7M+B]F_M.SDV0I,K.=JS%C\H/0
M$^U3AYJ*DY/4=:+;22/T5^,&I1>#_@KXRO(P(X]/T&[:)>WRP-L7\P!7XK^$
M])_M[Q5HVF8S]MO8;;G_ &Y%7^M?LG^TMX8U[QI\"_%^A>&;#^T];U"U6VM[
M7SHXM^Z1 _S2,JC";CR>U? _P6_8E^+OA_XO>#-5U[P@++1M/U>UO+N=M2LY
M L<<JN?E28L?N] #UHP\HQBVV.M%RDK(_44 *  ,"OR1_;ZU@:M^U#XGC5MZ
M6,-I:J1[6\;D?@SL/PK];Z_,7X__ +(/QF^(7QJ\9^(M,\'&ZTV_U*62UG.J
M62>9"#M1MK3 C*@'! //(K/#-1DVV763<;(^D?\ @F[HHTO]G5KO;AM2UBYN
M<XZA5CB_]I']:]7^/'[.GA+]H308K'Q#!)!?6NXV6J6A"W%N3U&2"&0X&5/!
MQQ@X->:>$_$#_L9_L<Z/-XIT[;KE@DD8TQ9D8S7DT\DB1ET++@!LE@3A4.,G
MBOB8_%[XY?M6^.XM$TS6]0FNK@M(FEZ3.;*SMXP1EF 8#:O'S.6/. 23@M0E
M4FYIV7<3DHQ46KGT/9_\$K].CU027?Q%NI].W,?L\.D+'-MYP/,,S#(XR=G/
MH*^4_ARWA_P?^U-H:SHT/AS3?%*1+]J82&.)+C:C2' !QA68X[' [5Z]'_P3
M/^+$L2W3ZUX62X8>:8WOKDR!NN"1 1NSWSC/?O7S;\3/ NM?#/QSJWAOQ"T;
M:S8NOVEHI?-4LZ+)G?W.'&??-==-\UTYW.>?NV?+8_<^BO,OV:/$U_XP^ ?@
M75M3<RW\^EQ++(PYD*?)O/NP4$^YKTVO):L['H)W5SD_BSK0\-_"SQCJQ;;]
MAT>\N<^Z0NP_E7X:@9.!ZU^UO[1OAO7/&7P/\8:%X;LCJ.M:C9&VM[59DBW[
MV4-\SLJCY2QY(Z8K\T/^&#OCI_T(_P#Y5['_ ./UWX:48IW9R5U*35D?I-X:
M^-GPLT#PYI6EK\2O!^VRM(K88UVU_@0+_P ]/:OG?]MG]KSP;=?#+5/ _A#6
M+7Q'JVL!8+FZL'$MM;0!@6/F#Y79MNT!2< DG'&?F'_A@[XZ?]"/_P"5>Q_^
M/UV7@/\ X)N?$[Q%=0'Q%/IGA&R8_O3+.MW<(,D?*D1*,<#/,@X(YSQ0J=*+
MYG('.I)<JB>7_LE_#&\^*GQX\+V$,#R6-A=)J>H2*/ECMX7#'=_O-M0>[BOL
M'_@J!X2NM3^'?A+Q#"C26^DZA+;S[?X!.B[6/MNB ^K"OHGX$_L_>%?V??#+
MZ5X=@>6ZN"KWNIW.#/=.!QN(& HR<*.!D]223V?C'PCI/C[POJ7A[7+1+[2=
M0A,%Q _=3T(/9@0"".00".E9SKWJ*2V1I&E:#B^I^67["OQST3X)_%2\/B6?
M[%H>M6?V.2\*EA;RAPT;-@$[/O*>.-P)X!K]#_$G[57PD\+Z+)J=Q\0-!NXE
M7(@TV]2[G8XR (HBS9^H '<BOB#XK?\ !-KQWX=U2>7P-<6OBS2&.Z&&>=+6
M\3YA\KARL;8!^\&&=I^4< \MX7_X)X_&37KX0ZCI.G^&X P!N-0U&&08.<D"
M!I"<8'4#[P]R-IQI5'SN1E%U(+EL?67P<_X*!^&?BS\4H_"+^'[S0;>^<Q:7
MJ%Q<"4W$F?E22-5_=%AG&&<9XSWKXW_;TTVXL/VI?%\DX;9=+9SPLW\2?98E
MX^A1E_X#7WU^S7^R'X7_ &>K<WX?^WO%DR;)M7GC"B)2,%($YV*>YR6;N<<#
MG_VQ_P!D=OV@K2QUSP_<V]AXNTV(P+]JRL5Y!DL(V8 E6#$E3T^8@]<C*%2G
M"I[NQ<HSE#7<\U_8#_:%\#^%O@W>^&?$WB+3_#NH:7>S7*#4KE85GAD 8&,L
M1N8-O!1<G@''-?.G[:'[1L7Q^^(,*:*\A\):*K06#.K+]H=B#).5(R-VT  \
M[5!X)(J_X>_X)Z?&75]:%G?Z-8Z'9[L-J-WJ,,D6,XR%B9W/'(!4>^*]V^,7
M[!-YH?P%TGP[\.[=-?\ $D6J)?:I<7$D=O+??NG3Y"Y"JJ%^$+="QR6Z[7I1
MJ<U]69_O)0Y;;'D7_!-;1SJ'[0=U=[<KI^B7$V['0M)%&/T<_D:]6_X*I?:/
M[-^&^W/V7SM0\STW[;?9^F^NC_8'_9P\<_!CQ'XNU3QKH?\ 8K75I!;6?^EP
M3F3YV:3_ %3MC&U.N,YXS@U[M^TM\!++]H;X;S:!+<+8:G;R"[TV]9<K%.%(
M <#DHP)4X]CR0!64JB592Z&D8/V5NI\'_P#!.SXB>%OA]\5-?;Q-K%EH27VE
M&&VN]0F6&$LLJ.R&1B%4D#(R1G;CK@'T+]N+]L?1O%/AVX^'O@/4$U.UNF U
M;5[<GRF12"((F_C!(&YA\N!@$Y./'9?^"??QKCUAK)?#MG+;!MHU%=4M_((Q
MG=@N),=ON9]J^E/AG_P3RM_!?P\\4OJVH6>L^/-3TBZL;&0*WV+3Y)8F3*DC
M<S'.#(0, G"]SI-TN?VC=S.*J<O)8^!_A3I!\0?%#P?I83S/MNL6=OM]=\R+
MC]:_<>\N/L=I//M+^4C/M7J<#.!7YI_L\_L7_%?P9\<O"&M>(_"BV>B:;J"W
M,]W_ &C:2!0@)4A4E+'Y@O0=Z_3*L<3)2:L[FM"+BG<_ ^]O)=0O)[J9MTT\
MC2N?5F.2?S-?LG\+OCO\-=3TWP7X7T?QAI=[JMYIT4=I86\XDE_=P@E'"Y\M
MP%/RN0>".:^+_CG_ ,$[?&^G>+K^_P#A[;VVOZ!=SM-!9&ZCM[BU#$DH?,*H
MRKT!#9(ZBK/P#_8!^*&F^-]$\1Z]?6?@I=+NH[Q DRW=TS(^0H6-MF#MY)?H
MW0\@;U73J13<C*FITY6L?I)7Y<?\%)/ X\.?':VUR&)4M]?TV.=V48S-&3$_
M_CBQ'\:_4>OSO_X*??$#1M4U[PKX/MD2?6=*66\NYP>8%E"A(OJP4.?0;/6N
M7#M^TT-ZUN34^2/A]X/UOXR^/O#OA6RE>>]O9([*%Y,LMO"H)9L?W40,Q ]#
M7[5^"/!^G?#_ ,(:/X;TB+R=.TNV2UA7N0HQN/JQ.23W))KXP_X)H_!3[#I.
MJ?$S4H,37N[3]*WCI$K?OI1_O, @/4;']:^ZZK$SYI<JV1-&/*N9]0HHHKD.
MD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU[ZW6?PWX6N(6D4/#;VMTLCKGE5)G;!/8X//8T_JU07MH'Z9T5YQ\</C38_
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MX9Y)ILH&\P;)4 4[N!@\#.><#7ZO4O8S]M"US[OHK\Q?^'G?Q2_Z 'A#_P
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MN%5R:[6OROUS_@F_\7=)T4W]NV@:O.%#'3[&^<3],D?O(T0D=.'Z],U]#?\
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MK3]XL]4M]:M)"JMC<DB&4;TR <9!!'!&3GYM_P"'8GQ2_P"@_P"$/_ RZ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%<KP9E;R;<'V<@EOP7![&OTC#QEBDI45=,_$,0OJLY4ZVC3L_D<W_P %%O\
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M#FSU/X7:Q!;S6BS+-#KC6S"9 VUP5!)_=;@00O/+$9/!]&_9A\1>(/!>L_\
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M]_\ 2N:E6_@Q^0Z/\1G-?\%)+&"Y_9YBGDB5YK?6+9HI".4)613@^X-?'G[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?L\^!/%\,@DT2'3+ANESI8%NZGUP!M)^JFOE[XH? [Q)\%;Z+6M.NY;O3(I
MT.J6N8Y;=L\!P#E3V# X/L3BONJJ]]8V^I6<UI=PQW-K,ACEAE4,KJ1@@@]0
M:WH8RI1=F[KL85,/"HM-&?*_P;^-%K?7&HZEJMI>^(_B1<;;2PCVC;-'CB./
M "PJ""SD]LG)Z#OO ?[,MCI7BP^*O$EU'JVK32-=M8QQ8MH;AVW$C))<*2<9
M^M> ?%KP/?? GXG6]SI$LD5H7%[IEP>2H!YC/KM/!]5(SUK[2\!^+;?QUX0T
MK7;8!8[V$.R YV..'3/LP(_"N''93AI3AB$KPW2Z*75^;?GM8]K!Y[C:5&>'
MA+EDURR?5Q6BBNR7EJ[ZLWZ***#SPHHHH **** (IH(KJ"2&:-98I%*/&ZAE
M92,$$'J"*\1UCX5:?\#Y;[QWX0<6[6R.;[3;Z8>1/:LRLT43$9C8%5*\G) '
M>O<Z^3OVPOB-)=:I:>#;.7$%L%NK[;_%(PS&A]@IW>GSCTI1P%/'U(QDM5JG
MU7FOZMW.JEF=?+H3]F_=EHXOX9>37]-=&F>6^.O&%[\5_'%]%X<TR6PM=4F4
MC2[1B!<NN<32J#M+\DDXP/4\D^N_#_\ 98TZQACNO%4[:A=$9-C;N4A3V9AA
MF/TP/KUKH_V??A;%X*\,Q:K>0@ZWJ48D=F'S01'E8QZ'&"WOQVKUN.,RR*B]
M6.!7L5*\:*]CAERQ7;\3R8TYUW[;$-RD^^NBT7W+[C)\/_#/PY8QA+/0=.MH
M5X++:IN;V+$9)^M:^I_#+PEK%L8+WPWIDZ$8W-:H''T8#(_ UT<,*P1JB]%%
M25YCJ3O>YU<L;6L?-7Q*_9 L;NWFO/!MPUE<J-PTVZD+1/[(Y^93_O9!]17B
M'AOQIK7@6ZD\(^(IM3M_#9N575-)C?9+L!^95)&5#9Y"D;AWYS7Z"5X?^TY\
M(H?&GA>;Q!I\"C7-+C,C%1S<0#EE/J5&2/Q'>O0I5XXB+PV*]Z,M#FY)X::Q
M&&?+*.IG>(O!\7[1MK96>C[=!\#Z/E+*_6W.Z[E "$11DKB)0"-QZD8'0UZ]
MX#\!Z1\.?#L&CZ/!Y4$?S22MS),_=W/<G\@, 8 KYZ_8[^(THN+WP;>2[HBK
M7=AN/W2#^\C'L<[@/9O6OJBO$EEM/!XB51J\WU\NB7:VQ[M3.,1C<+##)VI1
MUY?/JV]VV]=>^B04445N>:%%%% '&?$CX3>'?BE9V\.MV\ADMVW0W-NP29 >
MJ[L'Y3Z$=J\&^+7C67X6^$;WX:ZA:6NOQ^2G]DWCD!H+<DA?-08(ECVC:PQN
MX/8@_2OBSQ):^$/#>I:U>G_1K&!IF4'!; X4>Y. /<U\+^"]!U+X[?%">?4Y
MG99Y&N[^9?X(P0 B^G\*KZ#Z5KA<MP]:K+%58Z):_P![R?=?\ Z*F;8NC0C@
MX3;5[Q_N.^\>S_#5];,E^'_PG\2?&+4I-4O+N:.Q9_W^JWK-(\I'!"9.7(^N
M!CKVKZ-\*_ /P;X8C0#24U6Y[SZB!,6/^Z?E'X"N[TW3[;2;&"SLX4MK6!!'
M%%&,*JCH!6UH]J'D,S#(7A?K7;6Q<ZFD7:/8\VGAXPU>K*5CX"T.&$"71M/;
MC'E_9DV@>F,5S7B[]GGP+XNAD$FB0Z9<MTNM, @=3Z[0-I_%37I5%<4:LXN\
M9,WE",E9H^%?BA\#_$OP5OHM:T^[EN],BD#0ZI:YCDMVS\H< Y4]MPX/MG%=
MU\&_C1:WUQJ.I:K:7OB/XD7&VTL(]HVS1XXCCP L*@@LY/;)R>@^J+ZQM]2L
MYK2[ACN;69#'+#*H974C!!!Z@U\+?%KP/?? GXG6]SI$LD5H7%[IEP>2H!YC
M/KM/!]5(SUKT&HYG3]E4TJ+6+\^YE1JRRZI[2&L):2C>UU>]K[V?D>_^ _V9
M;'2O%A\5>)+J/5M6FD:[:QCBQ;0W#MN)&22X4DXS]:]RK \">++?QUX1TK7;
M7 CO80Y0'.QQPZ?\!8,/PK?KP,/@Z6"3ITHVUU]?,]G&YEB<SFJN)GS65EV2
M[)!11174><%%%% !1110 4444 %%%% $5Q;QW4,D,T:RPR*4>-QE64C!!'<$
M5\F?%[]D^_T^ZGU3P8AOK%B7;2V;]]#W^0G[Z^WWN@^:OKBBNFAB)X>5X&-2
ME&JK2/S!U#3KO2;I[6]M9K.Y3AX;B,HZ_4$9%5Z_3K4=(L=6B$=]96]['V2X
MB60?D0:S/^%?^%_^A;TC_P  8O\ XFO76:*VL/Q//>!?21^;%%?I/_PK_P +
M_P#0MZ1_X Q?_$T?\*_\+_\ 0MZ1_P" ,7_Q-5_:D?Y ^HR_F/S8HK])_P#A
M7_A?_H6](_\  &+_ .)H_P"%?^%_^A;TC_P!B_\ B:/[4C_('U&7\Q^;%%?I
M/_PK_P +_P#0MZ1_X Q?_$T?\*_\+_\ 0MZ1_P" ,7_Q-']J1_D#ZC+^8_-B
MBOTG_P"%?^%_^A;TC_P!B_\ B:6/P'X9C<.GAW2493D,MC$"/_':7]J1_D#Z
MC+^8_/7PGX#\0>.;P6VAZ3<Z@^<,\:8C3_><_*OXFOK_ .!G[.]I\--NKZN\
M6H^(F7"L@S%: ]0F>K'NV.G [D^RPPQV\:QQ(L<:C"J@P!]!4E<.(QU2LN5*
MR.FEA8TWS/5A1117F':%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1R&P[1P1JN[&_P"9AD#=SC-?=7[#W[*-_P# ^QOO%'BM(X_%>J0BW2SC</\
M8K?(8JS#@NS*I."0 H&>37U=153K.4>6*LA1I<KYF[L_//\ X*G?\C!\/?\
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M)HO^*QCO0(8QODM+C*?*/DY7HO3TXK\U?$TE?]RO_ U_D?L4> X2M_M4M?\
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M1110 4444 %%%% !1110 4444 %%%% #))%CC9W8(JC+,QP !W->.^,OVK/
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M/LN#7SYC/"O:K3G#TNKW_ ^NZ*PO ^M7'B+P9H6JW<7D7-]8PW$L?HSH&/\
M.MVOHH24XJ2V9\14IRI3E3ENG;[@HHHJS,**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *\5_:(^/#?"VWATC28Q)XBO(?.221,QV\18KO(/#,2
MK #V)/8'0_:.^*E_\+_!T,FE1*=2U&1K>&X?!$&%R7 [MZ=L\G.,'Y>TC7[3
M2K347\6PW6N^+[Z"/^R)KJ4S-IS?.5:0.V/F+JP4@X R1\U?)YOFGL6\)1ER
MRMK+MY>KZ?U;]&X:X>^LQCF.*AST[Z06\FG9M]HQW?>VVR?I6A^(M"\7>&[_
M /X3.VF\4_$?65%K;:2J;98H\ Q",A=D _Y:,W7J2#TKAO&/[/?CCX8_9=6L
MU?4$C19&NM)+&2V?'S @?-@<_,.,=<=*]A^!/[-^H>$?$C^*/%EPLVK0NQM8
M89C(-S AI7?^(G<<#W)/M]$U[60U\9AJ-ZZLG]E]?[SZ\S_I'@<51RZOB^7!
M2YK;R6R[1CTY(K;K>^I\1>%_VIO$VC1I#JUK;:W&O&]OW,Q^K*"/_'<UT,?[
M?GAS2=232I])E74795^S&YRH)Z#?LP"?0^HKZ1\2?"OPCXND:75O#UC=SL<M
M/Y6R5OJZX8_G7Y5?'SPGI6@_M=:IH%A:^1I,>L64*V_F.V$9(2PW$EN=Q[]Z
M^K53#5_^7=F?#N-:E]JZ/K7Q9^V%XHUF%X=%L+70488\W=]HF'T9@%'_ 'S6
M-X$^ _C3XNZK_:VLO<V-C.P>;4]2W-+*/]A6Y;V)POOVKZV\.?"7P=X3D272
M_#MC;SIRL[1>9*OT=\L/SKKJAXR%-6P\+>92PTIN]65SYFUR30?@CX9U#P#X
MITY+S1M1\RXTO5((@9)&SUN "&$D9*8=>JXP 1BN7^"?QT\4^'?'5EX<\47%
MSK-EJT\5O#+-)YCQ,[!8Y(W)^:,Y&><8Y'<'Z$^+WPCTOXM>'_LEV?LVHV^6
ML[Y5RT+'J".ZG R/8'J*^4O%T*_"W3]7^&FNV]O?/.T4]OK_ )9+6BML?;&I
M4ML+*0VT_P 3G!/!_+\TEC,+BEB7/W%L^_7EE^-F]C]NX?66YG@)8)4[U9?%
M&UN5:+VD.UE9RBK.36BM9'W517RQ^RKJWB_0?$#^&;ZTN)O#4T3W$%RR,\$;
M<$&*4?*5?/0'&>1@YS]3U]5@,8L=0591<7U3[GYUG&6/*<4\,YJ:W375/\GY
M!1117H'BA1110!GZ]K=KX;T6^U6^<QV=G"T\S*I8A5&3@#K7R7)\?M0^*/BZ
M:SUBZ;0OAT\@%ZD>%?R<':CR %B9" "J]1NQP":YCXD?%S7OBAXIO7EO)M(\
M+63&*2UBE8(8LX(< CS)'P<+_(!FK0LOAJ?CQKAE\#V2>'O"-G)'%+#=2?-%
M(PR\FT$ER0!U/8#('3\^QN:5<?45/![)[=9__:]^_P"7[3E7#^&R>@Z^9V4I
M+XM+4MK6_P"GCOI9.UO_  +I/%?P8MOC+?7NO?#W3;?2=%MXO*AED!ABU.93
MAC"F/D48*[C@,PZ#DUYOI/C3Q]\$-0.F3)<6**23I^HQ%H6]2OM[H>?6ON/P
M5X1L/ ?A;3]!TT/]CLT*HTK;F8EBS,3ZEF)].>*OZMHNGZ[:-:ZE8V^H6S=8
M;J)9$/X,"*_2\#BZM.A&GBES=_+R7DNG7S/Q?,*-"KB9U,'>,;Z=VN[\WN[:
M7V1\K:1^V T03[?X<Q*O66UNL#_OEE_K5[5/VUI?L[)IOA=!/VFN[LE?Q15'
M_H59'[;GP]\.?#7X,77B;PUI$&E:RM];PB:$MM",2&'ED[.<>E<[^P#X5T?X
MK^ _$&L^+--M]9U"TU;[/"\RD*D?DQMMV#"GECU!/->CS8-Q]IR/^OF>9;$<
MW)S?U]QCZUXV^(GQ\U(::@N-1CW!AI^GQ^7;ISPS]L#^\YX]:]8\)_LYZM\+
MM/M/&#/9ZQK^FN;J72)0/(,0!W!)#TE'WE;& 1CGK7TKI>DV.BVJVNG65O86
MR_=AMHEC0?0* *L21I-&\<B+)&X*LK#(8'J"/2N'%8J5:DZ-+W%Y;_U_3.W"
M4XT*T:U5<]NCV_K\MU9GQ9\2/C ;SQ(_BCX<W=YHT+"-]6MQ^[,DP8[99(P2
MK*00I;UX;[RY^G?@S\2?^%J>![?6GM?L=TLC6]Q&IRGF* 24[[2"#SR.G.,G
MP_XE_ 6'X4:I<^/]#>.XT;3Y([B30YE8[E:0(\8;G]V0QSD=,@YKR.;7]3US
MQN?%_@JR?3M1619&TO38]S6I"A<JJCYXF Y., L58<J6_+88S%97B9/$ZN6\
M5LU_-'_+=[OR_=*V5Y?Q!@(+ NR@M*DMT[+]W/9[-6EJELKO?]!J*Q/!>K7N
MO>$M'U'4;7[%?W5K'+/;[2OEN5!88/(Y[&MNOT*$E.*DMF?BE2FZ4Y4Y;IV^
MX***\E_:.^*E_P#"_P '0R:5$IU+49&MX;A\$087)<#NWIVSR<XP<<3B(86E
M*M4V1U8'!U<PQ,,+0^*3LC/_ &B/CPWPMMX=(TF,2>(KR'SDDD3,=O$6*[R#
MPS$JP ]B3V!\WT'Q'H7C#PUJ!\96\WBGXC:R!:6VE*NV6).L0C(79 /^6C'K
MU)!Z5YMH_B"TTNUU)_%L%WKOB^]@C&D374IF;3F^<JTF]OXBZL%(. ,X^:O<
MO@3^S?J'A'Q(_BCQ9<+-JT+L;6&&8R#<P(:5W_B)W' ]R3[?%4,9C<=C(U:.
MW;I#S?3FW:W_ $7ZOBLMRO)LLG1Q/Q?S=:KT?*NJIWLI;;77=^/>,?V>_''P
MQ^RZM9J^H)&BR-=:26,EL^/F! ^; Y^8<8ZXZ5=\+_M3>)M&C2'5K6VUN->-
M[?N9C]64$?\ CN:^W:Y3Q)\*_"/BZ5I=6\/6-W<,<M<>4$E;ZNN&/YU^IPQL
M9Q4<1'FMUZGX;+#M2<J+M?IT/![+]LRTM8>?#5PS9YC^UKM_!MO]*Y?Q9^V%
MXHUF%X=%L+70488\W=]HF'T9@%'_ 'S7S9\;]4G\'_M2:EX.T@K:>'H=5M+9
M+7&\B-UB++O;+<EFYSGGK7Z8>'/A+X.\)R)+I?AVQMYTY6=HO,E7Z.^6'YUM
M*>$I6DJ=VS*,:]1M.5K'R3X#^ _C/XN:L-6UI[FQL)V#S:GJ6XRS#_85N6XZ
M$X7W[5Z7KDF@_!'PSJ'@'Q3IR7FC:CYEQI>J01 R2-GK< $,)(R4PZ]5Q@ C
M%?3-<%\7OA'I?Q:\/_9+L_9M1M\M9WRKEH6/4$=U.!D>P/45\]F]7$XR@U0T
M:V71]T^^FWG\SZ;(7@\'BXO&7Y&]9+XHM;-/=6>^]UT;L?/?P3^.WBCP_P".
M[/PWXGN;C6K/5)XK>*6:7S'B>0A8Y$<GYHVR,\XQR.X/V#7PKXNA7X6Z?J_P
MTUVWM[YYVBGM]?\ +):T5MC[8U*EMA92&VG^)S@G@^A_LJZMXOT/7G\-7UI<
M2^&IH7N(+ED9X8VX(,4H^4JV>@.,\C!SGXO*<PJ8>HL%6O*[M?K%_P K[KSV
M_3]*XCR6CC*$LUPO+"RO9:*I&R]^/9]XVOIKNK_4]%%%?='Y"%%%% !1110
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&>UAN5
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "N(^+'Q4TOX3^&FU*^/GW<I*6EDK8>>3'Z*.[=N.Y
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M"#BV^X4445@:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLP^$P_\ ;.:K]TO@AUG+_P"1_/TWU_V;?@ ^A^5XP\4P,=8D/F6=G/R8 ?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEHW[%MTL:R:QXACR/O0:?"3^3OC_ -!KJ]-_9?\ !.G?+<V]]J##K]JN2O\
MZ+"U]!57NK..Z7YAANS#K7GRQE>6\CKCAZ4?LGDEO\#O MJNU/#=J1_TT9W/
MYLQJW)\(O!<BE3X8TP \?+;J#^8KM;JSDM&PPRIZ,.AJ'FL_;5']I_>:^SAV
M1P%U\!O 5Y]_P[ OO%++'_Z"PKF=6_97\(7RL;2;4-.?''ES!T_$,I)_.O9>
M:.:N.(K1VDR71IRWBCY<\0?LDZQ:JSZ/K-K?@<^7=1M _P! 1N!/UQ7E/BKX
M<^)/!.6UG2+BTA!Q]HQOB/H-ZY7/MG-?>-_?V^EV,]Y=S);VL"&2660X5% R
M237REXR\5:]^TAXYM_#7AN-ET>%R\0D!5=HX:XE/8#/ ]P,9-<6/X@GE]-1M
MSU):175OY=#W,FX:6;U7*4O9T8:SET2[:]7_ ,$\J\,^'6\1W4K37"Z?I=JO
MFWE]("4@3/H/O.QX51RQ]LD=L/C[XCT'3H=(\'F/PUH5N2(HXH4DGE/=Y9&4
M[G/4[0!T&, 4D'A/4?''BK_A _#T,EGH^FW#BXDFYS(IV27,V."QQA5Z $*.
MK,:GQ"^"?B/X=[Y[BW^W:6#Q?VH+(!GC>.J'Z\<]37PN3Y?B<ZQ<ZU:LXI_%
M):.3_ECV2_KI;]5X@S7 </X*EAJ-",VDN2F]8Q7\T^\I?T]V^W\)_MC>+-%A
M6'6K*TU]%_Y:M_H\Q]B5!7_QVK'CC]IKQ/\ %:UC\->%M$ETR6^'E2K;2F>X
MESU12%7:O7)QG'<#->!U[?\  O\ :&'P_G73=<LH;C2Y3@W\$*BYAR>K$#,B
M_7YAZG %?55^&<Q4'3IXQRAV:7-;UN?"4>+,G]HL1++8QJK9J3Y+]^6UOS]3
MH+/1-,_97\)QZUJD=OJGQ$U*-EL[5CNCLU(PQX],\MW/RJ<;B4^ /P3OOB)K
M1\>>-?-N[:67S[>&Z&3>O_ST<'_EF.PQ@X_NCGG_  _:I^T3^T7=RZG<>;H\
M+R3+%N(#VL38CC7_ 'LJ3C^\YZU]IP01VL,<,,:Q11J$2-%"JJ@8  '0 5\O
MEV!IXRISVM1INT8]VMY2[_TO7ZO/,VKY71]ES7Q5>*E.?\L7M"'9?\/N])!\
MO X%+117W!^2!15>[O;?3X3-=3Q6T(.#),X11^)KY9U9O'_QB^.'D6CWNE>&
MM*O6$-S'YB6IABDP9 PP)&?&1@]P,X&:\W&8U87E48N4I.R2_,]S*\K>8NI*
M=14X03;D_P EW;.A\0?LWZUX[^-%UK_B2^AN?#+3;TA$S&9HE'R0@;<*N>N#
MTSSDYKZ)AACMX8XHHUBBC4(D: !5 &  .PJ2BM,-@J.%E.5-:S=VWN98[-,3
MF,:5.N_=IKEBEHDO\WU84445W'D!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5\'?M'?MY>/_A#\:/$OA#1M(\-W.FZ:\*PRWUM</,V^".0[BLZJ>7/0#C%?
M>->/>.?V1_A-\2/%5_XD\1^$_P"T=:OBIN+G^T;N+>5147Y4E51A54< =*UI
MRA%WFKHSFI->ZSXF_P"'G?Q2_P"@!X0_\ [K_P"2:/\ AYW\4O\ H >$/_ .
MZ_\ DFOI/XJ_L4_!CPW\+_&&K:=X-^SZA8:/>75M-_:EZWERI [(V&F(." <
M$$<<U^6%>A35*IJHG)-U(;L^O/\ AYW\4O\ H >$/_ .Z_\ DFO8_P!D_P#;
M8\<?';XN0>%M?TKP_::>]E/<&33;>=)=R 8&7F<8Y]*]&\,_L-?!'4/#>DW=
MQX)\RXGM(99'_M6^&YF0$G GQU-=U\.?V6OAA\)?$B:_X4\,?V5JZQ/"+C[?
M=3?(WWAMDE9><>E<TIT;-*.IM&-2Z;9ZE<7$5K!)//(D,,:EWDD8*JJ!DDD\
M  5\C_%[_@H]X)\$WEQIOA'3IO&E[%E3>)*(+$-_LO@M)CV4 XX;G(\B_P""
M@W[3EYK/B&Z^&'AR\:#2+ A=9FA8@W4_7R"1_ G&1W;@_=Y^=_@!^SEXI_:&
M\136&A)'9Z=:X:]U:Z!\BW!Z+P,LYP<*/3)(&354Z$>7GJ$SJN_+ ]OOO^"G
MWQ(DNI&L_#?A6"V)^2.>"YE=>.["=0>?]D5W/@'_ (*B"2Z@@\:^#5A@8*)+
M[1)R=K<!CY,G4=3_ *S(QCGK77Z-_P $O_A_;V"+JWBKQ)>WHQOFLFM[:,\#
M.$:*0CG/\1ZCTR?)/C+_ ,$U_$7A>SEU+P#JI\501C<VEW:K#=@=RC9V2?3Y
M3V 8U=\/+0G]]'4^_OAW\2O#7Q6\-P:[X6U:#5M.EX+1'#Q-CE)$/S(P]& /
M0]"*^?\ ]M']JCQ9^SGJGA6V\-Z?HU['JL-Q).=5AED*F-D V[)4Q]\YSGM5
M[]A_]FN]^!?@N\U3Q"K0^*M<VM<6BRDI:0KRD9 .TODDL><9"CH<^&_\%3O^
M1@^'O_7K>_\ H<-84X1=7EW1K*4O9WV9R/\ P\[^*7_0 \(?^ =U_P#)-3V'
M_!3[XD1W<;7OAKPM<6HSOCMX+F)SP<88SL!SC^$_UKB?V$_A+X4^,GQ<U?1?
M&.E?VQID&AS7D<'VB6#;*MQ;H&W1.K'Y9'&,XYZ=*^UO$?\ P3W^#&M:9);6
M&A7F@7+ [+RQU*XD=3CCY9G=2,^WXUT3=&$N5Q,H^UDKIG*?!O\ X*.>#O'.
MI6VD^+M,D\&7TVU$O6G$]BS]/F?"M%D],@J.[#&3]>(ZR(KHP=6&0RG((]:_
M$'XT_"O4/@K\2]:\(:C,MU+82+Y=TB[5GB=0\<@&3C*L,C)P<C)Q7Z._\$\?
MB5>^.O@6VFZE.UQ=^'KUM/CDD.6-N45X@3WQN91[(*RK48QCSPV-*=1M\LCZ
MCHHHKB.D^,/VN/VS_&WP#^*T?AGP_I>@7E@VG0WADU.WG>7>[.",I,@Q\@[>
MO->*?\/._BE_T /"'_@'=?\ R36=_P %*/\ DXB#_L!VW_HR6K7[ 7P+\#_&
MR\\;Q^--$_ME--CLVM1]KG@\LR&;?_JG7.=B]<].*].,*<:2G)'"Y3<W%,G_
M .'G?Q2_Z 'A#_P#NO\ Y)K7\'?\%(_B9XA\7:'I5SH?A..WOKZ"UE:*TN0X
M5Y%4E2;@C."<9!KZE_X8.^!?_0C_ /E7OO\ X_5G2_V(/@IHVI6E_9^"_)N[
M69)X9/[5O6V.K!E.#,0<$#J*Q=2A_*:<E7N>ZT445Q'4%%%% !1110 4444
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M<VX4445F6%%%% !1110 4444 %%%% $5Q<16L$D\\B0PQJ7>21@JJH&223P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <1\<?^2*_$#_ +%[
M4/\ TFDK\0*_;_XX_P#)%?B!_P!B]J'_ *325^(%>EA=F<6(W1^[O@O_ )$[
M0O\ KP@_]%K4_B36H_#GAW5=6E&Z*PM9;IQG&51"QY_"H/!?_(G:%_UX0?\
MHM:R_BW8RZI\*?&=E"&,UQHM["@7KN:!P,?B:\[J=G0_$+6M8NO$&L7^J7TI
MFO;ZXDN9Y#U>1V+,?Q)-?L#^Q[\.K7X;_L]^$K:&!8[S4[1-5O),89Y9U#_-
M[JA1/^ 5^.5?M_\  _6(-?\ @WX&U"V96BGT2S;Y.BGR4#+^!!'X5Z.*^%(X
ML/\ $V=O1117FG<%?GG_ ,%3O^1@^'O_ %ZWO_H<-?H97YY_\%3O^1@^'O\
MUZWO_H<-=.'_ (B,:WP,Y'_@F)_R7O7_ /L6;C_TJM:_36XN(K.WEN+B5(((
MD,DDLC!510,EB3P !WK\)?"_C'7_  3J$E]X=US4M O9(C ]SI=W);2-&2&*
M%D()4E5..F5'I6EXB^*WC?QA8_8M>\8Z_K=GG/V?4=4GN(^H.=KN1U _*NNI
M0=27-<YJ=50C:QWW[8'Q*TOXK?'[Q'K6BS+<Z2GE6=M<H<K,L480N/8L&QZC
M!K[5_P"":/@^[T+X)ZIK-U&T4>M:H\EMN!&^&-%CWCZN)!_P&OE7]D?]DJ/]
MH.^DU74]?L[/P]ITRK>6%K+NOY>X7;C]VK8/SG/0X!Y(_570]#L/#.BV6DZ5
M:QV.FV4*V]O;0C"QQJ,*H_ 5E7FHQ5.)=&+<N=E^BBBN [#\M/\ @I1_R<1!
M_P!@.V_]&2UU'_!-CQ_X8\"WWQ ;Q+XDTCP\MU'8B ZK?16PEVF?=M\QANQN
M&<=,BN7_ ."E'_)Q$'_8#MO_ $9+7B'PK^!?CCXV2:E'X+T/^V7TT1M=#[7!
M!Y8?=L_UKKG.QNF>E>NHJ5%)NQY[;C5;2/U[_P"&@OA;_P!%*\(?^#ZU_P#C
ME=+X7\:>'_'%C+>>'-=TW7[2*0PR7&EWD=S&CX!VED) ."#CK@CUK\H?^&#O
MCI_T(_\ Y5['_P"/U]Q_L(?"'Q;\&?A?KFD>,=)_L?4;G67NHH?M,,^Z(P0J
M&W1.P'*,,$YXKBJ4X1C>,KG3"<I.S5CE/^"@W[.H\?\ @W_A/M#M0?$&@PDW
ML<2?-=V8Y)/JT7+#_9+^@KXP_9/^.\WP%^+%CJ<\LG_".ZABSU:!22#"3Q+C
MNT;?,.^-P_BK]C642*58 J1@@]Z_(_\ ;2_9Y/P,^)LESIEOL\)ZXSW6G[%P
MENV<R6__   D%?\ 99>I!K6A-23I2,ZT>5\\3]+OC=\8]+^#?PIU7QE/)%=)
M'"!81*V5NYW'[E 0>5)Y)'10Q[5^17A+PUXH_:+^+EOIZ3R:CXAU^\,EQ>3Y
M8(#\TDK^BJH)QZ  =A1XU^-?B7Q]X \(>$-5NO-TKPS')':C^)]Q^4OZ[$ 1
M?0#W-?H=^P5^SG_PJGP'_P );K5L%\4>(85=5=?GM+,X9(^>C-P[?1!U6K26
M'@V]V3?VTDNATOQH^'.C_"?]C/Q9X7T.!8K&PT5DW[0&F?*[Y7QU9CDGZU^9
M/P4^+FJ_ _XA6/BW2(UN;FVCEB:UE=EBG5XV7;)CJH8JV/5!R#@C]7_VMO\
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MLJG #\$D-G.,U\E_\%*/^3B(/^P';?\ HR6OU#L;^VU2SAO+*YBO+29!)%/
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M%?JO"_#GMN3'XR%T_@A_,_YGV@OQ\]$U);X:V[01AI?&]XH5W49;2T;JB_\
M3PP/)ZQ@X^\3MXV[TZYTN\FMKV"2VNX6*20S*59&'4$'O7TY^S_\#WT<Q>*_
M$D+-JTG[RUM9^3"#_P M'S_&<\ _=Z]>DG[2WPK&L::WBO3(?].M$Q>QH/\
M6PC^/ZKW_P!G_=KKX9RFG"K#%8R/^"+Z>;_O/\/NMCQCQ'.<)X# 3O?^)-?:
M_NQ[17XZ[ZN7+_LN_%Y?#>M1>%=9D#:3>S9LY)>1:W!Z 9Z*YX]FP>,DU]E5
M^7/.<BON_P#9S^*7_"R/ Z17DN_6]+VV]WN/S2+CY)?^! $'W4^HK] S'#*+
M]M'Y_P"9^182LVO9R^1ZO1117AGIA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4QR9(,^C\LO^T&')85K7@JD?:1(I2<)<DC]$:***\T[3\M/^"E'_ "<1!_V
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MX0^-&A#2O%VCQ:G!&2T$V3'/;L1]Z.12&7MD9P<#((XKXY^)W_!,$1V]S>>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]UD8$$>Q%7:*0SAK'X%_#;2[VWO+/X>^%;2[MY%FAN(-%MDDB=2"K*P3(8$
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M#O5^BFVWN*R04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD6/_ ,8K]<;*1IK."1SEVC5B?<BN'_X9]^%O_1-?"'_@AM?_ (W7>JHC4*H
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M="*]#--X?/\ 0Y,#M+Y#J***\(]0**** "BBB@ HHHH **** "BBB@ HHHH
M*Q];_P!;'_NUL5BZTW^DH!V3^IJH[@4.:.:.:.:L YHYHYHYH .:.:.:.: #
MFN(^-7_)*_$O_7H?YBNWYK@/CS<_9?A'XB?.,Q)'TS]Z5%_K6U'^)'U1G4^"
M7H?$-??W[.O_ "1?PQ_UQD_]&O7P#7Z#? .U^Q_!WPK'\PW6GF?-_M,S?UKV
MLT_A1]3RL%\;]#T"BBBOFCV0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K.\2?\B[JG_7K+_Z :T:K:E9_P!H:?=6N_R_.B:+=C.-P(SC
M\: /P2K]#?A)_P %#OASX"^%WA+PWJ&B^*)K[2-+MK&>2VM+9HF>.-58J6N
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M#K'B'X-_$6TU&*"32_$F@7H8V]U&08Y4;#(Z\<'E2.X)K]SZ\:^.'[)_P_\
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MVG%D48N*=PHHHKE.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7&X_0#)_"OTJKMS27P1.3 Q^*04445X)Z@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q9^WM^SS\0/
MC5XK\*7G@SP__;-M8V4L-P_VVW@V,T@(&)9%)X]*T/V O@'X\^"=YXW?QIH7
M]C)J4=FMJ?MD$_F&,S;_ /52-C&]>N.M?8=%;>UER>SZ&7LUS<X4445B:A11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C*&!!&0>"#2T4 ?F
MY\1_"[>"_'>N:*R[5M+IUBSWC)W1G\4*G\:]B_8W\7#3?&&J>'YGQ'J4 FB!
M_P">L63@?5&8_P# !5O]LKP6;/7M)\40I^YO(_L=P0.DB9*$^Y4D?]LZ\%\(
M^)+GP?XFTS6K3_7V,ZS!<XW 'E3[$9!^M?6K_:\-YM?B> _W%?T_(_3"BJ.B
MZQ:^(='LM3LI/-L[R%9XG]58 C/OS5ZOD]M&>^%%%%( HHHH **** "BBB@
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MP8!9EVS0YRT,H^\A^A_,$'O6>88?V<_:1V?YE82KS1Y'NCIZ***\@] ****
M"BBB@ HHHH **** "FR2"-&9CA5&33JR]8NL 0*>>K?X4UJ!FS2F:9Y#U8YI
MG-'-'-: '-'-'-'- !S1S1S1S0 <T<T<UY9\?/B@O@'PR;*RFVZYJ*,D&T_-
M"G1I?;T'OSV-:4Z<JDE".[(G-4XN3/#OVC?B$/&'C(Z=:2[],TDM"A4\22_\
MM&^F0%'^Z2.M<9\-?!-Q\0O&VEZ' &"W$N9I!_RSB7EV_!0<>Y KF><U]D_L
MG_"\^%_##^)[^+;J6K(! K#F.VSD?]]G#?0+[U])6G'!T+1]%ZGB4XO$5;L]
MVL[.'3[."UMHUAMX(UBBC7HJJ, #V %3T45\D>\%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>tcrt-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-04-01T07:06:12.7365+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://alaunos.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:tcrt="http://alaunos.com/20231231" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" namespace="http://xbrl.sec.gov/ecd/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/CoverPage" id="CoverPage">
        <link:definition>100000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/BalanceSheets" id="BalanceSheets">
        <link:definition>100010 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2" id="DisclosureDebtScheduleOfDebtDetails2">
        <link:definition>100020 - Disclosure - Debt - Schedule of Debt (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails2" id="DisclosureLeasesOperatingLeaseLiabilitiesDetails2">
        <link:definition>100030 - Disclosure - Leases - Operating Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>100040 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations" id="StatementsOfOperations">
        <link:definition>100050 - Statement - STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity" id="StatementStatementsOfChangesInStockholdersEquity">
        <link:definition>100060 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>100070 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/Organization" id="Organization">
        <link:definition>995455 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/Financings" id="Financings">
        <link:definition>995465 - Disclosure - Financings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>995475 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>995485 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
        <link:definition>995495 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/AccruedExpenses" id="AccruedExpenses">
        <link:definition>995505 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>995515 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/Leases" id="Leases">
        <link:definition>995525 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>995535 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/Warrants" id="Warrants">
        <link:definition>995545 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureRestructuring1" id="DisclosureRestructuring1">
        <link:definition>995555 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>995565 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/StockOptionPlan" id="StockOptionPlan">
        <link:definition>995575 - Disclosure - Stock Option Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
        <link:definition>995585 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/JointVenture" id="JointVenture">
        <link:definition>995595 - Disclosure - Joint Venture</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995605 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995615 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995625 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>995635 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
        <link:definition>995645 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/AccruedExpensesTables" id="AccruedExpensesTables">
        <link:definition>995655 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/LeasesTables" id="LeasesTables">
        <link:definition>995665 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>995675 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/StockOptionPlansTables" id="StockOptionPlansTables">
        <link:definition>995685 - Disclosure - Stock Option Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/OrganizationAdditionalInformationDetail" id="OrganizationAdditionalInformationDetail">
        <link:definition>995695 - Disclosure - Organization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail" id="FinancingsAdditionalInformationDetail">
        <link:definition>995705 - Disclosure - Financings - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>995715 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>995725 - Disclosure - Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail">
        <link:definition>995735 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation Expense Included in Statement of Operations (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail">
        <link:definition>995745 - Disclosure - Summary of Significant Accounting Policies - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail">
        <link:definition>995755 - Disclosure - Summary of Significant Accounting Policies - Earning Per share Basic and Diluted (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail">
        <link:definition>995765 - Disclosure - Summary of Significant Accounting Policies - Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails" id="DisclosureDebtScheduleOfDebtDetails">
        <link:definition>995775 - Disclosure - Debt - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" id="DisclosureDebtAdditionalInformationDetails">
        <link:definition>995785 - Disclosure - Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail" id="DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail">
        <link:definition>995795 - Disclosure - Property and Equipment, net - Component of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail" id="PropertyAndEquipmentNetAdditionalInformationDetail">
        <link:definition>995805 - Disclosure - Property and Equipment, net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails" id="DisclosureAccruedExpensesComponentOfAccruedExpensesDetails">
        <link:definition>995815 - Disclosure - Accrued Expenses - Component of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>995825 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails" id="LeasesAdditionalInformationDetails">
        <link:definition>995835 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" id="DisclosureLeasesComponentsOfLeaseExpenseDetails">
        <link:definition>995845 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails" id="DisclosureLeasesOperatingLeaseLiabilitiesDetails">
        <link:definition>995855 - Disclosure - Leases - Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>995865 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" id="DisclosureWarrantsAdditionalInformationDetails">
        <link:definition>995875 - Disclosure - Warrants - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" id="DisclosureRestructuringAdditionalInformationDetails">
        <link:definition>995885 - Disclosure - Restructuring - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail" id="DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail">
        <link:definition>995895 - Disclosure - Income Taxes - Significant Component of Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
        <link:definition>995905 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail">
        <link:definition>995915 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail" id="PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail">
        <link:definition>995925 - Disclosure - Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail" id="StockOptionPlanAdditionalInformationDetail">
        <link:definition>995935 - Disclosure - Stock Option Plan - Additional information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail" id="DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail">
        <link:definition>995945 - Disclosure - Stock Option Plan - Stock Option Activity Under Stock Option Plan (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail" id="DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail">
        <link:definition>995955 - Disclosure - Stock Option Plan - Summary of Non-Vested Restricted Stock (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/EmployeeBenefitPlanAdditionalInformationDetail" id="EmployeeBenefitPlanAdditionalInformationDetail">
        <link:definition>995965 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails" id="DisclosureJointVentureAdditionalInformationDetails">
        <link:definition>995975 - Disclosure - Joint Venture - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>995985 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/BalanceSheets" xlink:href="tcrt-20231231.xsd#BalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2" xlink:href="tcrt-20231231.xsd#DisclosureDebtScheduleOfDebtDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails2" xlink:href="tcrt-20231231.xsd#DisclosureLeasesOperatingLeaseLiabilitiesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations" xlink:href="tcrt-20231231.xsd#StatementsOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows" xlink:href="tcrt-20231231.xsd#StatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail" xlink:href="tcrt-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails" xlink:href="tcrt-20231231.xsd#DisclosureDebtScheduleOfDebtDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail" xlink:href="tcrt-20231231.xsd#DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails" xlink:href="tcrt-20231231.xsd#DisclosureAccruedExpensesComponentOfAccruedExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails" xlink:href="tcrt-20231231.xsd#DisclosureLeasesOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail" xlink:href="tcrt-20231231.xsd#DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail" xlink:href="tcrt-20231231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical" xlink:href="tcrt-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity" xlink:href="tcrt-20231231.xsd#StatementStatementsOfChangesInStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/OrganizationAdditionalInformationDetail" xlink:href="tcrt-20231231.xsd#OrganizationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail" xlink:href="tcrt-20231231.xsd#FinancingsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="tcrt-20231231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="tcrt-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail" xlink:href="tcrt-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail" xlink:href="tcrt-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail" xlink:href="tcrt-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="tcrt-20231231.xsd#DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail" xlink:href="tcrt-20231231.xsd#PropertyAndEquipmentNetAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="tcrt-20231231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails" xlink:href="tcrt-20231231.xsd#LeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:href="tcrt-20231231.xsd#DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="tcrt-20231231.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" xlink:href="tcrt-20231231.xsd#DisclosureWarrantsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail" xlink:href="tcrt-20231231.xsd#IncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail" xlink:href="tcrt-20231231.xsd#PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail" xlink:href="tcrt-20231231.xsd#StockOptionPlanAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail" xlink:href="tcrt-20231231.xsd#DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails" xlink:href="tcrt-20231231.xsd#DisclosureJointVentureAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="tcrt-20231231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/CoverPage" xlink:href="tcrt-20231231.xsd#CoverPage" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/Organization" xlink:href="tcrt-20231231.xsd#Organization" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/Financings" xlink:href="tcrt-20231231.xsd#Financings" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:href="tcrt-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureDebt" xlink:href="tcrt-20231231.xsd#DisclosureDebt" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNet" xlink:href="tcrt-20231231.xsd#PropertyAndEquipmentNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/AccruedExpenses" xlink:href="tcrt-20231231.xsd#AccruedExpenses" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/RelatedPartyTransactions" xlink:href="tcrt-20231231.xsd#RelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/Leases" xlink:href="tcrt-20231231.xsd#Leases" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingencies" xlink:href="tcrt-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/Warrants" xlink:href="tcrt-20231231.xsd#Warrants" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureRestructuring1" xlink:href="tcrt-20231231.xsd#DisclosureRestructuring1" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/IncomeTaxes" xlink:href="tcrt-20231231.xsd#IncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/StockOptionPlan" xlink:href="tcrt-20231231.xsd#StockOptionPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/EmployeeBenefitPlan" xlink:href="tcrt-20231231.xsd#EmployeeBenefitPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/JointVenture" xlink:href="tcrt-20231231.xsd#JointVenture" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="tcrt-20231231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tcrt-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="tcrt-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureDebtTables" xlink:href="tcrt-20231231.xsd#DisclosureDebtTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNetTables" xlink:href="tcrt-20231231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/AccruedExpensesTables" xlink:href="tcrt-20231231.xsd#AccruedExpensesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/LeasesTables" xlink:href="tcrt-20231231.xsd#LeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/IncomeTaxesTables" xlink:href="tcrt-20231231.xsd#IncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/StockOptionPlansTables" xlink:href="tcrt-20231231.xsd#StockOptionPlansTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" xlink:href="tcrt-20231231.xsd#DisclosureRestructuringAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail" xlink:href="tcrt-20231231.xsd#DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20231231/taxonomy/role/EmployeeBenefitPlanAdditionalInformationDetail" xlink:href="tcrt-20231231.xsd#EmployeeBenefitPlanAdditionalInformationDetail" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AdditionalLoansCommitted" xlink:label="tcrt_AdditionalLoansCommitted"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_FederalAndStateMember" xlink:label="tcrt_FederalAndStateMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IncomeTaxesTable" xlink:label="tcrt_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ClinicalExpenses" xlink:label="tcrt_ClinicalExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember" xlink:label="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MilestonePayment" xlink:label="tcrt_MilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AnnualLicenseFees" xlink:label="tcrt_AnnualLicenseFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts" xlink:label="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_WarrantsPolicyTextBlock" xlink:label="tcrt_WarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AtTheMarketOfferingMember" xlink:label="tcrt_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LicensedProductsMember" xlink:label="tcrt_LicensedProductsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OtherIncomeExpenseMember" xlink:label="tcrt_OtherIncomeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AnnualGrantMember" xlink:label="tcrt_AnnualGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ConditionalMilestoneAmountPayable" xlink:label="tcrt_ConditionalMilestoneAmountPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NumberOfDaysOptionExerciable" xlink:label="tcrt_NumberOfDaysOptionExerciable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MaximumAmountOfRoyaltyPayable" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SiliconValleyBankMember" xlink:label="tcrt_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" xlink:label="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TcellReceptorMember" xlink:label="tcrt_TcellReceptorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PerformanceBasedPaymentsMember" xlink:label="tcrt_PerformanceBasedPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MilestonePaymentMadeOne" xlink:label="tcrt_MilestonePaymentMadeOne"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AggregateAmountPotentiallyReimburseableAmount" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_UnderwritingAgreementMember" xlink:label="tcrt_UnderwritingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OperatingLossCarryforwardsResearchExpirationDates" xlink:label="tcrt_OperatingLossCarryforwardsResearchExpirationDates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MaximumAmountOfAdditionalMilestonesPayable" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SubleaseArea" xlink:label="tcrt_SubleaseArea"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PotentialBenchmarkPaymentsPayable" xlink:label="tcrt_PotentialBenchmarkPaymentsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsLeaseLiability" xlink:label="tcrt_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTypeAxisAxis" xlink:label="tcrt_AgreementTypeAxisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsAxis" xlink:label="us-gaap_DividendsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MaMember" xlink:label="tcrt_MaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_HogueMember" xlink:label="tcrt_HogueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LabEquipmentMember" xlink:label="tcrt_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_GainLossOnModificationOfLease" xlink:label="tcrt_GainLossOnModificationOfLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ContributionPayableOnPerAnnumBasis" xlink:label="tcrt_ContributionPayableOnPerAnnumBasis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PreStockSplitSharesAuthorized" xlink:label="tcrt_PreStockSplitSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsDepreciation" xlink:label="tcrt_DeferredTaxAssetsDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TenthScheduledPaymentMember" xlink:label="tcrt_TenthScheduledPaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_FinancingArrangementsDisclosureTextBlock" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AnnualCashRetainer" xlink:label="tcrt_AnnualCashRetainer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AccrualsPriorToFirstMarketingApproval" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PatentAndTechnologyLicenseAgreementMember" xlink:label="tcrt_PatentAndTechnologyLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EdenBiocellMember" xlink:label="tcrt_EdenBiocellMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_UnderwritingAgreementWithJefferiesMember" xlink:label="tcrt_UnderwritingAgreementWithJefferiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DescriptionOfFirstBenchmarkPayable" xlink:label="tcrt_DescriptionOfFirstBenchmarkPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ShareSubscriptionAgreementMember" xlink:label="tcrt_ShareSubscriptionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NonVestedStockMember" xlink:label="tcrt_NonVestedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PaymentTypeAxis" xlink:label="tcrt_PaymentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IntrexonCorporationMember" xlink:label="tcrt_IntrexonCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EligibilityOfBonusPercentage" xlink:label="tcrt_EligibilityOfBonusPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SecuritiesPurchaseAgreementMember" xlink:label="tcrt_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_InitialGrantMember" xlink:label="tcrt_InitialGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CommonStockOptionsMember" xlink:label="tcrt_CommonStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankingAndThriftInterestAbstract" xlink:label="us-gaap_BankingAndThriftInterestAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SvbWarrantsMember" xlink:label="tcrt_SvbWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome" xlink:label="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DueDateDomain" xlink:label="tcrt_DueDateDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EightScheduledPaymentMember" xlink:label="tcrt_EightScheduledPaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OfficeAndComputerEquipmentMember" xlink:label="tcrt_OfficeAndComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TerminationCosts" xlink:label="tcrt_TerminationCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MaximumRoyaltyAmount" xlink:label="tcrt_MaximumRoyaltyAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MdAndersonAgreementAndWorldwideLicenseMember" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_WarrantsDisclosureAbstract" xlink:label="tcrt_WarrantsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EarningPerShareBasicAndDilutedTable" xlink:label="tcrt_EarningPerShareBasicAndDilutedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AccruedPreclinicalServicesCurrent" xlink:label="tcrt_AccruedPreclinicalServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AdvanceNoticePeriodForTerminationAgreement" xlink:label="tcrt_AdvanceNoticePeriodForTerminationAgreement"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SeriesOnePreferredStockMember" xlink:label="tcrt_SeriesOnePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SharesAuthorized" xlink:label="tcrt_SharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseIncome" xlink:label="us-gaap_LeaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TriArmMember" xlink:label="tcrt_TriArmMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NonOperatingIncomeExpenseInducementOfWarrants" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OneTimeBenchmarkPaymentsMember" xlink:label="tcrt_OneTimeBenchmarkPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OrganizationalChangesPolicyTextBlock" xlink:label="tcrt_OrganizationalChangesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTerminationDate" xlink:label="tcrt_AgreementTerminationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DuneLakeCapitalMember" xlink:label="tcrt_DuneLakeCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IncomeTaxesLineItems" xlink:label="tcrt_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ObligationsDueUnderContract" xlink:label="tcrt_ObligationsDueUnderContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MdAndersonMember" xlink:label="tcrt_MdAndersonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_StrategicAdvisorName" xlink:label="tcrt_StrategicAdvisorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MilestonePaymentsMaximumAmount" xlink:label="tcrt_MilestonePaymentsMaximumAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_StockOfferedDuringPeriodShares" xlink:label="tcrt_StockOfferedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EmployeeStockOptionAndRestrictedStockMember" xlink:label="tcrt_EmployeeStockOptionAndRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ClassOfWarrantOrRightAxisAxis" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PaymentUnderLicenseAgreement" xlink:label="tcrt_PaymentUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" xlink:label="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IncreaseDecreaseInOperatingDeposits" xlink:label="tcrt_IncreaseDecreaseInOperatingDeposits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AdditionalPaidInCapitalCommonStockMember" xlink:label="tcrt_AdditionalPaidInCapitalCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="us-gaap_PostemploymentBenefitsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AmountOfPrepaymentsPremium" xlink:label="tcrt_AmountOfPrepaymentsPremium"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AggregatePotentialBenchmarkPayments" xlink:label="tcrt_AggregatePotentialBenchmarkPayments"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" xlink:label="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EquityDistributionAgreementMember" xlink:label="tcrt_EquityDistributionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ScheduleOfEquityTable" xlink:label="tcrt_ScheduleOfEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MinimumRoyaltiesAmountPayable" xlink:label="tcrt_MinimumRoyaltiesAmountPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MdAndersonLicenseMember" xlink:label="tcrt_MdAndersonLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AresTradingMember" xlink:label="tcrt_AresTradingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AccruedManufacturingCostsCurrent" xlink:label="tcrt_AccruedManufacturingCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EdenBioCellMember" xlink:label="tcrt_EdenBioCellMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AggregateBenchmarkPaymentsPayable" xlink:label="tcrt_AggregateBenchmarkPaymentsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_FairValueOfWarrants" xlink:label="tcrt_FairValueOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTerminationNoticePeriod" xlink:label="tcrt_AgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ClassOfWarrantOrRightWarrantsExercised" xlink:label="tcrt_ClassOfWarrantOrRightWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTypeAxis" xlink:label="tcrt_AgreementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EarningPerShareBasicAndDilutedLineItems" xlink:label="tcrt_EarningPerShareBasicAndDilutedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandTwelveEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ZiopharmMember" xlink:label="tcrt_ZiopharmMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TaxRelaxationOnTaxableIncome" xlink:label="tcrt_TaxRelaxationOnTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_RoyaltiesAmountPayableThereafter" xlink:label="tcrt_RoyaltiesAmountPayableThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PercentageOfPrepaymentsPremium" xlink:label="tcrt_PercentageOfPrepaymentsPremium"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PostStockSplitSharesAuthorized" xlink:label="tcrt_PostStockSplitSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ConsultantsMember" xlink:label="tcrt_ConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NewWarrantsMember" xlink:label="tcrt_NewWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AnnualExpenseIncurred" xlink:label="tcrt_AnnualExpenseIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_UncategorizedAbstract" xlink:label="tcrt_UncategorizedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CantorMember" xlink:label="tcrt_CantorMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TermLoanMember" xlink:label="tcrt_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OperatingLossCarryforwardsExpirationDatesState" xlink:label="tcrt_OperatingLossCarryforwardsExpirationDatesState"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_UnderwriterParOrStatedValuePerShare" xlink:label="tcrt_UnderwriterParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IncreaseDecreaseInRightOfUseAsset" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsResearchExpensesCapitalized" xlink:label="tcrt_DeferredTaxAssetsResearchExpensesCapitalized"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IssuanceOfCommonStockNetOfExpensesInShares" xlink:label="tcrt_IssuanceOfCommonStockNetOfExpensesInShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PublicOfferingNetPricePerShare" xlink:label="tcrt_PublicOfferingNetPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ReductionInRightOfUseAssetsForModificationAndTermination" xlink:label="tcrt_ReductionInRightOfUseAssetsForModificationAndTermination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EquityLineItems" xlink:label="tcrt_EquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NonVestedRestrictedStockMember" xlink:label="tcrt_NonVestedRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNameOfPlaintiff" xlink:label="us-gaap_LossContingencyNameOfPlaintiff"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_GainLossOnOperatingLeaseModificationAndTermination" xlink:label="tcrt_GainLossOnOperatingLeaseModificationAndTermination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OperatingLeaseArea" xlink:label="tcrt_OperatingLeaseArea"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TwoThousandTwelveStockOptionPlanMember" xlink:label="tcrt_TwoThousandTwelveStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CARProductsMember" xlink:label="tcrt_CARProductsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AggregateMinimumAnnualRoyaltiesPaid" xlink:label="tcrt_AggregateMinimumAnnualRoyaltiesPaid"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LeaseTerminationDate" xlink:label="tcrt_LeaseTerminationDate"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AccruedClinicalExpensesCurrent" xlink:label="tcrt_AccruedClinicalExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PostMarketingApprovalMember" xlink:label="tcrt_PostMarketingApprovalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_BonusDepreciationEligibilityPercentage" xlink:label="tcrt_BonusDepreciationEligibilityPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_InitialBenchmarkPaymentDue" xlink:label="tcrt_InitialBenchmarkPaymentDue"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_HoustonTexasMember" xlink:label="tcrt_HoustonTexasMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LicenseAgreementCommencingDate" xlink:label="tcrt_LicenseAgreementCommencingDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AdditionalNumberOfWarrantsIssued" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AccruedConsultingFeesCurrent" xlink:label="tcrt_AccruedConsultingFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LaboratoryEquipmentMember" xlink:label="tcrt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IncreaseDecreaseInLeaseLiabilities" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SubleaseTermCommencedEndDateAmendment" xlink:label="tcrt_SubleaseTermCommencedEndDateAmendment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCallOrExerciseFeatures" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xlink:label="tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract" xlink:label="tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:label="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DueDateAxis" xlink:label="tcrt_DueDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EmployeesMember" xlink:label="tcrt_EmployeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxLiabilityRightOfUseAsset" xlink:label="tcrt_DeferredTaxLiabilityRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" xlink:label="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_WarrantsExpirationDate" xlink:label="tcrt_WarrantsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_BlackScholesModelMember" xlink:label="tcrt_BlackScholesModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PlacementAgentFeesAndOtherRelatedExpenses" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:label="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CRADAAgreementMember" xlink:label="tcrt_CRADAAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_WarrantTextBlock" xlink:label="tcrt_WarrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ClassOfWarrantOrRightDomainDomain" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LicenseExpense" xlink:label="tcrt_LicenseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies" xlink:label="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalLoansCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional loans committed.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalLoansCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Loans Committed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalLoansCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Loans Committed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FederalAndStateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal and State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FederalAndStateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Federal and State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FederalAndStateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arrangements and Non-arrangement Transactions [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MD Anderson Related to the 2015 R&amp;D Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">M D Anderson License and the Two Thousand Fifteen Research and Development Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">M D Anderson license and the two thousand fifteen research and development agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One time milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual License Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Annual License fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vest in period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets capitalized acquisition costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Capitalized Acquisition Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized acquisition costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">At The Market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At The Market Offering Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicensedProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Licensed Products Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicensedProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licensed Products [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OtherIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other income expense member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OtherIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OtherIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Income Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense related to non-vested restricted stock arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual Grant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Grant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ConditionalMilestoneAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conditional milestone amount payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ConditionalMilestoneAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conditional Milestone Amount Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ConditionalMilestoneAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conditional milestone amount payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments and Joint Ventures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NumberOfDaysOptionExerciable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NumberofDaysOptionExerciable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NumberOfDaysOptionExerciable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Days Option Exerciable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum royalty amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount of Royalty Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of royalty payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on lease modification and termination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on lease termination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Termination of Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Silicon Valley Bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Silicon Valley Bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Silicon valley bank.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Description Of Option To Terminate The Agreement Upon Not Meeting Certain Milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Option To Terminate The Agreement Upon Not Meeting Certain Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Description Of option To terminate Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Relationship to Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TcellReceptorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tcell Receptor Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TcellReceptorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">T-Cell Receptor [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TcellReceptorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">T-Cell Receptor [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PerformanceBasedPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance based payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PerformanceBasedPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Payments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePaymentMadeOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment made One.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePaymentMadeOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Made One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePaymentMadeOne_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment made</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in licensing agreement (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Portion of income payable to related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Sub licensing Income Payable to Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of sub licensing income, attributable to related party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Subscribed but Unissued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Repurchase of shares of restricted common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of Shares of Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of Common Stock to Underwriters</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate Amount Potentially Reimburseable Amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Amount Potentially Reimburseable Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reimbursement of historical costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwritingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwritingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwritingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities, non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unamortized discount on Loan and Security Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized discount on Loan and Security Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Severance [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Severance [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Fund Long-Term Loans to Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to Fund Long-term Loans to Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLossCarryforwardsResearchExpirationDates_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Loss Carryforwards Research Expiration Dates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLossCarryforwardsResearchExpirationDates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Research Expiration Dates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLossCarryforwardsResearchExpirationDates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected additional milestones payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount of Additional Milestones Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of additional milestones payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SubleaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease Area</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SubleaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Area</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SubleaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease area.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, net of expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding options issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PotentialBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Potential Benchmark Payments Payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PotentialBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Benchmark Payments Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PotentialBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Potential Benchmark Payments Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value of stock option granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">DeferredTaxAssetsLeaseLiability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs and Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTypeAxisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement Type Axis Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTypeAxisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Type Axis [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MA [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Boston, MA [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_HogueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mr. Hogue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_HogueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hogue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_HogueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hogue Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock, shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Less: long-term debt, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Debt, Current Maturities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Component of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets operating loss carryforwards with expire date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term B Tranche [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment estimated useful life, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnModificationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain (loss) on modification of lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnModificationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) On Modification Of Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnModificationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain (Loss) On Modification Of Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Recognition in exchange of Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of payment terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Frequency of Payment and Payment Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ContributionPayableOnPerAnnumBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contribution payable on per annum basis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ContributionPayableOnPerAnnumBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contribution Payable on Per Annum Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ContributionPayableOnPerAnnumBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contribution payable on per annum basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PreStockSplitSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre stock split shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PreStockSplitSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Stock Split Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PreStockSplitSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre Stock Split Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Federal income tax at statutory rates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets depreciation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TenthScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenth Scheduled Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TenthScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenth Scheduled Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TenthScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenth Scheduled Payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of securities into which the class of warrant converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Includes disclosures related to financing receivables and financing guarantees in which the company is the guarantor.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Arrangements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposits Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net share based employee compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction-in-process</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualCashRetainer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual cash retainer received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualCashRetainer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Cash Retainer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualCashRetainer_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual cash retainer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments due prior to the first marketing approval for TCR products.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accruals Prior to First Marketing Approval</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments due prior to the first marketing approval</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PatentAndTechnologyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent And Technology License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PatentAndTechnologyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patent And Technology License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PatentAndTechnologyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent and technology license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EdenBiocellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eden Biocell.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EdenBiocellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eden Biocell [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Issuance Costs, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwritingAgreementWithJefferiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting Agreement With Jefferies Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwritingAgreementWithJefferiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Agreement with Jefferies [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwritingAgreementWithJefferiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting Agreement with Jefferies [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplementary disclosure of cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting Agreement Provides for Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement with Individual, Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfFirstBenchmarkPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Description Of First Benchmark Payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfFirstBenchmarkPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of First Benchmark Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DescriptionOfFirstBenchmarkPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Description Of First Benchmark Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Severance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term A Tranche [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition from Collaboration Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">the "2020 Plan" [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined benefit plan contributions by employer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareSubscriptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Subscription Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareSubscriptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Subscription Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Vested Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Vested Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility, interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liability statement of financial position [extensible list]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options available for future grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation nondeductible expense federal rate change.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Federal Rate Change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal/state rate change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock $0.001 par value; 34,666,667 shares authorized, 16,012,522 shares issued and outstanding at December 31, 2023 and 28,000,000 shares authorized,16,027,384 shares issued and outstanding at December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayments of Long-Term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment Type Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the disposal of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale of Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment Type Domain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Uncertain Tax Positions Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IntrexonCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intrexon Corporation Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IntrexonCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intrexon Corporation/Precigen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IntrexonCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrexon Corporation/Precigen</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IntrexonCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intrexon Corporation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EligibilityOfBonusPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eligibility of bonus percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EligibilityOfBonusPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eligibility Of Bonus Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EligibilityOfBonusPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eligible bonus percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assumptions Expected volatility Rate Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities Purchase Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InitialGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Grant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InitialGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Grant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InitialGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases, Operating [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock awards (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan and Security Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income , net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BankingAndThriftInterestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Banking and Thrift, Interest [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SvbWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">SVB Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SvbWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Svb Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SvbWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Svb Warrants [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SvbWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Svb Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate limitation on adjusted taxable income.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Limitation On Adjusted Taxable Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Relaxation of Adjusted taxable income, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DueDateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Due Date Domain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DueDateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due date [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EightScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eight Scheduled Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EightScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eighth Scheduled Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EightScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eighth Scheduled Payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares awarded</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets operating loss carryforwards without expire date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OfficeAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and Computer Equipment [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OfficeAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office And Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OfficeAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and computer equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on sale of equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on disposal of equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Property Plant Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additonal tranche facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TerminationCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TerminationCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Termination Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TerminationCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Termination costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumRoyaltyAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of royalty.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumRoyaltyAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Royalty Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumRoyaltyAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum royalty amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, Operating Lease, Liability, Maturity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, initial maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date Range, Start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with a public offering, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of stock consideration received on transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MD Anderson Agreement and Worldwide License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MD Anderson Agreement and Worldwide License.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MD Anderson Agreement and Worldwide License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss) per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings per share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commitments and contingencies (Note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Disclosure Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impact of Topic 606 Adoption on Financial Statements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases other than short-term lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EarningPerShareBasicAndDilutedTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Earning Per share Basic and Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EarningPerShareBasicAndDilutedTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earning Per share Basic and Diluted [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed asset impairment charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tangible Asset Impairment Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Tangible Asset Impairment Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedPreclinicalServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued preclinical services current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedPreclinicalServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Preclinical Services Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedPreclinicalServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preclinical services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdvanceNoticePeriodForTerminationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notice period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdvanceNoticePeriodForTerminationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advance Notice Period for Termination Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdvanceNoticePeriodForTerminationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance notice period for termination agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SeriesOnePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series 1 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SeriesOnePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series 1 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SeriesOnePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series 1 Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The maximum number of shares permitted to be issued by an entity's charter and bylaws.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of authorized capital stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lease Income, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second anniversary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss) per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings per share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TriArmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tri Arm</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TriArmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tri Arm [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Operating Income Expense Inducement Of Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Operating Income Expense Inducement Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash inducement warrant expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-cash inducement warrant expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-cash inducement warrant expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Options and Restricted Stock Awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options And Restricted Stock Awards Text Block [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OneTimeBenchmarkPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">One Time Benchmark Payments Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OneTimeBenchmarkPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One Time Benchmark Payments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OrganizationalChangesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organizational Changes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OrganizationalChangesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organizational Changes [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OrganizationalChangesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for organizational changes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement termination date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Termination Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Termination Date of CRADA Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of employee stock options (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DuneLakeCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dune Lake Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DuneLakeCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dune Lake Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DuneLakeCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dune Lake Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES, PREFERRED STOCK AND STOCKHOLDERS' EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Term (Years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Warrants or Options Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ObligationsDueUnderContract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Obligations due under contract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ObligationsDueUnderContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Obligations Due Under Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ObligationsDueUnderContract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Obligations due under contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MD Anderson [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MD Anderson [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MD Anderson [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Text Block [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage Of Commission On Gross Proceeds From Sale Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Commission On Gross Proceeds From Sale Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of commission on gross proceeds from sale of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based payment award granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StrategicAdvisorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strategic advisor name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StrategicAdvisorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Strategic Advisor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StrategicAdvisorName_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Strategic advisor name.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePaymentsMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments maximum amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePaymentsMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments, Maximum Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePaymentsMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone maximum payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Tax Credit Carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOfferedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued during period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOfferedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Offered During Period Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOfferedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock offered during period shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Employee Director [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EmployeeStockOptionAndRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock option and Restricted stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EmployeeStockOptionAndRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option And Restricted Stock Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EmployeeStockOptionAndRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options and Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class Of Warrant Or Right Axis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Axis [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected recognition period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock awarded</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ZiopLicenseAgreementWithTheNationalCancerInstituteMember</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ziop License Agreement With The National Cancer Institute [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ziop License Agreement With The National Cancer Institute [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The University Of Texas M D Anderson Cancer Center And The Texas A And M University System</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">The University Of Texas M D Anderson Cancer Center And The Texas A And M University System [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The University of Texas MD Anderson Cancer Center and The Texas A &amp; M University System [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment under license agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Under License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment under license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Threshold period for exercise or conversion of stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Threshold Commitment Period for Exercise of Rights to Participate in Future Offerings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Threshold commitment period for exercise of rights to participate in future offerings.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInOperatingDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating deposits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInOperatingDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease in Operating Deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInOperatingDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled restricted common stock (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation nondeductible expense research and development true up.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Research and Development True Up</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development true-up</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalPaidInCapitalCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalPaidInCapitalCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalPaidInCapitalCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid In Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PostemploymentBenefitsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Postemployment Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AmountOfPrepaymentsPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of prepayments premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AmountOfPrepaymentsPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Of Prepayments Premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AmountOfPrepaymentsPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount Of Prepayments Premium.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregatePotentialBenchmarkPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate potential benchmark payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregatePotentialBenchmarkPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate potential benchmark payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregatePotentialBenchmarkPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate potential benchmark payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MD Anderson License and the Research and Development Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MD Anderson License and the Research and Development Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MD Anderson License and the Research and Development Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property And Equipment And Right Of Use Assets Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property and equipment and right of use assets impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment and right-of-use assets impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Liquidation Preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, liquidation preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average common shares outstanding used to compute basic net income (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityDistributionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Distribution Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityDistributionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Distribution Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityDistributionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity distribution agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ScheduleOfEquityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Equity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ScheduleOfEquityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Equity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ScheduleOfEquityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Equity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Activity Under Stock Option Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MinimumRoyaltiesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Minimum Royalties Amount Payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MinimumRoyaltiesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Royalties Amount Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MinimumRoyaltiesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum royalties amount payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Net Asset (Liability)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Net Asset (Liability), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MD Anderson License.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Md Anderson License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MD Anderson License</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AresTradingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ares Trading [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AresTradingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ares Trading [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AresTradingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ARES Trading License</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedManufacturingCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued manufacturing costs, current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedManufacturingCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Manufacturing Costs, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedManufacturingCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EdenBioCellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eden Bio Cell</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EdenBioCellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eden Bio Cell [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Aggregate Benchmark Payments Payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Benchmark Payments Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate Benchmark Payments Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lease, Cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Royalty amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Component of Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unspecified monetary damages</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Damages Sought, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Expiry date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, stated value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement With Solasia Pharma KK [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement with solasia pharma K.K.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement with Solasia Pharma K.K. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee Benefit and Share-based Payment Arrangement, Noncash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Benefit and Share-Based Payment Arrangement, Noncash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation Expense Included in Statements of Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement termination notice period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Termination Notice Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Agreement termination, notice period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">MD Anderson Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Md Anderson Warrant Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Md Anderson Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MD Anderson Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement Type Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extinguishment of debt, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment of Debt, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EarningPerShareBasicAndDilutedLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Earning Per share Basic and Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EarningPerShareBasicAndDilutedLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earning Per share Basic and Diluted [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting for Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandTwelveEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twelve Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandTwelveEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twelve Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandTwelveEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">the "2012 Plan" [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopharmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ziopharm [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopharmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ziopharm [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TaxRelaxationOnTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax relaxation on taxable income.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TaxRelaxationOnTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Relaxation On Taxable Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TaxRelaxationOnTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Relaxation of taxable income, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Shares, Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RoyaltiesAmountPayableThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties amount payable thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RoyaltiesAmountPayableThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties Amount Payable thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RoyaltiesAmountPayableThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties amount payable thereafter.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants fully vested upon issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of employee stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions for Volatility, Expected life, Dividend Yield and Risk-free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduced credits carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Component of Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPrepaymentsPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of prepayments premium.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPrepaymentsPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Prepayments Premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPrepaymentsPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of prepayments premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PostStockSplitSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Post Stock Split Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PostStockSplitSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Post Stock Split Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity interest in affilated entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consultants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consultants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consultants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NewWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New Warrants Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NewWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Silicon Valley Bank Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Silicon Valley Bank loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Silicon Valley Bank Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualExpenseIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual expense incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualExpenseIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Expense Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualExpenseIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual expense incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UncategorizedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Uncategorized [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UncategorizedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Uncategorized [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CantorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cantor [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CantorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cantor [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CantorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cantor.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLossCarryforwardsExpirationDatesState_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Loss Carryforwards Expiration Dates State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLossCarryforwardsExpirationDatesState_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Dates State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLossCarryforwardsExpirationDatesState_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Excluding Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwriterParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriter par or stated value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwriterParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriter Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwriterParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriter par or stated value per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease in the carrying amount of right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The increase (decrease) during the period in the carrying value of right of use asset reported as assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Right Of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsResearchExpensesCapitalized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets research expenses capitalized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsResearchExpensesCapitalized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Research Expenses Capitalized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsResearchExpensesCapitalized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IssuanceOfCommonStockNetOfExpensesInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock, net of expenses in shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IssuanceOfCommonStockNetOfExpensesInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Net Of Expenses In Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IssuanceOfCommonStockNetOfExpensesInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of expenses (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts expensed for services incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PublicOfferingNetPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering, net price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PublicOfferingNetPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public offering, net price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PublicOfferingNetPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance &amp; sale of common stock in public offering price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ReductionInRightOfUseAssetsForModificationAndTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in right-of-use assets for modification and termination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ReductionInRightOfUseAssetsForModificationAndTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reduction in Right of Use Assets for Modification and Termination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ReductionInRightOfUseAssetsForModificationAndTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction in right of use assets for modification and termination.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life in years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assumptions Expected Term1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders equity reverse stock split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, stated value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Increase) decrease in:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Non-Vested Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant Exercise Per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Bonuses, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Vested Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Vested Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation costs related to non-vested restricted stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNameOfPlaintiff_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss contingency, name of plaintiff</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNameOfPlaintiff_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Name of Plaintiff</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnOperatingLeaseModificationAndTermination_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on lease modification and termination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnOperatingLeaseModificationAndTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) On Operating Lease Modification And Termination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnOperatingLeaseModificationAndTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain (loss) on operating lease modification and termination.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assumptions Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Area</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Area</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease area.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement With The National Cancer Institute Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement with the National Cancer Institute [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity method investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandTwelveStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twelve Stock Option Plan Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandTwelveStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twelve Stock Option Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement Type Domain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan and Security Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CARProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">C A R Products Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CARProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CAR Products [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CARProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">C A R Products [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Previously Reported [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Previously Reported [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateMinimumAnnualRoyaltiesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate minimum annual royalties paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateMinimumAnnualRoyaltiesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Minimum Annual Royalties Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateMinimumAnnualRoyaltiesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate minimum annual royalties paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LeaseTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease termination date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LeaseTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Termination Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LeaseTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease termination date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedClinicalExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedClinicalExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued clinical expenses current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedClinicalExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical expenses current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Subsidiary or Equity Method Investee [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PostMarketingApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Post Marketing Approval Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PostMarketingApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Post Marketing Approval [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses and Other Current Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BonusDepreciationEligibilityPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eligibility for bonus depreciation, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BonusDepreciationEligibilityPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bonus Depreciation Eligibility, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BonusDepreciationEligibilityPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bonus Depreciation Eligibility, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of financing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State and Local Jurisdiction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InitialBenchmarkPaymentDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The first benchmark payment due upon the initiation of the Company's first sponsored phase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InitialBenchmarkPaymentDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Benchmark Payment Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InitialBenchmarkPaymentDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First benchmark payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_HoustonTexasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Houston Texas [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_HoustonTexasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Houston Texas [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_HoustonTexasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Houston, TX [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementCommencingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement commencing date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementCommencingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Commencing Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementCommencingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement commencing date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional number warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional number of warrants issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Number Of Warrants Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise, net of commissions and expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock upon exercise of warrants, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedConsultingFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other consulting services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedConsultingFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued consulting fees, current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccruedConsultingFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Consulting Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options granted exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Terms [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The increase (decrease) during the period in the carrying value of lease liabilities reported as liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SubleaseTermCommencedEndDateAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease term commenced end date amendment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SubleaseTermCommencedEndDateAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Term Commenced End Date Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SubleaseTermCommencedEndDateAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sublease term amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial borrowing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan and Security Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Current Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Call or Exercise Features</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Assets and Liabilities Eliminated upon Consolidation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets and Liabilities Eliminated upon Consolidation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net Proceeds from Underwriting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure Of Earning Per share Basic and Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Earning Per share Basic and Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Joint Venture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum sales revenue on which benchmark payments payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Sales Revenue On Which Benchmark Payments Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum sales revenue on which benchmark payments payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DueDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Due Date Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DueDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due date [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third anniversary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts included in accrued expenses and accounts payable related to property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument description of variable rate basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Description of Variable Rate Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment and right-of-use assets impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Impairment Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxLiabilityRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liability Right of Use Asset, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxLiabilityRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Liability Right of Use Asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxLiabilityRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liability Right of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxLiabilityRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right of use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income tax, net of federal tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional option available to the underwriter to purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Additional Option Available To The Underwriter To Purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional option available to the underwriter to purchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average common shares outstanding used to compute diluted net income (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BlackScholesModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Black-Scholes Model [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BlackScholesModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Black Scholes Model [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BlackScholesModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Black-Scholes Model [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Receivables, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income and Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of original principal due as a final payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Original Principal Due as a Final Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of original principal due as a final payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Debt extinguishment costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Placement agent fees and other related expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Placement Agent Fees And Other Related Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Placement agent fees and other expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum Sales Revenue On Which Benchmark Payments Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Sales Revenue On Which Benchmark Payments Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual salary in cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Salary and Wage, Excluding Cost of Good and Service Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Salary and Wage, Excluding Cost of Good and Service Sold, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CRADAAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CRADA Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CRADAAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CRADA Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CRADAAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CRADA Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Receivables, Net, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables, Net, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument Redemption Period One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure pertaining to the warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Hierarchy [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting service amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Professional and Contract Services Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type of Restructuring [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class Of Warrant Or Right.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Domain [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of expense related to License payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with an at the market offering, net of commissions and expenses of $400 (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets start up and pre clinical studies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Start Up And Pre Clinical Studies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Start-up and pre-clinical studies</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AdditionalLoansCommitted" xlink:to="tcrt_AdditionalLoansCommitted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_FederalAndStateMember" xlink:to="tcrt_FederalAndStateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IncomeTaxesTable" xlink:to="tcrt_IncomeTaxesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ClinicalExpenses" xlink:to="tcrt_ClinicalExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember" xlink:to="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MilestonePayment" xlink:to="tcrt_MilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AnnualLicenseFees" xlink:to="tcrt_AnnualLicenseFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts" xlink:to="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_WarrantsPolicyTextBlock" xlink:to="tcrt_WarrantsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AtTheMarketOfferingMember" xlink:to="tcrt_AtTheMarketOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LicensedProductsMember" xlink:to="tcrt_LicensedProductsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OtherIncomeExpenseMember" xlink:to="tcrt_OtherIncomeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AnnualGrantMember" xlink:to="tcrt_AnnualGrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ConditionalMilestoneAmountPayable" xlink:to="tcrt_ConditionalMilestoneAmountPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NumberOfDaysOptionExerciable" xlink:to="tcrt_NumberOfDaysOptionExerciable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaximumAmountOfRoyaltyPayable" xlink:to="tcrt_MaximumAmountOfRoyaltyPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SiliconValleyBankMember" xlink:to="tcrt_SiliconValleyBankMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" xlink:to="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TcellReceptorMember" xlink:to="tcrt_TcellReceptorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PerformanceBasedPaymentsMember" xlink:to="tcrt_PerformanceBasedPaymentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MilestonePaymentMadeOne" xlink:to="tcrt_MilestonePaymentMadeOne_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" xlink:to="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AggregateAmountPotentiallyReimburseableAmount" xlink:to="tcrt_AggregateAmountPotentiallyReimburseableAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_UnderwritingAgreementMember" xlink:to="tcrt_UnderwritingAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeSeveranceMember" xlink:to="us-gaap_EmployeeSeveranceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OperatingLossCarryforwardsResearchExpirationDates" xlink:to="tcrt_OperatingLossCarryforwardsResearchExpirationDates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaximumAmountOfAdditionalMilestonesPayable" xlink:to="tcrt_MaximumAmountOfAdditionalMilestonesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SubleaseArea" xlink:to="tcrt_SubleaseArea_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PotentialBenchmarkPaymentsPayable" xlink:to="tcrt_PotentialBenchmarkPaymentsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DeferredTaxAssetsLeaseLiability" xlink:to="tcrt_DeferredTaxAssetsLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AgreementTypeAxisAxis" xlink:to="tcrt_AgreementTypeAxisAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaMember" xlink:to="tcrt_MaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_HogueMember" xlink:to="tcrt_HogueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LabEquipmentMember" xlink:to="tcrt_LabEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_GainLossOnModificationOfLease" xlink:to="tcrt_GainLossOnModificationOfLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ContributionPayableOnPerAnnumBasis" xlink:to="tcrt_ContributionPayableOnPerAnnumBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PreStockSplitSharesAuthorized" xlink:to="tcrt_PreStockSplitSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DeferredTaxAssetsDepreciation" xlink:to="tcrt_DeferredTaxAssetsDepreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TenthScheduledPaymentMember" xlink:to="tcrt_TenthScheduledPaymentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_FinancingArrangementsDisclosureTextBlock" xlink:to="tcrt_FinancingArrangementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AnnualCashRetainer" xlink:to="tcrt_AnnualCashRetainer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AccrualsPriorToFirstMarketingApproval" xlink:to="tcrt_AccrualsPriorToFirstMarketingApproval_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PatentAndTechnologyLicenseAgreementMember" xlink:to="tcrt_PatentAndTechnologyLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EdenBiocellMember" xlink:to="tcrt_EdenBiocellMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_UnderwritingAgreementWithJefferiesMember" xlink:to="tcrt_UnderwritingAgreementWithJefferiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DescriptionOfFirstBenchmarkPayable" xlink:to="tcrt_DescriptionOfFirstBenchmarkPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="tcrt_TwoThousandTwentyEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ShareSubscriptionAgreementMember" xlink:to="tcrt_ShareSubscriptionAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NonVestedStockMember" xlink:to="tcrt_NonVestedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" xlink:to="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_PaymentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IntrexonCorporationMember" xlink:to="tcrt_IntrexonCorporationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EligibilityOfBonusPercentage" xlink:to="tcrt_EligibilityOfBonusPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SecuritiesPurchaseAgreementMember" xlink:to="tcrt_SecuritiesPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_InitialGrantMember" xlink:to="tcrt_InitialGrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CommonStockOptionsMember" xlink:to="tcrt_CommonStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="us-gaap_BankingAndThriftInterestAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SvbWarrantsMember" xlink:to="tcrt_SvbWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome" xlink:to="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DueDateDomain" xlink:to="tcrt_DueDateDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EightScheduledPaymentMember" xlink:to="tcrt_EightScheduledPaymentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OfficeAndComputerEquipmentMember" xlink:to="tcrt_OfficeAndComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TerminationCosts" xlink:to="tcrt_TerminationCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaximumRoyaltyAmount" xlink:to="tcrt_MaximumRoyaltyAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MdAndersonAgreementAndWorldwideLicenseMember" xlink:to="tcrt_MdAndersonAgreementAndWorldwideLicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_WarrantsDisclosureAbstract" xlink:to="tcrt_WarrantsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EarningPerShareBasicAndDilutedTable" xlink:to="tcrt_EarningPerShareBasicAndDilutedTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TangibleAssetImpairmentCharges" xlink:to="us-gaap_TangibleAssetImpairmentCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AccruedPreclinicalServicesCurrent" xlink:to="tcrt_AccruedPreclinicalServicesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AdvanceNoticePeriodForTerminationAgreement" xlink:to="tcrt_AdvanceNoticePeriodForTerminationAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SeriesOnePreferredStockMember" xlink:to="tcrt_SeriesOnePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SharesAuthorized" xlink:to="tcrt_SharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseIncome" xlink:to="us-gaap_LeaseIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TriArmMember" xlink:to="tcrt_TriArmMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NonOperatingIncomeExpenseInducementOfWarrants" xlink:to="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock" xlink:to="tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OneTimeBenchmarkPaymentsMember" xlink:to="tcrt_OneTimeBenchmarkPaymentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OrganizationalChangesPolicyTextBlock" xlink:to="tcrt_OrganizationalChangesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AgreementTerminationDate" xlink:to="tcrt_AgreementTerminationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DuneLakeCapitalMember" xlink:to="tcrt_DuneLakeCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_IncomeTaxesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ObligationsDueUnderContract" xlink:to="tcrt_ObligationsDueUnderContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MdAndersonMember" xlink:to="tcrt_MdAndersonMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:to="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_StrategicAdvisorName" xlink:to="tcrt_StrategicAdvisorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MilestonePaymentsMaximumAmount" xlink:to="tcrt_MilestonePaymentsMaximumAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_StockOfferedDuringPeriodShares" xlink:to="tcrt_StockOfferedDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EmployeeStockOptionAndRestrictedStockMember" xlink:to="tcrt_EmployeeStockOptionAndRestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ClassOfWarrantOrRightAxisAxis" xlink:to="tcrt_ClassOfWarrantOrRightAxisAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" xlink:to="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" xlink:to="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PaymentUnderLicenseAgreement" xlink:to="tcrt_PaymentUnderLicenseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" xlink:to="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IncreaseDecreaseInOperatingDeposits" xlink:to="tcrt_IncreaseDecreaseInOperatingDeposits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" xlink:to="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AdditionalPaidInCapitalCommonStockMember" xlink:to="tcrt_AdditionalPaidInCapitalCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_PostemploymentBenefitsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AmountOfPrepaymentsPremium" xlink:to="tcrt_AmountOfPrepaymentsPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AggregatePotentialBenchmarkPayments" xlink:to="tcrt_AggregatePotentialBenchmarkPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" xlink:to="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" xlink:to="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EquityDistributionAgreementMember" xlink:to="tcrt_EquityDistributionAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="tcrt_ScheduleOfEquityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MinimumRoyaltiesAmountPayable" xlink:to="tcrt_MinimumRoyaltiesAmountPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="tcrt_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MdAndersonLicenseMember" xlink:to="tcrt_MdAndersonLicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AresTradingMember" xlink:to="tcrt_AresTradingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AccruedManufacturingCostsCurrent" xlink:to="tcrt_AccruedManufacturingCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EdenBioCellMember" xlink:to="tcrt_EdenBioCellMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AggregateBenchmarkPaymentsPayable" xlink:to="tcrt_AggregateBenchmarkPaymentsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_FairValueOfWarrants" xlink:to="tcrt_FairValueOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" xlink:to="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AgreementTerminationNoticePeriod" xlink:to="tcrt_AgreementTerminationNoticePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MdAndersonWarrantMember" xlink:to="tcrt_MdAndersonWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsDomain" xlink:to="us-gaap_DividendsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ClassOfWarrantOrRightWarrantsExercised" xlink:to="tcrt_ClassOfWarrantOrRightWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EarningPerShareBasicAndDilutedLineItems" xlink:to="tcrt_EarningPerShareBasicAndDilutedLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TwoThousandTwelveEquityIncentivePlanMember" xlink:to="tcrt_TwoThousandTwelveEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ZiopharmMember" xlink:to="tcrt_ZiopharmMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TaxRelaxationOnTaxableIncome" xlink:to="tcrt_TaxRelaxationOnTaxableIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesAcquired" xlink:to="us-gaap_TreasuryStockSharesAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_RoyaltiesAmountPayableThereafter" xlink:to="tcrt_RoyaltiesAmountPayableThereafter_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PercentageOfPrepaymentsPremium" xlink:to="tcrt_PercentageOfPrepaymentsPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PostStockSplitSharesAuthorized" xlink:to="tcrt_PostStockSplitSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ConsultantsMember" xlink:to="tcrt_ConsultantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NewWarrantsMember" xlink:to="tcrt_NewWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SiliconValleyBankLoanMember" xlink:to="tcrt_SiliconValleyBankLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AnnualExpenseIncurred" xlink:to="tcrt_AnnualExpenseIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_UncategorizedAbstract" xlink:to="tcrt_UncategorizedAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CantorMember" xlink:to="tcrt_CantorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TermLoanMember" xlink:to="tcrt_TermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OperatingLossCarryforwardsExpirationDatesState" xlink:to="tcrt_OperatingLossCarryforwardsExpirationDatesState_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_UnderwriterParOrStatedValuePerShare" xlink:to="tcrt_UnderwriterParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IncreaseDecreaseInRightOfUseAsset" xlink:to="tcrt_IncreaseDecreaseInRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DeferredTaxAssetsResearchExpensesCapitalized" xlink:to="tcrt_DeferredTaxAssetsResearchExpensesCapitalized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IssuanceOfCommonStockNetOfExpensesInShares" xlink:to="tcrt_IssuanceOfCommonStockNetOfExpensesInShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PublicOfferingNetPricePerShare" xlink:to="tcrt_PublicOfferingNetPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ReductionInRightOfUseAssetsForModificationAndTermination" xlink:to="tcrt_ReductionInRightOfUseAssetsForModificationAndTermination_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EquityLineItems" xlink:to="tcrt_EquityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NonVestedRestrictedStockMember" xlink:to="tcrt_NonVestedRestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNameOfPlaintiff" xlink:to="us-gaap_LossContingencyNameOfPlaintiff_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_GainLossOnOperatingLeaseModificationAndTermination" xlink:to="tcrt_GainLossOnOperatingLeaseModificationAndTermination_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OperatingLeaseArea" xlink:to="tcrt_OperatingLeaseArea_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" xlink:to="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TwoThousandTwelveStockOptionPlanMember" xlink:to="tcrt_TwoThousandTwelveStockOptionPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_AgreementTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CARProductsMember" xlink:to="tcrt_CARProductsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AggregateMinimumAnnualRoyaltiesPaid" xlink:to="tcrt_AggregateMinimumAnnualRoyaltiesPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LeaseTerminationDate" xlink:to="tcrt_LeaseTerminationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AccruedClinicalExpensesCurrent" xlink:to="tcrt_AccruedClinicalExpensesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tcrt_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PostMarketingApprovalMember" xlink:to="tcrt_PostMarketingApprovalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_BonusDepreciationEligibilityPercentage" xlink:to="tcrt_BonusDepreciationEligibilityPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_InitialBenchmarkPaymentDue" xlink:to="tcrt_InitialBenchmarkPaymentDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_HoustonTexasMember" xlink:to="tcrt_HoustonTexasMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LicenseAgreementCommencingDate" xlink:to="tcrt_LicenseAgreementCommencingDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AdditionalNumberOfWarrantsIssued" xlink:to="tcrt_AdditionalNumberOfWarrantsIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AccruedConsultingFeesCurrent" xlink:to="tcrt_AccruedConsultingFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LaboratoryEquipmentMember" xlink:to="tcrt_LaboratoryEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IncreaseDecreaseInLeaseLiabilities" xlink:to="tcrt_IncreaseDecreaseInLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SubleaseTermCommencedEndDateAmendment" xlink:to="tcrt_SubleaseTermCommencedEndDateAmendment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCallOrExerciseFeatures" xlink:to="us-gaap_CommonStockCallOrExerciseFeatures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xlink:to="tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract" xlink:to="tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:to="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DueDateAxis" xlink:to="tcrt_DueDateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EmployeesMember" xlink:to="tcrt_EmployeesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DeferredTaxLiabilityRightOfUseAsset" xlink:to="tcrt_DeferredTaxLiabilityRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" xlink:to="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_WarrantsExpirationDate" xlink:to="tcrt_WarrantsExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_BlackScholesModelMember" xlink:to="tcrt_BlackScholesModelMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" xlink:to="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PlacementAgentFeesAndOtherRelatedExpenses" xlink:to="tcrt_PlacementAgentFeesAndOtherRelatedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:to="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CRADAAgreementMember" xlink:to="tcrt_CRADAAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_WarrantTextBlock" xlink:to="tcrt_WarrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ClassOfWarrantOrRightDomainDomain" xlink:to="tcrt_ClassOfWarrantOrRightDomainDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LicenseExpense" xlink:to="tcrt_LicenseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies" xlink:to="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/CoverPage" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/BalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SeriesOnePreferredStockMember" xlink:label="tcrt_SeriesOnePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcrt_SeriesOnePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SeriesOnePreferredStockMember" xlink:label="tcrt_SeriesOnePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcrt_SeriesOnePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_GainLossOnOperatingLeaseModificationAndTermination" xlink:label="tcrt_GainLossOnOperatingLeaseModificationAndTermination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" xlink:label="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="tcrt_GainLossOnOperatingLeaseModificationAndTermination" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_RestructuringCharges" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AdditionalPaidInCapitalCommonStockMember" xlink:label="tcrt_AdditionalPaidInCapitalCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IssuanceOfCommonStockNetOfExpensesInShares" xlink:label="tcrt_IssuanceOfCommonStockNetOfExpensesInShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_12"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_13"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tcrt_AdditionalPaidInCapitalCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_IssuanceOfCommonStockNetOfExpensesInShares" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_13" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ReductionInRightOfUseAssetsForModificationAndTermination" xlink:label="tcrt_ReductionInRightOfUseAssetsForModificationAndTermination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IncreaseDecreaseInOperatingDeposits" xlink:label="tcrt_IncreaseDecreaseInOperatingDeposits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IncreaseDecreaseInLeaseLiabilities" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IncreaseDecreaseInRightOfUseAsset" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="tcrt_ReductionInRightOfUseAssetsForModificationAndTermination" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="tcrt_IncreaseDecreaseInOperatingDeposits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="tcrt_IncreaseDecreaseInLeaseLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tcrt_IncreaseDecreaseInRightOfUseAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/Organization" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/Financings" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_FinancingArrangementsDisclosureTextBlock" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="tcrt_FinancingArrangementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureDebt" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/AccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/RelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/Leases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/Warrants" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_WarrantsDisclosureAbstract" xlink:label="tcrt_WarrantsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_WarrantTextBlock" xlink:label="tcrt_WarrantTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_WarrantsDisclosureAbstract" xlink:to="tcrt_WarrantTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureRestructuring1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/IncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/StockOptionPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/EmployeeBenefitPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="us-gaap_PostemploymentBenefitsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/JointVenture" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OrganizationalChangesPolicyTextBlock" xlink:label="tcrt_OrganizationalChangesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_WarrantsPolicyTextBlock" xlink:label="tcrt_WarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tcrt_OrganizationalChangesPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tcrt_WarrantsPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureDebtTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/AccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/LeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/IncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/StockOptionPlansTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/OrganizationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_StrategicAdvisorName" xlink:label="tcrt_StrategicAdvisorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_StrategicAdvisorName" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTypeAxisAxis" xlink:label="tcrt_AgreementTypeAxisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankingAndThriftInterestAbstract" xlink:label="us-gaap_BankingAndThriftInterestAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SiliconValleyBankMember" xlink:label="tcrt_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_StockOfferedDuringPeriodShares" xlink:label="tcrt_StockOfferedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AtTheMarketOfferingMember" xlink:label="tcrt_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CantorMember" xlink:label="tcrt_CantorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_UnderwriterParOrStatedValuePerShare" xlink:label="tcrt_UnderwriterParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EquityDistributionAgreementMember" xlink:label="tcrt_EquityDistributionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" xlink:label="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" xlink:label="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="tcrt_AgreementTypeAxisAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeAxisAxis" xlink:to="tcrt_AgreementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="tcrt_SiliconValleyBankMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_StockOfferedDuringPeriodShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcrt_AtTheMarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_StockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_CantorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_UnderwriterParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_EquityDistributionAgreementMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OfficeAndComputerEquipmentMember" xlink:label="tcrt_OfficeAndComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xlink:label="tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PreStockSplitSharesAuthorized" xlink:label="tcrt_PreStockSplitSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LaboratoryEquipmentMember" xlink:label="tcrt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PostStockSplitSharesAuthorized" xlink:label="tcrt_PostStockSplitSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LabEquipmentMember" xlink:label="tcrt_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EmployeeStockOptionAndRestrictedStockMember" xlink:label="tcrt_EmployeeStockOptionAndRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_OfficeAndComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xlink:to="tcrt_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tcrt_PreStockSplitSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_LaboratoryEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tcrt_PostStockSplitSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_LabEquipmentMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_EmployeeStockOptionAndRestrictedStockMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_TangibleAssetImpairmentCharges" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EarningPerShareBasicAndDilutedTable" xlink:label="tcrt_EarningPerShareBasicAndDilutedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EarningPerShareBasicAndDilutedLineItems" xlink:label="tcrt_EarningPerShareBasicAndDilutedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract" xlink:label="tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EarningPerShareBasicAndDilutedTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract" xlink:to="tcrt_EarningPerShareBasicAndDilutedTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EarningPerShareBasicAndDilutedTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EarningPerShareBasicAndDilutedTable" xlink:to="tcrt_EarningPerShareBasicAndDilutedLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TwoThousandTwelveStockOptionPlanMember" xlink:label="tcrt_TwoThousandTwelveStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CommonStockOptionsMember" xlink:label="tcrt_CommonStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandTwelveStockOptionPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="tcrt_CommonStockOptionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_PlanNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TermLoanMember" xlink:label="tcrt_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_WarrantsExpirationDate" xlink:label="tcrt_WarrantsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TenthScheduledPaymentMember" xlink:label="tcrt_TenthScheduledPaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EightScheduledPaymentMember" xlink:label="tcrt_EightScheduledPaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PercentageOfPrepaymentsPremium" xlink:label="tcrt_PercentageOfPrepaymentsPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AmountOfPrepaymentsPremium" xlink:label="tcrt_AmountOfPrepaymentsPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AdditionalNumberOfWarrantsIssued" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_TermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_WarrantsExpirationDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_TenthScheduledPaymentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_EightScheduledPaymentMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_PercentageOfPrepaymentsPremium" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_AmountOfPrepaymentsPremium" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_AdditionalNumberOfWarrantsIssued" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OfficeAndComputerEquipmentMember" xlink:label="tcrt_OfficeAndComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LaboratoryEquipmentMember" xlink:label="tcrt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_OfficeAndComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_LaboratoryEquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AccruedClinicalExpensesCurrent" xlink:label="tcrt_AccruedClinicalExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AccruedPreclinicalServicesCurrent" xlink:label="tcrt_AccruedPreclinicalServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AccruedManufacturingCostsCurrent" xlink:label="tcrt_AccruedManufacturingCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AccruedConsultingFeesCurrent" xlink:label="tcrt_AccruedConsultingFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="tcrt_AccruedClinicalExpensesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedBonusesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="tcrt_AccruedPreclinicalServicesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="tcrt_AccruedManufacturingCostsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="tcrt_AccruedConsultingFeesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EdenBiocellMember" xlink:label="tcrt_EdenBiocellMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AdditionalLoansCommitted" xlink:label="tcrt_AdditionalLoansCommitted"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DuneLakeCapitalMember" xlink:label="tcrt_DuneLakeCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_EdenBiocellMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_AdditionalLoansCommitted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_DuneLakeCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MaMember" xlink:label="tcrt_MaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MdAndersonMember" xlink:label="tcrt_MdAndersonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LeaseTerminationDate" xlink:label="tcrt_LeaseTerminationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OtherIncomeExpenseMember" xlink:label="tcrt_OtherIncomeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_HoustonTexasMember" xlink:label="tcrt_HoustonTexasMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SubleaseTermCommencedEndDateAmendment" xlink:label="tcrt_SubleaseTermCommencedEndDateAmendment"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TerminationCosts" xlink:label="tcrt_TerminationCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OperatingLeaseArea" xlink:label="tcrt_OperatingLeaseArea"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_GainLossOnModificationOfLease" xlink:label="tcrt_GainLossOnModificationOfLease"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SubleaseArea" xlink:label="tcrt_SubleaseArea"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseIncome" xlink:label="us-gaap_LeaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="tcrt_MaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_MdAndersonMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_LeaseTerminationDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="tcrt_OtherIncomeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="tcrt_HoustonTexasMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_SubleaseTermCommencedEndDateAmendment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_TerminationCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_OperatingLeaseArea" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_GainLossOnModificationOfLease" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_SubleaseArea" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseIncome" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermLeaseCost" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AresTradingMember" xlink:label="tcrt_AresTradingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IntrexonCorporationMember" xlink:label="tcrt_IntrexonCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PaymentTypeAxis" xlink:label="tcrt_PaymentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PerformanceBasedPaymentsMember" xlink:label="tcrt_PerformanceBasedPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DueDateDomain" xlink:label="tcrt_DueDateDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PostMarketingApprovalMember" xlink:label="tcrt_PostMarketingApprovalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TcellReceptorMember" xlink:label="tcrt_TcellReceptorMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ClassOfWarrantOrRightAxisAxis" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ClassOfWarrantOrRightDomainDomain" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember" xlink:label="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DueDateAxis" xlink:label="tcrt_DueDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MdAndersonLicenseMember" xlink:label="tcrt_MdAndersonLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OneTimeBenchmarkPaymentsMember" xlink:label="tcrt_OneTimeBenchmarkPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CARProductsMember" xlink:label="tcrt_CARProductsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MilestonePaymentsMaximumAmount" xlink:label="tcrt_MilestonePaymentsMaximumAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LicensedProductsMember" xlink:label="tcrt_LicensedProductsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CRADAAgreementMember" xlink:label="tcrt_CRADAAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LicenseAgreementCommencingDate" xlink:label="tcrt_LicenseAgreementCommencingDate"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MdAndersonAgreementAndWorldwideLicenseMember" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PatentAndTechnologyLicenseAgreementMember" xlink:label="tcrt_PatentAndTechnologyLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AnnualLicenseFees" xlink:label="tcrt_AnnualLicenseFees"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AggregateAmountPotentiallyReimburseableAmount" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MaximumAmountOfAdditionalMilestonesPayable" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MaximumAmountOfRoyaltyPayable" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MaximumRoyaltyAmount" xlink:label="tcrt_MaximumRoyaltyAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ClinicalExpenses" xlink:label="tcrt_ClinicalExpenses"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTerminationDate" xlink:label="tcrt_AgreementTerminationDate"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ContributionPayableOnPerAnnumBasis" xlink:label="tcrt_ContributionPayableOnPerAnnumBasis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MinimumRoyaltiesAmountPayable" xlink:label="tcrt_MinimumRoyaltiesAmountPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_RoyaltiesAmountPayableThereafter" xlink:label="tcrt_RoyaltiesAmountPayableThereafter"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ObligationsDueUnderContract" xlink:label="tcrt_ObligationsDueUnderContract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AnnualExpenseIncurred" xlink:label="tcrt_AnnualExpenseIncurred"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AggregateMinimumAnnualRoyaltiesPaid" xlink:label="tcrt_AggregateMinimumAnnualRoyaltiesPaid"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DescriptionOfFirstBenchmarkPayable" xlink:label="tcrt_DescriptionOfFirstBenchmarkPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PotentialBenchmarkPaymentsPayable" xlink:label="tcrt_PotentialBenchmarkPaymentsPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" xlink:label="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AggregateBenchmarkPaymentsPayable" xlink:label="tcrt_AggregateBenchmarkPaymentsPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTerminationNoticePeriod" xlink:label="tcrt_AgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:label="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AggregatePotentialBenchmarkPayments" xlink:label="tcrt_AggregatePotentialBenchmarkPayments"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AccrualsPriorToFirstMarketingApproval" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_InitialBenchmarkPaymentDue" xlink:label="tcrt_InitialBenchmarkPaymentDue"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:label="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LicenseExpense" xlink:label="tcrt_LicenseExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PaymentUnderLicenseAgreement" xlink:label="tcrt_PaymentUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MilestonePayment" xlink:label="tcrt_MilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNameOfPlaintiff" xlink:label="us-gaap_LossContingencyNameOfPlaintiff"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_AresTradingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_IntrexonCorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_PerformanceBasedPaymentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_DueDateDomain" xlink:to="tcrt_PostMarketingApprovalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_TcellReceptorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ClassOfWarrantOrRightAxisAxis" xlink:to="tcrt_ClassOfWarrantOrRightDomainDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_DueDateAxis" xlink:to="tcrt_DueDateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ClassOfWarrantOrRightDomainDomain" xlink:to="tcrt_MdAndersonWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_MdAndersonLicenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_OneTimeBenchmarkPaymentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_CARProductsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MilestonePaymentsMaximumAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_LicensedProductsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_CRADAAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_LicenseAgreementCommencingDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MdAndersonAgreementAndWorldwideLicenseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="dei_LegalEntityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RoyaltyExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_PatentAndTechnologyLicenseAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AnnualLicenseFees" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateAmountPotentiallyReimburseableAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_DueDateAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumAmountOfAdditionalMilestonesPayable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_PaymentTypeAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumAmountOfRoyaltyPayable" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_ClassOfWarrantOrRightAxisAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumRoyaltyAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ClinicalExpenses" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AgreementTerminationDate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ContributionPayableOnPerAnnumBasis" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MinimumRoyaltiesAmountPayable" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_RoyaltiesAmountPayableThereafter" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ObligationsDueUnderContract" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AnnualExpenseIncurred" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateMinimumAnnualRoyaltiesPaid" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_DescriptionOfFirstBenchmarkPayable" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PotentialBenchmarkPaymentsPayable" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateBenchmarkPaymentsPayable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AgreementTerminationNoticePeriod" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregatePotentialBenchmarkPayments" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AccrualsPriorToFirstMarketingApproval" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_InitialBenchmarkPaymentDue" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_LicenseExpense" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PaymentUnderLicenseAgreement" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MilestonePayment" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LossContingencyDamagesSoughtValue" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LossContingencyNameOfPlaintiff" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LitigationSettlementExpense" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_BlackScholesModelMember" xlink:label="tcrt_BlackScholesModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_WarrantsDisclosureAbstract" xlink:label="tcrt_WarrantsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTypeAxis" xlink:label="tcrt_AgreementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NewWarrantsMember" xlink:label="tcrt_NewWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SecuritiesPurchaseAgreementMember" xlink:label="tcrt_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_FairValueOfWarrants" xlink:label="tcrt_FairValueOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SvbWarrantsMember" xlink:label="tcrt_SvbWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PlacementAgentFeesAndOtherRelatedExpenses" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NonOperatingIncomeExpenseInducementOfWarrants" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCallOrExerciseFeatures" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ClassOfWarrantOrRightWarrantsExercised" xlink:label="tcrt_ClassOfWarrantOrRightWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_BlackScholesModelMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_WarrantsDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_NewWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_SecuritiesPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="tcrt_AgreementTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_MdAndersonWarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_FairValueOfWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_SvbWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_PlacementAgentFeesAndOtherRelatedExpenses" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_NonOperatingIncomeExpenseInducementOfWarrants" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCallOrExerciseFeatures" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_ClassOfWarrantOrRightWarrantsExercised" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Dividends" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_SeveranceCosts1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxLiabilityRightOfUseAsset" xlink:label="tcrt_DeferredTaxLiabilityRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies" xlink:label="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts" xlink:label="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsLeaseLiability" xlink:label="tcrt_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsDepreciation" xlink:label="tcrt_DeferredTaxAssetsDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsResearchExpensesCapitalized" xlink:label="tcrt_DeferredTaxAssetsResearchExpensesCapitalized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="tcrt_DeferredTaxLiabilityRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsDepreciation" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsResearchExpensesCapitalized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IncomeTaxesTable" xlink:label="tcrt_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IncomeTaxesLineItems" xlink:label="tcrt_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_FederalAndStateMember" xlink:label="tcrt_FederalAndStateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OperatingLossCarryforwardsExpirationDatesState" xlink:label="tcrt_OperatingLossCarryforwardsExpirationDatesState"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OperatingLossCarryforwardsResearchExpirationDates" xlink:label="tcrt_OperatingLossCarryforwardsResearchExpirationDates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TaxRelaxationOnTaxableIncome" xlink:label="tcrt_TaxRelaxationOnTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome" xlink:label="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EligibilityOfBonusPercentage" xlink:label="tcrt_EligibilityOfBonusPercentage"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_BonusDepreciationEligibilityPercentage" xlink:label="tcrt_BonusDepreciationEligibilityPercentage"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="tcrt_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="tcrt_FederalAndStateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesTable" xlink:to="tcrt_IncomeTaxesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_OperatingLossCarryforwardsExpirationDatesState" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_OperatingLossCarryforwardsResearchExpirationDates" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_TaxRelaxationOnTaxableIncome" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_EligibilityOfBonusPercentage" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_BonusDepreciationEligibilityPercentage" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsAxis" xlink:label="us-gaap_DividendsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SeriesOnePreferredStockMember" xlink:label="tcrt_SeriesOnePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IntrexonCorporationMember" xlink:label="tcrt_IntrexonCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ScheduleOfEquityTable" xlink:label="tcrt_ScheduleOfEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AtTheMarketOfferingMember" xlink:label="tcrt_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTypeAxis" xlink:label="tcrt_AgreementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_UncategorizedAbstract" xlink:label="tcrt_UncategorizedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EquityLineItems" xlink:label="tcrt_EquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SharesAuthorized" xlink:label="tcrt_SharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_UnderwritingAgreementWithJefferiesMember" xlink:label="tcrt_UnderwritingAgreementWithJefferiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_UnderwritingAgreementMember" xlink:label="tcrt_UnderwritingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SecuritiesPurchaseAgreementMember" xlink:label="tcrt_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NumberOfDaysOptionExerciable" xlink:label="tcrt_NumberOfDaysOptionExerciable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PublicOfferingNetPricePerShare" xlink:label="tcrt_PublicOfferingNetPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcrt_SeriesOnePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_IntrexonCorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcrt_AtTheMarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_UncategorizedAbstract" xlink:to="tcrt_ScheduleOfEquityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="tcrt_SharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_UnderwritingAgreementWithJefferiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="tcrt_AgreementTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_UnderwritingAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_SecuritiesPurchaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_SharePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="tcrt_NumberOfDaysOptionExerciable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_DividendsAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="tcrt_PublicOfferingNetPricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="tcrt_EquityLineItems" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_PreferredStockValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EmployeesMember" xlink:label="tcrt_EmployeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandTwelveEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ConsultantsMember" xlink:label="tcrt_ConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NonVestedStockMember" xlink:label="tcrt_NonVestedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NonVestedRestrictedStockMember" xlink:label="tcrt_NonVestedRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tcrt_EmployeesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandTwelveEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandTwentyEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tcrt_ConsultantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedStockMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedRestrictedStockMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_TreasuryStockSharesAcquired" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NonVestedRestrictedStockMember" xlink:label="tcrt_NonVestedRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedRestrictedStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/EmployeeBenefitPlanAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ZiopharmMember" xlink:label="tcrt_ZiopharmMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ShareSubscriptionAgreementMember" xlink:label="tcrt_ShareSubscriptionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TriArmMember" xlink:label="tcrt_TriArmMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EdenBioCellMember" xlink:label="tcrt_EdenBioCellMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MilestonePaymentMadeOne" xlink:label="tcrt_MilestonePaymentMadeOne"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ConditionalMilestoneAmountPayable" xlink:label="tcrt_ConditionalMilestoneAmountPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="tcrt_ZiopharmMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="tcrt_ShareSubscriptionAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_TriArmMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="tcrt_EdenBioCellMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="tcrt_MilestonePaymentMadeOne" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="tcrt_ConditionalMilestoneAmountPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_InitialGrantMember" xlink:label="tcrt_InitialGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AnnualCashRetainer" xlink:label="tcrt_AnnualCashRetainer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_HogueMember" xlink:label="tcrt_HogueMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AnnualGrantMember" xlink:label="tcrt_AnnualGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AdvanceNoticePeriodForTerminationAgreement" xlink:label="tcrt_AdvanceNoticePeriodForTerminationAgreement"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_InitialGrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="tcrt_AnnualCashRetainer" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tcrt_HogueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_AnnualGrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="tcrt_AdvanceNoticePeriodForTerminationAgreement" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/BalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SeriesOnePreferredStockMember" xlink:label="tcrt_SeriesOnePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcrt_SeriesOnePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SeriesOnePreferredStockMember" xlink:label="tcrt_SeriesOnePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcrt_SeriesOnePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AdditionalPaidInCapitalCommonStockMember" xlink:label="tcrt_AdditionalPaidInCapitalCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IssuanceOfCommonStockNetOfExpensesInShares" xlink:label="tcrt_IssuanceOfCommonStockNetOfExpensesInShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tcrt_AdditionalPaidInCapitalCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_IssuanceOfCommonStockNetOfExpensesInShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/OrganizationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_StrategicAdvisorName" xlink:label="tcrt_StrategicAdvisorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_StrategicAdvisorName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTypeAxisAxis" xlink:label="tcrt_AgreementTypeAxisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SiliconValleyBankMember" xlink:label="tcrt_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EquityDistributionAgreementMember" xlink:label="tcrt_EquityDistributionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_StockOfferedDuringPeriodShares" xlink:label="tcrt_StockOfferedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AtTheMarketOfferingMember" xlink:label="tcrt_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CantorMember" xlink:label="tcrt_CantorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_UnderwriterParOrStatedValuePerShare" xlink:label="tcrt_UnderwriterParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" xlink:label="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" xlink:label="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="tcrt_AgreementTypeAxisAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_AgreementTypeAxisAxis" xlink:to="tcrt_AgreementTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_AgreementTypeAxisAxis" xlink:to="tcrt_AgreementTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="tcrt_SiliconValleyBankMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_EquityDistributionAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_StockOfferedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcrt_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_StockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_CantorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_UnderwriterParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:label="tcrt_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OfficeAndComputerEquipmentMember" xlink:label="tcrt_OfficeAndComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PreStockSplitSharesAuthorized" xlink:label="tcrt_PreStockSplitSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LaboratoryEquipmentMember" xlink:label="tcrt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EmployeeStockOptionAndRestrictedStockMember" xlink:label="tcrt_EmployeeStockOptionAndRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PostStockSplitSharesAuthorized" xlink:label="tcrt_PostStockSplitSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LabEquipmentMember" xlink:label="tcrt_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tcrt_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_OfficeAndComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tcrt_PreStockSplitSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_EmployeeStockOptionAndRestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tcrt_PostStockSplitSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_LabEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_TangibleAssetImpairmentCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail">
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EarningPerShareBasicAndDilutedLineItems" xlink:label="tcrt_EarningPerShareBasicAndDilutedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EarningPerShareBasicAndDilutedTable" xlink:label="tcrt_EarningPerShareBasicAndDilutedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tcrt_EarningPerShareBasicAndDilutedLineItems" xlink:to="tcrt_EarningPerShareBasicAndDilutedTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_EarningPerShareBasicAndDilutedTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_EarningPerShareBasicAndDilutedTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TwoThousandTwelveStockOptionPlanMember" xlink:label="tcrt_TwoThousandTwelveStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CommonStockOptionsMember" xlink:label="tcrt_CommonStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandTwelveStockOptionPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="tcrt_CommonStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TermLoanMember" xlink:label="tcrt_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_WarrantsExpirationDate" xlink:label="tcrt_WarrantsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TenthScheduledPaymentMember" xlink:label="tcrt_TenthScheduledPaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EightScheduledPaymentMember" xlink:label="tcrt_EightScheduledPaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PercentageOfPrepaymentsPremium" xlink:label="tcrt_PercentageOfPrepaymentsPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AmountOfPrepaymentsPremium" xlink:label="tcrt_AmountOfPrepaymentsPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AdditionalNumberOfWarrantsIssued" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_TermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_WarrantsExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_TenthScheduledPaymentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_EightScheduledPaymentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_PercentageOfPrepaymentsPremium" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_AmountOfPrepaymentsPremium" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcrt_AdditionalNumberOfWarrantsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OfficeAndComputerEquipmentMember" xlink:label="tcrt_OfficeAndComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LaboratoryEquipmentMember" xlink:label="tcrt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_OfficeAndComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EdenBiocellMember" xlink:label="tcrt_EdenBiocellMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AdditionalLoansCommitted" xlink:label="tcrt_AdditionalLoansCommitted"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DuneLakeCapitalMember" xlink:label="tcrt_DuneLakeCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_EdenBiocellMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_AdditionalLoansCommitted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_DuneLakeCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MaMember" xlink:label="tcrt_MaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MdAndersonMember" xlink:label="tcrt_MdAndersonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LeaseTerminationDate" xlink:label="tcrt_LeaseTerminationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OtherIncomeExpenseMember" xlink:label="tcrt_OtherIncomeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_HoustonTexasMember" xlink:label="tcrt_HoustonTexasMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SubleaseTermCommencedEndDateAmendment" xlink:label="tcrt_SubleaseTermCommencedEndDateAmendment"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TerminationCosts" xlink:label="tcrt_TerminationCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OperatingLeaseArea" xlink:label="tcrt_OperatingLeaseArea"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_GainLossOnModificationOfLease" xlink:label="tcrt_GainLossOnModificationOfLease"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SubleaseArea" xlink:label="tcrt_SubleaseArea"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseIncome" xlink:label="us-gaap_LeaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="tcrt_MaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_MdAndersonMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_LeaseTerminationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="tcrt_OtherIncomeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="tcrt_HoustonTexasMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_SubleaseTermCommencedEndDateAmendment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_TerminationCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnTerminationOfLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_OperatingLeaseArea" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_GainLossOnModificationOfLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_SubleaseArea" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermLeaseCost" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AresTradingMember" xlink:label="tcrt_AresTradingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IntrexonCorporationMember" xlink:label="tcrt_IntrexonCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PaymentTypeAxis" xlink:label="tcrt_PaymentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PerformanceBasedPaymentsMember" xlink:label="tcrt_PerformanceBasedPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DueDateDomain" xlink:label="tcrt_DueDateDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PostMarketingApprovalMember" xlink:label="tcrt_PostMarketingApprovalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TcellReceptorMember" xlink:label="tcrt_TcellReceptorMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ClassOfWarrantOrRightAxisAxis" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ClassOfWarrantOrRightDomainDomain" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ClassOfWarrantOrRightDomainDomain" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember" xlink:label="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DueDateAxis" xlink:label="tcrt_DueDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DueDateDomain" xlink:label="tcrt_DueDateDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MdAndersonLicenseMember" xlink:label="tcrt_MdAndersonLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OneTimeBenchmarkPaymentsMember" xlink:label="tcrt_OneTimeBenchmarkPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CARProductsMember" xlink:label="tcrt_CARProductsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MilestonePaymentsMaximumAmount" xlink:label="tcrt_MilestonePaymentsMaximumAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LicensedProductsMember" xlink:label="tcrt_LicensedProductsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CRADAAgreementMember" xlink:label="tcrt_CRADAAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LicenseAgreementCommencingDate" xlink:label="tcrt_LicenseAgreementCommencingDate"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MdAndersonAgreementAndWorldwideLicenseMember" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PatentAndTechnologyLicenseAgreementMember" xlink:label="tcrt_PatentAndTechnologyLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AnnualLicenseFees" xlink:label="tcrt_AnnualLicenseFees"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AggregateAmountPotentiallyReimburseableAmount" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MaximumAmountOfAdditionalMilestonesPayable" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MaximumAmountOfRoyaltyPayable" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MaximumRoyaltyAmount" xlink:label="tcrt_MaximumRoyaltyAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ClinicalExpenses" xlink:label="tcrt_ClinicalExpenses"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTerminationDate" xlink:label="tcrt_AgreementTerminationDate"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ContributionPayableOnPerAnnumBasis" xlink:label="tcrt_ContributionPayableOnPerAnnumBasis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MinimumRoyaltiesAmountPayable" xlink:label="tcrt_MinimumRoyaltiesAmountPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_RoyaltiesAmountPayableThereafter" xlink:label="tcrt_RoyaltiesAmountPayableThereafter"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ObligationsDueUnderContract" xlink:label="tcrt_ObligationsDueUnderContract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AnnualExpenseIncurred" xlink:label="tcrt_AnnualExpenseIncurred"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AggregateMinimumAnnualRoyaltiesPaid" xlink:label="tcrt_AggregateMinimumAnnualRoyaltiesPaid"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DescriptionOfFirstBenchmarkPayable" xlink:label="tcrt_DescriptionOfFirstBenchmarkPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PotentialBenchmarkPaymentsPayable" xlink:label="tcrt_PotentialBenchmarkPaymentsPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" xlink:label="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AggregateBenchmarkPaymentsPayable" xlink:label="tcrt_AggregateBenchmarkPaymentsPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTerminationNoticePeriod" xlink:label="tcrt_AgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:label="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AggregatePotentialBenchmarkPayments" xlink:label="tcrt_AggregatePotentialBenchmarkPayments"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AccrualsPriorToFirstMarketingApproval" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_InitialBenchmarkPaymentDue" xlink:label="tcrt_InitialBenchmarkPaymentDue"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" xlink:label="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_LicenseExpense" xlink:label="tcrt_LicenseExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PaymentUnderLicenseAgreement" xlink:label="tcrt_PaymentUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MilestonePayment" xlink:label="tcrt_MilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNameOfPlaintiff" xlink:label="us-gaap_LossContingencyNameOfPlaintiff"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_AresTradingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_IntrexonCorporationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_PerformanceBasedPaymentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_DueDateDomain" xlink:to="tcrt_PostMarketingApprovalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_TcellReceptorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_ClassOfWarrantOrRightAxisAxis" xlink:to="tcrt_ClassOfWarrantOrRightDomainDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_ClassOfWarrantOrRightAxisAxis" xlink:to="tcrt_ClassOfWarrantOrRightDomainDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_DueDateAxis" xlink:to="tcrt_DueDateDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_DueDateAxis" xlink:to="tcrt_DueDateDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_ClassOfWarrantOrRightDomainDomain" xlink:to="tcrt_MdAndersonWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_MdAndersonLicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_OneTimeBenchmarkPaymentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_CARProductsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MilestonePaymentsMaximumAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_LicensedProductsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_CRADAAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_LicenseAgreementCommencingDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MdAndersonAgreementAndWorldwideLicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_PatentAndTechnologyLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AnnualLicenseFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateAmountPotentiallyReimburseableAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_DueDateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumAmountOfAdditionalMilestonesPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_PaymentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumAmountOfRoyaltyPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_ClassOfWarrantOrRightAxisAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumRoyaltyAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ClinicalExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AgreementTerminationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ContributionPayableOnPerAnnumBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MinimumRoyaltiesAmountPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_RoyaltiesAmountPayableThereafter" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ObligationsDueUnderContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AnnualExpenseIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateMinimumAnnualRoyaltiesPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_DescriptionOfFirstBenchmarkPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PotentialBenchmarkPaymentsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateBenchmarkPaymentsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AgreementTerminationNoticePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregatePotentialBenchmarkPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AccrualsPriorToFirstMarketingApproval" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_InitialBenchmarkPaymentDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_LicenseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PaymentUnderLicenseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LossContingencyDamagesSoughtValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LossContingencyNameOfPlaintiff" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LitigationSettlementExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_BlackScholesModelMember" xlink:label="tcrt_BlackScholesModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTypeAxis" xlink:label="tcrt_AgreementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NewWarrantsMember" xlink:label="tcrt_NewWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SecuritiesPurchaseAgreementMember" xlink:label="tcrt_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_FairValueOfWarrants" xlink:label="tcrt_FairValueOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SvbWarrantsMember" xlink:label="tcrt_SvbWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PlacementAgentFeesAndOtherRelatedExpenses" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NonOperatingIncomeExpenseInducementOfWarrants" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCallOrExerciseFeatures" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ClassOfWarrantOrRightWarrantsExercised" xlink:label="tcrt_ClassOfWarrantOrRightWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_BlackScholesModelMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_NewWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_SecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="tcrt_AgreementTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_MdAndersonWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_FairValueOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_SvbWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_PlacementAgentFeesAndOtherRelatedExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_NonOperatingIncomeExpenseInducementOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCallOrExerciseFeatures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_ClassOfWarrantOrRightWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Dividends" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxLiabilityRightOfUseAsset" xlink:label="tcrt_DeferredTaxLiabilityRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies" xlink:label="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts" xlink:label="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsLeaseLiability" xlink:label="tcrt_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsDepreciation" xlink:label="tcrt_DeferredTaxAssetsDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsResearchExpensesCapitalized" xlink:label="tcrt_DeferredTaxAssetsResearchExpensesCapitalized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="tcrt_DeferredTaxLiabilityRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsDepreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tcrt_DeferredTaxAssetsResearchExpensesCapitalized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IncomeTaxesLineItems" xlink:label="tcrt_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IncomeTaxesTable" xlink:label="tcrt_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_FederalAndStateMember" xlink:label="tcrt_FederalAndStateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OperatingLossCarryforwardsExpirationDatesState" xlink:label="tcrt_OperatingLossCarryforwardsExpirationDatesState"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_OperatingLossCarryforwardsResearchExpirationDates" xlink:label="tcrt_OperatingLossCarryforwardsResearchExpirationDates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TaxRelaxationOnTaxableIncome" xlink:label="tcrt_TaxRelaxationOnTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome" xlink:label="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EligibilityOfBonusPercentage" xlink:label="tcrt_EligibilityOfBonusPercentage"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_BonusDepreciationEligibilityPercentage" xlink:label="tcrt_BonusDepreciationEligibilityPercentage"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_IncomeTaxesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="tcrt_FederalAndStateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_OperatingLossCarryforwardsExpirationDatesState" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_OperatingLossCarryforwardsResearchExpirationDates" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_TaxRelaxationOnTaxableIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_EligibilityOfBonusPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_IncomeTaxesLineItems" xlink:to="tcrt_BonusDepreciationEligibilityPercentage" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EquityLineItems" xlink:label="tcrt_EquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ScheduleOfEquityTable" xlink:label="tcrt_ScheduleOfEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsAxis" xlink:label="us-gaap_DividendsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SeriesOnePreferredStockMember" xlink:label="tcrt_SeriesOnePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IntrexonCorporationMember" xlink:label="tcrt_IntrexonCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AtTheMarketOfferingMember" xlink:label="tcrt_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTypeAxis" xlink:label="tcrt_AgreementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SharesAuthorized" xlink:label="tcrt_SharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_UnderwritingAgreementWithJefferiesMember" xlink:label="tcrt_UnderwritingAgreementWithJefferiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_UnderwritingAgreementMember" xlink:label="tcrt_UnderwritingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_SecuritiesPurchaseAgreementMember" xlink:label="tcrt_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NumberOfDaysOptionExerciable" xlink:label="tcrt_NumberOfDaysOptionExerciable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PublicOfferingNetPricePerShare" xlink:label="tcrt_PublicOfferingNetPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tcrt_EquityLineItems" xlink:to="tcrt_ScheduleOfEquityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tcrt_SeriesOnePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_IntrexonCorporationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcrt_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="tcrt_SharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_UnderwritingAgreementWithJefferiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="tcrt_AgreementTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_UnderwritingAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_SecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="tcrt_NumberOfDaysOptionExerciable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_DividendsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="tcrt_PublicOfferingNetPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_ScheduleOfEquityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_EquityLineItems" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EmployeesMember" xlink:label="tcrt_EmployeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandTwelveEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NonVestedStockMember" xlink:label="tcrt_NonVestedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ConsultantsMember" xlink:label="tcrt_ConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NonVestedRestrictedStockMember" xlink:label="tcrt_NonVestedRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tcrt_EmployeesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandTwelveEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tcrt_ConsultantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedRestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_TreasuryStockSharesAcquired" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_NonVestedRestrictedStockMember" xlink:label="tcrt_NonVestedRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedRestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ZiopharmMember" xlink:label="tcrt_ZiopharmMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ShareSubscriptionAgreementMember" xlink:label="tcrt_ShareSubscriptionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_TriArmMember" xlink:label="tcrt_TriArmMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EdenBioCellMember" xlink:label="tcrt_EdenBioCellMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_MilestonePaymentMadeOne" xlink:label="tcrt_MilestonePaymentMadeOne"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_ConditionalMilestoneAmountPayable" xlink:label="tcrt_ConditionalMilestoneAmountPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="tcrt_ZiopharmMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="tcrt_ShareSubscriptionAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_TriArmMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="tcrt_EdenBioCellMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="tcrt_MilestonePaymentMadeOne" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="tcrt_ConditionalMilestoneAmountPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_InitialGrantMember" xlink:label="tcrt_InitialGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AnnualCashRetainer" xlink:label="tcrt_AnnualCashRetainer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_HogueMember" xlink:label="tcrt_HogueMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AnnualGrantMember" xlink:label="tcrt_AnnualGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AdvanceNoticePeriodForTerminationAgreement" xlink:label="tcrt_AdvanceNoticePeriodForTerminationAgreement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_InitialGrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="tcrt_AnnualCashRetainer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tcrt_HogueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_AnnualGrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="tcrt_AdvanceNoticePeriodForTerminationAgreement" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UsefulLifeTermOfLeaseMember" xlink:label="us-gaap_UsefulLifeTermOfLeaseMember"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/BalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesNetCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="tcrt_GainLossOnOperatingLeaseModificationAndTermination" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RestructuringCharges" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_GainLossOnOperatingLeaseModificationAndTermination" xlink:label="tcrt_GainLossOnOperatingLeaseModificationAndTermination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" xlink:label="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AssetImpairmentCharges" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tcrt_IncreaseDecreaseInRightOfUseAsset" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tcrt_IncreaseDecreaseInOperatingDeposits" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="11" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tcrt_IncreaseDecreaseInLeaseLiabilities" order="14" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="15" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IncreaseDecreaseInRightOfUseAsset" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IncreaseDecreaseInOperatingDeposits" xlink:label="tcrt_IncreaseDecreaseInOperatingDeposits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_IncreaseDecreaseInLeaseLiabilities" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="us-gaap_ShareBasedCompensation" order="0" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="tcrt_AccruedConsultingFeesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="tcrt_AccruedClinicalExpensesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="tcrt_AccruedPreclinicalServicesCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="tcrt_AccruedManufacturingCostsCurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="9" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AccruedConsultingFeesCurrent" xlink:label="tcrt_AccruedConsultingFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AccruedClinicalExpensesCurrent" xlink:label="tcrt_AccruedClinicalExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AccruedPreclinicalServicesCurrent" xlink:label="tcrt_AccruedPreclinicalServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_AccruedManufacturingCostsCurrent" xlink:label="tcrt_AccruedManufacturingCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="tcrt_DeferredTaxLiabilityRightOfUseAsset" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="tcrt_DeferredTaxAssetsDepreciation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="tcrt_DeferredTaxAssetsLeaseLiability" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="tcrt_DeferredTaxAssetsResearchExpensesCapitalized" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="9" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxLiabilityRightOfUseAsset" xlink:label="tcrt_DeferredTaxLiabilityRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsDepreciation" xlink:label="tcrt_DeferredTaxAssetsDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsLeaseLiability" xlink:label="tcrt_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts" xlink:label="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies" xlink:label="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_DeferredTaxAssetsResearchExpensesCapitalized" xlink:label="tcrt_DeferredTaxAssetsResearchExpensesCapitalized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="9" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20231231.xsd#tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" xlink:label="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="tcrt_NewWarrantsMember" name="NewWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AdditionalNumberOfWarrantsIssued" name="AdditionalNumberOfWarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_IntrexonCorporationMember" name="IntrexonCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ScheduleOfEquityTable" name="ScheduleOfEquityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" name="MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_DeferredTaxAssetsDepreciation" name="DeferredTaxAssetsDepreciation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_WarrantTextBlock" name="WarrantTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_BonusDepreciationEligibilityPercentage" name="BonusDepreciationEligibilityPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PreStockSplitSharesAuthorized" name="PreStockSplitSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_MilestonePayment" name="MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_PaymentUnderLicenseAgreement" name="PaymentUnderLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AmountOfPrepaymentsPremium" name="AmountOfPrepaymentsPremium" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_AnnualExpenseIncurred" name="AnnualExpenseIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AgreementTypeAxisAxis" name="AgreementTypeAxisAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_StrategicAdvisorName" name="StrategicAdvisorName" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_OtherIncomeExpenseMember" name="OtherIncomeExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CommonStockOptionsMember" name="CommonStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MdAndersonWarrantMember" name="MdAndersonWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" name="ZiopLicenseAgreementWithTheNationalCancerInstituteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ObligationsDueUnderContract" name="ObligationsDueUnderContract" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_CRADAAgreementMember" name="CRADAAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AccruedPreclinicalServicesCurrent" name="AccruedPreclinicalServicesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_TenthScheduledPaymentMember" name="TenthScheduledPaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PatentAndTechnologyLicenseAgreementMember" name="PatentAndTechnologyLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EdenBioCellMember" name="EdenBioCellMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AccrualsPriorToFirstMarketingApproval" name="AccrualsPriorToFirstMarketingApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember" name="MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_HoustonTexasMember" name="HoustonTexasMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TriArmMember" name="TriArmMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PercentageOfPrepaymentsPremium" name="PercentageOfPrepaymentsPremium" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_GainLossOnModificationOfLease" name="GainLossOnModificationOfLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_TermLoanMember" name="TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_RoyaltiesAmountPayableThereafter" name="RoyaltiesAmountPayableThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_FederalAndStateMember" name="FederalAndStateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ZiopharmMember" name="ZiopharmMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_LicensedProductsMember" name="LicensedProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_NonVestedStockMember" name="NonVestedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EarningPerShareBasicAndDilutedLineItems" name="EarningPerShareBasicAndDilutedLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AgreementTypeDomain" name="AgreementTypeDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PotentialBenchmarkPaymentsPayable" name="PotentialBenchmarkPaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_ConsultantsMember" name="ConsultantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" name="PropertyAndEquipmentAndRightOfUseAssetsImpairment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ClinicalExpenses" name="ClinicalExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock" name="StockOptionsAndRestrictedStockAwardsTextBlockTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_NumberOfDaysOptionExerciable" name="NumberOfDaysOptionExerciable" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PaymentTypeAxis" name="PaymentTypeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" name="PercentageOfSubLicensingIncomePayableToRelatedParty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_WarrantsDisclosureAbstract" name="WarrantsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_LeaseTerminationDate" name="LeaseTerminationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TerminationCosts" name="TerminationCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_AgreementTerminationDate" name="AgreementTerminationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_FairValueOfWarrants" name="FairValueOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_ClassOfWarrantOrRightDomainDomain" name="ClassOfWarrantOrRightDomainDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EquityLineItems" name="EquityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TcellReceptorMember" name="TcellReceptorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" name="TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AnnualGrantMember" name="AnnualGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EightScheduledPaymentMember" name="EightScheduledPaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_NonVestedRestrictedStockMember" name="NonVestedRestrictedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_SharesAuthorized" name="SharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_DueDateDomain" name="DueDateDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_OneTimeBenchmarkPaymentsMember" name="OneTimeBenchmarkPaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_SeriesOnePreferredStockMember" name="SeriesOnePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_IncreaseDecreaseInRightOfUseAsset" name="IncreaseDecreaseInRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AdvanceNoticePeriodForTerminationAgreement" name="AdvanceNoticePeriodForTerminationAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_OperatingLeaseArea" name="OperatingLeaseArea" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_InitialGrantMember" name="InitialGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome" name="EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_LabEquipmentMember" name="LabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AccruedClinicalExpensesCurrent" name="AccruedClinicalExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_MaximumAmountOfRoyaltyPayable" name="MaximumAmountOfRoyaltyPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_DeferredTaxAssetsResearchExpensesCapitalized" name="DeferredTaxAssetsResearchExpensesCapitalized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_UnderwriterParOrStatedValuePerShare" name="UnderwriterParOrStatedValuePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_TwoThousandTwelveStockOptionPlanMember" name="TwoThousandTwelveStockOptionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract" name="DisclosureOfEarningPerShareBasicAndDilutedAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_SiliconValleyBankMember" name="SiliconValleyBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TwoThousandTwelveEquityIncentivePlanMember" name="TwoThousandTwelveEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AccruedConsultingFeesCurrent" name="AccruedConsultingFeesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" name="PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_SubleaseArea" name="SubleaseArea" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_OperatingLossCarryforwardsResearchExpirationDates" name="OperatingLossCarryforwardsResearchExpirationDates" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PublicOfferingNetPricePerShare" name="PublicOfferingNetPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AccruedManufacturingCostsCurrent" name="AccruedManufacturingCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" name="PercentageOfOriginalPrincipalDueAsAFinalPayment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_TaxRelaxationOnTaxableIncome" name="TaxRelaxationOnTaxableIncome" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_LicenseAgreementCommencingDate" name="LicenseAgreementCommencingDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_AgreementTerminationNoticePeriod" name="AgreementTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_DeferredTaxLiabilityRightOfUseAsset" name="DeferredTaxLiabilityRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_OrganizationalChangesPolicyTextBlock" name="OrganizationalChangesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_StockOfferedDuringPeriodShares" name="StockOfferedDuringPeriodShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_MdAndersonMember" name="MdAndersonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" name="CollaborationAgreementWithSolasiaPharmaKkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CARProductsMember" name="CARProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EmployeesMember" name="EmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EligibilityOfBonusPercentage" name="EligibilityOfBonusPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_ReductionInRightOfUseAssetsForModificationAndTermination" name="ReductionInRightOfUseAssetsForModificationAndTermination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_OperatingLossCarryforwardsExpirationDatesState" name="OperatingLossCarryforwardsExpirationDatesState" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PaymentTypeDomain" name="PaymentTypeDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_HogueMember" name="HogueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_DescriptionOfFirstBenchmarkPayable" name="DescriptionOfFirstBenchmarkPayable" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PostStockSplitSharesAuthorized" name="PostStockSplitSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_UnderwritingAgreementWithJefferiesMember" name="UnderwritingAgreementWithJefferiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_DuneLakeCapitalMember" name="DuneLakeCapitalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EarningPerShareBasicAndDilutedTable" name="EarningPerShareBasicAndDilutedTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AdditionalPaidInCapitalCommonStockMember" name="AdditionalPaidInCapitalCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MilestonePaymentMadeOne" name="MilestonePaymentMadeOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" name="LicenseAgreementWithTheNationalCancerInstituteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MaMember" name="MaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MdAndersonLicenseMember" name="MdAndersonLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_UnderwritingAgreementMember" name="UnderwritingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies" name="DeferredTaxAssetsStartUpAndPreClinicalStudies" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_AgreementTypeAxis" name="AgreementTypeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AdditionalLoansCommitted" name="AdditionalLoansCommitted" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ShareSubscriptionAgreementMember" name="ShareSubscriptionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AggregatePotentialBenchmarkPayments" name="AggregatePotentialBenchmarkPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" name="MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_UncategorizedAbstract" name="UncategorizedAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ClassOfWarrantOrRightAxisAxis" name="ClassOfWarrantOrRightAxisAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AnnualLicenseFees" name="AnnualLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" name="DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_NonOperatingIncomeExpenseInducementOfWarrants" name="NonOperatingIncomeExpenseInducementOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_AnnualCashRetainer" name="AnnualCashRetainer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_SvbWarrantsMember" name="SvbWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_GainLossOnOperatingLeaseModificationAndTermination" name="GainLossOnOperatingLeaseModificationAndTermination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_CantorMember" name="CantorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AggregateAmountPotentiallyReimburseableAmount" name="AggregateAmountPotentiallyReimburseableAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_ClassOfWarrantOrRightWarrantsExercised" name="ClassOfWarrantOrRightWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" name="ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts" name="DeferredTaxAssetsCapitalizedAcquisitionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_OfficeAndComputerEquipmentMember" name="OfficeAndComputerEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" name="MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_MdAndersonAgreementAndWorldwideLicenseMember" name="MdAndersonAgreementAndWorldwideLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_InitialBenchmarkPaymentDue" name="InitialBenchmarkPaymentDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_ContributionPayableOnPerAnnumBasis" name="ContributionPayableOnPerAnnumBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PostMarketingApprovalMember" name="PostMarketingApprovalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" name="AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ConditionalMilestoneAmountPayable" name="ConditionalMilestoneAmountPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_SiliconValleyBankLoanMember" name="SiliconValleyBankLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AresTradingMember" name="AresTradingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MaximumRoyaltyAmount" name="MaximumRoyaltyAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_EquityDistributionAgreementMember" name="EquityDistributionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_DueDateAxis" name="DueDateAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_LicenseExpense" name="LicenseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" name="NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_SubleaseTermCommencedEndDateAmendment" name="SubleaseTermCommencedEndDateAmendment" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_BlackScholesModelMember" name="BlackScholesModelMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EdenBiocellMember" name="EdenBiocellMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EmployeeStockOptionAndRestrictedStockMember" name="EmployeeStockOptionAndRestrictedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_FinancingArrangementsDisclosureTextBlock" name="FinancingArrangementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_AggregateBenchmarkPaymentsPayable" name="AggregateBenchmarkPaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_IssuanceOfCommonStockNetOfExpensesInShares" name="IssuanceOfCommonStockNetOfExpensesInShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_IncreaseDecreaseInOperatingDeposits" name="IncreaseDecreaseInOperatingDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_MilestonePaymentsMaximumAmount" name="MilestonePaymentsMaximumAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_IncreaseDecreaseInLeaseLiabilities" name="IncreaseDecreaseInLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_AggregateMinimumAnnualRoyaltiesPaid" name="AggregateMinimumAnnualRoyaltiesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_PlacementAgentFeesAndOtherRelatedExpenses" name="PlacementAgentFeesAndOtherRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_PerformanceBasedPaymentsMember" name="PerformanceBasedPaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MaximumAmountOfAdditionalMilestonesPayable" name="MaximumAmountOfAdditionalMilestonesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_MinimumRoyaltiesAmountPayable" name="MinimumRoyaltiesAmountPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_WarrantsExpirationDate" name="WarrantsExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886603356656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 27, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Alaunos Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001107421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TCRT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2617 Bissonnet Street,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-1475642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">355-4099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,012,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,764,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">RSM US LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886604089136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,062<span></span>
</td>
<td class="nump">$ 39,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,198<span></span>
</td>
<td class="nump">799<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,261<span></span>
</td>
<td class="nump">53,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">8,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">8,263<span></span>
</td>
<td class="nump">64,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">616<span></span>
</td>
<td class="nump">1,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,340<span></span>
</td>
<td class="nump">5,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Lease liabilities, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">558<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,956<span></span>
</td>
<td class="nump">24,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Lease liabilities, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,956<span></span>
</td>
<td class="nump">26,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock $0.001 par value; 34,666,667 shares authorized, 16,012,522 shares issued and outstanding at December 31, 2023 and 28,000,000 shares authorized,16,027,384 shares issued and outstanding at December 31, 2022</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">922,058<span></span>
</td>
<td class="nump">919,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(915,767)<span></span>
</td>
<td class="num">(880,627)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">6,307<span></span>
</td>
<td class="nump">38,555<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 8,263<span></span>
</td>
<td class="nump">$ 64,937<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886608881856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">34,666,667<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">16,012,522<span></span>
</td>
<td class="nump">16,027,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">16,012,522<span></span>
</td>
<td class="nump">16,027,384<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886696363520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 2,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">16,279<span></span>
</td>
<td class="nump">25,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,219<span></span>
</td>
<td class="nump">13,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_GainLossOnOperatingLeaseModificationAndTermination', window );">Gain on lease modification and termination</a></td>
<td class="num">(298)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">1,269<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment', window );">Property and equipment and right-of-use assets impairment</a></td>
<td class="nump">4,803<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">34,272<span></span>
</td>
<td class="nump">38,027<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(34,267)<span></span>
</td>
<td class="num">(35,105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,921)<span></span>
</td>
<td class="num">(3,154)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income , net</a></td>
<td class="nump">1,048<span></span>
</td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(873)<span></span>
</td>
<td class="num">(2,625)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (35,140)<span></span>
</td>
<td class="num">$ (37,730)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, Basic</a></td>
<td class="num">$ (2.2)<span></span>
</td>
<td class="num">$ (2.61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, Diluted</a></td>
<td class="num">$ (2.2)<span></span>
</td>
<td class="num">$ (2.61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">15,995,323<span></span>
</td>
<td class="nump">14,475,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">15,995,323<span></span>
</td>
<td class="nump">14,475,354<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_GainLossOnOperatingLeaseModificationAndTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on operating lease modification and termination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_GainLossOnOperatingLeaseModificationAndTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property and equipment and right of use assets impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886602942576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid In Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 58,057<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 900,895<span></span>
</td>
<td class="num">$ (842,852)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,408,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of employee stock options</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of employee stock options (in shares)</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">$ (45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of expenses</a></td>
<td class="nump">14,724<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">14,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IssuanceOfCommonStockNetOfExpensesInShares', window );">Issuance of common stock, net of expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,615,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancelled restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,527)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(37,730)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,730)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">38,555<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">919,166<span></span>
</td>
<td class="num">(880,627)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,027,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of expenses</a></td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IssuanceOfCommonStockNetOfExpensesInShares', window );">Issuance of common stock, net of expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancelled restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(35,140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,140)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 6,307<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 922,058<span></span>
</td>
<td class="num">$ (915,767)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,012,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_IssuanceOfCommonStockNetOfExpensesInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock, net of expenses in shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_IssuanceOfCommonStockNetOfExpensesInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886603444416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (35,140)<span></span>
</td>
<td class="num">$ (37,730)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2,315<span></span>
</td>
<td class="nump">2,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Property and equipment and right-of-use assets impairment</a></td>
<td class="nump">4,803<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of financing costs</a></td>
<td class="nump">1,339<span></span>
</td>
<td class="nump">981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash', window );">Stock-based compensation</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">3,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IncreaseDecreaseInRightOfUseAsset', window );">Decrease in the carrying amount of right-of-use assets</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on lease modification and termination</a></td>
<td class="num">(298)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on sale of equipment, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,399)<span></span>
</td>
<td class="nump">867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IncreaseDecreaseInOperatingDeposits', window );">Deposits</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(773)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(3,989)<span></span>
</td>
<td class="num">(668)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(610)<span></span>
</td>
<td class="num">(570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="num">(28)<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(30,142)<span></span>
</td>
<td class="num">(29,232)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(197)<span></span>
</td>
<td class="num">(216)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the disposal of property and equipment</a></td>
<td class="nump">1,543<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">1,346<span></span>
</td>
<td class="num">(193)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">14,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(18,105)<span></span>
</td>
<td class="num">(8,333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Debt extinguishment costs</a></td>
<td class="num">(125)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(18,138)<span></span>
</td>
<td class="nump">6,367<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(46,934)<span></span>
</td>
<td class="num">(23,058)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">52,996<span></span>
</td>
<td class="nump">76,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">6,062<span></span>
</td>
<td class="nump">52,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2,063<span></span>
</td>
<td class="nump">2,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ReductionInRightOfUseAssetsForModificationAndTermination', window );">Reduction in right-of-use assets for modification and termination</a></td>
<td class="nump">1,839<span></span>
</td>
<td class="nump">1,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts included in accrued expenses and accounts payable related to property and equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of lease liabilities reported as liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_IncreaseDecreaseInOperatingDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_IncreaseDecreaseInOperatingDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_IncreaseDecreaseInRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of right of use asset reported as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_IncreaseDecreaseInRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ReductionInRightOfUseAssetsForModificationAndTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in right of use assets for modification and termination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ReductionInRightOfUseAssetsForModificationAndTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479092/842-20-40-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886716529344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (35,140)<span></span>
</td>
<td class="num">$ (37,730)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886604662992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886601322096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Organization</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc., which is referred to herein as &#8220;Alaunos,&#8221; or the &#8220;Company,&#8221; is a clinical-stage oncology-focused cell therapy company that was historically involved in the development of adoptive TCR therapies, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. On January 25, 2022, the Company changed its corporate name from ZIOPHARM Oncology, Inc. to Alaunos Therapeutics, Inc. The Company was working to leverage its proprietary, non-viral </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gene transfer platform and its novel cancer mutation hotspot TCR library to design and manufacture personalized cell therapies that target neoantigens arising from common tumor-related mutations in key oncogenic genes, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s operations to date have consisted primarily of conducting research and development and raising capital to fund those efforts.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16,012,522</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares of common stock outstanding and an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,918,297</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock reserved for issuance pursuant to outstanding stock options and warrants.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, the Company announced a strategic reprioritization of its business and wind down of its TCR-T Library Phase 1/2 Trial. In connection with the reprioritization, the Company has significantly reduced its workforce and continues working to reduce costs in order to extend its cash runway. The Company continues to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. The Company has engaged Cantor Fitzgerald &amp; Co., or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cantor</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to act as strategic advisor for this process.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company follows the guidance of Accounting Standards Codification, or ASC, Topic 205-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Presentation of Financial Statements - Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has operated at a loss since its inception in 2003 and has no recurring revenue from operations.&#8239;The Company anticipates that losses will continue for the foreseeable future. As of December 31, 2023, the Company had approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8239;million of cash and cash equivalents. The Company&#8217;s accumulated deficit at December 31, 2023 was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">915.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8239;million.&#8239;Given its current development plans and cash management efforts, the Company anticipates cash resources will be sufficient to fund operations into the third quarter of 2024.&#8239;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company continues to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. The Company&#8217;s ability to continue operations after its current cash resources are exhausted depends on future events, including its ability to obtain additional financing or to achieve profitable operations, as to which no assurances can be given, nor are within the Company's control. If adequate additional funds are not available when required, or if the Company is unsuccessful in entering into partnership agreements for further development of its product candidates, management may need to curtail its development efforts and planned operations to conserve cash until sufficient additional capital is raised. There can be no assurances that such a plan would be successful.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements, and substantial doubt as to the Company's ability to continue as a going concern exists. This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has elected to make a reclassification in the presentation of the cash flow to show non-cash changes in right-of-use assets and lease liabilities related to modifications and terminations as non-cash for the year ended December 31, 2022 in order to conform presentation to the December 31, 2023 disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886603823584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_FinancingArrangementsDisclosureTextBlock', window );">Financings</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financings</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 Loan and Security Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 6, 2021, the Company entered into a Loan and Security Agreement, or the Loan and Security Agreement, with Silicon Valley Bank and affiliates of Silicon Valley Bank, or collectively, SVB. The Loan and Security Agreement provided for an initial term loan of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million funded at the closing, or the Term A Tranche, with an additional tranche of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million available if certain funding and clinical milestones were met by August 31, 2022, or the Term B Tranche.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective December 28, 2021, the Company, entered into an amendment to the Loan and Security Agreement, or the First Amendment. The First Amendment extended the interest-only period through August 31, 2022. The First Amendment also eliminated the Term B Tranche, which remained unfunded, leaving only the Term A Tranche, or the SVB Facility. Under the amended Loan and Security Agreement, the SVB Facility was to mature on August 1, 2023. On May 1, 2023, the Company repaid its outstanding debt obligations under the amended Loan and Security Agreement in their entirety.</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to Note 4, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for further discussion of the Loan and Security Agreement and the First Amendment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 Equity Distribution Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 12, 2022, the Company entered into an Equity Distribution Agreement, or the Equity Distribution Agreement, with Piper Sandler &amp; Co., or Piper Sandler, pursuant to which the Company can offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million through Piper Sandler as its sales agent in an "at the market offering." Piper Sandler will receive a commission of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the gross proceeds of any common stock sold under the Equity Distribution Agreement. During the years ended December 31, 2023 and 2022, there have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> sales of the Company's common stock under the Equity Distribution Agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 Public Offering</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 29, 2022, the Company entered into an underwriting agreement, or the Underwriting Agreement, with Cantor Fitzgerald &amp; Co., or the Underwriter, as the sole underwriter, relating to the issuance and sale in an underwritten offering, or the Offering, of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,615,248</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, or the Firm Shares, of the Company&#8217;s common stock to the Underwriter at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.2865</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The net proceeds to the Company from the Offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (before accounting for the partial exercise of the Underwriter's option as described below) after deducting underwriting discounts and commissions and offering expenses payable by the Company.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Underwriting Agreement, the Company granted the Underwriter an option, exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30 days</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to purchase up to an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">242,287</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, which we refer to, together with the Firm Shares, as the Shares, at the same price per share as the Firm Shares. On January 5, 2023, the Underwriter partially exercised its option to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,420</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_FinancingArrangementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Includes disclosures related to financing receivables and financing guarantees in which the company is the guarantor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_FinancingArrangementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886601362000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Significant Accounting Policies </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s most significant estimates and judgments used in the preparation of the financial statements are:</span></p><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trial expenses and other research and development expenses;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration agreements;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value measurements of stock-based compensation; and</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes.</span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents consist primarily of demand deposit accounts, certificates of deposit and deposits in short-term U.S. treasury money market mutual funds. Cash equivalents are stated at cost, which approximates fair market value.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to expense while the costs of significant improvements are capitalized. Depreciation and amortization is calculated on a straight-line basis using the following periods, which represent the estimated useful lives of the assets:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:54.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.44%;"></td>
        <td style="width:3.88%;"></td>
        <td style="width:26.68%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office and computer equipment</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#65279;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#65279;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#65279;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#65279;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_fa18b81e-dc37-4248-8153-57693071a98f;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Life of the lease</span></span></span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs, including certain design, construction and installation costs related to assets that are under construction and are in the process of being readied for their intended use, are recorded as construction in progress and are not depreciated until such time as the subject asset is placed in service. Repairs and maintenance that do not extend the useful life of the asset are expensed as incurred. Upon sale, retirement or other disposition of these assets, the costs and related accumulated depreciation are removed from the respective accounts and any gain or loss on the disposition is included in the statements of operations.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-Lived Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assessments of long-lived assets and the remaining useful lives of such long-lived assets are reviewed for impairment whenever a triggering event occurs or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An asset, or group of assets, is considered to be impaired when the undiscounted estimated net cash flows expected to be generated by the asset, or group of assets, are less than its carrying amount. The impairment recognized is the amount by which the carrying amount exceeds the fair market value of the impaired asset, or group of assets, based on the present value of the expected future cash flows associated with the use of the asset.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Segments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the Company&#8217;s chief operating decision maker, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrants</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assesses whether warrants issued require accounting as derivatives. The Company determined that the warrants were (1) indexed to the Company&#8217;s own stock and (2) classified in stockholders&#8217; equity in accordance with Financial Accounting Standards Board, or FASB, ASC Topic 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As such, the Company has concluded the warrants meet the scope exception for determining whether the instruments require accounting as derivatives and should be classified in stockholders&#8217; equity.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></p><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of December 31, 2023 and 2022 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of<br/>December 31,<br/>2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,744</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,744</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of<br/>December 31,<br/>2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,058</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,058</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cash equivalents represent demand deposit accounts and deposits in a short-term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset. There have been no changes to the valuation methods during the years ended December 31, 2023 and 2022. The Company had no financial assets or liabilities that were classified as Level 2 or Level 3 during the years ended December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair value of non-financial instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates assets for impairment whenever events or changes in circumstances indicate that indicators of impairment exist. In those evaluations, the Company compares estimated future undiscounted cash flows generated by each asset (or asset group) to the carrying value of the asset (or asset group) to determine if an impairment charge is required. If the undiscounted cash flows test fails, the Company estimates the fair value of the asset (or asset group) to determine the impairment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following the Company&#8217;s announced strategic reprioritization on August 14, 2023, the Company determined that changes in the intended use of certain property and equipment represented an indicator of impairment, resulting in an impairment charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which was primarily related to leasehold improvements of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and lab equipment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Company determined certain prepaid expense balances to be impaired given the Company&#8217;s strategic reprioritization, and therefore, has recorded an impairment charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to prepaid expenses and other current assets, which is recorded in research and development expenses within the statement of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 9, 2023, the Company executed an agreement to sell laboratory equipment for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and recognized a gain on disposal of equipment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand, which is recorded in other income in the statement of operations</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition from Collaboration Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue for the year ended December 31, 2023 consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand and for the year ended December 31, 2022 consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. For the years ended December 31, 2023 and 2022, the Company recognized revenue through its Collaboration Agreement with Solasia Pharma K.K. primarily due to the achievement of milestones, as further described in Note 9, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commitments and Contingencies.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company primarily generates revenue through collaboration arrangements with strategic partners for the development and commercialization of product candidates. The Company recognizes revenue in accordance with ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers, or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASC 606. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods and/or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and/or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes collaboration revenue under certain of the Company&#8217;s license or collaboration agreements that are within the scope of ASC 606. The Company&#8217;s contracts with customers typically include promises related to licenses to intellectual property, research and development services and options to purchase additional goods and/or services. If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contracts that include an option to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer&#8217;s election.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The terms of the Company&#8217;s arrangements with customers typically include the payment of one or more of the following:(i) non-refundable, up-front payment, (ii) development, regulatory and commercial milestone payments, (iii) future options and (iv) royalties on net sales of licensed products. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the most likely amount method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company reevaluates the probability of achievement of each milestone and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company allocates the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contract to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require the use of judgment to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenue, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the process of preparing the Company's financial statements, the Company is required to estimate its accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with its personnel and third-party vendors to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the services when the Company has not yet been invoiced or otherwise notified of the actual costs. The majority of the Company's service providers invoice the Company in arrears for services performed, on a predetermined schedule or when contractual milestones are met; however, a few require advanced payments. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known to it at that time. Examples of estimated accrued research and development expenses include fees paid to:</span></p><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical research organizations, or CROs, in connection with performing research services on its behalf and clinical trials;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">investigative sites or other providers in connection with clinical trials;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">vendors in connection with preclinical and clinical development activities; and</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">vendors related to product manufacturing, development, and distribution of preclinical and clinical supplies.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company bases its expenses related to preclinical studies and clinical trials on its estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct and manage clinical trials on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company's vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed, enrollment of patients, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low in any particular period.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. The Company evaluates the realizability of its deferred tax assets and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates this tax position on an annual basis. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense (Refer to Note 12, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">).</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting for Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation cost is measured at the grant date based on the estimated fair value of the award and is recognized as expense over the employee&#8217;s requisite service period. Stock-based compensation expense is based on the number of awards ultimately expected to vest and is reduced for forfeitures as they occur. Consistent with prior years, the Company uses the Black-Scholes option pricing model, which requires estimates of the expected term option holders will retain their options before exercising them and the estimated volatility of the Company&#8217;s common stock price over the expected term.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized the full impact of its share-based employee payment plans in the statements of operations for each of the years ended December 31, 2023 and 2022 and did not capitalize any such costs on the balance sheets. The Company recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of compensation expense related to stock options </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the year ended December 31, 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of compensation expense related to stock options </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the year ended December 31, 2022. The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of compensation expense related to restricted stock for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the year ended December 31, 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the year ended December 31, 2022 (refer to Note 13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Option Plan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). The total compensation expense relating to vesting of stock options and restricted stock awards for the year ended December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2022. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents share-based compensation expense included in the Company&#8217;s statements of operations:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:64.713%;"></td>
          <td style="width:1.56%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.643%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.56%;"></td>
          <td style="width:1%;"></td>
          <td style="width:15.523%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">439</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">868</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,361</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,660</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,800</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,528</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. The estimated weighted-average fair value of stock options granted to employees in the year ended December 31, 2023 was approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.58</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">per share and was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.54</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2022. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company&#8217;s historical experience. The risk-free interest rate is based on a U.S. treasury note with a maturity similar to the option award&#8217;s expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The Company calculated expected term using the simplified method described in SEC Staff Accounting Bulletin, or SAB, No. 107 and No. 110 as it continues to meet the requirements promulgated in SAB No. 110.</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The assumptions for volatility, expected life, dividend yield and risk-free interest rate are presented in the table below:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.173%;"></td>
          <td style="width:1.62%;"></td>
          <td style="width:13.443%;"></td>
          <td style="width:1.62%;"></td>
          <td style="width:16.143%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.51</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.01</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.63</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.21</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected life in years</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.06</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.27</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89.69</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">112.12</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74.49</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88.75</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;%</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;%</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Stock Split</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 31, 2024, the Company filed a Second Amended and Restated Certificate of Incorporation (the &#8220;Charter Amendment&#8221;) with the Secretary of State of the State of Delaware in order to effect a reverse stock split of the Company&#8217;s common stock at a ratio of 1-for-15 (the &#8220;Reverse Split&#8221;). The Charter Amendment decreased the number of authorized shares of common stock from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">520,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34,666,667</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Charter Amendment does not affect the par value of the Company&#8217;s common stock or change the number of authorized shares or par value of the Company&#8217;s preferred stock. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Charter Amendment became effective on January 31, 2024 at 5:00 p.m. Eastern Time, at which time every 15 shares of the Company&#8217;s issued and outstanding common stock automatically combined and converted into 1 share of common stock.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No fractional shares were issued in connection with the Reverse Split. Stockholders of record who would otherwise have been entitled to receive fractional shares as a result of the Reverse Split received a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing sales price per share of the common stock (as adjusted for the Reverse Split) on The Nasdaq Capital Market on January 31, 2024.</span></p><p id="bkmk_220" style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All share and per share amounts of common stock, options, warrants, and restricted stock in the accompanying financial statements and notes thereto have been retroactively adjusted for all periods presented to reflect the Reverse Split as if it had occurred at the beginning of the earliest period presented.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Share</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company&#8217;s common stock during the applicable period, unless their effect on net loss per share is antidilutive. The effect of computing diluted net loss per common share was antidilutive for any potentially issuable shares of common stock from the conversion of stock options, unvested restricted stock and warrants and, as such, have been excluded from the calculation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The computation of basic and diluted net loss per share consists of the following:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.72%;"></td>
          <td style="width:1.72%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.92%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.72%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.92%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,140</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,730</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,995,323</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,475,354</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.20</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.61</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain shares related to some of the Company&#8217;s outstanding common stock options, unvested restricted stock and warrants have not been included in the computation of diluted net loss per share for the years ended December 31, 2023 and 2022 as the result would be antidilutive. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such potential common shares on December 31, 2023 and 2022 consist of the following:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.967%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.357%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.357%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">465,898</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">693,909</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62,604</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,452,399</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,528,156</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,918,297</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,284,669</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued Accounting Standards Update, or ASU, 2016-13, Financial Instruments: Credit Losses (Topic 326) as clarified in ASU 2019-04, ASU 2019-05 and ASU 2020-02. The objective of this standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than-temporary impairments on investment securities are recorded. The Company adopted ASU 2016-13 effective January 1, 2023, with no material impact upon adoption.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances the disclosures required for operating segments in the Company's annual and interim financial statements. ASU 2023-07 is effective retrospectively for fiscal years beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this standard.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for the Company prospectively to all annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this standard.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886601352912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Debt</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> debt obligations outstanding at December 31, 2023. The carrying values of the Company's debt obligation at December 31, 2022 were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loan and Security Agreement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,395</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unamortized discount on Loan and Security Agreement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">630</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,765</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: long-term debt, current</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,765</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 6, 2021, the Company entered into the Loan and Security Agreement with SVB. The Loan and Security Agreement provided for the funding of the Term A Tranche at the closing, with the Term B Tranche available if certain funding and clinical milestones were met by August 31, 2022. The SVB Facility and related obligations under the Loan and Security Agreement were secured by substantially all of the Company's</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">properties, rights and assets, except for its intellectual property (which was subject to a negative pledge under the Loan and Security Agreement). In addition, the Loan and Security Agreement contained customary representations, warranties, events of default and covenants.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 28, 2021, the Company entered into the First Amendment to the Loan and Security Agreement. The First Amendment eliminated the unfunded Term B Tranche, among other things. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The SVB Facility bore interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and (b) the current published U.S. prime rate, plus a margin of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All outstanding obligations under the amended Loan and Security Agreement were due and payable on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In connection with the payment of all of the Company's outstanding obligations, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company also owed SVB </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the original principal amounts borrowed as a final payment, or the Final Payment. Effective March 30, 2023, the Company entered into a Third Amendment to the Loan and Security Agreement, or the Third Amendment. Under the terms of the Third Amendment, the Company was no longer required to maintain all of its operating accounts, depository accounts and excess cash with SVB or one of its affiliates, and was instead only required to maintain a single operating or depository account at Silicon Valley Bank. The Third Amendment also modified the cash collateralization requirement, such that the Company was required to cash collateralize the entire sum of the outstanding principal amount of the SVB Facility, plus an amount equal to the Final Payment, which amount was to be reduced commensurate with each regularly scheduled monthly payment of principal and interest on the SVB Facility.</span></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 1, 2023, the Company paid SVB an amount equal to the entire outstanding principal amount under the SVB Facility, all accrued and unpaid interest and the Final Payment. In accordance with the First Amendment, the payment was subject to a prepayment premium of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> During the year ended December 31, 2023, the Company recorded the remaining amounts associated with the Final Payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and the prepayment premium of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as interest expense within the statement of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with its entry into the Loan and Security Agreement in August 2021, the Company issued to SVB warrants to purchase (i) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,856</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock, in the aggregate, and (ii) up to an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,856</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, in the aggregate, in the event the Company achieved certain clinical milestones, in each case at an exercise price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33.30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with its entry into the First Amendment in December 2021, the Company amended and restated the warrants issued to SVB. As amended and restated, the warrants are for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">43,308</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, in the aggregate, with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, or the SVB Warrants. The SVB Warrants expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 6, 2031</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The issuance costs for the Loan and Security Agreement, including the First Amendment, were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and primarily related to the SVB Warrants, which were amortized into interest expense over the term of the loan. Interest expense, including the amortization of issuance costs, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886601365632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and Equipment, net</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net, consists of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.213%;"></td>
        <td style="width:1.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office and computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,183</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,291</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,561</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,232</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,267</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,807</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,460</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense for the year ended December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2022. During the year ended December 31, 2023, the Company impaired property and equipment by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Refer to Note 3, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, for further details.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886696630304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consist of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.96%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">568</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,160</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">717</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">534</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preclinical services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">198</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Manufacturing services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,177</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other consulting services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">169</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,340</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,454</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886608661568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Related Party Transactions</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Joint Venture with TriArm Therapeutics/Eden BioCell</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 18, 2018, the Company and TriArm Therapeutics, Ltd., or TriArm, launched Eden BioCell, Ltd., or Eden BioCell, as a joint venture to lead commercialization of the Company&#8217;s </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-generated CAR-T therapies in the People&#8217;s Republic of China (including Macau and Hong Kong), Taiwan and Korea. The Company licensed to Eden BioCell the rights in Greater China for its third-generation Sleeping Beauty-generated CAR-T therapies targeting the CD19 antigen. Eden BioCell is owned equally by the Company and TriArm and the parties share decision-making authority. TriArm contributed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Eden BioCell and has committed up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to this joint venture. TriArm also managed all clinical development in the territory pursuant to a master services agreement between TriArm and Eden BioCell. James Huang was the founder and serves as managing partner of Panacea Venture, which is an investor in TriArm. Mr. Huang was the Chair of the Company's board of directors until September 22, 2023 and had been a director since July 2020. He also serves as a member of Eden BioCell&#8217;s board of directors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, TriArm and Alaunos mutually agreed to dissolve the Eden BioCell joint venture. The joint venture agreement has been terminated and the Eden BioCell entity has been dissolved as of July 2023. Refer to Note 15, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Joint Venture</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, for further details.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration with Dune Lake Capital</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, the Company entered into a consulting agreement with Dune Lake Capital, LLC, or Dune Lake Capital, which was founded by Dale Curtis Hogue, Jr., the Company's interim Chief Executive Officer. During the year ended December 31, 2023, the Company recorded expenses of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand for consulting services performed by Dune Lake Capital with respect to the period from January 2023 to August 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886604399520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Leases, Operating [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2022, the Company modified its real estate lease agreement executed on December 15, 2020 with MD Anderson for office space in Houston, Texas, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which reduced the Company's leased space from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,111</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,228</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet. As a result, the associated lease liability and right-of-use asset were remeasured to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million based on revised lease payments. A gain of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recorded on the lease modification during the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, the Company executed an agreement to sub-sublease </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,772</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of subleased office space in Boston. For the year ended December 31, 2023, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">43</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand in lease income, and for the year ended December 31, 2022, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in lease income. Lease income is classified within other income on the statement of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 19, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company terminated its office lease in Boston, Massachusetts, which was set to expire on August 31, 2026. In connection with the termination, the Company also assigned to the landlord its sub-sublease of the Boston office space, which had </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a term expiring on June 30, 2025 with an option to extend through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">July 31, 2026</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Termination costs for the Boston office lease were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. A gain of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recorded on the lease termination during the year ended December 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2023, in accordance with the lease agreement executed on December 15, 2020, the Company notified MD Anderson, as landlord, of its intention to terminate office space of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,228</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet in Houston, Texas. As a result, the associated lease liability and right-of-use asset were remeasured to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand, reflecting the revised lease payments and term end date of November 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 1, 2023, the Company and MD Anderson, as landlord, agreed to mutually terminate the leases dated October 15, 2019 and April 7, 2020, which represented office space totaling </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,037</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet, effective November 15, 2023. As a result, the Company agreed to make a final payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to the landlord. A gain of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recorded on the lease termination during the year ended December 31, 2023.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p id="bkmk_231" style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of lease expense were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.493%;"></td>
        <td style="width:1.839%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.915%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.839%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.914%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">428</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">756</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">428</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">756</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average remaining lease term (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.13</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in operating lease costs for the year-ended December 31, 2023. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize new operating lease assets obtained in exchange for operating lease liabilities for the year-ended December 31, 2023. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have any leases, other than a short-term lease, as of December 31, 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886602505008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commitments and Contingencies</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusive License Agreement with Precigen</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 5, 2018, the Company entered into an exclusive license agreement, or License Agreement, with PGEN Therapeutics, or PGEN, a wholly owned subsidiary of Precigen Inc., or Precigen, which was formerly known as Intrexon Corporation. Except where the context otherwise requires, the Company refers to PGEN and Precigen together as Precigen. Pursuant to the terms of the License Agreement, the Company had exclusive, worldwide rights to research, develop and commercialize (i) TCR products designed for neoantigens for the treatment of cancer, (ii) products utilizing Precigen&#8217;s RheoSwitch&#174; gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (iii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the License and Collaboration Agreement effective March 27, 2015 between the Company, Precigen and ARES TRADING S.A., a subsidiary of Merck KGaA, as assigned by Precigen to PGEN. Under the License Agreement, the Company also had exclusive, worldwide rights for certain patents relating to the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company was responsible for all aspects of the research, development and commercialization and was required to use commercially reasonable efforts to develop certain products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In consideration of the licenses and other rights granted by Precigen, the Company was required to pay Precigen an annual license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, reimburse Precigen for certain historical costs, pay Precigen milestones up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">52.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for each exclusively licensed program upon the achievement of certain milestones, and pay Precigen tiered royalties up to a maximum royalty amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the aggregate. The Company was also obligated to pay Precigen </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of any sublicensing income received relating to the licensed products. The Company was responsible for all development costs associated with each of the licensed products. For the years ended December 31, 2023 and 2022, the Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in annual license fees under this agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Precigen was obligated to pay the Company royalties up to a maximum royalty amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> royalty amounts were incurred during the years ended December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 3, 2023, the Company entered into the Amended and Restated Exclusive License Agreement with Precigen, or the A&amp;R License Agreement, which restated and amended the License Agreement in full. Under the A&amp;R License Agreement, the Company still has exclusive, worldwide rights to research, develop and commercialize TCR products designed for neoantigens or driver mutations for the treatment of cancer and non-exclusive rights to use non-driver mutation TCRs. The Company further maintains its exclusive, worldwide rights for certain patents relating to the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company remains solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. The (i) products utilizing Precigen&#8217;s RheoSwitch&#174; gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (ii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the License and Collaboration Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">effective </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 27, 2015 between the Company, Precigen and ARES TRADING S.A., a subsidiary of Merck KGaA, as assigned by Precigen to PGEN are no longer exclusively licensed to the Company. The Company is no longer obligated to use commercially reasonable efforts for the exclusively licensed products. The A&amp;R License Agreement further eliminates any royalty or milestone obligations to Precigen, with an annual license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand due on the anniversary of the A&amp;R License Agreement effective date. Precigen is no longer obligated to pay the Company royalties on the net sales derived from the sale of Precigen's CAR products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreement and 2015 Research and Development Agreement &#8212;The University of Texas MD Anderson Cancer Center</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 13, 2015</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company, together with Precigen, entered into a license agreement, or the MD Anderson License with MD Anderson (which Precigen subsequently assigned to PGEN). Pursuant to the MD Anderson License, the Company, together with Precigen, holds an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR T-cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells, and TCRs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 17, 2015, the Company, Precigen and MD Anderson entered into the 2015 R&amp;D Agreement to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. The rights and obligations of Precigen under the 2015 R&amp;D Agreement were assigned to the Company pursuant to the Fourth Amendment to 2015 R&amp;D Agreement which was entered into on September 19, 2019 (the &#8220;Fourth Amendment&#8221;) with an effective date of October 5, 2018. The activities under the 2015 R&amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As provided under the MD Anderson License, the Company provided funding for research and development activities in support of the research programs under the 2015 R&amp;D Agreement for a period of three years and in an amount of no less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and no greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million per year. On November 14, 2017, the Company entered into an amendment to the 2015 R&amp;D Agreement, extending its term until April 15, 2021. In connection with the execution of the 2019 R&amp;D Agreement described below, on October 22, 2019, the Company amended the 2015 R&amp;D Agreement to extend the term of the 2015 R&amp;D Agreement until December 31, 2026 and to allow cash resources on hand at MD Anderson under the 2015 R&amp;D Agreement to be used for development costs under the 2019 Research and Development Agreement, or the 2019 R&amp;D Agreement, which the Company entered into on October 22, 2019, with MD Anderson, pursuant to which the Company agreed to collaborate with respect to the TCR program. For the year ended December 31, 2023 the Company incurred clinical expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from MD Anderson related to the 2015 R&amp;D Agreement, and did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t incur clinical costs from MD Anderson related to the 2015 R&amp;D Agreement for the year ended December 31, 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term of the MD Anderson License, the Company, together with Precigen, shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if the Company and Precigen are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if the Company and Precigen are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by the Company and Precigen, if such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both the Company and Precigen and may be terminated by the mutual written agreement of the Company, Precigen, and MD Anderson.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Research and Development Agreement&#8212;The University of Texas MD Anderson Cancer Center</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the 2019 R&amp;D Agreement, the Company and MD Anderson will, among other things, collaborate on programs to expand the Company's TCR library and conduct clinical trials. The activities under the 2019 R&amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will own all inventions and intellectual property developed under the 2019 R&amp;D Agreement and the Company will retain all rights to all intellectual property, patentable or not, for oncology products manufactured using non-viral gene transfer technologies under the 2019 R&amp;D Agreement, including the Company's</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology. The Company has granted MD Anderson an exclusive license for such intellectual property to develop and commercialize autologous TCR products manufactured using viral gene transfer technologies and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any products outside the field of oncology and a non-exclusive license for allogenic TCR products manufactured using viral-based technologies.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the 2019 R&amp;D Agreement, the Company agreed, beginning on January 1, 2021, to reimburse MD Anderson up to a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for development costs under the 2019 R&amp;D Agreement, after the funds from the 2015 R&amp;D Agreement are exhausted. In addition, the Company will pay MD Anderson royalties on net sales of its TCR products. The Company is required to make performance-based payments upon the successful completion of clinical and regulatory benchmarks relating to its TCR products. The aggregate potential benchmark payments are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">36.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, of which only $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will be due prior to the first marketing approval of the Company's TCR products. The royalty rates and benchmark payments owed to MD Anderson may be reduced upon the occurrence of certain events. The Company also agreed to sell its TCR products to MD Anderson at preferential prices and will sell the Company's TCR products in Texas exclusively to MD Anderson for a limited period of time following the first commercial sale of the Company's TCR products. For the years ended December 31, 2023 and 2022, the Company incurred clinical expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from MD Anderson related to the 2019 R&amp;D Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2019 R&amp;D Agreement will terminate on December 31, 2026 and either party may terminate the 2019 R&amp;D Agreement following written notice of a material breach. The 2019 R&amp;D Agreement also contains customary provisions related to indemnification obligations, confidentiality and other matters.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the execution of the 2019 R&amp;D Agreement, on October 22, 2019, the Company issued MD Anderson a warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">222,222</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, which is referred to as the MD Anderson Warrant. The MD Anderson Warrant has an initial exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.015</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and vests upon the occurrence of certain clinical milestones. As of December 31, 2023, the milestones have not been met.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreement with the NCI</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 28, 2019, the Company entered into a patent license agreement, or the Patent License, with the NCI. Pursuant to the Patent License, the Company held an exclusive, worldwide license to certain intellectual property to develop and commercialize patient-derived (autologous), peripheral blood T-cell therapy products engineered by transposon-mediated gene transfer to express TCRs reactive to mutated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS, TP53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neoantigens. In addition, pursuant to the Patent License, the Company held an exclusive, worldwide license to certain intellectual property for manufacturing technologies to develop and commercialize autologous, peripheral blood T-cell therapy products engineered by non-viral gene transfer to express TCRs, as well as a non-exclusive, worldwide license to certain additional manufacturing technologies. On May 29, 2019, January 8, 2020, September 28, 2020, April 16, 2021, May 4, 2021 and August 13, 2021 the Company amended the Patent License to expand its TCR library to include additional TCRs reactive to mutated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neoantigens licensed from the NCI.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The terms of the Patent License required the Company to pay the NCI minimum annual royalties in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which amount would be reduced to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million once the aggregate minimum annual royalties paid by the Company equaled $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company was also required to make performance-based payments upon successful completion of clinical and regulatory benchmarks relating to the licensed products. Of such payments, the aggregate potential benchmark payments were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, of which aggregate payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million would be due only after marketing approval in the United States or in Europe, Japan, Australia, China or India. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The first benchmark payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was paid during the year ended December 31, 2022 upon the initiation of the Company's TCR-T Library Phase 1/2 Trial, which was a qualifying Phase 1 clinical trial under the terms of the Patent License.</span></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Company was required to pay the NCI one-time benchmark payments following aggregate net sales of licensed products at certain aggregate net sales ranging from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">250.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion. The aggregate potential amount of these benchmark payments was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company was also required to pay the NCI royalties on net sales of products covered by the Patent License at rates in the low to mid-single digits depending upon the technology included in a licensed product. To the extent the Company entered into a sublicensing agreement relating to a licensed product, the Company would be required to pay the NCI a percentage of all consideration received from a sublicensee, which percentage would decrease based on the stage of development of the licensed product at the time of the sublicense.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Patent License was to expire upon expiration of the last patent contained in the licensed patent rights, unless terminated earlier. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The NCI could terminate or modify the Patent License in the event of a material breach, including if the Company did not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company could terminate the Patent License, or any portion thereof, in the Company's sole discretion at any time upon </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days&#8217; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">written notice to the NCI. In addition, the NCI had the right to: (i) require the Company to sublicense the rights to the product candidates covered by the Patent License upon certain conditions, including if the Company was not reasonably satisfying required health and safety needs and (ii) terminate or modify the Patent License, including if the Company was not satisfying requirements for public use as specified by federal regulations. On October 27, 2023, the Company provided the NCI the requisite notice of its intent to terminate the Patent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">effective December 26, 2023. The Company discovered multiple proprietary TCRs targeting driver mutations through its hunTR TCR discovery platform, including many of the same </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mutations licensed from the NCI.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023 the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of expenses and incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of expenses for the year ended December 31, 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cooperative Research and Development Agreement (CRADA) with the NCI</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 9, 2017, the Company entered into a Cooperative Research and Development Agreement, or the CRADA, with the NCI. The purpose of this collaboration was to advance a personalized TCR-T approach for the treatment of solid tumors. Using the Company's </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology, the NCI would analyze a patient&#8217;s own cancer cells, identify their unique neoantigens and TCRs reactive against those neoantigens and then use the Company's </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology to transpose one or more TCRs into T cells for re-infusion. Research conducted under the CRADA was under the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI, in collaboration with the Company's researchers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company was responsible for providing the NCI with the test materials necessary for them to conduct their studies, and eventually, clinical trials pursuant to the CRADA. Inventions, data and materials discovered or produced in connection with performance of the research plan under the CRADA would have remained the sole property of the party who produced the discovery. The parties would have jointly owned all inventions jointly discovered under the research plan. The owner of any invention under the CRADA would have made the decision to file a patent covering the invention, or in the case of a jointly owned invention, the Company would have the first opportunity to file a patent covering the invention. If the Company failed to provide timely notice of its decision to the NCI or decided not to file a patent covering the joint invention, the NCI had the right to make the filing. For any invention solely owned by the NCI or jointly made by the NCI and the Company for which a patent application was filed, the U.S. Public Health service granted the Company an exclusive option to elect an exclusive or non-exclusive commercialization license. For inventions owned solely by the NCI or jointly owned by the NCI and the Company, which were licensed according to the terms described above, the Company agreed to grant to the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world. The Company was also required to grant the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world for any of the Company's solely owned inventions. The agreement could be terminated by any of the parties upon 60 days' prior written consent.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2019, the Company extended the CRADA with the NCI until January 9, 2022, committing an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to this program; however, for the third and fourth quarters of 2021, the Company was not required to make payments toward the program as agreed with the NCI. In March 2022, the Company entered into an amendment to the CRADA that is retroactive, effective January 9, 2022 to extend the term of the CRADA until January 9, 2023. In June 2022, the Company entered into the Fourth Amendment to the CRADA, or the CRADA Fourth Amendment, which, among other things, extended the term of the CRADA until January 9, 2025. In connection with the CRADA Fourth Amendment, the Company agreed to contribute $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million per year, payable on a quarterly basis, beginning in the first quarter of 2023. The Company recorded expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023, compared to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the year ended December 31, 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, the Company announced that it had provided the requisite notice to terminate the CRADA, pursuant to its terms, effective </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 13, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, in light of the Company&#8217;s exploration of strategic alternatives.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent and Technology License Agreement&#8212;The University of Texas MD Anderson Cancer Center and the Texas A&amp;M University System</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 24, 2004, the Company entered into a patent and technology license agreement with MD Anderson and the Texas A&amp;M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes darinaparsin.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the agreement, the Company may be required to make additional payments to the Licensors upon achievement of certain milestones in varying amounts which, on a cumulative basis could total up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In addition, the Licensors are entitled to receive royalty payments on sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances. During the year ended December 31, 2023, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t incur any milestone expenses under this agreement, and the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand in royalty expenses on sales under this agreement during the year ended December 31, 2023. During the year ended December 31, 2022, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">was incurred as a one-time milestone payment under</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terms of the agreement, and the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand in royalty expenses on sales under this agreement during the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Agreement with Solasia Pharma K.K.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia Pharma K. K., or Solasia, which was amended on July 31, 2014 to include an exclusive worldwide license and amended on October 14, 2021 to revise certain payment schedule details, or, as so amended, the Solasia License and Collaboration Agreement. Pursuant to the Solasia License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms and related organic arsenic molecules, in all indications for human use.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As consideration for the license, the Company is eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenue generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company&#8217;s licensors, as defined in the Solasia License and Collaboration Agreement, will receive a portion of all milestone and royalty payments made by Solasia to the Company in accordance with the terms of the Solasia License and Collaboration Agreement with the licensors, as described above.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, Solasia announced that darinaparsin had been approved from relapsed or refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare in Japan. During the year ended December 31, 2023, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t earn collaboration revenue and earned $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand in royalty revenues on net sales under the Solasia License and Collaboration Agreement. During the year ended December 31, 2022, the Company earned $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of collaboration revenue under the Solasia License and Collaboration Agreement primarily related to Solasia's achievement of certain sales-based milestones in Japan, and did not earn royalty revenues on net sales under the agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KBI Biopharma Litigation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 17, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KBI Biopharma</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Inc., or KBI, filed a complaint against the Company in the District Court of Harris County, Texas, 165th Judicial District, asserting breach of an Amended and Restated Master Services Agreement between the Company and KBI relating to the development of an autologous gene modified T-cell therapy product, or the KBI Agreement. KBI was primarily seeking unspecified monetary damages in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. On May 1, 2023, the Company filed an answer generally denying all of KBI&#8217;s allegations and asserting affirmative and other defenses as well as counterclaims for breach of the KBI Agreement and conversion. On October 20, 2023, the Company entered into an agreement with KBI to settle all claims asserted by KBI against the Company and the Company's counterclaims against KBI at issue in the litigation for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886603491008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_WarrantsDisclosureAbstract', window );"><strong>Warrants Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_WarrantTextBlock', window );">Warrants</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrants</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Company&#8217;s November 2018 private placement that provided net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">47.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, the Company issued warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,262,626</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, which became exercisable six months after the closing of the private placement, or the November 2018 Warrants. The November 2018 Warrants had an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">45.15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and have a five-year term. The fair value of the November 2018 Warrants was estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million using a Black-Scholes model with the following assumptions: expected volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">71</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, expected life of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 26, 2019 and September 12, 2019, the Company entered into agreements with existing investors whereby the investors exercised the November 2018 Warrants for an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,186,869</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">45.15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. Proceeds from the warrant exercise after deducting placement agent fees and other related expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">52.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company issued participating investors new warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,186,869</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional shares of common stock (the "2019 Warrants") as consideration for the warrant holders to exercise their November 2018 Warrants. The 2019 Warrants will expire on the fifth anniversary of the initial exercise date and have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">105.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The 2019 Warrants were valued using a Black-Scholes valuation model and resulted in a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million non-cash charge in the Company&#8217;s statement of operations in 2019.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 22, 2019, the Company entered into the 2019 R&amp;D Agreement with MD Anderson. In connection with the execution of the 2019 R&amp;D Agreement, the Company issued the MD Anderson Warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">222,222</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The MD Anderson Warrant has an initial exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.015</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The MD Anderson Warrant expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and vests upon the occurrence of certain clinical milestones. The Company will recognize expense on the MD Anderson Warrant in the same manner as if the Company paid cash for services to be rendered. For the years ended December 31, 2023 and 2022, the Company did not recognize any expense related to the MD Anderson Warrant as the clinical milestones have not been achieved.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 6, 2021, the Company entered into the Loan and Security Agreement with SVB. Refer to Note 4, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In connection with the Loan and Security Agreement, the Company issued SVB warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,856</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33.30</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The warrants have a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> life and were fully vested upon issuance. The fair value of the warrants was estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million using a Black-Scholes model with the following assumptions: expected volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">79</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, expected life of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends. On December 28, 2021, the Company entered into the First Amendment, as described in Note 4, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in connection with which, the original warrants issued to SVB were amended and restated. As amended and restated, the SVB Warrants are for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">43,308</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, in the aggregate, with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17.40</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The SVB Warrants expire on August 6, 2031 and were fully vested upon issuance. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">none</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the SVB Warrants have been exercised.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_WarrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to the warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_WarrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_WarrantsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Disclosure Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_WarrantsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886603362608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restructuring</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, the Company announced a strategic reprioritization of its business and wind down of its TCR-T Library Phase 1/2 Trial. In connection with the reprioritization, the Company reduced its workforce during the third and fourth quarters of 2023. Concurrently, the Company began considering certain strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. During the year ended December 31, 2023, the Company recorded termination benefits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, recorded in restructuring costs within the statement of operations. The termination benefits were fully paid as of December 31, 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886705117664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no provision for income taxes because the Company has incurred operating losses since inception. The reported amounts of income tax expense for the years ended December 31, 2023 and 2022 differ from the amounts that would result from applying domestic federal statutory tax rates to pretax losses primarily because of the changes in the valuation allowance. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets at December 31, 2023 and 2022 are as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.923%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.923%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">148,009</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">171,070</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Start-up and pre-clinical studies</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,754</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,838</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">681</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">698</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized acquisition costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,570</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,180</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">618</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,176</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,156</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211,031</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">237,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211,031</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236,827</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">481</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">481</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">481</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. At December 31, 2023, the Company has aggregate net operating loss carryforwards for federal tax purposes of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">704.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, of which approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">341.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million expire at various dates through December 31, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2037 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">363.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million can be carried forward indefinitely. The Company is reducing its approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">497.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of state net operating loss carryforwards to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as these state net operating loss carryforwards all related to Massachusetts filings and, as of December 31, 2023 the Company no longer had any employees or property in Massachusetts and, as a result, the Company will no longer have income tax nexus in Massachusetts or an income tax filing obligation after the year ended December 31, 2023. Additionally, the Company has approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">39.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of federal and state research and development credits at December 31, 2023, expiring in varying amounts through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2043</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which may be available to reduce future taxes. The Company has reduced its Massachusetts credits carryforward to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has provided a valuation allowance for the full amount of its net deferred tax assets since it is more likely than not that these future benefits will not be realized. However, these deferred tax assets may be available to offset future income tax liabilities and expenses. The valuation allowance decreased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in 2023 due primarily to the reduction of Massachusetts net operating loss carryforwards and Massachusetts research and development credits.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes using the federal statutory income tax rate differ from the Company&#8217;s effective tax rate primarily due to non-deductible expenses related to the Company&#8217;s issuance of warrants along with the change in the valuation allowance on deferred tax assets.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of income tax expense (benefit) at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.360000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.34%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal income tax at statutory rates</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income tax, net of federal tax benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development true-up</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal/state rate change</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company adopted ASC 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting for Uncertain Tax Positions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on January 1, 2007. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements in accordance with FASB Statement No. 109, &#8220;Accounting for Income Taxes.&#8221; ASC 740 prescribes a recognition threshold and measurement of a tax position taken or expected to be taken in a tax return. The Company did not establish any additional reserves for uncertain tax liabilities upon adoption of ASC 740. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> adjustments to its uncertain tax positions in the years ended December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has not recognized any interest and penalties in the statements of operations because of the Company&#8217;s net operating losses and tax credits that are available to be carried forward. When necessary, the Company will account for interest and penalties related to uncertain tax positions as part of its provision for federal and state income taxes. The Company does not expect the amounts of unrecognized benefits will change significantly within the next twelve months.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is currently open to audit under the statute of limitations by the Internal Revenue Service and state jurisdictions for the years ended December 31, 1999 through 2023 to the extent net operating losses continue to be carried forward to 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Beginning in 2022, the Tax Cuts and Jobs Act of 2017, or the Tax Act, eliminated the option to deduct research and development expenditures immediately in the year incurred and requires taxpayers to capitalize and amortize them over five years pursuant to IRC Section 174. The mandatory capitalization requirement had no impact to the overall deferred tax assets due to the Company's loss position and full valuation allowance.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886604401200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock', window );">Stock Option Plan</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock Option Plan</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company adopted the 2012 Equity Incentive Plan, or the 2012 Plan, in May 2012. Including subsequent increases, the Company had reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">933,333</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares for issuance. On December 31, 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">65,728</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares reserved for issuance and no shares available for future grant.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company adopted the 2020 Equity Incentive Plan, or the 2020 Plan, in June 2020. The Company reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,400,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares for issuance plus a carryover of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">71,085</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares from the 2012 Plan for a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,471,085</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, returning shares from the 2012 Plan are available for issuance under the 2020 Plan. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">400,167</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares reserved for issuance and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,302,411</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for future grant.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock options generally vest ratably in either quarterly or annual installments over three or four years, commencing on the first anniversary of the grant date and have contractual terms of ten years. Stock options to directors generally vest ratably over one or two years and have contractual terms of ten years. Stock options are valued using the Black-Scholes option pricing model and compensation is recognized based on such fair value over the period of vesting on a straight-line basis.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> proceeds from option exercises during the year ended December 31, 2023 as compared to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand during the year ended December 31, 2022. The intrinsic value of these options amounted to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand for the year ended December 31, 2022.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity under the Company's stock options plans for the years ending December 31, 2023 and 2022 were as follows:</span></p><p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted- Average Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted- Average Contractual Term (Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">711,058</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43.05</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">313,167</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,750</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">328,566</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">693,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27.60</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">259,122</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.35</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">487,133</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">465,898</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26.85</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.81</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercisable, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">415,376</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28.80</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.64</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options available for future grant, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,302,411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 31, 2023, total unrecognized compensation costs related to non-vested stock options outstanding amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.53</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023 the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t issue</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares of restricted stock and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,667</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the year ended December 31, 2022 to directors. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> repurchases by the Company for the year ended December 31, 2023. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2022, the Company repurchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,250</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">36.15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share to cover payroll taxes for one employee exercise, which is in accordance with the original terms of the award.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the status of restricted stock as of December 31, 2023 and 2022 is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested, December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79,905</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.54</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,667</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.30</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,441</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34.21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,527</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47.23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested, December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62,604</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.04</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,322</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,282</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.60</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unrecognized stock-based compensation expense related to non-vested restricted stock arrangements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Options and Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886601333696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employee Benefit Plan</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company sponsors a qualified 401(k) retirement plan under which employees are allowed to contribute certain percentages of their pay, up to the maximum allowed under Section 401(k) of the IRC, or the 401(k) Plan. The Company may make contributions to the 401(k) Plan at its discretion. The Company contributed approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to the 401(k) Plan during the year ended December 31, 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the year ended December 31, 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886601362000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Joint Venture<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Joint Venture</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">15.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Joint Venture</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 18, 2018, the Company entered into a Framework Agreement with TriArm whereby the parties agreed to launch Eden BioCell, to lead clinical development and commercialization of certain </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-generated CAR-T therapies as set forth in a separate license agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 3, 2019, Eden BioCell was incorporated in Hong Kong as a private company. Eden BioCell, the Company and TriArm entered into a Share Subscription Agreement on January 23, 2019, where the Company and TriArm agreed to contribute certain intellectual property, services and cash (only with respect to TriArm) to Eden BioCell to subscribe for a certain number of newly issued ordinary shares in the share capital of Eden BioCell.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The closing of the transaction occurred on July 5, 2019. The Framework Agreement and Share Subscription Agreements were each respectively amended to be effective as of this date. Upon consummation of the joint venture, Eden BioCell and the Company also entered into a license agreement, pursuant to which the Company licensed the rights to Eden BioCell for third generation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-generated CAR-T therapies targeting the CD19 antigen for the territory of China (including Macau and Hong Kong), Taiwan and Korea. TriArm and the Company each received a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% equity interest in the joint venture in exchange for their contributions to Eden BioCell.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that Eden BioCell was considered a variable interest entity, or VIE, and concluded that it was not the primary beneficiary of the VIE as it did not have the power to direct the activities of the VIE. As a result, the Company accounted for the equity interest in Eden BioCell under the equity method of accounting as it had the ability to exercise significant influence.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, TriArm and the Company mutually agreed to dissolve the joint venture, which has now been terminated. The Eden BioCell entity has been dissolved as of July 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 323<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481543/323-740-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 323<br> -Publisher FASB<br> -URI https://asc.fasb.org//323/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886698980128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">16.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsequent Events</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluated all events and transactions that occurred after the balance sheet date through the date of this Annual Report on Form 10-K. Other than as described in the notes to the financial statements, the Company did not have any material subsequent events that impacted its financial statements or disclosures aside from the following.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 20, 2024, the Board of Directors appointed Dale Curtis Hogue, Jr. as Interim Chief Executive Officer of the Company, effective immediately. On January 21, 2024, the Company entered into an employment agreement with Mr. Hogue, under which he will receive an annual base salary of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">250</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand. Mr. Hogue was awarded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock of the Company with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 15, 2024, Michael Wong gave notice of his resignation as Vice President, Finance, effective February 23, 2024. On February 22, 2024, the Company and Ferdinand Groenewald entered into a consulting agreement, or the Consulting Agreement, effective February 22, 2024, pursuant to which Mr. Groenewald will lead accounting and financial reporting activities of the Company. Mr. Groenewald will serve as the Company&#8217;s Vice President, Finance. The Consulting Agreement will continue indefinitely until terminated by either party upon </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30 days</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217; advance notice. The Consulting Agreement provides for compensation at a fixed rate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand per month and reimbursement by the Company for any usual and customary business expenses incurred by Mr. Groenewald in connection with performing services pursuant to the Consulting Agreement. In addition, the Consulting Agreement provides for the Company to indemnify Mr. Groenewald on terms customary for officers.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886696328656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s most significant estimates and judgments used in the preparation of the financial statements are:</span></p><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trial expenses and other research and development expenses;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration agreements;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value measurements of stock-based compensation; and</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes.</span></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents consist primarily of demand deposit accounts, certificates of deposit and deposits in short-term U.S. treasury money market mutual funds. Cash equivalents are stated at cost, which approximates fair market value.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to expense while the costs of significant improvements are capitalized. Depreciation and amortization is calculated on a straight-line basis using the following periods, which represent the estimated useful lives of the assets:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:54.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.44%;"></td>
        <td style="width:3.88%;"></td>
        <td style="width:26.68%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office and computer equipment</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#65279;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#65279;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#65279;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#65279;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_fa18b81e-dc37-4248-8153-57693071a98f;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Life of the lease</span></span></span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs, including certain design, construction and installation costs related to assets that are under construction and are in the process of being readied for their intended use, are recorded as construction in progress and are not depreciated until such time as the subject asset is placed in service. Repairs and maintenance that do not extend the useful life of the asset are expensed as incurred. Upon sale, retirement or other disposition of these assets, the costs and related accumulated depreciation are removed from the respective accounts and any gain or loss on the disposition is included in the statements of operations.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-Lived Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assessments of long-lived assets and the remaining useful lives of such long-lived assets are reviewed for impairment whenever a triggering event occurs or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An asset, or group of assets, is considered to be impaired when the undiscounted estimated net cash flows expected to be generated by the asset, or group of assets, are less than its carrying amount. The impairment recognized is the amount by which the carrying amount exceeds the fair market value of the impaired asset, or group of assets, based on the present value of the expected future cash flows associated with the use of the asset.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Segments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the Company&#8217;s chief operating decision maker, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrants</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assesses whether warrants issued require accounting as derivatives. The Company determined that the warrants were (1) indexed to the Company&#8217;s own stock and (2) classified in stockholders&#8217; equity in accordance with Financial Accounting Standards Board, or FASB, ASC Topic 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As such, the Company has concluded the warrants meet the scope exception for determining whether the instruments require accounting as derivatives and should be classified in stockholders&#8217; equity.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></p><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of December 31, 2023 and 2022 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of<br/>December 31,<br/>2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,744</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,744</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of<br/>December 31,<br/>2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,058</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,058</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cash equivalents represent demand deposit accounts and deposits in a short-term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset. There have been no changes to the valuation methods during the years ended December 31, 2023 and 2022. The Company had no financial assets or liabilities that were classified as Level 2 or Level 3 during the years ended December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair value of non-financial instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates assets for impairment whenever events or changes in circumstances indicate that indicators of impairment exist. In those evaluations, the Company compares estimated future undiscounted cash flows generated by each asset (or asset group) to the carrying value of the asset (or asset group) to determine if an impairment charge is required. If the undiscounted cash flows test fails, the Company estimates the fair value of the asset (or asset group) to determine the impairment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following the Company&#8217;s announced strategic reprioritization on August 14, 2023, the Company determined that changes in the intended use of certain property and equipment represented an indicator of impairment, resulting in an impairment charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which was primarily related to leasehold improvements of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and lab equipment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Company determined certain prepaid expense balances to be impaired given the Company&#8217;s strategic reprioritization, and therefore, has recorded an impairment charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to prepaid expenses and other current assets, which is recorded in research and development expenses within the statement of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 9, 2023, the Company executed an agreement to sell laboratory equipment for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and recognized a gain on disposal of equipment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand, which is recorded in other income in the statement of operations</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition from Collaboration Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition from Collaboration Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue for the year ended December 31, 2023 consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand and for the year ended December 31, 2022 consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. For the years ended December 31, 2023 and 2022, the Company recognized revenue through its Collaboration Agreement with Solasia Pharma K.K. primarily due to the achievement of milestones, as further described in Note 9, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commitments and Contingencies.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company primarily generates revenue through collaboration arrangements with strategic partners for the development and commercialization of product candidates. The Company recognizes revenue in accordance with ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers, or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASC 606. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods and/or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and/or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes collaboration revenue under certain of the Company&#8217;s license or collaboration agreements that are within the scope of ASC 606. The Company&#8217;s contracts with customers typically include promises related to licenses to intellectual property, research and development services and options to purchase additional goods and/or services. If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contracts that include an option to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer&#8217;s election.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The terms of the Company&#8217;s arrangements with customers typically include the payment of one or more of the following:(i) non-refundable, up-front payment, (ii) development, regulatory and commercial milestone payments, (iii) future options and (iv) royalties on net sales of licensed products. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the most likely amount method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company reevaluates the probability of achievement of each milestone and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company allocates the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contract to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require the use of judgment to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenue, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the process of preparing the Company's financial statements, the Company is required to estimate its accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with its personnel and third-party vendors to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the services when the Company has not yet been invoiced or otherwise notified of the actual costs. The majority of the Company's service providers invoice the Company in arrears for services performed, on a predetermined schedule or when contractual milestones are met; however, a few require advanced payments. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known to it at that time. Examples of estimated accrued research and development expenses include fees paid to:</span></p><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical research organizations, or CROs, in connection with performing research services on its behalf and clinical trials;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">investigative sites or other providers in connection with clinical trials;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">vendors in connection with preclinical and clinical development activities; and</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">vendors related to product manufacturing, development, and distribution of preclinical and clinical supplies.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company bases its expenses related to preclinical studies and clinical trials on its estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct and manage clinical trials on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company's vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed, enrollment of patients, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low in any particular period.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. The Company evaluates the realizability of its deferred tax assets and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates this tax position on an annual basis. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense (Refer to Note 12, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Accounting for Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting for Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation cost is measured at the grant date based on the estimated fair value of the award and is recognized as expense over the employee&#8217;s requisite service period. Stock-based compensation expense is based on the number of awards ultimately expected to vest and is reduced for forfeitures as they occur. Consistent with prior years, the Company uses the Black-Scholes option pricing model, which requires estimates of the expected term option holders will retain their options before exercising them and the estimated volatility of the Company&#8217;s common stock price over the expected term.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized the full impact of its share-based employee payment plans in the statements of operations for each of the years ended December 31, 2023 and 2022 and did not capitalize any such costs on the balance sheets. The Company recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of compensation expense related to stock options </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the year ended December 31, 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of compensation expense related to stock options </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the year ended December 31, 2022. The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of compensation expense related to restricted stock for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the year ended December 31, 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the year ended December 31, 2022 (refer to Note 13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Option Plan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). The total compensation expense relating to vesting of stock options and restricted stock awards for the year ended December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2022. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents share-based compensation expense included in the Company&#8217;s statements of operations:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:64.713%;"></td>
          <td style="width:1.56%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.643%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.56%;"></td>
          <td style="width:1%;"></td>
          <td style="width:15.523%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">439</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">868</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,361</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,660</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,800</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,528</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. The estimated weighted-average fair value of stock options granted to employees in the year ended December 31, 2023 was approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.58</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">per share and was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.54</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2022. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company&#8217;s historical experience. The risk-free interest rate is based on a U.S. treasury note with a maturity similar to the option award&#8217;s expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The Company calculated expected term using the simplified method described in SEC Staff Accounting Bulletin, or SAB, No. 107 and No. 110 as it continues to meet the requirements promulgated in SAB No. 110.</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The assumptions for volatility, expected life, dividend yield and risk-free interest rate are presented in the table below:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.173%;"></td>
          <td style="width:1.62%;"></td>
          <td style="width:13.443%;"></td>
          <td style="width:1.62%;"></td>
          <td style="width:16.143%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.51</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.01</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.63</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.21</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected life in years</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.06</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.27</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89.69</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">112.12</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74.49</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88.75</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;%</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;%</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Stock Split</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 31, 2024, the Company filed a Second Amended and Restated Certificate of Incorporation (the &#8220;Charter Amendment&#8221;) with the Secretary of State of the State of Delaware in order to effect a reverse stock split of the Company&#8217;s common stock at a ratio of 1-for-15 (the &#8220;Reverse Split&#8221;). The Charter Amendment decreased the number of authorized shares of common stock from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">520,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34,666,667</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Charter Amendment does not affect the par value of the Company&#8217;s common stock or change the number of authorized shares or par value of the Company&#8217;s preferred stock. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Charter Amendment became effective on January 31, 2024 at 5:00 p.m. Eastern Time, at which time every 15 shares of the Company&#8217;s issued and outstanding common stock automatically combined and converted into 1 share of common stock.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No fractional shares were issued in connection with the Reverse Split. Stockholders of record who would otherwise have been entitled to receive fractional shares as a result of the Reverse Split received a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing sales price per share of the common stock (as adjusted for the Reverse Split) on The Nasdaq Capital Market on January 31, 2024.</span></p><p id="bkmk_220" style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All share and per share amounts of common stock, options, warrants, and restricted stock in the accompanying financial statements and notes thereto have been retroactively adjusted for all periods presented to reflect the Reverse Split as if it had occurred at the beginning of the earliest period presented.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Share</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company&#8217;s common stock during the applicable period, unless their effect on net loss per share is antidilutive. The effect of computing diluted net loss per common share was antidilutive for any potentially issuable shares of common stock from the conversion of stock options, unvested restricted stock and warrants and, as such, have been excluded from the calculation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The computation of basic and diluted net loss per share consists of the following:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.72%;"></td>
          <td style="width:1.72%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.92%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.72%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.92%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,140</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,730</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,995,323</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,475,354</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.20</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.61</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain shares related to some of the Company&#8217;s outstanding common stock options, unvested restricted stock and warrants have not been included in the computation of diluted net loss per share for the years ended December 31, 2023 and 2022 as the result would be antidilutive. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such potential common shares on December 31, 2023 and 2022 consist of the following:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.967%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.357%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.357%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">465,898</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">693,909</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62,604</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,452,399</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,528,156</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,918,297</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,284,669</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued Accounting Standards Update, or ASU, 2016-13, Financial Instruments: Credit Losses (Topic 326) as clarified in ASU 2019-04, ASU 2019-05 and ASU 2020-02. The objective of this standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than-temporary impairments on investment securities are recorded. The Company adopted ASU 2016-13 effective January 1, 2023, with no material impact upon adoption.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances the disclosures required for operating segments in the Company's annual and interim financial statements. ASU 2023-07 is effective retrospectively for fiscal years beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this standard.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for the Company prospectively to all annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this standard.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886705048720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of December 31, 2023 and 2022 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of<br/>December 31,<br/>2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,744</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,744</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.38%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.22%;"></td>
          <td style="width:1%;"></td>
          <td style="width:9.184000000000001%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of<br/>December 31,<br/>2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,058</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,058</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Compensation Expense Included in Statements of Operations</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents share-based compensation expense included in the Company&#8217;s statements of operations:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:64.713%;"></td>
          <td style="width:1.56%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.643%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.56%;"></td>
          <td style="width:1%;"></td>
          <td style="width:15.523%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">439</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">868</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,361</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,660</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,800</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,528</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Assumptions for Volatility, Expected life, Dividend Yield and Risk-free Interest Rate</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The assumptions for volatility, expected life, dividend yield and risk-free interest rate are presented in the table below:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.173%;"></td>
          <td style="width:1.62%;"></td>
          <td style="width:13.443%;"></td>
          <td style="width:1.62%;"></td>
          <td style="width:16.143%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.51</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.01</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.63</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.21</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected life in years</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.06</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.27</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89.69</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">112.12</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74.49</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88.75</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;%</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;%</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock', window );">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company&#8217;s common stock during the applicable period, unless their effect on net loss per share is antidilutive. The effect of computing diluted net loss per common share was antidilutive for any potentially issuable shares of common stock from the conversion of stock options, unvested restricted stock and warrants and, as such, have been excluded from the calculation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The computation of basic and diluted net loss per share consists of the following:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.72%;"></td>
          <td style="width:1.72%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.92%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.72%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.92%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,140</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,730</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,995,323</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,475,354</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.20</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.61</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such potential common shares on December 31, 2023 and 2022 consist of the following:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.967%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.357%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.357%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">465,898</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">693,909</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62,604</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,452,399</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,528,156</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,918,297</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,284,669</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886601416912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> debt obligations outstanding at December 31, 2023. The carrying values of the Company's debt obligation at December 31, 2022 were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loan and Security Agreement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,395</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unamortized discount on Loan and Security Agreement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">630</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,765</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: long-term debt, current</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,765</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886604712224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Component of Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net, consists of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.213%;"></td>
        <td style="width:1.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office and computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,183</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,291</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,561</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,232</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,267</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,807</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,460</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886608864992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Component of Accrued Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consist of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.96%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">568</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,160</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">717</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">534</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preclinical services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">198</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Manufacturing services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,177</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other consulting services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">169</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,340</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,454</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886602941968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Leases, Operating [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text"><p id="bkmk_231" style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of lease expense were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.493%;"></td>
        <td style="width:1.839%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.915%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.839%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.914%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">428</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">756</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">428</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">756</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average remaining lease term (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.13</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886601267200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant Component of Deferred Tax Assets</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets at December 31, 2023 and 2022 are as follows:</span><p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.923%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.923%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">148,009</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">171,070</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Start-up and pre-clinical studies</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,754</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,838</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">681</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">698</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized acquisition costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,570</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,180</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">618</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,176</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,156</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211,031</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">237,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211,031</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236,827</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">481</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">481</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">481</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Income Tax Expense (Benefit)</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of income tax expense (benefit) at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.360000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.34%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal income tax at statutory rates</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income tax, net of federal tax benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development true-up</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal/state rate change</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886696480624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity Under Stock Option Plan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity under the Company's stock options plans for the years ending December 31, 2023 and 2022 were as follows:</span></p><p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted- Average Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted- Average Contractual Term (Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">711,058</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43.05</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">313,167</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,750</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">328,566</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">693,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27.60</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">259,122</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.35</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">487,133</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">465,898</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26.85</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.81</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercisable, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">415,376</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28.80</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.64</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options available for future grant, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,302,411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Summary of Non-Vested Restricted Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the status of restricted stock as of December 31, 2023 and 2022 is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested, December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79,905</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.54</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,667</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.30</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,441</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34.21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,527</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47.23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested, December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62,604</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.04</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,322</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,282</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.60</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886602923344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Aug. 14, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_StrategicAdvisorName', window );">Strategic advisor name</a></td>
<td class="text">Cantor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,062<span></span>
</td>
<td class="nump">$ 52,996<span></span>
</td>
<td class="nump">$ 76,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (915,767)<span></span>
</td>
<td class="num">$ (880,627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,012,522<span></span>
</td>
<td class="nump">16,027,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,012,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,918,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_StrategicAdvisorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strategic advisor name.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_StrategicAdvisorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886702171984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financings - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 05, 2023</div></th>
<th class="th"><div>Nov. 29, 2022</div></th>
<th class="th"><div>Aug. 12, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 14,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tcrt_AtTheMarketOfferingMember', window );">At The Market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase', window );">Number of additional option available to the underwriter to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Term A Tranche [Member] | Silicon Valley Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Loan and Security Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Term B Tranche [Member] | Silicon Valley Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Additonal tranche facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tcrt_EquityDistributionAgreementMember', window );">Equity Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_StockOfferedDuringPeriodShares', window );">Stock issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock', window );">Percentage Of Commission On Gross Proceeds From Sale Of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AgreementTypeAxisAxis=tcrt_CantorMember', window );">Cantor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,615,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_UnderwriterParOrStatedValuePerShare', window );">Underwriter par or stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings', window );">Threshold period for exercise or conversion of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AgreementTypeAxisAxis=tcrt_CantorMember', window );">Cantor [Member] | Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_StockOfferedDuringPeriodShares', window );">Stock issued during period</a></td>
<td class="nump">14,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional option available to the underwriter to purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on gross proceeds from sale of common stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_StockOfferedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock offered during period shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_StockOfferedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold commitment period for exercise of rights to participate in future offerings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_UnderwriterParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriter par or stated value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_UnderwriterParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tcrt_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tcrt_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tcrt_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tcrt_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcrt_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcrt_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AgreementTypeAxisAxis=tcrt_CantorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AgreementTypeAxisAxis=tcrt_CantorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886599998448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Nov. 09, 2023</div></th>
<th class="th"><div>Aug. 14, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 3,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PreStockSplitSharesAuthorized', window );">Pre stock split shares authorized</a></td>
<td class="nump">520,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PostStockSplitSharesAuthorized', window );">Post Stock Split Shares Authorized</a></td>
<td class="nump">34,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of stock option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.58<span></span>
</td>
<td class="nump">$ 11.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders equity reverse stock split</a></td>
<td class="text">The Charter Amendment became effective on January 31, 2024 at 5:00 p.m. Eastern Time, at which time every 15 shares of the Company&#8217;s issued and outstanding common stock automatically combined and converted into 1 share of common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed asset impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,803<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,543<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">2,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_OfficeAndComputerEquipmentMember', window );">Office and computer equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property and equipment estimated useful life, Description [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:UsefulLifeTermOfLeaseMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tcrt_EmployeeStockOptionAndRestrictedStockMember', window );">Stock Options and Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PostStockSplitSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Post Stock Split Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PostStockSplitSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PreStockSplitSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre Stock Split Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PreStockSplitSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_OfficeAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_OfficeAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcrt_EmployeeStockOptionAndRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcrt_EmployeeStockOptionAndRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886604853264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 5,744<span></span>
</td>
<td class="nump">$ 38,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 5,744<span></span>
</td>
<td class="nump">$ 38,058<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886603815920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Stock-Based Compensation Expense Included in Statement of Operations (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 3,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">439<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,361<span></span>
</td>
<td class="nump">$ 2,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886704594624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">3.51%<span></span>
</td>
<td class="nump">1.63%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">4.01%<span></span>
</td>
<td class="nump">4.21%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">89.69%<span></span>
</td>
<td class="nump">74.49%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">112.12%<span></span>
</td>
<td class="nump">88.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">5 years 21 days<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886704974288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Earning Per share Basic and Diluted (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (35,140)<span></span>
</td>
<td class="num">$ (37,730)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">15,995,323<span></span>
</td>
<td class="nump">14,475,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">15,995,323<span></span>
</td>
<td class="nump">14,475,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (2.2)<span></span>
</td>
<td class="num">$ (2.61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (2.2)<span></span>
</td>
<td class="num">$ (2.61)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886602924160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">1,918,297<span></span>
</td>
<td class="nump">2,284,669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">1,452,399<span></span>
</td>
<td class="nump">1,528,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tcrt_CommonStockOptionsMember', window );">Common stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">465,898<span></span>
</td>
<td class="nump">693,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">62,604<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tcrt_CommonStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tcrt_CommonStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886603860400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: long-term debt, current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(16,765)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan and Security Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount on Loan and Security Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (630)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886599963024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2021</div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Line of credit facility, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=tcrt_TermLoanMember', window );">Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment', window );">Percentage of original principal due as a final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Line of credit facility, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Warrants issued</a></td>
<td class="nump">43,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_WarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="text">Aug.  06,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms', window );">Description of payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company also owed SVB 5.75% of the original principal amounts borrowed as a final payment, or the Final Payment. Effective March 30, 2023, the Company entered into a Third Amendment to the Loan and Security Agreement, or the Third Amendment. Under the terms of the Third Amendment, the Company was no longer required to maintain all of its operating accounts, depository accounts and excess cash with SVB or one of its affiliates, and was instead only required to maintain a single operating or depository account at Silicon Valley Bank. The Third Amendment also modified the cash collateralization requirement, such that the Company was required to cash collateralize the entire sum of the outstanding principal amount of the SVB Facility, plus an amount equal to the Final Payment, which amount was to be reduced commensurate with each regularly scheduled monthly payment of principal and interest on the SVB Facility.On May 1, 2023, the Company paid SVB an amount equal to the entire outstanding principal amount under the SVB Facility, all accrued and unpaid interest and the Final Payment. In accordance with the First Amendment, the payment was subject to a prepayment premium of 2.00%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt instrument description of variable rate basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The SVB Facility bore interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) 7.75% and (b) the current published U.S. prime rate, plus a margin of 4.5%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AmountOfPrepaymentsPremium', window );">Amount of prepayments premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="nump">$ 17.4<span></span>
</td>
<td class="nump">$ 33.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AdditionalNumberOfWarrantsIssued', window );">Additional number warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">Debt instrument, initial maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member] | Debt Instrument Redemption Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PercentageOfPrepaymentsPremium', window );">Percentage of prepayments premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Issuance costs</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AdditionalNumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AdditionalNumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AmountOfPrepaymentsPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount Of Prepayments Premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AmountOfPrepaymentsPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of original principal due as a final payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PercentageOfPrepaymentsPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of prepayments premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PercentageOfPrepaymentsPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_WarrantsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Expiration Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_WarrantsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reference rate used for variable rate of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateRangeStart1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateRangeStart1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of the required periodic payments of interest, principal, or both, and the amount, if set, or a description of a formula upon which payment is based.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=tcrt_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=tcrt_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886602952016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, net - Component of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 18,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(9,807)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">8,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_OfficeAndComputerEquipmentMember', window );">Office and computer equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">2,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_OfficeAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_OfficeAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcrt_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886696349888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 14, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,315<span></span>
</td>
<td class="nump">$ 2,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,803<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886597075712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Component of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AccruedClinicalExpensesCurrent', window );">Clinical</a></td>
<td class="nump">$ 568<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Employee compensation</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">1,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AccruedPreclinicalServicesCurrent', window );">Preclinical services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AccruedManufacturingCostsCurrent', window );">Manufacturing services</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">1,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AccruedConsultingFeesCurrent', window );">Other consulting services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,340<span></span>
</td>
<td class="nump">$ 5,454<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AccruedClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AccruedClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AccruedConsultingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued consulting fees, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AccruedConsultingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AccruedManufacturingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued manufacturing costs, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AccruedManufacturingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AccruedPreclinicalServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical services current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AccruedPreclinicalServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886604276064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 18, 2018</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_EdenBiocellMember', window );">Eden Biocell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties', window );">Payments to Fund Long-term Loans to Related Parties</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AdditionalLoansCommitted', window );">Additional Loans Committed</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_DuneLakeCapitalMember', window );">Dune Lake Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Consulting service amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AdditionalLoansCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional loans committed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AdditionalLoansCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToFundLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_EdenBiocellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_EdenBiocellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_DuneLakeCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_DuneLakeCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886603600320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 15, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 19, 2023</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 01, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_LeaseTerminationDate', window );">Lease termination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 19,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SubleaseTermCommencedEndDateAmendment', window );">Sublease term amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_TerminationCosts', window );">Termination costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on lease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,000<span></span>
</td>
<td class="nump">$ 133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_OperatingLeaseArea', window );">Operating Lease Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_GainLossOnModificationOfLease', window );">Gain (Loss) On Modification Of Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_SubleaseArea', window );">Sublease Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease term, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">a term expiring on June 30, 2025 with an option to extend through July 31, 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Recognition in exchange of Operating Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Leases other than short-term lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_MdAndersonMember', window );">MD Anderson [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on lease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=tcrt_OtherIncomeExpenseMember', window );">Other Income Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseIncome', window );">Lease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=tcrt_MaMember', window );">Boston, MA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on lease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=tcrt_HoustonTexasMember', window );">Houston, TX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_OperatingLeaseArea', window );">Operating Lease Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=tcrt_HoustonTexasMember', window );">Houston, TX [Member] | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_OperatingLeaseArea', window );">Operating Lease Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_GainLossOnModificationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on modification of lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_GainLossOnModificationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_LeaseTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease termination date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_LeaseTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_OperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease area.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_OperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_SubleaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease area.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_SubleaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_SubleaseTermCommencedEndDateAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease term commenced end date amendment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_SubleaseTermCommencedEndDateAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_TerminationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_TerminationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479092/842-20-40-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease income from operating, direct financing, and sales-type leases. Includes, but is not limited to, variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and payable to lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_MdAndersonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_MdAndersonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=tcrt_OtherIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=tcrt_OtherIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=tcrt_MaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=tcrt_MaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=tcrt_HoustonTexasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=tcrt_HoustonTexasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886604242704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 428<span></span>
</td>
<td class="nump">$ 756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 428<span></span>
</td>
<td class="nump">$ 756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 1 month 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">8.26%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886592118560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 20, 2023</div></th>
<th class="th"><div>Aug. 14, 2023</div></th>
<th class="th"><div>Mar. 17, 2023</div></th>
<th class="th"><div>May 28, 2019</div></th>
<th class="th"><div>Aug. 17, 2015</div></th>
<th class="th"><div>Jan. 13, 2015</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 03, 2023</div></th>
<th class="th"><div>Oct. 22, 2019</div></th>
<th class="th"><div>Feb. 19, 2019</div></th>
<th class="th"><div>Oct. 05, 2018</div></th>
<th class="th"><div>Aug. 24, 2004</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,279<span></span>
</td>
<td class="nump">$ 25,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MaximumRoyaltyAmount', window );">Maximum royalty amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">2,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Unspecified monetary damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNameOfPlaintiff', window );">Loss contingency, name of plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">KBI Biopharma<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ClassOfWarrantOrRightAxisAxis=tcrt_MdAndersonWarrantMember', window );">Md Anderson Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant Expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember', window );">MD Anderson Related to the 2015 R&amp;D Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ClinicalExpenses', window );">Clinical expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember', window );">MD Anderson License and the Research and Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AggregateAmountPotentiallyReimburseableAmount', window );">Reimbursement of historical costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ClinicalExpenses', window );">Clinical expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AggregatePotentialBenchmarkPayments', window );">Aggregate potential benchmark payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AccrualsPriorToFirstMarketingApproval', window );">Payments due prior to the first marketing approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_CRADAAgreementMember', window );">CRADA Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AgreementTerminationDate', window );">Agreement termination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 13,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ContributionPayableOnPerAnnumBasis', window );">Contribution payable on per annum basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ObligationsDueUnderContract', window );">Obligations due under contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AnnualExpenseIncurred', window );">Annual expense incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonAgreementAndWorldwideLicenseMember', window );">MD Anderson Agreement and Worldwide License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_LicenseAgreementCommencingDate', window );">License agreement commencing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 13,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember', window );">The University of Texas MD Anderson Cancer Center and The Texas A &amp; M University System [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MilestonePaymentsMaximumAmount', window );">Milestone maximum payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MilestonePayment', window );">One time milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember', window );">The University of Texas MD Anderson Cancer Center and The Texas A &amp; M University System [Member] | Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PaymentUnderLicenseAgreement', window );">Payment under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_LicenseAgreementWithTheNationalCancerInstituteMember', window );">License Agreement with the National Cancer Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_LicenseExpense', window );">License Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_LicenseAgreementWithTheNationalCancerInstituteMember', window );">License Agreement with the National Cancer Institute [Member] | One Time Benchmark Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_InitialBenchmarkPaymentDue', window );">First benchmark payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember', window );">Ziop License Agreement With The National Cancer Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MinimumRoyaltiesAmountPayable', window );">Minimum royalties amount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_RoyaltiesAmountPayableThereafter', window );">Royalties amount payable thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AggregateMinimumAnnualRoyaltiesPaid', window );">Aggregate minimum annual royalties paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DescriptionOfFirstBenchmarkPayable', window );">Description Of First Benchmark Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The first benchmark payment of $0.1 million was paid during the year ended December 31, 2022 upon the initiation of the Company's TCR-T Library Phase 1/2 Trial, which was a qualifying Phase 1 clinical trial under the terms of the Patent License.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones', window );">Description Of option To terminate Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The NCI could terminate or modify the Patent License in the event of a material breach, including if the Company did not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AgreementTerminationNoticePeriod', window );">Agreement termination, notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember', window );">Ziop License Agreement With The National Cancer Institute [Member] | Performance Based Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AggregateBenchmarkPaymentsPayable', window );">Aggregate Benchmark Payments Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember', window );">Ziop License Agreement With The National Cancer Institute [Member] | One Time Benchmark Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PotentialBenchmarkPaymentsPayable', window );">Potential Benchmark Payments Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember', window );">Ziop License Agreement With The National Cancer Institute [Member] | Post Marketing Approval [Member] | Performance Based Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AggregateBenchmarkPaymentsPayable', window );">Aggregate Benchmark Payments Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember', window );">Ziop License Agreement With The National Cancer Institute [Member] | Licensed Products [Member] | One Time Benchmark Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable', window );">Maximum Sales Revenue On Which Benchmark Payments Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable', window );">Minimum sales revenue on which benchmark payments payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_CollaborationAgreementWithSolasiaPharmaKkMember', window );">Collaboration Agreement with Solasia Pharma K.K. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_CollaborationAgreementWithSolasiaPharmaKkMember', window );">Collaboration Agreement with Solasia Pharma K.K. [Member] | Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_IntrexonCorporationMember', window );">Intrexon Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AnnualLicenseFees', window );">Annual License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MaximumAmountOfAdditionalMilestonesPayable', window );">Expected additional milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_IntrexonCorporationMember', window );">Intrexon Corporation [Member] | T-Cell Receptor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MaximumAmountOfRoyaltyPayable', window );">Maximum royalty amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty', window );">Portion of income payable to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | MD Anderson License and the Research and Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | MD Anderson License and the Research and Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AccrualsPriorToFirstMarketingApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments due prior to the first marketing approval for TCR products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AccrualsPriorToFirstMarketingApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AggregateAmountPotentiallyReimburseableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Amount Potentially Reimburseable Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AggregateAmountPotentiallyReimburseableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AggregateBenchmarkPaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents Aggregate Benchmark Payments Payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AggregateBenchmarkPaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AggregateMinimumAnnualRoyaltiesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate minimum annual royalties paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AggregateMinimumAnnualRoyaltiesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AggregatePotentialBenchmarkPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential benchmark payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AggregatePotentialBenchmarkPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AgreementTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination Date of CRADA Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AgreementTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AnnualExpenseIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual expense incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AnnualExpenseIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AnnualLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual License Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AnnualLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ClinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ClinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ContributionPayableOnPerAnnumBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contribution payable on per annum basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ContributionPayableOnPerAnnumBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DescriptionOfFirstBenchmarkPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents Description Of First Benchmark Payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DescriptionOfFirstBenchmarkPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents Description Of Option To Terminate The Agreement Upon Not Meeting Certain Milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_InitialBenchmarkPaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The first benchmark payment due upon the initiation of the Company's first sponsored phase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_InitialBenchmarkPaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_LicenseAgreementCommencingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement commencing date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_LicenseAgreementCommencingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_LicenseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to License payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_LicenseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MaximumAmountOfAdditionalMilestonesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of additional milestones payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MaximumAmountOfAdditionalMilestonesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MaximumAmountOfRoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of royalty payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MaximumAmountOfRoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MaximumRoyaltyAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of royalty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MaximumRoyaltyAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Sales Revenue On Which Benchmark Payments Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MilestonePaymentsMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments maximum amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MilestonePaymentsMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MinimumRoyaltiesAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents Minimum Royalties Amount Payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MinimumRoyaltiesAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum sales revenue on which benchmark payments payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ObligationsDueUnderContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations due under contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ObligationsDueUnderContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PaymentUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment under license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PaymentUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of sub licensing income, attributable to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PotentialBenchmarkPaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents Potential Benchmark Payments Payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PotentialBenchmarkPaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_RoyaltiesAmountPayableThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties amount payable thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_RoyaltiesAmountPayableThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNameOfPlaintiff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identifies the plaintiff in the lawsuit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNameOfPlaintiff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ClassOfWarrantOrRightAxisAxis=tcrt_MdAndersonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ClassOfWarrantOrRightAxisAxis=tcrt_MdAndersonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_CRADAAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_CRADAAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonAgreementAndWorldwideLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonAgreementAndWorldwideLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tcrt_LicenseAgreementWithTheNationalCancerInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tcrt_LicenseAgreementWithTheNationalCancerInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PaymentTypeAxis=tcrt_OneTimeBenchmarkPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PaymentTypeAxis=tcrt_OneTimeBenchmarkPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PaymentTypeAxis=tcrt_PerformanceBasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PaymentTypeAxis=tcrt_PerformanceBasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DueDateAxis=tcrt_PostMarketingApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DueDateAxis=tcrt_PostMarketingApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tcrt_LicensedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tcrt_LicensedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tcrt_CollaborationAgreementWithSolasiaPharmaKkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tcrt_CollaborationAgreementWithSolasiaPharmaKkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_IntrexonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_IntrexonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tcrt_TcellReceptorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tcrt_TcellReceptorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886599864144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2021</div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
<th class="th"><div>Oct. 22, 2019</div></th>
<th class="th"><div>Sep. 12, 2019</div></th>
<th class="th"><div>Nov. 11, 2018</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Fair Value Assumptions Expected volatility Rate Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.12%<span></span>
</td>
<td class="nump">88.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Fair Value Assumptions Risk Free Interest Rate Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.01%<span></span>
</td>
<td class="nump">4.21%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 14,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="nump">$ 17.4<span></span>
</td>
<td class="nump">$ 33.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_MdAndersonWarrantMember', window );">MD Anderson Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities into which the class of warrant converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_FairValueOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant Expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_SvbWarrantsMember', window );">SVB Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCallOrExerciseFeatures', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">33.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ClassOfWarrantOrRightWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants fully vested upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_BlackScholesModelMember', window );">Black-Scholes Model [Member] | Silicon Valley Bank Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCallOrExerciseFeatures', window );">Exercise price</a></td>
<td class="text">17.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="nump">43,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_BlackScholesModelMember', window );">Black-Scholes Model [Member] | SVB Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_FairValueOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair Value Assumptions Expected Term1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AgreementTypeAxis=tcrt_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities into which the class of warrant converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,186,869<span></span>
</td>
<td class="nump">1,262,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.15<span></span>
</td>
<td class="nump">$ 45.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_FairValueOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Fair Value Assumptions Expected volatility Rate Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Fair Value Assumptions Risk Free Interest Rate Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair Value Assumptions Expected Term1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PlacementAgentFeesAndOtherRelatedExpenses', window );">Placement agent fees and other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | New Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities into which the class of warrant converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,186,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_NonOperatingIncomeExpenseInducementOfWarrants', window );">Non-cash inducement warrant expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ClassOfWarrantOrRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ClassOfWarrantOrRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_FairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_FairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_NonOperatingIncomeExpenseInducementOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Operating Income Expense Inducement Of Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_NonOperatingIncomeExpenseInducementOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PlacementAgentFeesAndOtherRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Placement agent fees and other related expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PlacementAgentFeesAndOtherRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCallOrExerciseFeatures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describe the call and/or exercise rights, prices and dates of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCallOrExerciseFeatures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_MdAndersonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tcrt_MdAndersonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_SvbWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tcrt_SvbWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_BlackScholesModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_BlackScholesModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AgreementTypeAxis=tcrt_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AgreementTypeAxis=tcrt_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tcrt_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886602493728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Termination benefits</a></td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886782149648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Component of Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 148,009<span></span>
</td>
<td class="nump">$ 171,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies', window );">Start-up and pre-clinical studies</a></td>
<td class="nump">13,754<span></span>
</td>
<td class="nump">17,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">39,838<span></span>
</td>
<td class="nump">40,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock-based compensation</a></td>
<td class="nump">681<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts', window );">Capitalized acquisition costs</a></td>
<td class="nump">1,570<span></span>
</td>
<td class="nump">2,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DeferredTaxAssetsDepreciation', window );">Depreciation</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DeferredTaxAssetsResearchExpensesCapitalized', window );">Capitalized research expenses</a></td>
<td class="nump">7,176<span></span>
</td>
<td class="nump">5,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets Gross</a></td>
<td class="nump">211,031<span></span>
</td>
<td class="nump">237,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(211,031)<span></span>
</td>
<td class="num">(236,827)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_DeferredTaxLiabilityRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(481)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(481)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized acquisition costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DeferredTaxAssetsDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DeferredTaxAssetsDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>DeferredTaxAssetsLeaseLiability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DeferredTaxAssetsResearchExpensesCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets research expenses capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DeferredTaxAssetsResearchExpensesCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets start up and pre clinical studies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_DeferredTaxLiabilityRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liability Right of Use Asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_DeferredTaxLiabilityRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886604124192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 148,009<span></span>
</td>
<td class="nump">$ 171,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Deferred tax assets operating loss carryforwards without expire date</a></td>
<td class="nump">363,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">39,838<span></span>
</td>
<td class="nump">40,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Reduced credits carryforward</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Uncertain Tax Positions Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in deferred tax assets</a></td>
<td class="num">(25,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 704,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_OperatingLossCarryforwardsExpirationDatesState', window );">Net operating loss carryforwards, expiration date</a></td>
<td class="text">2037 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=tcrt_FederalAndStateMember', window );">Federal and State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Deferred tax assets operating loss carryforwards with expire date</a></td>
<td class="nump">$ 341,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_OperatingLossCarryforwardsResearchExpirationDates', window );">Net operating loss carryforwards, expiration date</a></td>
<td class="text">2043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=tcrt_FederalAndStateMember', window );">Federal and State [Member] | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">$ 39,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">497,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_OperatingLossCarryforwardsExpirationDatesState">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards Expiration Dates State</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_OperatingLossCarryforwardsExpirationDatesState</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_OperatingLossCarryforwardsResearchExpirationDates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards Research Expiration Dates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_OperatingLossCarryforwardsResearchExpirationDates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=tcrt_FederalAndStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=tcrt_FederalAndStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886602947856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax at statutory rates</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal tax benefit</a></td>
<td class="num">(92.00%)<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp', window );">Research and development true-up</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange', window );">Federal/state rate change</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">73.00%<span></span>
</td>
<td class="num">(18.00%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation nondeductible expense federal rate change.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation nondeductible expense research and development true up.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886599834096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 11, 2018</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,666,667<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Initial Public Offering of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 14,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,012,522<span></span>
</td>
<td class="nump">16,027,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,012,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,918,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AgreementTypeAxis=tcrt_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="nump">$ 47,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_EquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_EquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AgreementTypeAxis=tcrt_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AgreementTypeAxis=tcrt_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886608322096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Additional information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>May 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding options issued</a></td>
<td class="nump">465,898<span></span>
</td>
<td class="nump">693,909<span></span>
</td>
<td class="nump">711,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for future grant</a></td>
<td class="nump">1,302,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based payment award granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of Shares of Restricted Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tcrt_NonVestedStockMember', window );">Unvested Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs related to non-vested restricted stock outstanding</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected recognition period</a></td>
<td class="text">1 year 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tcrt_NonVestedRestrictedStockMember', window );">Unvested Restricted Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based payment award granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense related to non-vested restricted stock arrangements</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcrt_TwoThousandTwelveEquityIncentivePlanMember', window );">the "2012 Plan" [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">933,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for future grant</a></td>
<td class="nump">71,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcrt_TwoThousandTwelveEquityIncentivePlanMember', window );">the "2012 Plan" [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">65,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcrt_TwoThousandTwentyEquityIncentivePlanMember', window );">the "2020 Plan" [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,471,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcrt_TwoThousandTwentyEquityIncentivePlanMember', window );">the "2020 Plan" [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">400,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=tcrt_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=tcrt_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcrt_NonVestedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcrt_NonVestedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcrt_NonVestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcrt_NonVestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tcrt_TwoThousandTwelveEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tcrt_TwoThousandTwelveEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tcrt_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tcrt_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886597052368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock Option Activity Under Stock Option Plan (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance</a></td>
<td class="nump">693,909<span></span>
</td>
<td class="nump">711,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">259,122<span></span>
</td>
<td class="nump">313,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled</a></td>
<td class="num">(487,133)<span></span>
</td>
<td class="num">(328,566)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance</a></td>
<td class="nump">465,898<span></span>
</td>
<td class="nump">693,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, at end of period</a></td>
<td class="nump">415,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for future grant</a></td>
<td class="nump">1,302,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance</a></td>
<td class="nump">$ 27.6<span></span>
</td>
<td class="nump">$ 43.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">7.35<span></span>
</td>
<td class="nump">16.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled</a></td>
<td class="nump">17.7<span></span>
</td>
<td class="nump">50.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance</a></td>
<td class="nump">26.85<span></span>
</td>
<td class="nump">$ 27.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, at end of period</a></td>
<td class="nump">$ 28.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, at end of period</a></td>
<td class="text">7 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, at end of period</a></td>
<td class="text">7 years 7 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, at end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, at end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886696341824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Summary of Non-Vested Restricted Stock (Detail) - Unvested Restricted Common Stock [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance</a></td>
<td class="nump">62,604<span></span>
</td>
<td class="nump">79,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(33,322)<span></span>
</td>
<td class="num">(20,441)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled</a></td>
<td class="num">(29,282)<span></span>
</td>
<td class="num">(15,527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">62,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance</a></td>
<td class="nump">$ 21.04<span></span>
</td>
<td class="nump">$ 31.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested</a></td>
<td class="nump">17.94<span></span>
</td>
<td class="nump">34.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled</a></td>
<td class="nump">24.6<span></span>
</td>
<td class="nump">47.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 21.04<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcrt_NonVestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcrt_NonVestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886601404208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Defined benefit plan contributions by employer</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886603679328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Joint Venture - Additional Information (Details)<br></strong></div></th>
<th class="th"><div>Jul. 05, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=tcrt_ZiopharmMember', window );">Ziopharm [Member] | Eden Bio Cell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest in affilated entity</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=tcrt_ZiopharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=tcrt_ZiopharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=tcrt_EdenBioCellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=tcrt_EdenBioCellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139886696704384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 22, 2024</div></th>
<th class="th"><div>Jan. 21, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options granted exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.35<span></span>
</td>
<td class="nump">$ 16.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AdvanceNoticePeriodForTerminationAgreement', window );">Notice period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Consulting Agreement Provides for Compensation</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Mr. Hogue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Annual salary in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Common stock shares awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options granted exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AdvanceNoticePeriodForTerminationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance notice period for termination agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AdvanceNoticePeriodForTerminationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483043/710-10-30-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=tcrt_HogueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=tcrt_HogueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>76
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M[,\.X/B8 3S29 ?KE.S6*0D&\$K"I*D2KK5BCM:CQWO189R.6R%$C";C&1[
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M@9*1"I@DG"$!>>RL_.5Z8>)MP"\"K3P9(U/)GO-G,]EDL>,9(:"0*D/ ^G:
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M<A,<GFKL"V>_NZ4T^JND$)U, B32_4F6=E_$W?-G=L_FXK,UH?3B5Y.K?%O
M!*;T]LP[>R[F+TK\167[XF V%O/I_. %>0>]?P<L[^ 9>>=99EL3M%F**UOI
M3"LO_GF^\,$!#_]ZRN,H[_!I>50C[WTC,W4Z0A%XY>[5Z.S5#[/7T^,7K#WL
MK3U\2?HWL_'R[MF^& H0YY5LC?7BME1.-JH-.O-C\<ED^V.Q*G56"NVIL)1S
M*A?!"JQ3&I7BQ:L?WL[GT^,D8<R7LV-AG0BEZIY>VKJ19MT_A30I,EBE,UGM
M^8"B%M8 H7:YWBLLT PU&0J0A,"BM<BB!%S+(%;06VH@WM'^:BVTN;?5/?;
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M6FNBQIJ+:*?$*XX'M#_N4S2*]G?(VV^]VP_R]I^1=\>/GBY2$]_3W^=3YRU
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M\WC2GT2C9]P;;'M+##M/NXSM/#Q@I1* @NJ5U^ZV;^3SZFGX1%X]L-\K.]>
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MNE8@97F]V6;5#L<O=955N<[*Q, 0!;+<FF2=W:EDH525 (JV6:.*1%?T7%/
M: 4"T*[IO:RZ;31,LBUAW96J5).5Y0Z_5]N6GVUAW<^5QG>WN Y!=KU1#6P@
M3>HF^3RYG21_N;[^.$D^&X7?OC6MWM!0!)H!X4W EX-@PSIY7:$6U.V.8733
M@G;ZO=. "I#,"E09/I&T-;S[HA+EELJJ(LD,J+\MKF0 [JQ-LN42%!3M :"H
M&]Q%ML&]TS9@O&KYT5)G"UWJ5LM4^$BA35[6IFMH5P @8@Q7'WN.5RH 'GP
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MDU0ULVRC%>P+4 V?@U(S+,:FRST8\<,+56I@>QC6)MK-4R.? I9P1"BI(8Y
M" [@XV,#3F\#:AZ_1MYEL8H^5N[C(28!8V40Z&X#.@Z_ =8$#:1%_BI2J,#(
M_Z /)LE;E%B KD,C D:&R: J,H@X'#6(;I@C\W76K'B/(NE(B%(1F^#Z++7!
MUO4&N/7.:QG8\U:W6:G_H4 ]OSD$&R(6M% N^\ 1"?I'Z.T>HQ>!3K%&?6?U
M_Q)T37WO];_CDT9MV5V@859Q%J@JEUT)['''(HW?LOUZ<?3+$K; *$#5TX%
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MB4GH /L #Z '@*D!NL"(LBY!5FJA5KJJ@F()F#ZLYK;6"W*+@#P -C_0K1F
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M4WJSG5GTYSH?X23_;.?[+GF:G)REL]-I\HS?7*07)_#FZ.]]'@_1;T*N3 <
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M<MLV$'WW5V#4M+5G5%U]JV-[QHZ;:6:2::9.TH=.'R!R):$!"08 +2M?W[,
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MX%3.0;GW%F\5Y/SU'4W\9=]#$S_WDTKJ-DJ-GI :CL0'D_NY$[_E*:7K"OJ
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MG0+)2T6A'C;.07^C+K\#4$L#!!0    ( ,P[@5BHVJ$7G@(  ,@%   9
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;(U46V_3,!1^[Z^PPH1 *LVUEY4V
M4CN&X&&BV@0\(![<Y*2QYMC!=M;MWW/LI%F'NHH7QSZ7S]_QR7<6>ZGN=0E@
MR&/%A5YZI3'UW/=U5D)%]4C6(-!32%51@T>U\W6M@.8NJ>)^% 03OZ),>.G"
MV38J7<C&<"9@HXANJHJJIS5PN5]ZH7<PW+)=::S!3Q<UW<$=F._U1N')[U%R
M5H'03 JBH%AZJW"^3FR\"_C!8*^/]L16LI7RWAZ^YDLOL(2 0V8L L7/ UP!
MYQ8(:?SI,+W^2IMXO#^@?W:U8RU;JN%*\I\L-^72FWDDAX(VW-S*_1?HZAE;
MO$QR[5:R;V/CV"-9HXVLNF1D4#'1?NEC]PY'";/@E82H2X@<[_8BQ_(3-31=
M*+DGRD8CFMVX4ETVDF/"-N7.*/0RS#/I*LM4 SFY?L0V:] +WR"J]?E9A[!N
M$:)7$,*(W$AA2DVN10[Y2P ?Z?2<H@.G=706\1-D(Q*'0Q(%47P&+^YKC!U>
M_ K>AC[1+0=-J,B)*YAR37ZMMMHH_"M^GZJY14Q.(UJES'5-,UAZ* 4-Z@&\
M].V;<!)\/,,WZ?DFY]#_JR=G$4[SFXS(O\B] 0Z&3*+>M"&R(*8$4DB.LF5B
M-Q^\NR!,H%$V&M]1OW?=L4LTN,+[648YN2#CR0S7:(A#87!=U5P^ 2!H9>&I
MTV$2DW"(+S78*%F MNK&3,N194A@&D[).$[0"]D!MG=^(.'E;'!#15-@XQJ%
MQ)Z=^",B\'0Z^(;,E:L$I?DB!/,GG=MN+P<7F!(G@24^3,8).=4]_TA=%:B=
MFR'VI1IA6J'UUGY,K5IU/H>W,^Z&JAT3FG H,#483<<>4>W<: ]&UDZK6VE0
M^6Y;XJ@%90/07TAI#@=[03^\T[]02P,$%     @ S#N!6.4T]VMD!0  5PP
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M6 #G<PMRKE_80/N_Q/A_4$L#!!0    ( ,P[@5BYS,?#P@4  &T/   9
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MT8V,:&CF#+/,KQ=H4NKJ.C''(T_S-/#"7-2EI^E=<B@M@AM=+7.<+A]:KV"
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MY%%L\/?L[B:^>T[I$BPT<S^O@O)1=TU=:>/5E Y[<@VZQ6FS&PP]V#^CZF)
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M_O,A_G;^(RR@P2L\U93+)3QZ/'UR=L!9#?NAK6KZ8R( XMJJH%_7$AQK@S?
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MIRM_60B.(D@;\#S7@$Q[0PKZ[T#7_P%02P,$%     @ S#N!6%Z)%-5H P
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MY2@<=0N?Q6IM:6%\=5&Q%;_G]H_J3N/3N$?)1<FE$4J"YLO+T77XYB:A\^[
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MNOGBT#Q85;FW_(6R5I7NYYHSG CH .XOE;+= PGH/_M<_0M02P,$%     @
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M/98XIMG+!GR?.1=7"W&P_@]B\B]02P,$%     @ S#N!6"J; \[W!   :0L
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M*2WF$\K2;/$,WF)T<A'Q%K_J)/U[MO+!(27^V^=OCW:P'TW*Y+5O5<ZG">K
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M0CD6X@A$Q#@^CE#3I:.FRZ/;_[X!#Z4!-8H3(#N2V!HBH]\R3A)=5N[R$/^
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M2@3U!H%ZS'9@$8@JRD@\*')D<7T80%%#H9)@&[B,,[--;P/5<G" Q#HH+NW
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M74N#M>^F)39;4-8![8649K^P!W3M._T'4$L#!!0    ( ,P[@5C,AOY?C0(
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M4]\0U%[Y\0HP;P'L'4#(X%H*DVNX$@DF;P$^J>DDL;6D.=M)O,2X#X/P&%C
M!CMX@R[$@>,-=H9X#-]K5-P4(H/?YPMM%/T0?[;%V]*&VVFV2":ZYC'./*H"
MC>H)O>A@+QP%9SNT#CNMPUWTZ$)6M10HC :9@E,.5\]4@1JW2=T-N\\1XC?
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MFH0&H:U R-8P5RU,\@Y,G)"O4IB%)K>B@.(U0(B<>F))1^PJV8MX ^R$I'%
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M;!F@AUD09V,R"N+1V/L-GU61A"29E\08HM0"9$$:Y6@3(_I$JZ9%IO;%J&!
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M**M-:';@4G76%%Q1VZ+<&472@NS,Y,[([!%N&K=%LU+4&DY^B'F)^G0\,.3
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M41)[Z<BFQA,_C0DO933Y^"'EC'_JW6SH@%UN]E0YB,)B+QPF%B7UTX!0DN@
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MH/WPH;0 2@M1M+YP.C.5VLW4O=JU?*A799J/]1M)MIK63CY8*U W%4KSH;0
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ML?(&JP))"T%IN*;MC_?[DT--K-NT-6F,(,=J-LP7/$W)+1>5!V#647E!>[4
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MGIO4)$85B> ("3\@MX+K3)%W'%_?!7!1D4:6X$F647 2<0+)!0G]-R3P@O!
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M8%(U+V:8J/X2N Y0[V/&Y&&B/U!UK,%O4$L#!!0    ( ,P[@5A9I9EV" ,
M ,H(   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;*U676_:,!3]*U96
M39W4$I*00#N(Q$>G[:$3*NOZ,.W!)!=B-;&9;:#[][MV0@I50$SJ"]C./2?G
M7%_NI;\5\EEE )J\%#E7 R?3>G7KNBK)H*"J)5; \<E"R()JW,JEJU82:&I!
M1>[Z[7;D%I1Q)^[;LZF,^V*M<\9A*HE:%P65?T>0B^W \9S=P0-;9MH<N'%_
M19<P _VXFDK<N35+R@K@B@E.)"P&SM"['?=,O WXR6"K]M;$.)D+\6PVW]*!
MTS:"((=$&P:*7QL80YX;(I3QI^)TZE<:X/YZQ_[%>D<O<ZI@+/(GENILX/0<
MDL*"KG/](+9?H?(3&KY$Y,I^DFT5VW9(LE9:%!48%12,E]_TI<K#'L"+C@#\
M"N"_!72. ((*$%BCI3)K:T(UC?M2;(DTT<AF%C8W%HUN&#>W.-,2GS+$Z7A6
MWAX1"S)C2\X6+*%<DV&2B#77C"_)5.0L8:#(-;FCDMLCP#K(J 0RHHHEA/*4
M3%B^UI"2RPEHRO)/&/XXFY#+BT_D@KAEN"*,DT?.M+K"0US_R,1:(5KU78UF
MC"0WJ82/2N'^$>&>3^X%UYDB=SR%])# Q2S4J?!WJ1CY)QDGD+1(X%T1O^T'
M#8+&Y\/]$W*"^F8"RQ<<X:N2K6RV9S;;OX9SI256_N^F?)5TG68ZTPUNU8HF
M,'#PYZY ;L")/W[PHO;G)J_O1';@O%,[[YQBC[]C\\J%:BR*$AE9I.E0F_@Z
M"+U.N^]N]N4WA76[P6O8@;"P%A:>%/9DFP(6.=V Q!Y'$E$4V(NJXL8FJ316
M,][:E>DM+&ER4+XBW)/FA3<W86!J[L!#0V"GTPV#L-/L(JI=1._F(BU_U4T^
MHG-]- 2>]-&M?73/*A.RVK6C$UDOJ7K[!>&W_#=*RZ";PZ#(:Y;9JV7V_EOF
MB;3VSA':.TNHNS<6"I!+.RT5L9V];(OU:3V0AW8.O3D?X: NY^HK33GE[ZE<
M,JY(#@ND;+>Z>,VRG)SE1HN5'3YSH7&4V66&?S9 F@!\OA!"[S;F!?7?E_@?
M4$L#!!0    ( ,P[@5BS=3^4D@,  )P/   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;,U7;6_;-A#^*X0&%!W011)ERU9J&TB<#BW0#$:,MA^*?F#D
MLTU$$C62LK-_OR.ER)8C:PL@M/EB\>7N\3W/\23>9"_D@]H":/*8)IF:.ENM
M\TO75?$64J8N1 X9[JR%3)G&J=RX*I? 5M8I35SJ>:&;,IXYLXE=6\C91!0Z
MX1DL)%%%FC+YSS4D8C]U?.=IX8YOMMHLN+-)SC:P!/TE7TB<N37*BJ>0*2XR
M(F$]=:[\R[D?& =K\97#7AV-B:%R+\2#F7Q:31W/1 0)Q-I ,'SL8 Y)8I P
MCK\K4*?^3^-X/'Y"_].21S+W3,%<)-_X2F^GSM@A*UBS(M%W8O\1*D)#@Q>+
M1-E?LJ]L/8?$A=(BK9PQ@I1GY9,]5D(<.?CA&0=:.=!3A\$9AZ!RL,JY9626
MU@W3;#:18D^DL48T,[#:6&]DPS.3QJ66N,O13\^69?J(6),EWV1\S6.6:7(5
MQZ+(-,\V9"$2'G-0Y \<:L!%EI ;GA1&?[+<,HE['Q[CI%C!BJRE2,E<I'FA
MF<T3 EMCW/L+3^5GH119@"P=R=L;T(PGOR.XLD@35R,K$YL;5PRN2P;T# .?
MDEN1Z2T&D6$$30 7Y:@UH4^:7--.Q!N(+TC@OR/4HT%+0//_[TX[P@GJ% 46
M+SB#=X62KVJ](2XDU_R_-/_ 9(;9.];Z^V<$)I\TI.I'F\QE%(/V*,SKY%+E
M+(:I@^\+!7('SNS-;W[HO6^3J">PAF"#6K!!%WI3,'40#!J"Q4W!X$FP' 6S
M9_$=8:DI@C:MR@"&-@#SIMS-_,@?TV@T<7?',CRWHW0\",.HMFLP'-8,AYT,
MOS$IL4P5^7X+Z3W(UGQV0KPTGSV!-=B&-=OP511 V*=@/8$U!!O5@HU^=0&,
MGA? 8$B#*#HI@!:[(1W[P["] ,8UPW$G0TQVBF'CYS%^("(W'+J+H1/NI;GM
M":S!/*J91Z^B&*(^!>L)K"&8[QVN.-ZO+H<J@N-S/@B'XVA\4@XM=F$41-Z9
M[X%_=(WS.SE^R7:@S"7K#A^2QV:XM-71517=H"_-<E]H30GH00+Z*BJC"J,O
MT7I":XIVN%OZG3>QGU(;P;,S[YV6Q7.3D(;>X*0JW*,^)P6YL>V?(K95*:_W
M]6K=8E[9QNID_=JTGK9_.L"4?>LMDQN.WY($U@CI78PP)EFV@N5$B]QV4_="
M8V]FAUMLGT$: ]Q?"VR2JHGY@[HAG_T+4$L#!!0    ( ,P[@5AM2_FIY@(
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MPRVP$*0)P.N1$/II8+;6U:>4Y7]02P,$%     @ S#N!6,.%G\3. @  J @
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MF_V;/%V7CT3YEN9YNBI?+GDPXZ+80/Y\GJ;YVYLB0?THH9N_ 5!+ P04
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MAX,/EPQ,W)RHD&[#M*XTN=D/8NT>&S3>P9VOM::#XA/TSU?Q!U!+ P04
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M=%JS*V"O!?8J/V^T $V;%+2)5&VZ-4%Z4VGKK>-6%B2F*POV!DG%D5KK'W_
M@?.SJ2??*=A5PO,VX?EDAQX4$6I6%@C6&X+XLQ@L8/VF2*HR8=38HCJDWZV]
M%_KS7H<,5J'KS,T-\EM>?Y+W'BI 1'RH>!-ZA'VTR/2,Q= UIKZ]O/P!E;>(
MO*C'/K2:.Q@'9O:@90^^46L>/\_TIID@V#5 2231>[$),Q@ !!'N01IL%I$9
M,6P1PTG$#2F8(BG[%Q!)_+5DDE5J$7.IC.4,ATWV.T-8@PZ-7!R-3&K4DD:3
MI+]3J"-*&7EB*5.O)K9H\+-]L*%%@$<JN&BY%I-<6PI3%+/1QBZ&!>M!#2U<
M;V&&PLY%IIPW-U:<9XB^Z#5HGO$F7A<CQ&'08S58^=@?F1/<$54\2?N7.E!A
MI,+#XO21#";A"-!%Q_"TD)GD^U<!>F:$= WK'3M>O]$F.R_TG)$5B"\BAB<E
M V8#A/9(TI+41[T4#ILDCZD1UAM S,RT)D,OB$:+>Y$@/*U!CQQ6ICX[]J77
MR#N4E?Y4&TSFG<WSFO(B/-A_^]'@O.^ 0!K/!WA2Q?[O >%[1;O._");>%JW
MJKN)/L26L.-6G3&F/)2C06.&)K/QSEPT"T^+EF']=/IC9!TJTH!U:#+!>E$M
M/"U;^D3<)1WABP:GVP'?E$D-9W>N-?I.^0<1>Y9+E-(=^#@W(20GZFM:_:)X
M4=UTGKB">U/U>("K+17: +[?<:[.+_KRU%Z6U_\!4$L#!!0    ( ,T[@5A2
MMJJ=L00  %P8   9    >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;+59VV[C
M-A#]%4)=% FP&XF4KZEM('&Z:(I-$22;]F'1!T8:V^I*HDO2<0+TXSN4%,F.
M9'KC*"^Q+IPS<SB<X1$S6@OY72T -'E,XE2-G876RU/75<$"$JY.Q!)2?#,3
M,N$:;^7<54L)/,R,DMAEGM=S$QZESF24/;N6DY%8Z3A*X5H2M4H2+I_.(1;K
ML4.=YP<WT7RAS0-W,EKR.=R"OEM>2[QS2Y0P2B!5D4B)A-G8.:.G4]8Q!MF(
M/R-8JXUK8JC<"_'=W%R&8\<S$4$,@380''\>8 IQ;) PCG\+4*?T:0PWKY_1
M/V?DD<P]5S 5\5]1J!=C9^"0$&9\%>L;L?X-"D)=@Q>(6&5_R3H?VV<."59*
MBZ0PQ@B2*,U_^6,Q$1L&M+?#@!4&[*5!9X>!7QCX&=$\LHS6!==\,I)B3:09
MC6CF(IN;S!K91*E)XZV6^#9".SVY3 .1 /G*'T&13^0L#",SO3PFEVF^2,QD
M'UV YE%\C"/N;B_(T8=C\H%$*?FZ$"O%TU"-7(W!&$@W*!R?YX[9#L>4D2N1
MZH4BOZ8AA-L +K(HJ;!G*N?,BG@!P0GQZ4?"/.8W!#3]<7-F"<<O9];/\/P?
MF=EO7_ MN=20J+^;YBJ'ZC1#F5(^54L>P-C!6E4@'\"9_/P3[7F_-/%L"6R+
M=:=DW;&A3_[ SH,]1N*Z2><D%DJ1@$OYA&MIS67S0LD1>QFB:3L/$]H9>-YP
MY#YLTFH8UJ=>WRN';07<+0/N6@.^@!E("2'1_)%PI4 K*P&L3XVK7A-X7$82
M2,@U-)'*O78WHO5[/C;7%Z2LP1V8JUY)O6>E?H.(7 8+@A6,K>\!>_H2.[0F
M <Y'I/<GKE?G.!SX@Q<4ZZ,Z'J6]YK3UR]C[>V(/5P%F+0]U.T=-H?9K0;S,
MA-7?@9D8E&P&5C9W:0 2.VQJV@6Y%BIKP@K;\3^X!9B<-'$:[.4TJ)7,CFH9
MEH$.K8%B4T.QH( <A9!?'9M](*P745/ PUK GUAW4*L):P@'9H)ZU8;HV1L"
M=FVEHR!+Q=D*BUU&^HE\NX+D'F1C][8COK9]MX6VS7]#$-#V]JT"JRWF+:%M
M,V<5<];ZWE5 ;I98W^L,:VO:[OI0:I46H=9-?R^UC_EVEJN]75N:W4<S!^;Y
M?=*8Z_=0*;22*=2N4SY#B+,19UO?K4;"]@*W@KUZF;>$MDV]$CRTVV*!MR10
M"N;O(7=HI7>H7? <I/7V";W"YV8'\#NT7^\ UM@.Y5[I)6H73.UT +L/YG4:
M/[SL9H=2K\05M:NKW;5._B.E"#;;_307OM,]8M+N[]5%T1+:]NQ4BHX.6VP'
M+6FS@OE[*#U6*3UF5WIO_OXI\+=*?UC7L_8P#J59"3IFE4V3?,D;CE]$@&7P
M^TI&*HSR8S3;KF?'?6VRVT+;GH5*W#'6WC)G+:FU@OE[:#]6:3_V-NW7. %^
M_:-]V*_+6KOK0ZE5*H[95=S;/D=9_42IQJ]5J>9NG-,F(.?9\35F0ZQ2G9]S
MED_+(_*S[&#XQ?-S>CK-#[HKF/S<_8K+>90J$L,,(;V3/J90YD?9^8T6R^PT
M^%YH+9+L<@$<-T@S -_/A-#/-\9!^0^%R?]02P,$%     @ S3N!6,EJ:PEA
M P  !0L  !D   !X;"]W;W)K<VAE971S+W-H965T-30N>&ULK59-;^,V$/TK
MA(HMO, F^HH=)[4%Q$X6NX<%@J3;'HH>:&ED$9%(E:3L[+_OD%(4VZ"E1=&+
M35*<-^\-.<-9[(5\406 )J]5R=72*[2N;WU?I0545%V*&CA^R86LJ,:IW/JJ
MED S:U25?A0$,[^BC'O)PJX]RF0A&ETR#H^2J*:JJ/RQ@E+LEU[HO2T\L6VA
MS8*?+&JZA6?0W^M'B3._1\E8!5PQP8F$?.G=A;?KT!K8'7\PV*N#,3%2-D*\
MF,G7;.D%AA&4D&H#0?%O!VLH2X.$//[I0+W>IS$\'+^A?[;B4<R&*EB+\D^6
MZ6+IS3V204Z;4C^)_1?H!$T-7BI*97_)OMU[C1[31FE1=<8XKQAO_^EK%X@#
M@W!VQB#J#*)3@ZLS!G%G$%NA+3,KZYYJFBRDV!-I=B.:&=C86&M4P[@YQF<M
M\2M#.YU\Y:FH@/Q.7T&1"_($J> I*QFU018Y>=] 'E[Q\B@@DQ5PR)G^2";W
MH"DK/RY\C5P,HI]V?E>MW^B,WS BWP37A2(//(/L&,!'$;V2Z$W)*AI$O(?T
MDL3A)Q(%4>P@M/YY\VB 3MP'-K9X\6A@R3U3:2E4(X'\=;=16N+=_=L5LA;Q
MRHUH$OI6U32%I8<9JT#NP$M^_26<!;^YY/Y/8$?BKWKQ5T/HR6?(0-*2L#8(
M&H- -5&:ZD8+^8-(JD&Y(M#"AH'%-25HEP274;CP=X?2QG8=<9[VG*>#G)^1
M'1PP_D0X5E',@+P38U1LVIOOHCZ,/KF)+H/@@RM3UE.7G"!VRYGU<F:##I_P
M4*E,"T)YAG5MAP6[QO*K22HA8]H9_9F32'02_;%=1W2O>[K7_XVNE@U<-+6+
M[C#B)#P;\!%#UTD=B9KWHN8C5TJD+Q?FE<D(7BM3/6U==8F9.Z)Z$OAA9TZ]
M1[1O>MHW/Y.]OK(987*5I 7E6W#Q'H::Q&</8<1P.J8F#-Z?N& 0:VW)8VJ3
M'2V;]F6C)38PE*=.31W>R16_CD_.8\3M))R/:CAXIL-!L(<\!]OQV#)DSL1)
M/!R_1<-[6GK^04-1@=S:/DOA'6ZX;E_D?K7OY>YL!W.ROC(]GFU4WF':!O$;
ME5O&%2DA1TB,+E9!V?9<[42+VK8M&Z&Q";+# OM4D&8#?L^%T&\3XZ#O?)-_
M 5!+ P04    " #-.X%8 ,@NLR $  "N$P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6RMF&V/HS80Q[^*14_MG;1=L$.>MDFD;+A35^JVT:7;OCCU
MA1<FP5K .=LD=_WTM8&0AR5TD<R+Q)B9OST_S#!XLN?B1<8 "GU+DTQ.G5BI
M[9WKRC"&E,I;OH5,7UESD5*E3\7&E5L!-"J<TL0EGC=P4\HR9S8I^I9B-N&Y
M2E@&2X%DGJ94?+^'A.^G#G8.'9_9)E:FPYU-MG0#*U!/VZ709VZM$K$4,LEX
MA@2LI\X<WP6X;QP*B[\8[.5)&YE0GCE_,2</T=3QS(P@@5 9":K_=K" )#%*
M>AY?*U&G'M,XGK8/ZI^*X'4PSU3"@B=_LTC%4V?DH C6-$_49[[_%:J B@F&
M/)'%+]I7MIZ#PEPJGE;.>@8IR\I_^JT"<>* _2L.I'(@EPZ#*PZ]RJ'WUA'\
MRL$OR)2A%!P"JNAL(O@>"6.MU4RC@%EXZ_!99N[[2@E]E6D_-5MJS" $1&BE
M>/B":%:U8IY$(.1/Z./7G*GOZ'T :Q8R]0']C.91Q,Q=HPEZR,JU9^ZA-E&4
M)<;B:16@]^\^H'?(13*F B1B&7K*F)(WNE.W_XQY+O5H<N(J'8>9C1M6<UZ4
M<R97YHP)>N29BB7ZF$40G0NX&D!-@1PHW)-6Q=_Y[A9A?(.(AT=-$VIW#R"\
M1;W"G?0:W(.WNY.6:'KU/>T5>KTK>M4=^_*;[D</"E+Y3\.D[DL1OUG$Y)L[
MN:4A3!V=4"2('3BS'W_  ^^7)D VQ0)+8F?P_!J>WZ8^6_ TU6M9FF?@YK!V
M::YB+MB_EXNM!-DJV!5D*=8OQ$S2WLUZ_L <PXF[.X7TVI",O.*H#<\ ]&L
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M%[Q0)'GY/[JOTSH#%&YR)=(Z6)<@C;/J+WNH*V(K@(R>"2!U -D)P,\%N'6
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M+CIH+2EBMZ2,J5HY[:H5-:9M_*$XYH=.W%C;,W2^5ZK+9'O59R]VW[L8E!:
MTB@4S6P K?-%[,Z76G$T*!9>E*MF!M81W([J>_."TGQ06@!*HU T4^+6/"/D
ME4=P NJ]@=)\4%H 2J-0-+-AM!8=L5MT]=2]ZK3K#*+M5\O%&AF6A9U^JYW=
M6W-0TPZ4%H#2:$W;GK-,W>)?,P*::K9V''EAD=,W+1(@7>N3G,EX=SP&]<Y
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MYLIB5_MEC7,7M O ^THIN]NX#_23//L#4$L#!!0    ( ,T[@5@8377H/P(
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MAOPEB<O:OTIH0X#W5\;0DQ%NRO#.%7\!4$L#!!0    ( ,T[@5ATS9^9"@0
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
MS3N!6-MAE[()!0  ]B<   \   !X;"]W;W)K8F]O:RYX;6S%FEMOXC@4@/^*
MQ5-7VBZ0"[UH&(FA=,IN%U!!G<>520Q836S&=NCEUZ^3+-,32H_VY;1/$.?V
MQ4[.=XZ3+X_:/"RU?F!/>:9LO[5Q;GO9;MMD(W)N_]!;H?R:E38Y=W[1K-MV
M:P1/[48(EV?MH-/IM7,N5>OKE_VQ9J8-%[03B9-:^<:RX5Z*1_NZOEQD.VGE
M4F;2/?=;U?],M%@NE<SEBTC[K4Z+V8U^O-%&OFCE>#9/C,ZR?JM;K[@7QLGD
M3?.\A%SPI:U:'%_><0_2;_4Z_H K::RKMJB.SSWC3OB-ZZ7"Z6N9.6&NN!/?
MC2ZV4JW+P_BK:(/+J/IA_UMWXJ7Y/]VH5RN9B"N=%+E0KNY'([(24-F-W-H6
M4SP7_=90[X1A,[X6Y47YLXS3^@*=)P/=92ZE7V'&:<5(Q_-M<#N8#$=L?C,:
M+>: *4"8@H]D8B<S;OP.&U'=%+\!QA!A#&D9YXO!8O3W:.+YIM=L.AO=#1;C
MZ03V8(3011])-[P93+Z/YFP\8?/%=/C7#8",$<CX0R$'\QMV?3O] ;NPA]#U
M:.EF_)GM+)L)4^VN$L&NI$TR;0L#G]TS!/&,%G&LK$Q]-%D8GOIXQ@;&<+46
MY5X6$)XCA.>TA%.SYDJ^5"L T05"=$%+="V5'TO?6["'NATL '>('X,BS[EY
M9GK%YG*MI-^-*\<&2:(+Y23$1#U!+(HKL720!?-#EU@0/@O9^ASAF7&5LM'/
M0F[+'7YG2C00,3UTB?W@A\\4PM,]^8-8T;C;,#%TB<UP5S9Z+N]4WW\^<BC+
MJWRN08A9H4NLA5O!#_H+LT"76 -#G>?252&UNMN&/F'UT4/X&-*$Q#S0)1;!
M#UY&_D;0[V)1OTL<]N^$=:9(7&%\5T$H+/!WB2/_6"4Z%VS!GQH#%V"Q/Z".
M_4XG#VRZ+5>P6<:A) ,LV@?$T7Z4;S/]+ 3[)I182?<&#BT/B,/_GUIZ0=[[
MC9JI6( %_("Z("B65OPL_$9LM#O(P (LX@?4M0"67_P30$PL[ ?4U0"*&4),
MS <!L0_*-(B=++@_JX6E:(#%_X X_B/Y4,D*,3$M!,1:.,R)CO8CIHB 6!%U
MZG$,*\0L$1); IKK*!QFBI#8%&\4=AP1\T5([ M8A;)3-DA36?[E&1LK?T"(
MB<XH$1ODM30] IG#ISC$?!)^JD\BB(GY)/Q4G\00$_-)2.P3'+,',3'#A,2&
MP3'/("9FF)#8,#CF.<3$/!,2>P;'O(!SR)AW(F+O5+G.*9O[0Z5%)DK<.OVY
M$H[+#&)B!HH^8&;J:,2LXOT)Q,0L%'W>I)6G'T),S$(1L85PS '$1%]P$%OH
M32[INU#G6ZW* DRO("9FH8C80N]/MU5W+,3$+!016^B_Q/>]APAB8A:*B"WT
M"_/74-LR*%7-_DZ F)B%(F(+H7.&[!1B8A:*B"VTGS5\9]CA2T+,0C&QA1J3
MB6]9(29FH9C80HTB[;3A]?)NA9B8A6)B"QU@(K50C%DH)K;0 >:=2+1_>C)9
M.[TQZ)B%8F(+S8Q8"6-\@*_+X/)IK_YM=):*1F^B+]JI:Z'#&KTY\A 3LU!,
M70L=P01M$!.S4$Q="QW#?,WH(29FH9C80D>G\%\''F)B%HJ)+=28S$?#>P^S
M4(_\+?W!]/Z[CU /LU"O_N1L_YU9Z@=&B73B3V%]>\*S9&98^5._8X_B\I79
MJLBRH6^;JEO-T_UG:_M/[K[^"U!+ P04    " #-.X%8]4F2S $"  !>)
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M4635*+)J%%DUBJPS%%EG_RGKH[6K/XX?GT5GFOXSGXW_[;EZ!U!+ 0(4 Q0
M   ( ,P[@5@'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ S#N!6(5+K<SM    *P(  !$
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M970R+GAM;%!+ 0(4 Q0    ( ,P[@5B!JS])/@(  !<&   8
M  " @705  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #,
M.X%8T3^J><,$  "_$0  &               @('H%P  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ S#N!6$>S>:!R!0  )2   !@
M         ("!X1P  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( ,P[@5B]-FU>?@<  *PA   8              " @8DB  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #,.X%8#&/='$D"  "D!0
M&               @($]*@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ S#N!6&0ZHFM# @  B@8  !@              ("!O"P  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ,P[@5C3$]S[B@H
M .(:   8              " @34O  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " #,.X%81OM'C5<&  !%$   &0              @('U
M.0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,P[@5CT
M0^4QF",  "5S   9              " @8-   !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ S#N!6/0#DPO@!P  )A4  !D
M     ("!4F0  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M" #,.X%8:N,9WCL#  !=!P  &0              @(%I;   >&PO=V]R:W-H
M965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,P[@5BHVJ$7G@(  ,@%   9
M              " @=MO  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L!
M A0#%     @ S#N!6.4T]VMD!0  5PP  !D              ("!L'(  'AL
M+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #,.X%8N<S'P\(%
M  !M#P  &0              @(%+>   >&PO=V]R:W-H965T<R]S:&5E=#$V
M+GAM;%!+ 0(4 Q0    ( ,P[@5B81[:.<!P  &EF   9              "
M@41^  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ S#N!
M6 C@TF"M!@  $Q(  !D              ("!ZYH  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " #,.X%87HD4U6@#  !Y!P  &0
M        @('/H0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( ,P[@5C6?K5!Z D  /\9   9              " @6ZE  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ S#N!6#<7&W0"!P   A(
M !D              ("!C:\  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " #,.X%8_6\^X-("  " !@  &0              @('&M@
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ,P[@5B4T2AA
M3@4  $T,   9              " @<^Y  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ S#N!6"J; \[W!   :0L  !D
M ("!5+\  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #,
M.X%8YP<"S),D  #&>@  &0              @(&"Q   >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,P[@5CEMI<&G08  "D2   9
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M970S,"YX;6Q02P$"% ,4    " #,.X%8%CO<4'T$  "5"@  &0
M    @('$^P  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M ,P[@5BD,WT\,@0  -X)   9              " @7@  0!X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ S#N!6!!1R2Q- P    X  !D
M             ("!X00! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " #,.X%8 W"Y(>X&  "".P  &0              @(%E" $ >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ,P[@5@!/%3C[0@
M *U-   9              " @8H/ 0!X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ S#N!6*WX%W_> @  R0@  !D              ("!
MKA@! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #,.X%8
M9[[;\T,#  #N"P  &0              @('#&P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( ,P[@5A?:=N)-0,  +T*   9
M      " @3T? 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ S#N!6%FEF78( P  R@@  !D              ("!J2(! 'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #,.X%8LW4_E)(#  "<#P
M&0              @('H)0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( ,P[@5AM2_FIY@(   X*   9              " @;$I 0!X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ S#N!6*_W?61_
M"   ES$  !D              ("!SBP! 'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    " #,.X%8@\#BD)<#  !6$0  &0
M@(&$-0$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( ,P[
M@5C#A9_$S@(  *@(   9              " @5(Y 0!X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ S#N!6!>1:&_Y @  50D  !D
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M=#0Y+GAM;%!+ 0(4 Q0    ( ,T[@5AED+4>[ D  %9H   9
M  " @0IE 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
MS3N!6&V&U0@_ @  R@0  !D              ("!+6\! 'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    " #-.X%8^99.&R<$   X#P  &0
M            @(&C<0$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( ,T[@5A2MJJ=L00  %P8   9              " @0%V 0!X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ S3N!6,EJ:PEA P
M!0L  !D              ("!Z7H! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    " #-.X%8 ,@NLR $  "N$P  &0              @(&!
M?@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( ,T[@5AT
M=%]U;@<  )M!   9              " @=B" 0!X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ S3N!6-ND]RBN!   [Q0  !D
M     ("!?8H! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,T[@5C=Z8G<4P,  ,X5   -              "
M 8.< 0!X;"]S='EL97,N>&UL4$L! A0#%     @ S3N!6)>*NQS     $P(
M  L              ( ! : ! %]R96QS+RYR96QS4$L! A0#%     @ S3N!
M6-MAE[()!0  ]B<   \              ( !ZJ ! 'AL+W=O<FMB;V]K+GAM
M;%!+ 0(4 Q0    ( ,T[@5CU29+, 0(  %XD   :              "  2"F
M 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,T[@5C6
M3,"2X $  .,C   3              "  5FH 0!;0V]N=&5N=%]4>7!E<UTN
9>&UL4$L%!@    !% $4 VA(  &JJ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>176</ContextCount>
  <ElementCount>353</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>73</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100040 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Financings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/Financings</Role>
      <ShortName>Financings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureRestructuring1</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Stock Option Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/StockOptionPlan</Role>
      <ShortName>Stock Option Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Joint Venture</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/JointVenture</Role>
      <ShortName>Joint Venture</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20231231/taxonomy/role/DisclosureDebt</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20231231/taxonomy/role/AccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20231231/taxonomy/role/Leases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20231231/taxonomy/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Stock Option Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/StockOptionPlansTables</Role>
      <ShortName>Stock Option Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20231231/taxonomy/role/StockOptionPlan</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Organization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/OrganizationAdditionalInformationDetail</Role>
      <ShortName>Organization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Financings - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail</Role>
      <ShortName>Financings - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation Expense Included in Statement of Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Stock-Based Compensation Expense Included in Statement of Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Summary of Significant Accounting Policies - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Summary of Significant Accounting Policies - Earning Per share Basic and Diluted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Earning Per share Basic and Diluted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Summary of Significant Accounting Policies - Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Debt - Schedule of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails</Role>
      <ShortName>Debt - Schedule of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails</Role>
      <ShortName>Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Property and Equipment, net - Component of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail</Role>
      <ShortName>Property and Equipment, net - Component of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Property and Equipment, net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment, net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Accrued Expenses - Component of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Component of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Warrants - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails</Role>
      <ShortName>Warrants - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Restructuring - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails</Role>
      <ShortName>Restructuring - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Income Taxes - Significant Component of Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Significant Component of Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail</Role>
      <ShortName>Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail</Role>
      <ShortName>Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Stock Option Plan - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail</Role>
      <ShortName>Stock Option Plan - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Stock Option Plan - Stock Option Activity Under Stock Option Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail</Role>
      <ShortName>Stock Option Plan - Stock Option Activity Under Stock Option Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Stock Option Plan - Summary of Non-Vested Restricted Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail</Role>
      <ShortName>Stock Option Plan - Summary of Non-Vested Restricted Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/EmployeeBenefitPlanAdditionalInformationDetail</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Joint Venture - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails</Role>
      <ShortName>Joint Venture - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="tcrt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995985 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="tcrt-20231231.htm">tcrt-20231231.htm</File>
    <File>tcrt-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img160836378_0.jpg</File>
    <File>img160836378_1.jpg</File>
    <File>img160836378_2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="493">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>82
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tcrt-20231231.htm": {
   "nsprefix": "tcrt",
   "nsuri": "http://alaunos.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "tcrt-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "tcrt-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    }
   },
   "keyStandard": 274,
   "keyCustom": 79,
   "axisStandard": 30,
   "axisCustom": 5,
   "memberStandard": 25,
   "memberCustom": 45,
   "hidden": {
    "total": 6,
    "http://fasb.org/us-gaap/2023": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 176,
   "entityCount": 1,
   "segmentCount": 73,
   "elementCount": 726,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 493,
    "http://xbrl.sec.gov/dei/2023": 38,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://alaunos.com/20231231/taxonomy/role/CoverPage",
     "longName": "100000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://alaunos.com/20231231/taxonomy/role/BalanceSheets",
     "longName": "100010 - Statement - BALANCE SHEETS",
     "shortName": "BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_4764432d-361f-42c3-b4d4-131225ea696e",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4764432d-361f-42c3-b4d4-131225ea696e",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical",
     "longName": "100040 - Statement - BALANCE SHEETS (Parenthetical)",
     "shortName": "BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_4764432d-361f-42c3-b4d4-131225ea696e",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4764432d-361f-42c3-b4d4-131225ea696e",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations",
     "longName": "100050 - Statement - STATEMENTS OF OPERATIONS",
     "shortName": "STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity",
     "longName": "100060 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "shortName": "STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_9e81976f-0dda-4005-94a7-17763001d331",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9e81976f-0dda-4005-94a7-17763001d331",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows",
     "longName": "100070 - Statement - STATEMENTS OF CASH FLOWS",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_10887a30-fe67-4725-98ec-6def6ef0869d",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_10887a30-fe67-4725-98ec-6def6ef0869d",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://alaunos.com/20231231/taxonomy/role/Organization",
     "longName": "995455 - Disclosure - Organization",
     "shortName": "Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://alaunos.com/20231231/taxonomy/role/Financings",
     "longName": "995465 - Disclosure - Financings",
     "shortName": "Financings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "tcrt:FinancingArrangementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "tcrt:FinancingArrangementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPolicies",
     "longName": "995475 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureDebt",
     "longName": "995485 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNet",
     "longName": "995495 - Disclosure - Property and Equipment, net",
     "shortName": "Property and Equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://alaunos.com/20231231/taxonomy/role/AccruedExpenses",
     "longName": "995505 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://alaunos.com/20231231/taxonomy/role/RelatedPartyTransactions",
     "longName": "995515 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://alaunos.com/20231231/taxonomy/role/Leases",
     "longName": "995525 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingencies",
     "longName": "995535 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://alaunos.com/20231231/taxonomy/role/Warrants",
     "longName": "995545 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "tcrt:WarrantTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "tcrt:WarrantTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureRestructuring1",
     "longName": "995555 - Disclosure - Restructuring",
     "shortName": "Restructuring",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://alaunos.com/20231231/taxonomy/role/IncomeTaxes",
     "longName": "995565 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://alaunos.com/20231231/taxonomy/role/StockOptionPlan",
     "longName": "995575 - Disclosure - Stock Option Plan",
     "shortName": "Stock Option Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://alaunos.com/20231231/taxonomy/role/EmployeeBenefitPlan",
     "longName": "995585 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://alaunos.com/20231231/taxonomy/role/JointVenture",
     "longName": "995595 - Disclosure - Joint Venture",
     "shortName": "Joint Venture",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEvents",
     "longName": "995605 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995615 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "995625 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtTables",
     "longName": "995635 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNetTables",
     "longName": "995645 - Disclosure - Property and Equipment, net (Tables)",
     "shortName": "Property and Equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://alaunos.com/20231231/taxonomy/role/AccruedExpensesTables",
     "longName": "995655 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://alaunos.com/20231231/taxonomy/role/LeasesTables",
     "longName": "995665 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesTables",
     "longName": "995675 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://alaunos.com/20231231/taxonomy/role/StockOptionPlansTables",
     "longName": "995685 - Disclosure - Stock Option Plans (Tables)",
     "shortName": "Stock Option Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://alaunos.com/20231231/taxonomy/role/OrganizationAdditionalInformationDetail",
     "longName": "995695 - Disclosure - Organization - Additional Information (Detail)",
     "shortName": "Organization - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_018d6e8c-001c-45fa-97e4-4efe0b2a752b",
      "name": "tcrt:StrategicAdvisorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_018d6e8c-001c-45fa-97e4-4efe0b2a752b",
      "name": "tcrt:StrategicAdvisorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail",
     "longName": "995705 - Disclosure - Financings - Additional Information (Detail)",
     "shortName": "Financings - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6804cc66-48f9-4973-9521-76cf1de8e41d",
      "name": "tcrt:NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "tcrt:FinancingArrangementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "995715 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1a75d2a0-9d24-4504-a3dc-2dac5fdd0e65",
      "name": "tcrt:PreStockSplitSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
     "longName": "995725 - Disclosure - Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_d20f89b1-a277-46ad-a886-0783d93e0131",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d20f89b1-a277-46ad-a886-0783d93e0131",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail",
     "longName": "995735 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation Expense Included in Statement of Operations (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Stock-Based Compensation Expense Included in Statement of Operations (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d8ef632-f188-499c-855f-f56d87eeb09c",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
     "longName": "995745 - Disclosure - Summary of Significant Accounting Policies - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
     "longName": "995755 - Disclosure - Summary of Significant Accounting Policies - Earning Per share Basic and Diluted (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Earning Per share Basic and Diluted (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail",
     "longName": "995765 - Disclosure - Summary of Significant Accounting Policies - Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
     "longName": "995775 - Disclosure - Debt - Schedule of Debt (Details)",
     "shortName": "Debt - Schedule of Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_00cfa7b8-8106-4392-b55d-bf6ad7d81305",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_00cfa7b8-8106-4392-b55d-bf6ad7d81305",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
     "longName": "995785 - Disclosure - Debt - Additional Information (Details)",
     "shortName": "Debt - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_4764432d-361f-42c3-b4d4-131225ea696e",
      "name": "us-gaap:LongTermDebtNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_70ef5a8d-4cca-4f80-ae99-5f24fedd40fc",
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "us-gaap:DebtInstrumentDescriptionOfVariableRateBasis",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
     "longName": "995795 - Disclosure - Property and Equipment, net - Component of Property and Equipment, Net (Detail)",
     "shortName": "Property and Equipment, net - Component of Property and Equipment, Net (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_4764432d-361f-42c3-b4d4-131225ea696e",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4764432d-361f-42c3-b4d4-131225ea696e",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail",
     "longName": "995805 - Disclosure - Property and Equipment, net - Additional Information (Detail)",
     "shortName": "Property and Equipment, net - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails",
     "longName": "995815 - Disclosure - Accrued Expenses - Component of Accrued Expenses (Details)",
     "shortName": "Accrued Expenses - Component of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_4764432d-361f-42c3-b4d4-131225ea696e",
      "name": "tcrt:AccruedClinicalExpensesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4764432d-361f-42c3-b4d4-131225ea696e",
      "name": "tcrt:AccruedClinicalExpensesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "995825 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_01c537c5-d7da-43b7-9828-3dd4fac7a6b1",
      "name": "us-gaap:PaymentsToFundLongtermLoansToRelatedParties",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01c537c5-d7da-43b7-9828-3dd4fac7a6b1",
      "name": "us-gaap:PaymentsToFundLongtermLoansToRelatedParties",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails",
     "longName": "995835 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "tcrt:LeaseTerminationDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "tcrt:LeaseTerminationDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails",
     "longName": "995845 - Disclosure - Leases - Components of Lease Expense (Details)",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
     "longName": "995865 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:RoyaltyExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
     "longName": "995875 - Disclosure - Warrants - Additional Information (Details)",
     "shortName": "Warrants - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c4120da5-aa3b-4ae8-8a1f-b0df2ff0da10",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "tcrt:WarrantTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails",
     "longName": "995885 - Disclosure - Restructuring - Additional Information (Details)",
     "shortName": "Restructuring - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail",
     "longName": "995895 - Disclosure - Income Taxes - Significant Component of Deferred Tax Assets (Detail)",
     "shortName": "Income Taxes - Significant Component of Deferred Tax Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_4764432d-361f-42c3-b4d4-131225ea696e",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4764432d-361f-42c3-b4d4-131225ea696e",
      "name": "tcrt:DeferredTaxAssetsStartUpAndPreClinicalStudies",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail",
     "longName": "995905 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_4764432d-361f-42c3-b4d4-131225ea696e",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4764432d-361f-42c3-b4d4-131225ea696e",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail",
     "longName": "995915 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Detail)",
     "shortName": "Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
     "longName": "995925 - Disclosure - Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Detail)",
     "shortName": "Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_4764432d-361f-42c3-b4d4-131225ea696e",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail",
     "longName": "995935 - Disclosure - Stock Option Plan - Additional information (Detail)",
     "shortName": "Stock Option Plan - Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_4764432d-361f-42c3-b4d4-131225ea696e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ca613479-d043-416d-8cb2-0957fc2d9f3c",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail",
     "longName": "995945 - Disclosure - Stock Option Plan - Stock Option Activity Under Stock Option Plan (Detail)",
     "shortName": "Stock Option Plan - Stock Option Activity Under Stock Option Plan (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_00cfa7b8-8106-4392-b55d-bf6ad7d81305",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail",
     "longName": "995955 - Disclosure - Stock Option Plan - Summary of Non-Vested Restricted Stock (Detail)",
     "shortName": "Stock Option Plan - Summary of Non-Vested Restricted Stock (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_3c4cb663-e0ce-4562-a60a-f57ab1bd16cb",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cd40fe04-39eb-4618-9e08-4ccfc8585a11",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://alaunos.com/20231231/taxonomy/role/EmployeeBenefitPlanAdditionalInformationDetail",
     "longName": "995965 - Disclosure - Employee Benefit Plan - Additional Information (Detail)",
     "shortName": "Employee Benefit Plan - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
     "longName": "995975 - Disclosure - Joint Venture - Additional Information (Details)",
     "shortName": "Joint Venture - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_c4e43b9c-1c1a-4ee7-8310-f49b0b04362e",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c4e43b9c-1c1a-4ee7-8310-f49b0b04362e",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "longName": "995985 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_05605a3c-4399-47be-99a9-52abcb18dab3",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2a4b610b-874a-4c4c-a87e-050473791707",
      "name": "tcrt:AdvanceNoticePeriodForTerminationAgreement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r702"
     ]
    },
    "tcrt_AccrualsPriorToFirstMarketingApproval": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AccrualsPriorToFirstMarketingApproval",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments due prior to the first marketing approval for TCR products.",
        "label": "Accruals Prior to First Marketing Approval",
        "terseLabel": "Payments due prior to the first marketing approval"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee compensation",
        "label": "Accrued Bonuses, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "tcrt_AccruedClinicalExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AccruedClinicalExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical",
        "label": "Accrued clinical expenses current",
        "documentation": "Accrued clinical expenses current."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AccruedConsultingFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AccruedConsultingFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other consulting services",
        "documentation": "Accrued consulting fees, current.",
        "label": "Accrued Consulting Fees, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "tcrt_AccruedManufacturingCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AccruedManufacturingCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued manufacturing costs, current.",
        "label": "Accrued Manufacturing Costs, Current",
        "terseLabel": "Manufacturing services"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AccruedPreclinicalServicesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AccruedPreclinicalServicesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued preclinical services current.",
        "label": "Accrued Preclinical Services Current",
        "terseLabel": "Preclinical services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional services",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r153",
      "r538"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "tcrt_AdditionalLoansCommitted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AdditionalLoansCommitted",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional loans committed.",
        "label": "Additional Loans Committed",
        "terseLabel": "Additional Loans Committed"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AdditionalNumberOfWarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AdditionalNumberOfWarrantsIssued",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional number warrants issued",
        "documentation": "Additional number of warrants issued.",
        "label": "Additional Number Of Warrants Issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "tcrt_AdditionalPaidInCapitalCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AdditionalPaidInCapitalCommonStockMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock [Member]",
        "terseLabel": "Additional Paid In Capital [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r361"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AdvanceNoticePeriodForTerminationAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AdvanceNoticePeriodForTerminationAgreement",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notice period",
        "label": "Advance Notice Period for Termination Agreement",
        "documentation": "Advance notice period for termination agreement."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AggregateAmountPotentiallyReimburseableAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AggregateAmountPotentiallyReimburseableAmount",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Amount Potentially Reimburseable Amount.",
        "label": "Aggregate Amount Potentially Reimburseable Amount",
        "verboseLabel": "Reimbursement of historical costs"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AggregateBenchmarkPaymentsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AggregateBenchmarkPaymentsPayable",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Aggregate Benchmark Payments Payable.",
        "label": "Aggregate Benchmark Payments Payable",
        "verboseLabel": "Aggregate Benchmark Payments Payable"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AggregateMinimumAnnualRoyaltiesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AggregateMinimumAnnualRoyaltiesPaid",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate minimum annual royalties paid.",
        "label": "Aggregate Minimum Annual Royalties Paid",
        "terseLabel": "Aggregate minimum annual royalties paid"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AggregatePotentialBenchmarkPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AggregatePotentialBenchmarkPayments",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate potential benchmark payments.",
        "label": "Aggregate potential benchmark payments",
        "terseLabel": "Aggregate potential benchmark payments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r737",
      "r747",
      "r773"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r740",
      "r750",
      "r776"
     ]
    },
    "tcrt_AgreementTerminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AgreementTerminationDate",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement termination date",
        "label": "Agreement Termination Date",
        "documentation": "Termination Date of CRADA Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AgreementTerminationNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AgreementTerminationNoticePeriod",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement termination notice period.",
        "label": "Agreement Termination Notice Period",
        "verboseLabel": "Agreement termination, notice period"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AgreementTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AgreementTypeAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Type Axis",
        "label": "Agreement Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AgreementTypeAxisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AgreementTypeAxisAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Type Axis Axis",
        "label": "Agreement Type Axis [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AgreementTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AgreementTypeDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Type Domain",
        "label": "Agreement Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r732",
      "r741",
      "r751",
      "r768",
      "r777",
      "r781",
      "r789"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Net share based employee compensation expense",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of financing costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r329",
      "r455",
      "r817"
     ]
    },
    "tcrt_AmountOfPrepaymentsPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AmountOfPrepaymentsPremium",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of prepayments premium",
        "label": "Amount Of Prepayments Premium",
        "documentation": "Amount Of Prepayments Premium."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AnnualCashRetainer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AnnualCashRetainer",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual cash retainer received",
        "label": "Annual Cash Retainer",
        "documentation": "Annual cash retainer."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AnnualExpenseIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AnnualExpenseIncurred",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual expense incurred.",
        "label": "Annual Expense Incurred",
        "terseLabel": "Annual expense incurred"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AnnualGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AnnualGrantMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual Grant [Member]",
        "label": "Annual Grant [Member]",
        "documentation": "Annual grant"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AnnualLicenseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AnnualLicenseFees",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual License Fees",
        "label": "Annual License Fees",
        "verboseLabel": "Annual License fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "tcrt_AresTradingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AresTradingMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ares Trading [Member]",
        "label": "Ares Trading [Member]",
        "terseLabel": "ARES Trading License"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows",
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment and right-of-use assets impairment",
        "label": "Asset Impairment Charges",
        "totalLabel": "Asset Impairment Charges, Total",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r46"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r155",
      "r177",
      "r209",
      "r222",
      "r226",
      "r267",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r424",
      "r426",
      "r446",
      "r531",
      "r609",
      "r702",
      "r715",
      "r846",
      "r847",
      "r898"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AssetsAndLiabilitiesEliminatedUponConsolidationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets and Liabilities Eliminated upon Consolidation [Abstract]",
        "label": "Assets and Liabilities Eliminated upon Consolidation [Abstract]",
        "verboseLabel": "Net Proceeds from Underwriting"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r161",
      "r177",
      "r267",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r424",
      "r426",
      "r446",
      "r702",
      "r846",
      "r847",
      "r898"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "At The Market Offering [Member]",
        "documentation": "At The Market Offering Member",
        "terseLabel": "Market Offering [Member]",
        "label": "At The Market Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r720",
      "r733"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r720",
      "r733"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r720",
      "r733"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72"
     ]
    },
    "us-gaap_BankingAndThriftInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BankingAndThriftInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Banking and Thrift, Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_BlackScholesModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "BlackScholesModelMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Black-Scholes Model [Member].",
        "label": "Black Scholes Model [Member]",
        "terseLabel": "Black-Scholes Model [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_BonusDepreciationEligibilityPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "BonusDepreciationEligibilityPercentage",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eligibility for bonus depreciation, percentage",
        "label": "Bonus Depreciation Eligibility, Percentage",
        "documentation": "Bonus Depreciation Eligibility, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/Organization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r108",
      "r109"
     ]
    },
    "tcrt_CARProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "CARProductsMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C A R Products Member",
        "label": "CAR Products [Member]",
        "terseLabel": "C A R Products [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_CRADAAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "CRADAAgreementMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CRADA Agreement [Member]",
        "documentation": "CRADA Agreement",
        "label": "CRADA Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_CantorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "CantorMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cantor [Member]",
        "label": "Cantor [Member]",
        "documentation": "Cantor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts included in accrued expenses and accounts payable related to property and equipment",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash balance",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r151",
      "r678"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r105",
      "r174"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r105"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r158",
      "r159",
      "r160",
      "r177",
      "r198",
      "r199",
      "r201",
      "r203",
      "r207",
      "r208",
      "r267",
      "r298",
      "r300",
      "r301",
      "r302",
      "r305",
      "r306",
      "r336",
      "r337",
      "r339",
      "r340",
      "r342",
      "r446",
      "r563",
      "r564",
      "r565",
      "r566",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r597",
      "r618",
      "r641",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r796",
      "r819",
      "r826"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "tcrt_ClassOfWarrantOrRightAxisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "ClassOfWarrantOrRightAxisAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Axis.",
        "label": "Class Of Warrant Or Right Axis [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_ClassOfWarrantOrRightDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "ClassOfWarrantOrRightDomainDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right.",
        "label": "Class Of Warrant Or Right Domain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise per share",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Warrant Exercise Per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants issued",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of Warrants",
        "verboseLabel": "Number of securities into which the class of warrant converted",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "tcrt_ClassOfWarrantOrRightWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "ClassOfWarrantOrRightWarrantsExercised",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised",
        "label": "Class Of Warrant Or Right Warrants Exercised",
        "documentation": "Class of warrant or right warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_ClinicalExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "ClinicalExpenses",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical expenses",
        "label": "Clinical Expenses",
        "documentation": "Clinical expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "tcrt_CollaborationAgreementWithSolasiaPharmaKkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "CollaborationAgreementWithSolasiaPharmaKkMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration Agreement With Solasia Pharma KK [Member]",
        "documentation": "Collaboration agreement with solasia pharma K.K.",
        "terseLabel": "Collaboration Agreement with Solasia Pharma K.K. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 9)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r79",
      "r532",
      "r596"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_CommitmentsAndContingenciesDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued Payments",
        "documentation": "Commitments and Contingencies Disclosure [Line Items]",
        "label": "Commitments and Contingencies Disclosure [Line Items]",
        "terseLabel": "Accrued Payments"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_CommitmentsAndContingenciesDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies Disclosure [Table]",
        "label": "Commitments and Contingencies Disclosure [Table]",
        "terseLabel": "Commitments and Contingencies Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r292",
      "r293",
      "r662",
      "r839"
     ]
    },
    "us-gaap_CommonStockCallOrExerciseFeatures": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCallOrExerciseFeatures",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price",
        "label": "Common Stock, Call or Exercise Features",
        "documentation": "Describe the call and/or exercise rights, prices and dates of common stock."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r89"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance",
        "verboseLabel": "Common Stock, shares reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r706",
      "r707",
      "r709",
      "r710",
      "r711",
      "r712",
      "r822",
      "r823",
      "r887",
      "r908",
      "r911"
     ]
    },
    "tcrt_CommonStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "CommonStockOptionsMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock options.",
        "label": "Common stock options [Member]",
        "terseLabel": "Common stock options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Initial Public Offering of Common Stock",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r597"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20231231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r89",
      "r597",
      "r615",
      "r911",
      "r912"
     ]
    },
    "us-gaap_CommonStockSharesSubscribedButUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesSubscribedButUnissued",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Subscribed but Unissued",
        "terseLabel": "Common stock",
        "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock $0.001 par value; 34,666,667 shares authorized, 16,012,522 shares issued and outstanding at December 31, 2023 and 28,000,000 shares authorized,16,027,384 shares issued and outstanding at December 31, 2022",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r534",
      "r702"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/EmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plan",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r124",
      "r125",
      "r126"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r138"
     ]
    },
    "tcrt_ConditionalMilestoneAmountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "ConditionalMilestoneAmountPayable",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conditional milestone amount payable.",
        "label": "Conditional Milestone Amount Payable",
        "terseLabel": "Conditional milestone amount payable"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r179",
      "r424",
      "r425",
      "r426",
      "r427",
      "r481",
      "r672",
      "r845",
      "r848",
      "r849"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r179",
      "r424",
      "r425",
      "r426",
      "r427",
      "r481",
      "r672",
      "r845",
      "r848",
      "r849"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction-in-process",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_ConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "ConsultantsMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultants [Member]",
        "label": "Consultants [Member]",
        "terseLabel": "Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_ContributionPayableOnPerAnnumBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "ContributionPayableOnPerAnnumBasis",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contribution payable on per annum basis.",
        "label": "Contribution Payable on Per Annum Basis",
        "terseLabel": "Contribution payable on per annum basis"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued",
        "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued",
        "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r34"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r176",
      "r307",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r323",
      "r330",
      "r331",
      "r333"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r85",
      "r86",
      "r131",
      "r132",
      "r179",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r456",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r820"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, interest rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total debt",
        "terseLabel": "Loan and Security Agreement",
        "totalLabel": "Total debt",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r132",
      "r334"
     ]
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument description of variable rate basis",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "documentation": "Description of reference rate used for variable rate of debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan and Security Agreement",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r76",
      "r308",
      "r456",
      "r687",
      "r688"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r332",
      "r456",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r820"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDateRangeStart1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDateRangeStart1",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, initial maturity date",
        "label": "Debt Instrument, Maturity Date Range, Start",
        "documentation": "Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r179",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r456",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r820"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument Redemption Period One",
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third anniversary",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second anniversary",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r55",
      "r58",
      "r73",
      "r74",
      "r76",
      "r80",
      "r118",
      "r119",
      "r179",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r332",
      "r456",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r820"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unamortized discount on Loan and Security Agreement",
        "terseLabel": "Unamortized discount on Loan and Security Agreement",
        "label": "Debt Instrument, Unamortized Discount",
        "totalLabel": "Debt Instrument, Unamortized Discount, Total",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r76",
      "r851"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting Agreement Provides for Compensation",
        "label": "Deferred Compensation Arrangement with Individual, Compensation Expense",
        "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r123"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs",
        "label": "Debt Issuance Costs, Net",
        "totalLabel": "Debt Issuance Costs, Net, Total",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r851"
     ]
    },
    "tcrt_DeferredTaxAssetsCapitalizedAcquisitionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedAcquisitionCosts",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets capitalized acquisition costs.",
        "label": "Deferred Tax Assets, Capitalized Acquisition Costs",
        "terseLabel": "Capitalized acquisition costs"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_DeferredTaxAssetsDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "DeferredTaxAssetsDepreciation",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets depreciation.",
        "label": "Deferred Tax Assets, Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred Tax Assets Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "tcrt_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DeferredTaxAssetsLeaseLiability.",
        "label": "Deferred Tax Assets Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred taxes",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "verboseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail",
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r885"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Deferred tax assets operating loss carryforwards without expire date",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Deferred tax assets operating loss carryforwards with expire date",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r885"
     ]
    },
    "tcrt_DeferredTaxAssetsResearchExpensesCapitalized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "DeferredTaxAssetsResearchExpensesCapitalized",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets research expenses capitalized.",
        "label": "Deferred Tax Assets Research Expenses Capitalized",
        "terseLabel": "Capitalized research expenses"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_DeferredTaxAssetsStartUpAndPreClinicalStudies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "DeferredTaxAssetsStartUpAndPreClinicalStudies",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets start up and pre clinical studies.",
        "label": "Deferred Tax Assets Start Up And Pre Clinical Studies",
        "terseLabel": "Start-up and pre-clinical studies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail",
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credit carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r885"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Total",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r885"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Liabilities, Net, Total",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r884"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_DeferredTaxLiabilityRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "DeferredTaxLiabilityRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Liability Right of Use Asset, Total",
        "documentation": "Deferred Tax Liability Right of Use Asset.",
        "label": "Deferred Tax Liability Right of Use Asset",
        "negatedLabel": "Right of use asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Defined benefit plan contributions by employer",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r349",
      "r357",
      "r694",
      "r695",
      "r696",
      "r697"
     ]
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits Assets, Noncurrent",
        "terseLabel": "Deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Total",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r47"
     ]
    },
    "tcrt_DescriptionOfFirstBenchmarkPayable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "DescriptionOfFirstBenchmarkPayable",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Description Of First Benchmark Payable.",
        "label": "Description Of First Benchmark Payable",
        "verboseLabel": "Description Of First Benchmark Payable"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Description Of Option To Terminate The Agreement Upon Not Meeting Certain Milestones.",
        "label": "Description Of Option To Terminate The Agreement Upon Not Meeting Certain Milestones",
        "verboseLabel": "Description Of option To terminate Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Employee Director [Member]",
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r909"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Options Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_DisclosureOfEarningPerShareBasicAndDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "DisclosureOfEarningPerShareBasicAndDilutedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Earning Per share Basic and Diluted",
        "label": "Disclosure Of Earning Per share Basic and Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Dividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Dividends",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends",
        "label": "Dividends",
        "totalLabel": "Dividends, Total",
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r120"
     ]
    },
    "us-gaap_DividendsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends [Axis]",
        "terseLabel": "Dividends [Axis]",
        "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends [Domain]",
        "terseLabel": "Dividends [Domain]",
        "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r720",
      "r733"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r720",
      "r733",
      "r769"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_DueDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "DueDateAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due Date Axis",
        "label": "Due date [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_DueDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "DueDateDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due Date Domain",
        "label": "Due date [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_DuneLakeCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "DuneLakeCapitalMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dune Lake Capital",
        "label": "Dune Lake Capital [Member]",
        "documentation": "Dune Lake Capital"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_EarningPerShareBasicAndDilutedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "EarningPerShareBasicAndDilutedLineItems",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earning Per share Basic and Diluted",
        "label": "Earning Per share Basic and Diluted [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_EarningPerShareBasicAndDilutedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "EarningPerShareBasicAndDilutedTable",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earning Per share Basic and Diluted",
        "label": "Earning Per share Basic and Diluted [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income (loss) per share, basic",
        "totalLabel": "Net loss per share, basic",
        "terseLabel": "Earnings per share, Basic",
        "label": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r185",
      "r186",
      "r188",
      "r189",
      "r191",
      "r196",
      "r198",
      "r201",
      "r202",
      "r203",
      "r205",
      "r437",
      "r438",
      "r529",
      "r542",
      "r680"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income (loss) per share, diluted",
        "totalLabel": "Net loss per share, diluted",
        "terseLabel": "Earnings per share, Diluted",
        "label": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r185",
      "r186",
      "r188",
      "r189",
      "r191",
      "r198",
      "r201",
      "r202",
      "r203",
      "r205",
      "r437",
      "r438",
      "r529",
      "r542",
      "r680"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39"
     ]
    },
    "tcrt_EdenBioCellMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "EdenBioCellMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eden Bio Cell",
        "label": "Eden Bio Cell [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_EdenBiocellMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "EdenBiocellMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eden Biocell.",
        "label": "Eden Biocell [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "tcrt_EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "EffectiveIncomeTaxRateLimitationOnAdjustedTaxableIncome",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate limitation on adjusted taxable income.",
        "label": "Effective Income Tax Rate Limitation On Adjusted Taxable Income",
        "terseLabel": "Relaxation of Adjusted taxable income, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Federal income tax at statutory rates",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r406",
      "r419"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r882",
      "r886"
     ]
    },
    "tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange": {
     "xbrltype": "percentItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation nondeductible expense federal rate change.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Federal Rate Change",
        "terseLabel": "Federal/state rate change"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "Research and development credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense."
       }
      }
     },
     "auth_ref": [
      "r882",
      "r886"
     ]
    },
    "tcrt_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp": {
     "xbrltype": "percentItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation nondeductible expense research and development true up.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Research and Development True Up",
        "terseLabel": "Research and development true-up"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r882",
      "r886"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income tax, net of federal tax benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r882",
      "r886"
     ]
    },
    "tcrt_EightScheduledPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "EightScheduledPaymentMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eight Scheduled Payment",
        "label": "Eighth Scheduled Payment [Member]",
        "documentation": "Eighth Scheduled Payment."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_EligibilityOfBonusPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "EligibilityOfBonusPercentage",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eligibility of bonus percentage.",
        "label": "Eligibility Of Bonus Percentage",
        "terseLabel": "Eligible bonus percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee Benefit and Share-based Payment Arrangement, Noncash, Total",
        "label": "Employee Benefit and Share-Based Payment Arrangement, Noncash",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense related to non-vested restricted stock arrangements",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected recognition period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation costs related to non-vested restricted stock outstanding",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Severance [Member]",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_EmployeeStockOptionAndRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "EmployeeStockOptionAndRestrictedStockMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock option and Restricted stock.",
        "label": "Employee Stock Option And Restricted Stock Member",
        "terseLabel": "Stock Options and Restricted Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail",
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "EmployeesMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees [Member]",
        "label": "Employees [Member]",
        "terseLabel": "Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail",
      "http://alaunos.com/20231231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r146",
      "r165",
      "r166",
      "r167",
      "r180",
      "r181",
      "r182",
      "r184",
      "r192",
      "r194",
      "r206",
      "r269",
      "r272",
      "r344",
      "r393",
      "r394",
      "r395",
      "r416",
      "r417",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r436",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r474",
      "r550",
      "r551",
      "r552",
      "r572",
      "r641"
     ]
    },
    "tcrt_EquityDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "EquityDistributionAgreementMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Distribution Agreement [Member]",
        "label": "Equity Distribution Agreement [Member]",
        "documentation": "Equity distribution agreement."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_EquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "EquityLineItems",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity [Line Items]",
        "label": "Equity [Line Items]",
        "terseLabel": "Equity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r266"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Ownership Percentage",
        "verboseLabel": "Equity interest in affilated entity",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments",
        "verboseLabel": "Equity method investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r262",
      "r811",
      "r832"
     ]
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/JointVenture"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "verboseLabel": "Joint Venture",
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r265",
      "r268",
      "r797"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r737",
      "r747",
      "r773"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r734",
      "r744",
      "r770"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExtinguishmentOfDebtAmount",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extinguishment of debt, amount",
        "label": "Extinguishment of Debt, Amount",
        "documentation": "Gross amount of debt extinguished."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r444"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r444"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value, Hierarchy [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r441",
      "r488",
      "r489",
      "r490",
      "r687",
      "r688",
      "r694",
      "r695",
      "r696"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443",
      "r445"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r349",
      "r354",
      "r441",
      "r488",
      "r694",
      "r695",
      "r696"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r488",
      "r489",
      "r490",
      "r687",
      "r688",
      "r694",
      "r695",
      "r696"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r445"
     ]
    },
    "us-gaap_FairValueNetAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Net Asset (Liability)",
        "totalLabel": "Fair Value, Net Asset (Liability), Total",
        "documentation": "Fair value of asset after deduction of liability."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_FairValueOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "FairValueOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of warrants",
        "documentation": "Fair Value of Warrants",
        "label": "Fair Value of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_FederalAndStateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "FederalAndStateMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal and State [Member]",
        "label": "Federal and State [Member]",
        "terseLabel": "Federal and State"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liabilities, current",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liabilities, non-current",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r332",
      "r341",
      "r434",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r541",
      "r685",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r828",
      "r829",
      "r830",
      "r831"
     ]
    },
    "tcrt_FinancingArrangementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "FinancingArrangementsDisclosureTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/Financings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Includes disclosures related to financing receivables and financing guarantees in which the company is the guarantor.",
        "label": "Financing Arrangements Disclosure [Text Block]",
        "terseLabel": "Financings"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r741",
      "r751",
      "r777"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r741",
      "r751",
      "r777"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r741",
      "r751",
      "r777"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r741",
      "r751",
      "r777"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r741",
      "r751",
      "r777"
     ]
    },
    "tcrt_GainLossOnModificationOfLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "GainLossOnModificationOfLease",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on modification of lease.",
        "label": "Gain (Loss) On Modification Of Lease",
        "terseLabel": "Gain (Loss) On Modification Of Lease"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_GainLossOnOperatingLeaseModificationAndTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "GainLossOnOperatingLeaseModificationAndTermination",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on lease modification and termination",
        "label": "Gain (Loss) On Operating Lease Modification And Termination",
        "documentation": "Gain (loss) on operating lease modification and termination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows",
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on sale of equipment, net",
        "terseLabel": "Gain on disposal of equipment",
        "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnTerminationOfLease",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on lease modification and termination",
        "terseLabel": "Gain on lease termination",
        "label": "Gain (Loss) on Termination of Lease",
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r620"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "tcrt_HogueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "HogueMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mr. Hogue",
        "label": "Hogue [Member]",
        "documentation": "Hogue Member."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_HoustonTexasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "HoustonTexasMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Houston Texas [Member]",
        "label": "Houston Texas [Member]",
        "verboseLabel": "Houston, TX [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r720",
      "r733"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r114"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail",
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r286",
      "r625"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail",
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r625"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r403",
      "r407",
      "r408",
      "r414",
      "r418",
      "r420",
      "r421",
      "r422",
      "r568"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r404",
      "r405",
      "r408",
      "r409",
      "r413",
      "r415",
      "r562"
     ]
    },
    "tcrt_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "tcrt_IncreaseDecreaseInLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of lease liabilities reported as liabilities.",
        "label": "Increase Decrease In Lease Liabilities",
        "verboseLabel": "Lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "terseLabel": "(Increase) decrease in:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_IncreaseDecreaseInOperatingDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "IncreaseDecreaseInOperatingDeposits",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating deposits.",
        "label": "Increase Decrease in Operating Deposits",
        "verboseLabel": "Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Liabilities [Abstract]",
        "terseLabel": "Increase (decrease) in:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non-current assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInReceivables",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Receivables, Total",
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Receivables",
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "tcrt_IncreaseDecreaseInRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "IncreaseDecreaseInRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in the carrying amount of right-of-use assets",
        "documentation": "The increase (decrease) during the period in the carrying value of right of use asset reported as assets.",
        "label": "Increase Decrease In Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r732",
      "r741",
      "r751",
      "r768",
      "r777",
      "r781",
      "r789"
     ]
    },
    "tcrt_InitialBenchmarkPaymentDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "InitialBenchmarkPaymentDue",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The first benchmark payment due upon the initiation of the Company's first sponsored phase.",
        "label": "Initial Benchmark Payment Due",
        "terseLabel": "First benchmark payment"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_InitialGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "InitialGrantMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Grant [Member]",
        "label": "Initial Grant [Member]",
        "documentation": "Initial grant"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r793"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r793"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r793"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Expense, Total",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r135",
      "r168",
      "r212",
      "r454",
      "r626",
      "r713",
      "r910"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "totalLabel": "Interest Expense, Debt, Total",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r327",
      "r335",
      "r689",
      "r690"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r172",
      "r173"
     ]
    },
    "tcrt_IntrexonCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "IntrexonCorporationMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrexon Corporation Member",
        "label": "Intrexon Corporation/Precigen [Member]",
        "terseLabel": "Intrexon Corporation/Precigen",
        "verboseLabel": "Intrexon Corporation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_IssuanceOfCommonStockNetOfExpensesInShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "IssuanceOfCommonStockNetOfExpensesInShares",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock, net of expenses in shares.",
        "label": "Issuance Of Common Stock Net Of Expenses In Shares",
        "terseLabel": "Issuance of common stock, net of expenses (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab Equipment [Member]",
        "label": "Lab Equipment [Member]",
        "documentation": "Lab equipment."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Lease, Cost, Total",
        "label": "Lease, Cost",
        "verboseLabel": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r701"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Expense",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_LeaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease income",
        "label": "Lease Income",
        "totalLabel": "Lease Income, Total",
        "documentation": "Amount of lease income from operating, direct financing, and sales-type leases. Includes, but is not limited to, variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and payable to lessor."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "tcrt_LeaseTerminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "LeaseTerminationDate",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease termination date",
        "label": "Lease Termination Date",
        "documentation": "Lease termination date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
      "http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_LeasesOperatingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesOperatingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases, Operating [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lease term, description",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r177",
      "r267",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r425",
      "r426",
      "r427",
      "r446",
      "r595",
      "r681",
      "r715",
      "r846",
      "r898",
      "r899"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r133",
      "r536",
      "r702",
      "r821",
      "r833",
      "r890"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES, PREFERRED STOCK AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r150",
      "r177",
      "r267",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r425",
      "r426",
      "r427",
      "r446",
      "r702",
      "r846",
      "r898",
      "r899"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_LicenseAgreementCommencingDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "LicenseAgreementCommencingDate",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement commencing date.",
        "label": "License Agreement Commencing Date",
        "terseLabel": "License agreement commencing date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseAgreementTermsMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement Terms [Member]",
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_LicenseAgreementWithTheNationalCancerInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "LicenseAgreementWithTheNationalCancerInstituteMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement With The National Cancer Institute Member",
        "label": "License Agreement with the National Cancer Institute [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_LicenseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "LicenseExpense",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to License payments.",
        "label": "License Expense",
        "terseLabel": "License Expense"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_LicensedProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "LicensedProductsMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensed Products Member",
        "label": "Licensed Products [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Initial borrowing",
        "terseLabel": "Loan and Security Agreement",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of payment terms",
        "label": "Line of Credit Facility, Frequency of Payment and Payment Terms",
        "documentation": "Description of the frequency of the required periodic payments of interest, principal, or both, and the amount, if set, or a description of a formula upon which payment is based."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additonal tranche facility",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Table]",
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r820"
     ]
    },
    "us-gaap_LitigationSettlementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementExpense",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation expense",
        "label": "Litigation Settlement, Expense",
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 0.0
      },
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: long-term debt, current",
        "terseLabel": "Current portion of long-term debt",
        "label": "Long-Term Debt, Current Maturities",
        "totalLabel": "Long-term Debt, Current Maturities, Total",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt obligations",
        "totalLabel": "Long-term debt",
        "terseLabel": "Long-term debt",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unspecified monetary damages",
        "label": "Loss Contingency, Damages Sought, Value",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r840",
      "r841",
      "r842"
     ]
    },
    "us-gaap_LossContingencyNameOfPlaintiff": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyNameOfPlaintiff",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency, name of plaintiff",
        "label": "Loss Contingency, Name of Plaintiff",
        "documentation": "Identifies the plaintiff in the lawsuit."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r116"
     ]
    },
    "tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MD Anderson Related to the 2015 R&amp;D Agreement [Member]",
        "label": "M D Anderson License and the Two Thousand Fifteen Research and Development Agreement [Member]",
        "documentation": "M D Anderson license and the two thousand fifteen research and development agreement."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_MaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "MaMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MA",
        "label": "MA [Member]",
        "verboseLabel": "Boston, MA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_MaximumAmountOfAdditionalMilestonesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "MaximumAmountOfAdditionalMilestonesPayable",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected additional milestones payable",
        "label": "Maximum Amount of Additional Milestones Payable",
        "documentation": "Maximum amount of additional milestones payable."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_MaximumAmountOfRoyaltyPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "MaximumAmountOfRoyaltyPayable",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum royalty amount",
        "label": "Maximum Amount of Royalty Payable",
        "documentation": "Maximum amount of royalty payable."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r358",
      "r515",
      "r549",
      "r587",
      "r588",
      "r647",
      "r649",
      "r651",
      "r652",
      "r654",
      "r673",
      "r674",
      "r684",
      "r691",
      "r698",
      "r704",
      "r850",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905"
     ]
    },
    "tcrt_MaximumRoyaltyAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "MaximumRoyaltyAmount",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of royalty.",
        "label": "Maximum Royalty Amount",
        "terseLabel": "Maximum royalty amount"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Sales Revenue On Which Benchmark Payments Payable",
        "label": "Maximum Sales Revenue On Which Benchmark Payments Payable"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_MdAndersonAgreementAndWorldwideLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "MdAndersonAgreementAndWorldwideLicenseMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MD Anderson Agreement and Worldwide License [Member]",
        "documentation": "MD Anderson Agreement and Worldwide License.",
        "label": "MD Anderson Agreement and Worldwide License [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MD Anderson License and the Research and Development Agreement [Member]",
        "documentation": "MD Anderson License and the Research and Development Agreement.",
        "label": "MD Anderson License and the Research and Development Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_MdAndersonLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "MdAndersonLicenseMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MD Anderson License.",
        "label": "Md Anderson License [Member]",
        "terseLabel": "MD Anderson License"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_MdAndersonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "MdAndersonMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MD Anderson [Member]",
        "label": "MD Anderson [Member]",
        "documentation": "MD Anderson [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_MdAndersonWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "MdAndersonWarrantMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "MD Anderson Warrant [Member]",
        "documentation": "Md Anderson Warrant Member",
        "label": "Md Anderson Warrant [Member]",
        "terseLabel": "MD Anderson Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "tcrt_MilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "MilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment.",
        "label": "Milestone Payment",
        "terseLabel": "One time milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_MilestonePaymentMadeOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "MilestonePaymentMadeOne",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment made One.",
        "label": "Milestone Payment Made One",
        "terseLabel": "Milestone payment made"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_MilestonePaymentsMaximumAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "MilestonePaymentsMaximumAmount",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments maximum amount.",
        "label": "Milestone Payments, Maximum Amount",
        "terseLabel": "Milestone maximum payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Minimum",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r358",
      "r515",
      "r549",
      "r587",
      "r588",
      "r647",
      "r649",
      "r651",
      "r652",
      "r654",
      "r673",
      "r674",
      "r684",
      "r691",
      "r698",
      "r704",
      "r850",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905"
     ]
    },
    "tcrt_MinimumRoyaltiesAmountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "MinimumRoyaltiesAmountPayable",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Minimum Royalties Amount Payable.",
        "label": "Minimum Royalties Amount Payable",
        "verboseLabel": "Minimum royalties amount payable"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum sales revenue on which benchmark payments payable",
        "label": "Minimum Sales Revenue On Which Benchmark Payments Payable",
        "documentation": "Minimum sales revenue on which benchmark payments payable."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r107"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
      "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity",
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows",
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r107",
      "r134",
      "r148",
      "r162",
      "r163",
      "r167",
      "r177",
      "r183",
      "r185",
      "r186",
      "r188",
      "r189",
      "r193",
      "r194",
      "r200",
      "r209",
      "r221",
      "r225",
      "r227",
      "r267",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r438",
      "r446",
      "r540",
      "r617",
      "r639",
      "r640",
      "r682",
      "r713",
      "r846"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_NewWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "NewWarrantsMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Warrants Member",
        "label": "New Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r741",
      "r751",
      "r768",
      "r777"
     ]
    },
    "tcrt_NonOperatingIncomeExpenseInducementOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "NonOperatingIncomeExpenseInducementOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Operating Income Expense Inducement Of Warrants.",
        "label": "Non Operating Income Expense Inducement Of Warrants",
        "terseLabel": "Non-cash inducement warrant expense",
        "verboseLabel": "Non-cash inducement warrant expense",
        "negatedLabel": "Non-cash inducement warrant expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "tcrt_NonVestedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "NonVestedRestrictedStockMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Vested Restricted Stock",
        "label": "Non Vested Restricted Stock [Member]",
        "terseLabel": "Unvested Restricted Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_NonVestedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "NonVestedStockMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Vested Stock [Member]",
        "label": "Non Vested Stock [Member]",
        "terseLabel": "Unvested Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Other income (expense), net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional option available to the underwriter to purchase",
        "label": "Number Of Additional Option Available To The Underwriter To Purchase",
        "documentation": "Number of additional option available to the underwriter to purchase."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_NumberOfDaysOptionExerciable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "NumberOfDaysOptionExerciable",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NumberofDaysOptionExerciable",
        "label": "Number of Days Option Exerciable"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_ObligationsDueUnderContract": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "ObligationsDueUnderContract",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations due under contract.",
        "label": "Obligations Due Under Contract",
        "verboseLabel": "Obligations due under contract"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_OfficeAndComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "OfficeAndComputerEquipmentMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and Computer Equipment [Member].",
        "label": "Office And Computer Equipment [Member]",
        "terseLabel": "Office and computer equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_OneTimeBenchmarkPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "OneTimeBenchmarkPaymentsMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Time Benchmark Payments Member",
        "label": "One Time Benchmark Payments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpensesAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "terseLabel": "Amounts expensed for services incurred",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r221",
      "r225",
      "r227",
      "r682"
     ]
    },
    "tcrt_OperatingLeaseArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "OperatingLeaseArea",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Area",
        "label": "Operating Lease Area",
        "documentation": "Operating lease area."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r701"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Lease, Liability, Total",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Present value of lease payments",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Recognition in exchange of Operating Lease Liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "verboseLabel": "Operating lease liability statement of financial position [extensible list]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r468"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r701"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term (years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r701"
     ]
    },
    "tcrt_OperatingLossCarryforwardsExpirationDatesState": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "OperatingLossCarryforwardsExpirationDatesState",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards Expiration Dates State",
        "label": "Operating Loss Carryforwards Expiration Dates State",
        "terseLabel": "Net operating loss carryforwards, expiration date"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_OperatingLossCarryforwardsResearchExpirationDates": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "OperatingLossCarryforwardsResearchExpirationDates",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards Research Expiration Dates",
        "label": "Operating Loss Carryforwards Research Expiration Dates",
        "terseLabel": "Net operating loss carryforwards, expiration date"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_OrganizationalChangesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "OrganizationalChangesPolicyTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organizational Changes",
        "label": "Organizational Changes [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for organizational changes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureAccruedExpensesComponentOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Assets, Noncurrent, Total",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_OtherIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "OtherIncomeExpenseMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other income expense member.",
        "label": "Other Income Expense [Member]",
        "terseLabel": "Other Income Expense [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income , net",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r739",
      "r749",
      "r775"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r730",
      "r742",
      "r752",
      "r778"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r730",
      "r742",
      "r752",
      "r778"
     ]
    },
    "tcrt_PatentAndTechnologyLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "PatentAndTechnologyLicenseAgreementMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent And Technology License Agreement [Member]",
        "label": "Patent And Technology License Agreement [Member]",
        "documentation": "Patent and technology license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PaymentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "PaymentTypeAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Type Axis",
        "label": "Payment Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PaymentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "PaymentTypeDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Type Domain",
        "label": "Payment Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PaymentUnderLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "PaymentUnderLicenseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment under license agreement",
        "label": "Payment Under License Agreement",
        "documentation": "Payment under license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt extinguishment costs",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToFundLongtermLoansToRelatedParties",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Fund Long-Term Loans to Related Parties",
        "terseLabel": "Payments to Fund Long-term Loans to Related Parties",
        "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r895"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage Of Commission On Gross Proceeds From Sale Of Common Stock",
        "label": "Percentage Of Commission On Gross Proceeds From Sale Of Common Stock",
        "documentation": "Percentage of commission on gross proceeds from sale of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "PercentageOfOriginalPrincipalDueAsAFinalPayment",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of original principal due as a final payment.",
        "label": "Percentage of Original Principal Due as a Final Payment",
        "terseLabel": "Percentage of original principal due as a final payment"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PercentageOfPrepaymentsPremium": {
     "xbrltype": "percentItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "PercentageOfPrepaymentsPremium",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of prepayments premium.",
        "label": "Percentage Of Prepayments Premium",
        "terseLabel": "Percentage of prepayments premium"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "PercentageOfSubLicensingIncomePayableToRelatedParty",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Portion of income payable to related party",
        "label": "Percentage of Sub licensing Income Payable to Related Party",
        "documentation": "Percentage of sub licensing income, attributable to related party."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PerformanceBasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "PerformanceBasedPaymentsMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance based payments.",
        "label": "Performance Based Payments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PlacementAgentFeesAndOtherRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "PlacementAgentFeesAndOtherRelatedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement agent fees and other related expenses.",
        "label": "Placement Agent Fees And Other Related Expenses",
        "verboseLabel": "Placement agent fees and other expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879"
     ]
    },
    "tcrt_PostMarketingApprovalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "PostMarketingApprovalMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post Marketing Approval Member",
        "label": "Post Marketing Approval [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PostStockSplitSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "PostStockSplitSharesAuthorized",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post Stock Split Shares Authorized",
        "documentation": "Post Stock Split Shares Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PostemploymentBenefitsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PostemploymentBenefitsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Postemployment Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PotentialBenchmarkPaymentsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "PotentialBenchmarkPaymentsPayable",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Potential Benchmark Payments Payable.",
        "label": "Potential Benchmark Payments Payable",
        "verboseLabel": "Potential Benchmark Payments Payable"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PreStockSplitSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "PreStockSplitSharesAuthorized",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre stock split shares authorized",
        "label": "Pre Stock Split Shares Authorized",
        "documentation": "Pre Stock Split Shares Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r336"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r597"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, stated value",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r533",
      "r702"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from private placement",
        "verboseLabel": "Proceeds from private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows",
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the disposal of property and equipment",
        "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Proceeds from stock options exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r12"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Warrant exercise, net of commissions and expenses",
        "verboseLabel": "Issuance of common stock upon exercise of warrants, net",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r516",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r676",
      "r692",
      "r703",
      "r799",
      "r843",
      "r844",
      "r852",
      "r907"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r516",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r676",
      "r692",
      "r703",
      "r799",
      "r843",
      "r844",
      "r852",
      "r907"
     ]
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfessionalAndContractServicesExpense",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting service amount",
        "label": "Professional and Contract Services Expense",
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "PropertyAndEquipmentAndRightOfUseAssetsImpairment",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property And Equipment And Right Of Use Assets Impairment",
        "documentation": "Property and equipment and right of use assets impairment",
        "terseLabel": "Property and equipment and right-of-use assets impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
      "http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r139",
      "r142",
      "r143"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r152",
      "r539"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r530",
      "r539",
      "r702"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r139",
      "r142",
      "r537"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Component of Property and Equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
      "http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment estimated useful life, Description [Extensible Enumeration]",
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "tcrt_PublicOfferingNetPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "PublicOfferingNetPricePerShare",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering, net price per share",
        "label": "Public offering, net price per share",
        "terseLabel": "Issuance &amp; sale of common stock in public offering price per share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r348",
      "r358",
      "r388",
      "r389",
      "r390",
      "r491",
      "r515",
      "r549",
      "r587",
      "r588",
      "r647",
      "r649",
      "r651",
      "r652",
      "r654",
      "r673",
      "r674",
      "r684",
      "r691",
      "r698",
      "r704",
      "r707",
      "r837",
      "r850",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r348",
      "r358",
      "r388",
      "r389",
      "r390",
      "r491",
      "r515",
      "r549",
      "r587",
      "r588",
      "r647",
      "r649",
      "r651",
      "r652",
      "r654",
      "r673",
      "r674",
      "r684",
      "r691",
      "r698",
      "r704",
      "r707",
      "r837",
      "r850",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Receivables, Net, Current, Total",
        "label": "Receivables, Net, Current",
        "terseLabel": "Receivables",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r734",
      "r744",
      "r770"
     ]
    },
    "tcrt_ReductionInRightOfUseAssetsForModificationAndTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "ReductionInRightOfUseAssetsForModificationAndTermination",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in right-of-use assets for modification and termination",
        "label": "Reduction in Right of Use Assets for Modification and Termination",
        "documentation": "Reduction in right of use assets for modification and termination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "terseLabel": "Related Party [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r478",
      "r479",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r614",
      "r616",
      "r646"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r622",
      "r625"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "terseLabel": "Related Party [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r478",
      "r479",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r614",
      "r616",
      "r646",
      "r897"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r569",
      "r570",
      "r571",
      "r623",
      "r624",
      "r625",
      "r644",
      "r645"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Repayments of Long-Term Debt, Total",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of long-term debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r566"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r881"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r881"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r401",
      "r906"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": [
      "r147",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r205",
      "r270",
      "r271",
      "r417",
      "r435",
      "r436",
      "r437",
      "r438",
      "r457",
      "r473",
      "r474",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r735",
      "r745",
      "r771"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r736",
      "r746",
      "r772"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r743",
      "r753",
      "r779"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "auth_ref": [
      "r147",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r205",
      "r270",
      "r271",
      "r417",
      "r435",
      "r436",
      "r437",
      "r438",
      "r457",
      "r473",
      "r474",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r810",
      "r818"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock [Member]",
        "verboseLabel": "Unvested Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureRestructuring1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283",
      "r285",
      "r287",
      "r291"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring costs",
        "label": "Restructuring Charges",
        "totalLabel": "Restructuring Charges, Total",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r288",
      "r289",
      "r838"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r289",
      "r290"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20231231/taxonomy/role/OrganizationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r120",
      "r535",
      "r554",
      "r559",
      "r567",
      "r598",
      "r702"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r180",
      "r181",
      "r182",
      "r184",
      "r192",
      "r194",
      "r269",
      "r272",
      "r393",
      "r394",
      "r395",
      "r416",
      "r417",
      "r428",
      "r430",
      "r431",
      "r433",
      "r436",
      "r550",
      "r552",
      "r572",
      "r911"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations",
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue",
        "verboseLabel": "Revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r220",
      "r223",
      "r224",
      "r228",
      "r229",
      "r231",
      "r345",
      "r346",
      "r516"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition from Collaboration Agreements",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r619",
      "r675",
      "r679"
     ]
    },
    "tcrt_RoyaltiesAmountPayableThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "RoyaltiesAmountPayableThereafter",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties amount payable thereafter",
        "label": "Royalties Amount Payable thereafter",
        "documentation": "Royalties amount payable thereafter."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty fee",
        "label": "Royalty Expense",
        "verboseLabel": "Royalty amount",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalariesWagesAndOfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual salary in cash",
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold",
        "totalLabel": "Salary and Wage, Excluding Cost of Good and Service Sold, Total",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with a public offering, net",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "verboseLabel": "Sale of stock consideration received on transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "Previously Reported [Member]"
       }
      }
     },
     "auth_ref": [
      "r147",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r194",
      "r205",
      "r417",
      "r435",
      "r436",
      "r437",
      "r457",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r798",
      "r800",
      "r801",
      "r802",
      "r824",
      "r834",
      "r835",
      "r888",
      "r893",
      "r894"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Component of Accrued Expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Potentially Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "terseLabel": "Assumptions for Volatility, Expected life, Dividend Yield and Risk-free Interest Rate",
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Debt",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Significant Component of Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]",
        "verboseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method",
        "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r40",
      "r825"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Income Tax Expense (Benefit)",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Share-Based Compensation Expense Included in Statements of Operations",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r266"
     ]
    },
    "tcrt_ScheduleOfEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "ScheduleOfEquityTable",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Equity [Table]",
        "label": "Schedule Of Equity [Table]",
        "terseLabel": "Schedule Of Equity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441"
     ]
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]",
        "verboseLabel": "Impact of Topic 606 Adoption on Financial Statements",
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r41",
      "r42"
     ]
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "terseLabel": "Summary of Non-Vested Restricted Stock",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
      "http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r621",
      "r622",
      "r625"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Activity Under Stock Option Plan",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r62"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "verboseLabel": "Issuance of Common Stock to Underwriters",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r118",
      "r119",
      "r120",
      "r158",
      "r159",
      "r160",
      "r207",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r563",
      "r564",
      "r565",
      "r566",
      "r691",
      "r796",
      "r819"
     ]
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Subsidiary or Equity Method Investee [Table]",
        "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement.",
        "label": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r584",
      "r585",
      "r586",
      "r648",
      "r650",
      "r653",
      "r655",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r677",
      "r693",
      "r707",
      "r852",
      "r907"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Operating Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r229",
      "r683"
     ]
    },
    "tcrt_SeriesOnePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "SeriesOnePreferredStockMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series 1 Preferred Stock [Member]",
        "label": "Series 1 Preferred Stock [Member]",
        "terseLabel": "Series 1 Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination benefits",
        "label": "Severance Costs",
        "verboseLabel": "Severance costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail",
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock based compensation expenses",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vest in period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Cancelled",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted",
        "verboseLabel": "Share-based payment award granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Fair Value Assumptions Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected volatility",
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, Maximum",
        "verboseLabel": "Fair Value Assumptions Expected volatility Rate Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Risk-free interest rate",
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, Maximum",
        "verboseLabel": "Fair Value Assumptions Risk Free Interest Rate Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockbasedCompensationExpenseIncludedInStatementOfOperationsDetail",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock awarded",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Options available for future grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable, at end of period",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, at end of period",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Cancelled",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted",
        "verboseLabel": "Stock options, granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock shares awarded",
        "terseLabel": "Stock option granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of stock option granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, at end of period",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Outstanding options issued",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Contractual Term (Years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanSummaryOfNonvestedRestrictedStockDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted",
        "verboseLabel": "Stock options granted exercise price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term A Tranche [Member]",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term B Tranche [Member]",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Accounting for Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r366",
      "r385",
      "r386",
      "r387",
      "r388",
      "r391",
      "r396",
      "r397",
      "r398",
      "r399"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Par value per share",
        "label": "Share Price",
        "terseLabel": "Price per Share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_ShareSubscriptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "ShareSubscriptionAgreementMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Subscription Agreement",
        "label": "Share Subscription Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life in years",
        "verboseLabel": "Fair Value Assumptions Expected Term1",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable, at end of period",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, at end of period",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, at end of period",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "tcrt_SharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "SharesAuthorized",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Shares Authorized",
        "terseLabel": "Shares of authorized capital stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases other than short-term lease",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r701"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r175"
     ]
    },
    "tcrt_SiliconValleyBankLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "SiliconValleyBankLoanMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Silicon Valley Bank Loan [Member]",
        "documentation": "Silicon Valley Bank loan.",
        "label": "Silicon Valley Bank Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_SiliconValleyBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "SiliconValleyBankMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Silicon Valley Bank [Member]",
        "label": "Silicon Valley Bank [Member]",
        "documentation": "Silicon valley bank."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software Development [Member]",
        "terseLabel": "Software [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r158",
      "r159",
      "r160",
      "r177",
      "r198",
      "r199",
      "r201",
      "r203",
      "r207",
      "r208",
      "r267",
      "r298",
      "r300",
      "r301",
      "r302",
      "r305",
      "r306",
      "r336",
      "r337",
      "r339",
      "r340",
      "r342",
      "r446",
      "r563",
      "r564",
      "r565",
      "r566",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r597",
      "r618",
      "r641",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r796",
      "r819",
      "r826"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail",
      "http://alaunos.com/20231231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r27",
      "r146",
      "r165",
      "r166",
      "r167",
      "r180",
      "r181",
      "r182",
      "r184",
      "r192",
      "r194",
      "r206",
      "r269",
      "r272",
      "r344",
      "r393",
      "r394",
      "r395",
      "r416",
      "r417",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r436",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r474",
      "r550",
      "r551",
      "r552",
      "r572",
      "r641"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r584",
      "r585",
      "r586",
      "r648",
      "r650",
      "r653",
      "r655",
      "r661",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r677",
      "r693",
      "r707",
      "r852",
      "r907"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r206",
      "r516",
      "r561",
      "r583",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r597",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r616",
      "r619",
      "r620",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r641",
      "r708"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentOfDeferredTaxAssetsDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureLeasesOperatingLeaseLiabilitiesDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/OrganizationAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r206",
      "r516",
      "r561",
      "r583",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r597",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r616",
      "r619",
      "r620",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r641",
      "r708"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r726",
      "r738",
      "r748",
      "r774"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock in licensing agreement (in shares)",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issuance",
        "terseLabel": "Issuance of common stock in connection with an at the market offering, net of commissions and expenses of $400 (Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r88",
      "r89",
      "r120",
      "r563",
      "r641",
      "r657"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedLabel": "Cancelled restricted common stock (in shares)",
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r88",
      "r89",
      "r120"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Restricted stock awards (in shares)",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r120"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureStockOptionPlanStockOptionActivityUnderStockOptionPlanDetail",
      "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of employee stock options (in shares)",
        "negatedLabel": "Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r88",
      "r89",
      "r120",
      "r372"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock, net of expenses",
        "terseLabel": "Aggregate offering price",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r88",
      "r89",
      "r120",
      "r572",
      "r641",
      "r657",
      "r714"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of employee stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r27",
      "r120"
     ]
    },
    "tcrt_StockOfferedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "StockOfferedDuringPeriodShares",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock issued during period",
        "label": "Stock Offered During Period Shares",
        "documentation": "Stock offered during period shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "tcrt_StockOptionsAndRestrictedStockAwardsTextBlockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "StockOptionsAndRestrictedStockAwardsTextBlockTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options and Restricted Stock Awards.",
        "label": "Stock Options And Restricted Stock Awards Text Block [Text Block]",
        "terseLabel": "Stock Option Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased During Period, Shares",
        "verboseLabel": "Repurchase of shares of restricted common stock",
        "negatedLabel": "Repurchase of common stock (in shares)",
        "terseLabel": "Repurchase of Shares of Restricted Stock",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r88",
      "r89",
      "r120",
      "r566",
      "r641",
      "r659"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of common stock",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r88",
      "r89",
      "r120",
      "r572",
      "r641",
      "r659",
      "r714"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets",
      "http://alaunos.com/20231231/taxonomy/role/StatementStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r92",
      "r93",
      "r110",
      "r599",
      "r615",
      "r642",
      "r643",
      "r702",
      "r715",
      "r821",
      "r833",
      "r890",
      "r911"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders equity reverse stock split",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "tcrt_StrategicAdvisorName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "StrategicAdvisorName",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/OrganizationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Strategic advisor name",
        "label": "Strategic Advisor Name",
        "documentation": "Strategic advisor name."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_SubleaseArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "SubleaseArea",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease Area",
        "label": "Sublease Area",
        "documentation": "Sublease area."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_SubleaseTermCommencedEndDateAmendment": {
     "xbrltype": "dateItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "SubleaseTermCommencedEndDateAmendment",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease term commenced end date amendment.",
        "label": "Sublease Term Commenced End Date Amendment",
        "verboseLabel": "Sublease term amendment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r483"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r483"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r483"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r483"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r483"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r484"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeLineItems",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "At The Market Offering [Member]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_SvbWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "SvbWarrantsMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SVB Warrants [Member]",
        "terseLabel": "Svb Warrants [Member]",
        "documentation": "Svb Warrants [Member].",
        "label": "Svb Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TangibleAssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed asset impairment charges",
        "label": "Tangible Asset Impairment Charges",
        "totalLabel": "Tangible Asset Impairment Charges, Total",
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r113"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduced credits carryforward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "tcrt_TaxRelaxationOnTaxableIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "TaxRelaxationOnTaxableIncome",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax relaxation on taxable income.",
        "label": "Tax Relaxation On Taxable Income",
        "terseLabel": "Relaxation of taxable income, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_TcellReceptorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "TcellReceptorMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tcell Receptor Member",
        "verboseLabel": "T-Cell Receptor [Member]",
        "label": "T-Cell Receptor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Preferred stock, liquidation preference",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, stated value",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r51"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "tcrt_TenthScheduledPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "TenthScheduledPaymentMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tenth Scheduled Payment",
        "label": "Tenth Scheduled Payment [Member]",
        "documentation": "Tenth Scheduled Payment."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "TermLoanMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan member",
        "label": "Term Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_TerminationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "TerminationCosts",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination costs",
        "label": "Termination Costs",
        "documentation": "Termination costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The University Of Texas M D Anderson Cancer Center And The Texas A And M University System",
        "label": "The University Of Texas M D Anderson Cancer Center And The Texas A And M University System [Member]",
        "terseLabel": "The University of Texas MD Anderson Cancer Center and The Texas A &amp; M University System [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold period for exercise or conversion of stock",
        "label": "Threshold Commitment Period for Exercise of Rights to Participate in Future Offerings",
        "documentation": "Threshold commitment period for exercise of rights to participate in future offerings."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r896"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r332",
      "r341",
      "r434",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r541",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r828",
      "r829",
      "r830",
      "r831"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r89",
      "r120"
     ]
    },
    "tcrt_TriArmMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "TriArmMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tri Arm",
        "label": "Tri Arm [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_TwoThousandTwelveEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "TwoThousandTwelveEquityIncentivePlanMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twelve Equity Incentive Plan [Member]",
        "label": "Two Thousand Twelve Equity Incentive Plan [Member]",
        "terseLabel": "the \"2012 Plan\" [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_TwoThousandTwelveStockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "TwoThousandTwelveStockOptionPlanMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twelve Stock Option Plan Member",
        "label": "Two Thousand Twelve Stock Option Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_TwoThousandTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/StockOptionPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "verboseLabel": "the \"2020 Plan\" [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r289",
      "r290"
     ]
    },
    "tcrt_UncategorizedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "UncategorizedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncategorized [Abstract]",
        "label": "Uncategorized [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_UnderwriterParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "UnderwriterParOrStatedValuePerShare",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriter par or stated value per share",
        "label": "Underwriter Par or Stated Value Per Share",
        "documentation": "Underwriter par or stated value per share."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_UnderwritingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "UnderwritingAgreementMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting Agreement",
        "label": "Underwriting Agreement [Member]",
        "terseLabel": "Underwriting Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_UnderwritingAgreementWithJefferiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "UnderwritingAgreementWithJefferiesMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/PreferredStockAndStockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting Agreement With Jefferies Member",
        "label": "Underwriting Agreement with Jefferies [Member]",
        "terseLabel": "Underwriting Agreement with Jefferies [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unrecognized Tax Benefits, Period Increase (Decrease), Total",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "verboseLabel": "Uncertain Tax Positions Adjustment",
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45",
      "r136",
      "r137",
      "r140",
      "r141"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in deferred tax assets",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/FinancingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "verboseLabel": "Warrants [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r706",
      "r709",
      "r710",
      "r711",
      "r712"
     ]
    },
    "tcrt_WarrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "WarrantTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/Warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants",
        "documentation": "The entire disclosure pertaining to the warrant.",
        "label": "Warrant [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "terseLabel": "Warrant Expiry date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants fully vested upon issuance",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "tcrt_WarrantsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "WarrantsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Disclosure Abstract",
        "label": "Warrants Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_WarrantsExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "WarrantsExpirationDate",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants expiration date",
        "label": "Warrants Expiration Date",
        "documentation": "Warrants Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for warrants.",
        "label": "Warrants [Policy Text Block]",
        "verboseLabel": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding, diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Weighted average common shares outstanding used to compute diluted net income (loss) per share",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r203"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEarningPerShareBasicAndDilutedDetail",
      "http://alaunos.com/20231231/taxonomy/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding, basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted average common shares outstanding used to compute basic net income (loss) per share",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r203"
     ]
    },
    "tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "ZiopLicenseAgreementWithTheNationalCancerInstituteMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZiopLicenseAgreementWithTheNationalCancerInstituteMember",
        "label": "Ziop License Agreement With The National Cancer Institute [Member]",
        "terseLabel": "Ziop License Agreement With The National Cancer Institute [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_ZiopharmMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20231231",
     "localname": "ZiopharmMember",
     "presentation": [
      "http://alaunos.com/20231231/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ziopharm [Member]",
        "label": "Ziopharm [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "e",
   "SubTopic": "470",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-12"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-13"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//323/tableOfContent"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479092/842-20-40-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "323",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481543/323-740-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482190/360-10-35-3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0000950170-24-038868-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-038868-xbrl.zip
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M9UEKZE%E71&R941Q5XZ]#"0KVHF-S,;U?J\)XG=? 0O\[B3S>7K<.I-HS$[
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MV[#!HYF"\>NBE)CQ$8;U,Y_I>8Y^<T')R#(UX9 9S?>YW,)?C;G%^EA!DP]
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M1:+C33.>0*F^S HH8?8[8=R:!A(^"3E"?$914O?F7*X7H(%EN*D,\AY*&,-
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MX; 2DVMP[T6JH@&6.32P5X52;)^N)&N\R:8ZY&= \39Z@ECH.?;00*"^*1K
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M>2>XA^W=@I!F1B3A'@O!&TQ-ZWF^YX])?:*4ZIIFG(4EI+0->:-;8CF2'N"
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M4\6W^^[WY/X>S;%'X;;Y\^=G\=E_%S(\F[]Y]CS<X?9V44($QP=BJN_!E#\
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M [S0*83.OM?.#!3IYH8'ZHOJB=DA0]"M53 Q.E86!A]HCB6L<:]R$W>Y!89
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MY'<=%(Q;(O-J'CLU<QP2[R,,Z>X4BCPKA238QOU=LA0=.SAWI@O75@JO45;
MDQDEA^2Y<CWJT;]9-7ZF7>-$ :<IZE!OK2*7$!DOJ@2+/9J9=-C_=,[_=86
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MHFPPDRU0T'?3:(14'\YP=W)V,122KO4CCK83SQ0:7GR,'$ !V,='\C?G/Z&
ML>,UY;G_94TKDUT>?%V9R7)8M@685NZVEW!./34 40LAL/\_(L.9-^NT(KW;
MU-EOEKDW&FL,IPF4X;LB%QTSJBJ42-#U^)9]#AB_R*;SO$IO*\$8A+ZP/ZCZ
M6(@"P%*ZMYTO.>*IDH%-3*P/ S867:S[[Q>[;64EF'_U;<$:4]5S3CZXGVQV
M\B+_;:=520\%/*Q44/W$^F-&@5L=:OG0(?1>:3&,&=-<+U#B"Z_\YZ#GK>8_
M'B&]1QYH>$6U>$YE5_M:%\*>Z#75.IE-S6XF8TV!#;W?0[8VZ4T/X<G>**/T
M.1:S\6*CWLA1V9MJAH$$A0&^[X,L@>>^;P766QU[\-^96=PHUD8:F:7NA<IU
M;WUDZ!^6Q3>2+XK<&67ZG&9Q4R*;E[8WW_RVR/@'C:M&NC8X7SX-#7_RO_"<
M+94LQ(@Z]TS?\^7(46/%(6'SC%AW*3)#"2P*5:PWD5.1+T8]KZF/]8Y-X:B.
M'8PAVG8E>Z$%0C=-\"X8E'9QB8=C-%)=?BOYE$>V"&,M0[66-,64]*BVALHL
MY?$U@Z7LZX-Q&R0(4Q4Y=)-PU[>5R+Y.JE=W+0-O1L>UHJTR1$UL?4XC-Y(L
M_II/FU7ZI*4I9:I.BMC@(O_S_N[XX, Y[J'2%9/1A0)%!+1SJV&F=8K(NIG:
M6:XIWM+&%]*6SR50B>.0-6C",U@3KK4A_':XRDQ=X8:"7X-JHH2>IB"!"K+R
MC.9J'IQ8W<&^FFUHOLMQ4R*5Q)?C2\M;LSJI+U@.2]:,+ _[S-)MAQ8_WM0P
M$Q\]O!)2D7^E$8^OR5 DPG>;HJ>I0X(!+.,R%X4K[\1W;LLP6J M#C[+-2LM
M"3S_2C!^!6O W.KY7H_.A47O\54\C;%FO!" E$_!Z=TCD?I*OC1U^B'56:0*
MT9V4P*&J ZW/W4_S&RW4Z14ES83JFAP>62X-/YOT[;OSR2%3-N1 HU1+NU_$
MWO9BSE!&F(I6RKC_/EO;L"W)S;).'Y6A!GL!'7S30<.XV+&AP>']P.;T9KLW
MTUDM8JS7 A:'TJV4%.[J62Q.71K^#U8U$LCA@L?'X=G.F0PZN*UL#(X^C"^\
M9/U0Y*J4U]M,#/)*]::,SDYDG0 3?P_% (MNEB/32OA]RK!2[JZVKY+S 5\H
M8^/#U0G0/^3RA>6]:<S[M,U&."0I>:Y_THKZ(DNFPH/Y@XLE[TQTRW-PFEJG
M;Q=9GI>BUO,_;]*:]C3R2N7-B;%G.6(Y5-8?=I@W^F4'%@M]#:/]G^0M7RC[
MA)?)DN.7_YQ-%/?Z 2'5!L46][:D,1.S</A=OR3LON)\;V*VNX'W!#R_?=.+
M=$CD#K8.Y5:98GGO\'H=<&;[W)Y@*L$A%BM+&"?HVSLQ9!9[PV]:E2E@U\V@
M3H.O/HDKB2+U<>2MKL=/TBA&>WF)EN_-^@5XN)D-.4T]BY_IPE'JJ&O'UAB6
M09MT,5?(LF;'8936P=66>&HXAL;^N9 )JW$S31^M%*/?/_C^SNC#2/H$AZ%E
MJ5EZE;8SU#9SUI=LG?*W@ZM,+/L;30F&K:J!J-:)B<LI:2E2@SC"\]U&HUXW
M [/H4BOJ!9A?.%]Z,5(9]%(L4/)E=,/K_L%:)W=K*)L\S& $IH\"C-^='6K%
M8[S:S(:^)N"/RY7O^#1<//(Z$6$AV_W&G8'H,N^1;K(EL8N2:&2!?-?MR/K+
MNCG?'/&/7-R\@Q_:<#N-;N.Q,(:P5!UY\8J-A,#\,)_J@^M[Y@A^\7L4NN^O
M/[OB\=C^,.9(X(BM5854;%)]3!-,?VWUQV_RS4G5861R=9BJAVD8DT<VFLL>
MM!+G!NNTB&',O/5P;&.+H-#P*;5R3)"9(-G*+_=\-I00KI9TD7O5FLQFB4!U
M,3S*F%'G8!X%H&=(CAUL@D6LE;T=AQKF[>7H]LOOE<C>)B6Z<O@>75))U]*:
MZDZ(4CT:_$*-O&>ULA\@BHBC>&[)L:RFG*;5FVBMHBN&_^#RCZ<<-L?9&?=2
MYE@;#J^"&8JQFBKR&F?<>EPO76KD7=C(T9,-*N3JHK9L^[TD,<WO]Q(!D%V8
M.O,Y?H;9[W>W049+#SHLZ3M4_W$[)7$TUOOF^7V?XN]W<$KH"C)/$^N9<OOW
M.T>P1+#?COWV(#;CM]NX!OAA93H1FN]ZI!_&ZZM27<SZ@;R&90+AE&@7[U!=
MU(=(@Y'14S &C%\[8 AP!6/85:VZS(MZJE^%M LSQY ?9])AQT/G:[8^9;SI
MZ(6@7\9%PO(AA\O0O7#HN-P3V.91,AA7C5% 35_2_HE)R9;X%&8@:TEYT'UD
M-VPU[Q_'7$_/I1UU@@^;K&F),%A5Y%<P=AZ"D::BZ_BT&Q)_!PRFT$'XT4X4
M0M8)=A*9MNI@"ET4@.5\!P5$+4L@#^60-^%[#P8A"!1@ MT=A*USS2/_Q%I"
M $?I_SX+ 6,N#!WIYGES@1N(-ZE!V(&-GS?BW82TBT4.>L9.$S=LREK'18XQ
MO>CFC *.-YJ^#^5OQ_PWR71)WL0]-3+GCS!FRIW0,+Y^Z[B6'X;L^ '&<NCW
ML2F^HS>KVP1G_0OG$J=(W$(!)W0P[J,7P^WJT[([C:1I%^*$3OO;D?U]'AJV
M<3W5N>)[,4-#IS0U7VO8T*+I\4!8=-XI_P5GRSKF/$T6C?6Q[]L=OS'U^&^K
M6WV3/YK8GE',7,D[^Z9='D6)%E/+)F6-PW[ FC'WI%5+-1UZJ/Q@ML%U/YKE
MV8\$-B=0+L*?.SF&V.?9D^E<BFE6'42Z"@4T(UR/PO-_ Z_KAS[2?S']7\WQ
M*]_#4(_,=HO-?(#.YH&I+5$N]/;71S;83AS9.--O"MN0+6-$ 5KFE5ML6G;Y
MUGV#8Z^W4L/21SO)\36O;ZA:!BA@FO6/1+J:-CSY9%6.A'E+JQ1N]\ZFFS(:
MXWHE:)"3#<\ER9VG[_GV,&#G"!$\-G-^@4?_X &+7^VL#V?KE=:G3'$:=!G-
M7+&2&[QO.BHV]:*I<3BT%<28M6"9;#HR,"U<$PW\0&2GE2E9WX8QD8?(;3QZ
M1[Q0\RU%>;P(&']-2:76S<GJ!Z8[O9,*8;(X,9>]\3_8\2HNQ '/&PY4HXR=
M\GL#:&I"$M#DT(8JIML;JC'64WH++YG:7ZIBX+@[7E74%(CC2%Z+Q;]8B(#N
M^S7+0M/Q>AP&1\=$-:"7U',DS;!EK5C)2HN;/%R#+&8U/1]6ED<I5D;NS.^V
M"X3:;=],[?(Q-BV*7]GZ_13C+TXKIFO(X8Z,:F@TXX>,9\A@4AJS;A!\FRQ<
M5%,>5-?IKS=(4H\;HEGBQJ4I[Y*J>4!D..@X>(&<G9=:22E(1C0ZR,Y(T#1Z
M=&00^S4BFD1MTF\::R/E:"*U>Q)C@W-1\+S&W.T&BZ>%F(/B?@G5#,F-#?5D
M6)7G/AB'\Y6_6F@R;=35K5U2*_3UO4QD-S%U]3.945\"%:>ZF\>-5W>=2U<,
MZ3[O6Z%5040E&RG<G3JMS7=(960"$E\X[9Q?W;V.Z5M%17>%^,MTU78MPQ,>
MLZ=!4C1IY^^.D3UH2UZIB+[Z=:>-8S"/\O+\X/WH3%MC]O:SF#0^PH;4P328
M;<K"&->?=P;5$'8L$.V2II<?!>0'H,7F?9,LDK]=R;*JKT?.MBK!4>[5E*:G
MKJYIPD'<$;K[1"U2HBH69RJRNSE5-;?$U)$$FUE(_U&3" DZWI*I3;6%V;F$
MEGCU9LN5K,9++1/7'UU?89 "(IXO2&@J0RYK&.^$SA.^9Y<SG:97>S%5/$OC
MM1;9/YGHW#6SNR3'4FK-QRG3D,EL%G&=NV,_1VCU[<TSZ!3[#?49QGVDE[;3
M@[0D*:O,-BG51 )9Q^RMMTE2#T*B^]0)X7ID7]_KPZ]F6>(V+65[\4VB]?5&
M):MQ^84;[Q3:L:>W?-IY$USN75BHZUZ3@OO -_(^+WYQE,)&'/]L]>Y.P:A-
MVCWE7CY*?^'V:SPC%^-B>!-'GM@79'OIDKV4OF'K69UG3>'SV?X;4KSP;77T
MF'&':VRO!IL]62$/WH@$HW1US&":I$B0K[]3Y&=2V9&,%^S8S<DTCJN!*D_T
MK[R\>\F+QJ9-D\QV(O1VH3H\V)9UE=.TE-&(8UA]Y?7T<N^T3 PO68;35AL?
M^2)SGNTEIJ7@A,"#IJ<51(U%:B3UNUG%GU& ,T9D\$=UL9&K-(9@TLXN6KKZ
M$K;!-0+K>P.F059]:%J[5=!]TI7*Q5H4L,6[R( "J@W?N7$Z<UG#)S3F,I+L
M9+CSW\@3BEY_>&^ @0?'TFW'RM^]3U6-D *2EU-:7DI_,525HZP9&HA61WPF
MCX?6URU_*GT;62#(D[6[3OC^RKW.=FK1RVE(_2OT7\RBW55G2":I.'$OSR=2
M(I]%>[M$T0TUT(SY]6_LK,RWWX_HY73#MBI.Z%:>?A+('=0@$/74YS LE#JH
MD-Q+4$!Y'R% 9=)I8K>;2M[XT0#N(M C$3H=3&79)B$H3C_'),,T(4MO3HI1
M]"S@\6;$;>8*]4<1V8R>WRB*MA85)=+[FR\&4MUWR8F).^3T$"F-&2BTPHBT
MZN^1<A'8*=H6*RNY0BY*/&$=8#:HA/?V@E"Y8&D/;$]L;,F0>":KT"Z I#7=
MV]- &6/:,C.$;#9YOBN=">CTTN[*H/'AI0E4?7?^S/6  K]:MZ<LC0U4,_5W
MYM656S3V[@Z]H?%?P3_D]$3T+S=)BP3'TQ%#L>P?>>"2;&=$>NEN'Q]C_7TU
ME,)YW6EEIKI:A8C;_LI06VCUTVP^<<VZ;]_\G:YJ"Z" "Q;>T#EH"NR;?M2D
M=O6_O _IH#[XOFD7<KJ_!(*F@AH%1",_H8#G@3 _CI,;.O@_[(FEBMK^.]W]
MT, @M1:R%X1\<9"$/"]U?#Y#8T+N '<A:H^$=J\+^I,]-;JO7/]CIY:'75W<
MR#.[6?A)0'SH:WY78/J?9V9.#R2*).^=U%?MV#YG?,WD?('EPV\1.'R\Z,CS
M47_9!^2\)($"3O+0<9K&>S_?_HP3[OYQ<L@I?-I_L0_Y_^87E0/%^H[=U"DH
M;,B)L,0F/TO\CZ,Y3.NT1QC;<HB+00@3HK650A+A Z'HA"%0IE9%D[QDUI:X
MTW(_$DAZ/NYTS^/S3H4U45N0'N@:N]QZXD]WJ!6B34SF="Z[B,0M!(S()H_H
MB/(&CL[8V1JL^@:]F#.=(\?5S%['"26,26JNH/WVZ;!AI,?K,>-L.?8_MF@/
M7'LB)-[3%CT/4'".%&[<@B!+#K!%OCZ]S9<@D32_;N;G: AU$E]I<0YO2R@A
MP@Y_IB"F__#D>5]XINL1+;(*S(SFF#0(3CWA?Z:+]1'^9\=>7"9_R%5AI]\N
M>5:O__C_T,LD__3*V!SG2'%(F<O^_-NZ@";Y#SM2.9D(;F.)28D\QW4PF&[%
MM<,/QQ(>Q)9]H'AO\_V>P@4V>L3P$?\A=N3Q'=WF)')W7FDN]K/F]SN)*,AN
MI722&.'9V>]WM_=00/F!,C]=%M%OMPJS]4>KG9\ZQ-R+O]_!A:"K;L'W?6Z=
MD]5^TI89[3+"HE-X)-"JCCP>GM'O;VS*V&JF+S'&.QF=F%CU/6@\/]F1(?/E
M"Y@_P8BVT:]7[)]9L\Y())[$QS'J7UB([VBH?D_Q_@3/,[ U,&=' 4+A44<'
M<DAF^)X&$G3 4;)RR.,3_4025#CZ_S7,F*:UDG0_@WQ(V%]& ?<W52J_3[IA
MB@)\G,A[>C\PJ"^<,<NXUU["V4BAY%W?WL<,52_]Z]A3C_]SN-2WP.^=4)Y-
MZ(] _'64 "]V08X_]9&Q!?0H)Z& G(;67YRL8:O]&/5WO]&7R?$7('[8N>,C
MMJ'J.JFR9>U_)?T_P$#W/\6,@);YD];>-Z_FW01@7?2,.K_!QQVS+G>G-/S+
M9'XW4%A\56BN*R [%!Z5\5!Y["^Z0O0W 1'Z0;<P8A%27VW+I6X]/I0MR[$B
M*193UCOZ>H?"-"M^4C?)^K0UT_]MZR?@&HAC2="MG$8*C?YNVQ][D<A0%* #
MPG@SW<3N[+\[QR\]3 >GOONUH&6Y/]X!<=^O/W5\1;0$5'GHAD*^SJ$>"HA5
M+,::]V^H/5[^E_<X\>[5C]>E)[!N">0<4NE _P_O[(37_\W9$U_AWN_>'"W.
M;SI SX]DQ/]L<B/44T;0;R0%HR@_DH 6:"21EYO40 )^.G4J]U& ]>6-["VL
ME[T5?IP\@UL;?HJ+JAH:4N;C/@OLJ;.X)6=#GD[RI<T^"!YJ0@%]PYJZ+15V
MO(Y,YC?\]$,N*$!6<F\ 1Y>D#\P05N\IFJ;E+X8\"<-M)^BJY2[,F+,>'C9-
MMT(/51#CBENA)K0()2&F*"/M6K_5;#\)R?Z2H=DXHRV&UG_.UD_X\^U9C*0D
M)^V.33H4H 5M<?%IT^G3V>"E7\I8?L>YDWLWR5W?-QGZ440[9J*TH+!S>RBJ
M4 IFX6RSH^2%T9SWC(^O<;&>F#B3)4DZ+KQ(R8OJ^"6>O_U:WC33\E(^08]Y
MOMJ(N=D*C6B=X9VG[@A/2_&QT$N1^QD9*9K&3J[#\X*M?FE=M".!DLKOW5[Z
M^FS [\ULK5Y>,#4V,K8E,T0N\*KWY^"5RXW=XN@1OF7E'QNR6JNJLFS]-8WC
MSH[QS/.66^YA#9,T%;KM\ACW.;0>B&"WDK5>X<SVP&OR:,+5I!A(F93JNB-9
M+9=W7OZN5Z-.E*!-/=^J;-Y(38"?;;J)D^DM(F/36[L*N#F.DDV)9OW] WH!
MKQY$\E[2HEP9Y+FL0?:6E4,Y*=MG8J5W0G2@X%9'TC5[/-\CX0;( Y5D=%"]
M;GB>>%,)K(M>(,5,Y0Z.=([.+-::SNF0S'UU>,[YD7U&BNJ5:75Q['76&G;6
M.I&M-.CIM<9X_<#N-@6S2"8Q9[F?K>'VV,18<]0F9QK_8EV5[^M_^V::%7O*
M<>HCQATTT_M$JC>):(*>3TLB7,JM7VRG5IY>/I\5:6HGC"U/^MG*,-BHX7]T
M(QOY8SQD'WD[NHG5-G@6LEMR<UAM;.^+:?T53WX<%8=\@F7H+W89P';B#D4-
M5"3M3U4[M+',C,NXS&V_"G4@KE7VXB]7'F4B"QQ;#><J+VX)$BGZ[VO/+$CN
M^YF32*?"G $<,3O;JX'.!,3]8&KL<?(%UHL?_WQ[/>W$_3_ULA@2WU>#E8E1
M0"]+M_+"O5\?97_][Q]E5]2H,2KVN=$S3(>X3_^<G*#;(>3A$A=]M$>SU 95
M$27;9147^KE^OMD*8PLF#7G_:EG_NDYR484=[U'B DR].F&+ZAFH@EI*J%3(
MN&&'9Z))88G@V& :#9YL7N*$#X(B[B)FZI6]-TKA.]CM>;?L+QLU.]R0?-VN
M4W(>1MI3V9&>P<SY08/7+T_6?$/6BOVM=&J!5N6Y-L'/*>$9@9N:58/Z\HV&
MZU>Q1>^K*7T+&3XS$EEF/^FCV6&^C'$K,/M2O8_MA\37S0YL^+$&2MYX]OZ^
MPL#5[=8'6HKKMA;+(CP'%A]F'1-$]C<C)HD7ES4."%\%S3-O#I3EZE"G/CV4
MPGNJ:&\TXJZPQ:4J4N0CH#93FI43TM8CPR%%J"T!M>)8@0D_*5->*B"/7[8O
M_G"4GWS-M%G/*LQ"?]-(U,>>VR8R@NS@<;*J5$)ZWN #B:<%5TR89IK6AT5K
MEI0;,*WRR,X+FI@*7.,LS>Z,S_>1RU=W[+H_,)K6H"4=L8:OM]CV9$:A(JIO
MR[-INN\ ^;ZI0TOPE1?Z!0=F,EFGD)LZN?MJ2BSN4=QNNVTX;'L];W2PF:/2
M!IB6GC<-FX5?H!PD9@AY7 QE]WT4<68^W#Q>GH[;7]1'A>^Q<)V<M'3.;W_1
ML?+E'/6Z[%<^% "GO0VK"*Y2=5V#(\5+,P_684<X_$V5:P,)$#^*+SOZVR9"
M+9'I#U3Y1VF#F6F9$@O[Q\L(S?A;L"UHA 78NFX)S)0%VRTY6<C*MN?2IBH<
M=V@KZ%,Q$TDW\.?M>1SR@.ZCEK 4M[4$6O?!LW1LTR&-_GN]H:S#XC@\->-U
MKNSTSXH<L7^?YB%W)'VXQC4MT449!\Y#CQ@CM1=+PY;8S&?0>$E(ZDR?::M_
M+"I^N?*VINBM]22?P@JKP^*7Q"X1*S>PK\1 4$^JT&9-B5C$)483PK8K2MY5
M]UZF<IC-1K(U"GWNC>67(6V\QA@'-#598PIB<IJ@PPSE5.*6&A=ZN/#=O<#_
MNUW?"ZHGQKK?.&1WRH> 7WY*CK[(I#UR/CWZ8B'//\[V'\_R8J_<WD9W/!7[
M@X"WV:S,>,'#B#AF/4M+"<$+F>2G:_IT?++@1NM<H<C?Q\P,@_UD"2!I:<S*
M)DKNF! X"*=J"_2?KVEU+(U9SOZK \<-5(RWN0K^#K0.ZT_75B1RCU^*<OX=
MDPK='P9#7AF[ OL*4T(!GQNA=7##0R^^K5T0F>1C8ERJ?[Z81M&ZBV,SYVHX
M<CXN>F-X+  %!/X#U^G9=:%*1O%.4Z>@/+-R;"T^AGXJJDB<"Q#OI!_(7>K_
M7X'2_.KO-K7O]<-H>S(N8"4F<@269&C4QR_7?5@AF_UZ,%*"G4X4,H/ 17C2
MF!X=4Z4=5'. 2+@8/AH_PSWJF1&Q_!0OH!T#'?D,!?QUC+\_9=?8[U:T&>FY
MCE%#*O2)O'O0KV>+RIMIQ<A(17NOD5?H5<7SK]O-D,OS5B;?WR[#BBKS&WEH
M1YEX_'99\Y]V2'#N\M$_A*K4+8\._=- S^#^#IRL&*!K6C 'D9XNKO1U\U-'
M 6"KM!'GU7GHSF4X2)])?^+)GO_4M#%_]QHI)G1G(;]S'>X#G.Q 23B7ALGT
MI55&#/_,7_XJ2A1^@M@>//5L/[1X&07<4RP"Z\SCDJN+/.#-<* /_,^RE/[U
MJ4>ZL](,T!-5>?0%NF3$B1K.G3HV[D3-!_R]SMPQO_\5PX4R5=9]^DT4@+ED
M/&;L=8@"8C)%N/0\DZR/7ZFH/D(!7SMVPF"5!Z3_7W=?'19EM_8[" **@("4
MI )2 @:=HC0"$H)T2P_=,4HJ*:V @'0Z]-#=2'<C(#7$T#DS9Y!W?Z^ZW]CG
M?&=?Y]OGC^>Z9CW/JN=^UEIW_N[)_:0>J3(2BVOB>KF3I;CI=GO.@K=HK_"P
MP@9J#X#V.#TS:+80_D&?U.-Y-)J=U<P<X=&&-U)TN0[(I=XMT]\S$?2\_]QX
MB/U;;<Q>#]26E<1$@L7.*_K)3ZW3F5+B+:=0FR3P^/.M&*5B[&3N)3X<8@=:
MGT3[R,3DP&Q/$,/VVZ>V33=8BY@,L,RO+>[3)T3(2W-]O)BC\"#^(1+P1#RU
M7$=B;/ORCCD)Q+:H[>"9-Y/R[7NDR:WNA_L=.:,WHXK'&9)#>3^I:R@5>O,\
M=.83"D"?*/:Z:"PYH8] :;RF)4]FN%*&XV;&VBZGERB3?9&S^53=F E6G6Q?
MH#4A9CS8[QU7O77MDK'/^ORRV:Y@;;S;0B9YJVVK!>G/!!'WMI-\PAC(H</7
MV&1%&9EF<3<KTSV*167'!K^3_YJ[BM7\%:^Q4=MQ]1:!MSR5K,9!V4JNAJ%I
M<WHFI?H7781=?(>!;Z]TQ,Z1*-^_4NK%*%S.CXO/43%/16;AN#07CU)6[G;D
MUAY)(@%TVJ-PESI$ )7K[,5;6=0=2=H2;&N/T""T= L19XXA3C7QG"E)_$*?
MR\<%V3P.#^T8:A-"N XG#.L((4F$WUQPBC^CT;A3CFK_8##XQIII/^"62QF5
M>+TZ3B!KQD5%EG+M:K&C>QB7:#VEGMX<G-5><E"G Z@C1<*<26=+&C$%K*_O
MDD*C\3,]_L$(1G67"F@W4HE7<(*;$>!2=E]#O$"6\V%UV.U<8+U2("DOY>)0
MV-<-\:47/)-L*;-=3@R$/!\"\%NGRS%(H8G# S]VA5N&)0 /R:'!GUS-$""V
M> (T<(PNY(A:F[TWOF/$8345MWJ](N1I8,X1A7?"*\]03!"+]0\FDF>3!J5O
M?]XC[SK^>L/-"=_3F-)Q>=DZ,W+%Y ,XUM+VUDO>D(YZRCTPQ3\AL,ASN\F'
M]_#CTZ$'2$"F:^Z%$<N,O#R7<,')H^+O 'V*/[ZIB.DISKMC^[_R-]7^.-,+
MS%;27V&V:'X@Q05R3NOOD',_DN8"A;;\-R@TR=\74-0%@.ZO/&ZL:S\>8*D3
MP@WM'D7_NFOLY*%ZW,.L%1$>V=W)[\%R_XUA__<^SP6$[^]<1R<_GM;?P8?L
M?P,^]/K=X'<!X_LWKP!U$![4-@H_=>VJ=EFRA0E%Z,/7;8P A,H_H2_CIOKC
M\TEQ!\Z<D( ,I=\,Y/]'0P+[JB^#+332G,(RI]6;72/<WY 3DU8L7DL210*@
MX.02*LRFIC@5-Z\DDK'1&,/#-.!Z6T4NXG>Z*#/SX4HT1ZG\0*IGB@S$/P[T
M#..GQX\(%7_Z> #CGU#G!A;%$KHR3:"N,\^:N-*+):_\"V]-^YL>I<5_7/AH
M?S>=IT024F@5PD,G@./8^;:SJ&[=W^RO#ZI$@FAVE+E %^;7\LYI2Z-SE]C[
MRS=4_?TR,W+!+\QV!&YK3=$_[1K"I#52EMEL!+9Z$L]VS,WB-ED+#:Y5AGN/
MG*WNOK:,C]."J2VUSE3T"CKD7]EC>R@&\RK,,#]4HS$I'27&*.O+E4("*A>\
M'U%2)BK(A!I;0[O..K\Y(ZJ1@/;=JZP#P#,AFH!JU@56*JC-;7=2?X/W!J'C
M-$]\?-1%"/.'7+Y^>DW (PH Z$O(<,PQSVJ+Y+.S4AH35\=(-IZT5,=U^Y7N
M6+&_8YC@O[]1_@GX<#)X5 VL;19GW<H$YAC@M31X8>PH591\3!L6Y30=R%&@
M:=^=]7FP->/D].F@H^KPW%#)JH[4O,MZS'BJ;4AG9VKB&!]72]_'UF'OW[Q\
MZ!(B^]*(E4QE%*%4DC8#'9W80GG^-?3]"@VVR*+E;YE?^L-'DT:3/6B1@/"B
M"SR^A*2BVMS+* 2G^_,;BCJN4W_6C]%:W0YQ7QT4M0[V$C5&\CZJ(1Y7DL*]
M1!"171I#?YHN*3(71> G3U"C+Z ^\9U\\XYA)&#Q%DI6&T7UU$^D6OJG,S>"
MBFSOIZ(JPE 5[51+?RW_14,0"'4H@5>0@,CS9C^6_K01O\A^T#ZQ6]9%#**2
MGD?7MB%"YB7X-_<MN7922]@Q<US=;V*PL679@^_V_DOY9K$[JQKIGS]=2I6U
M8NE\W< BDQ \%\H<HW:[YX#"'^(_)S$9_#";"?$%C=*+:T5C8]K[2/=1W&23
M&[T:_Q>[O%!:_6_7)T45XGUZ7+MOYK[@=$^(FF&IC>O<'$Z!7'$$P9,768VD
M>]&3JGI'9TK2CORRY$>3S <Y<]]O;OI-A<OA% 5<O6&X-*<'"F\Q/?)>%H7%
M@!D#%F#3Z2>:+.G=W5]"&:([O67>V?@DR8ST<=YRG(-?7>MJTO!*'N5YR+8>
M"UCB]8$Y \GJ>P7WLE5+1V9ALXO^6YZ@?"1@+D%[-KA4]M3*@"(<(VD"3-0S
MB<W\+2'K*25:GQT^L:'Z=O/).F'^4D"J9XI4,\C\!4WW,TPTC KR^KTLKI#+
M2>K#)K#]Z.ZE$(N'EQ-Y)Z2&)1GO"N K3\:MT0V7+,$P*K=AGWT.TH8N9RD4
MUS:F\YA0[":<#@S&()(6!80MJ#WU'<K4"J>$\DAE/GSA 40![_=@B^1;F^MP
M)ZF,W![:Y+2B[ E4'&U_*:UF^HSL(?4K&PE<D88)N=!<]QSSFU$,ZR50M6IW
MT_?@]Y)BO<_XDJ>:YD]SM>GD8$M)AIZ<#09QT]./M"C],=YYVF\,Y#J%"XU_
MR#L*A*K[3XPGEY84ETTO3DRT*G&Q#>U(TY]$JA.O3%B_HGFZ31TDU)6^[PN!
M6CV0M:#7Y;[2.GX#J.S3OA#8O:V39&+Q58[%A4T_T(P#K#A]_5)G$2 YZ1&_
M4J4F2'>X[25J(>KN\%;^(_HR&+06">^7SVA#9(M,WUA;UZ2T_IY(C#4;AO<!
M,WN>F:X"$NJ24AJC3.E[F9X=4WK.3MQN&)QB 1KK-S=G.QNM*7%_=GIPK%\8
MV;><*<\LS4,2K@AY4#&4X6>88:'!X7^G.-3S\;Q+>FVY8_M5>8]R>.%P@$9D
M2Z7QQXP@K]$XH8QXYX/N.#W(L8YID3.)=AL=V3)Z7$?A=CTD4JR\<M!KT#G-
M7RRI=\(HV)M8:L)K5?!F8%LK@:2AOE6V61*0F\?*'OW#@1ZU#$W4(K#AC)61
M7/=D4R/*"N[TLBSUZX;P8 -$51:8J3FXX+^YICM_Z;%H&.+2U4@ISES3,XK+
MF]'IJQ-I(&.V+*F=PG)(9**3/]GSA>2EXH4CO]S."6]SX&$9Y)TTP:MR\<?3
MV'-[>UGX@7GY>Z?O][JO4E!TY8**%6P@>'.?6C>RO%9YH9'BF2:V,Z1B,YC]
MD<KQBA_6#2I=V'K'8^;"<9Y*3>39/9#JP;1@U"F+["5MDN(W(BP,ZIB1(KR#
M/D?]J&/%S21?(=4ED *794&VIN#4.*'X[AJA/4Y:X#UL/7S@6"XU\[;IMAA)
MB@41QL&X2KC)77+\EQAV4Y[KNZLJQQ5;?7Y=789J3;$Q(K" M=%8?LQH@=5L
MPA;Z\/MFY+,T?-.]U._SV5CE3TT"'."/1QM'U")U9SN6T=#)OOKJZ5&>^8#I
M1XFL\N'QC8>5#R87IWLI\[D1K_G9I]P.NP6>;6/$QI'$IDL2B5(%2N6)51#&
M6BX&7_,JX:TJJT(D+7$Q&-6!H=EC+U;=;IN[-=]\T?]YD_I(U-@ZJ[W%"2 ]
MZ1,A>QV-L51O)>C:Q,9T6B57T%I$;Q$3D*:KS =CBVPZPATM\FA8B$9[L,37
M&[0N'J\$L=O6*NVZ/'W&D-J*)_0FTPQ!5Q1(@ACLUZ\K/Y6NU'S-$74:]JP9
MO<*^AS<M97 +#E+#HN]$W(44E6[+?[+.;.R;E&0?#GE-(87.BY5@PMMKWIKK
MEI$J#,[16B,5\("^Q2GK?_5PS/VY3/F=E,@[<GS<*$:70\_:)WP=U#Z.$L5T
M.)" 5#JP"/C1$4I0HC/^KO(%AZ: Z[N9STP/<ICR6.7L-#\:+(TG=I)M3$=_
MC7C,.(%U\L6!!13K-;S\L76#.,!]7M9X8!-X-]ZC7XQ!+(;QT9H4A?^C*;XU
M%MO\R1;Z5=L'Q4'^@9S>Y%2USS$6 =*MKG2AX@#S_A=E)R'P0__\4@I]RTA!
M'8N\P!9;G_J&;O;P' 6AZ.")H,FTV+5\X+M41Z87WO+NZ*L#'R$[Q-UQK.P*
M!*N*UTJ[#/&:WVC-L5H9V/ "0J7G$RH/XOJE:3^^"HF6>9]PG^W0)LVX>!*P
M%.UOIJAN/<_&AJ'YF<8AK[WP#67MMU91[0H,(TJ"P<1H\U[%LB$>BI?APZ#@
MYK7\'F%56LS52<X7."J_L2S[&::A]3W7$@OH<76\*9C"?8,MN(F)$J"@Q (^
MNYMT!=2GB00PI)\#(.@6L,X"1Y+V3^I.T$<#1\(#3=]*9WBB(P$XC(VZ>R1(
M0(?9>7[FKT9'L@COV6,V%/F)=$44%<8_V1>OT!RI"Q.BU!X(0E;V K[Q4ZOC
MDT"A.#RGO^]-LEBTIS<9]--MR5\FNKS&=&#*-[Z'__/]<R]5Y%>.$QS08DG=
MF9P'7)RZ&TM ^/7/MVE@11X,2("H]5E,[#F((RDK=3QYV:1\3?>Z((>M:[HT
M26:%7M4#*:]>IHG:IT$HCGH7:T'CGUMEMOO]"Q-E=N<4=O(42(-J.%69 DLF
MT\M][RL]HO59$06$M8)'>X2OCSAJT^F\6F4:['J(8:$_H+_B*5Q3^P&<>KU8
M(CW6XOH5K66L@13%0D5G*O$;*E'_@;)/V;["]8^RC_L=^BT-^ VD4A3O>'1W
M5_'6MPIG%+(<1%0JZQ#D2;O$5"EPO\D[K;)ION:8C!>QT!KW,JM?&ZI#YGVJ
M(H8-]!ML+9K3(WTD;'@4/&PJ:&UOG&D:<Z#:.&/%,J\^(GJ+E=8^(MZVOHU*
MWL)$&0;ROULMFFD:KK.VY>P"NZ[!VXCQ+G@W81-P8LC5 T40##O(5CBO'AI\
MF2KAWJD$Y2WZK4Z%>IZJY.(K)8)S)3VSI[56#W;,#D9QJR?R6J*(1BGQA I;
MGL8A>C$[OFX5FWBN5.V>];R7JW):V.X!794%7[$X4)IHLT_7:CZ4I_/E7[!/
M#%KW#'E:>V7[H18]NGC5+KE@??K]G65RX823_<ST?+@IJ7.%;E,M;3EL*67T
M60OEMBS%$Z'J5&9.JV$Y\\P@AV[NG9%=4=@B-^D]>88'70Z[$0#:Y)Y[:42)
M&44;U:Q@'2VMR<E5-0ZNXC?+CQ):VWC;-_IV!U(K84N%AE23TV:[8F66N;;E
MAEULA_;K[M11VD!6H9"&!59LKGA<F5[405=628I79(Y/ZU7'LJ@O*>Q[.@(L
MGM?=\+S9JW#*&'U@\79Y5[![LGID.EC/D+H&GLMR*%\U^.7V)J9O+V$W&3 O
MI _!I1%T:QH)T!U]_P\=P_0W$<7R0F+YW%+8^EU5.P^4P07AF!V<@ ,YH13I
M+[U=O7F5O25'RL"")%C!\X/YQB+CSN@;!%.1C?5\!@HY<V&?A2QPFMRB^$7>
MK'-1^(5_@D0)Y.F1T$W2JP:Y=&XX4'3?YAWM2E1C%@#EA=ZQZB8[H+^&X")<
MJK1E%RPS%T\B=E$5$-)4M;IEF_E"'"-DB8_M+:!5R)6S4O+URZHXH]I*" 1=
M[M0!5(M^Z_6$O.334$^6X;:@O2#HM(' >^N8-L522)"#>:(!YR-[;QM1VL-,
M&K*5C5Q6S\1C2TT)Q!?@]<ZZ#;Q'0C4L0OL4($W0!YT%9T0EJ.%>_AE=ELZ3
MNS&#8T\[JO,4IS]%/'^Z::RU&(H_4FI5384]Z( KNFFUS#.X$3&Y<4LVV_%9
M=JM]Q_2JFH,NF8N[6&"?IKH.G5@1?975USN6BUCL7I9S85'7A>#V>8+2Z9+I
MI@3:DB[L)4&I3#O1,E(AM(9#WGAH;;LYU>!OF5 D * :$K@U=PJMFFR%R%H(
MJ%2YFXH/#WP^Q-IDYIV2S!>UF)M6G6=]2\]=%F1E>V 6,@2E;FNU[=5M+,W<
MEGB;DQF9W91%[W2XJZW)5?!8V\BJ18NHX1!CV-.B!6;!KYJ.,]E!U3V3!C''
MO,J",8'&U^/FE$XJ1(0H0P*\N3\YPYV1@%=*"ICF,XZ+SC3&)201;XS<X_U"
M<,+?)4=VT,75.S"M!Y KB39@>!GFNV%OMT8@;@UQ7<'+8 /J/+ 2S$KDBW[&
MC)<GCR>Z:!(X!S22_KP4P^2K6%5\5V^1EO'UT7/1CC.Q#HD)@O]*G^*&U8A_
M3,%^@=PP<ES>_T6/'7I^1)XN$D(]_,)Y F,BO1%>N\]0%O(Q50PR3CN5;J/K
M3(LI=,.I&WBNT]H/N@#=<U\&+C^3U+<X>/&!=K)46DD6M\WVF#0#JU1*4(13
M(W)V4B=%?J!S5E @UL+WLFVYW57TI &(::8-Y+%?Z(<#-CPVGI[9(AK6+Y/!
MVZ/D.6UBX9QP%FSV:)/!LO7P^2FP+Y/=IX!GGA8&@6HXE(M>)$:01.[:J4%-
M!31K1K('%9YCO98+Q((SU ^TXJ.JQA\<8]XV;%<-LND@7[R^'"I<6B%.BD,V
M$D?4D,UP!GDL?=A%'V\PD:>MZ$+."Z#=[Q:1[9^4KRY/Z@FSK,>_@QULBB=]
M5\V6(M0M6+7TAM8_0B;P%-KBF+>),V+3@\**/X#QM[B!K6-IP _4T1U(0.-[
MT D^!^(2Z,!Q10-\YN? <7(&@C/&E.9$Q6D0&?4RHGCI/12MJ77/,)" ]96?
MB] 1IM1$T<ZP_^Q:5%5',B.Q)/=!5IBG*DN4\'@*D--64EWOU/?_57DJ L="
M20!H(J?\>VRZB,<W:> @&C@!EX7B.?A7 0FXJH\$K C6'5U! L;[?RZ.YBE*
M"OI$4X)]!?&-OZJX>O26ZG0TE!M-^B'6@A/<=[L=5125ICME&GX-\)8O1@)H
M-$3@('PX*8.%ZL_%/X\+EX<<[M6=(,*.N5!M?O_]IPW04R\R<.0$@Z"D:RS[
M=["^U)&(+&:8(P$7_VY@&SUZIE'A+?)VHK&Z/Q>?D;8 "RZC1GQ097U\%(0X
M)2YR(Z_IR,KR&K5" D0(0+,&8:63H-YFW<.Q3-OSO&*?)Q%>MY& VA8:"]29
MD?2F;JM0O'Z/3;-9X_EHLS;1<W^H8W31Q%OCG3&K\9 I@L@P?35.,+F9AF7E
M\)=BSB5M<];VVV/C$5Q.#/X2: V4E&KO_ZA+607HL$B?"+AQ-GLMEIIE\/:P
M%7V 9DE,Q[[4YZ5 7*;&SISF3:=6V6L+K^S58R8@ 5NE8==UUD83C8JF2 LM
MTN*D/O!$V&6)]MQ_9</:6_O/+Y,6H3N:>8Q;=I[(HF(]-LX_>EY(I-7YV9JN
M<4'2.OH&+OK'M&O753RF)0007+I/1^]R]9)_CB2(@$IXTK^8EH<65#:G5Z]3
MOZ<+WM5Y6AEE1M0,R2FLY4F.12L<I!/LITZE%*C.'9+K?%[6B2FZAB_$5(2H
MN4OZLO>MH\_G(__-,]Q"@0T_D8J;,)^=2T7F-/^85NJ&T^SN-BG\@#F70<^M
MR)SE#YY,G3O2_HM2DA,;=<OS'*?KBC9<"[\9#25Q6)^07\-FP:;=GT\*AVJ_
MS:4,$0@2OR.93TY=LNGWDNW&!^H2([=^!Q*#?NEPJ(1D/JGH?_OFKP?Y.'7I
MB@A6@S7)M!^YB+Y7TOX ?T_N(;G#X+)DJ:+\SNQIR+'BM[I#BIW/Z.56-[;8
MD(#RV6AJE-QM6\<"^+?<:!L&+;)^ HVBR+0J6)JO[E8D<E#FMP,Y\Q*Q/G&.
M*:V&(!:\5  3S#,7#03_+66TL%]-I5TC!$A "2='=-W"V86/3;,+M,GS[1%N
MRL?O%$K]OUXD.^D]\T0I6_MG(GM:T2A2#(A,E(#.)W#A"8'$( %3UIVO*,0%
MOC>0_#>5[^__F&IHO]GS1+=S=AMU-%J_S+>^^'H [D#GB]IA_\X;!!>QX\-R
M!,V!,A#%B<\H]>CU-@0A<U"%! "1@)/;_'.L=4>3*+W071L)@(#@!%0V-U[]
M503B^;5Y5V21"G7Z:$4>7RU\OOY#03O($//OC/H7AGTDX#)HT:X:"2AP1S&B
M=F@/:S_B*FH-?7-% O0.OPM)O5\-0Y>K^L6).RW_K!_#-21@AQ2E5\*]ZA"1
MW9K$W]>A;A-J$9R@7D^!RU(9D!+(_(?6_;!\4+OL(]0$4(KX@&NN0>$^^/B*
M*<W!=9&_:?<9U#82A 3HHZ%6>EI^8-NHR )4'-7/*]2LE51;[OV(&_WQ(CLY
MG!T K=^B07@/%[[XL? 4)0"E_1GWPVJGH0 M@BWJ#K90 ])]OH3Z=B%U.VJE
MLZ<HP;:?8!3M$;4/+%6^KQ174M.:0"/M@.3$L/V+Y'V/-1YP.<;(X6L$Q<28
MR]*&AP*A0L:$-L/'HH)C:X98N#IUSO4M$3_7Y0 /<;B/5?Z3 UV14_F&]>(E
MJYW#Z\X.?*N#8?D6ZAY2(W35L,G9<%>+Y'9J;'3+!X892PV+  #OW/,[%9$(
M""AS/[F2"VXI[3HG&8$$2+@ 4T+9[)42!VY@@VR+GGT0W.&#LV8/>A"DR64<
MN<O4W://GQ<(8MZ,H:MU? KX0/G*M4WP90'GUEO5,M@8#A* E[\^ ?S$MA&<
M9&EZ5DP7P%+/T=T^M[W'17$F^TXZLX,D)N? ;:JR@$UX;K+'H]J*2J3F1*5)
M+!)1&G9&F)YKY8JH@^%BP<KB*D%!&WL5=SENE565^;$;0][) G5>:K^1W@@F
MZC&/R89UE_1N.$)&+<%;G":J-26A?,0Q#^J!E_VO+!JAM^5STU"9(;P*K2U2
M2S_6%CM;" 8?)II$&$95T90_P/,L#-W/7="E,9/..XJCP5\M_,"E_EC+_/%J
M&I$8-J\8'4["M82DQC>K%DB JBQL]@NPNVCTK?!-[OP%Z^O=!H6KE4)1_8\O
MUR1$4FW<+!L.96"D7$STX?(7)C+?F9DU&SE4W357Y;DO*51PV?;:*^($HC/*
M8!CVEK*VA[*<!!*@?NKU9F>U,FI["L<4',=\*_KZG6]1'+2OVUF?.]2]16_:
MU9HR=7N@,36ME=I-#V$3ACJB']+P]I#MM F> )@")T\VD "L;TNRB#HP5)<N
M,7!IM$F'(:$)+^FS9GTW87S6BR8.JX8GZ'M+-42MSU8'H=0TL)&/7[L)FZ%.
M,78U4\_NQ9!&5XPY&U(ZT&XG6G0YNN?*;FBLK36VCTUTW7+9"*XUB<*'^=>W
M[RVD6[I$MA)95&:$9VE.QC.73/*RI>JS[VBPA_49)D[!34/[ES9K-T0W-^"6
M#M1W1@0?)D-OA@6P"5+I"Z7'"T$F,F,4[78X,.6^%F!N.BT03YHA;A1&RL%R
MY;YJL\AA+LM([UO)6[;"$B@+WMUK6'&[.<?%06WJ]J5HC3_,.__.R-)3:0<.
M>BGM[9 E@MFZ&:@L5C,T2/N):'F O"ZCW*!$O#UP%RC;7C%%\>W8/LF#8,;/
M77WKR!()T 1) 4<'K8\,$[4)$=SQZ@4#[&!.34UO\2\QFWU%K#94 61TY(N.
MGY$ Y1&'+.&;9EZT80V)%*2QH_::4G4O/0-S>%EWET64++Y8<_A&3K&]2QQI
ME2:/&.K1NAW9&/FZBKH\7Z"7" ZNG[#VKVTK7E=3FO),[>Z!P\L6@MT6!TY)
M]N#L-.:HA8SG%<B405=>@ 2\<X3 [10665K4?BPXL063'3TR6\ P(@&$M=90
MM.I<@U2.;K0%6(WP+B:H3SWV>6-<;S73J;(,XUHF*.L@WOZ81JFFX+B0+UUJ
M97!0CR,V?(.^D&06@A/L\[KG88_ 0/0>).D\V9/I[#:''V=572&[OZ$_-F?'
MIHY2!0^ULA7]:8)CCO -V)?;5L('L"?VN/#HJ2"<MH_^]QX)'O9R2;2USAK)
M\3,.^A9HON@R?$#^9C?BL33MZYVDGLR@-AM-*B$V!VL6'%;W-X0BI23TLE,1
M-9+0C6=#>0.[<-#<C;A*KZ3,,\*!(PMI2!DL#3;]A&MZ+ZB2W.!=VO$[/'=
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MCS6PX+[X%Z+T+_+Q>Y0,*_5'8*=KGO8(X1+=4VQ\.#&#)6H[G5N!.."^6(C
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M4G\L;Y0X?SLG:!:LO,(Z6\)VM:VI4NL\E+H]\A^AU/DL+ P\M[+24#M6^GO
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M+,MYK_]P&&-7D2K10%F *CM4%Y$=M^,?QY>&_'#X8Y :K?/G.*BH VJ)M:Q
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M>6_GHW[1XM;'RR>_VR?\7W9S=P+ J<0OW U^BQ=&.=T8%OID-_F8,U/D1Z^
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MX+F$2?(WP.\S;0@!>,V+$;ZR_*LJH!(GWE*O&?!S:(6['28R_"J 3@-JT:S
MO]]/^\.?9#V'%\>*&NN>C_;_TKV0&AL2'1/U66CYW8/N'\TJ&_&Q@0EF%Y5(
M>/17,+M#ONZX5 RU9T] K(5#XRT/EK49OUQ^?O[8TR^G1N_!9B,N7E1^+$?7
MX]5LGW_?5:%X[\\7W]^R'I7IG5I\OZ3?+!]YM);6E\ ,X45QF<V%^P0<MQ:*
M_.J/?29#0;N4JA3?EDW[;./E$;B"EQ;VVHF7%SK:"&:T:C3A&=!J:6ZO'7TB
MN=@_(A!P<.U%/-8T:.Y7VG[,JB+)VL#^-80+8X^'JD.1>+*[* +;,":JSG_C
MG*KAX38)T4)'UD4"1 96CN_)81:U5A$O52IK<$CHZ.\78$.+-N&HO8UB[9DE
M;VOU:PMWR9S.X6_/58K?*4@Z-9AV-3,5L#[2%(U+@A8F_ ;7P8CPI!BO57"H
M][Z(QM1^1)G8C ^UKC5/\%(O\4;GRF*3>_,WP'B=)J8$9O.;A771[R(5(=MP
MOO_2X]SX )U8MN"TH)5::"VQ-&_Y,(WN699 W+1$-9HO##.-R% 7K$:B6^W)
MUL?FA]>J>I=?+1JBQ,..+U1U&]^KW7GXVE*9QN-Z7-K("P) ><"5+5N9/Z!6
M@Z'MO1E-;_RLB<C@)=&F#'$+11?J$/>NXP8!J'89PT<[KK;Z/OM=:PRZ]OMX
M<16&8US\QN'VYOAW J]#G7],KU^BZ"DE>O!S]'0UV= CQDK?L- ?VFH"+SW
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M_A4PN.EZY$>=(=DJN\YS/(3EQU\[PDH3@&XOA!6*%=Q _7E[:ET[U!"QBPJ
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M/U.M0Z2OJBN*R!GF7Y.>W9PNVDBRH.E$NQ* Y&",!P%X=9* ?Z=QEHRG2"$
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MB\EW0E0X"J4<\H,44TKD_:KRFZG*@ERLN[J^O'VQ.13UX8/A_!Z(">2@$T$
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MSJP-3>5.5(M";O$%N!]P:X9'/P56$Y_!85#K/2]V'GFYC+&%GP4I\-P1)RK
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MNF0+72[.%C'9&"7%H:@ -F4I[2*O>U<R+LC@PV)=/DMKK;<)#X&B"^D<WBS
M_>;/@"HU?]V85"&"29)C))H<,[/%^;D6^LU"4[OHFW=?AJ\>MRSUO0V[P? 9
MS^N"IF=87(*TBP [9Y3*5#/-(7ASM7Y]$ /&%1N[C':YWGFI2ZW#7^Q^L;6C
MU)M>7V>6,M&5Z#_/^I0>#/)%'L!M,&%WK6_?'R5 G:B R<'*QDCOB@48.?5)
MBLY1@DFM.\PS8,;3M5;5L'3,T5VP+RGYV;Q:<47%/1K R4M_AW'W[REUBJ_2
MS/]^EI^#&F3P6N"9=$:L;<0],T)X!V?8MQ*= .UE%D;+GZA&Z\Z4%LQ1,&[^
M&<_WSE;?;_[WU?K)H$!RHE3L-F1ZJX6-T$GD>TL%(%YZ(_ ^*\F-%E?*3H/
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M#$M17@M*/.A1CJ<"1HRWP*>L/DZ)CU)OAEA?1<*0=\A)+_:;:-89TXYC7:D
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M86OR(5> 5QZ='MT^1:B*]'IQQ-Y5.2RP-0Z+8]&%6?EA_K[S>1(KQB@.304
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M#ML^<!=9:XF]W"V9[%XE$82H*^G)Q@ 86QO9&B;Q+E1 O,"R\PE:@!+C<UA
MGCQ7PI2 Z#W55K^-Z[0DVG-)IW<\\G<_[3EO@57/=K%C8,/I"%LJ9) YQP--
MJ8"KS2L!6#%RR"[B$&YT(>""*:$,9XO782<O9&21(D1V^2O3Y3+CLE+N,\3?
M; .=^ZBRK8*L1MC&Q@[[J?_49C=-D6W0=FK@9;'X!O3W=0:V9V_*_H:%%_@J
MS$;+;RJD:OZIK(VHYA^J57^T>6F%\]!UKJ?$%)K.V;%;?^J<VUY?=M4?*;;Y
M"J5H^]T[1=5NG/K(8B5-UV!U]]NE0893.9I]5V(3&B=S,KK >H.\N.<3%_-E
ML,^@:2U!TXRP[6CV?W#WWE%-?=^^Z%94_ **2$<@*DVI*B)%(#9 1(QTJ5$1
M$9 .TA,5*8(0 0%%($H1D!+I4D.O4@.$HH3>6X"$]+S@N.6=WSOWW#_NN>/>
M\<9@CXP1=E96UEISSL]G[KD^*\31"M7YPC;V5XYL\QSIP;3'JBO.G%))=_IA
M@6)T@;>M=A&46=8@95C5OJZ#$XU8PX7-@F-/(>@GAP,<J0007NE7MS:+]=Z3
MHYVD?=J+8=GS3V3G=1V^^X=,;B2?Z.3+%5?GRY?C>GVT\4C](5+-5HX526F6
MN]PJ)$/K7-_"<G6J9,S/JXF<W-6KE-FSZ&MR"\@)ZY9.]@@?L0,@91N;\KDH
M[C,\=XI"WGJS%BVV&W]<//'NJ4)5IYN.JZ[<_6IR8I%?/[5SZMOQ^\2'Q+-X
MO4*(NWUJ*;V4H 76'3R=K!MJ.G22"VK3>3Y27WKF2'_^J^TPF0I]P-.Z EY!
M3%]E)$X;?+0>/-7Z'I9;_I:J1F/?VFQ1BJ@<1T8^?Q+OA!*1TY_Y-.NC8]8I
M=/7>@Q_D5]1RW&]&6_WAU-?)@</H,K^+2#J'LIVNL&/YLZ9RC;??JL=9D(<.
MR6[7/M$\X_PHOS_^@W6-1?G>X."8:T6X+&/"2F"D+YQPPK--&I'2B!=<+_=6
MJ&G_ZN]\-2"2[*94Q/42WL#'3>>H8:,*D,Z5S)IA7VYHDM19-%@E/Y/1@>;>
MK6+[K9.[\E-](L#W%1-X/RR7/3C#D;Z::I&.G/,H@!PQ@@T8I:8L;\)*##:U
M#3"N!%P,DF>]<&,SK V5#RDO<CO*\?*\Y)3'P>^IYW8;4/VGW(\LC]3_ ^4\
MJTI\\(/1)X?\V&;RJ)-P.CW$,)AGID?F/DD.[^Q?&-L=(TUP4Q"KXA:_V0;)
ME;T&CD3U@XZ37F-;ZL4PY9^?MA:NE]A\F]TS^R *\NRGRXF?>L>'/U& #@IQ
MGT#-HCN69U,2Q33%GBN7<]I=&>S317-:5^0L;I1F^R=,*;7XFGD[?7\ _NSJ
M)7A>4^_TA3ZS1^_UAGSY-QG\]/*RO$)[",^2GWGEM4<+F#O=IT"V10VYQ&Z+
M4)H9W@'7QAV%M1"XJ-+P,^VYSY*)^K-F5X3XVKW-?)&],?3C- Y7[2$=%'0<
M=_3^O=:3#U*N'9G)#SO-F_Z/RMP\$["+L>J6]?N&M+8D_J;<79Y7;GZ4W7*Q
MW$G/?W*U_H\B!6<]NHPE5I."N_Y!WC?6N_G,G^XD24=I@_2$'REFGP$U543(
M[*@5<3&:8>DJLXQ&*+TZ#;2F\:H1+B)P;]JGEI=$;JOK<V\![:R 6=A:,A@Q
MK*;$>.VXQW(D[R\3^B;L;X8+BH C")Q5 1SNMJ=MB.#S7GKS4&U]F;<P;=KM
M/Z7K&D5?3Q_2S=)Q/='01SV728L/(""C0"5%GZ= $1I%-4[Y4&>KL/<QM(I;
MM[L$S>PK#VW]HQ5D G\<XLP)Y_>/-@C)"*JYO1CS6;C%[>8Y"OGE+!WIC"_F
M:6=1WQ^6[PJR"Q-KJ;Z#?UR]5RYX=WG]1O&D//$A9W._V*ZC^"VA0D[6(;[3
ME+],D"R:J]T0+CUU,;4OEEH>_C!CD_D]"XYQ-M*!?1;*;=6]*K&EWVLFN:CZ
M@O!(A\_LQ/]Y/:K_@.[,@"JD)4ERGJXQ@[;.+TYDP7'V7A&@]UHA<A.KS4S
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M*[T#'8"\E:X:JE4^5B88^"&JNCPKXK'MZ8>W(D>U;;XWOYB.^;VH?J;N9I.
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M9OL&L>I--].Y9QRCXE?'!*9B;<P^>V457S+(440F(O*2B0HD5029MP2^)A/
M!-J_.X'MW4-1!V\$GQ(?5C\$_1-.>V"00$HA[7\V!\G'60SE)NF8:!XIJY;D
M1HT[&\!)YS=;6A.427Y-7NV(&K'R+E'ZW46RA071 4S> U4)P0LMFW&G+)C
M$0BMKY@)3$?#CL'[/S.!1(,^AI8^$^#RVYJYH-WC7F!Y&^UE$/)X[E+(I<5*
M_FT'%(W_5-OM0B+RR))QA?]%@TL'R*7F!"2-_PY>-21_NHS7LSVA4(@)I!XS
MH7^",$*4JO@9Y4_IGN6@@CDF<"5$CM7VY^F.;05-BUE7+6[3"FP6@+2[ODAC
M.;-PAYK*JX7:2L'ZNIJJX[[%%]I_7'P7XM*T!I_*LQ-_SP2^D;A-*H5!^,T0
MT5J_E7Q&B%P69G\(P%Q%%RJMN*,4A)"U"H5S][6\9-AW\QB]4=3#\(*Q:%(^
M;EB&_"TP@J:,BO0NAEWRG[).M[1:498.0;JSC9<%JVRY-X&/?!O2]"YT"2RJ
M^FYI=1NSRI"J4[UD?8,O>:R!XV+ZRU11Q_3@MCT&A^%6$@ZB>N+F#&=-[$CQ
M: 9ZQNK:3QK$BD0E?J27UNI3K]WRL;:&DO2"SQ:)+N,[%PQ\&N:M'!LZ#AWD
M PZL_GRI^V&;M",]6QG$^"84>[;=+%OV7E&\>?#WB]5KOXVK-[T[M17]B= H
M$&^MX4R>V7OGRD$;O5/TI9E>B9N,E</0)K3IOF#JH9XI^%AETWV;M@';%9[.
MO*["9>5D1"RN9GMUIYVH3T_=A(&#;[UR._UD*RE9UC#?UH>KJJLAA]KW6HV:
M*=,/PI(>Q4[R14D^R(BYD?4,,+M_ 6#[4D2[FYAX.7C^:$U5R1T:@IY1RPI[
M1Q'M2B++7S5SL<;Q,Y<9:UX, D"<.(W"<M!6F,#K4-*39:B0S[JM((_S^!.'
MSR,//L5%T'?F&;[;ZOOB*R&?J(BPCWV/4ONX)A-/,T@LPBN'O,MHT99A F^B
MB4$#4XZX*XF>G@\7U37!'S.W]._#^#<3\7HTWM"6Z4*:T_08*-$EY 9?7^ZS
M.7"6&;'.;YZ@]4V NPOW(J(=_XU[1?-Z=%92K V.)++P5]KK&NG+?TN!QH.G
M,E6/HH_1E [(_ IY\),BK\C->".W&DA:9'!<]Q)LJN>HE/BDY"9Y;+F<#[Z&
MRPZH2J@X"<>:;*H):/[6>V/GOO7NTRS\QUTEI?8E80LY\<]>&][]CW3AE\ :
M=%E4+X0D4U=CB.^B#[T\T[\A5KJ\T% +DY?;=:LJ@>^Y?]9B KSS/<B),HE]
M/"DW 9;D.)?K5C15_*;;^_(+_'&4W&$C4@J0$M7 !,)>3<,IPI<1M./13" J
MDR' 'L8$EIX,@K<TE!BRJ'C;MPL(;]C__,Y8_1?'G^VI+A5PDQZ("[((4<)M
M)M"PA"9]!T\_](<RP@U9^( M@PG,Y,XE/_Q?;7.D9$C!]USPJL%'MZ^:_YSQ
M6"6'ZK<6]I,31DMU^$S?_4^5O-^3XF;R:,J9+0K')VJ2SL7SI+T\#MD_8\;0
M$WX,S37FOH&2_@F/M'H^>1Z3(;"2X?)",0HR><A+F<3=5?XM66-A]"TN<73;
MH'LBYL:+E 4G12DWE(0 N/"ZE1')W2S)_;P/-88)K.M>H_7Q8YR@7/,)+BN"
M!R\R <VO\VCE!KK+L/<[\\6#;[+[IRDCDY^GUBU,FZ6*PUG+7D&:S#X_Q#A8
MIWQW:R$M<VK":E_B,BEF1W7!!9*RD"1!-AH0 ?_JE;M'<G05$"'.+[HM"XVC
MD284"\BCC%$G.'[5152&VNB%^[2 \M93Z3O?95WJWW1QC/WR?O+/,DETH(?U
M!_Q'+S=5L@2YN'ZTGQ=U>"^"H%[!,$).,P&TBWE59HK?XV*+__Z.'M$UAT9A
MT0+82"&K>=NP*/18!7)GF9U.M0*7NH(7![FIQ'*7%/6,-7DS1@_+")&WP9OC
M _3/3BP&\!Z.*\^W&>@1?/08]=\;*J"/VSU;>!7QM[^WV5+4,U/4O_Q'+X<(
M,R4JW/\L6R7=K8B*A<]G0<_0-1@JQ3VB&,/"-X-!Z?"\X$MQ7B.JU]N?+0J!
M/S(!CGE?!?;[@_I4LX(XU!X^D=;.OVXS>$+HA.[U%;D,E;G*H2;3QT1-D2A"
MG4FCAGEVU1OPTP\[]=S)N\L4"]!WVM4A^4JM?(4U^Q(:B@Q_5?1QY%UL@/&'
MN[82+2*QH=)4SBH%<J>9N@G!I!%UO1]VB:U"P0[K[EYFS03,P/T,_@7>FU*U
M,:+%9<9*9IZOP1P.IGE-01GVZGKVRX9*UL78TSL%;IE5]ZC<<@0QO5F+U04F
M<&P%*Z)8[N3KUJ+1P79N:04B"RO?#0LHSPNZ\@*#U& 1CQ\J_V,)HB*7-BA/
MK>K4*4_%NGSK40'AVP^2$IG 'YUNGLUW9KJ*]P8L'KOJV*8I\$^E1*S'3:U:
M5E@[4>IF0AD_=$3.4QQVR*_,X--EFDI,X)H6=)MEK-%%J#PL_&'S*A_Z(T4@
MBKS*.'6SB<4,V(:9P#DTJ1K\;^_.(6CJ;;./G(=?W%7@W\'2KD3L&SI[/L,(
MCO>!-S]C>8B7@>AYEI$+Z@WA01V@!]FT]OXRBS[HUOB^Z7\11Y%UF$#K &LD
MOK)\Q@%6#/@ I=F"3%K@IT,>)^^ ;@Q M?YM0^:[3&!"HK'2^$T5AA!] 4)I
M"U<U(C0O;A])'EIE G\_)D[0\89QD]Y.]X&LRZJ/H]QS74^E2TDY7,?(QX2S
MK<AE%5GJM([?^?5'1<J'Q;UN-_UK*O40O?2K$XQ_],*R.(I7%=/U$7Y);AX2
MIAR"G(EX(ZDT_RI_W.WY+%NO#4.H)\2!:@_OE(Q@-'FP?OQ)B_;)H\BU^LO]
MTA(>B/N5(?4_XPQAULB@JBP'!B^%-Q23UXR)2,5.P5(&=/@I<30B?SL-^M&:
M)HL/Y:G1,!R$XXPN,0&K-;G7I'7EFUOPUH(ZPVC4E ?WDDNR -F# -J#S@6J
M^P04ETE,&M$&R&/0'!@OB[-9Z^ZS./CN >C'1(K?-)C,7^9.V8Y@31;_5K ,
M?F07FD=A<5A<4Q.EFPFXJCS+B*(+T33_.LZ9O@D#QIVD9";P\!EZ-YA 3 NV
MI#K!.XWWT\3'!!F(]'KKM^ Y.Q9_%3S(!#H6P--Q*^AB1UK\'Q-&,ZN[2Y%R
MN/P&^.,^LE1U#CW<@0D,G+! 6WQ-8-U<C_@ZXPFFQ7J"9SAHLR362I)R;\41
M>9%,EDNBJ$-3X2+HN4)2#:/)F]70TUIQV?TJGE4*R&$:1UV';S%RJ7Y3(%H<
M^A\F@(UG LJV= \0P 3F8D@01FTR.65S=64+NE&&;D)+[!1@Z$R AZ$._WOT
MQ)KFC[^1F[4J7=Z^00LK#EV9%4L]JK<',_:D+.)1U7)3B/$4^-79\/HW]ET&
M3U@#E-F&&ZF_&27VXZ+M'%H:ECQ-"RAUTNZ'IQKM??_ARY7%+W$Z5D>#A:*W
M.4N90-%YUB*.JH3:I WW]61565^'JC(FE"^1P,W%7,]=]KQ7XX39F, -E=VP
M8#35XVY^#NF&:%J/ N; VJ%KK!][HU:>:%/E:[%,SES]J:LYMB 6@&Y22(^A
MRALN!I_HMQ#:3I_71J/C2BG80HM86"=&'GUX=]AFX6KT&[>KY#=,X*S<Z&JI
MO%^C$0L)PR5^]24KND9!<<D+37^?L>]S7NY>< QTV_SOAC-UEB4K0]UHK"[%
MJTZ#*=O0!9<9I?_PWSOU(-;:2I)89 +9H I\,BUR"T[<9+SO97QWQFUSUK*&
M0&F_-*S23,6=?'@2CA7<+PN#A2F%(:,PI %R=!9K!9AW,VID6$B)((!6+$.2
M.<;@V">LV\)@&=A&#V2S->,/'3)*TR-MH8E,@#'.LL@0,JGC;T5^ [Q<D)8,
MX85/H!CQK5#8O[XAU@K>N,\$3M*R8,CI35J,,QQ;R>KJ-8K?7[D:F2PXU@5!
M%QU>)<R!_B6K!9?_>V()/QDDAH1W3/ SU&'/Y>;A$PF,)RAJ",O)!%(RZBWH
M5>"%.TR@$D>O+#K.BHYQKM#]_9704/A<$,NX*M&[;_G!_Y):\MUV7 ,S@3,0
M =:*/>5.Y[A#Z<UAW3QG"UDDEY P##V6EU['T:7VRZIT@_?W(!SHH['"9!Q[
M"YK(M;\%U! J"/LW"CSUT]@RW'H:MQ&F$["=T#\"@7QB=<N*)#@E7LZ"U<@V
M]^.&WM1$54/'<[ +3\RCD7<%0(G!]_SIZ>!_C*VA!+T5FG1=!>23441K-[D-
M.@<+,_I;>+;_ )R]#521^@O'>SGR+5GP=LS+/>6[W-O\X_[OLY%K)DXG7]\:
M(?ZA\+XH@L<5"1)[/STAY>7DJE]<YI$+"5Y&;)^M08KH]C/: HU_C!O69<*.
M.$CLGD6K,8&/OQI9(PS]2HV';GU*T&.D-S*>"J[I'7 _0<IX'I/GPL&#2[9G
M B4IE(7ZN_3(!W 7_S)'I/3H+..P5(@C5*\9MZV8LT,;V_KMC"/.N[-0XO)^
M11[EYO3K^HOTW/JSI 1#4K$TTKY@\H'E,O[:UDT79=V:K@C%:YJIZ?2PD#0H
MP,"(M&A@VQ G+@M=G/BX;G!\+>Y[/2PFCF31Z:EB:=+8GF3N9K#MN"S*'A$6
M/.B6Q1<?^L>N=QG^:4_UC:]P.9SC62567GQAI4MX_N$%SLO.^NU#*:,%D,-.
M)4N3Q_I]R-W"Z_(*4PF_U%V[1?+ZZG5<L4/&Z%+$%:+>(BD6ZJIM6+2^[,$"
MZR;_5Y_S1&Z>=5R3V=J961_NS7/D2^?!'VJIF5Q^IOG)A@GPO0=]2,]*/*>O
M+HGMF+S (FFN-)-^-Q#U_Z'NO:.:>K=^WUB19D0$I:L@* @H13I1$6DB D+H
M$1$I$9#>0J*"]"(@($4B':1$NM30$:G20N^])I002#MA__:[[]E[O_><^XYW
MC'O/_6.QQ@AKL-8*SS/G]S.?9\[)[L#?,CQZR,F(*OVM1M2ZR0#\$S6,UKM9
M.&_QMG])(HN#+Q[!1"/J5#2;M--E.P0VUNZ'E\UCK8\Q:ZNHV21=SD_JJB'C
M2_Q770!*ZJ@\]!O$Z%E$U,&84TB9GSU&8[AL7=).8NT$*>2%H=VEK?O&FJ5H
M;$K@9B0\NX *N(#X1:='<WAVB+U3VIB4S$R&SWJVI$!R*L(V%WZ6"FA239\@
MP,=;+*[@[IB:OU#?YFF)GWWU1"UP#'V[_^V#GON_4.F@6<SP6&OON!LJA-<P
MR"W=5^5>]%(7_PN.4RP2']ZJ=;]'/NBO9T!-.@5-[UPE0"F-\=-'MZ!%M5\5
M9/?E5K*4;O01FL0)-^ IQ;FQ<](#'5&)">H&IXE V?G=;'-$H\B;L3NB]0(Z
MK,OQ"8_!5_8:4GP]4;6Y13I.^E5_-BQ'2 I1LQ:E!3##6BPP*)TR-LP_*"9%
M=)^(IP)L[TI^F%8X8Q8@=*:NQ!X8 F%4U,4&M6BE>=4\H70,F9RIHED6VU"G
MR>)KIFYO.H=T.'K9MB TS[Q HWDJH#CY.07,ED8%G+E)!<0&5U !/W@J*>%)
M=6PR/1D+SBY%8/&[-) Y/4%#KF<3XQ8$^WW!8,U\YKWOWAR,NTVUE-3]C[F(
M1I#R/6/''9B<#2+<:N,HZV?O@"]*DVR,I0)([]RFC_!AQ]HBS0QDG#BT<14.
M4B6>)SDE;6]0 =@/7:@4=BCQ/M)\RA%D@D<'H+%/ZEPH.UR]P3Z3]7$O<ESM
MJK4.,1*(DGZ68N4,Q.P@/$SW4;&D_3CSLP]W%($SYG2SZ,!"*2#SZH]5$^W<
M%@]LY'+^7<52WJP0@8/"HYM%*M]$%L0)-S&!K=/O8;=0PC%X^8#X5^__O([R
MT*EXP8>L\_.UX">^7N$W)W^MU2E[;2I^?0?D$"LX3P7 +A=QNREE<SKOD,J5
MT0'.$/W>'^Z(^HR=A&J:N*!=,*+2@AA!\!5L=&YJFS3-_5I.N_:H&=<%0M7!
M$\ +X@U^OA069 0OPZ#G&_5]J%MT:?CC+18J #<L?;1OX:BE;'\QZK7?<N@(
MQ#I9M^5&YBRA%?WG.(2^ FS]A\BLIPF'#[%F\F,D9?]35G7$V&EA41HY]T7X
M%4(8$8WJ13+0U#/^73V=OI4[NP.NCR2C_-!9WL895, K9.>NVLH4KUIRR-LI
MVOP\>A3I2Z$?>L,UMQSL*.'*&XC[N#_I?((*&$68D!E0[VDS,,5CMM9Y[I!4
M^WD@_3YAM=IL'C=^!)YFXZ!Y$&N+@G6<H-F$JH%'.&CO,Q7P+#UTIW=,<NX1
M^CR%MV=8[TNY@VI]A_V:=Q2_^-4C<1T/DX-;C8-) 9XVBRXQ 69(E3#"(O&I
M>,"V4)_B3<NJ(:O?9M,_@#PUGJH\'.TPK/R+E/E%T 6O###.?-=\G3.N)\NE
M76%+0#3JA?R)#=F"IM80@854#2DPIJ]9_ULA&\JU(<_$P'RJ4?426/?=/Z7X
MD"];#-8J>%7Z&)![OKK4W2B/RW#*?K#@:\!P2]KO"AGXO9Z!,@3,LS"UA4N^
M,LZZ+BMM?>)YY?T;I]XCM\\KJ>E#GH(7N_VJB+=)&LEM%+K8)^C/W7DK73\X
MKBQF?GR_,Y*ZX$ 3KN_\I^I]^0(BI#?M"N53*RY?6#@4]#6XI&MQ;?7?>VDD
M%T&'+7A*960&O'67&;Y9?SDZ,8&)]4+.9:<5. 4VR_NES0LC?*8--PEP]W)Y
MO;SBE.\WMWS40A0]L[Q>26C+(-WD39L_-*^/(CAW>B^0G@Q+MUN'ZN>,>T1.
M!EOM.^;L\0YUE/['EJ^^CU>:S4?;A4NBA[UTVL=2(_(>B8EEUY9Z, KHR[TY
MZ9.GQ.S3VI8CW79?X?(?1%NM4Q.%O7K8Z5I<ANW&D+]BP9US/ G#=="DI:*,
MK@(WW;KR\[9+D;9+53WOCD^1MH#_8T\GL].R3.RC#ST]5B7PM^7X5 ;!//DP
M22:M50P78I4V:/\$$>#24ZYJTIGVF@H2-\YUN@9BMYM7WZ#2J]'Q]W:^2*AR
M" FX"41;Q#H5*'I=C+KC$\ELLZLFE2,DXWWZ97I!9.34FD)<ET/LZE1VD;%Q
MW'N]!SRMMB;K0%YVRUJ$EWN!M]8]VP+Q"UZ=3[&+H1-FZJ_LZ%F:^<3:5T=\
MDY:DML.K_5I_16[U0&5#VI.XNDZM >AVNI_;]6BN7EB^4G//YP;;F:\+G!^K
M>QTD=!CWO'Y='=Q/_.=MBVQG%B=,_%(.]"M^78O(BJYC>R! >?A.$8$/(*PI
M7UG%K?IH1$)8)K,7Q61$"VSXN_AK+BH_\YJ)':";*]0WK,5(TZ/*&?-03D(.
M_3H*"1[*"\-1$;4&[O-.;&M)BZ-6H@N;5PWE1NK8Z$IR3V$+-(G<8KRR7C<P
M>;M#^?+]Z/LT\_1C^5\C#**K\JUX_]P'B!SS;FM?1L=(+^[\6T=1.]!-Y.C!
M? Q,=^#50+GV)T)DSYU^AQ.&2\JI+R/;92?D7<[-S,!D3*=.XQQZW\/,L];C
MLVH[Y>)&+\UW167D_/D<3<"PBP"Y'XDZ^/!<$I'7VP%IWLPMW.*OK@SU,M*X
M%,K#[2;\^$$>=+XW[5\?25$<WT;3]1I <L LS5P*H,+=C).FC7_$F4*S6MYP
M]0722>,3-M_3)\R>G[F_LW_.C(B=/\(T[Q^J7?2M^DA*6$.H8H7U.U(0=>)]
MY&?IZ96)CE=#GQ-+;EHB'TKJ8=:6=[/'[J DR9DW+I!8<2J2#F=O)H",,ZZ0
M7"T2+;2)^CJ+,"!F@&.7=U09N<J"7+6 OSA\ZXX\L#Z4'.NPZDZR!),5@VA\
M\$%D;[>914J9J]_*N;R_GXV_+X#M, B26ZU#^D#SD.NAB)7K]>(!F#IC*B!H
M'_0<QT/\8K ,(I=5TNS>2M#<<3[("0@[? RR\[P,33RE2B/39539^K^2^L[$
M<=K9P5I4W\_+%+6[- R,,B"'@1;BUY!X#MI5CQY8D"U.$=D1':)#H U)<4KP
MA[JC.B8D177/#\@:0E,,KK0?%\#+?&VH0Q&X&$TJI-!\"@?JS^]_8_49')A8
M!X+T$<7/4P'3T.,'5QM'_S.)OR/040$"3DV(_05T%P8! 7^@ MRSCB'KZVOD
M-B$*UTD%:!YG/5LN_JW^$1Q&^3/@305P*3X;)W5I<R[+K3(PP:^TST*^#1T.
MX?J=G7&(UH*S=Q'7$=,@\3U4Z%P.I5,;X;MGLU;/JT:Y)*)%1!)=J #^;2J
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MW$A9 ;CZ)VVTVQ@]87!V64I:05M,#P<E?L86627+]MQ9R*8,5E3&3!ZZ[4J
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M";+&;%<./5FXN7TS\NBRO>D^R.[IC.VV7"#XMUBP5I<G^&6UA2=\0J7_WGA
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MN]2^N>ORFD!8>7[B?(+#E8/%<1#A8!62N7^((#J:,T:-J;3DGCA[I9!?C@I
MV8Y'$==J;R^.,]6!U^#-LV_D2D?K!Q>H@!U;U. 1'X6^$UHYNQRZ)6/3-<2N
M]'.U@DVNMWZ[O[X*E8"82?7(!G[P*<@4>XVQ>:%FGG[N,AV.;A>5FU\I;MC4
MW'?X5!I9-L=M1=FO7_@$;D=7!)&BDOC(_@A\/F;$ +=]W!.$?RF("G@Q3?Z^
MOV>,(#8=(E/GJ(" WM25]-"CTJ;C0:%DBO<EZ&;"C##E6J(6<_@Q$5/K1,Z.
M/T;%;^4F(MI$)M&SX20:03W0]J4"3EZE N:E=X'-.J&<[4V%]GY::J9VKY)8
M3_^8S%!\4W7ZE<BI3VI6%HE4 '/B/.3HS J(  11 ;PH(18=-N&(_O@@=XYG
MS\I5\]8@V#8X XT=LNMH(' !@4L"_=MM%M'8T51IVC46_E3 NUTJ +=V%#9;
ME#/'X]2(EX\*22LM'RS"]+ /.U??UOWQ^^S$AJ=5[ !'FRQ*N;2U3Z/'QEHZ
MZ/OF%:0 _ _DK!LD (&-H@*L)B$T?+/UR^@FN@6/[) *:SS2J0#8LMR*2%O^
M*,(>P8L*J^=71KY9P\L+)QM8RS'?NOH;<?(D%=! NV"B:9=XI3HYU=P18CMX
MC_;U58<_K&O&TUXQIEB<[/^:IGGF44#46S+M3@L%QR7N1M%[LNL);"3Z(ZX^
MRFV=\MST4$+SRM]<4J)4'I.#0'@>9WCIW893@TG=.+J0VS#:W L;]5C>>EQ;
M&]3'@(.P$]:H@%:]SZYXWPLN\;^\CHJW$)I37V\]WY/XJ@K4']V$F6= S,*\
MI$6\!848TMJ[_.A0LR8R,M%C16:[HVKZD+N88J^G%#^M9GSLA*3&K3-:Q1UO
M[@(H#\OR5!^82]@-+GO8/'!'W/C3J*!/3,\_#LT8)?^5?'"?[K]\DDXL(L1J
M85MK]=<P6#NLUM60&S\=OAM]<$Z=.'5HB)2.FW-B'O&J4:WN+Y<]C4]@+ ]R
M5TK4>4WWR3X#2AQG%1G7[I3W*+0J4%DVLAB?:J4"E$07C2_OGBURA="3'F+%
M"K$YK<#7N^JYH[Y:*QHZ\J!G:@_E64:(+Q++(!&I,GT>88@+DT_"2)<#S( Y
M/?2D"!_TZ):&9DI18N-^#[A3=A3IZJHFO5,?0C2!XFO S_MONY_F,6&WY2;K
M=(&NF6^%$0V]3(CV:^P^@8G7UL;9C=KG<CPI"F;]C9BHT:I:9ZFL07R][=)/
M+42DQ>GJ<'FOF$'@D6U1T([UV3)+0M[,Z)?OA QU.H[#;7[=PUBSGCC56LB$
MP^95O(U!-_<PM[(<=K)G6JB%TZRF?JMSI ?^Q;[N?&6.V<F7Z/+/Y[,$]<GV
MW*\J55V%2L5IW^>[0(#_)Q]."WO-O_:?O/OW$W0Q*GB:3Q$RBP[FG$+F3#?C
M&4UC+SWK<.(Z P \=H[M\<6H<EXLFGAI95A@)[#@I]/-C>DP1)1[AA5BA4K[
MBX+R'ZY-9\SO%06VX^N_>M5BNUP0Y6=FS>!G@+M%0>^+*L!WC:IU\O9RI%PM
M^+,IP\J7?S9-V8U]3>8MR(VY2E(Y=00VSB+!L(*%[Y+V/+9\"@=UV$'L9O#R
M@!_[&;7&!5#]^'XEQB2Y@DGQ%A/#GS5EFT][R'X.-AJ@O8M0K:1ENT*.$L^1
MXS26C"25_]NW_']VNK._?6X4^MT\X5?5IJ)5[#[/>O<^BFG:UH5%4766PI'!
MH4_AB_ 5DG(U;2I(RU'AT--3S&F4OW046&7S]D^U<:/PKYUY_[+E4X,IX'JU
MZUUIT?ZWMD02ES(KJV.&*OFM!CVDOVK(1RX^Y YMUU(U*$5'KEAM=4SJ[.4M
M1%\S[Y=(/RIN*')]L*<G<O;9@].\ 7I])\QLVA"' A11&HG1I/?1B:*>G[WA
M--NO03(]-@W'Z2(F_10!/UU6@O'A*(WY)O@D_H8D!P<-B$ \%7"^]I35Y9BS
M>7Z<$].::EWF-)E_B=L*(U0'.S60M*\ &7.=$ZT+B,\Q-VX6BB_I@+)$R[:I
MG.%0WDR-6YZ_.8ABNZ(D_]7+YU.6T"U^#%P$/IR@S(63GHJ:C9#OV3#6M$S%
M$WWY?\[&L1E[T46T[/;R]+IB+\_GD$0[?=>UUF]N2(?=,.9Y(= JS"MS4[$(
M>/JB3Z2.T\>%Z*SHKZ-?1Q83(S6$JE"95,!+-'!"N6J.^4V>J=%F?(?1GLWK
M\_>/3G-0 5Y@02'ZQ_$\9>7FVKF8//D\F0QYOG&NA@H,+]\ R>"T?4+%@&A6
M\\W&&,'3><I91B\0]7XB"]^)6GCT\+=B@M7YU$U*-,+W2H3"YI-2OF^':J1S
MX-;R@80J>88EH[(X\Y/'^_?G_XK^_6OG='VSRB;TX0W*<:\I)20E6',-.OL=
MYC1X9 L[WA[=]>,?"8L"Y&_U#),P\_XW)LWZ1!X\LBZ]\@OR^LL1X@BQL)W9
M?S#*>=T-?(\?J,.F^=P^O_7K"+<#K(:%VY!GS'D<E;  ?^V5TW"T_6$?N5%G
M\R3U]U[*=8D%K1Z)<%GGU)DDH@+>E2"(9-H#;HIJWE 6&+S@7<5!E+(Y_4CI
MB%WY)T^)WP<MKVRO*?7H,<G/KY]I(G57]3#O$Q:DWDI/PAT=,:L4IRWE3OEY
M;D/G@$C6V-C# HJX^(U%CV-!_^#PN-78B9V#35VL&/0P*ARF\'IWXBYC[NAX
MVFMXD[7NX!YSE!5YWL(!FX.WPO%%C2E,ZK["4L)2#C$L2&5=2HL-%?#PS7D7
M28B[+N2N:1"V'*?#HC"ZS1N!]/LXK]A.EU# IF!NF[EOYU$QYN:4HR+41.$J
MQ08%E9'9&]1O;Z1?:%^J6+KJ*32X@^ <ILD*H]:'PG<-U0G_T>(2GG;<XQ)<
M7ZNMW#:W9G;X['%__=FGERXBXN"OO/S-JG'WJA#?IZIBMG9L4A\+*1;WT/U8
M40*@!D1?MJR9:.\G_7C\\_T<DP_S[\<($U)3=7E\VQK4NZ]54>S/KX@A(^X+
M"$[20=@-\0E4*6HZC:@3=#>',B1>OD6>.E@_XBTGBGBE.P%)%@.;*M'0[VHW
M,CM3@;_-SRMYWN1["-UF(%$!Y"0W;W=D.(6/)>^6_8ZY9C/!@"58:&U<;1[R
MC6T%6YN-==$;U1C?4@N9.VW7+N4?N473+;Z5,V\A/(JZ,OX45D*87L6G5C?1
M%A;Y"@Z3QT;-0.<:SUG(U[BC,T0-V_YUQ!F2VB7AWMMWVUUH,L)#CHTF0*:O
M1<U"D.4SN"=9^[E"E6)(7_2*7U10=';)40F$-;4^Y?MTLG(6.82D T+.B0/5
M-X9G+QY=4F(I+:8"%-N/6_P.N>\(;6AE]@J%**KE;5X?XU+?#+/ZT$-\1S=R
MC=3JYPDQ;M[Y7++BZCW>O[S,;<?IW+/N"]J:QL3]/97BN:OFIT<[O]:Y;1DE
M[S8 W 4SLS4X.[D>S[O\&'NPQ2RT( U=@[\E@7'-I$<X?&'1Q6F;)//XWQ,.
M'^'/KVPV=!P(YMG1#!1,/]_.*<_8RU._^L>#GQ.JMAL!/OZ1" ;B<C/Z+(QU
M5B'6.=O+OHTK8CR@)"UQD HH,8M!!XJ4H]Y',3TM6P2S@:<\?<3J4:2H46'G
M?6Y16<L=$JCJ4LR2QQ]O$?+!(5^"H0S&1##/R=.QV\G73J*3RXHIAO\D<) %
MDL5+AS- 1]3R9ZY73*CZG>RL!#E72U"8SI&$D6'U5[S [9J(2BD%K=6[48I%
M'>_V+HI=@;NC9JD X"J%[4^AVU?A$1,[?'[)%8/$BO 8;X'8#B4=G_V2\.\5
MQH9VW9H7(0I'B$9E:(AL&"-R=E6V_VW^6:*TS7(]?G7B\#*^!3<[7&MG-YOO
MV5T4S7OX3E%J!X#@R:O$O6:;2^7%.M;-=3#8CBEM98.WN8PXAN"93, V] -W
M<7\*T["BEAC:;W9=:]+0S#O6[.3:"."DE9"E[*D4F]!U40?+XDIUT;3(<_Q7
MC-*??<_H.]'_4P2[;^8H[(YC>Y/</UGM5)&:4^H_;\)A =&B^_!M/'2H8]35
M<2JA;CKM\/UW.YDQGODQ^WN>[)?M#KY5A62X'^5QH"H0K[:YJ8 F VRW5,?"
MM%^Z!MZP8Z')Y27HB>,#*L!L?5AZFVF5]U;IO>JV1&C>.!70JY ;?U^I38UN
MPA#R09F3X#3;Y9DWNRGMME_[=G<._*F88_Q@9(8IE:[0S7KTQIO*RYMV@T^9
MI8Y XJ(]BKNAV-$MTWV?,C/[["2[[%JB$BH+J4(3OR(;P*X/M3GX;^5)ZS-1
MP8\>D0*G'NN2-(6B0 F0ICJ3TOU-=DQ+T@U*G$^J==8"T$DXLL98779/<;_(
MS.!R<)I>*%$#5<<;" DQ4K3FU@(_^PR9& ")KZ^@1]*G#'%M=;*],4D>;4J5
M4KEJ*X5F.J%4P&LT-\&WY:*1B>W .GO!@NG4&$!/=<,4^>DH\& A$KH&&5V>
M94(R* H)3W]V<-)UC]_NO!9@^6#TBA)^L<3/:#Z4-'"CT_EN>YO!U;FTNMXI
MV7RE!BVAE)L&^G&F K'HY^/0K 1X-6\A1!(^7K&C_''6KFE)H.HK1]WHI?=4
M0"3R=WUBD= \7?.7^EM>[ >/[-@9"T(V!>'1755C.L6G\_!6D&]+7[Q?_G"_
MV>Q1=F@/%V\FC'E[V*FP@F?#,!U20Q1PU6$GQ ;>6E'2BITV3"1$FNOB@9FZ
M'Q YLQ#E<4H/Z$*1])\LY/E>1J<QQTQK]AF$;U?/N>TVG0HO5&4]-X%W?!;C
M+]5]<JCV#Y1O6[!-<93^QC3OA@Y/X!F8VOD9D>9+Z\_]0T.A!@[&1VANFROR
MB;"W9<*W?CLH<7IHF:[N% _HJK(=&1..&?C$KMIF99:9]NPVT]JY*V/C9MU,
M/U<X5?5H(F"Z@K2^8$^6P=E\E)KF\H+OJ@Y](ZI&]#NXTS'ER#'EE)X\03=6
M_PAGL^$YMRG^S#FM&UIH5$P>ETKG>.XC4<EQ<)K"=MB&^#PG_-)",,#L<Z&O
M8]* U0$O\YPB&Q-#P\NEM)LRK_>T9?SPU4ZHN*A3J#ZGT79MI 9!9-9+3/]5
M!%/L.T2-0.]U9*L9.)1TEQSE#MQ4%Z^U460Q?M38DPP5/$CF:]J0-=AO%-@=
M*/2SY+9CLN.V+6Y[)_P]_,RI;Z?Z:[P\;Z,^IA2S842'8M:K/4E \8A=DJ"E
M9BHCO9BO\NOA<:D8/T_/0UX_XD,[L#RF$77)U.2L)*-[,OU@@8M .&@[SIZT
MAQH<-H@V-E:Y=5QQ+$KS4&<.N8'P%LQSSB6(05VADI?ES9LW[K(./E[^4/^^
M.$I?)[CD-R%/C>6!J[%Q$8V&];SX04W6V+P/K9W1&KN"^+H8N_ID$;>)0Y_Z
M4G*P6\=L/\PXMX3%P5FZC*5>5I3S5Q?HA##%O=D+C%?$!>;!_4WB>Q^5&)+G
M#].]U:D 2W X61U55,LURRS34,]5^D?J"RQ?P:!I2\[&JE.!=^.I1A&3_ZV6
M@98";=N?N5.8R8K"X@WG!)89Z,R-=TW=3_7M-^UCM)7P=?TRQWTDKI+N_$<P
M!L<W=N0,;#K[Y%4GXB30J7:ZO_X%MO8&G(&P]B8"A<B^RD.01)*_@ = %3*D
M&'7$AA"0\OZ&UW)#5% L[!G!=/[K^;'5VUMC2SVVK[[PB?L<!C&_3V&)CAXH
M FJ2EN_ER!^B2C_4O/6@H?<K^'1S^>JLK+OA]TTV0U&TF!</8D.&"I!$D:L0
MFZU^NA8/B HDMGH"*'N=[GE]90UZ,#/*9<SQ[G4UM",C0$-A7-&#;7U_/U&:
MX0N,6=[ (!.5D_^&M!QZU\UYM [VF->L#U8!C]:@'.M"?%3\L9Y4OG*\V%ML
MAL"D\!W1%R'F@T@P+WY*JQ+MOJI)$^1"06.X).0FW=VQ\0P;S&LOTKD"2.1]
MM5S"PY,/8H",J\7*\F=96$G!J'::SVZEH6P(_ TEN8,*F"P9H@*>3E-B63>!
M'] [&C!^&@S\ NV=,"]T1IZULH6S$AZ8O?@J-HD^=85_[WJ-/!G"2-G6^0-7
MV\VVI!!-27JD$=J$'/2>_3\@W/A?.>A:J "LGM*-)+Z3]M"OH9CXWM68Z]84
M'3,=$FN["3ODLG2A](CPM-WYW[*'J7)65X$$1CF2R(K..+HI8D[\7:5,<?:A
M%'1%_.F?GN8OR5CRBA!YC!"$M\6E>S'.)P24&R_L;&I/CPI9]:G=N<NNW.SE
M1&"&!8H<<'RV5_J*_D5)GOU%!;QY>P/&+?V93=5)ZA"S%#4<>C.]OI;RZA^;
MRY;J;WB]\]*9W0XI3Q_7#DQV?ILC>QA_3U@Y\QV(<Q6ZU#O>.7?2"SS3B^?6
M.U./8_X]+KRG_.25AHB?!+\^%6 NDLRJ/_(G3NT/[Y;JNWB[)$NL,W@Y1J?_
MP&FAJ+?GG*5O2,S-P=J8.ZJZ@S%OS\#[O)PTS$\UCUG$_Q2QAK+]&!\X]QZ1
M!3> =RLS*BL2%F=YI-J73-M]*A-.<? ^!]6]\(ML0&.%R38H1H$<VYX<7WX\
MB+TXU"A<C%[I9980%> DE4").<YJS@8A_Y&MCP:!H*C1@?8D3)NY?DN28(CG
M'(^DT85:%V/Q)&S)H^C/;^7X7*_N-7(O<))/I?_$&1F]7"7*U;@KYP1Y!;$V
M>[6'-ZMJ_/Q9AB^UV]M5QTV/JLU&YF"1,TO(3*BN:'VAXL[41$,!UV^;J\(7
M906$BYS;7.36+5I5V>J$[3^SR6Y$7>:+R$]\N38O C/@BJT8P^\P$ [P?51
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M7W^Z6!IV%2DE#CU'8.[MHTJ$ X/21@C0QR7];IVOR@8VTHQ$9Z+2KX>?.&1
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MEKTWIH<IF\;2&V([H2P$R'SDIMTB%1"-OG!XO'3._W&[?:1;;!%^>J E\7[
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M,UEF5F.!K+;@L,[_^($Q/'C$LO',;_@ <+(/_QU-N>Z?;(@]C/#AJ4'233W
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MSZU3K>S[WLGY@1W]-0[Q&VQC=,=FWXYA)*[+=U2[)L>EPWLKU7@[8AHH "8
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M37=;I+M[MO;E604/7N/8VP;?%7M?S<4EZ4/,XY*-H@LK/?UB^8@ZNC3(KH;
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M]29WCIM*#[[3?IK>0F_-]32Y,_MR",21=?B(V>/QG6#$]2\WIWZ07)&;."J
MGCP:>IX$B>Q4%<:=2BOYM';=81@S\J-2]WHSUXHAX"Z#_IAC3Y?^"<:M&(GD
M*>-J,^4[*=)!0([066#U8/L<,^DZCATNBV0K0\1L'UQUR"!+%5Z:M(#Y!U=1
MS"63LZ2-_FSC;&$<4A4)#L$B(DA:#N2\W#GMYW476MPZFR2;RE$R,A7MXMFG
MUR Y0.RCG2-YZ\<4U)\4$L[(<)CMW)$R["0,_1A)%LEHO-I#O+ SO5*47O.
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M&)E7_)#$V3; B%:]/"/[P,.NKC):5'C%Q/%=5=AOG2NP&2Z#=%$V6QV5L6=
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MS*(4J  'X)$B%1")P'-''J/7&+=H8'XE#P,GTNCY\$8@:8Z< EO"4 1AOVR
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M)F$,B W0$BV>FN0:5YR,_1(BO;W8'9YKF !S>:Z2TR6 $R\ 5>L[!X&4>(T
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M\7M4O6HL,A*.2R72XA^.$1]"5(8A_#F=:V:;S6EVS+?19%_NN3TI3-I[*YL
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MB\G>6_UPP;K)_4 &;-_.KY(HGPM 7?P%(.LQL*ZK((#6#5KL-P#IL:$^99K
MF%V5HKU;Y.^W-P0L#I R_RLBKT=R;#XZW=!*F<&(Z_?_:4KE_XV7F-J(P[0,
MG>6C*R;&MC?]@N4%0RX 80%8LPO ,V0K$,M5>0% >2X,:SRJ8DR:+?RY697V
M".9BE3NM9&/CPM)VI;C"6CI3^8Z!LO;E#P  S95W=5TM;N%-G&,EDNQ&S8',
M8\?7PQ8DY];BW(1^51<^YN(A:'A]UO&JNLXM]02]EK0D+\ N_FQDYRC@T:U.
M07F%.<Y0J5L#E3<!8NJ\9/GWORQK46TT/1S5_ ;?.&%9#<-P5?Y/24@5+>E]
MTPJ=$I0,+2T>B 9^/#;VE*=O46 ?KN3SOK8O0;@_3YGT5F#&XB9=O)JT/&7Q
M'+0M32M*(K]BP.U%^83$5.27-\?7WV<P32N)K+Q5; %$QWYG&<F,:NRP=4\#
MM4##Y]G'=H^%!9LSF$<E6;T6;LQEQ+E1ESUZF.SY1+%%_H;7>QWEF=E'DX(Q
MXTTW?,@LQV#:8_@;2XTJA$'3K7VUZA1=OY5Z+E"QESZIO3=Z3\X#BG/2IA5=
M&!X5U)/3?3=N/;_"9ETK+[H(;YNCUP_1'6V@6$J_H4)Q:-50.;R+2I,B'M1]
MY\2%6.0P6(0&UX)N0NZAI:)$%9#%6/&V\X$%$&),HH8W4%.K?T/K?ETO7[W9
MI80EQ#4'2]J*1W4TGW(=O'*+9%VRO3;'8'4?:(JZ, J5<&6&,/<Z9 LLG,@S
MSCMV#+V,=388<[WF"!=]'^7[,_X#0&CG8P: +6.\<6GA^@:1;I1>XW=%.CN]
MIHJ]F8;LE/"R(2_/QR< GN/E2KY<[]*BX-HA>H@4.C6&QPA#&UIAX3NV:J8W
MNE3#'?W60LMI8R/+)<RCB1GKL02Z4BX5WO PRT%H)47V-8RQ5@; MJ,S2=M;
M)\"7%=#<AP&&'KG=<2S.=9Y6CJW.%:=PUE"9$KDK)'LK]EKW<8>5 _0J_M)2
MC.$-+14T*.SHV_/9I!NKL0ENU,,KC(\MM$DCO'C$8V2CS.1/U2T8.=Y$B9=#
M5@K&J.JAF<(D67&I8AJ>WEDS?4)%?N6/N80">DHF(D4FFNTW_*Y^68H16'@Y
M7+&MP:M13:YD;W.YC=KW7NR8-J"'!RV;9,J@HV;UG^J5,%X9'S-\]&M6<UG:
M6G>OJY3=X9(KG+,\KK\F39I[L\F("B1N,&-8E?A[P$W.Z/JP*2^U^#'C8H80
M1H+(-YY=%_^KE6;2BO<C&"._F<$XMC8J66CX*4*=QWCE);I7DV1"!).#^?.O
M\U.6$[]/I*QW3&+55_ZA#.&1_5\29<BX #C0QH*GMCV6H+3F#^I[8L]/N.,$
M)WA \\?<N9JUG?"N"T ,%/UIIF]I]Y8;]FM_34V-TD !W6_@?CSTTI"Y4:]0
MQU^)[[1XTDY*C36=#?(J-GS_*E)N[+[B']X,"Q)=_L2)H8C@Y,_*GW-S0EW=
MN #X(B9):7/3-ROL=;0RWLJ=!E'<%D-UO_^!] 4@KHH">-HL'^ >9WK>*3W!
M-T[W]&[T%9T/%-^+W?\:!,^-+A2*MUF=D: )76>92EXD'</?%(PKC_\T!TUK
M_K]%SL(V44BGO)Y<F?7+7XL V43GU'$%02RWDG5:7/3[&_)!+6;%NM>Z%6#B
M<4IG>N76C;'P-!FX3/I)--:,.CH&0]:6\WEQ9\S:"GOSK=-J7!<X[#REQ06U
M3]W;+T:/LYP% 7=2AS:UDD^8Q/:\S8<']$8]G=FM:65;3^;/@6>;+@+=B+]X
M?Q,-/-(2_SWB_/_GUHNA"#V",9JP:H"UJL<X=\HY[P6,'>OMW7 Z5)48=?=^
MZBC/?)C:3CME0GYKWN?Y:D/'&:+<=?;F? _71D#Z(>-A9T[.O$/UR-3"S M[
M;[JV-C%&N_,0<.97)#]J*,R/J=T,R&U023BG5O:EN>W0%#/KSQ;G=)QGLPKT
M*LD[W+;B%K;*4I# NJ.B8.%-0N7CNZ=RSR'U$?JH@8\)M8&-736,IZ]3"TRW
M35TJ"9\+Y7/ZG85T155TQ6Y K##BB[&-Z"UU$2KV%RI#?=#+7_F.$J ?B!G'
M&^!?%X#VH?+!^9MC]]IU;Z=J>8$\ZQK <4+RIWZ1&YUZ,3[^3GZ373=D=&'E
M,+W-P+_)8@UDR'];.]'YL3&:$%L36?UVSP[WB[^-MK."A+$<*POHU3?Z$318
M>PWT[K)YRZ5$.U3_YSU.H&8STBN:1[OW7;8MRYI,L?#=0\<#-G3@/G+D,US8
MF"<E ID9*<CU+Q?,&,]T,-PG,]C1[_AG&)4O5BC0W<X^@[JJ8-&=POM3+"][
M"Y,H>0&7$CW D,">0#ED(&_@4-.?<P!NB(K*POU*0N9V3ZPP3F0M)M!X7-]*
M1Y6LNMA-5BR7X[4=2Z1F]_$Y7UY)R:W!"<>5P>[X>A=F:3+>RZ62]S(1[! /
MG#5$'^,=LR>) S-MU;%=MCZI>PU[/VRFQ!&H[]#5=_^JF#D;<C-UIQYCC4,9
MM<B3M9]GJ]\NY$N<W^^UR#M06;V>MUL#F-R@Y*Y\KY\EX/C(AJK M?LX4A"3
MU 7C:+H_A=UN-SRY -!!3,CIG(SXV72V4Y_G91I>>D+[ ; ++H0!) 4'[!>]
M/X@>7\^'PTO>/Y;)K:N-[Q$J^9UO_YHGQ5J=)T-#X+.%1+H55:1K]_Y&9F3S
MY']:7+"$%T7;T7A],?7#?H/>,J6QJ5D"FR'F59^'N+VM&JVA-._D92T <AT4
M!UK,@C'*J><]G^<( +7>9@V*9/4WWLNA$F_K$2NU]AB[2QAN7G^LER60EL4_
M%BT%TLN#QX%>0:>9NA"L\ 8+9Y2PH;REO(B@+^>7-\M!;6J#UQ1,\[@INYBW
M!P+"=:1K7B2G,O,+?L^,%*#Z#Z0^P4/P208!KB",?XS%+._38/T[8%/G\C'M
MCFXNA'1'D8X'G>VN/E_BA+1XCN$:A+ +@/,^'407XYJS> $ ;@UOR1:W0QU'
M7(E##%=.R-9:GSD5:"Y\=?\J>.!3$O[426Y-H,B\5JN*U%OKCZ@$4LH+I[!0
M]<9Q2<J1B=9>BMJ:#*706 G=_JY)@/,!H@N(UA:-,D5$53HC:'PB'/RHJVG>
MO/]3Q$W]I?;Z->:,^]:3+7+'O'?N,%;*ZN;[,P]FAJUO[3(>G.XP8=([02QR
MM,LN2IVF72<=<QF9I8J\4U8AUG="Z"(2%%>.[S;]*%IEHNCMC:Y-_JVCS'CO
M7Z[C,H:CW)@=0;1R_ 4^219U9L*\&A^'Y+J2@IH!WM9JVK*)3_;!7\'T%X#%
M['D0YG:.7"!U93DZXS.EL6T*0UV]54*8]6(G)=G>1^E97]=K$]_X]2<'/;EO
M#(VF"2XN3$)/LK"I&/_EU:%PB%F):M%FX<\!WX&/-^O$Q/C:GD5U#0UZ3#<=
MY$C+NB7'BND9*2HS&-K]SYEJ]!?$GI#50(=FK,C&N!RWTSM9JU2'3<S]M,ZO
M]F![>]68QN\P-OP&+Z_M_9'Q#)CR.P1UX#T'&),<L\TRC%9=HDX#I58FA[DS
M^]E+I3<#)I:VE3?NT-7T0YE!]_^SMH'/)/Q$.(,BZDX[:6]..<SSC<M)9FZ<
M?YQXE.)GT#?C2B?S]("!L]8ZIW2*3+K#13,];R=Z7?**5V#),%B6V+; 5HF(
MN0!0[O%B6*-BG%4;'HG-DU\_^3Q9$MM,[=IVTQWI(+^]43"HX^XJE->C;D%J
MFJ[V_^G*C?\=EU$RWAQCN69Q:PIK+M\#MBR (0]*]CL".>/:9(5.X2&<K-9*
M>$T_VJV ('A&B0A/0TV*[]<>H6B+J;I$3?62?GD%^\%SMO%<N]Z(PB+TU2#"
MC[R .H,+@&K5&SA.:^9@^\Q()G>R+W]!R?E:?^*CX=TMZ"7+@9S-84=9R*/X
MN$3)3O^D65A^2=KHJJ'%RWRE+W,I9W^#C</!Q7\KEM;0AH)V3#:Q;BS8_;)+
MLFQ06E%M.3#*36O;_DJSXD=F,11Y'!5#T986EN5H)9+KX4;GL\O%[,A:2LQE
M6V0C U_QB6MG(@I,E!QK:-K(K[;M><E=V@#L )K)IAN%;K,;IDI4J=+<KRXW
M+YO[[%KRL[$N97E9)<W7O"%1ID^</E']>, OM7DAY!W^Z5A83EZ6ZA+.J"TC
M;+63-D6^46M11N8.]!J1:0ZO@;GVP37D177;O,6E4Z-?HBX#@R#ZZ2;DR/MT
M#8J75:,[G&;.C]_3==QZKPV"C1W#59DC3UY,M4&[46W:)W$99O0S_W*I2O=/
MK4&PM+_B?_.BD,_"+B7NN0.0',_J[7EE-2-_61WD;I/3)5;OFPW,,-!+CO'+
M^+)(HZ%OO;+SZ9V.D;TZQA^5^C'PVD9? ,G']:5I!P[DSL2)K:W$[=WW@U:T
M\^TY+R$B20XTC@W[T[<8SWL%\;%B_FDOHZO(I%^J565@9"TSKJL8<E;BG,&+
M;4'9-R#2ML&8V[E\.OB77;_R-@HHGCP L(<&B*,1)Y*C;XJ7FC!%NU"O9JD3
MNZ)0KKBI6<B@7\ (A66C\VA.F&7N-SVZ X57&-XX.1U48<ST&J+ .;%VR4TD
M.SVC^;*F0G#.*)'9!V%HX RZ[BS%-\?QF/(YT=\=G!7(@7X=LB3]S.]1G,U/
MD0<:Q759P'PR7DQQY+Z^D4?HQ %(^CN6%D.U]$+TH^>32UW[7)-0<P-_1#!1
MKLQ0# LR:?T*%.E5!QW=]#F%CYCRXQAG86]PP%05>>=6J3XN,\+MX\!MJ\5X
MCTFT\QC^.NX5Q!#-EE#$P0<SKM"LJON-,RT]FEUH("-,,)[:K<8T_7#];6'6
MY7$]8&/MR5;@=V0JMN_$&DT1?4N5Y<FPZTQ.YV?(5^#I ^T+P(+,:=&JXHO^
M$<G=%2.T%IXA2SEC6AIOL?1B^W%&C$+LIH3+_B\5W:P9#Z.L2>("^!J<>TXD
M-]^$C>Q7@.S30-C]I:Z))F,DR&K.DM<CRR>E=U/\H/A(E)+L=_("K+?6##:Y
MO<QPXZ.%R"+4[W$#+=Y7^=V+:_7LS@PX&"D&MKE!;E\ ?HQ> /B-$/C7<5B7
M_>"%(UGHJL#I!2 :V7P!0/<@;B$V:-TN $&_+P 8@_6,1V@%./K4/(#;+,@%
M/B$9WYDH%.),0Z.?8-(@8#9;^<G-&9BC%S@/I,B,^>(YTQ-Y9'PTU>+V4Y]V
ML%%J2:L32HEW&-Z3!%)M@5U>V-/-MO&X,)0^),^SL_K]X:V*8LMZ"#@)2DND
MP8XN)W>E+KG1@)UZ66W,5=(Y58X<C3_J'4N>T^-8B -^R.88*0L$AGV\?FNZ
M*Q%F4^&RZ<;F/]2/9;8V1TM?4N65L]+]REGAESZ:+R-O&#X"^7OM[QW[?\<D
M)..)N1^3E6"H-NEB9Q6ON'4-3HO]A)-N<?<D5"_VA"44/EWVK)RKNO_V';4]
MT:0*2@/S:AQ*DRG.'__&ZU,N,QJC[,BV\ &O[K&L<55JK!BH->%R ? (<+R[
MR\^Y1^'IUG -10%G'/%0KZ:07I](31O4D'I?9*[WO/\?F=Y_4AWQ0[(,!87$
MGS+I[V]+@9T^/,2AP@HE6[?F1<-;'Q:5_'3DZ39F0'D]7B\M^B:%>I*XJWL!
MT*(S*VM)9!(RF@V6^9FO^7R3N2XAJMP^3T>G34"+Y04K14RSG9T,.8<BXSUK
MAW]>D MDQ8,O (F5*#?<C?^7/?"8J*%*LJ<3P@4@!\EXYHR!$I\C8Q [4@$7
M@*QYA"[BU?Z9))#L C!S2DPU-\J)(+)(.^#?G&[Q93:,UN"QV"C<73SU>!,7
M>'X*_P9] 0A]8[HYO?_4?UO5!^B^P.8Z*IIRJ7NZN\//WV@&2H676H)10N1_
M5\"N]KB!PHIWF\LS)CR_W-=5%_.-?+OZ5XJ0-$\:W@:+N #<<^Y<.&%MN@ ,
M[X-+@+_B\.GA;4,X<B6"<U6#:;#+[&H.S\I.7#?H/ZKMX*[CY!?,'!'EN6WU
MZ?41Q2XH]''86>[;B-I0"AZTS%T$1Q,WM.<I!D0(%4$<.1OE;]:!.F'3J4^&
MWP?0/V\:)[U@O;3$MIF#A7"1]4'6]9J&Z+R1>#'U>V%O'SP0_%FIX%-8?T<O
M5=#/G*#W.U $2]_A%SRYD2&)WBOS:[L[W680[$O+&3#^SB\>Q+)=B$8N\[8.
M,4&X)E"C$)-,"P?O_B9;2]<)$X#T;"*70#/'ED; X06 '$?X*0F*2$EMNHPQ
MP(&W6=Y<7M=HK+$>&7*]9A0S25A[JA_\3LV&,(N\]YRM;"VJ3I;+[,M!C_$Y
MLD-!&KT05+P(:P_D',&#R/=T^3U?3.ZFJ)#Q\'L!OGHQ-#%AJL,A[LZ20^&2
M!-'VV[\1J3S3%BO>?#'1N];13Z0Y%\^1W4"T/O2,MXGR E":C3@7:+J+]<:4
MM\.N0^XM[S*U5;]SW%]^5AVV?, DR./>M6;+Q<[<T._*%O35LYM+*8.M9TO&
M<#4Y#60MJ17-0?:[\O5(I2BKC[?FV/B)9/)$L1M#2WE,#G.;O9P-XT0A)8-8
M?*^*(OLVVNAY::KQ>-%.)O6AA69\GK:Z4#\ 5=L#'Z'%\HEV_#EM>UTB@$(3
MG9VKA&[*I5=2@-L:6U"F$HW#+P I2J^OV3U.OQ%\^6OMTIEM9L9RC///Z<ES
M>/L"G9S@8B,"'>^3KOJ[^F863I,H"$FD)%NW&B,[8Y$3Q5QO;9(6BZ,A/4;V
M@[=!O_:7:Z=&2SJEMT /P7'S%(3T0$'\J^H \%-T1DZ!V="7V!^^=\VR5Q)2
M3'@];]W2TM:"*IDO1#8PH<!!30_#9DQ^C<D)+K/J\E8GVTZBR(-X='^T40=+
M<7&'#(#',X]TQV NPF?O0>Z%Z1BM=M@U+,?R-3GUY6],;8>:.4MQ^F-658X,
M;+=^3-K:CS0XG_ 2?I0TR4$D,^1=E5,[6!@^N00(?%#X'4T9^8[BZ8PQF_MG
MWNA%R-(%X(K:!2!ANWGAY ;L J 2N1XC.+:24%%@RK9!N((^_50!97)TS'<P
MK8RMS%5[GC,/>YMZLXR"G.*I(B?:MX@O\*$/U;JIQET@*_:=A<G*04J+I+/'
M8YF-3'G<IY..0+F-"P!KPXNE_8]2%P!:B?H>H?<Q+W2<M]=#NWT_=['XFNR$
MOS:&,I%]ETD_<1LQ,\42T'MC7/'L?H.JVI2]V;V[HU4,2-7Q-^EONF;F>[B/
M>X@@O&BLBBHV88G!4UI@>C>/\QPX;^2<NV68UO&1:8))>W[*G#.1-<J7/*$[
MVU:L=#%D2_# YF0#JZ)P&^\UEEL>TC/<\!14Z?(T+MEB:#_>SUJCG:9ES&@,
M@=80C82A$R!2XPUTWB*N>! (YE0TF^[X5QD 6GX??P% *A?E*@LXN=MU9GFL
M..!$:ISW8V$W*F9ZBD45.+&&(WL4#_O(S\=_R;VAH?J5VLUY(IF$>X[7!%UK
MNH8M;$]07UWH<'+9T7P;.,Q/UZE:,N$R>:3WASEYJ>F.%B9I>3U<3BBHGZF:
M"\ZCU^_5<]@_=3S)RK%"I9^7W]&KV4.3HWH[,VYZ%Z1=.5[DLE_D:M7XJS;F
M=?#RO"+/NRSJPD*R,-UKG+$TCLC4E/. KZ?>'JHNSI<E?@V(?U0;5C'Y$@<
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M>[L"E>.=?+"_8X^3]$DZL:O&-!"%QH[,(B2?5?BLC-HG3]S[H&G>;1OSX*$
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M0M+S>=/]0F;Y#!2):_[(?$V!K_I^Y6$N [7O%:K_G 2%]DAB4@FAI!SD67%
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M]B\/06--+Z(,A((T"J>>?X?SN:Z@_>++ENH)"0MRO+'+Z=JF2Y?E1BHE.=(
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M1^"CT-E*U$8HGKGDT>3B.EX> &B\!^RBW2U%CON*-+/@I#+NF.*EY^*^Z7S
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M<D$[$GW^=2<LP,\U9$_BE"GK": "V1'Y/A6[>(<+XYP>6R$XM_0.M0:4\K(
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M_[#P%FVB_Y06I1>5/RE.M<!FW:Y"TIXQR]H<D_= S<LU[UP),QE=8D'(,>8
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M:D#6V.MEEYB]F.,1*F>AIR@YR]%2>^GTXX8N]X)[[I]O=8B-%>+MEC)362F
M# _^VC>*XFIX>E0=CU.-%#H'H1*GG[N:-8UWR7<#.H1#!:5']X?-=WF"MC43
M"ZY7KRM9#%5G4WGTI_9_5?+9(D:J 3O/[(>;?LBDP4BUJZ+%[DOG%2W*55P5
MOQW#J]B>R]RS%_+@D!N!:A% N1#%E@:-3!J'ISRW-=P$>RP2LKQ)YQ =0!;?
M< J@VU)PXKA93:UNHEJA4+3 ;?_ICO%BD/;Y!LS1Q-Q\[WJI#*N-A/YO+S>V
M;:#/#XMY)_EO X'CYD\/!X4#/FL(5J<NN<5R3LPB/DBMU?*\X;3I BO5(2;A
M4ZDX[Y&6"WC:YR%*\I>P6ET- T6.SL'Y#FF/[']C$SCA27=:E_EM$BT'S9ZQ
MVMGG"#S>VH6'I,?%PW)Z^9#E]16)LC/OZ-5@MY6ZH.&PMK^,NH27@.Q!=>;Q
M5](6Y=VF9?R@L'U%"D!8T9K7<L>G)Q U\[D]L7NT]R._\U_]'3?C']^)DPR7
MBI/2CWUH8' #P/B>KCN?;UH]I?M33I_P+%Z!3)>P.+5:C@%'+\6FSW.(2LY$
M[)0LV41"%02(Q7TP*F7G<%;F(!HWCQQ_#*L<5]2^ZEW\CL^*>?/&%Q_>MMK>
M^F/;#0E(+HBUA6.3BB$TQ7AM4SV<TF.1;%M $S.CKOXP5A@0A(W[@%J.Z!8+
MM>3'\RTKP!GQT8,Y"<899E5Z*_.J7Z_P*;4=;0%I+]7D".AFY/_:$KIRF(/#
M11_ IO3(S&YX.^1%6#L$!]^E "ID,G"SI_-&Z60UXB%<J'][&"&',$8H/TNN
M\A;R\EA%S CC'B4N3WBW\&,F1DQ]V[M!E55&M#9&(R&:66Y+7OR[UFVTM.\O
M$[>QVJW@2#)]4X"+71OG:@Z?RR%;UVI4W+N#WO<YT NHW4'6<6VF>TZIGM;R
M]UZL+_$@0Q15?8=JSBX52O"Y6/%\C=$_XQ:[U# 'Q+G@"]'2("M\ %K0<)-_
MVO.3FO^1WWF$]3S2::.4]^Z1&LS(P@0_B 9.@99IPSU12"2&K1!G/-%8C4AU
M[\\I%&:1.(</0'%A%M ^4>1K^"(>GP[.I&G+G"O36W)QML,/^B/"]3:@.1=H
M(/5>?_<$7[R)OYB_@<.!6205I*K2UU9,G)@>?M'@2?JR=YGGRCV#>'>]%HVQ
M3+YI99/2WF^\JH-L01""#-%O'&8O%B$]32H2R2^@H7=YT0K"G]0!6&HS=5H.
MX"JAO5);U:<F_QA,%@'^0%96^9YFXDD!,)OV.?';$%N<[<<Z>V9=O$#'(ZBM
M;^Z&$97?$L9?F&,;J4KZ4^I_/7S\_Z7E'%>>H\!3E,.?V?[-V%(621[$9!9(
MO^UFX229K8*&OAI)/-6:,L<HZ1Y7BVAN[;8<'5058/G'-@UATYS)I37B @GZ
M)(GA30/A GR '0[.=/_#NPLN0LLGZH<DX>G$OU/SK(/\\;J;K<O7F_XF.)_]
M_]-BCW.#5$2[X1DD>D!>W V99,]4.S+0[3EB=4L_^'N*?"?H#XS>+=MP1CKK
MMDE!V979!?S63Z*3Z5M<HLZ>JH:[:B_^Q&AB;;+:;.[QXEY=8]KZ)PJ@ZI<&
M22N@=B=Q*>M=L9/\T<>#F<Z:3Y_!44-K?+,7(82M%BBB&F:'I-J[=C"F4G,V
M0[!%)$"HY?  1%@4"&*3AP[%W]O.0B]9#QKN9VW^TV@&MNW]CS7G_,=2Z9[
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MWT'Y8"6,:["\2,<17[5)K25;7<;O6U#T.MED)7!PX:*ZG/#9M:+R'P;G#-0
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M1&1/>?=5H0Z.% !&'Q@I,<\V1A19*E9X_HX5;6ZN[ Z+M8WQ[,&@_# ]9+H
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M.CQBPX45J[YK17#V75[4[NHCBGQWL 0UCH_UTP<+YKDI#-2W]?8_#^7VUT.
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MWSH%\!Y9"8^$RFVK[/R8AD5\_T0_:&J@P)ZO^X#H;EW[J/MI[_ FXGW3Q>Q
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MM4S5@3(Y\ .'P>-_.VWD_^Y *8,6,DU CH2^G)F"17>YQUJNA_89SV&Z52=
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MDN0X2GI;,*1.U\U%7!$A/VXBN;A>>)4Q9'1#:?I MG4X_%HAITN&CCJ'Z:^
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MYQ@R-%P.4O%9Y"^2J%?<RM*>7)&LX?/:YKW>(I_JM#!?-0(#(J(#GH<FCN#
MB<CK@[!%/MRMXISC>2<B_<P8TG<V%7_7>J*KW3/-;G315F!X)&7'4B6.)OT0
MV"^_IH%S)$&L27BA?\M6RL_T; N+V0?D;_X4JWRVPEO+[_.;&#X]+JDP(E<C
M 2X6;F-P&.8<XJ9[EI-8=:H&TN[+G3,RI;>]S@E?V@7+013^O@:D IJ;";!%
M%#OMAS8B [X=3D\%3,+*E ?$>N\3%<C?W6DWPHSY88T+)[&+42Z!&%T"YTDW
MX54PAXF!@"78"]=]Y9I)_ Y1J]T7HZ@XH!W.RS_/CCI<LDBR=%5JL=#<LLTD
MH"6]@)P;?HL.; ^RYZ9LNNSYEMPP6TT3I^\IE:HT\9NN?8 R.J/V+E91 26%
MI#8HUH6WZN>[G/E7?OO%53&?6;T]E<@3&/6;O<%OSU X%3]Z515W:%B-_[&V
M-"W[\V;R\((>?EZOM-IZW]JZNTR=]Z1"&L":C^ =I0+<$"$6(HN_:G#+10FG
MTL=\_12D#X5VV]BE/"Q(4^0<F+/41<H?F]LUM;]K4H9;?/?B?SIM+&F>9_[@
M1Q?V.;8H^/7MVQ*_"+"_ ]X)Q9A=EFD7>KDXEB:OJ)NW74QE.I2$O!@?H[WJ
M;<.:ECR-2G&1#9HOK9VUILZ1A0DPW/@B%="F8%8OB>Y3,/UMMT^?X[55,QV]
MV@4!T2%Z.@)W)7!<:--F!"\$@/N A*.9G"O=3&Y7WTG^4F%O1=<:KTT#ZJ]S
MJDDGDD0FRK IG*]>+.AO0;7NJG^%VB.'WU?H@ESU+C^+PSS;JRXQ.A2[9!A^
M,R!K)^J#C6./B$/@;IO4%-_B49/E)A^(9Y,*F!A7&*P<6\=+1!P5I+%_S7Y^
M][ 0>9FPN*#/X\^&:0\TC2A:QK95U'MO*- 7#UVV<C=E^V /DEFX*,/SN%\=
MHD8%T--H8_QFXSS^ IP*T(@\#EJ,>P<)P$4ZD3@7E8+Z#$<=%?;,B^HD7W@5
MA 5H735=!IP.V+JK*,^O;$\O,?'-Q#,U)FZ$$>0>]V[06K[.?T-F8T6FY^><
MC!W_:[1 3E!H[#'"&AL>0P+AZ#1U35L"VS*J<\NF\5'B7]29[^5WJ&T%(+KG
M(\&E\%;4>PI3+4Z%"L!K%.9:B*7ZIACW)NBXIME/VLAU\JPZNS[/2!M7(HJ2
M'$>@%R"V@[<R:WT&?22^;OGH6%%V'EO_VA4B=EKZJ[:^$9/#8C][Z$:8)/BF
M@.RN9T4NW.M%<,(Z$46P\;3YDU.(W@VR-,Z4%'G200[H^\>NEGY$9C>%AQ0G
M(5#_,/(ZXO7>/UHY#DLQ-0F@P@Z^OJ "G@GD7/_*??P0 -(FX0D_T!(#'*0'
MXXA=ZQ2-N@0Y$[$CIR+CIX$  "<^>>L8TZGL@QU_HNH4K*8?X5J"&>CE.<L9
M1^P^-5 2+-$.E8/V3%$RT3UDE^8RM3R+#;:JUB]N,FW"AM(]F(#S1@F/5V._
M'A[W\F<_K,28:@02/G87*]:\\O=H28?NMJC>^U/%)\Y[-ZLN^F+N;OYS'M:R
M,W'M*,V5#[>N)HAS*'N)FSS[$W);'8+ FN(MQ][0T#7I KT5*Z%XTXY=/3>G
M4*+K6EJ^5T[>T_N*70-Z$M-0!<C]7P0_+-&P/L#88^>EB\OUHQ<I)MQG6-7[
M,0='G(J3'9=,I'\4"O+*_-#M#A3:W[$W6XDWJ+Y6=NKWDF.Q3*3$NC[_WZ21
MQ(Y'"&I/FR1/!=B$'J<0') K! DJ0!C1 CY< WU#",E0^(/UU>AQ*+7J?[ZS
M6HVS^[<O-TAHQ \JP YXS$!(I?QNHHFH 3+NR5A=\^6:ET'DZIHG6)/2L>]>
MC3,R(R)<)P?R/L/TQY"Y I1=J>05?T4P1F@-^<_YHV9'_XLY0O]'3Z1MFN%-
MA'498SO([S0I<5]0CVH1_?,$<052$I@9-L$!6SMVR0IO?_%_D??>44UUV]IX
M$!0! :5()PHH2!&17B,J(B(@"H0B1$1$0$!$>D@4!*1&0$!J!*27B#2ID=ZD
M([V&WA-*""0D7SCO.7?<<\X[[E?N/?=WQ_C]L<8:8Q/=>Z^]UIS/L]:<S[28
M4=<E,\Q1!\7"G (H]G<YNER.RG%<V"*((DA13H[D%@;T;N)875I1PN:KDQR&
M#_XW!>/^N:%Z* ""&)(4R\I,M0_\U!M+[)Y @RB F73XMI$:U4,\<:4 ,N8+
MKY!NVE%Y6KTB>CYH#8F7,3A.K"G;\Y3?1I#8?<EWG2LI !L."N!0SQ$"=GML
M#%/PD2/3_57PS^&_H4C8<#.H5)L4)WT6/HXFQS1#'-T@[.3>?DDT-_1FVVN:
M=_!S=$_(Z;6/*PBH@3UM9 29=T^*W(7>!LNA#Q= Y% 'HF(BH0?O&)&$&4J^
MT69J)SKB_1*4P(FWDRL!SDEKSJ"#=_X(#*LI^5LA[@-V? X%$)W =12 H0!Z
M4VL\:L/^\4H=FHG$?0A4A1"^,XJE5]W_2R!&72H6N!Z0[6BN$96_"A.NC)O"
M#_%E.#HY%%_?NC'N&?=RK\4C]""H5K<17HI&0&5=[!S/9[MXVMBSW>(L[/KJ
M>^("X*J1A. I#3Q<T#&&G;<_U,@R,O1Z-A>QV6W-A8N0K4L0GC&M:\^8FC0S
M;1+R'^L^_^R&"H]("X==/GMRZOM$@F)SZN4:7'R(/+,S*;>Z]E/'+&P5SZC^
M%L":Z7> S6[M@S["2F5]'\IW$:F>J:P0?4UOQ7UF[^$U[[UF*)QX%PHJ)?CB
MA%[(+3?Q.NU*^-*):YA6G#?17.?1H?WV1.)7YX3U0Z/YVIT2CN0OV5R;J19:
M'. :;^O_S+D3:]SQL4]%OSFL:[M9T,/28>A;>P\V8HO4"VZ&?(M$NN20!^N8
M+:*_WL)7]O$1)IUL)1"O8"X$9E@0;!1&\X,00E0FE#=T*,21^T4&GT2<TN5^
MK"HFT'YCAO6AQ';2S'Z3#ID=JH^=#BO$R*9<W7@>??:5[0?_[U_4PX2OT9<[
M]J=M/72U2#9^DY,$<LV?0XQUXA_AD,W2']#83X1G(U/CG?8<;.9=KO,=D0G\
MSGSWHB+=DI<B]_; _E"G=-)M;'/P!S40_'QFIE6+2) 78K% )9^V_E';A0"+
M,LS3:[U-C:.#&B7"/3)FIZ37?JBZF14:#QAL;DR0FBB ( %"+05P@P]"XJ9:
MM^;?G: 1$*9V:%JA]7Y)>_T.JG=N8GT2DKD+CC^*"-HD4Y<T_?)#G(&Z0P?'
M\%&U-/DN:;/X+SI)MY'6/X:@B@[9RI!2_4T0#0O(?+B"^A=70EK&(\6PT@_3
MA#@EVU<:[]\A.^H.TTO-]#G?P+WK06P_0BV,0G?]CYRA4A0 R_@@>MF7BM7J
M'>&XCL@Y,D-M@:1W0 O^.FC_V3=WX&<W4O[FF#@%\/T;LI. WE$>_E"C2P%H
M,E$ QT4UA* GW:AX:@%GGD,$A>[:&[B*O,[>?F2F",$:L'[H/0@2L&GT9$2[
MPP942F"G^%F[T;>7<[SU.7?AW@.LU"=1'0S;\S^2A#E.P'Y2 !PS'\6U,R;.
MV+WQ' $:)&CFRFV-L&,"%R9<'\-M1AH,NM0J,OT1Z;FBVZC^>^*@8NP4W)N*
M"\_= I454HT8#7SQ"8&]86T&0;<L*&@15V,IWL)W\=7<*0.I$YLM^K*1"7.9
MWHH;S7EZ7\F=5LIQ4[.%"W$2CGX=K\R>504*P#F>TX\D[OL0P&1&:UQT__2-
M?AB?Z6/)^'WVJQFY>< ]0S$-(Z?-7YYS.>=RR1<AFC<%=VT$H@[.7R[-J_R=
MLW7%$FT"S24"IQZ/POJG +Y@L:V<#Y^#)3X]LW7]25Y1\UQI-3^*176X$$2#
MWR[B[#:8[?(_7>YL+(^QZA@YT*WBMH$4/9,$K26@?B<N-X/\^$?@[PFR9$;5
M+]Q0R,R&BW7S[_ A6_3:IW?4H6I;(BT6'MMPT@VAH1K'M!+;[(J*V@@_NI?+
M2]3/(KI@%46%>*>P/?B*^FIF,_;K*RK)SETK'*%]%60-&]1G^%,(![Q!D7CS
M193L>K!1D)_&K62_^:D G%<O3![[&^V:>,6S E, -UA 8XMG]\R9S!X]I #:
M+W6CF8#9@X9:?O:D_G^O>?$:?OZ9:1TGH7W27VBY(C A$B!X:]MQFUWSX=AB
M,@>;WJ\G--.+G(?CN*';83-(Q.B(F,K)PWE<>\4K^D4MV ,O%H7X5D&!VP\W
MQR)^&!M&Z\1Z<6Y[=Y?9H];<#@T:>MRD6@9W(._-B+)4XS,$['KW_V4MH\?[
M37J<)%TL!= T=OO6FZJ@!/<78>'S[>QBP,(W<H]HL:(G=>B>#&] UG]CEM5<
ML%P_$PNK#Y)*/TLM*'=?#KS]D)6XP8N6HQ(:R+MA"#U,Q@'\X$9C8R+INP,O
MM$/#6'(\,W@D@_W=47]0!=P&/79$!DQ,>,&;KO7 9SI7:N;FF0=,?[TZ\X'A
MX.-;16FKZ\IM+OJE?F7R8JE^RK[*9<)[#J$[S*SX5((N1D!=V@DF1'@M!DF?
M=I 9T^D5M/F<S\+J.BR<([\(X46[((/A+'*5Z=C)70T%'*VS:6'I"D-9N/^=
M%5%:^\<!#<ZBD6^#4.J/DE.B51]C8L<UDO_A7 L\#O\^O6&= >OST>LJ[6U-
M)WSOE';+]$Z*Q?1T2M[>[NQ5=%?WNH ,^7OI026O'X,E,H67Q"P%%ZCV XV]
M2IVNIQ&AT"?XW*L_W%G7VS8%-&5N%&M?/.WK;*^\-U(7N_^GA62(YXL+27?L
M=6>T?R*QCQ#O;=&S0$*$#?U]>Y48(0J@!JM, ;0.(O=/^8 O4O]U'R%'31W'
M!\:JSU<[R1,T!EYP[U:]9S."U_*\AJ\E#D^#N.H$QJ"F!'L,D,'*R71/U21$
MQ#J*/X.9?1?D_ML"BVI.DIATFX5'F-\-6TDD1[B+2+).!3V[)&#0N\GY6WN_
M-)FGY]&^VR-M.-&$=)\""*S$K34=UI92%Y@$8IW(7!-P!B3TG:AZ"DX0@'V!
M=4&8P#/(GY/T-^,$$D,MDB:U!R?:%-M ,VH7\)J09& Q?0.$8(X6?!-7%=#5
MMRM-2+)R?IRVW;;]$7_P]4KKJ\(M2%'3*;IS488?HD.-AF\NYU<HP!@=#C-;
M*O*M5A4-%BVM]/?9*O*KS]L<)!ZA" RS1!=&$COV:L*+T(^-&>8Q%824=+ '
M!?!.5A8F3UC#>?Y4A#"1+Q/B&X9=Y0RRIMHY?-&1DILAK24738#F1UI'$3#5
M%T!V\EDO%QU+_4DU@XQ1[6PK^WXE,\2G)!/CAZ\[VM*^*]$+AYM\3GF2.-(=
M%&V?@MZ0F"52$1P5GYZ5=.ZSDDF??)PUPR(2*BOI1%"Y0I+ 933XU)"!./V(
M/ L9W22^$>>GMB)GVV;?T;D-LL0>9A.=H&]Z8?PD?IS@VZK8FE3182F(7H!^
MZ(T!\7O5SZ(&GZ5_&/VF?_TN;9'V(O(G$C !U2.@9T$L%@T#4HMI7&/79,M/
M.NW(' H5D\0:5TY-U5N8B2#Z60EBV:0D_30*P%K"X.C,<"/HVQ8I!?0.M%8X
M3([6@[C!Z[5 \V/NK$0&<_CR\SJ:HVBHY5<O+OP'[/,*%$0[:\5DYU>)I5Y*
MU);_W<%B@5-+CU,#E)7X^[0)THLJR&;M]2[80^K_(?FT]"@3M1!QLW8HR5[N
M/6M-/2-U[OXTU)Z%Y,1/7>W=[6&MJ_8L,!U?SN7YM,KV^$O BQ[5G?!7OL-S
M%1M:.//I.<46JI,CQ!O8.5V:E"I@RGWX).2$Q)-MQ;,] 6W3H:U,7-VCF1Z5
M+_VRCY?28%;2+"AT_7%QT+3YCDW/#:O3];1D C %ZD2THEKP3N@-"N ;=;7U
MGJ_#4>&"&X%MK@%20AC<G)/IPC#?M"#LGP%>$&]")D2,^%Y#!: =IP^473X
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MW/-5/,S#!?R6A-ZOO^F;>%!-)?/^5EZ8J>6B,,P6Z^KY XSN7NIO''GU:\9
MK<=.7WY!A;*WPP#!( ]M!QQG:@26FN3FK)PW=U\,+C1KQ$?9>ZQB7MPZ*1E>
M>U>RDHXE@V=)4!C'1V9\/,5%B,A=/I1^?W&P5%UEH]!J=7$C(W'.AM/S!D<@
M74"%\AS=G)+ ]'H@D6L:UD.^/*AF@)%R&'@T=+E4X8&%?1KI@W&"V4AUH*3.
M#?H. (_:O$TC!> L/2K;.'UF]PB,N1.3;ZDEF)M+IR)\HY#70,;NN9GGB1R%
MXO&RJG<?56RY^]RE>OOULR_U9(!>(,8V08%46P65FF,]L]*WJE@G;CH_$//
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MX'AN*BZ_;6 ,>DH!')S=ZR$RP#=$\N'E=J3H(VERXSGX<LAJ]CH5? D)5E(
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MTTMD]T4D5G_<0''N<L4K8S/KWLP'!@^Z7$_)$$Z1UE8-QL+P?DES2X%OUIQ
MAF'Z0W+MB1;/*\]8?U2BZ</[:T\^Y*8=X%X*!XX:X"UK":R747F./BE%:860
MEO).@:"Y,S*G)F#/C25- ]=E*NH<EQRL'3IEC)TV5U!M1XWT3<I.+*=SXZK0
M:&AG7/=A]_Z&LQ5:JB>=ZI\/A;'8_P&[J/_[5JQFCS'"NKS?LW2^R[ORTFD,
M?HF%:>:5[/C:6$W)C.@&C3?.QFRPM%!7K^)[947 AJ%ZOL+0C7K3LTW)_IUM
M>\NJ&[RRGP1NE]YYG<O=KKG9XXP"!<]E^V?A @C/',6JHN\^F5CN//>)G[LQ
MRG]TKC>5ILO%:ZO5'-R(9.DJ6&.[6U[\_8LIV*UM*3VG;2E@,#*H3@;7VCCN
M<M[4P4H9"QHK8V8H$D"]M$-P*;"\VHBE"S)(4OV4S%++4)1\55"^:-7R*N)7
M0ZW9HXK+!8=;F/B&%""F*!@OH 5-ROD^5-'W;O%&$RS/JV._U<9?@Q4W_<[=
M)1@FA+PS='%[4_@@6FOA<GA,\*T)?F#6:;4 JRXL")_Z [L4E4:H,I.62WL?
M8*CL[=3ZY&A2_1#AVGM4O%6X)^79,.P1T^KF*!]0XW:[/FH037=N$)P9&/%2
M'F*C_A2OM%;EGDN\NQGY: :]OI]'TO<JDVAQDFU\5UG5NB5:7V_Z;I_.68WU
MM0SD!>%1@XJVOYSIF\+S':H22@=C 9(;DY_WGBOQ(^]MHX) Y^1 011 R7Z0
MNX#S^HW4^^EB[(MQ'FSHCK")W:4O/2+@'A"[A@(!.<>"$@A,-W#,JDF2>I,D
M]*M?1LVE];K,;@N]]6!RWLVZZQEZ8U3^9945%:LFQSYUG]@?>A#<#&%3L\9*
MS"H&E";%A1J<FSSHDI@$JHTWA#.F+<4$&TXP?V5IJ8V?04=*PX2@J@/RM3?I
M_+=M1%Y[WSJ]P%\THTH;F5J)4L@2-)K=4(Q8][A9:GM5/]M-RUNQ>7J,2Y>@
M5VAF_W"E9#4^YN95D7-WSVKQ/,V(9M$1GW#M=>ORT0[>ZW1A6S:'%3XW';/Z
M&7_.A=NIX,M;;93\I]QNF4>.=UYD\RAR[-V)X# T._^W&$4OZ8T$"D $3?4A
MWYH@AT(^N42JAVH++H*/4"_97[+XCR [RAK^ _2HAP+XC(H"M5  8PX&P:D7
M_&AO?JNH&_S".*S(%1AN& =XS_CUO-*%F*CPN517MQF##:K=85(U\F,U^Q[4
M:#K27W\I5\-HUMN6L2GVB?+J:YJ52-@+ HX*G@*:(7L$^,="R"B"K!L<A-Z@
M4EJ=S*+*)RN2BO)E95O;RD-"V>5EN[61G?\AV*_S.2H%S4.I/UGGHP#*K.H"
M":S4=X8WH/<600E%]_^@ GVZ1QCXL$WM7\C%?\H H$X3TNSP$!ZKL]=*Q.\I
M[3U@767VK?4&MN1+)::F>-"SW>QC)Z_940#/BPI42]>MS7RSD\'E+RH@+_O6
ML[IU&[X>N?:L68E:%<[P(4N]G#F[[U_M0_: VD)7FZ3=97FEIXK[_]B5^ND1
M_&<Y2><>6V1.UGR[IZ@MQ&&[1_=D>"FN,*L]8W6XG!U>5)8R ]^/#44.@I?C
MY7&*&S3'J@8DDZ$;EL66UR>SZ_9.(H[VZVK#RTV2TR9V7(OWC1":1U'RA8F(
M#V_BG)^%JGZ%Z'W-!Y+\0.*'-HD$)-YO&/2-+/%B(>DEV'8#..WS,8-,9("\
M=#-=/+=0"%O\H6P56_W'@UG9C_UK3ZA=2!Q)Y'O45;[."-J%EAU>ZH)Y4GW<
MO8ONA+19^WOG^%XLW++QO[W-!CJ#Z/X;10#],T6@,D]_[WSI>LLGL1<4/X@*
M"^<0U;^1@[=1.1)9OLE4(&)TYO^6'?X))3CZL^B >_"S"9M_LO4*S?BS35I.
M2$1J!.C='\-KQONGL^&_IA-\1-2SH/)O1N=IP('B-9TV"L#1!;C_&UJ+W6\=
M0S2BSFGECBCL$N//_WI5TIIJ= B\-3(\- UTZAIND#YWH;W)%=1)_M4VW5\G
MC$K_>4F%Y?K84D18C4.N<!XA$[-<XS97:&!6P5(^?)).]T*]L9%QZXHE9+TG
M/06,R?PZ;RLIM5"I@?3L!!:\)7,N&.=_(62#L=6/%6)R]+)U7ODKBU0X%1GQ
MSUR;=UMVK*.2E3<KC661=WOVD[?W-,CHP8+=?#?UC<'SKR*_/[Y[3ANC]QH/
MYX)>R7/$5UU%YA5EYCR6,8[L5HBZ0R,23^L,H*^%@ER]X453::F^$3<W[S!F
M@?\7>^\=U=3W[8M&45%0(TVD1@%!NH+T$A&I"@A(+T%Z$1&1'A(5*0(2 0&E
M1:2)E$COH1.* E*EER"]))002'OYGM^[[]Y[SN^>>W_OO'/.?>.]/];88V2L
MG;'W7G/-^?G,-8N'D*,A@*M'1([ V#+PQIBL_ LV!8LYIBP"E>J/SHW<*]B5
MT#%=!Z"8JB]G\7-FE![SEZC>V]#_9:Y3^+>]^B=SX9_QKN<@UE)HT^6S&LM6
MK\@ \$C,QA%*F9CI7W_<.P=>QTKID# @DJ2WGKU[;U&E5:=%,92C8LJE<(;E
M<$FWE?Z*K/#]:_9&]FNXTKY-V,6:)X]+A8*-5BIA,>(%E[884F(.^]$Q-U 2
M._\(GP4K-/N@&!6BJ/)2W]_&ACWO$CT,V'/B-P62_@B"<6('***(47SB1CM,
M&!<WA% ?6O 7?^'4$W^'!;]9_);88S>^]1/72?;'153%*CZH3XW\HY#CWL<3
M<"4#^/GLRJ0R$3*OTZE'O0@U'(+J7?&0%'0ZO7ENS"9P 3/RK)V2Q['+@1SQ
M [I3.8]WB,CA"6_P0<-K>R;NL=PZ$^J^'&*.1SI]$U;_ZU%EF'4?9.C)@9KR
MLDH?<W=*D)2 DA7+2['V]0MVJ%+#XYRC>.-G3V7,W>E;S_FO2 9VN1G/@?80
MJ>PB3]9HB2<.B<O!1KBN&"O$T@682M!.9ZJZ*CZ_9I&G\>V!2H]4#%OFJX_O
M7Q[?:$,\AMC"9D"5]S@3[N/FVL?%Q8I?5:5__,C1FU%2*UCKP-5TEIFR8"]"
MND[F@\<B.38C?O"[OLHIG_.4:/_C -Q>!.]\[P+7\Q)0"3^*5.V"%@J]? :H
M)RAR+9^>!'F)H)"NXJF9=E*-L3X9LWUDM8%FNE&8.]G<WOP:QO%K);:WB20]
M6?HA[F:*B;.+C_\T)Y7!/EV+X^#1?&&KQI-*<(;OQV\?-PT>F$%BGC^'E4S3
M7W<0^P_[,/ZS!]YH,JEC5@+7_.8%"7G!P-?CJ=OCL$#/NJ!Q!@>1;X5*2X$
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MN]Z8B1^<$X>Y(DGL=IOCJL;>26\EYY.XL']<^<#S_LNA2L.M_6SF'G10-#7
MY2AX XU<?@'G!;L0_0<J-]# ",DJME3D?5L)OZQE]=ZYS7UU#*HW)'Q.H\:P
M219#D']Q>7CIBB7R4P"RH7LI9'QM!HH@>7@$!* %<%N;\K\Z _U/M04GW/$(
M8&=N&'FI.U# 8<G[Z,]U[1#"9;$WCIFZJT&'KZ' 14C,9!4Z-0\C^;M&@RO-
M58!9=]=(A*A]G_>B7O\).0*\S>A5&F=;NH:$OMP%[_$GDQ_Z]D*+G8B<:SW;
M1E?R2-)36L!6R1/8MRS+7JD)R7>DVA:U^OA7F,X8.3!Z'H3\Z7(L4-)/_"5R
MF/YX5?N6:4@UU(ODXCGG18S-_RWN(K%_(!2BTI!T? J5JWYF#?0;>98L_L3"
MPTLH(\[ID]\U&F!P [LSR?80?@GZ! ^(VQ;WY?LB72^0#3H<!&>&-G< )T,U
M<!?3+T<L:,7:-U=%>(_-\UIK5=V-US@:X.-$$!HLS#QE,YD>?6ZD 5"-79FZ
M7<7K>ED,^+T.$.X#U %_ONW.M<B535V;[:_19WN.GYJ#WX5(QX ]2>_XA]JU
M<&H? HY=D><#UH+A_"O)QG?CKBH:OYH368.HV=GV!?M)=O0[IUG(J&05=RPA
M^YO<YM4+<0/Z(^8^7)K/CF/0= T&ENE1.V>V5$-J00USH>[F7='.",[YV3>(
MC=!3:E"Q)0$7FM^6DEWF[3BMT54VX@U3_BFZJ=?\NGM7,GB?<@V<>AXR;F!V
M>^;NP*/A^8;A[6OUY<F:6G(-9[0A#W6N%/GO/B=F)B-@*E>_Q(AI_S]*%?;F
M,(@C"7XQ^F=K)T=X4G_ =VU5Y6@ '_"Q@:0+-(B.<EH74<=D<+<Y:A-#ATSM
M[1 "'3_E#HV721]:4$&#>^-X*KQP C8)VE5WAQ/HZ&D2!;E+9J3?"5Z '.^!
M?HP/0*JCR(@T$"4<3B@:'VP^00,L(8@6U$;,GAQV$3R]1@/8#=Q-)770 *68
M4"UVB_B0?]LI#V>7.(B.UIE?RHSMQ2&U'#0H >.AEEFR9=0A7&DA@">]Q\UX
MO6\/.,(TE/XGS=G 7A*D,AZ&0^\LH:M%LJTX#QB/F.:]"HB!*EJ+US6&+#_9
M'-$ ^@>>1:T9MV?R$:9_<__WJ5WZ'X0W>%)**UEKTLY4QK['-V6\B_^H,@C'
M#AQ9##6.IU$'J?PTP)OP!==\LT #QYY04'5[)/BP7<U_P6US0RN#&+UGZDX<
M-VA.U1\I\7%0S)I\] F8(WH*]J7Y[HNFNY(V!I7H&I7/]1$B[YK,/MRD7( %
MC$_,52"CFVNHG![XAFVD46 %_$M& 56Q%\QTX'?#G@7I--"J/^2['0+_)P )
M40_]=_)>_Q<PQ8)F#=)<'$/ZN"S.7+S@R!P@?2X@:"DN(;SJ5_)+56>&\%>K
MXJCE>(_\L:\&$+]WN)6(V_!3'I=6)R]FGDG-F[K,8F-3RO%<3V0DT5!/-8UN
M!JCU1H>(/3KT6U;[*\I-X_][;427T!*3E(H%9 P;5Q?R=J;OX<.:?53XQCY;
ME_GB7IOR$N.5E*X7*I$ZM[ZO09#^^UQ>AT((0>ZFU>]?8@A&$X?S.V3AM,2-
M^DJEP2VA(P'?SI'PFOJ+U"8UW[710NY;?@GM9Y43C=].4OO!C+!V=G6)L<\@
M]X1 #\(N\, 3_J>0OX 8QJC6I?YF.6E[: \B8EU<9-"O,VB:7ZB3_#=:8OG/
M*8_<DKU\ \GB[=-N)<ON.!@#<EQNPT3W>U<_ANESF7I;H_SZ0FEI?B9U/[X?
MEKM<C]LP[_?<N1==M 8&_J9#K]60L,(K[I^U? Z_RQXOH^&XGU&$@NC;&[8N
MSIF:0()?TC$#1->D4^W]5\G?QEH<+?[_2(D-.BW'^)]_;\!M<#[&&)N@86YR
M4X/QJT"S%-S3Z"4GY!396R+E68](A)PHMX$R-E%P0/@,>-9^8KU6O99ROUB:
M.TA<FQBQT/"3$5(>3P,\J+<KOT?1V.P-*6+H%GSOU8]QP,86>.=6JZ^\J<U"
MG<>&E=05&NEA^G+LO0K"+&R02'#YSI:W+RZ8K1TFJ%<%/*=WS3T7(2D7SK;'
MSKBC;70]E%5WZ3U<0Q6$;09"[PPE&>.6RSR*K;Z?ZO&ZZEBWN3%J5 'PVMO
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MG_"P0!D:X)1FJ5I/&\(/XKL68E<:6V!C:=E2/9:R*A@CQ"L6LS?P$GP1OL"
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M=.,598@PJVH8E5.[(ZOAY,K.PIW!&> 4P:7(IZ=6*Q3**'<T1<=APG3Y+%I
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M2[[X%4J0#7P50Z?,\X6@7;4@'FIK!0VP^DM'(JRIY',=LKRI P<ALR/L!M'
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MG,T#+8O;3B]=/;P?G+<NO^;GH[SO_#@!X[0.O/KZ @P,&T,ROQ@(I^OA*AH
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MUP?_YUKJ/%_N32=H3>A'(Q\N-YNJNW](ON,[K!N=GJZ00> P) (,E8@ 82*
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M!=[PS+V7<\TT;Q\1N#_Y=->9SK#.NK\-/BG3 0!H!/D-7(.VAK6@#RKE#Y9
MK4Y22Z!W+Y 36=XB7P;DYN>MU!NICNX9"C'SV<V$ WH1?HF)5E%_[,J]=K91
MCE[-]!];/_[7WU1=73G*FA*?[3#>+_*.C[W\C94'^DS_2C!F$D47Q($1\46\
ME=3X-3L->]OA1@0HW\1[Q9Z@V.]["754,22H]2J>S.*L,1%\'2XL0WXAH1DN
MV*B[0RS1P";5$D[M)3DCX_9%DCD,MC-%5K+60'WVZV>J,UW:IL54;;V'L,*V
M$1,'BY%%+Q_);=EQ86#\/KP2^D%$V$FT2=MM1)6I!RM9*A=NK!-DRPWGMCN7
M#*0<,!BI;G1BUJSY7AGQO+HVYD6DY"8C%47=0,")0WF-Z@-_B2*L]-VPORZ<
M_6\5#-?!=)*06H>HUS&?R\(&8O?]"$K ,C\7R94%D='U[Y/[N/%;K^,+5'8-
M8WW./7""7S]HF66>9*S=+YE1I+<#3\]0+C[]D7Y2*3ZF(L9\) -*]C4./99I
M4BXUGWY<JE3[\KEXA5P%#E00R.IRU>N[*I4ZO?38[6^[@)],/FG3;FG#L4T=
M2;K*OMW/_S+TE@$5A7@0CZK[Z9U-/RDB6N:Q4W0[?FUTGOZYS=L5DN$P'?%.
MK_&T95KZ+4ZZD=6QDP&C?I51&P&8[S<+GNM%? !F-P#/)U*%"[L^9JBI47R#
M],8QP!#P#P&6N3Z1W>:H9Y,SRL=L'^GF+&=99I[FFS)*WUA*YE5Y^ZC;%:QO
M3%N(<\.XE#C<F'@ NBXO[._O*=!.4M-2X\23T--!\D1GM8K^(<!-K7RY6"^I
MY?:+W);KN9$"E (.Z98I=85S)@X/4LY#8MI8UFL:(EY&&BH8)K^_ZL]V!N\"
M(K4N4 DG?Z-CE+FF>?NS@^9$U>9+M!;OJH3>JRHPL_SL$MQJ$%CA5T6\_%'D
M'/>YB>\"[NYB'B$R\K/W)XU1K&KRG9IFF#<K7P0INLB&I&6& F(%-_',RJ,X
MJ0)S^W3#F):,0K/"5)*"4@U&7='<XG> DC%=?G4P PD31_PRG),(>/FGANRP
M67GR-Y]$W8G2KZ//?6Y9BOC8&!DY==2E,:RN>MTN#;B$3Y47Q,IHEO4BRI1,
MFITLK4V)@)K7D0];= ,;O9Y\)@),W#./.02GON5E6S35_9:Q"7)T8%H! T&O
M(.2$X=3TOU',UUV: C(V[^SU.UFL;^G-UG6<88-9NOW09@(V?,P>#Y*2TY:)
M   1\$J4/&BP(046B&A6-6M.U8^XE>9IBH@WU(U@O[B7?'8]+/$?Y2:PK@.H
MCK95@4^GH:(159CLZ2BH) 29-BZK&4NVCJ>A(5,0O,!_#K#I;DM\.0_2.$J>
MLG2S)#?F7I.[0Z7%PU&>_*?1Q;=>7+)X.Z4X/J[9)\E8S*+)1V/"^6? 3S!@
M!"3*S*5CGK;3[XEL;?;PUG[4'</E@+EWJ!_MW/[!>R/-AR#,G;@VC[&!83A*
MO+4)/I5^#A0DQ;C=6GQ/0/OL&!,!+X:FW3O!53&3404HD9R\19'RE!+ R->4
MQRVZ2;5XU!W0!)6- JWZ>6RR.BSK4.%REF1??7Q?@ S&' '^V'!]1)XWU]QN
MPI2:ZR,#SZ]K4D]W->3\*Q2301W:EZ<"GB$5JQ!.>H[A$GBCN=D!WCR!OF+7
MOA0C &J.;>MNN6/CW$+?A*(1$H9C@"+J@G&Z>3L3?HN1!4TC![=:0O@::^]7
M=2#&[MU8^J0>O10<N]Q2E!M9I*Z'^9S'Q!&7W2(>U&%U#;.R4A+'M-, "W>2
M)$?$WHC2^O'^]B5F.RYY(?<XOV/@>_@5#^ T$=!ZA'%IG_2+68N>C L8<7!3
MY6F<IGM*0G?M/LM>=M-DKJY29OJ:R\.U2._OO3D:X0O\NB\CQDJXHT-)/Y#M
M"VY @$$_+VQ2WM-78<:>V8JU(:U.;E/J\M5!]PXM&-NYM0%-H"\L=[. 51U$
M2<HD/'Q8%W9A#1E0LFK'/.%9GV#+9\&K#FP?<EW'7K.L./L?S48;#Q/HD,XA
M2\(T',#V!LVO45\?JYF;2W^T3QR/E:W8U^9KENM<$!IIHD0T*X$G15K:\^U1
MK.7.\G6)_8\6'2YWPYX[]E:#9LV7NB,DRT!/1YM>H;,>$Y;E-.P@E0?&OY*G
M!$3,KE]3N\+S?L#<4T!PN]?BTR$?YA3+AU%%1XY[E"EUI,?6O'J0<:658LN]
MG:VRRIFWJ0?*QUW!9+-$NUN/ $_W.3EK4SNP=>XX[% ,X4LD]$@.H_9F*WFZ
MS]LS-[YL674J:\O7^[KD6%3 )6LHCA:CH)<"Z%#MVA]F.QO$P&I.T*H%E3VF
M#AFN3Y7\@S0R^O%[Z<<" OKV\]3YQ[:],V <@S9"$1J0RK#HDZ$?X3<S#WY<
M43?632&U.KZ;/KF[LB1LCE#8:/\L\?0XCMJ2Y(Z"W*E;:61KBLXN2]6'O'6G
MZ2X:5::M:L.&1/]*@]NUJA$!)/B$@%M8N9WT[!+$@*IY\X\QX<[JDF)MJG#&
M>V^^/?VTP5TO*=H]-*W1!JXV*L@'_\VY%(S>]K&V%+AP+L;/M?90BMI7O@K.
MW"T8$G%VW%8TF4V9X91#DJ(MD+#=M0=U?*$UU"].:CQ#; GCZ?R7SY31>]/T
M-GCK0???'K 7N9%ZB8F-;.H"/8(_6Z2"NCC),6<K$BBI<$G-H$&\DTT5W5;=
M=1[SZQ6DM)29N UX(=-!M2ZK=.,75STCVYY_.@>Y0B"/0E9?A]0U606V3#L2
M 3WC)VM,A;5%<W&V--UQN'OX1$7F .XQ!MW?3>)4Z=5.#0I*NEX-Z;=E6?H3
MN+G''RJ>[#+JFLK(R-6:J;T)( )0,+0@4K4[CETJ4A*OWW'#[WU=[&S_J#/7
MT]JO;]\BZX?XFKW@EPB7,!"T+[(9'8R8'5!'#QZB8/F!>B:KGV2>/+L<_Z7K
MNM>@VGJS2&2YKV3?PH>UF .GI^NA<M]>AMI-F.3KQ;&_,TR*OOYHFPR6A0O$
M7L;=0LWOGL9O207];='825UF'/1_LHV"#1M0[,(1I8IT1$#;!:XE@^/X9+W1
MW1FK3AW9JFF93EB514&9E8.3Y6:'=/?"55&O(-M^1?8_-7IQMW_#@H:]/ ^N
M<W%%!:KCC13%B0!YFYCZ<S0L/T <X01L]1.NC?^RE=*@DN;<^**F*EPE:ONM
M;.)<MMKJ1!EC@8S&LDVT@=<C"U#'Q>^U4&!ZOQ9 HYI CB5D7;=^<'6[TF(3
MBFCRY#_1T,A<:XS\F\V6; XEN,"7TJ 4SOOYZ0K&G4:N%3UU']!SN?[42/&@
MEY.E.'Y\$H$5Q]YBJ=1.X% ='[/V%'ZL\B,+-"?<!O0 '%DU*IL7R0@^4/]H
M5$1BXU/7QB8:>\Q>QM#!]JH%5F I,NWDK.]6]S;P$>DG5:Y#ZC?#IBD!.460
M5DE%!K"#DR?U8H0'AO*R4!EL^=ZW8Q*$;>OI&^SD=YP"/B.( R>*)!3DVW'>
M_$#F*>==W?(C+=T\ZG.F=7S^"W-[8!L9!\HJ2]EN6TM]X%,.4[%J_P+EGY:2
M.&FD:(R$"X/]3'?$PJEZ<R1A@3VJT2N\R9G#\-V[^Q9Q.JX++3D75IU4@+K?
M)2!W :9U=/YOUS?[A]<EE.J>*X(A)T#=TDA"T*G4O+2^BS3]'?=[S%4;PDD@
M-S*N(P7.I'A]*F/H.%BXQ'YRLYNGH;Q[J)&?F@BXS&2.#L4X$P%T+4 +97M@
M6HG]QI[7.QJ+=]XJH 6+);\06";H-2BR=PG(K)A8I+EFUU EY+S_]OLS:57%
M=QOVYQ^"]OPA!R:&_2BE<T(SK3A&<AX=OYXM@XQ9?"]O6F3G_>5LPBV)-IJ<
MH5@:_:H5YTC1,H4O4*0$=2AP2)9Q4A.X1D==DO(ROOGR@A:N)BBXJ;J"&<62
M7Y12?)?F.F':L7:EI--4;-:B&,MBG?UR 46]6/X?5A.8BN7VN:Q-@Q';Z&!V
M9=FO2=&G^+YJ_M4+ZM11<7I)TX?O9URP-YA)_DGEG K*QV^@M>G'UCHG;4(A
MMCOZ_ KT&3X8)=6=[MT&OCST+2F&C?$&^H;C801/%QV L'F%[_<5*Q'%JN3O
MQZ?^V2DWH,+;_2\#1K%@S+#GT,T9NP>'SL&J8:<_Y'U'K#\'43!LJC$= W=/
M$3>0WFU9;#,&A_O[GQ8&:2U'W"Z=DG\/8CJT;5TDL0JPQGR)^29N:1X1FU,T
MQ#5X,O^CZ-1+&J>V!PX4" %<>B<-,+XC62R!"(O3-*UEE4U,MATSNYO;Y#[\
M']:H$5SO 3FNIP7HJ88!" -1 ]5$P-,+!"B_&G6:^=:=RUF![!0&QBBC& @W
MPM[O24Y48ZE&Y#J%*+!C8K5B-*17GV-M;Y[ 1&G3K%T-%;)8+6>P"HD5!RN5
M-]M%\O90$F<V'G7:1K!AM)SZW=QFI9__\G^LXAY],[6K,ZFOCZ057S=\O7%8
M7JPR%3TE_#Z3YFN+[5@-^8GYUO[^S:;1^Z_YS@))/(8+]]CK8]0SPVK,K&87
ME==GGR5VCWJ\(3LWP$W&8;0MG&B-8J9[:C_M)GFU'F @,7Y$0*'$MM)T(TWF
MV>^FOPD9+QW^10?:CX3Q!0;";V0+%-:1EJJ=VOLY[FSM#H!O$Z&*HYIL=#>U
MXO]MC5(-DQ2^L\)IN$I+]T)QBSOT3TR-^7#1;C$_6JR$UIZ4X6BAN7')I?LK
M,BXYQR?4.%%ER\7#;<"1T+NO?P+4RA;UM1>!^BJ4[E3:O;2;#V35(L-U*H&-
M]3(%55/,@2#RODP8P['9X"'UXPG!#-.\^KIDI6Z)9ZPW.3_2M3*!))$'[:!H
MV<5V\R^U0^AY_@RQK:/[4X'JP"475TPPV )#N:P2@6+6Q!HENZ<9T,J.:-WY
M2 14*RATDTZT.-*%9)$&3KK/YH7'6#ZPU?\;5YZD&_OO[>0[+EBF\+)?];"N
MT,;8-R\]?V8J35G-]+-(##N3=;":N?[#Q/*;MK_/C9PZH]H3%#U.F(99BV[J
MYZ]46$7>+:-Z_!^'[.W\7/U]R<A)Z->B.'41;MO1$I2GKAA%D(3L3X@5#7-(
M;'E^BLPQ(&&YG/4W?2'K?ZC&*^F> DH.^Z##1T,KE5E*@/-L[# ^VPA4XJDX
M13CQ@W8, <UP,LB"P2+%:1':_3VG7B+ G/\F[9?MP)  \1*'.K/U0L]O8/71
M^;F>D7YN3R$MB*C#R7=IB+VHO7#JNB^F>*XDWKDO&2VZ>X0<(ER/HX38+716
MF8R-O_QT[RPGJIBO8H-O[OU,DPW:$V--!)!#(T U!XCYO*U8=D?:%/N&8O_W
MIW%+<I.3N(GI4&Z"1??ZJ^ \(D 4V/-WN0HY9/#OBEDE*0W"Y07.78<S@I][
MVTJ_L03Z%G]O&^VK@!E)ER=(=]PO%E5F8<RH_6D\>IRA(/! 0^ZIDV'];1Y*
M:+GL>,/=TI__LL3L?S(X9A(/A:PVXR2)@(H,32)@Y-L.>@%.#[)=/!.%4$-V
M7X]"CHME\77EI<8=L0&@MK8+WCX[&_A@T+^Q?J6FYCU5PI#XQZ=C5"FOY0&D
M[A9\I@I,AZ(=0QA^T7<!M[Y9F/@X/FM!)?U>TQS3$G9B?=]U0X7JERRN]9Y/
M*]>J6] ?#%6PZ>W=*GD 6-SR^ABW:'\>:?GCY(Q-.FS'O%B2K3FZN?1!_:DD
M4U^ )"8' 8W*9@VS0I:7W"@JK)_"BE4^QES-#_=58;T)U%%Y=*UI%%V(+R0"
M$.D21 "M):3MXJG(@>BF*N6ZO0O:?-CT/4SF$.KEC?4H37JYUI=24,]3W\"Y
MIQPPCA4A3(.1(U8BX]7:F"<@! >6)&Y6G@C8 ]6XX)>_SK>HVQS8RBC(&H]4
MJXO0C)#UJEF2,"'Y< K&A"((P0*([P>[8VPNH/+'Q'99K;)5/'0/_6G>5Z[N
MS<+[VHTKTH/B[PUEW0I1MU1<4[H11$"'R]E=JPON_+U@DA#C@(_!9\!7%X-N
M0J::+_!G+CW\9@LWI/<Q"H0/$8$?.QKONOPYI;B#1:X0.G> ^.O)LQ$8NGZE
M9=N\8; ,811:ZQR!E=V>"8KBC%W@FRSG/EJOBD6:EU4_06BT=,ME9(HL!/-$
M1Z\1!HB 6I4ZK(I/FY-(.P*.-DJT!69 2GK+6/7F;N[JP&TM!SO>-H9=BO4I
M!]DJ6CG:>6"?+J:<0W5T+:0ZP3'95!CAO/*\Y3UG#LF7/1^FKO!VK'H]315:
MV&!A9;W=HH]BQC$)/JIIH/R"H=09VSN<3M09HQ^HZ"(S4/,[6HRFJ5^*D1E"
M*"6M<$R?"C,=,K==V G?^R;[XD>%/GEJ#4B+T>]/&A(\&ZKTU*X$O-=-Q/CR
M5[]<?2<6U/!/I;G2'NN,/'5-2&G?A"41 79#LX4$1M*.HH"+,2731I^F.C(-
MS8)J6@:REK(:Y<.V8NO+-.)F1W^:@5OG*;O2H]T[B[=WN*+:C2J%)C5NRZC.
M+=ZE"[4(>RY&2Z%E8%R9E5B[BGTZ7P)]I@N^JD0$D.B'E,>_PMC>-D^]E*_I
M(1XRQ",Z_9./HU*Q>6=;^SVHVCOXXD\(LSG":2PT2/#EBM,%5G<UPL6'OY-3
MY1^_XO&2EM<5T/_0]$DE_^5NFC&ZE@A(=/H3'_6\CN (3H1?@:_6!( NEF"8
M]L42_+QS$O6/7P&2.-^NQO0NR6S$WPI5\&M=4&,1*(X*[^7)?D>QVTX$T*A*
MNL0 ?R09=Q,!C*"E DXR9%#1 R@BD.V@R^WG&N>>[8V4Z$>MAZL"N_BSJ4LK
M5X/3%9F(@%:U)N85S=>+FBC%",^E7A%@?RRJ7'F^..&M?#=9=-K)S,/]A^OU
M"C$:5MVJU2%[[KL4_-]V;@OFD1JQ4A5RQ9EMX'Q1E.UPJ@ 9UW),GE'=\/$/
M'W$MW]==CV]'5U6TMGWC62FP:0D?V_P&"_];4K4*<@$:@/)Q;Y6-K7$N-]YC
MGBQZ]8-VV= @:2GSI+5+UH/MXEF(@*6O5N2H.SDDT$AYT#>?9[]F@\9OMJ$7
M%'U$6G5_GM\BU, KBARG^F?:':$VPX82S7I#%J-.-=2*V^P[[-\F3$2<YN3=
M\JA"C6Y>5_4[.T7GXV%P1/K) .T?.5'C3WDO.7L1^:$]T<HS?Q.1^VN*[MGU
M3$DO5L^,UNKOEE1MS@BNPRX3YCFI)PF4B[B'**;\%O8;QGN%#Q)OMFW[KDV5
M?V#XN%AO_D/G0:W6->ULC!2!PM!Q13O<#!BZU\(YI^Q2XG#=1-EKIC*-L6\[
MLNL6C>SW%<B*F8"X]^B+P'R/,:Q5Y$; ?SQR 6'+0Q@!J=!C[$94>S;YF&>)
MIQO<KJ590_@GA+XXO_#J1CG-_=$OGT<S"8PR6O?GH2ZZX)L!<A=.-<V'KR/]
MXXV@NTA"#D)<W EKX$XYZW.VU$BB>F4S['QR,MVJR+;<OG8F%.I)?1(SYBC$
M_&"?4T8W5$F0AHR[F?^Q#N;3RMW^U^:Y]<"(1:: ^TC_=K&=!<%Q[E$AIJ8?
MAY1J$A_IN6-(A;I)W_^^K 6XT_($18IC$E>I:7DYK A<='@0L.R(UQ2^>=3=
M4]$G"ZG1DM@ A5#H1WO;SDMV![P8/<DR1X"B2YL431Q3V93'C*Q,V]/,[E P
MHE_XD(Y%GHTB8#C&C)^*(BT?NCL:+(F X*\9%"(O73WM2K7NC=PUNE+X2Y_#
M347FO%+SQ7RUU+@3;^SYY.[Z.O^M3V+J&=Z72\7(N',XJ]7%ON)7*703AJ$7
M"^G%#ZSMM'R$XOBZKY5*.SS(M<[%8B/:>&^HE4/.?)A BQ'K[O G NJ$CS/L
MRCL*12K)?@IT-])<.KW6PDH$A(7[Z!/HM3%/X8@G=HO(3[;>Z#KT1[##$"P#
MK3"-<SQ64AZ#UTKX7[!9T5ZL =W0VOY\G5MHE^N@N*5TA%K!KU)KE?N:TW.-
MR@%#J!+T*0:"3#6M_[V;UX!RKG,8X.B0=1>8;>7JN=\T@'N(?!S:S;44;9QH
M#T4:4K*6CWL"0T]OU/Z0RZ^9,++E_&ST_A(1T%)"HI*?/"+IR965H8C*;6I?
MJMOC6'*),Q+K1P1JQAQ3<*YH-#]BFN-:24B[%<;E_+@_,7JR<$)3NE'\R:CQ
M(V5&/9;_'Y#F?[^B2#>TAK151EZF>&AYC^WRC/+*?G.HY-#T5[Y4M HH\:;W
MY9;V;Z)OOHR5KE<WA(@(%ZK$FN1;]FVKD'&=7#76XFSZ?K0.%F<;2S8YK%HG
M J;;T2&QYY1@<DSV*N^R4V0;0;^C_4M$[V;[NT),@R=VGJ_K8+JXOWM$LW23
M^D8&[-Z\T)O[U,,G;P(GB0!'.,3L$!P+KM(\"'[]8Z))G*KNG%:4MWAMO9H#
M/TT*TY$]'@"20QQB]%N1[068%!G/9MY[16_+,CX;C_)%D%9P8=$PTQ$WB$DK
MW! /L8PED1.U"0>+=\MK(A3 K0UY6^>#T =0+WBKV-*]$_WAL!\\1II!X5M!
MMY&J79HWVZEF(.'")L[^&A^O/<7_>B/%?]K]>Y)\&3A-VRI;'<?[,3TT<J]'
MP_=C?%QK*PB#+,OYW.E?DSLJGD)]H#D/9!P&Z\\%=7RJ6J=E46,[5RN\!OJ<
M9)2=BKVQ>:^')F^9XS%*_-1I^:D[)NND\=<]- 9^[=6)67-<O.\@B;]MF_9T
ME#FJ^KL#V[9&SJ8O=02S4V?;^6UH ^UIQN0[QVU:4AP+$MR.L]AJD*=T9YES
M*1_*$,"&OME;P?XH!R^#]A00VE?S:V<\VCO,BE?)WBR>WH7,IA8N-<;=7*[G
MBRTR/;1>.9+E#@T!^57).?8O4N'8D$]M#ZNS;G0^Z&8+W'#NRRMI!'8<JFT[
M+D/#X=<E%V,7I.I,G/)?V1Y*[(G1FS_G@S7>O#RPMRD@[-X1)([!+V]:\XOD
M>75$^;,_-Z+TW'\XR.C1?_^X=PMLC*/%T%HCRWNLYAE;4#>W:AV_*#XU6+G?
MG;U0-H:E$6"T?A^GH.H7[=3/>&:=KUN!!",LZ]J@9 7O!!\4N3V9G!0<7NVF
M $WKO 4Q=#G^OIO;I#9HR+,F/+W5)<"O_._(4F[0ZRV\=E JCUE'O)M:PL*R
MRRTJ.E::O8*&P$NEVP8A+#)C7AI%S6Q,KI), O?=$J>%I\>'P1P^+NA,%-_'
M %=!3.C6R1#5PGT?K]O73#0X$IX\9.7.,=HGD[;NGJII??_K[CJ%5O)H[!8!
MZ+O[>EI$\$[2C=L#FI:25?L-<B7;C+K*?K;O@MQ-S1Y7!#SJ7%7MJYD%]EUX
M$:!S</+*^Y\[<4T*.SLNTXJ,84L#[TU3]'E_[?9](>P><-N?_B1%P3Z_">+
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M#-*VYV*%Y$QSS=DQ4RA9B/)H3%D6_+9"DJ_'^_I6;7!,OAN@=2! &0L*T&G
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MEN)NTDH]3GG.P$[:$FF?Y&L4@2;%DXB@:EM%(95_*-YVB/H^_1! :L7]Z,[
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MOL E3@$TSHY_A!\$?D,R(XV2QN1FCS)I"$TF<4++1#"I#T_>LO:V%5\!G*X
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MK2.:%AW('/&-;"5X)R<IMZ5KPU?!H?K@G7;0%: 5 KM_!4C%#%P!;MB"L'/
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M'^3.S!M+/]"F&_YWIS3^5S +[.>HE.W?/WGUL^$_0]#I& <L1R.P@;5]B:6
MD:@7PMTR3VI79L-^HUEI)RGT"G 7.06_"^\B5+\"(*W@QP3@N 64,N),1)'G
MXK;A]1K]N-92B%8I/2Y/6>TM)K\1^R3\QU.$:5PCI6UJPZL%ZV3#1Z;!&HCX
M#\1?LP@)N:9V.A6RKP#D>5> O-0K0-P5X K@K+W@I 76R9T=F6PM1K'A1//Q
M>8%X_2O Y1A8SJOW"E#*';\[MC1GU,%H:^-U\>['TZI:#WO;1-6[P<7['TT<
M3>-$!JPQ-1QF>HY:'W-&0@V')>6QEU> :P11@IU \ZBAPY"AZRC<>7"'K8WI
MB/]TO-SXBZYY:ZI;JI\<?WG%%EZ\Q+=6@$H7PMG0O\]S)K;%+YAYZ$/'.W>C
MVAC"^EK['#H)"")OJ]Q< :JJ*4X/Q,>=$Y:&G17F'FWLR5X\GL0/QXL^0:,?
MS#.,EG7-4[*7T?#VTM^=?%9/Q!Q.9+L1C!8;P#[Q0CSYD3 -DZD)V'L7\MU\
MF%IN[2-*[6:/JDFQ^4G7%MAU2%D@F\JT>23TQ[3D]2</U(2/J5ZS#O@5H";G
M__IC_D$-1T.Q1K5D!V,$S>4WN'DBSQ2R533KQ^URP4:/7 .N4QJ'5\QO.?:D
M=4X%>6-BJC8DQ]8:F>"+"!<P'?ZIM=>+,G3&/#!&G;*\/2/!LA;,J_ITS4[@
M!9'FHN\OMTZ"G3P.*OE<1[9<6!0D;AK(A^]K++[N@;T5SH-[O<NY=;)P@73=
M%I\V/=E[I9PB+-?-LZHJ B!#.?!F7ZAY=6+ 95F9:=MP5+324K^LLG]AR&6D
MH2R76>6-4G=C;[:DTRWPFR'%:97$A// T@@>[C(0._SC@6\<^,:N%P-4I@=O
MHZH_::C"O=IUMY=S(.[]YQ_I*01LWMT2D&-9C%G4VF6R%T.\N>.EOR5?ISC1
MUQM8 .$2F/8*T*P.6O5"@2Y]KY?MH7*,Q1\*"$\/4#OX)I?&<RYM:9DY]@H3
M);UTN>-S]K2J7Y%_YPC5C8+4T7Q C\PU0M2J'-XM6.73GVJ^&>@SU)8'?\$Q
M]^#&6N,]<:-SF9R/+W>EA55'Y%X)LT4")"=!80[G*FUW9(;7O":O )!*MG7U
ME!>G-^$L>HW4=2!'2)%DWH/ZS"[57R#O%O_F\\\@O47(6#:1 M%24D;&@&-)
M7:!J>?CRO!2K.ED %4A@!4^/%N@,+!+NBRN"NU&<, 74ZZN,<I\HOJNJB%2\
M[[I/D7HLT*N>Z'LH:JPF[Q97_1>0U3;Z7S@ND9MK%9?0'EKA.CYD.-TC6,?/
M;&:\?P>VA^;$&$+K9JX 1*!O"+>RZH5UX$E_]\;FPO<ML,(U9QZ2J=NL;?XV
MFDD2/"R[H81!.&;.*T+<[+@+^Y0JY,Q?AV</^@X78N%M"=G^SC<;ANVR?M:
MSZQ(35@&PT,E@MH]6U<B A((VSA!G-HE6M^U*>?:#Y6 0_42X;+EL%XT!<81
M3>';5ZGWH:(V$RFV-W(Z%(%)W_;*1QAQSJ>'9NLZ#,BNNU&]&,DX8%3;!%/
MK2'Z \\'VN.6?]GZJE:H?P =9#_Q2F=)]JE?41KC.@EA1W(]3ZTK_VKVU+LU
MW9,(^:N%))JHF5':#JK2J7?@?2 YE+;-KQOM@":H$0'-OVG&E>IJ]2YQ6VU>
M 0@4H-6R\MN>5X!^A@D?+ TF9T3@2?A,&R9;L7K1LVB2QKN^Y_ Z.D5X2GMX
MQ>?K0K2L7(U=[^SE7TX5KI)GHZF61]/50\J&ME\7<'"VQYW]I>&;_BN=\R]V
M!134T!TIE$0.0F\TM82,+ZIXCN4ZK/ARP3DR:=A,_::#:X7."H#4V)4W*(&(
MZ?+"UV(O00[\1_)L)3FK$P/)$I=Y/"<4?!,MF,:I02;)&0>"/L\Q-TV<(U8[
M8-L]<[W<[<G<Y>A$O#I#W4BU"^@+4BL<_ RB(8U-]GQK:I(A()&X#-P#Y4/F
MS1 !RS8/NU;ILYAGJS"[B "5>NC7HVYG_MZ785Q%KB^C><T_>$2[)R0J#1\(
MA$P6[')GU=5$+CWR)JWU!"!A6-<+K@''-2-LA:,=#=G+&?->A(5]RR4-VZQV
MSAP9@X>7Q:V\Y2>S:#MB*)L>NB.%ZQA"]WRU:X&9-IS9HY;I>N5YW)",M;@0
MML13\H(AYA(03? W%IYS<;;+6! T0@OG[Y[\)65KGGYDI7AX=ZFX+&*_G60/
MJ+'M.2"0V@\=0X_D[[?^[O[N4W%V0?D'SVFC/W!9_S\^;?,?KG=<7-HDE>,R
MST",K. ZEBT\&+:Y1F?EYMD"*TQ/ZN(N#.K=PA5ZNM(O\H@!VMF;R1PC)Q?>
M=C8LI $7Q7*"<>?NHT9/L2J7A6*&4X:L-'R.K X$/Q&JLBR'A5O=&O&-J?Z_
M;\O.B0?7@Y<:6Q=*S_0:LFD.&D[J:RFJ-W<E/ EM&Q6][F$UJ".@E0FA0_.*
M='WVCW\$P^L<1_%4FR]WM!MK?[,:KB@AN0Z6RBG_[C.M_\.-H!?/!S-3"31B
M@O0#=Q^.I]X:;G4VPT0:$76]-XQ5E@%^. 0%%^$8L)U9,(/!:>@#W>V*)M+>
M>U/L*C(:<Q1(V\"%%DD)V!WT\Y 5"((::DYW K%YK9U@F1HJSTK>%*]E8)QN
MG)Q.^T1_(=R.3A<G45DZWD"SK='J*%!S!;"=Z2?I*N;ET'PG]_WPE-JP*0F6
M4B$WT#K:;Z]C8)K\2(]T]Q3<SXC<F/("%AIC77GZ^&KLFWL3RLHWQM@;BI,Q
MVVE[^94#^S6< 5@QM"@PA(DL0D?1O*PJ7 /B3*&I&ZL9/C(G9\:R$SXVOIU0
M'O?%]#0A;)5:L/ARJ\B4,N4\IMWSQ\.?;:\%GM5F%Y^YL%%H$^HY<>8K/.^G
MQ/KB7XG&7WHH7@%2'N(JK@ ^UXRENT<7/LEW< 60HCI%A(*L!@!Z.F!=_6U'
M:XUNTC;)3MOV-W=?G24"PMU]($MV4T 5T,T&/CUH?)M&Q_F'J0';A0]S+/FB
MGX69[8^1'\*9D*7Q-2?BP;'& XPJH^><P2A$!_@V=/I=H/S$7F:U+?7TQU9.
MX*NB&W:M M,3/]A[R(>UQ%B>/'':IUH#TX(LN6F6N-O+8_0KD'F]1Q))?'XO
M.L/I$@EOHKTG&,[-*SL'P@=Q;#^#.YKO[;2Y6K(&/'OW;3G"GLED,70U $ P
M"E3VLD93_:@HS[@"M-A[PNT\5PS5-UQQ+%_N7H[O[G[KC.ZKU=1Y1BOV-0E)
MN,;_=FIH/=4?\L-ZP>R\D>58F6FI:[F:U\T/7!P7I7 :<U0QM# _8K(O0?CN
MX7I@MK4BG;\==WH594QT[:@@_P)=(<G9!.8=UFU9Z5$Y!17D</;WFE#)=]25
MTJ%%I %\/T&NK/;)RO);H9=41N.$E!KW \/T(M?LTG%XBY[U25$=,E/4L?6S
MG!-]=^<9B/\#-<.-<"K%=^-<+Q6=$6H-%3^]OSWN=N;HR/RI?..#2).XQ\-:
M(T]TZU((3 <EMO5BSC/ZD'A\?RQQ_V5P02JX89CA4)2!R=YW("A6P2F30VT]
M6N_YACGYCX>301IM*M%WMD]+]MW&8R^TI6W0]PY>H:D3J1.SGK0V4Z?3%P-L
M+V?#*5!\B_L,#A3*D$WI]]MT<APR4@S!6+[.%DS-[Z[N;&U=/"\5JVQ^..E_
M87FO>RC3\8F6]LW[C93N9D#2.;R99YJFS1X[S$.$'7&>F9.+PXP4\*8WK0+R
M7 !TM"9D_*,,D= SKEKA)(O=8N2RNU6>9^9,KY+*<.DOVDQ1HP7."-2*&R1C
MXNB-Q\FZ]M!FT>EY0C!G,-KBC]'S5#M0:V(OK=KHX31#/P?B=0XQN),*@P[-
MVJ-R/'23ES:L!9+]0\C:#JSHR(5<O,*6ME;B:1)[*T<^KE;&(D?;=+^?WDFY
MO<)4A<QLM%@(QY.A!EH:B:!@[3%ZY='C.4%2D=#!QJ^FTB2?%BG#19.TTS4H
MM"?;'4K#J8SWZ*N/_:D4%<:Y!'I9ZT;L; [VP/O]-NQ1%(.^P>;U1;I0"]FZ
M,0$Z__JP#!NNX4CE,:;6:,_\WAA5I5Y%)C\6CF@UGUH/2FQ(FYZKW[%^H;9F
MC:(8J=D"*W)F\,9L3!-!M)+;00M%A!:"IKQ0JV=$/E$EO(>7H_]E<VBP/L$:
M@2\V 86X!S-*Q'BCB5'KJ0*5 3#JTL08^$N/C$JB4,J,#\U>YH_LMYM,3U>=
M> )K)D+KS*[1:*?_V^[45L?'<$B*,=EFZ+O9VG!Z9E@>^>U7#-&=RQ +9PLC
M"J+JW/GQ';:SS'6O0K\E<0DN1KEU]=5",\Z=7B)<05)R9=CQT/GEB;3FR,=K
M3EEVH2_U*%+J7GM]3<7@;94UK?R]V+W<L]\+$N78TX(__*VM8N:ZT@#\N*)'
MT+BEJ6%16-?C.I7.Y!N)K?SE_7EETR;)]+E!UVRVOOZ.QP]9<<JYUVB%$%9E
MDI(77<P8@4+1\,0:_J0'0T>WK"TE'U6C+B>^$R_<AQ?X1_2TXCQW,M$;K=]?
M4GOL2>@9"A_V=EMZ->0?G)U/W#'*^VHMJQ1^.XENSUVRU*9PFG@/\6FSR^L0
M^)KC"B"PK*=5Z)@VQ]U>D$B?"EXRWI1U/U$AQR;,M%&?A9ZYDDA"=0XE.G.*
M.+XF">@S?MU^9GDJZ/9G92FA__KI*/&+SFL^+<Z_LA9M5=A86BZXL3?^GK/X
M"O#1"=Z)L <+04\Q<+2L#ZPW:!$_-:*-*-?-Y4H?6]EN#'AU@BR[)B;[Z:'Y
MLHIS#.4O!G.+^G#+Z^4XH>4]B^93A/50.6>8)'CY,'$-YF(F_@+#/#$E*8IE
M6[)C<HLQU/4,4;,[\RIM<[B_W;I?N<R_S[EQ0._5-_\4M?!=,K827&* .+:O
M^"2QPH; $K--UR= >P3BN<I.Q+N7\C1<]<X9+7RNJ1BA4AR>?036/+)704"X
M/103T49YC'1 (2-@H!4=\7[Z=Y7UPKVO"RLTKP!NY+1>FBB!L8)Q[7M2]F21
M*G33Z)Y,7954PLR[!HH0/J6;2+(NAQ*9=EV5')9,:8-;' FMKW.7-QB?Y)[S
M7U.%C@;*RPQQ\-*/R#F#K$K+.C?75KX;>\QGI7@,9%J<\T(5JFTPPY15NBE$
M&+% (<C3/&IQI&:D^9;*VO-Y7<1KVCS''9/)ZQ;+S(3H>=5:/W>:F?&X<+P"
M<'-GZM)L15H?"+3FS6[7_YG_RWCQM^YO_K]WJ34U/AWSBB'?TRM]!.8/>YHU
M7VW+B]\PH&F+")L'8ITB;D9? 2RWL6<?N2?-5.QX:YBW#@;>@+E@K[#%RQ1?
M:'1&GY-I2952(^QBOW@2 ]OF-U#MKH/-ORJ0O]N/M[4DAVAYQB[Q,%@9"8>?
MVS#I/K>Q>7KX<,-89PY%/*FBRB?2Z;XI4J2X!/:3]<819FQ]]+;5XA'<&.VY
M O![?E)>2 O><2M22,I3>F.2Q3";G_CI&G$3M"6+HTY]5[@+K#$5W*%GRF>1
MEW?-(A8YN\1U+W2M*FJ749AX;MR/6^U+A^F$H^R]+\[W"I\-YFLO?KE?2 *_
M+W&1L(@S0Y>V&!$?L=2,QAV>P-=^==[K1KSQ+5>Y:-/N\>+!=B\O/#P(O]",
MII==G-;%KW.YWQ4QQJ,%VK5S%;EWU"X[;[VUDV.9AME<J$$##8^XCX4U7I?9
MBC?!>GU \RRD6+((/?3,SLX/A6W%Q-HOMD6F8LE62;7%)ZR'UO.^2_7:[30^
M(_(C^P*DX5N_44]+R&\25B/M4"J[Z6Y.)E5HZ?,IV=$IW<A#H#F\!G1G0<T0
M-PE[7+'PO=NZ*G 6I4]/?_U@,8C<DYKJR#TYX]?[G8,WNI$?432[E?D0)L.)
M+\]!Q7LJ(+,0BD^MLX>YYPACL#16I2F!PGM//(Q>*:"/,O#KG6'0Q2\W4#(G
M/.&(T_Q>W->Q\&VH<*%%[@#V39,[C??'AOYT*_3TJO%ZQY;I]2098-L:=*$:
M_&/'P>AMQNK^U&9&6L%_E/RC_:_>&86'B-LS_6@8;HY3+ ICTXS J1SFAQK,
M_:5\'0\TNWUPD_=;^HS #D6<9._^PI*1OIN;P&7K@#V+(F=2G+5I=-WPRVA^
MN5V'ODY6A)[<BI6A&M6/R46.T&A/SJ%L)0W9F^OKO:)O8][DZ=97&XOV^0N>
MS$4%GW^H.UVZ K1Z9[QTC\NJ138<JYY0>B"T\.#>P7Q?2@$172?1G/9VZP=J
MT@Z)_O^9/,O_MG^:D44+1-$QW):A93Y^W*"##MRMS86".Q216"66QL%4>_OG
MT<- \2RXVV^_\3XN606H,.^);'OE%6DLNX;OX>FQ/&H3;&HL+;7O_:X O;J)
M?N L-\FFB=N<SS._.;2DC4D\G..?[G5,4E9Y]LOWU+20%0,YG]J'\H0T/(->
MLP.,2S5J?YUH1C,L[JC5G(_Y]0TUSI3_@[SW#FJR^]I&@XA8$*2)=)4J193>
M(P_2A0A(+Q&1)M([!*(@H%0! 44D#[T3Z3VA5P&I@2 M])Y0 VF'Y_>;[X_S
MSOM^Y_O^.>\I,]ES3S*9>]]S[[W6OJZ]UKKVW4Z1G]>U<%2[&0?:;R%!A">N
M(S[\*6^4K*X$S0[6UM'BM1S.A?F/UWY@%]J:$GM&N&UMWD@A9^(*MHU:GE,)
M?%(R^^FHT/N22N5G6.^HKQ4O_6;:>=AW-^[\S!MU\KEWJ!?^9*T<N&X*C^>G
M&K_8S%L[W8$E;VX>JD)9/Q9GF)S4<JY:BF[MCNT-?BNO(#%<Q5( .[&.E<53
MM;.?\MTK-W$E@%#J1Q<@9N%^$QQO#[P^Y-Y+,#8/-U*U'F2F.N8Q'UFW7<BS
MI O:4TDGNIK^3)-LAC+>8- 1]89QX+=/U'&\T4O)VYVGE?CPRV<M\0C]-IZV
MY/+$5]=V1*([)=!Z7<B;>\.I&.$]OU!9)GO7D!R-R6KZ1^R-;9NU3?[=H=6V
M*KC#19O"KA\\;B#]]W=Q*E7N"1K+N[JTYX6[,$T5>6[1@JS'IJ1Y 1O5UCB!
M:-\%%6X"EU!L#;=4-YDYHB>86+F-D$+=9\2'Z/\4U,[N>>99 AW4CXS5'I:-
M^*SU"EF]L'-:OD%^0 %\:.Z>=\@_;DF8FHH7#N+WORR=_$@H\>NB$_^!5P*$
M<&*%"X5'(@0%?Y3,%H6LR,H>#GT^J4H;;F-XLK[*QSZ\$$SP1H 8/X_EQIF\
M<1TL.20?-3<3DTY]\:7,RI=_?O$U-DT_-3MH]XUOM9K<NS#XX,*!_S$K><"X
MP<7RPNXA5CKO&_K^0U8[ 6(&G5G/W(%-7J@BY<,^58LE7NJ->9I1#V4YG+C]
M>&W@Z-X1G/$I,4^X9-Z:V=XS68YN]O$PF>H*(A<>#WP#CV$*;.[66[)1J-]$
MOYA.?]F?L7V9D0*@ZK<.3CNI$'Y=X_6UUD(46#L#EUFH5MF":,6VO[2]V=\@
M;E^>Z3 V4GMJ)1/ZO3%RF1?-V1,F61G1>6)V</7%UYM#<9JB\>K)K%\OZ:;=
M&9!@%X*KA;0CJQ8^RO39-TY5+/]>@G[]RVP(QK-U]08^\SSF&!8.I-EMH2KH
M+MYZ+#9_O^%9\Z/+EL5DFM-CCS8OU-3NDARSF.L?LLG16)<6 ZL675FZS2R!
M I"%%%:EW7>O#9VOLY1H=-M(9!L'VE, =-9WF;8LFY-.\RQ>&>(9Q"@ Q6*,
MQ'1%^Y+C;XBZ%UT;I'+K<5E,[[@W32_I8M8[YYC;7XVX_N"X]QB].:<]NK0I
MXVZ\J*^N@8\@*&WW>_*$2OUZ*S#9')26_L1?Y3MI"I#0P.V*;I'"64+1BDK0
M:W\$$!%N*Z1<2SM!VRT9.T(1U:JZIWE**A?=,?#)=@8]#.,FLJX_*6[?6ME@
ME*Q^MX_OG'$Z0<L0? WB@C<.P 9TQ[(P]<NF!):=F/%__O6#1XBOX69$0G9T
M!:V&]OC0 T49UL)3</^9*D*]TS3+PE9F<RM]>-[5S73[UU:+&M9VO3=+6(\W
M.HV!-_RV%^-$/O2/\F 2?_/7O52SU,NO/?\ZYB=Y+,*NH?&<'4WN$:\/]-P<
MV-*J=+U_Z?"G'//#>JI4;^$[#7#(SETAPW$W3&7DJULJF7<OUR?).[?MT!KN
M:/C['7Q5+LFZE+?N$;H_$R0PRFN5@;O")YMO$ %MCIJS@@X)38$]#358MWFE
M_V>A/IDOBJDOV;7;:;/A#R[H!9_'VAL.98<<PAA:PN04Y.$QF)!5J>%R_8*8
MW#<T,G4:3!4OGZ@+N*;,)&V4/5"5I1%, 22$<6B4!:6C+<OD%H*6-B[ 7P04
M.-42AIFWTLEBSW7.5Z_-]0IGR&;=&B_FB%4/?^X9G/5MR8-3O?1#7;,HS?J3
M8#$82'W7QDQFL55TM(4:XW)\.^1&O60_AT>"YM:3N[="@V/62G7GCPQB_#SV
MJFO^'=S^O/6_7;_Q2-EP$<B '^.5L!@KW]>^8V'AWY=+2K]CA^? \=X)ZX^9
M7<<.EU8W5$]<T?JMG7L&7P9K'FK)C(,831,[?CEILJKR0Q@Q\"B$(-98[@21
MY.5Q/3,TWPPB1+[2R/M^'=V80>)RH,]C;."Y*M.&+UT$1T#,;76.\BL;/<X"
MQT>2%ZP9OL"\;P9_.12HU2;UPI29"73X:KW)_1JK_,;Q_8=B[FQY=0<U;F<1
MMM^6X&C['LO;?7MK]5,O;67GM:)[JROH0V=E)@._G^@@(WPSZ*MOHH\/)+[T
M+#P9_ R:N'Z0R 01PSE%RG'K_=44(["M[++6!5QT^0QDMOF#AV@YG66VU!;M
M^H92+2V@.SM/9YG-QCVD&QDL[G?A$B%Q<F1%UW%IWD]9K#C9T8+M"UXCIVWY
M/)D73VV'U,4+QG0$A3Z /.P9[7D!OEVXL2_M P9L0&\IZRRUYCY#293SV2:)
M[5P8.H)A\-P,FD.>L)4:]Y2XF5#2.M3%R8E]G,J;[SGXL AQ^]LDUUO>KK)0
MZ 4+&E'4V@UR)IB]P![]I@""]93>"X;%M$-_^%N"=\47;=0]?H3Z%5:2.4O-
MR"X-8;7]8N+.^\PY\C%&:*T2'RV901<DBS)?J?W.//\X^_<<E0$^7OR-6U#=
MC=V]OUL2?X4[KR<21G_:G<6L?W'@'JU*3OOU_5_8LTCX?RT(LM)BAS/NY+EB
M:F-F\LE=B]BD3NA/)%[V/:^C"03'(=^0=$]_170&![N,\M!,KO%_WV+>*S[?
MJR@Q?U.+8,T>,6I5#*G>@#,'ENI@PS).S[N/3$T'?_>%.:G&Y*:I=B"<\*F$
M9V^R[A^^A<A6.9][#7Q/AHXY\!J>TH[#PB97+$\_R8!8P)RMEN3EYPT]U,.K
M=8E/%*EVY,NV3C9>VH'FL^!8Y8&&XA=CBO=LT)I._F*_O"T2=%1K1XD*3:-'
M% "[2WW33OGM[RY":&XCR5T^"9%W#*;4"LOL%>XQ1PX\KT>[V9Q\-D&,9-3M
MS2856O5D8W3H7T]RR7CK=?(YZVJ8(!ZW#&+>U_$+^%GOKARO',2WV0#IQ<FT
MJWF(3_2S/&X9:^SHY4A[%0I@70CT6)2(;]&O3=$.5;U" :2AWQ\\H0#>P;Z2
M;UB_2>")*A?8\FVJ+75&4K]+ULK0#' ,L$_^Y:US+#UI] O ^6F1"OP,;W^B
M4Q7QNHE<+3YN+^[Q*EQFI."DGP_+NDUFPWLLP:\ ?.-YT%//'Y^$-Z]>3+19
M\?,I&:GKAF,<&>JT"A!+7OY T"(P#F)3I7W4,UYN!:O94HCTVF+C3%Q\;#N[
M2 ',@)^,R>I7S.F7#S^"I/YZQ/"6NA'Y^ CN<>%,!HL32HV?[K0DX.U<.B_X
MFL[HCK2H=,UXV6)E':B9M<6.;?O]?,7A/WR$#5&V/?V_DJKV'[2XD[63-(=W
M&%E>5W,!1"J*2RTW3@I"BI^Z3$.9>9\HH;X&IG2C+ EG]J>WWQ%_%F_O]3:6
M%X_['$G^T& &=]LJNY:?9+BR1.>.C,)F0FF\P,,QX[\AP!",WJB;P^V3K;T_
M(@RF*J6(Q_'27@H*53]2OYQ'3OA/C4J/]WD6Y?*C:O"\2SL\'";-S;->Q8RG
MT:)L582+Y3HE?PEX92;0 ,7(H+C;P]]@=RCW\XAG\C>*QG+/=L=?L7AL]5^8
MQYO[OS_S]O\/+1#:^X\*^JT6]C*7SW@]K9!61><;@W[<*=8P.2].>M4]%NK]
MAG.S]$[<[+*QE37CTDS>]1?LT,K\7T$C7%XC#;NV]'P*V=&E(E(?OMND14^_
MQ(/9$SI[F0WR9=@#4K-.4.H[U\_43\9P>OTESCQ<\3B6QS+$$L7;KPRE]BXA
M2<>F$%H<;/EV.:945 EVH_:(R>E75(A0M4T#H>=5GB"]PMWU DF-(-CN VC)
M%I!9(-UB/'=L7R-/],2\ C%6TB#?N6O;./QXOG4GD5/O I POD'-R>!W4:TC
MU*H#C]F?L;@:/#S!OX:%?3^:GSI4_8"_L21,%,*BGOT*<3^^S%9=[VU]*1>K
MG\O3"-<P$6O7,O(4R4KAZ,Z;R;E9\C/G_<:EF-'J7G3VB/[R&4I?1V&H_UBY
M04-31'C#/DZ+X^^-7)9SX8I7_^3!,GP$OOGG'+X.-ISYEBE@MK?D_D*N5D]_
MQ"W\Z1_J4%M$!Q;X,3H6PIVSK4P=ZL*UQ_:W=ZXGD9,/"\]"NC5@#HB\@D^^
MR[VYHB!*2$%-+Q^6(AD@#CCJIW@:NX<12\(24U?Y;Y\BWTKJ=@[;-5A='KPE
MU4/V@KW9[S6-5Z83'9)SD]9'M+;2'1#%</+]=ILU<#=TS)R?6\",ZTJHJ 8D
MU.6? ;1IR^T\?&8Q<756\S/M^MX*%6K[6?IR?4_#7,2&V56U=O".A?S))IB5
M_-.N/$R' E@$8D&_H1._0G=W72Z^0;$,E<)E0)HMQ8+R)17!4\MJ\LBD4YU6
M8UT[CU527_M** -?/@CS?5=='SM?&I!O>6-7]X8%?UV= FGGO8Y)VW9*@A+J
M=\FG\9,?XE!@ SY=4[>^LJEU%_%]-K1\[<THF!O:@<=/W*'.MG:2GR7%"ED?
M;1HM0/SQDZP3[2U*,G53"A^=QSYGS2@LX^!9%(#YHRDD/P6 Y<4+S4*+OQ)F
MT>,40-O%@_(:!<YV47=DW9JJC0A_ZR;P0]W7T41 "^,)Y, C3_RP,[CHKJ6B
M!6;%S2W4@73F_M>?UT&(M;D+V@,WQ17&J]X-C%CDR9?XV/+@Y@>?-N7M0W^[
M=(^,;-!,S&NG]Z?1ULM<9G($WIQORN;XLW<UST,3?Y O(68EX!Q?'Z *,EKK
M]55_D$(91@ZY^+$-TTM;-6ADQT3:?O7!S/9**-_0&^<D:-F78T+N.06@.[A6
M=P3%'_+N<RRG=:<7Y<3\NM0R<O(1^S9,$F]6=C=.9A[&CJQ_Z\WQ2(_J6+]S
M2R/8P7@R5Z?F^T3*5S2M:=\(C4%@^8/^CC=ZV<PQ7ZPM#A9VK#"%T>:H%@6^
MM0?95AM?LJ@?7,6?WDLAX^%EHHO(F?KGDS7[GWX/YFQ6;J&BIAP(8O501Z,&
M=H&3^F?TCVT+<<S+;#WB;-URLG59K+*WBTI7>SV<3_N\_UYYQG)E)>N=?8'D
M3<V@^/QWY4/R_?.S@A0 =U- X^9K!0,^V6@!]FY+"H E>7<\K!D][S0A;=:[
MBT,MFTW;?0[T?UFV=WE9,UTB[I**O.K<2'ZP5AOP$YA1V0&CMPUB=1[Q*-!R
MM[;1>3TU*_"GP3"+\VY*0@OU,5;8Z<5C5GO=1ZD+?ME'YHC;/2^QAUT3Q?I%
M^RXVQ!H53(PP/!"_^%\%LN%7\)T$0_- GH-E+>P1X]9YU].\<6W0S.XLH9#V
M86?#9:KMSQK6I")5,?U%B1N=>2X^THK#9>Q/^SQ_/Y%WHJUF\H\@X[9H(/K#
MWJ[HML5)D]TW;K\/*^6C:?MO#A]V ;E;@C 6W_8@>J'N\;VI]D(S*3Q?$]EY
MK5$27IAR]P.0Y+(Y,NN9O6^Z02^OD>O#F--E \:Q!WP#WE_J':.)_!R%I,MP
MX/[%TABORLOB*CN"X+8]%^J1$QB,..?XE5.:ZB^X,TL!?%CN@A[Q3@*QLB"R
M2"+>0%F+ E C&5, U*\I $PI4XP"WS1D;,_MGW M!GC.L 7#<PI1 *Q:1"$>
M/@K@;W(Q!?"^"HHS^:3!E;3#]9_\4X\W45F?.1K$^*9O.5=\Y^]$8O#/C?Q^
MGO:AA^N%>+.36%QZU)J:5[!,Z?,P9X^HM5Z(MNI;D@[/Y!&JTR.F2:YK2"7O
MIV,](E*MH?(K^4#YE'?>^I0W0=&L8[)X"<H,Q@.M:R9K^EN^-P?\ 39U-OW<
MR_/4\'KUR'>KM-OBQXM*J0+2KN$Y\Q#7E%P$4=]U68)N\WP(=FNNB]?=V[!)
M$N;9EMA1%P3_YM(]DX4),/NW.,)$W/\"LEZ#J&%1'?,/_OBI7!]>T]R6[*WZ
MY\59RVW;NL+#!G@X$7_.'7-#\QLWX)^6>=]W0I<G_ZF]\_VKU1)*%^>@R8Q/
M.G"O)SP(S.GU<4&E<63:Y^P_ZH->X83BMA9K$S^$2?[V.4'2@VELX9?#O!-+
M!35"%R[(QEN?ZY7X9"?IG[[SP[WK8K_[/?BTQ-Q88CS[%L-5<[Z!<Q2C4NQ+
MM587+*SFA4[=[UO0KFAX*\+:&:C?S+;LTUMJ@H ;S7_W+GXP>^$C3"K*W*=Y
MF*S*!<\#ON;D3>DZS?.3Q5X,*C(2>6*YY<<P VY'??@>5"O*///JAX46Z2B/
M7#L-D< [N&"1.BV5M<W)1]9_@M9TGHLRI+Z0X YFQD]@O+YLC7HE[)3(!XT7
MY8LGC/^+K,"O'JO_3[*$&%1PO=WM2V;)%Y0N>+XVN/6RJ5$O XDHVG?Z7*L5
M<K8,C5U@5#9([N4WRQ!/\'Q969\L\5;J I<'GL K@W(S=G-M?X@'/1RV_%)H
MO#M-7&^(<K:2TKJOY$-H4U,E3IB<*PV9_"/R,[>&5KMP+:U-,@KG.)MMJ7V&
M7C)5_S'O?ACMN@/K^36_Q;E+YRKI'#S?%:'^>MK383D-)->3(.S#ZL:HSV\%
M/,Y<'*0N;"1A!;YIV2L9@<\996H'Y:J*%G8*I4A[O[60_>E6(5G(M9BH>VYF
M24IZF_<'#?KX\.Y1P@E-"A K()HXT*#B>@+&%7Q/J]43-PD5KY"MQ_#?.&>V
M\>K^#4,KK$:7\D2W$IEQO%$0PZ74QM]'@^+W#^XR'0RC!33C2=Y7=#.9KAWU
M/G<=;81_) *=EA,C$/=C33D>9KNN>CT*O-,N#>V*:V/EPRTNHE#SUW!IL.41
M^MFM<]>]*%#JLD<KR[N;??/+P$3:UL# $IYA:UQ K,HS%5N'00''^'_7VK8<
M_A=J8A70GBS%T1:J?$[2J^W^N!^57;F^R?6GAB&PWP'W:V1(WJC.8/&]XF"R
M37F>OM@'OS9NVF(5P+$,MC 1XE4$4<-Q]Y07R=Z _.Q@&*0+.GL>JA*2F;'?
ML82H%&U-ZO\(WS']7CT.,2.8!$88?1O_J[9^=+<Z,EF#^5GHV9G6..VV=0@D
M&+?]6*C+^'4FCDZ= GA=<2GF_,Y24;>%!H]RZ8N4YA2E?3Q8584"R(Z!$H[9
M* !F+:($C(<"^-T-))W'4@"?*J[$P.WUSLS^2+@:GWU;@':<X?9)=!=FNU"$
MQ&< ER#X4W+4 PI@?P),U/>4-MQQ@8H0(M 39,> !2P"$D(!J+-0 *=;$F3!
MQ/_0E?5-EA .\ !B\:06^.W'Z7_H.)?,-I((W7@%(Y,T*( N%+4&3T_Z ;Q!
MI1RTYN2-9"<:R_S.()_Y*7O581Z/_W;K$45@T[O<@%W#=7NJW9!@=;[70$(A
M<KP\4$/,6]J](LYD8D4R\U:HQM.?V.0JTZN3R<%;H>F+^X!Y?(E&:K5;8<2A
M]2/"_( 2+"SB".XZ6F.E<JE;7"R;\6D+;/_QL5 C7)+TG2S"^W'^)D%F4V/*
MM_PGJ(:&J0 8<)>[BHJ6>R)+DB9X%5)Q;TB_PX;!/R91Y$OP/Y69!4O_YRK"
M=(P$BS/YUCC8".7GRLULH/G"M55S51QC*@1@\[ZBLSD$>&-H[1^!2VQ3?3#Y
M]]B1!U>@A]G$^MS*S/36U.&0($LE.F8U <"_Z'L996\PY"ZZ\#(GY@'=?Z9"
MK8,98FAO"D3BKE07;O@KA8<6&C7I!=;S1/A\EMI]PC%AHB_QHFKJ""]QM-T@
M<X,S<N'F4%DIOY%$257RU7.3IO\':%O]O[/A>-'4BP]+<3ZF8_LUNXZ<&K7O
MVJ;J0UHJTX2"=VG7% "X42V9-49R-X+/2N$]3C SN?).I)$Z)Z':OOXW"E5C
M%OFQ_Y%Y1E6YD<2WL^IM+,0L8_$1MN-WAF'"_-9^6.]@V"52TO'^37S6B%$3
M[IG_-7>=0^GPCN54ONO##=PA$>W*9IR$%X'7H5?Q*5J(4#/#*7M$G3-YO%A1
M^?VRNYEPS.-H:Z^L%A1Z<AW($\8%^P1FJ-@IS[U98@FKM?#_%4-O3+Z<EUA,
M6QM\ILEP,W72(+DJ9.L\ZZ%?IGUU$050JR-;-RJ.,)-29<0G UF("K_AAO7:
M=8.7Y\<T9>76-,,^F-ES95E_["SY[+H"G#G%9.!I;6!/I[C_'H._;G=1-723
M7_9Q^EL></Z2IP?19$K_=T0#CQKK-J:H289CXT292T7#Z$:38NK+@:LK/!KB
M3IMR?VE#"H"*OJ>LV;9!8Q<V9=8-C>'PZ!BY,50TK]@?<O>!DQ,L(^CQ!;R*
M"P?9[3UY^-@G.<ZT[)N.A@U,.FPZ3$3?"D.3D,B\IR^(.HT@5 VH,U( D(\4
M@.*Q%>\,!6"(P.NYY/0NW_0!-65TJ$Q)B$'M=3CI<5]>,-1[V9VV#@?STN/O
M+992 '$P5E[3R0#KF=D14G;1K^75I-C;YA=$YYDBU)>#D-/LHRA=8IC %)R/
M*/?8$*MFM;IA@]EH5MKTS4(?-Q[0)%YP@J=-G_)QM[]?$KWD\-[!R3;X_?L1
MS(-X BO^6Z$"ZBB7W0/QM+DRJV$6A8/_+(+'4 !FW@2K5-(.B9H4, R'.B.Q
M+':!0IU5>%"'HF:BS/(6T_0L_TWOQ? 5^H;^MJ/U I'>&.E/$+6E5N-GX7MZ
MU^#B>>\?YA!&;QM1,Q2$0D4F<Q"1QC&%.U-3]7WX=-N\TA!_TO;">LAN)0Y#
M[E85./1$D[_PC<Q?,O+:CD=.Y2-(L2UZ D?EO!^/9C\X\NLK#E3)-=/Q7"!)
ML"%8A5RQ>E(O2I@Y6=A&^(40+ESUN]QVV$GPA._(A],FSD"D):(A8=@H[5;_
MG>H ]M=/XB+K]GIQ?BOV^8$+.^48[2,XM\UF<L/3B=VZWJR#>W]H20?@(WB]
MZY)'POR55KP>[LF;#,<-,?=U\N^?W[0&.??^C/Y3]5M_JDM H5=]78QRQ?BE
M]5U*0X)A5!FOMC';939.06 ;IKF%'*UIKJFZ6,%7@80(V'#+]E)BERO#)U7.
M&/),FE)?FUZS-?%W_P+Y4M#=4Y[%][/F?TAI2V!\L-Q8XSK;[66!(DU=W8V-
MHCQ3NK\C/@<;3='0> '9(<9L$>0[^(CG =<D9BRO2DT,WIW^RHVU CYQK7&\
MFO\U\KFDSH8H9@%MCR%"&975//YV3B85:HZO8+0;V<QHXP>W_F;*18D%739S
M9(HM-WD8ZY/5JF' T,Q.$ N\!&4+3#=%Z!L_'\W]6?>"S=(U1P>AN>2]T<EI
M4OT^*_/\A )@!+YNA7:K"C=,E"N_D,"DO@C*&)>RIA.^(_:I)D&^C==@?4J5
MBBCG$85DV'V[E^)>'+C@VK*9ZD]][8)2/Z=%";4&:P3-()AO9IB$3=J(UX8R
M^ @,X1K%C#OZ!0EYIV?69]<]INN[8':1S%T9(7UEW=E^GS6_4:?**PAQ816O
M'T'?(:OGR[&P+K.,BNQR-=_J64YHU4S4=%?5YU_F]%^7$S'*YX1:UN7G%_XK
MN++<X.&VF\7>*WRU3*_=>F2Y]+(X:9*LIL%BU@()_"].BZ;")NYJE.F40APF
ME[V?^1MVNMY2^:+)10$L#R_\"%()!NZR4@ "N5T4P#$:2&))76<]F?9[\TBO
M2M4=CA/88C'4<'_]GT6[0@T) EL'-H%:9N.9:59ZE?>=JOI::3$?R#)[+:@1
M8!4#\8+L4  V+R\@B"TB:@UA?*?<UE0U@FY?]]Z_& Z*<>S?.B" _Z[+N*E,
MHM*+AP8&5R1!P0'_%^H?/'P$,]=$^T77FXIRLR>$RC5H35+X- 6 B.'M0#R'
MYU, KOMGM'@G<M/(A=O,AXR"#=_I/ =+=70#YW_FQ(C^EO_/JLH9;$FIM6>^
MT#B.T*KJJW["#K6I(5SWD@R \VIG&80<I J"F@+H?XF%D\(85ER/!!%.4C$F
MQ@<JF<RMLBT7-X3?/?K7K1J!,6!F:? 'U2N3RB;P7_;C._8CZ3QT*=H&3-*T
MI8_;>+^U7499@*G^28*%6/D7MB'8X[^)95J_D7H8F*Q6)X^_P++LP/VFJ4R5
MO(EG6WIIXC!5R$L2'"% =$?Q7)71&V+0R3#1LV'02%VFA7U6>LAC)L0=.*+!
M=?TPWGAI/Y',TWN[M@COVI7%'@_:.^8LO1'[Y-KR)W8MF^GM>40>!1#^<B/X
MYFF7Q.TMN8YK,@1.8<V,Y,6FGAU,T"V>#Z\$^M:9&/^L'[D?#-_\:\K5JHBO
ML?8;G7>G)*T.2QSKR\"["3W-3A:&Z?RO?#2_%S5^!RI0 *_ :!C&O1+'IX-5
MS1= Q?N&=,R_KD]$K'4\4O@^[*XKP6XFI$#EJ4T[@UPL4-P_"6B+%P69=F5$
M-5ZO.N])TEVY@-QJ0,73A6C>2\1KV 2"22LV,5J\1N^'X?NF9+:D08#.]>;I
M'>N4@P*V0J[K9[SDZS_*/XR3>3:VO%^G'>SV%HPR2:PW4@ B/9+QNOW=YF.Z
MSPO&G>(N7K&B+W@7A#8:6'?<WYF3W-L&S@U\]*$ DBKQJ*W),"]HN_@15 G#
M%E^KWTB036>MV_$]=)A+[.TGB1Z]<4F>ETLS,\=HB VO4SU920ZYGJG7^E<1
MA'H#GMD")81"[F&YCZ:\ME!9@DV1==I--QN^49VDSO#9[95I2"WM[Y*PZ9@K
MY?09I^CH*'='Z$,^N%698;-77%_"QK?^U1DMV@DG7B<EVYZL,;G:D3SAO,N/
M+G/%E):\2;,4A'E!B^9F-T]D-UYG;&V9) A_\7-TO$NUYRHYZ&OVR_;1Q2A^
MNNB^]M#*\L\664!XE4.?I^]..W?G,UP4S_;GL$R4#C;]!(6WP868U8^)R2B5
MLUDT*KVLG%JZ)3V4?*FT5-HA\8[-C%(4E0(UR$D:_DIA.<3Z-$.D+COT=KJ=
M3Y#"+$V+OG2<DD@X:$-T#0F MO^ER@%1QZ4E+95:\3*ZI&?D=UA:C119MOT\
MJ_@K)SE%@?/K._D>D'QQG ,_6MW;\,^Y?\PA,G:!MX4!*]MS(_'V]@,GE5[9
MDT?%:6MVF4R5<"6MTP3:.\.!<$&L%I%%?4DBKK;/MW]E2EEV7%Y[SZ_4>?E=
MY3!5X$IH;J'X.RE4Q0/C+ZECS)G&U4[CM6?V%  -]Y3,+!Q][8BDLV9S?P14
M[_90D%_3WN]7,M6XX),M$/@S?0?2F/5##+NV ]_=A&,<:E>?H$:D3>E)S[J&
M3UG\X=J%COK81S,9][@HKI]#KTXALLN;*NIYYSOM?<OG[E)-9O>K6M[.)1B3
MKWF4NHZ[S,N/Y[N\QDXVSPY>(>XDK-9'7]LS>9ZT@V@AK=H:$A[C8]MY'N#U
M"A>(*E@BF0/;J2_M.?.G(ZG/QLJUV2W@CPYO8*40%XH&)WJ"QP=@ZWO1]1]J
M;:2ZS-C.WP[2G=XV_:G,&5/*=?N'^;(_P^ $A[%1L>',9;>KHM6;NJ*?4&%2
M@1(=9*I*7$$EYH:-7&?]U.B<E8V!P6;R4_KW?(#F2B/ZR<O'RS'8KQ>(+9_W
M&O^4:5\[1G@WUDTQUEQKA2IN_9*QH%+H+X)]QK#TJGB2NU?"SGE5S #V E#!
M.)QO6\Y'0^D+\^9[UV;GK.I6_/IYWU^^I;9R\3&9W=YVDQQV;1[\6"[^4IV_
M>GB)289:X%LB@.K/Q&WS'(0#KI#((K?$\,%C?@R]_P(GE;L3)&VEX=Q^S"#:
M<R>DF"^C=1$\N[U( <0'E*&'4%%.A@T:%;-!5E%>G3TV*O)S66$-J)EA5"6L
M)G[79V- =%!Z!)VXI%E;;.ERHJHTY@YW7].^&ZYPS87?\7K)%07^ST".8\6A
M@GJ-@JQV< 80:[SK:4-\B1W^4N@]XQSN>.+B])GQ3+,0!Q_;(J9<6,H[5S!Z
MH9;VTSW:!W8>3F\*R7-CZN=]6DLVY@Z$SNL7Z $SSXKWP8QP:WA)1!$ER@.C
ME/QO2&U:0E#W[WL_>17C:<  UFTL(RKA%CI3(UY,MDAA).AHH'.VMM,@EZC-
M@V:1P[Z-$-0&&Y&904L6>86H4RRYZSKDE6,44N:I$7'6'&9RS-#5*J<_I<J-
MSQ@QCU$X:O2=?>^=_,[,*:TK*_3QYQ#&C/G :/:#Z1[IH-PAGP/"22BIKL4'
M6]AE&5J'++,-_-XAMLTZF95]+\OY_F83^YT]&BV-X;$KC^3YCJ/&MD2WS=W=
M5BQ>?KNMO6(;E_>:\?@*DAIK_NZ*?M@Z1&*LHD8B*HMIW*,^M&Y$NZ8>YN^S
MQB]<GDF(L,#DWIG)V=!I+O!C,9-:WO_$<P</SD948EK=Q]5_TMX0&"2.R=D4
M18CM)BX]!]5"-DNA[7JJS)NG<)K6Q$^UVNGY0_EQ>IRAEU/XPERMDS[D8W/S
M!Q[/P<Q';5VQT)./6-Y>82<*X /(TNK[H%=3J.H2G=SC"J]F^]#5%<A@4M_E
MB.Y@$SV#A[]<"BK"8]IPA8D0)>R^EIMQ%WHRZ]/+0AZ_E6QJWKVBK=[I2Z[K
MX%O0=AU51F=4F'Y.8(1-(NPH'@@R,5 I2)9=WSPST61*[_BP>F=OI,09_HW(
M>>$AZ/ :F-D^<<>FR1:@],%'>X[\:)J$2\EV+H#+F:^S'OF\'PI)[()_O&!;
MR$O;/*)33!@;.;WHX0PE$]/4]R__%G9\KB.FF*3^(6?G]P.-T@+?([/!,+J+
M^?01HHA#Q1Z!Z%W0;/\<%F':&M5S)6ML6A/.]X'F8P._L!#_NT#:"+"1H?
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MMT$,FR=#N1L9(>)SQ\=;?-;4??%V@,^-G>ZO@KV.#_?9($8I)PE3?-B=@YE
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MW]H6E,DV6X/%M$?-RO;J[]Y/$(?L3;'\Y=;6*%IJOE4G*N2S*?'@])W^7 K
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MR+.T8J^@NUR#/O>C4D?@OSQ56%_XPS] %PLYEEKQJ+]=8GRX$Z(YDS8.]!\
M\5OYBG[6)=[ED8IO'C7_.>;%"XS$5NRWB"]#;P[QM5;\\'$+<B^;N;8N%K,8
M3-=1R),'LUP&+N;!N&HY]]FLB%+C[K8+.C^CE%KU[=^&%@10+6OUFCQ%3^^!
M^2$EKA?^.MS2&7.!DT]->N7DINH:+Z"E83-T]\W9P@D).[<603 (3-A:D[4*
M->6TFC43>1)(_/!Q>0,G3WR@(?31WJU$> _Z>F3:"82?6?199F![@T[XGF^C
MBW,Y05O$"WSA8PVRF..B^</^Y ;L2^81_!HI%T%7WP:.0:='TAR^,4W*"Y"M
M?]9LL^37]X>6\_U IJ?_>MQBZ"J!)VP,3.\+GUE7'SN&LVR&\4P<W<D+WQIY
MWJC]&CJO5-I5II;N_3GLB8&WBA1V9%<.9RF1L, E [_E\OP7&C+"G?6#/>XL
MD4E80REX=58\(=>3NU37NU@D&=&EKZ9FY;-PL88@9^[/]B"Q\423";_](QLE
M0RFUW$Z/0^G?.E\D[KD#'#3;C+.^<5, 6J6#%( C++(*PHE_L 2C^[-,T+Q#
M=YK'E5BCVZ-E?7K=REFE(\(VVYK5<5UP>,#+\*,9!KFK4LYP*^SWPBTXU9]<
MR\;W5@I]GWX](6N+GGS[JOGOQ(9=< 1":#*A%6-C9<P/JYL;\DI!K7LO3#4]
MBC7]]9CA:6(AT DZ6ZX*($K589,#V0AN.0T92_O06O+(&MM;TL@]W/OWIXFZ
MT<LC1!;J;O =B%#0T@]1C7IL6B($8;.9L%GA+ACW_BMQJ(B5\\>T]6>O3">@
M 825]"F,,3!BB2%"QBVDX\JAQ81TK-5@XZQQ2UQ-\M.*L!=?A0G3;=3Y7M!:
M\(X<EM!! 5P[AM\.?#B\W(E.B 4TAH!K![UH?ME%8>==I43=^,,YN5XF>(L;
MQ&:A4P:-4T+II4X$20F[RH:AA9 G.-72_"W+T"^Q*@6)!7.]WL_:HHR]^W3_
M-HY87><G[0#4"",84&+-2"2"9JK%I$QU]J;D7('?Y2M)3?RNY/'')CP[H@=L
M)W;XXC*(,+Y_:7!7<LN\7$+"KFI"W 2A]SW@LZ@H_8=WW5].[IJA>;'&^[='
M"B"/L?712]Y)6^B4$5E@_%U04VB];O163D&Y@FZ)_L9 H0"'6Q[$>#F1*Q!U
M4HQO]!!H2WD^)6/UWJ5@L[)^S\W>\>S5,VQ);IK]AD6B,=A&B,@LT:D(ZAP<
M+/?H"0[')]_0^E&QR*A5V#'0G+#R^F'?(^_9B:1A6EU\Z>)I5^(MH@ANL@"Y
M9!7XT&]5J[[.HCQNA?W*>"6MZ=W4\\?PEU/0I4*HB[#&C^/$&#]Q2?LN\3?2
MLVQGE>'^O<P7'CTP^5'H=LX;W8&'?3WB2G45(W?Q0IAXJW;D[1:!DHT49<L/
MEE^NOJ=7G@RX/@HS<1#0/I(Y/\;M+YLF8=F6ADX_'3]Y*&B\8CX=A48%T-%/
MM^_(BX$<C((6>;]3  [(:7IPM*K@.-%N>7;6:LZRO>M$4?^3! LS=6J:SE7.
M;Z![+U[>H@?IXN#X!V9=#XAJN(S>COX'!-KHG>=?([Q./K4E?4T\5<X^.Y^2
M7(6;"/R>4I[X>U;9WW7_(P50Q]!=&A(DF&*)\K!H*?H68SG]A-Z*.HE%;Z$1
M..^XOK'_$88%(6\0A?#<&!#+MJW0I!_HEDO:347QKS'SX\/*(JFO QS^#$@U
MZO2^70Q8P#Z#1?NCS3I#0WJ,-,N+ME % P^N]NL%/I&GK5MW'*GH/JI8)E]G
MQQ"@].2A\X*,@YTFE(1X6;;:Q&Z2H\_1+",M:6G[:0G0N;CS*6/XBD_:^AJ\
MW88%G[+,]OZHM3EROM[IAE?F@Q_4O&VOR:SG%YB,AGJ*/IWP"!]%U8YLK*X=
M(=7K,&RR$[<78=,I&HK[NVJ+@76K=[-<Z^0W5]OY(BB 4)'$'D3+A0?-VM9W
MQ09<X.;,T&HK"ZLY^W##Q&$-8*2)C:L&,TC7VZD76AF6@%[?55F4O[1WL+?2
MJ,#%(,+./T)6.$/M.(2940#M<KX1Q6&C4>N.2X4;IV:<R.:T!#$*8 4TA32
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M(,C!RCZ[2T"I86VCV5/$/VE[59!*&(;A#+ %/MZ5(+]S/9@E7[M@^$(/'"B
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MV)=H][?5^NWXC2PAFZL;&>+=N9\R^^WLGS2\*=6WQ MJ&YX'[2,M0@E7ABB
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MK0'N=&&(@N.8^I?:84#EIQ=U.0YEV"/#,;&R-W;42R_'UU+N/"[A\Y08HOU
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MR1,XW58K;YS]R;?'[B%W[N\<OQCT7V]!NYJ>:>4O4)D@$MP[H;3RD(\@\Y,
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MMNN0-7F\\TQ>S*U_$K[EBI,9/:?V?E0I":.NU([<=@_0[XAATIV=IKF3<_=
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M(GKBL4F=LR8?;]=7U?O93K[);3#]_;,MF;[HZCM% R+@&I@(2)Q$(2[9\HB
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MCT>20SFWEZX20$LV01!T[=[>=$3-^4;#CU&7_!2SF[.R#C[W4EYJ\6=IR:R
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MN=ELVPFK87TG\[VXRHH' $:#5Q1;9, T0B])@BX@"1>^IA/()=J-X6."'KU
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MS30%HPWWSTV;XZ]I@XC"=:6+N%L(0H*RXCE T;H3V8XW02?>420P;TX*>I$
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MNA6XW89%6!"S!7Y K_P1=<+0DJX;)-ODN+SW?P7U/ZGIDHU;P<40MAOX!LB
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MJ-F;^TNFN.*O(M,(_>0P^:E>+TCHN/)M7+V+DNUFE424W@W60AX@(9/[^P'
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M3XRG:G8IF/- <<JI!0[T0N8R%\/8\]'RU,GNB<MJ[ F_LW6U^4[YB_PI6QO
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M^-W[R2<HA=[HS;:)B&="O;R3+700&8+(N#(U06.RZ4[1;[CNU'.$Q:CX1);
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MK%4QE?U6/;L[&>%Y+P4IV5[J2R3+DG\602[E93'O2[))_HKH0%DJ^%TN8HK
MY^N>MHJS_B8" #W53P7'PW5H]#-D[^7%9$@J.EE@;%>U_-7:'3Q*X6J-/RKN
ML<OJ?;"548BFBOL9J*X"J6MA&X_YT"21MQW#$N]:LE(OYCG;3.Z,DX#$02JS
M=I=78F9 /<R_M9P]@2$MPQN.#6M+[T&-(H4;!S_F(FEBS07"\53X\J%.:KI
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MV ]]^"1F.WQ2'#@_G0UE-AU*'!^5@$-AU,V8@#*-E2P&^?DNOO3QET TJJ.
MZX(( .#6+4=USOX=\!70B@#=^(ZOB):@;QY8^3/T(HE4Q8/S5A9NGR/NF0>F
M'' GQ,^ "/X]H\5X#TO+LF\C\))(>*N3RJF7F'A%J!JK[?-8Y5U5]Q/_8I?1
M_<GYL7!S8)Q!@E\6 \X> X-Q8V;61YAXM>N!]I4N;92RNAC*[^?/3HN4+N,>
MN(80 =>JL&=\H (+8,5"F??AQYB/1$##Z\40^<EA2!4D8+(KBVZC*41Q)B0A
MO? #YT<T=IP(:%$[^$J%F6F)H),*S^X#J_E(Y6R.-_GKG8>7L%ZXJKQV78M$
MBZ0Q2YC9Y;>?7B;XGZ03 MP2>J<N=^.>()0^3Q89]ST-*I"F^'FRS"]3))+]
MGR9R_GOWW_R_"J:#$N=J+5 $J,^[;'>?U_YE;09YC]#=#I#@4B#E1>XK4IWP
M#B4<R<7G."W3X:[-$ 'HAH/-+^GF5+W[ZC1B_V51VT_ U\_/ !3W+VFH,H8P
MT8[G24\<FL]U<'72TR(8"]E,?*]Y2TDQDK5;XB@P#G!WX:ZA#B25A85F5UZR
M,_UTQM0Q7V*OU+A]"W $)^LH7)4A/J15 R"C_41)]?JNS!,*\O#AG(S9.2-E
MBXWP%DZ,08^^>>^*+HW]P@V_9WWDC@U0XUL\;K'Y8ZLR;#V?RZ+#S5])I*"0
M[8N7O06>Q&,[6J[__,?$K>;!E"\JSKQJC_BI;P8^33*(3M7;LE1E-&@^)>?M
M)!W49/?B3I-RSM;,WD?GE47]ZNB5NQW9,TN1D]).*.!R1M28]#TBX"I.P-6-
MNB1.FSGT55GD594+##Q!@5?*]L-%)MHKJ&[GQ X:=R*IH RKB@\=N7E0;P/*
M%C]T/MC1'^6I2WG&%SRWK7-9EVW?"41@.UUVQ3- KL"70B:)@*A)N*JQQ#Y(
MI(>,"*#!HFH)88CW8)2*$Q'0O:T%>4?Z<=<EN[X6X[4L[_?!TB;<ODK>UN/9
M&]9KJ1<YKZEZ>>@-B"S_:.2,^:!TW9NA:R8O+;E^"7%U1RXR0&7!D?TI0W\K
M#<#R9\([ .=)J2L-!JR,LHR8]O9[.%K%<<N=UWPK.6ZVVR226>@=#4KVI#1<
MT'*76=G"J!BEM;S06&2QS9[R#BI6")FKC_<K+F6?,;6U'D]-I7SAKU$V0;KS
MMOIE9%7*^RKP)4(?_-H1209NSL""GWEL\=]K<"YYBV;A?S/[A"PA8%">"E?Q
MK\A7)?RZ O5SM$3K^5!PM489S^BQN;NK9')DL5!1CY"I"7G/:Z<-UZM$0)M\
M"YLW2R>[7=BS2>C3T<U)/4>QDE.C 39[BT?2EVHO1B)XKKE9>CAV7W>TU/%-
MG,M+4PI%2W> *3 3*[(XE65M!JM,L?<I!J/9];9;/QOBY>A^5!T!:;>XF;Z9
M"[-H5@SOIN0W!S<HLZX"/0%,*UFH!? %$I/S)@)^J)X2 :RY!(Z>)0B>#GCV
MZ,]J$Z90?NV2 9_L>6Z\15:8$CT&V,T>-^9Y<!D#-Q^C^LK1K*45N**?FW/@
M(4 ^*O4+^<^G*UM==MVC1)'.9/@+CPB2(@+VTB-8)\S?8[DZ.9C"J-SO.-+Q
M' V(F/:82RK9]VEEV 7C6$B/C7RJSVYY@%K[IS!_[ !_2XH=5Y4+AMSM*8#A
MW67?)3K-F9SP_F]E7IV+5Z$"JVI&:+H026>?V, "@]&5.EY 0-2V'\/9I*JJ
MXKL-!2G48KL5S1L"$%43D2W+'^'0 +VW%G]7]WMN+=/PL"K'_D669*/SJ.)9
M2V6F\:8@.IKO7!Q('I135,02I,->E/E0-+2%*9K$P<R#AYW?!_S.:*NQD]V0
MFAM6G9DRXJVM#9^XLA0H&<(Z=E.=/=CPR5T ^3M T1\;<>U$TD)Y5S68(=<P
MQJJ3-@:QY\D9M!U7Q<;'3E;R43TD&D[CS6_A[=?AJQ8(E ])L6:JV5V5G<J5
MG4'&'I6>"\[/M%?,@9+0HNU9%S%#>NRA'Q2X/CO5KHA=:QBK^B["/T5YPTLN
M(2"AVR]MNS!G[Q7'1Q@+2CU4@<Y)L394DE:TX^0W./6.G&7BVUY>:XZ/-]_I
MR/26_KB=)T'7V4*!VHA<OH8)NC]R/)42P)UOQ]4>R1G-I>N;N[P8K$2)"IYN
M^-G$]=F^5OWB0(%#K#F2K:<_G,[];-)05;XYV(9)RVAX5T'YRYS#3'Y437[!
MG$"*8OZ:UAU]Q*DIZS7U<J:WX2HR3L  .&U5XZQ?'YCT"*L::^->AJS0,D_S
MA8T%EI0PW @ !,I>-'8W7>"9/#J@VDR9Z49X,86D6E/KNKF+M7>'BVL0 3N>
MB"P< Q8&%43W1-U K;&P?TGE[\RA=L)KCK^H3NUM?]?6)Z+[8#LWT\TH5W"[
M^A8Z.K3".V(9&- $*6K)+\.(=LQ,?-XNG/2-3KK4F7^_]=(\92N7[!_WH/(
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M=V&\I%M6;6'!N';\'E@V;R31:9H\\YD>!ZDJS?E(A) @-6'3>C8Z]W#]?.L
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MFUR0.!BP0B3,JODMJS+J_[?L_D)-MG2" Z]7-\6J!1$@E5^J71]_8W9=*GW
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M6;%K1J-U$T8"M+$*PN"Q#IGV!0DL"([0<#"A*447O9&4JE2IJ+=V=.-6G#E
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M,W:9[5_=^U_I:G7GM5_RE74[>VZ6[8'$E<8RJT5"+-BH) Q$2H2/!_0(+E4
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MQ72<O]59-1F)RS?XZ_7 7)0U0[69.'3;QV_^,:WJS%YVP[I[B<GU6UE<X O
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MZU-1N_ORHO;@Y[HH47M[5JBZ:><%]U7%V'A*5#!1!;LBC9=A4D=F,WBNO/2
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M?/- D(#3)H,4Y];.8-O[TH7'[[E 8C(!\QU?\1Y@!],%<3(S2-QD465EAW-
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M8]XUTI[FW0&N"\Z1=F;W])PO'1<[8*B!RALJGYQ>5H *1'NHVBS0V1;U86+
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M!7'M; "(<O+$^B/@[BNET5>P7&G>COI0C-?/?^:F"L1E9!V::CVE6M#<2(P
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MRSN=#X&/<%J%\+I)?9 ^+!V7$_?V=*&;4 X:KU*%+FR7S_'EX=)VVMX1')4
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ME[1O^)06.&/,6($>+C(!<92B1-7')>V>M8<)EJU"%A4X@+1H2WO3<H4@-3@
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MB>B238H/[[R<%_4K-_63^;__GZ,G#[\54''+WW :7[Y^-;KZ7;U8G$<:A1R
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MJ)31/^MV&:?7)<,O)=LUKA?3O^++?_0^N5NPEQZ6I#S/ N,Z58#['9'KI\#
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MP&T()TC=[H"3WEZ!?(CJ&<"*MBBE875$FYMBVF//6UCVC<?_G^@SZQF"^^>
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M.J>%V\,Q#G!/NY. :A-BAC;"7[-3-'#YH?;]"$RP$/FUO6FY>QI&$T8?]F"
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M5;>ML.Z%9NKD:5ZHT/?\V\:?2,?<H&%2:24AZ2O2Y*&,VW^-SQ\:H5W\14X
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MP'";4/$S&$PI)76TT_@7H%4Y+A:Z/[_H.W3ZM4&Q_IF>/0EI3KI[+F:6DC;
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MV72[2'RA#XHF>#EHW./Z#WX1F-@D@QCO.G0=6NY@;7'WK?MFE<MIDNK/8)I
MUFD;/@V0LI 7A%>.:B@/S?(OU&73M(44V&GLEX/?VYN_5_R1CLB\Y=2%1V2=
MXW"#7J74Y&AM#-[<O[7#^]'[#IO*M_K*G?>Q[AER>TU^!03+M;QD3.9IEE&
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M H[S8WX=B^2\.4Z^Z()PRM3[$9:F+QE,RAB G>>(.[L""WF@5'^!/(\0N*V
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MDY=9+*O*^/@^N5"+T\MS[;3UFQVG23 H:TQN_W.7!+*"E 1"V]U$*&XCNM-
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MZ.D//"XP2-_<O_^5!R&92>5[G-R[-[SJ'V/ (6JI7+1_A.V>V:MKH,CP+YM
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M:3J3 \+<#5!7C=*5O2;'DVNG) V+@.RIM219TW0DH7<R:!335;%?""I6?+*
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MWR,!&T)>\%&:M^HEG$_[>L<;]40NDBJH:1GXF:Q%7(S-?J^!BGD=KEGXQJ3
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M4KSQ3@]ICLA'6MHP:F56$U63O16M%D70(Z2KB4DFR,3\[K"7(VQ> /,"L O
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MM>2ARK1 $TG;UJN"CJB>%$TZN:[2_TV;S)V"C3H;V>]5OH']SGF+3\;[>=#
M_G[00.%,_I&;3 2VRMK.-I4L'P>RI;HL0=YR6\M(3DOD6"^OD(=8NB@BOY:B
M*+F/=(VL@.F46%,#(7E>)-/H?Z[<)4NO.N-VX+IE@*8P&85[,S^HFO ZS]"U
MA"NEBC^MX6_+]$:[9BE"YVQ$R,IKJJ?<)3G<J\<\>*GKU<HYWZJC'II_]LU.
MP12AM44+!W9\A%$@4.2UY&"8C:_R%^114&9XF0,-FR6B,<]B=#O3@IFEF_12
M64OPD5G30B=%.$J]/:D1L)JQJ"/7592,7"1N)TPK*NYX+?&%W)&W)[\!+9@=
M?$U">7$2<PS$>*<7(?@8A;7T0&T;#4BV"_?@DW:1EK%9HF:>9D4M^GVQE=ZD
M;9>'R@N,7_-7M5E+:"(#96L%V*UMVF)K2YEDME5Z69[[\:3C_P)_Y&\\Y_,.
M:-.W(E$_>%VZ/ H?,A/*05XY!8?,M;J?,4)-A0[WQ "?2WLC15!A <*P^V+.
MZ'\:.R.#[5MSQM;#DGNQ7EA>7R[\>H$(W;UFX'J(J8_]_NA%L_-5?(]S43DU
MCZ ^>XF6>*+:<;_ETF@$H:32+]PV#0#.P(.%2)^%]VQ-X6N]V)9368 -ENFN
M=0VK!CJH[2;LD8,\7V4]O#B8%/8]UD6D\RMEZM36$VC$0.$)0Z+H'9FR:_"&
MD@Q1NG.WWJ RG%-_)O@*J7@O0% WK(( C;2Q FM7]YT;KMLD1H$NNWGA9IP+
M#W,6YX_Q24]R<&8 &HV.YBH[ !B94\6SR1!A"!\U/#7;MF<JS-D^9ON@R-<=
M>K,FO>%#T$ 78*O5J>IVBKYSE]G'Z3)[.'>9_3Y=9K/SNU/.[QE4W-) ,42%
M"B726^Y",;Z=N7)G@QGMEB0?:5KS<  5S,8<?\\6(X7WMI,&1";0"%Q=LXG,
M)D*]5R:E1I1Q@ 8X']-D#(AUQI+?,@"?S>7/;RXO?6L/:&UFLYC-@LSB)Q$+
MDDZGV2QFL] R5E&](Y:+D*.S_<SV\Y?_.$TR B#F'KUWA69-:C*\<UA1BTL*
M9,RKM&EVP]1I42F;@X N!L75\#DWB%JD4\VE5&7+6: MT#:0"BDQKV:0@(,%
M+5S:5H2I: N9NM@)0$#T1@0M2K3(MM+SZ@4_?>>L>9!.4$=*' T BT!7++5X
M=54LBT[07Q/5WP&AL*^AZ[A]_S<8 ZD;EI!9[A67Z;)N*!\S(T<_"3#(8T6-
M.E?5]%M.G EY-5B3J G2*Q3Z3G.*4&AA3 "9F'JDXDJG@*I::7*'1#?(*=\#
MN_19.IP8G*Y:8W4;^KO5ZX3D)2F(61P:TQQ40"^DQ+L-!\Y:P\Z-N^<N2D)P
M_NA>5P<@V47^)IW"CWN,H>&?VM8W.3:%NND86-CE98YEWV-<_#MI<0>4A- M
MYMM7SHL"Q('_7Y=UG;G_YFZ+O'(>[C7]L: ?NI<!<BKG'E+A,!5K<9\I&"??
M%AD@I)9SMTJ=R;%FL9OGHXWSG;!5@/@:!JVH!1.QM=KP@BKKWC/[;OP59FB#
M\WEPB]Z#JO]2/XYIIGR@F^641:&'G%& \GA(ZO*=%I-Y+[_O0OK3.K-?286T
M8%CS0EDR/I#E23J<@=V*Y(^)1!:-SJ)#%7/NPRYDU:#CF7?\U6X162DQP7$O
M!<"#6U6]2CM[.?<EU9%U0THMZSZ1L.R6 )K*5=QG!"DF#X*G!UQ5V'1;J( 0
M(M8.W/,"UP.(JD8$?:M,4 !T$2D@FC_89X7K (?U9@O/QGT'(9SA57A;"6E>
M%@/"!*_84<KT'D+7"K98@1(S&O-3V @% U]#<ACN=T4 1EUXP>I U8V_G+UZ
M8;>!6+ 0_(WJVFEI(K1D<1EN[ZH!80SV/EPW97Y):$R1!,$^RCG:Y"I/W1'!
M&C:Q#B.0QP]H;3G[I>C96K^+:WNVPGRS+>M=3M0XTR(CZ4 NV^Q@_H(DPL)
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MEWDS=+=>^O>V%H!O.&XGU42)A$VW8]X*Y2+1*27C3BZGC&(B?UMLO5<EN@+
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M/9>*F8G6>V!R;<5FSR6,('\KCIA/2B(K$+8#+7RD'!I12C2G<C/=^J9G3=3
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MTJ'CP+6)+Z="ZJ5(7<0X$A\)F/T$?V][\%.S"D2@UICL)\QIF#JPF;6+%8L
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MV5O+_? !Z,V/A]/2.4H7OG-YW^T_7FQLRU/V4?](&]F;B[AN<:HF!V@3D%>
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M=SMINN;YJ4]_?NK7"W@$G[SGQ.'!L"UU-^J_SAN1_:XD%C>;[=$\AS?;$6-
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M.RZ;OA(>T,) A M*UFB1IK01;7B(;Z)7I;^3/J)W_\GK %AT)N<2]?&Q6+1
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M)K.)"], )R5>NW[1?'-"3T74&M<\D>@A;N 'VFAM$TQTAZX;P683W$\'@JY
M1*5'XDW#-R0(=ZV6\<D&\F=&XE 0IB2Q, 4C5)XP.B3X7>H)S"(&+3'465 .
MI<=4.J\KI\T9+OSQ#NO;$27L1-IOV>CN5I@_XPT_.-[PZQEO..,-W\6"GID1
MGPE>V,& CP2]8<A/Z\/6.=K!/YF.'\PBG7*-JQS(C DV0*IDL<9KK\ZT*XAV
M^6L4V1EE)#P:KES6;7=$-!#)H*&_<3C26%$FZ)NE_B.<FC^C'<][^4=37&H?
MTER4*YC9K6(*I*738W8?$W6NCX9FBC&N(B!("K@G8/V9Q2<X5M09:UY-O5E
M#+5"4/E0F/H+_N=KH1ZW;U[3@;)X1<!'%=MBH)<J<@6AHLD@P"I_R9BJD2:*
M11K!#XE(4:S9+'+2!1&%HJ(! &?+HE!,:B?\M7<K/KR3?N_T0A"?5/O?)FV+
M%)JIA;8 J]$*7U+<,UV=F'IJFR=4@,LR7X*[D5(P:"3SCV96^QG_T;QRG9#X
ME^4AONMWH?<]4_$6I243//24U1N'+@_FC8-[(N/-DZ<T?U75HC8;+P8D-,W<
M+1N0JW56;$S&E@/FC#Y'_361)Z=,/8BSZA%!)85PIU%%_#H6\C=PHX7.#-+[
M-L*I])]E&CCR"#=Q*!Z%(7(T.ALOGTFUU3NN_5PW&<V(GIP@/78V.H)OQE>D
MGOMHKIBJ-.W1WMM77T78XOC[ \0#;HD122GB2QQQA'L=P@-!5D[2;+H[WAF%
M5,:F%A C@(&<! /OL)<)N<^9F\A43&.10+#(N*N:$4("V\!/B^QPH511-/;
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M8G(RR@/D'ZBBR9^L^#EFR2@'C1-36\(@Y7E*(@8SFG@:5'(>M)Q#C,4T$"H
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M+<J@,$^L)Y*KSU8T6Q'U+'@ 1P8@@&+2T8B,#C >V.&YV\%4A6DWLGC!4+B
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MQ,K[(AY3/21UAA27H(FG LR*!$/,_](SH<U28>ZE%E(VQXW^=C/ALYI2;1W
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M9P8J>S@&MCL1*/LS-6\&5(5I@L=(QG\V\'?7\ ('V"N/I3&>B\E"0,4?)^Z
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MI''BM7DX#F?XSOS*SPUNI"Q+X(I1Y(R  1430+P05X"330KD7:6" #8\>S:
MAM/ ^6<!7 -.!#<.?+W;<KZL 8RQ!,/ /,_"3O#PXO;*!XF!/@<Q _Z9*3^!
ML7@RRGVX1S0D<&6 H(0E,DFX"7@$$&A\!<P2^5V1LN@? [;!.2\1K"U@6?1N
M8)VIA/W4GSO7*$:F "Z4'Z -D?:07R49:JXW!'3VKXQ]G!<(QQ]3$UEF_7BK
MR;C@:]%6J))52"E^"MNB;\VK3)/+U)]F/"90Y"%IL/A4+L97,3I9D8W2*4#E
M\O,%7,B0W5\6D0\\>*XWI%FW^22(1) ! 1P;4<*$8(&PQAM ">-?^V%$,\^
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M!2B%3&EP-5T"*LD*&MNEV,G"&B,Q3^3*R&!@+XCH:1&#L#)@U<#9RK' H68
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MOC:<O_F ! U0ZS$$ ,IOPSF_ L&*3WV*@]"7<:HP!:5_Z1Q+V@IZI'%;^@X
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MA8A4;@R'(2)0*A1%===MC14A54RB5'XS:\BL&&?#)"M&?U!@$UOA7R:Y&ME
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M;#IC\7)EH;C1;I%Z\,%6,70<Z'XB%;$;)RD6<5?22V?4\U_]JDRV!?8I**&
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M_J0@XXJ@4J/^IOS.5J"]2,FKD1%*\;)LALD,E%"8I&46FC*%IM@>U.>.8WZ
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M:B/#[R&9\^"NL_%.#O-LAWQO]FPU/MLJAB2M!-K^+IG3$Q)P16" ;'$7_O/
MW'EQ9*GW^;?09-;Z?9RUD(!5\9O_^,G[:3-4M 4JW06#T]XL=[(D"@-';6K%
M"9X<DF0I[\P_8%H>:\TO,/(?AED;83BA_]J=0\2_9^=L=)808Q8YN2<6[@,
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M,-]6;8I^VP0.\FZ4W")$<4ZKG,(*GVS)WQ\SVO?!PR07MK/Q]6ONHS^LW 4
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M<Z=#LMKM6%%=,ZH\5&YS&'=J1?6N177?BNIZWO<NS&ZOWQ[TAF\"^*[=?M[
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M?G5^>MF+SM^?[L;[O%\=#V8('0 =T'J/_7[UZ 9NW3=>U1U')\-1WH^FIQ3
M;.M4!VPP.7Z[/6ZF+^;^I9DS<#B.RJ*?VR[TTJ_EK]$;Y9=?IQ/?\#+Z2_%Y
MXGK1?XZ>K7\.%+8.WC2A PZ] S9B;H <F'#0 = !.X.<JK1%?A.=7N<N>Z08
M]9MJ6[@8 1#!-(0.@ YH8$/U.2$[/V]0)/\7\%/#[(0.@ X /_6+(S[XJ0_5
MW,!/O0,_]:I#I@&TP#"A Z #ME/9!P 'IAMT '3 K@#GOW+CH@\C5U;)?KVI
MM\<!YL",@PZ #MB]._K$F&(R&/LF/LO?#.G'+SV^6\W?>F:BUETFUKQ(S#09
M2[M^\766A)45??];F%I#-RJK[/S!+$]K>K.%A*\JE;X^*\"HD LT+S%3U*_:
MJDK:/)T?DK<@>6LKR5OK?I'B;61V+4^%_2&RS=+5GY/=<SG+8-Y?ME_=20<E
M>+8_3Z[R<1_F",R1I^9(V,1KZ4*\\SL_SP\7;K#SHG_)JC^8M:8;#\JDH0.@
M R"PI=78O$U<;DOW'+S%[2CF/MK(8?,B8;;[.Z8PJ=>?U-^-XVL!MW1^1?#<
MT Q8#W3:C*$#H -@/= :9*[[=WO8W)8N.GBK:S[&::?R_YEA#?L[/C!!0=__
M\ #LOMK[4PK_8Z%]NZ._%-F-R\NQ6YF4#_*^TU8,'0 = /*^-<RX)4AN2\\<
MO+%MLA/T1.6<_>T0F!$@H[LAH_]V%'THRO&- A5]<$8,'0 = "JZ-<2X'41N
M2\<<O*V!B(89 2*Z6R+Z/Y6_??1?N2O!#7V !@P= !T  KHUI-@\&K>E4P[>
MSD \PXP \=PM\?R7HO_9C:*_N;P$[7QP]@L= !T VKDUG-@X&+>E3P[>S$ Z
MPXS8O70^F(I_-O\R;U[??4.VLIF\&(1:8Y.;P6N;E\.^NCT.[\ZGP)U&S>O[
M31D+']'PRM\GY3C/;F?WKKZ+W,!ZB?LM-,)?XGBN=K\]<PX1NK[\WZR,SF;=
MGK![$\UW>-7QUZ,[Z_OL:H9'*O./>:SZ7]5M.:VJMCA"]^UT==]OTL6[G,9I
M4[/XKDOG+9P^:56OCQXQ^M/#<5R<5N((BQ^<6=/?:R#T-R#BIX9GV[J]<])7
MDT%11E?7SE_033R&E[WH?&".'MC]>GV%C^1VNBK*K9^8L^H$G\JQ&M?U.1NH
M?+5YKYZ_?W/V?Z.KB^CM^?N3]Z?G)^^BRZN3J[._GKV_NFRB8W_,\+[3IYL7
M6B4-50A]M(CF]*&?7T8SC9^LHKE1S4R9'I$GZV;2(TR?*H%)C@A^ZOOQ44SC
M9W^_\4/N'DBYF]S:OGN,$>A^*=<';:N?I)MMZ_*X0=M:W+8G/%3)I@ZJ'['?
MI#'.#&O7!W^HE\[;6W=&3>+82_=#DR;C^S2\\Z=7]-737?%P<T0F"]LCTR%9
M\=S;[KYJR;73>JT?_&IQO=GT9!?.=YC:.>>:MKTG,"W=%-.JIN2#4 :BNM@*
M5]IB)R]^'(7/SU;YE5*>+UF:7C<\?QQ4=#URV9]>_4M]^L&G(OL4'G?HJF=^
M?*"R[(G:[M:9PDOWX&B:^.N,^OG /5BI/1IH7A_"4&1^73M_C.AC=::"&SD;
M?9CH?FX6JV&\S4<WT<^K2G'<OZ5O3/[M>% ,WD]NW,A?(RQ+WW[*4D)3FW 4
MR\PB3JQ#4NL8"8HS92333NA74?6$W\8?0U^=?L(BQD(Q@SA+4\03[5":JM1_
M1VFCB;1*LU?10-WXA[ N/SZ9V'Q<C-[[%YKLTD<[\?*OT>^7T;MW'^;F<:_E
M__&=NB7;&MS7*PNF/&N4B, B$T0A2PQ#/-,&*9%29#65VC^R5#QM:)3>%:9J
MWBY&ZK>B'!>#7O37D[:-U(?3DXO?HO,WQ^N/&=,<QY0F**$Q]F-&'%*:$D1B
MRUF2LC36LJ$Q"QAP;G<Q8CQMUTC=%0%2S2C0M$,*= ^;O_N%R$J%VW3/+-RD
MZIT&F_T6K5F&Z[$+$IA/G1/7+S$,<VVM53^4B_M47COWU*Y'@[JBOF-T6=TQ
M4M51:&^<<3?:C2)6;Y*SJH"T_X$"AP"' (<TR2$,YA-P2),<<K=K'GPTQ=#5
M7+ 3-KF<WSO0R,7\WE%6C*IS+/_;J5$9G?D+66 98!E@F1VQS,HP1YA/P#+K
MLTQA_K@N^IX1RD_A).7Q[>X)YK0ZH3F<BQQ=+CS/__@724GR.CJK'@NX![@'
MN.<%N4? ? +N:9)[C"JO/V7]XNL+K&E._;VCM^'>P"O *\ K+\@K,<PGX)4F
M>650C%WY:5Q\^K$4E.:HYGUX@&A<+)S0><<^0"! ($ @31)( O/I^P2R,@?Z
MA;/:JK Q_<?-'Y^(Q'?@L&^YS/N9+P[)RVU+7F[4PN[EXM8VQLFL7\)KC\5_
M;W#"8;-YNA_//EQ\O(HNWD8A8_?#F?_K_55['B_Z>/;G\\NKLX]G;Z(/O__V
M[OPT.CD]O?C]_=7Y^S]';\\__K5%S_I86O-V"C1LG+.\;CNOBLJ3L[B)4#EN
MPHN_%6IDJZBH:2&9R@_TXRGV[>NR9N?*Q3 ?>):-_'^AVYY<PCR[:W9?[&_S
MCOB;BZ[5%Q>I$''NZDFDC"EN_(/<ACR4:91?5$?Y/3V;HNCG\/W3^MN_?#=
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MNZM'PA:NUA>J'WZMN/S6]]SMHO7."/<1OX'ZPPWJA?;7ZZ+O:IR>B@5_Z5Y
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M?5#J7Y.9PD[KI<(61L6$\21%%G.&. GI"$93A%.19(:&4[A,>^"3]M*5A^,
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M'=I/%S>:/^J1&(ZCLNCG-IH-R%[8SYJ#_?W6[SV1-"T G^BR&I(PZ_24 7P
M? !\ 'P ? !\ 'P ? !\ 'PX9'S839QKHA5QQ ID&%>(TY0BQ76*4F*4<%GF
ME%@J9;%.J/][-SX?F.+&O7MXYON3#J[2]ZS_Z3N>+I;T$K;%M.*60BOD 0#&
M L:V'V.)EG'&,X4$SS3B'',DE4J1QIP)XK1(Q%*0Z#J;"X"QK<)82#18RX9^
M4_TJST"-HS?.N!OM1A$CO8CB$#8#5 94!E3V_'UM+G":$(P21CGBB>9(I=:A
MA*:QQ"H6."$/J8<+)3F5&(F4IH@S+^]39A.$K2:2> KC\?*^=I5K<#$9EV,U
ML/G@\^:9"'$/TZ3'Y!9WL%O*.> R.2 ,?)[ ^%< P\W!T!A.B;$:8:^N$9="
M(IVX#"E#-=8QMV(YR&<M, Q!/M=%W_=R>?:/23Z^;2JB)P8L!"P$+ 0LW!@+
MM24VEIJA-+:X2H[P6(B)Q[4T)E:RQ+$EOV^<2JVHAT$/E%Y,6N*_G;H8"6,)
MCBG7Q*0[P\*4I#T2 R "( (@ B"VS^EKE<8FRV(DG5]T<ZX3I 5VR&62.,MH
MJI(EL9FEBB2:,21TYA#',D&*X0PY&2MK/>!@)9H$V.=Y?J7$O9@F!X>TL+T&
MD N0NUWGI,>Y-$&4^U4X5ZE"RLH899QE."78^9<>0B3VH*H2+9'TDM.OQU/J
M8558I#,/D8F5A.%&(?+I/3'9$V*+A;5:"HR0A;.CK;!JXB(=ZL*%FENAUH\*
M,PPHI],Y:X>:F@DIU6"W[6DNV"W8+=@M#&5W[7;UJDQE1'-!&))&,<2U2_T*
MRW&D>,RXE"2+#7^X*I-:*8L-1SA5"O&8),C_P!!FBC(M8JU"P?C[J[(3^_=)
M.;[QCU)>%2?6YN$95/^#RNWYX%0-\['J5V$EE?X]79"_'YU?Q)6^H9=N]"4W
MKJZA\-&9XO.@NDJ3A9-I3^)NG5@%6 =8=W!8!QH%[+8]S06[W3!Z01M*E<A0
MZKPRX3'U:D5CCG1&L;7.QAHO%8;$(L9",1.<QFD(A74H356*!%7::"*MTDM9
M:Z!1]L9 (-L"CG4 ?@%^:28KFIJ$Q10C+2U!/)/&,XU(4$R$B[G A/)X:0U,
M,RH)E<BH#(<L/X\J+'-(<Z6U8E2:3+S8L0Z\Q^FA,P2@U:$/Y=ZC%:QBP6[;
MTURPV\U4!N66^;4H0UDX@86'4PJ4E0+%62)LZHA@&6O"T[[+HL,I'&T :'78
M0[GW: 4J ^RV/<T%N]U,9:12IHE.'9)"",1)$J-4,(L2;M(X9B(F:LF7L8ZO
M'%1&J[W=$%#MKW,:_&W]OK/1R)7C46[&=63UW.T-S-!ILSE49MA-RB..4R.8
MHR@37(;#D"WR0E(BJUU&M&7*\N7(L1_PFG^':6I?^<>Y85<?._FJ1O9M,<J<
M;Y[=V)%.TQZ5W2(?2',$9#Q<9(2U+MAM>YH+=@MV"W8+0PEV"X,-=MNAH02[
MW<?!AIAB.#P6*B/M'"P/H" 2'/X&4@GP ? !\ 'P ? !\ 'P ? !\ 'P8;\"
M/A2FSE*%4:)UC#@7,=*:.<28C>-4)RIA:BG@ VM,94I"A <)!\XZI#2+$>,T
M(;%(3.+X;@\V%#W"X6!#"/L C 6,;2'&4IS&+.9(.)P@+C.#TL1H9&668A)3
M+/%2DM@ZX=N L:W"6 CP;OKP6 94UHQYT2,:[,L6$]UW!TAFJ]N_]W2VFG[B
M6!'MZ<23#LX0UR&F.\X<2IQF"0DDE,@E^LETS*E02%OA);[+*%+<\Q8FF>.9
M(,)BO9L#9 GM";K%<.TG)P8X3@ )6R4TMG=HS4%!HF..LCAV2%(<3NER-M1&
M5L@E%!.M,O_FLB)?!Q+W_QA90$1 1$#$SB.B%LY(0V-DXI@A3G@XZ]!K1L=B
M9Z6P*M7+!WG%G-&8$B13I1%/:(920@P27$B79B)A,M[=8;*4]K"0 (L BP"+
M (LM=04+1ZGPF(JT4RGB+*$H3;,849F)%!,2*T&6STMDDJ22(,N,19S[I;LB
M+$.,$BJMLIE5C9[9_3Q_<$I$+XEW=J1LB_ 6MMT > %XMUV^V9HDX4XCPVV&
M>.9%J<H$1C'&@A)"M.7Z(5#R).9>D5K$8N*_0PU#FEN."",!=56<QFYG>C3N
M,7R(Z+A^BH[_5_G'KWZ</_7T[N%.OI6,_O2ZJ79,?Z^F<[@T$3^M-J;OPN+=
M$Z7^@9Y\AN=V3KOZH+))_<?-'Y^\#OEQR]^\?ZZN7:1,.#]7#6[SP>=H4(S]
M%]7(O^P1PW_L\TCUHZ$:50<>C*]=Z:(L'ZB!R?WKY5B-774$R-&#/K;YE[E]
M]-TW9/.1JRSUV+=K<C-X;?-RV%>WQ^'=UT-EP[[&PB9U7C_S=%L7>S/TKX0#
M1_+L=O;\U7>1&UAOM-]"/_A+',_M]]LSC;3Z?4T[73V7=S)R;]&:NGKS6XM[
M8.-'NAKQZ_E>_%!]=O4VNZ<6WS_'JO]5W9:O7_WZ<&K,QKTRL$<&?9.QW;YR
MVP)$W77I-ENX#$$4XS4G\M=ZP+1G^P8ZY&23B=WLH_359%"4D4=)?P,W\7*A
M[$7G _,0[9XQ4.*(;XXS"WS!12L&Z_+JY.KLKV?OKRZCB[?1O9$+SVI4>?TI
MZQ=?RU?_T9YA/3VY_$OT]MW%WRY?:!S;T D_YP//Y\6D5 -;_O+C'=&H(%H#
M;PEI4A-6"GF5+E23<3%;%(1G"3SDQS1\''G]4DR\#,F_.?NZOA7!^ C_-/N"
M']F^&I;NN'1>0GFM=+\?JFN_>AC*]B4O<YWW_8KI>/;]53%JU>WB^"A-V4]3
M:EWQ 7(4TZ?>?NH]>B0EPW=_GOQPJY[AB0A!^>,!@BLGXO*(?+>ZQ6R2KS N
MV3"K;PXPCUE/]+V5]H]XVIIJ]K8=;;X#PSM_>A6_>KJ9/Q3:W8GY\+88A65A
M]-].C:*S@77V7G3I>K/E.3'+;>C(AN88P!7 U5;@B@)</>BYYP2[ R:!C1RX
MC5"PD<UX>YT::.L1]_XE(IVJ\CJJG$)1-BINHF+H_-HX[#Z$S;PO^3AWY7&3
MF+0W&_K/!J5V;$[OC&H.K+DPBSLYK)UJ[M:3<*MVY ,;-GJK*ZZ3E;OHR:TN
MLGA5W-AV/]0+;6_0VXMKHUT$M+4#6EH?)<R)IMKJ-)1\,(AC(Y!43**4.8$Q
MM5RHY2CA0RL8T5J#@<C?[HTI@.#.0= X%A-C-4JH)8A;*Y!2C""KA*4L2QAF
M]B$(&A43QI,46<Q#%EMLD32:(IR*)#/4IADSNP7!I.<?%$#P)1U12PJ]ZV+\
MQ(8(U"K>-1H7T<CYMTS>=]%@JM+#J^'G$/8434IGHWP [BUP#!R28P!F\8$.
M:Z>:NU/W%FW"O47WD5'?./\1DZL@WF!UMT=B%4X'VVP1AA--F=82*1?*0ULN
MD-2$()&PA#M)!6;+94'6\$0M&EA#"9BTQXCHU,H+"GT +@$N33WDC%F5882S
MU"*N7"A7Y)2'J90+9YUP-&G".;057$I$>N"XM/53&4&VANM\& 6GSO@V4@,;
MN7],\F%P"E6_56:*B@Q-2A>ILG3C,LIOABH?A8\ EW3:_(!+[A4#%9IG2L2(
M$B]TO5Y-42HS@FR*,8^=5HE>XI)U-.Y)L++SN8V=7ON&NQ_8<7B257A/8G;@
MK ((=>A#V5&$DH)+DB4<:8D)XM@*I#.FD,'$2F$P<WSID*9UU&Z3"%5E&Z-_
MNE&Q<-3=0<,3^&IWL_MY4_@&_K-:LH5B0-,R0(//WD#*,40H=MO(@#CNE1N5
M5GB@IQ[_&4=<2HVD$!EB&4^Q]:K7D$9.GEJTN8OL[<SB3H/!-57QOL?8H;M-
M *<.?2B[BE,F%H93BUPF_1)<Z1BEQ"CDTG @!],I(7$C G?[.)5*<N H!<[=
MG>C<JG(MTBJ$[X7*F&Y00GQ"]ZT+B..>[U9:;:65R CB$'<BB-4X02J5B1+!
M;6)Y$P+W[&;8+VZ=^\T-G'^N\F1@J^/N?@OF=[I@?>^+08BJ;6RO4.)N18^#
MZ 7L NRJCX4V29S%4B!AC48\Y12E/)'(9DPX*V-IS1)VK2-Z7PB[6$_0+1['
MM!<3'ER^.PK/-;Z32A=5M6)=9-1H5)6)5S>^;ZN2\"OB'8!L.FU[0#;WA+(B
M"5;4H2SCGFPD4TC:E"#I%,-"6F+4TGDJ/R*4QV8T/CX?U'8XL\?SP<?0N(OL
M]])5>XM-IU=2N<5S4+L\RP&P.C.4'04L[L'*@XU$F&.)>!RBLC1.D7&:*IG)
M.''9)NKX90"+'SQ@@7=X)Y+XSRJD= ^B?J6+;PJ;9[ZYE7V%\%\/$_Z;X"_N
MOKT=*JOLIDB)%ABGL:6("1..'"0*:248HI@0+92+#6\D/RZ8<ZA/<C&XNK/<
MB^Q=L.ZF?,UIM[PU4*P)X _@;\LN;(>93I(8N8P(+]))C-+$ZV^#A>/*\3C!
M2_"WC@M[!_!'6+?2)W9:I@F\UFN85)C00:*7?K8&%_4\0:\7BC,!+^V1L0$O
M;5CKS\B4&J40B85#/,THDDQQY)@@U#))*5^*_]M,1E]ZH[O(9@FR'_IJ,#Z;
MV5_33I\M'@/>Y;D.L-69H>PH;+D,Q[%A#MDX\?*7,8(T41FB%CN.C4FL;21L
M&6"K Y[J-:J5TA^L5KJ7,OCGV2;,+V&6SN(XH/+HD^UL!Z!"S4:H/ JS^#!G
M\4Z=1*P))Q';1W;\Z(S+OX1CW"%>L=MR$Y96BTLKAE5&F8Y1[-=6B$NBD,*2
M(4EQ.!M'Q;%=.OUA'8_0B@B@.XMK_#2( U]1 5H=^E!V%*U"#2:A589P&A/$
M>4J1YHE B;-I*C(=*R&;< 3M%*U(CV#P >TP6O%P5>Z'D1NJW$;N6TA&\P\1
M8A2+\;4;168R&E5%2R%GI_OF=JBLLIMHG9BQS!!*@XAV7B0+C60:BOEKE21Q
MYIS&8CN:>FK?;USFO#7;L]K,3P;V(MAX%6G?8)VHM%MUHB"0$:#Q<*%Q-91E
MTM%$2H*P"M7M$I.AU-@4I41C'=M4)\IL1W W"V7/4^(R!AT.WN:=)-(/BS('
MF=UQ:P(NN1?$+D4L;*J0E:'^O\PX4HIC%%PZL9:8>@F\A=3XB]EYJS.C:^HD
M 'K@7 % =>A#V5&@$H:F#EN&,AD.XV.)!QVM,"+*K^RQ%LHL1TDWD!+?$%#!
M@0#@7'X145LMS"(_S1#XD@_(NH [[G$'2W&,688TTUZP:HR1PHE&A!A#7$K#
M65?;\?U6YA=*"];&MQT/B8 RJ8!<!SZ4'46NQ/_!)LF0THF'(FHDT@F+D;6:
M.T6\ADW(=ER].T$NPN"\@$9]NY!GLWH 9O,[^GF69O,+Y-E AL(A-Q=F<2>'
MM5/-!2?1;DZ--":4"B^CH;H-T;2PQ.JTYCS4)=9N @VMHT2E1"!,PD:%XS84
M&V>(QC'G+F.<X(UV5!]?LLW,^$-MQ8V71$BZE<(#H84 A@"&6SZ\G2N%-4D1
MY9H@3C.!)'$4T<Q8+C+&+$VVX[_:,AA2 5@(T8F[U>BCB;O+$@):VB/S EIJ
M&2U9JYE(*<J(XHAG3"*E'$>2.1(K3UF<;&E#>&K&[W*E\WX^SK>09]]+)>0
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ML6\=M7X \GVG#]7OB4[\^-YFNS]J8VSDB"-''#GB7I7 21HH&?@DECC:,$Z
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MS E>H5<@2^N)!V)_G<EL'71 3T+ZIRMF&P3!=]*[^]WH5?CT(/K3U8 ,6-P
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M11'A,DJ($CJ589;Y M,C;XYOQCT.N(41"0 F6*<M.-[/_U:5=?T!J]>TJM\
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M(PI9!,M$3L#8 BZC8H$65JB2C78.([-XYLSB5YL*4U:7HY;Q%!A'(+(@\S%
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M#LKKJU4-YZJKU]_D=*6*^3F:#/"?^L2_':J_\3$*!J-&[($^],C1)V)!Q#-
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M4'X?GS"7'RE,WKW_]/K,^_3>>_/VW>F[5V]/?_7./IU^>OW;ZW>?SC9HV]A
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M)HYI13A0%,[V&2YGV%##O,[-KW45;/6@0?Y5C33X8E&5WYJNK&.):)<($@;
MQD5*,H:Z;9JE!)W71/B!SFB61RE5=Z</GU85]DO'A*R?+[M+W$BB4^R68GO"
MU'_#TZ_?SFT%XM\=XIQ:O#%?_@)G^P;PYW\0?=;E!A965>8%K03Q^Q*$7B-
MHI/HJ'J&/-RK%S@CZL*,_IBK+;1U=!B>4E_J@"?$3P*P^*@$BR_1/@E!L5&Y
M5"S(-E*=#J? /!H,#X*3B!T3BG>(=KRMM1YN9;:\_+2N5S,G'RM]SLV<KUY_
M[<FP6_;$ W4&AZ@K[[+04S<OKJ@_D[S2NAL.@06L;A:/&QK? &(HXWM"O=?3
MF[>+VFB5OEXC?5& C*_:>715@7-L[ -W+:O_2.[]?G)VXBTKTTW^$AM/:]LH
MG>/HCI69FUX7 %A>-2/$G%YB.G&UZVBA-"UR]_[!1S@KK"D,-ZWGG;[2#*7+
M[8PZ,\UF75_9,I2G7"V;B6C#II\ "!PMMG2SS[LF[)V6!=M93.W,>#M9"6B\
MEE4A;"7ZV>M7WMF2Y[G7&T?P\VJ*P_GF9L;TV>G/$^]=>>(%?F(0P/P<^-A[
MOEBVY?MF\-L,9ZS;L4 &$6PY.[#[V6IZ;I:)KSS]N7G&R2V9_XZ19W' )$W2
M@*#KCC"?<I)I'W265-,T87F<;;+PV_5(Z!'6[X!LIA?/OAT/]EGM W4\,,C&
M>TP#Z7HKNT"L_VYVX6BDZXE@B^V%GI9?'Z#MP=X'\60MVJ?5]B Y"9)]VA[$
M]/J+PA.V3U.#O9X5GP0;S[JWJMU-5#N>JKN[+RL[X@8$]U55V18=AK<N.GSL
MV/#=+0=&*AVI] AJGY\^9=Y'T?R(*$\#4:ZH$[^3A+/;-$-Y? EG'[?;;X?G
MT(\S0^)95=/%8::UB@.BHL GC.J < 96<A0D(A%AH%,>/VCPI_5V]_PQB,!O
M '_?.O3]"-C[6S$O9JO9P">^6/5<X83V?>'L^I:CNXLE#G0B%BF-!S)X>5-'
M\G>F<D1^JG008A-82IA,.>$A%033M[62>9KI.\Q].^1Q\V^'/&YVXM_Y<?]I
M9+#/D<'*6/D<.&HN XVC+R@1TH](HOTH2G+!%=U@L/<:>WP@!AN<Q <;OG5$
M#)9K2BD/8B)2.&DF0O@I\!G)11*J..2:Q^GC..Y#,UCZD SV3BK,GY?5\'H0
M#2WF=B3P*-..5Z9MCZ1J%6B=!RG) N&C.I>35$642"E\'2=))J.-^4W23R58
MY: G!KDBS$\$R03GF!"<:JZ2Q BQ+1Q*7,^AQ#X<JD&^3[J:!0-60VHM7ZA5
MA=AX.&2/3OSXFFCEG<NH[<<G=13'<<A(DO$4CB)2)(L5)3%E89+Y@4\CMC%^
MBU*9<#\@</(@8+C.0#SIB$2A3UF4R2#A_$D=7WQ"HSV"S2/#>AP,R_=9Y(>
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M^&8G=M *X VG<XJ"^5[;^R3E ; #T"._XS_WA.O;?3"7:\OSS))$9K"G%NA
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M4MI"4 72((]!."2:R +$A'4R,YG@,;5VAZIL]_"]M[N6$@4] *T>^-9A2U\
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MG^4E-AVO3ZOWBXGY'6@']OOB]PJDTFG546K*G74DI_'1=N?*SS^+;4ORP4E
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MC#*@'2;!6,B*F @!QH+E4N2%2FAJAC#J/?)I,0>>=^AX+7:TURY"EL8%<\
M+*( ,.RJS243).=:\)1R49A!?5FLTL08DY)"6X9HGXP('G,B62959N+4.?,H
M+L*]I(:'<Q'NM"Y,VH(:./D@3!)+6)$:D EY02SEB9"9$@83B'91%P93Q[B
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MJUB'.&>G&Y_W1'F.VE<*NR]YWPE3U=NP]3TC1;2ZOJ*XG]'U0N:QM((3DQ?
M'U6NB& Q!J]R2BU/<CO$8LI< LPT*0CE<#:89B#H91P#[>?<:BTDS_5/T?NV
MM*)@:9QG:4R$Q=;F%OO69L(16I@8CFZ&M9CK4^*2Q10;%D@:2PS&@!XB$D9
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MT:';0GCND]>O;7H8&5#&VSR3R01](G5SGJ[T"76REXU/'%@>L>UG8WLTI1G
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M/8/EQ<4"GH&OZ*:3X^?%6,Z:U\)Z3^%&J<_Q_9_D?(%O_ULY'J,'#)[ZZ6_
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MOY]?T3&[\YYQ!(NN>U=)?AU!::1=><?2Q$BV8S]MU%5L#PC0:$ 2]]>?S&H
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M+U-(#KCF!YKK?:*E;AF=&_+D!-.ZD+'FR2D^!1S3D[YA2+HMF;UM\ZTJC2-
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M;G#OBKAVK<%<5C5/#^F>.@"+%M*-=BYZ\&KBU-Y1#=549": 8%P.1$;+@&
MH20-P0N5DL]K=0XZ6<,IU<1*=-.@JZ]0C>1<:*.5*[^YGV2H?1TAL0U7.INJ
ME'[?3?8 Z(-2)O3#ZF3@&+T@'JM\O=&!@K 1=CU'Z28P,#](6&''XQ^F$YPE
M@8T(_NJP.=/D;.]'J%UL/*'W,ST G4NS^3>H]HQ"Z2DZ[ 318IS'H"G3B)::
M$5P80C]K4C7Z/,0.;[-HPMR\WT2L,V6YQ71F>,DA#@T#G7AEEELW>;ZHV.B(
M:.>UP)-1U^$+[YGB8?5V:69CNZUO45GM>@.0>1>%\Y?OIIZ?SGJ.K?0*V[20
MV8RL#5O4^2CPYEU;IZ[70UQ1^/LFZ<^D23KKFZ1OWO.^2?J>-03OFZ3W3=*O
M-]A2=SUM+_'H_#*:34*<>0G.UCKT_OW58?4;SJ)$>?M^!!:.W-RAYJ&:!_V<
M_.0A/=E;?%W?V=F-_BW8Z,V!Q'VS(*W.BG-=$Z4PB4.BRT%:3X#8N,QU5D&L
M]9&/7BN:)"=@.\)O(C/$!*6("(PY 5JA]6N='%\7OTTI82V.@_;CU,]:EKZ:
M3OXV[/;MEI%";@Z,>@2UAAU=W4EH;=L<;EY+9NM$A'(8[.*1V( =[T+"TF6O
M-5O+2@\L.L5U(,$Q#;]AB<#!UL1SFGAMZ\BE^,XQHW_RPWCN6GJ;T*J$XWR(
M8Q#B4-#],PZ7TLX^G4> VWDAW]U0 N62QYPP08?#J8)V2$S6#/X3I=16:Z77
MDL-OPO#?\S!@F<'>51G _Q1OQO[122E8*0-',:B:I]BJ")T*&%I%KT(S2YS:
M5NNY(*S]K^ZLD[?&8D6PQ%Y77$AB; I8NI"B#E(ZOUY.%6O.K:4@O4KN+%SN
MG=<D"9-K[;*HM;TGA^:>AE&?07$G%X*95'N2M:9=0R;G:D:B\<YY)D-6:P,9
MKT,X]UC<N;.JSGU*F'I<59V<@UZ: (%\M I=ZJ#Z:!^)<)2EX%VP;KV"ZJ&I
M:5-5YZ[*.=FAV*=<ZOLKY]2UU$EH3K24V/%9*V($*$Z1"<M4--G7:RD_-Z:$
MYU'."?_35W->ISUA=ED9!\87QR1?:8@'>XUHYRQCG-8Y[X0"GTDU)_;17$2N
MN+F27^UM,P9A59KHSN8$+D]<:89[ZTF[CS?:]OQFW9-6.BQU>ST:-Y\;S)Y>
M&"?SS+!1YSPK13)+;8O'L[;%A]51N_&+V<0N^.TB"143.C"LN9_9^U%&RAVM
MB8L26T<(30Q3V'K2R*@LDW7B:WU'DS?>@WW$4\A@'V4PC6*V1"A04KBTQN/8
MQUOED[UQX7CUVEMZY:0X$'2O[*)MY:*SB/FBROC@_AUU6@:C/#8&# )['$5.
MO R2,,5Y#;H&!S7T(E&DP*)2H)Z"-  )P8"D?'#HX1/6J1QU2OIQ..I8?2CW
MWU&W@C'G91;+H1K!KN:P.2I4N&$"U+Z!E9$T!^4M42[C]":OB)4R$TUK5;O@
M F5KI49U4+7BVA)N/ "<"MCDDG.2>79!:@TJBEMQS&Q$JOE.SPGT>D&"#7K)
M,.T3%LUGP"W35'$ EXR617.$!VBB[!0U*IM('(\XY*LVQ"@'.F7F6IFLHW3K
M?4VOT43Y?$!..QE/9Q,!T5W<900=P=%\*9+IYZ;%;HN 2GVOY=WW6F:/L=?R
M"LT\IX;+YRD!LSFW%X8 G(\_=/!BZ%_[# P]3J"WC%#/.Y^PV0#0>/0,XZR,
M(JP:''DT^KKX]M/KW\BGZI?&C[%>\-<2OV9_Y-6G<>,&6T/E%Y^U^GYC;)N
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M1\,K/4#V /D4 ?)^HMV415L+I0FC$<MC'276*- +A8R11UW+]0$]M^G9L%O
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M5/P*;+!R[R]IV>H<IF^@L:W=$QX(V[]T7;><:N3!UI\UV<P3N!\^ZBRY<94
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M)+5M\(?-!/UX)R-0M0;-[V@(3HYAK<,11F_=9&:5SY0QGX8IXSUGENT$E3>
MU#(6^[#ZS]%7L W&![,?;7KH)H5OE#-\-W_&DN&['.=%RR/-9G%WZN"F;0
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M1V[M[XC)*N;03<:5 910@AA:>V)"TD8PYIUQNT"6C^$8MG20/N0W\R/H#AF
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M][/?,@-F%'XGOK2. ;)'BBZ4WLNN*Y2_/">DWS*FEGE/G:Z)50[[C0KXEQ8
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MTW;2(0HP)\Y07V6F.3.W\S&N9\F-6T"IBV/TNA'6" HX;>=9S)%>!JQCUQ;
M6L)S_+A!- <0*QMSF@"Y"BS-]G()S@&:1@MU&$ RN&E;ACUO&@:]/OA[-HD>
M3VS6@0]^Z."QXPM#[0%^<49X ^\W&Q-^6/WC&.!X"&?9MB#<#I8?"8)E,)C+
MLX*U6U:T-+YZ&P'!#IVZ<1$4^'ZGXQ'.E040P-O..WKC7=L+;;]!/JT*AU'J
M-KN3*YW(+1/CRSY.E[A\WAV\[18RFY"-H0*0UL$-)X.S(CMG!S($LJHF7]/@
M2ZI.X)R/G\= ].7-;=HJ3,?C5+8&B&R(1^JF0%*PL7!&2R.A"WT.FA-0[&9D
M>U:^?8<D@D+ZM_0E#:>I^@BBN@EIZ7#_.04-)S:A^QT2P'>QA5EK4?4833\?
M=T S&Y,.NX>ZQT:&")VAN87L\5.\T[,XX%<)WFF(>P.$COC<,3EJUJ^GDPX[
M_C+R;744"G]RRNJ#:G8J>!5\?E E/.MAQ^;P^4RI@GWLD@2+3K:Q>U$9+0X4
M!*HB8-_)"0 4W&5PMBQ3D-^G93 ]_GJ<_C5M\&I@_U-WEL9%/ 5W6HR(_^U(
M"7@>C'3X ^YQ4HW 9 =5^<N<C$ZGXW;JL'?2J'KWVVL@PD[E8+7LX 0V++HR
MCVMQWRXW;/;P\NK'#A51>&DXD\F<ZO!1#N DS@*8W82O$L*L8D=P2QCZ?]M"
MD>=Z,;Y[GL+O-Z2C'5YJIX*9_B?XWQLHJ@OU:W;#>2\<(3QW3('"B.FFS')B
MDW0D:REB9EDH0V^=L%\*V3\4BFF/AO$WD"#P!D!*Y8LCY,CV$]S_U0#^7/SC
M!S  X'#P)N-I@O=?6GALVM.!.WN1!^G;,H,R#MN 6DV3S^8L4"X",Q3$S\O"
MBP3X[*1]@87U@V:8UKCVG)'DH1+USD;%+T\KO!%?SUYGOOAFB*]/RAY\9\T_
M_)F= ]W2'BZFQ%^\XX.M;T/[@ZHCF^K7@3OO>U \-E?VVSQ*T-[DN4%8 7#F
MU1N J,D9&O%P,8(>[LX"LLLEW2< L7]U9^630[Q\ *(<Y$ []2W '$)<,S-\
MVE7-#Y%O9F7'O3.167*!2BV(H!8LQI@X,2)EPFLCL^ T<;T^0\X:'ARKB58)
M@$O#;[RAA@0K >X<]8!V%RU&V(P3[,X.9/BZ$Q*E^+7];;8Q;T?CMU.4:^]:
M%#87$E;:<NVRN4@OFT,AQ($0V],*'\!$[!;1Z?ZS11Y6'X;KQE\AGWWUJ7AE
MK*U#@ =:$'(&J,9IDXD,5G"M0F#U6KB8.<6B8HE$$3612GGB@M$D)).,JB.G
M=LVG<M\$H]5!S;?G-#T<O2R@8YEPBNH#ZM3LFG/+M)B 95^JSV-0VIZ%5KX=
MX#F]%.#AD@7 _V4Z[#Y:M9/W%KV#4MEE$0FKD1D3K8D)P1*NG(Y<B)R,66-&
M+IC-E!&*6>92@KYJH@4<QUQ&3&7T1EYDQLV-"H[&8_0"H'K_ZNS\DE_=&7Y4
M5%%0D '9/N2.=X^FD^/1&-T)MV16=B I/8!-W$-^76'3T\$4'?]H,I\5NPIL
MPGTC(LM!9%O.L7$G!73&.F.6)0%ISFJ7C.1LS4L>I6-!,$:$LPFD@&'$UJ:&
M$_*LQJFTR=9W141SK ,)\!\(<;>DI9H=4+.]5.X!"6D\.EE50@MM.;"*01KN
M(R4)R:.A8,SZ$!P8L\83FY4E08L:4(IF'=;J+1\2CG9,28!*^TI,A_<0H=[V
M"N^&BWCCP2Q&60RGK52^ZFM?P=-SS^E"<#_DTHZ*G_QQ*?#4\>B]E$11,/L
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MXX.M;Y71YL11S:BC0O)8L$:13E>648]R+NBGI1'3[2DHC*-Q6[GJ7U-XL=P
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MC+9JTP2-%C@TV#\'?\)!X=QN6%IQ[[KYR5X7+!XK"_S%#:=N?%:)P@#V8(5
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M4T5E+6K+:KIHMS,)X\F+H_@%=^=]H=T.S\# ^C1;,,+B?)O6R[;B=+PHVWH
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M?T#Z^U$\^_/_^=,?CR<G@S__/U!+ P04    " #/.X%8T7H'A*J) 0#>/1<
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M70CEZ-BG?GTG(NMF>GF[GM31:<1+(,#SY3D]2"2Y<EPVJ:N(O:?N;KZ4?MI
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M._1% 4[I2J]I[C F0#*$.W%]Z('$G_B3!#\UVJ*:>XRGJS Y@==H#X.8>*+
M)I6Y,;BOYX%2E+I)?=F+QO%9JKK4& V$Q]55N8&L'42ATDZW6.#- *PR5A 0
MZ"]^#2/?>Z$G2J S-YL#]NH_&9D,5%BWIT#&VT[1'+^_\7W4@B+A!F?IR]W5
M0VI;3\\=W3]6="\2DP"&59Z/^&RG_J4%3&,/ IJO,NDJ[?12=;6>0![Q'7Y1
MI*\H#.B/+LZ^:98K%U\':AM"O_"MWP-*3^\@XR=-9.:MKIR)O.&(PE 8L6*]
M79.N::C;5\W?N<(S!YD//,>\KCI.[VYC/I:Y(!AX#S@A',QG'\]U;PJCL;F@
M7R8D0#/[?1X(VUZTMJ/3N 4WLF*Z]*"S98]Q]-Q6R**KEU73#;---$+?JG\=
M;97O<-(3R:MAP?<@8*(^#I4;(NS2QE"&@Q<B:W+;]^RD>Y;>,^2FWX4)'83'
M.ER%D6*6SO2CVNGV[ZT]K07J$<P#3)>*VZLZ *;:.UCR*5V$+K,0\J5J3E6N
M;V<"@+"CY+QAD* ^%U1#5;C\;U/4<?OK5WL2F8C<*GW+O637K/&XCN?:(-"Z
M%A-Q03Q@#_.,07X-+%["5J-;W]Z3,6<)X;NG04NVMGH#4;D!8'OR,J*XONYH
M>UO=CN6(S*+ZF@75O^O'<RPE\XL\D.N ,B\P_J21HFYR^Q&8@LNL*^AM>-C<
M5&Z<SCKPC<UUBR9*2@_7D"K)@;DMI[4^_(&4Q@^D4R!]X^R7/Q-ZA")WW5[\
M:C\:Q^=A*Q8' =.-F5H^C>.,Z8XHER<7R7DBLK_;O;\7"=V!NP%>D U6Z]6P
ML]D2MMO>8UJ?:19YVBJF]>HZ(HZ[QU!Y'1_BV:\#4?6^&Q6S1\>CO6F4S&K
M^;ZR!3BN#C8=24BY(+K+73;UTGVS1"LG(+\[_ 0*'U![LG;_?KI-;M(FIMC)
M:NQ [6W'<RF+&YB>RP>\%>@PO6!SNSM.$^=BGT)F!Q#2GDD:X!OG$Q;W;_/3
M6M]PQ&#O['X !7K?I)C>W;4#%XFT8=R8O]+<SH1!=\#+4ZIO\8!!/V!^JH"M
M7>KX< VUA2?8GL*HBO,YE/*,8A:[#S\EX%F2RK$T8<PCP1J_%=HBB ^C9S4=
MADIY]"*C+R054?S_(MOST&LNU%W;6/?#_^23%3MDD.?$*EC+LU+[WK<TM[J0
M+&O48<@#]#UWZEV"G<U'#"PCSU0,N?<=MQE*KJ.QL9#0/F&?8S]W536\!,K8
M6WTO]QO/'5;(LFJU4-4V'2\N14KZ'3)&M=TT$XSHM49B=BBP=_G9I4U;4;<.
MHZ4;=SK#@^4J 8ECAK["@!>JT.G-ZL90:L=GI.@L.6X6:G+?X:T^L[]BW_][
M$+X$C_14AP$5J$!J*K\-W>WMACW@. LA;PA^*+70[GZA5P%>$7?F/9.X%F^]
MN=UT/Z"XGZ$?9V>UK>#?H9^1WDE8EEG='"^=93F<PU,0[5JU@/9>XTDK3@R(
MZ? ?N,&>Z4,0] 5Q[==W1&N6N!M*59+CEL#4]CZZ177BTPN,TL_<.3Q[NR6]
MN[W'-** F7^9)8OTKF7;O_]TK]6#!0->\+/AGF-2 YBZ,W^9=<%EW_E9NHQO
M* W_?DT_AEJW=VV3Z66@-5E+]^@X*C@G\8@3[91DYK;+M;']\7W5U: ($U*2
MIM%'K^;2JW"+H?KRS-NT7.*HSA?5'"O5V&/<1Y8%;8'$U0YZ6-]V?%%LOH3Y
M7/GA2R>4;UL7JWKH!8FP2TDUI@B5&NC.]-ML_7"'L>(VK4;PM:#4[M%]Y/QR
M")+@*18==M/&YM-[W_MI4KV[6T[0F05!ZOB\T'=+?DZAV:AY*,)\>>]$\XC=
M(!Z3267P?$OR25=/W?C^4/TYB_">1P_P?(,LU%0"M+W#>,D,\GKAH?[U$LU=
MR &N/!%H'/*(N.SOD %Z%R;_P,E#5O O2Z,3OX)V35YCRY.8WBUSMEOL:JO'
M[M/S^(3P4OWLIA0^<^-, &OB<$MK'4B ?OI6135A#FN4U(I_UWRE_Q<)MP(Q
M*8M7_)4DZ\4:W\G(2D@3CL#60I(T:0%F.IC6F'=3YDX$;Q',#K!4BS$/S==3
MG\ZZ$\C6^&- 6*P1%.2D4I83WU[(T B^ON<80DY8^1;,&LSHS[=YM\<=?5+:
MDM!TCS%B>, &W!?1CAL,^5VH1&DW1@MT=!LO=HT %D+0G+F6_5VWDY]?DBSL
MJOR1U[KQV]IK_R;H]D#(:)Z0G0E!TJ@T7S+ADXI0@ 9%7+*E7^EU<)4F:829
MX0025NN_!FW41TP-@4(X[.5;A WI'NR4/Y4?S0=,/P'Z04LYE;.NB)9M]GWC
MPXZ?1#0 T+Y-EM%'?U0O;<G-6K3P%4PZ98=L;;UT^F\_A0OX\K/+\CV@X!,O
M ]7B[K4XB3%3.V"W8UD/VO&[;)5M/<;#Q,<!CAP?YN1M2$!B!J+[C/O44N_7
M5W\.03DE4P;C7>!M2&^PII2"SF['I]H*#P]]%Y>8P,MGND9RW4B6K8U7)'A,
M-LEE%(71>1B!49W.[,IWRK)EST[3S*.JR[T7BW]8/E4[0=W>B-I"@2!,!!#%
M+"UM'@8,$ "L$U>&=/(!V"!^QG[(K$^+*,4?M[5N"Q/C: <-Z\KU;=8+>_>=
M@(EI%B3$ ]@9NAV/(!8QR8D^V?3MQA[H[+R:%*\4N2PCUO2'--4VD*6+ZQRR
M>^BCTQ#X5_CSZ#[XXA>A/ PR\X<J7#A:AM&&7AXL!BCN-"OKH3V>I!>"805\
M!^R!I$+/DG36F.WH= 08D1T,'D!(]\7*PAG! (BW(M"1_K@AZ:;V*FUNK3UE
M?17A%9@DPX0.0QR_@LA1.\$>W8QE@4F#$;,N-GROTIC4)V/L 'JZS6?"EU6H
M#TY53[ :S9?TL'(]/P?)K;6I[4UDS,HOZ29E ;%J05#ZLX]%. ?]!*)$X#<T
MNOJ:#$NZR$]5TSU,QYV,H?V&T/]X8NT!3H3>'4T\]>HZ&F.E&,6B5U5Q";35
M]]B/AF[EAZWJ!1P5\I06@'U; K Z.QVC: C"6VN,EA[:4Y.FKDC@4 5TN#35
M1FABYT%<B#P4;:_=+O;4'=B;J8W\"VNL>5#?</Q8V-;XBV*C"1@!ZNV+!5Q)
M?I+[%7340'@"B]*O7$Z_0)M]:&E/1 ORJJ%P$S&-JAZ!H4<'ZV;C&-)\A!_9
M3<LZ6'O;:6(7*$6K&PY.[^ZZK]UT0Q77'?UNR2H@2^*"&E I-=E\&>_1?7R/
M-'V\F1Z8+6R7B[G:P;1BOX?./KZX67_#]:\2L ^%R7_84(A^\1(._+XE%=VF
M+JI.T17VFF!<&QJ-:23A%6/")68H)XY_A9MJS/3L-+Z(>--51+7:T$SYGELG
M2)>.4K"I1_6>YCZZU7(/!V<D/,=^"\YCM=%X9W68FZL5Q4@/;=W)+KV*NS2)
M#'OT-F7OK]CK6V3C[D[CUG]I*5LXA1*+Z5.,_Y6"\>"YSP78U'P\(R=/T&H-
MKRJVT7QH,UFTO0!)7;/Q)$.F2.[:#?:E1A-0_ROHWL78TCT-(?M1FT*:9>LA
MGU H2[%>2]>=TM1ZO&L;"N5DS][NPMDX*QP_ANEJG;2%C'?W&_N6C*7+577=
MW#H@,B:[&C#XO;M/Q8FW9T)RW][:Y32?3D1@E!7RSAY#WXF)<T]'W3A_;XEK
MVY?$Z(G+60!/X#7F#;M.O&[8J;W)3 SI;9:P$ESTNVF[2?KU'3?>-J^F4(B1
M;<7,ZNPW 2&C5W+[S&?38#I=.7V=J=[]Q1#=XXT;>U_)AJI&Q#]UHRM=!PD]
M&3%QV:EH@B$P.*"%VBMJ]>)ZO;:CCU403D6Z[,I$[=EI8N:@SB*$G=V,>1[:
M5-S6IA.X34&XWULOJW2Q%5\>/N.H(;ZD^O?Q$ZG;BV:66HTV7<"SA,";YK!V
MM<4HSFQPZO1S9><M;0 42;VKJ?[3/CU'++&4B.(GCSA)?*Q$*C4ITBT]QKO3
M<@Q-N/3G2\4AVOHA]NAH3-RH3R=I:#2>;O@9/O^4Q&L.0 @O0*O7I:6#;E\7
M=]A("P +<X6@.UX5O,FTM5?7B27+9IB%UP$4LZ#2#H2>QZWAB(=0FAC;^DM.
M3 ]9>M_YZ<8Z>0D7ZS"-J0*P>,'^,Y835DY'"[)/_]Z69 BA!>PDF$)-O8K&
M9@:PL,#0UXYPI;083W@--R#MN:(:0ZM+H[ZM[E/I?(8PI\_\R@KH/[E! -*@
M:\]A6_L1X^=?E+"^* SHCQS%2]RW_8!1]R8S(OZ9<-\IYH5.1,*.3M,#FF25
MHQJ9:>TTGBLF8A@_.W6-73JWJ'%;VGI,5TSH*JE3@_ Q1F6??:=AJYP$7CD^
M-Q/6:"AU+<8+3^:Y0XZ?BU8MQHRFUIJ?K?I<@ 45^+"S3.IE@,X^D_1/@_W[
M +\TZS8U2!HF5VNH[-U"QZI;X'*#HQ6=%7UR7I(UW%!.4%82NUI/]X;?MV8:
MP[@NNI)TZWC[#&WI),SHY#QF(:U'CBK^?0(^B1G]G#9\'2$Y=$_W1'OO\:0N
MYS,O;\MB!)9A!*>EU8C6UF,*N\2CV@^/[^LDH!LG0ZG^V@])I:.'[OF%<<(E
M["U=C@Z-J4^/T0X)@PAE&ZSFL?54<7MV'L\8SLQ:MY@NLW?-2B@P&_=+@*-X
M3;;YF6FRC??NKSV:+8A3/P%YK"U>K=Q(\RSN\(N4"IMG46TT)@9 >RG&?;+U
M#B U8I!P*?R:_B!_)YQ]!=DH\&3,7V,<\<$$QPL2K//=9B K693)N>/[@&5Q
MZ;CK8MNF ,+!='6G,=,GV&70US[>G3G!IYNPS=C?UERWLY054Q('Y#H %.KZ
MU["^H55UZXKXS=4W*TTT+]3'P(6RV_SQ;XB2:6DXG8NFS:C:T%CW4TD_M(8"
M=]6_Z_9WX&C3_O&56F@>/T^QAG0)1?6@2NV6\$!V<$/&+ "_;GY[4A@QCX1;
MH2 Z <+16W.C&QH?)P1^2UC[X32U7V<>CE[H.XBCGMDBO;L9!VHOP2;6S;.[
MTXCQBU(,G2^+A3.8O,KBV2N!VUVX7P.):MZRRC,B ;N$^! +_.DFS7NO_KJ/
M6U802HG?OL/TZ,C!KX/F:KY[]!X3O )T?YD@W@E:4==X(LF5+8ZHFH;'9VKO
MC&G*RDQ.+]QJCZE-1SB&^60I1R].,_9IGYZCL96)B/+2:6"BVDZWT35]HIJL
M+*-%[T'F9&\3,#IZZ'8C\X(.85"1#R!PX#;T&&:8L)<HF4BU[N5#:=ER5*4>
MH31N1"9=G:NJU.+X<NG4XEO2305G&P1J6'+MN73= X[K@X?J=SB*^67]@*'$
M(\Y]&FU>]XZ>5@T_,\^C$E,L_G-# ORAT0)4UW8B87IM[W!=2ZMK_+AQ?/\L
MC>F"5<Q#3:WL3G"-?;\KQJ+0:+1M;RD2)K!6VK6Y_OTGX*G.Y#P.Z748+&\O
M(GJ9[2CNO" )3.PZ\""3,'7\&EVCN9T1*/B;UGR;4I-I.74*098Y!I3X:]ST
M+A]&:VQ8R+,P2..>:)"EMKK=P6'P"_NL2E7;6GS#[3VF=:I:$P_;>HR. ],*
M=Y%=ADS$C%EPF_IWL.;=A<D_<)*#8>24>*>R-MX4+C':?/[0QIB'T/>ON-=F
MPG89=98CR_OE!Z*][<10C[(%S:WT+2ZB?OTGAA_2&_+U;%=/H,62:W+$J:#L
M\=3X>Y\^3@E9+AN]I*V=I@*C"BGU[9@ C>V/[U6HLP ]D/C3580!5PG36RF!
M8K*BB(7NZW[?X34+F#_138-3.0^*V/'[F4X/H#*F;A]N< Z%+HRE+?=76X\O
M^+P[GT<][V+X*;B6E!A\J-C1X<GO[/=EG!EI)9= 30_-^*OFQSV*ZAU75'QI
M$@SV)6,LJ@U&ABK4[9%K62O-\Y#E8E4DV,4:WSF\^/DYN&4CT(U(DB8MQ6P.
MHC.QG(E&E;^AM6FX$R5?<T^HD_J>XUZ#G4GKP]+)^T!;U8K8C<TF$K$C,7Q;
M<_-:NUCU MQ'(7CUYY$PD#4X 6J;Z8Z:GCV(8=H2C"J-+*,!O?_PQ#PB-?::
M2A.K._E(;W0G(N%]A)\)O5W\W0/>AA&5!&I7LU<74P5@A++&4RXRV()[AS1
MY79WT_W.P@.NJ&,UX/G-[72O&G>DG-.65%7TLQ#1SHI133TFX%,% PGQ")0N
MC*KO-:ZM7G0H%=VI3KU*+MZTN3+W)6$@4_C6B3YAYF_?;J/PV6DI]=76?,S
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M.:LI"C<5SX2S'+YF@,42ZAWC4]Y5C-&0,6HUTDU+\N[M;)*S%$?J=F8)3?;
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MQ,!80ZY3Z8&D"J^?>O2@>1EIR)?GR8?TZ"WE-.@O74R>P6/'P0'SOZQ2AQ5
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M'3F6\=>3Q4@3-Q&)^(,V,J<E8_<MB<5:F*@$[Q\M)\4PA8]<:??0:$Q)G_X
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MD\4.O!\&.AEM2,"UC2<<X*6%+.V!TY>7G:3"XQTF/NGB^<GG;B5NIKN@\3S
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M:82=&\F<<A"FW]2M*..L^N0@ *G$B '-<E 8G"3"@$E$U(@*@&SM6QO&3:%
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M+W(C;'B?FHO\8)B/>\O<);;9*)\[-5XF)2^-K/1KK/R?_G;W?ZPPLP)<VD(
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M=_IW(S;14.8PO_+K6%C4I'%X\D#.O'(HS&]&&LR95\,R.JN#&5W3>#3OPH_
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MEW5D-FBPOT_A:XAHXVOL[%UEG=AA#RE^(Y+90^0'!OC6]I+VEU7E7M[I?^[
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M##3FIQZU'#D:8L"EHM+(C1]0$P2_P2^2-$W>X97K[\B77)M:<TA])PB6GH8
M^[M*Q7%]@WPJ0'>\)_65G""MOY5EG(W&"6)G?TP!\>Q^M_*6J[IW@MV&U5':
MN Y:6YK:3A"K>MD]HA QI0>;#[/@W:>>_2N-XV7$<MJ3ZPA3-QX4?MU!G'"<
M)1$.V9HV@4<?V(YU$?*Z!.M.+QGZM0%!12GBR,)L8OPW-0DED*9^C0YJPOYR
ME3%2VW.7&U?J\":<F&V#]WO/M!C]:SM![(4?0<3"TP:A'BH.<VDGB-&@%<$M
M7P%RLZUG4-[TJ>HHF<V$6OUH;-:S?_!P!]TG/T(9X,?%!5K%OVYPL*E;[P4
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M#5+9X!&1Y9WA'#VA] T'$"R"D_ 1!<EK3%OAF1>U;)B]6[LG!0MTN*):0#9
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M N(>O(9.XGXXF)F'K,C/>EG4T(>/\L;X3"#$$QZ\>B.L KS+P.[[2=P3-.P
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M%;Z+K!#+>SCN&,<F_84%J9X/^D&E[9I^SQ#7J$+F%V;8[ EX#?)RS( ] ;]
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MM+,4MAO0?K*65(FTRNMC"3_^$A28E(Y8^JM4<Z]%  LQ9DSK:W!IM46Z5H^
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MQ;I%;7W/?PF1A>K-W:*WOD<:!SV*PWB+U^61,<"+Z*'>8K7 8\)4OKAGF!T
M+(Y7:80K'!TJDPLHNCI'6" AMJCSR750.I%.KET*KI]3]-?#R=7#[V>N5GE7
M6(0Z25:Z+N'NQA9(G=?D.(MNVJFC?8OZ#6:Y](+J3O8MYOJ('0X9.45$>MJW
M+#PU9OX?D9Z* _DVVRT2RM&WZK)+ ';?I(>_<_N8JQ<?AN6^3' 6VEN [I0P
M;E*8'A)0"1%I=%6GH*[^G8HW97^4#6^.ZV?;XD> L[U^@B2C[S._O7W'BQ[6
MR.QB+HL&"'*PRY+H87^ V6=5+#)G[@:KAV*^@.3,#.+61P&&0&]L+N(ZJUZ
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M2&ZH!.(<A+]\9)^_1B"NT45_.(&*_O+'(_@(DCOT_B=R6U(+Q3!=%6\[\"6
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MOE7J\&(#JPJ\[>D_70PW09* Z/K8M,N;AK35GSNJ77#4K"^O.7/W8S?;O\B
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M!)WT042;VLR:F9@/FJNWJCDXE$T>MK&-6B'$@<Z5#\KU\=3F.3CB?ZOF?EI
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MWVSG."A\+YHAF8C;_1R/"5OJHJ?8#VQ&;Q'^+'0)VHS2 ER;9N9U%):9C%K
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M Z>)P+.[*2$$U/F36EHQ[:<L#85GWFOLK,V)(U_T93SB76[SLU[X@<"04N@
M.&!]X,OZO'NATT,R;W&O0) X WU!P&H,A-2Q=*&7CH!GVM/S(-"K[%Q0B33[
M0!#E,<?5(;/!&$MRCL?%2.! % 0=#XJ9N?R^0.FB-NPJBN)ZC@_I-H/[NHB*
M8:481G^SO8$ S0W=P54.,)YJC-W'W..#,"V6FHS>WI+WZPN(0)U7[!D@>H^$
ME6?$CI8N2D)Y0NGJZ\+,:XC>8)#F6P!Q-?)7 #_C$-W!F^U]G 9I&&,^UJX@
MQ_&\.?DG)A!*/W&)??!4'T]BU8TT=)U!F/U 1',3'- OQ5&"VU.'L+.>T*4H
ME,&B4!?KD0W6H^'Y92>8(S55'2V+GB9L%$<MC %'N#49O)_6^B*)B'W"O.C&
M%C W*;L^NFAO2_@ *U?FM*$EDY9F7N:)2I-Y3Z,,XT:I/O9Q>_N1G7%83[V-
M+N\F2S\1;T73JO]4@.@TY^9IE&]@XYC_D.<EB&AU\.:/9^L.HZ^<PY#[_15+
M."V4=S\/,:PUEM-29*R6RB6NM-BU?H5MPDJ6^$5O;M5K]AZ"/TN0AL?-MLW"
MF;;SQ5Q41A?+'TMUDGN<UDQ\4UC-+3FAMR /87RH?9=_#V",]<*XF -.2R:F
M,>$,H7@+$",(T4>##T0-&QA_(-$T>88Q$D\/07*+:U1<W5?_5J--VA;9(2S9
MJ@K.UP,$ 1),^SBSK@^A[AJWZ!F"0PUCCOZXCR>5,T5ZF,N-\!,G<BOC?(?G
M4WMW,YWL&!T4@UR/*@HPH[5=J?2[9*)=$,$-ULM$U\>[(-P-V]*>%&>/:Q<D
M=S_1Z8AS@%A4"+H?\^;7G';ZYXVEFDH[4W"[ >TG:TF52*N\/I;PXR]!@4GI
MB*6_2AG[6@2P$&/&M+X&E[8%Z-T:U:H><)/E1?X$Z+[$Y-;&IM\6[L-EJ=*\
M\D*@3)W4TEE/7))0_,AT,Z&[#CCBBB?LC,AR*J [8-&,VXZ@(^ZHJ!(>;R*V
M=6C?'4W1(>P(SV I/&KRPAU>"0^FV_@=1>=2I-VI(NV7J \A$%B&K5,BN)&M
MW.HU"PE6')MZG[FIO4$=@8XE=1G"SA&1[!)D),MYV=ZWXI)[SS/":GS$RCA1
MO20&]9N(W-N1U;-XS/SENQ%^IN<M0N7,-D.AY4%R5NR1=3CPGAY#5QE'%ZGW
M<NAYXM@<B:F'+Y"XJ<THZ& )9W@R.0Z5I@/5=WRR.:AW";4?6?5L,RHJCQC3
MV\QQ$&0/#]_3S>8(<+5G9:1)M'GA2VG%!7P%'8=IUH%A>B'J .3?+*8;.7=&
M'>C\U4)TYKE*ZD#GWRU$1]Z_4@<R_V$A,D+^FSK ^)N%8(AX@6I1']AHO>8Z
MG6I!PF:UF0+_52V8V:Q7F.G@J@4G:Q^'?*=9+7C8_#H0]+S5@HO=TB_%;5<+
M$C9*NDP/8->RISW#[ !@<43/7%QIY%!9LD'1U1O!-R^Q19U=S5ARM796N*9%
MT9_:9,O&9:GY'<T53^Z*.E!GR<JZ)MS=V *I\_H-9KGTCM6=[%O,]1$[R["J
MN OTM&]9>&KLBN\"/15'^VRV6R3!H6_5%7$ [+Y)CY'E]C%7,SH,RWV9(!DC
MN@4'",*X261Y2$!U5:;159VYMOIW*MZ4_5$VO#D&F6V+'P'.^?D)DHR^S_SV
M]ATO>NP3LXNY4'L0Y&"7)='#_@"SSRK@B%QZ7J2'8K[P&+QG$+<^"C $>F-S
M89E9]?0(\3E\P"?Q TF:;'2979R--Q.7\\AUQ'F"E-6^> (5PF?!PQ/#K 9%
MK%BUN&PF!$Q?]K$:G3-(9BK?=?HAOIAE,R@S2C"*O;^$2*=/<8Z[_LWC-NJD
M6E_A(Y\\ :'7<<\WQ;>7-C6D#9"P:80IC#ONXC7GPF+(_X[[[\PD$/:#P@VM
M-443S2C^84P]W97OYJFC"0TOZN>+QM8#C:V"!$$G89$R_T&3E6O"SM<^YSDH
MT(2"&.+YW.P"^ %H!X+2V%D]$YUA>ZA7NJA0SI/!Q(AER+\<7[(K[Y*+SL@R
MI8?86:'=/6X\3$[N-"^@TG,]!VA7J^0:0?7BRJTL4$B9+._)PNUFP0.&M@_7
MQ\$O0J\9F;',O0$:Y^BW[+Y,(QQ?7S1)@= _]>894R4ZF1&,+;././-E0VBH
M.C-[!-+K. M!DC#RL4\:60$=G8P9;V") :Q8I"1]G%T#AIN0N#I+-]E^'Q<%
M+Q'QJ*WB.=V6*7@,OH.;X! 7 8-^R0U-:CJV(,\KA"IK9%I 1(5UZBJ0-YZX
M=&6'2&=GG["BUSGY02MU8]HLN0O(I'.0DKI@/<*'%A$\O?VL7K20RD/^BNQ3
M" DU1S!AI?I2#8H;>0)GO/]GO#EH2/%P=EPG(,-_.3*41TA0."U%5G/<SV'6
M%2PH_;FA-*I4HW8JAMRT7K=S86IUAHT6K9C9??LWD'W X+"+0T3'Y%+;]+;+
M3KE^H_0G07Q5L]NZ-V5=NH O ?VIW?WFHO)$.5 18O  YAFC_O>DC17 N:5:
MXQPF0E+3WO'I_[IL[>%A+8?)Q(:_+X\8A:F??EMV2B!O;Q/:Q$8M3$V/RJBG
M;>R?HJX[I)(;<2ZZ.&46#2:V,U@N#8G"X"0OXH_@UPB=)[)ZV+8,YFW)[J,Z
M(+K8 5A_L7D/,0*A:6V7%=A"D ;HQ?8,P6><E7F"[KQ#AG/_4OD[MXMB4/^.
MOE%DZ1OX&9#]^FBMEKT5AVG&I[?BX'?%$+V6Z#W5,!RLG@%I"**[-,)<YPK]
M+2+$I4MT5#S;'ENL$MB0)C9I8XSI_(;XQ&.6YYNT-Z?-MF+P%)[#[**:Y1P
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M'_D-'X/\\NB[//HNC[ZE0J0ZY5FK0[PMP1,ZZV\_0/()OB!I>$?;EMG#60_
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M0%SS)/2'$RM"?_GC#HD0% 8T^5EUTNT=^)JB!S5$0O%QLZTSF-RV6?EN,,'
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M.JV>-!M2,]7G[_.=SP6FC<R)DKL UN5I;K(]UJO4$;6GN-#KXZE)8ZFY^A'
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M<= ]+GI9.JB>$%8O_E+43&#_F3X6@[5//1JL7KK0[LO[/ QCS:=GQVI,Z.1
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MMRJ7.S S^K(G:+P&3_?XGLY<E7Z*]MJA96HO\_J5QV[P 20DS_%5&IIAL6E
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M&E"Y@&258?K>T,%K#_,'T&E2P#PT!3]TERX]=I</B_R>1/Q=8EY&I(!5>.P
M^V1?OSRS1*D5$%&/L&'CUM+RR7![>2X]IWSO%@#V&E>O6^M?\O;)_CD/W_2E
M4K@>YY.M=!KOQ%E[W@6W807Y<O#)PCH#Z\H#0?R.J'?ODTGR\MM4\N0A&1-V
M@=*4.9Y5:I%F]PZ0$3E2!QI!_;B>4;/%K.U,YH>Q2]2,&*/03&;-B!_QCEDV
M+>:L#+/\T)EM")?12_JVAHO\#A)>:!2-\S&@WSGJ;3-*JYB\9\;\BK-%IVSE
M_^'52N7GO_T,'/@E.!QHLDWYI_)#DJ2YZ$%\XY](+*J7_HY&Y8P_D^]? \:"
M),^>R/Z5NS:28 ^SHVF0TQ;E[/?\;]DO4;H/:/( ZN$&_OW3[[+B-<LI'+WP
MBY]96AS^_A.?1OI+J4&*OQ_$LT\;V57!2J=%0N.8ERN&43&>XA) 3RP(\_+?
M/YL)6$01E<K=<\&'N=Q6P^;%PKE92](S#"?)DZ/,N&S+3B"-)ED>\#/*3-DV
MB#,K:0])SL@'%ZGLD$I.=>?( H!RKIK*GKRZ4W[<R,K6DAA#8V=6<I[5/4A$
ME/^R@W86%J_DX8+D/-&$[@OQN%+V G(_*<@R^;JCX>X32<+=/F#?JBC^NHJW
MI'4*9IL1^S0A>0 *[F7G4Z[0$ODUB+FH^OM/H7!]V!@SX*&4/!@ .C.YSOM1
MI38BKW9B2S&R(1_YIU@\8R#IZW]7]V1>-5UE&BTDB (:;?;?Q?2-EGDHL(\
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M,7]M/%O<BV_=2D*CT9"*7FY:(7'P49I5M-88.PQ2PM2L97X.\GHER5LG6&8
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ME\.I\73VOM5]@B2TCH?(]%Y04Y[(LX&@W/Y.C_=VHC+&8& .SA J"U!0Y8C
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M@O$L8H$HYD)D[#CA9:8,NY@*6(,H"QF: 3O-PB$.*:H17ZLTY]FB&H\Z^5T
M*D2<_<;#3V+!MNK&M +>FM]6H28"NM2LV>][K@LI3-5NN X!.G92[O1@?/1
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M[#%=,E*@2]#1%.\A)-*%C4!TIG"3.O)/BPG7I&# #&*)>(TF"YF1U12W9<"
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M,V?=(K-5B0E*^'.8F-KZ)FNYZT@_K[RB,);&$ZRLK:%3LD(K<-(O*PR8!=(
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M&1EV74^V.6@OKI/VG>WN)J73?_VTB)<\L[W3?;E3>P;^R)OCLU;[K8WN*]B
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MRCNGBH48H 4Z"OD8,3$O%73*06R#'4PE2\IGCX6H'T/D6J/T &F"Q*M*"KH
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M*T0O6:G!;#'>(Y(5HI0$/*=PP0"GN6U\N=^E6PQ?[](N_4 NYBZ(J8T[U%8
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MSWL,9QW#>?4X4LGR]=]>/9Z56?KZ_P%02P,$%     @ SSN!6(1<OG$U(0
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M#58C"._K[/_KGWLO=F?%?R=OUD'>[#\N>7/F*+J3.2QSWE;&LUGD1"V-GT1
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MRYO2T5[9+QF#VZ4B^)F-Q5!-JF'PWJR?#*W/BHBJ@5"PU0>,74;+W'#S=[0
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MYEUEKY]&13+]\6^OGX[*+/WQ_P%02P,$%     @ SSN!6'UVBK81 P  ?PX
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ME>* 8%53>U%HB)I",]91(@@AQB-2%'4)_*]+,07CP''%NG$=M BXQ&@$V#^
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MXV4+F"R)+W.@]&SK4(D33GDL#O7S>"SP<[UJ*9R/WZP#?7;\U3C$MD@/AKI
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M5PF_^//9D[DOBQ?_!U!+ 0(4 Q0    ( ,\[@5@NRK;-0#,  -L[   2
M          "  0    !I;6<Q-C X,S8S-SA?,"YJ<&=02P$"% ,4    " #/
M.X%86$_18*)P  !_IP  $@              @ %P,P  :6UG,38P.#,V,S<X
M7S$N:G!G4$L! A0#%     @ SSN!6/;<<V2PF 0 GX(% !(
M ( !0J0  &EM9S$V,#@S-C,W.%\R+FIP9U!+ 0(4 Q0    ( ,\[@5A@8U"
MO)(# !E6(P 1              "  2(]!0!T8W)T+3(P,C,Q,C,Q+FAT;5!+
M 0(4 Q0    ( ,\[@5C1>@>$JHD! -X]%P 1              "  0W0" !T
M8W)T+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( ,\[@5A>;1XU.!4  $.Z   0
M              "  >99"@!T8W)T+65X,3!?-3DN:'1M4$L! A0#%     @
MSSN!6+EE5W(@*0  (DX! !               ( !3&\* '1C<G0M97@Q,%\V
M,"YH=&U02P$"% ,4    " #/.X%8"01^Q/X6   UQ0  $
M@ &:F H =&-R="UE>#$P7S8Q+FAT;5!+ 0(4 Q0    ( ,\[@5B$7+YQ-2$
M  0P 0 0              "  <:O"@!T8W)T+65X,3!?-C(N:'1M4$L! A0#
M%     @ SSN!6'UVBK81 P  ?PX   \              ( !*=$* '1C<G0M
M97@R,U\Q+FAT;5!+ 0(4 Q0    ( ,\[@5CH#X6## @  ,LS   /
M      "  6?4"@!T8W)T+65X,S%?,2YH=&U02P$"% ,4    " #/.X%8\;/J
M5><$   @'   #P              @ &@W H =&-R="UE>#,R7S$N:'1M4$L!
M A0#%     @ SSN!6,=[Z^C#$@  ?I,   \              ( !M.$* '1C
C<G0M97@Y-U\Q+FAT;5!+!08     #0 - "H#  "D] H    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>tcrt-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:tcrt="http://alaunos.com/20231231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tcrt-20231231.xsd" xlink:type="simple"/>
    <context id="C_e0870a39-743c-4197-a2bf-d7b68c1a75eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_37060ce3-beaa-4b5d-8b6b-3b25f9e47087">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:ClassOfWarrantOrRightAxisAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-22</instant>
        </period>
    </context>
    <context id="C_31df6cae-3411-4d1e-afda-0b2df9d5828c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:MaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1b0fea0c-fa5c-4f28-a5af-abd1ad3285a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d5a914c9-36ee-47c1-b8f0-1cd50fd2cc9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f1be53cd-8ca0-4fbc-8225-e0b9cea77dc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="C_ca613479-d043-416d-8cb2-0957fc2d9f3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bb295f58-cf1f-496d-99a4-62856a01fdf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-28</instant>
        </period>
    </context>
    <context id="C_cc7acd0c-a196-474b-904e-2422719555e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EmployeeStockOptionAndRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d86720e4-1c24-43a1-bbdc-09b83278c5c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:PerformanceBasedPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-28</instant>
        </period>
    </context>
    <context id="C_c4e43b9c-1c1a-4ee7-8310-f49b0b04362e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">tcrt:ZiopharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">tcrt:EdenBioCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-05</instant>
        </period>
    </context>
    <context id="C_86d41d2a-3fa1-4e8f-a00d-faeb00c9cc56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bcbf392a-4dba-4a84-ab43-3ee5a35cd906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:DueDateAxis">tcrt:PostMarketingApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:PerformanceBasedPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-28</instant>
        </period>
    </context>
    <context id="C_a0517427-ae4d-43a0-9947-ed007458a817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c34e2ea2-6bfb-4c2d-919a-3fb69b17bab3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6ee1d3ea-fecf-43a4-b0be-9cca9bc302be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4bade1a4-e2fe-4751-93c1-f31838539841">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-11</instant>
        </period>
    </context>
    <context id="C_b3feb1b1-0ac3-4b26-ba91-a5e0df500c8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4c598769-068f-4e4c-b4a0-a1504cfbdf40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonAgreementAndWorldwideLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-13</startDate>
            <endDate>2015-01-13</endDate>
        </period>
    </context>
    <context id="C_12319f01-0ffd-4415-8d9c-445e79250b84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_03dd637f-957e-4172-9001-e07d902c6e28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:AgreementTypeAxis">tcrt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-11</startDate>
            <endDate>2018-11-11</endDate>
        </period>
    </context>
    <context id="C_8d3c500a-8039-4aa4-9783-2c2376933de5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:AgreementTypeAxisAxis">tcrt:CantorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-29</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <context id="C_2d71e8ff-49c9-42da-a181-17cbc8b8e234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7c575269-28b3-45c2-9022-f2fac466229a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_61083e15-726c-43c1-8169-eca505a1dd5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-08-17</startDate>
            <endDate>2015-08-17</endDate>
        </period>
    </context>
    <context id="C_11127a99-f933-4bcc-a852-9e3580fee74e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_698ba229-d584-4d13-99e6-5cd10624b1c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1270a725-670c-4033-b553-4b1ffa03336d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c2285624-3869-463c-86d8-22c65f4a4ba3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-19</instant>
        </period>
    </context>
    <context id="C_5f040735-cf7c-45e8-b576-fbda049ff33e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9e81976f-0dda-4005-94a7-17763001d331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0a9aab26-46d9-488c-b695-2646b51f35c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tcrt:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2d8ef632-f188-499c-855f-f56d87eeb09c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_01c537c5-d7da-43b7-9828-3dd4fac7a6b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:EdenBiocellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-18</startDate>
            <endDate>2018-12-18</endDate>
        </period>
    </context>
    <context id="C_c56bef7f-3b74-416e-b3f9-37e431049ea5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tcrt:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_759b438f-e084-415a-bd3e-33a77795c829">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2023-04-19</startDate>
            <endDate>2023-04-19</endDate>
        </period>
    </context>
    <context id="C_db1f1c30-f159-463f-bb42-52af80ab87ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cc9a8a39-bf1f-4865-b472-106ea73fc8f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_a0e9f476-c0cc-4b3e-b34e-81e4371b4b81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5d5825d4-3830-441a-87c7-7eaf314a9d2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d601659b-5678-4e9a-8c2e-09453abc5b8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f9a17b33-5bfe-4087-a30f-e86addf030a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c3fc31a6-03ef-43cc-97ab-fa4366fe7871">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-22</instant>
        </period>
    </context>
    <context id="C_59b1d649-d101-49bf-a3c7-bd6b2abc3d7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ffb8b599-3fe6-43c2-9fb2-30c91dd8802b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="C_c6b3f307-9aef-450c-9206-261565a5306c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="C_95d872d4-ff79-4993-afa4-1fc260f3a843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tcrt:OtherIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_112e62be-1071-454a-9093-81a7c718e165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9fc04f3c-c57e-4e06-b36c-5fbfcaec5cd3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c5e88f0f-cfd7-41a4-bf45-de43957559af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e4e17587-5901-4339-8423-005a5407feac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c513888a-3b48-4024-a189-900f74620507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="C_8437c692-33c1-493a-b928-11fb26d089fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a5f0ce97-7e26-409e-8300-d1a1644a54a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="C_df6734c9-10ba-4183-bed0-db726b38f022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EmployeeStockOptionAndRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ae07e329-a5b4-4996-9101-5c81cefa338b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:OfficeAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_220d9373-ebbf-48e2-9ada-0496f791e56e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:NewWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-12</instant>
        </period>
    </context>
    <context id="C_9e105059-91f4-41fa-bb01-cb0f4ed0fb32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c4120da5-aa3b-4ae8-8a1f-b0df2ff0da10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2019-09-12</startDate>
            <endDate>2019-09-12</endDate>
        </period>
    </context>
    <context id="C_9bfa8341-1726-4852-8e7d-295f0376fd93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2024-03-27</instant>
        </period>
    </context>
    <context id="C_8baad0c4-09aa-4617-9aa3-03a23b56ba42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5d722990-44ad-48ec-bab6-e38f76af3769">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="C_82b0d417-0325-416b-9745-26ad2cfd0d65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d276298c-740b-42ff-98cb-ed95e869f300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:AgreementTypeAxisAxis">tcrt:CantorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-29</instant>
        </period>
    </context>
    <context id="C_0a5a10cc-553a-4c9b-9781-bb8cb6a5dd9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-28</startDate>
            <endDate>2021-12-28</endDate>
        </period>
    </context>
    <context id="C_c1da526c-ca16-481e-9bc7-b20e2797d243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="C_5192514c-c4a7-4570-99f5-e8a967b213de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2023-11-15</startDate>
            <endDate>2023-11-15</endDate>
        </period>
    </context>
    <context id="C_178ac7cd-5b14-4544-b80c-336bc2dd52d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-12</startDate>
            <endDate>2022-08-12</endDate>
        </period>
    </context>
    <context id="C_42fcfea8-a421-4581-aa9a-f10b12c3fff7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-28</instant>
        </period>
    </context>
    <context id="C_b4d53f28-56a7-404b-af45-6335e67f7941">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_97c705ca-f124-47df-ba05-d7327601d771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2023-10-20</startDate>
            <endDate>2023-10-20</endDate>
        </period>
    </context>
    <context id="C_a62dc996-32ea-430d-9357-c8af5aff9a7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d5b52643-6d79-400f-8b1d-031a3c875379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9eeb8156-fd64-4f9c-a68b-13acb840c000">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2018-10-05</instant>
        </period>
    </context>
    <context id="C_9eb8bb51-2ecf-42fc-9df9-3543c2498b7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-28</instant>
        </period>
    </context>
    <context id="C_8e377f39-2755-46fa-ab15-461adb70dd68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:OneTimeBenchmarkPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcrt:LicensedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-28</startDate>
            <endDate>2019-05-28</endDate>
        </period>
    </context>
    <context id="C_5f261627-186d-4c4c-9a00-ee68ecc9a86c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c3c26aba-b1fb-4834-9c5e-b8e01a5ecc3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fec7df81-6165-4556-94da-9ce5e0afffd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:DuneLakeCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_941cd6f3-5783-415e-b2da-d758935f04dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_00381981-d3cd-44fe-a13f-32128dadfda9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_36cd6252-28b4-4775-b0f9-58a9b230b1c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="C_d4b60ecf-6d80-4fa1-b071-1864dd9c10b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-28</instant>
        </period>
    </context>
    <context id="C_9372d727-0118-429b-87d8-c76963744d6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cd40fe04-39eb-4618-9e08-4ccfc8585a11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b4ef7ff5-bba3-4349-98dd-d7df9d126723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_47de4d35-3a62-44ad-a1e3-078eb736401e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2a4b610b-874a-4c4c-a87e-050473791707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2024-02-22</startDate>
            <endDate>2024-02-22</endDate>
        </period>
    </context>
    <context id="C_c08c022b-51fd-407b-9baa-ebc8ead77d26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c30dcdbc-ca80-4f40-8509-a02802f4927d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2023-11-01</instant>
        </period>
    </context>
    <context id="C_018d6e8c-001c-45fa-97e4-4efe0b2a752b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="C_6eff864f-3158-4523-99bb-a0cf8c94ad47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-12</startDate>
            <endDate>2019-09-12</endDate>
        </period>
    </context>
    <context id="C_61732725-ae5b-416f-8f67-a2ab46a40cc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4764432d-361f-42c3-b4d4-131225ea696e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_53b2cce5-dd6d-4584-81a2-934fca6f36e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6240eae2-8099-486d-9b0b-6163532f0ff8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:NewWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-12</startDate>
            <endDate>2019-09-12</endDate>
        </period>
    </context>
    <context id="C_7dad8626-c247-4cc6-80b0-0ea99635780c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1a51d51e-d3d6-455b-ac86-ce8e857d2093">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f2dfc65a-f1b4-4bd3-ae8f-235fa879ba0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-12</instant>
        </period>
    </context>
    <context id="C_1eb9814e-4de9-413f-980e-56701e4ada9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ed3ce84b-d7e9-4796-87f3-b1cbfed8bb7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_66a9005c-fc69-4b3a-83be-3826cef87dcb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e64be0f6-91d9-4db7-86b4-e80514f8c958">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d63de51f-7fcb-4cee-816b-0f40bc587e2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="C_271f0dcf-64b5-4fbf-a9a4-9481a9d78720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_63da8372-4842-42f7-846e-29d35b96baad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8d19272f-497c-47f6-a99d-591f9130da04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c03e3f83-0461-4bff-a6ec-c8e8f6eae256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:OfficeAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ec1d55bd-1201-4107-bcad-9c39a5fd6ee6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-28</startDate>
            <endDate>2021-12-28</endDate>
        </period>
    </context>
    <context id="C_f8995cf5-f0d5-4e4e-99fc-41441a44780e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d4a1c311-3a9e-4881-9787-deb17fe41e97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0982ca17-65ec-46e2-b808-c94e4aa0b3df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcrt:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-05-31</instant>
        </period>
    </context>
    <context id="C_d22c7a01-1ee3-4ae9-b8e5-5302459c17aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b2c1287b-cb3c-456e-a570-1593261f684d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:AgreementTypeAxisAxis">tcrt:CantorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-29</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <context id="C_d20f89b1-a277-46ad-a886-0783d93e0131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0d7a6c39-7681-4ca3-99fb-8b12b128396b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_919b08ce-ab39-4642-b52f-67c2d4317819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:OneTimeBenchmarkPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-28</instant>
        </period>
    </context>
    <context id="C_9251b0d7-fe5b-457f-a984-b77be81cbbed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6e982006-943b-4fee-97ab-42236865abf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-22</startDate>
            <endDate>2019-10-22</endDate>
        </period>
    </context>
    <context id="C_4104f83e-9d9d-42d3-ba02-e04dc9b2ed5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tcrt:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ab6d30fd-d037-4c8b-a225-3af57f8a921c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8d0c8320-b169-4c12-9015-18779c3f403e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tcrt:HogueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-21</startDate>
            <endDate>2024-01-21</endDate>
        </period>
    </context>
    <context id="C_70ef5a8d-4cca-4f80-ae99-5f24fedd40fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="C_38467bd2-81f8-405d-9362-d3b8371c7945">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_45a84280-5929-4306-93d7-0db1814fb46c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8a40112e-a10a-439d-a924-dded53c33f05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_25fd3671-b6ec-42c5-a84d-f3bb943d4679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tcrt:FederalAndStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c44e0959-6f71-4672-bea1-d6bc634b6ad9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_60aa9216-7e7f-400b-9d0d-65567c8ce942">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5b40d2d6-501d-4e7d-8b78-1a53bdaa393a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2023-03-17</startDate>
            <endDate>2023-03-17</endDate>
        </period>
    </context>
    <context id="C_c5399d8c-4124-42b7-a6a2-756bfbee1738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-22</startDate>
            <endDate>2024-02-22</endDate>
        </period>
    </context>
    <context id="C_532e995e-0f74-4893-864c-58c3f779b2e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-11</startDate>
            <endDate>2018-11-11</endDate>
        </period>
    </context>
    <context id="C_10887a30-fe67-4725-98ec-6def6ef0869d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b07e679c-ee37-4ba5-b372-9bfc376e0ba0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcrt:TcellReceptorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-05</instant>
        </period>
    </context>
    <context id="C_f58e5ef7-a8c3-4cae-b017-bebbe49b3b1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_614aa634-42cc-4d32-8a9a-8b4df7e3a7b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d5434f85-d96c-496b-8794-5fd3bbc24ce8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tcrt:FederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b1dfdf14-86ec-4861-a350-a0829f3f94bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-09</startDate>
            <endDate>2023-11-09</endDate>
        </period>
    </context>
    <context id="C_3bcbadbe-09aa-42ba-8a38-e52fd3a5ad82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:PaymentTypeAxis">tcrt:OneTimeBenchmarkPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-28</instant>
        </period>
    </context>
    <context id="C_1a75d2a0-9d24-4504-a3dc-2dac5fdd0e65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="C_9f6ea145-3408-4127-8187-484ad479069b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tcrt:OtherIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8c63ac11-1fe7-4822-9cb9-1e975eedf1b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2024-01-31</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="C_2e188d5a-6779-4f0e-aeb1-22f1285c7349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tcrt:FederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_80b02891-b4a1-429e-ab36-34271657c7e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9b52611a-b9c3-4f92-b8bb-c439f1b299fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:AgreementTypeAxisAxis">tcrt:CantorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-05</startDate>
            <endDate>2023-01-05</endDate>
        </period>
    </context>
    <context id="C_4e1408a8-5e0e-4b89-8b8c-917a420bac4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_82f28128-caf0-440d-b3fe-b4abba328cf5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_06432621-89ab-472f-911c-5458e9f57386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6dbf0481-cdd5-4b3c-8af0-560dbff890e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0b32ddd3-7ce4-4f74-9808-a45ab5d03ffd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:MdAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_41ccee47-b234-4941-b8eb-978d9f5b2e42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="C_11b50a8f-e3f7-4d6b-85de-985e603d9114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f95291d4-e96b-46f8-b36c-1c199e1f5e39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tcrt:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3c4cb663-e0ce-4562-a60a-f57ab1bd16cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5d7932fa-9451-44de-93c6-0aeabfb182de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="C_6804cc66-48f9-4973-9521-76cf1de8e41d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcrt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-29</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <context id="C_db650e42-fee8-4d18-8c55-3c11a3ece9bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="C_9081085f-fcee-4652-b4bf-4c50be103e98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c83e3ba4-ff7f-49bc-b367-c3a48773a81c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:EdenBiocellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-18</instant>
        </period>
    </context>
    <context id="C_dada01c2-0448-4544-80b7-17e67bdfc890">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-03</instant>
        </period>
    </context>
    <context id="C_9bebd57d-5315-4cfa-aa91-69cf64124596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-08-17</startDate>
            <endDate>2015-08-17</endDate>
        </period>
    </context>
    <context id="C_56dcfc15-8dde-431d-a7db-bbfed94629e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-05</instant>
        </period>
    </context>
    <context id="C_5a00674d-0901-4260-8a18-828129c14592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_46848514-696b-4f06-9e6b-d4096db50827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-22</instant>
        </period>
    </context>
    <context id="C_0fb6425a-bd51-4ef2-a4fc-01fe4f515d0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c84cbaaa-b7b5-4569-80f5-59327bf2d4e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:ZiopLicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-28</startDate>
            <endDate>2019-05-28</endDate>
        </period>
    </context>
    <context id="C_aec61900-53b4-4857-87b4-484cc2b801ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcrt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="C_ae242319-1a7e-447c-b3ec-f37cbc585f56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tcrt:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7076c57a-eac4-4967-be0d-548e7041b7f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="C_aa3c307b-d3f5-4b67-b1f6-1018ba02f672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tcrt:HoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="C_f075a278-5164-4d2a-9bd2-198370833aca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bef1fda7-f827-43a9-a2e5-5a8bc3c58ab2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2004-08-24</instant>
        </period>
    </context>
    <context id="C_63369074-a4f7-4fe2-8674-f1c4a1a3245e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_05605a3c-4399-47be-99a9-52abcb18dab3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_afef85da-f505-4cb3-8378-c367deebf43d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_4bf44b7f-9ed1-4682-9e9b-9ebfcef178ea">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_01232f89-8180-4996-b75a-96eddc1fbf4c">0001107421</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_a16a1e16-840b-432d-809a-bb4535f4b98d">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      id="F_15b0f2c7-17af-4d93-a8cb-5eeec14ce40e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      id="F_51f9a637-4669-4919-8023-57118471f122"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="C_53b2cce5-dd6d-4584-81a2-934fca6f36e1"
      id="F_fa18b81e-dc37-4248-8153-57693071a98f">http://fasb.org/us-gaap/2023#UsefulLifeTermOfLeaseMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_3ad5ce14-f747-4cf5-bff0-a5dee5721dca">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_7f599f6b-8e34-4ff7-9b2e-5f44eb8610cd">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_4c5b6da5-3072-4041-a87a-4ca38632f90d">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_6e759e77-b9b6-48ab-adaa-08586db20fb2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_f261cfc8-2694-43c4-bd29-cb066d991134">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_06fb3557-1b97-42f6-a7ac-6dc2cbc3d4b1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_c3dd913b-c0d3-4109-8f52-38292ded97ae">001-33038</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_b6d9e610-1b15-403b-9c27-6749404bf63b">Alaunos Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_8d5096bf-08c2-4db2-a512-2425347bda2e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_286ded9c-a1d2-4800-99b9-4555a349817f">84-1475642</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_6af8c6b8-f505-4c70-9f6a-712c707a5c85">2617 Bissonnet Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_d03bce70-7343-4e0c-994d-7f112da278de">Suite 225</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_9a37ae7c-8eef-49da-b371-11b3f05f6987">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_69282c88-0487-46be-b0c7-73e2b519a6d4">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_c5aaca85-6848-459e-ae6e-bde8035eae25">77005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_381474df-d9aa-4b38-a034-188cdf505993">346</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_c8138210-29ca-4083-a8da-156375c27747">355-4099</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_212b8c1b-51c8-47c9-98d3-9dd87c8d0177">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_e15797ff-0af5-4953-a1a9-7f600142b734">TCRT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_7bcbed53-51b3-4d20-aba9-c2c9c5c9b731">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_80715f7e-4f92-4fa2-b90d-05b2d9f08f27">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_7df54698-575c-4176-b3c8-bda0701e67bd">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_5703de69-5af1-4772-9502-36ff0bf6351f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_cf091147-2ba6-467c-82be-58dda0f79c4b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_744305d5-efe7-4ad0-9194-eee0754de725">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_9881cfb7-1692-4ab0-af85-130c020acf79">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_5e5ebd22-2778-4ffa-a088-3c9a4c9dcca8">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_496a5465-960a-4e37-8922-01eb97c2524f">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_96432cc7-bec9-4ed0-aac8-012a85c8da69">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_1b76a4a7-be47-4c8a-b4ea-76e3e98d4155">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_cc9a8a39-bf1f-4865-b472-106ea73fc8f0"
      decimals="0"
      id="F_917114b1-77cd-408c-b85e-03e464948e69"
      unitRef="U_USD">94764946</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_9bfa8341-1726-4852-8e7d-295f0376fd93"
      decimals="INF"
      id="F_19e057d1-8587-4ea7-be3f-2b9dee18afc8"
      unitRef="U_shares">16012479</dei:EntityCommonStockSharesOutstanding>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_10887a30-fe67-4725-98ec-6def6ef0869d"
      id="F_f3947dd5-f476-4cb7-bdd2-1f9ba0596998">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_10887a30-fe67-4725-98ec-6def6ef0869d"
      id="F_befdf3f8-3000-48b7-9e2d-e7fe761d4ae7">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_10887a30-fe67-4725-98ec-6def6ef0869d"
      id="F_dc224997-9be5-457a-8f4f-2518f487b083">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_10887a30-fe67-4725-98ec-6def6ef0869d"
      id="F_f1364332-7b85-4dd5-80f0-ff67e0ee898e">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorName
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_f9129d74-68fd-41de-8bb6-520fac83be5b">RSM US LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_1505f51a-d1c3-4fbc-a592-db28b0008a49">Boston, MA</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_3b406227-7260-4f1e-ab21-16d4379396b8">49</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_ba5d5e08-085b-4a40-aa26-a5f55d9a7e4a"
      unitRef="U_USD">6062000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_00977ef4-8f4d-4488-8883-a9732574babe"
      unitRef="U_USD">39058000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_28305217-72c0-411b-96ec-73e754a34a43"
      unitRef="U_USD">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_8f26b0e5-a3a2-44c5-bea6-f48a314e1f37"
      unitRef="U_USD">13938000</us-gaap:RestrictedCashCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_7e45513e-d34b-47ae-937d-6d8f0e15c419"
      unitRef="U_USD">1000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_10ddb40f-2f35-46d7-a7d8-d1375d38a721"
      unitRef="U_USD">4000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_7b400a21-76a1-494c-b186-49c6671e5b07"
      unitRef="U_USD">2198000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_b8edd913-0cce-4cae-a783-8da304d55831"
      unitRef="U_USD">799000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_cef09b50-2028-4bfe-95bf-8d323da28afe"
      unitRef="U_USD">8261000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_fa8dd556-7d16-4a9e-a32a-e44eb1ef7f23"
      unitRef="U_USD">53799000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_a7a53a3a-df64-4806-97cd-b7ae426b4711"
      unitRef="U_USD">2000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_490aded0-787d-49c2-b764-8028b336682c"
      unitRef="U_USD">8460000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_d8ca5726-846d-496e-b7bd-db4f1fc1552c"
      unitRef="U_USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_5588d3f3-1c66-4d94-a415-64d76fa0b89d"
      unitRef="U_USD">2136000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_449221ac-b90f-4e65-bb47-3d132b2fbc0e"
      unitRef="U_USD">0</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_fae5ab64-1176-4998-a4f2-89a68413d64f"
      unitRef="U_USD">42000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_f7691098-840c-4998-b24a-94ae814dc22d"
      unitRef="U_USD">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_252b46d7-cc97-42ba-a80a-b1da7ab2857a"
      unitRef="U_USD">500000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_483c5d77-5ce1-4b07-883b-f38132d5883b"
      unitRef="U_USD">8263000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_dacb71c3-a771-4aae-a37f-71f7bd07ed59"
      unitRef="U_USD">64937000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_4837e603-55d5-45c8-8faa-74416154601f"
      unitRef="U_USD">616000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_813bb7d3-554d-484c-bbfa-014645421a92"
      unitRef="U_USD">1389000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_8a0d02a2-370d-43b5-a1a5-e52d3b8ddc5f"
      unitRef="U_USD">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_0aa0bf11-d508-4345-940b-405a49966a21"
      unitRef="U_USD">16765000</us-gaap:LongTermDebtCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_8ae5422d-2117-4492-bc9f-8e5e0950ef44"
      unitRef="U_USD">1340000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_8a224fe9-a276-4d28-8a3a-396eab0ef326"
      unitRef="U_USD">5454000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_6c92552e-5f1c-4f90-97b0-568ad0d5b326"
      unitRef="U_USD">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_3d303e93-b1d1-49bc-8446-94a2ea56d85b"
      unitRef="U_USD">558000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_04d8a268-f2e0-4e6e-8936-1492974cf25e"
      unitRef="U_USD">1956000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_85e18570-fd73-4fc7-8daa-ddbd9ef2bfad"
      unitRef="U_USD">24166000</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_2351335d-1fe3-4e11-a6c3-d4f6f5c21f97"
      unitRef="U_USD">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_a5012be5-d125-4a4a-a865-94550e881191"
      unitRef="U_USD">2188000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_e58290ae-af3e-4f60-9897-6b8251d74bdb"
      unitRef="U_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_3f6e08e6-2a32-414b-a5f4-81e67ff548db"
      unitRef="U_USD">28000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_757ec81b-cd85-4810-9435-c0c69b1f33c1"
      unitRef="U_USD">1956000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_87f16a0b-9857-4090-82ba-38ad519ec158"
      unitRef="U_USD">26382000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="3"
      id="F_07858731-3d09-4dbf-91e3-d03fb8137b60"
      unitRef="U_USDollarShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="3"
      id="F_bfe21680-2949-44b3-b695-331d9f356f92"
      unitRef="U_USDollarShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="INF"
      id="F_301c8352-8566-46a2-82c4-ac73f2dbaec4"
      unitRef="U_shares">34666667</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="INF"
      id="F_690111d0-0bce-42f9-80d3-df593d986214"
      unitRef="U_shares">16012522</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="INF"
      id="F_a0ee96ee-86dd-473d-8a05-83d4f96fe581"
      unitRef="U_shares">16012522</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="INF"
      id="F_a40347f9-f198-4ee9-a9db-410f1978cfbf"
      unitRef="U_shares">28000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="INF"
      id="F_128dd82e-2c6b-4b78-b7d2-1e3903706b67"
      unitRef="U_shares">16027384</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="INF"
      id="F_8ef15a32-88af-4b02-86b5-91e5cdb34103"
      unitRef="U_shares">16027384</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_97a5556f-a03f-4935-bb8f-7fecf921aa52"
      unitRef="U_USD">16000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_94b82d4a-5547-4b90-8e2b-b738c880af96"
      unitRef="U_USD">16000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_c87ba1f0-b136-4c29-8092-27fed7d9a03c"
      unitRef="U_USD">922058000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_f3f066e8-f6b9-407f-b673-7eb4ae3e3d7d"
      unitRef="U_USD">919166000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_ec3f0a8b-874d-42a7-86df-b5c9435edd63"
      unitRef="U_USD">-915767000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_8783138b-d369-4978-8863-d14685a9e8ce"
      unitRef="U_USD">-880627000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_7171e49a-155a-4cfd-b7cb-a957ae1ffd73"
      unitRef="U_USD">6307000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_7ce1cb40-a052-40cb-a995-2483806cea80"
      unitRef="U_USD">38555000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_0c14da8e-c9db-486d-8a4f-2e7ac5ddddab"
      unitRef="U_USD">8263000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_3114bb7a-6bd0-40be-9012-94b55aea0513"
      unitRef="U_USD">64937000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_ccaa974d-88d4-4e4e-a025-10e5956cb892"
      unitRef="U_USD">5000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_4f5182a2-42f2-4477-93d9-92a28fa0ebbe"
      unitRef="U_USD">2922000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_6bd6bb73-c6cc-448e-9406-3fee63ba6774"
      unitRef="U_USD">16279000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_56f7bd13-dfbd-41be-b238-da8225ff7c48"
      unitRef="U_USD">25018000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_e607b17d-d27b-4307-96e5-2e949d44e365"
      unitRef="U_USD">12219000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_592cf4e0-1265-4599-8eff-2e668b2f7390"
      unitRef="U_USD">13142000</us-gaap:GeneralAndAdministrativeExpense>
    <tcrt:GainLossOnOperatingLeaseModificationAndTermination
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_cfe8f009-e07b-4c13-9027-8757da0ea741"
      unitRef="U_USD">298000</tcrt:GainLossOnOperatingLeaseModificationAndTermination>
    <tcrt:GainLossOnOperatingLeaseModificationAndTermination
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_b2689ec2-5222-4347-8cd0-3d9526c24d04"
      unitRef="U_USD">133000</tcrt:GainLossOnOperatingLeaseModificationAndTermination>
    <us-gaap:RestructuringCharges
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_3b6f9d14-b31e-4c71-8f57-a08852729d80"
      unitRef="U_USD">1269000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_6172cb06-2e03-43d5-9da5-efb9c8e5318c"
      unitRef="U_USD">0</us-gaap:RestructuringCharges>
    <tcrt:PropertyAndEquipmentAndRightOfUseAssetsImpairment
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_864217d5-ea23-462b-92fb-e4d0dc2d1b3a"
      unitRef="U_USD">4803000</tcrt:PropertyAndEquipmentAndRightOfUseAssetsImpairment>
    <tcrt:PropertyAndEquipmentAndRightOfUseAssetsImpairment
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_fe73eb30-6ec8-489c-be41-389739af9e65"
      unitRef="U_USD">0</tcrt:PropertyAndEquipmentAndRightOfUseAssetsImpairment>
    <us-gaap:OperatingExpenses
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_e02db245-b81c-491f-96ad-53a8dfb3ab3a"
      unitRef="U_USD">34272000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_a51bafb1-2927-4953-8cfb-1b8e44bb94d8"
      unitRef="U_USD">38027000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_6c5b1493-026c-4979-8352-c0fe4c98bb90"
      unitRef="U_USD">-34267000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_604a6880-314d-4ba1-aecb-c1001720d7e1"
      unitRef="U_USD">-35105000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_e4c5d1df-6488-4cc7-957a-4aebfa103b8a"
      unitRef="U_USD">1921000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_18f631f6-2ef9-4a2d-b516-b21263f97616"
      unitRef="U_USD">3154000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_f4d1d627-790e-4a0b-9b8e-e6d70ca9eace"
      unitRef="U_USD">1048000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_eae22e88-bdc1-4269-913d-3695fa22ce55"
      unitRef="U_USD">529000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_48a432fa-2f91-49d0-a7ae-3980852c283c"
      unitRef="U_USD">-873000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_9c546660-9613-4a7f-9dcf-d1828f7b9af5"
      unitRef="U_USD">-2625000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_826da2a3-f208-482b-9edd-3f5f79cbb596"
      unitRef="U_USD">-35140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_0ad9b430-0928-453b-8053-25fd7365ae34"
      unitRef="U_USD">-37730000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="2"
      id="F_25dd968d-64cf-4849-9ce0-c6c8a4022dc6"
      unitRef="U_USDollarShare">-2.2</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="2"
      id="F_85287abe-c784-452a-9e66-443f3defd027"
      unitRef="U_USDollarShare">-2.2</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="2"
      id="F_c85ddfd4-4604-460a-b678-bf66622b06cf"
      unitRef="U_USDollarShare">-2.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="2"
      id="F_8b9f4203-60b7-4808-b221-ba254285ea3c"
      unitRef="U_USDollarShare">-2.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="0"
      id="F_3c4a4ec4-92ae-4302-a61f-9e09c0715e8c"
      unitRef="U_shares">15995323</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="0"
      id="F_f0e875eb-3a5b-40f1-9c42-13132d1bbaab"
      unitRef="U_shares">15995323</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="0"
      id="F_6f605a62-ec01-4743-9089-dff614ebddfd"
      unitRef="U_shares">14475354</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="0"
      id="F_eea3525b-1df9-40f4-8680-59266fc124a6"
      unitRef="U_shares">14475354</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_11127a99-f933-4bcc-a852-9e3580fee74e"
      decimals="INF"
      id="F_2dae33c0-e428-401a-9b97-44eb15d652ec"
      unitRef="U_shares">14408496</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_11127a99-f933-4bcc-a852-9e3580fee74e"
      decimals="-3"
      id="F_11199501-8636-42f1-b468-1807760d6d2c"
      unitRef="U_USD">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2d71e8ff-49c9-42da-a181-17cbc8b8e234"
      decimals="-3"
      id="F_1a1c240a-5582-49d3-b0e4-fc04cf8de98b"
      unitRef="U_USD">900895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e4e17587-5901-4339-8423-005a5407feac"
      decimals="-3"
      id="F_d2689c65-10c3-4c55-8d75-05f6207c2333"
      unitRef="U_USD">-842852000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9e81976f-0dda-4005-94a7-17763001d331"
      decimals="-3"
      id="F_d4f75342-07c8-45b3-b271-3ee6334c979b"
      unitRef="U_USD">58057000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_9081085f-fcee-4652-b4bf-4c50be103e98"
      decimals="-3"
      id="F_f91f1c8c-bee3-4b49-b367-ec9e36d5f50a"
      unitRef="U_USD">3528000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_3cf698fa-b9c0-4fee-83f6-bee81f239894"
      unitRef="U_USD">3528000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_f58e5ef7-a8c3-4cae-b017-bebbe49b3b1d"
      decimals="INF"
      id="F_c5d50adb-f6c6-40d1-9a6c-f8b4a10ad4f3"
      unitRef="U_shares">18667</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_f58e5ef7-a8c3-4cae-b017-bebbe49b3b1d"
      decimals="INF"
      id="F_5d01c5f2-bf63-4d2f-a0da-2f75778a16dc"
      unitRef="U_shares">15527</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_f58e5ef7-a8c3-4cae-b017-bebbe49b3b1d"
      decimals="INF"
      id="F_93f8ef12-24fc-46a0-9ef9-04f65f72f7ac"
      unitRef="U_shares">1750</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_9081085f-fcee-4652-b4bf-4c50be103e98"
      decimals="-3"
      id="F_46f65749-08f0-49c4-b6fe-02bada2fc0ff"
      unitRef="U_USD">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_9ba4ceab-5c7a-442d-a8da-587a6799e11b"
      unitRef="U_USD">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_f58e5ef7-a8c3-4cae-b017-bebbe49b3b1d"
      decimals="INF"
      id="F_e3f70d09-0ec3-42ba-8614-910883470569"
      unitRef="U_shares">1250</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_9fc04f3c-c57e-4e06-b36c-5fbfcaec5cd3"
      decimals="-3"
      id="F_87adacb3-53b1-4cd7-80cd-dac38a99c042"
      unitRef="U_USD">45000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_e81bfe72-4ba7-43e0-8142-c775bc38f817"
      unitRef="U_USD">45000</us-gaap:StockRepurchasedDuringPeriodValue>
    <tcrt:IssuanceOfCommonStockNetOfExpensesInShares
      contextRef="C_f58e5ef7-a8c3-4cae-b017-bebbe49b3b1d"
      decimals="INF"
      id="F_1bb77925-e5dd-4e8e-aebd-c93d94543f90"
      unitRef="U_shares">1615248</tcrt:IssuanceOfCommonStockNetOfExpensesInShares>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_f58e5ef7-a8c3-4cae-b017-bebbe49b3b1d"
      decimals="-3"
      id="F_d86b8c22-f74c-4e30-9ed4-da788ef1d26e"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_9081085f-fcee-4652-b4bf-4c50be103e98"
      decimals="-3"
      id="F_447b1517-e010-4a67-ba9c-2ac1359d2d1c"
      unitRef="U_USD">14722000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_d3304f86-775e-4b3a-9a1c-dd4683691c87"
      unitRef="U_USD">14724000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="C_9fc04f3c-c57e-4e06-b36c-5fbfcaec5cd3"
      decimals="-3"
      id="F_7ba1e1d5-c34a-4292-a4b9-91ca5effea5b"
      unitRef="U_USD">-37730000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_1b86f4fa-54fb-4404-8aa9-b04351eb5750"
      unitRef="U_USD">-37730000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_45a84280-5929-4306-93d7-0db1814fb46c"
      decimals="INF"
      id="F_d4509710-7324-47b4-a9de-729680a65071"
      unitRef="U_shares">16027384</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_45a84280-5929-4306-93d7-0db1814fb46c"
      decimals="-3"
      id="F_cc421cdb-0ca6-4858-b7ef-ac2b0b64d587"
      unitRef="U_USD">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_698ba229-d584-4d13-99e6-5cd10624b1c9"
      decimals="-3"
      id="F_bd1d68b3-96d0-4c50-b701-0d961d837e3b"
      unitRef="U_USD">919166000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f9a17b33-5bfe-4087-a30f-e86addf030a5"
      decimals="-3"
      id="F_dab0cff6-8eb4-44b7-b50e-ef81ed329a77"
      unitRef="U_USD">-880627000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_d45bfe97-24ef-4a9a-ad86-f43f0910e4a9"
      unitRef="U_USD">38555000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_8baad0c4-09aa-4617-9aa3-03a23b56ba42"
      decimals="-3"
      id="F_af1b4513-8ca3-4be9-b5e4-a4634881f6c4"
      unitRef="U_USD">2800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_bbc22a5f-9ee4-4623-8b04-bf20dded6b0c"
      unitRef="U_USD">2800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <tcrt:IssuanceOfCommonStockNetOfExpensesInShares
      contextRef="C_82f28128-caf0-440d-b3fe-b4abba328cf5"
      decimals="INF"
      id="F_72c73620-b8d1-4f8c-9e57-615e64501246"
      unitRef="U_shares">14420</tcrt:IssuanceOfCommonStockNetOfExpensesInShares>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_8baad0c4-09aa-4617-9aa3-03a23b56ba42"
      decimals="-3"
      id="F_24d33993-fed4-44bf-ad85-6f75d9e153f3"
      unitRef="U_USD">92000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_98897b9e-8555-4176-953d-74c9663561a6"
      unitRef="U_USD">92000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_82f28128-caf0-440d-b3fe-b4abba328cf5"
      decimals="INF"
      id="F_069c53e2-f548-4e8d-8218-dbef1bd3ad44"
      unitRef="U_shares">29282</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:NetIncomeLoss
      contextRef="C_80b02891-b4a1-429e-ab36-34271657c7e4"
      decimals="-3"
      id="F_a02ed2a0-7bb6-4456-bb3e-33d669b7a73a"
      unitRef="U_USD">-35140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_a2096364-5e07-48fc-97cb-d8f901620803"
      unitRef="U_USD">-35140000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0fb6425a-bd51-4ef2-a4fc-01fe4f515d0b"
      decimals="INF"
      id="F_66a1b560-970f-4b8d-86fe-7eb371d8f978"
      unitRef="U_shares">16012522</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0fb6425a-bd51-4ef2-a4fc-01fe4f515d0b"
      decimals="-3"
      id="F_e3e2366e-820e-40ed-a46a-e7201baf2363"
      unitRef="U_USD">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_06432621-89ab-472f-911c-5458e9f57386"
      decimals="-3"
      id="F_b5ec8c26-c663-4147-b560-e36ed85da9b9"
      unitRef="U_USD">922058000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_00381981-d3cd-44fe-a13f-32128dadfda9"
      decimals="-3"
      id="F_5e225e36-bea9-4372-99f6-28f590116a51"
      unitRef="U_USD">-915767000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_7dc774eb-c4df-4f63-af50-60052111bd4b"
      unitRef="U_USD">6307000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_41b2bdb9-99ac-40c5-8a38-93e5002d45a1"
      unitRef="U_USD">-35140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_ce361cdb-72d1-4dd5-aa31-da5d23f7303d"
      unitRef="U_USD">-37730000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_07b23bb8-aeb6-4d45-8b11-57374e825039"
      unitRef="U_USD">2315000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_4133daf0-0f9d-4ae7-b5ea-ae945ede5e27"
      unitRef="U_USD">2759000</us-gaap:Depreciation>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_e5b4fa56-21b8-47b9-98f1-d90046eba7b7"
      unitRef="U_USD">4803000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_85481f74-b801-40d5-bf3a-c01d85c03e4a"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_58d59f32-4134-488b-855f-3f490d4fac13"
      unitRef="U_USD">1339000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_5c65c42d-ef88-4ab6-91ca-e972013b9116"
      unitRef="U_USD">981000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_e8dbd8d8-c51e-4e5e-9967-a987a55481d4"
      unitRef="U_USD">2800000</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_ac76f685-5dcb-4942-9478-df35ed868dc4"
      unitRef="U_USD">3528000</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <tcrt:IncreaseDecreaseInRightOfUseAsset
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_ea170a2e-ff4b-483a-8d91-8ea3058d1cab"
      unitRef="U_USD">-286000</tcrt:IncreaseDecreaseInRightOfUseAsset>
    <tcrt:IncreaseDecreaseInRightOfUseAsset
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_4a2e9a98-0408-46b9-9b09-ceb2a8f867ef"
      unitRef="U_USD">-486000</tcrt:IncreaseDecreaseInRightOfUseAsset>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_b50096d2-35cf-421a-ba53-2011b5ae6c49"
      unitRef="U_USD">298000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_ae03b776-ef15-4616-9779-c05e4ae46709"
      unitRef="U_USD">133000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_cc892caa-165e-49f2-83a4-e3512d382246"
      unitRef="U_USD">-7000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_ef066c3e-d675-4331-b1af-2d0e40cc7dd6"
      unitRef="U_USD">-7000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_30af23b6-6d67-481a-a083-820b2bda66dd"
      unitRef="U_USD">-3000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_5c035baf-0961-4492-b475-7ed995fb6a58"
      unitRef="U_USD">-1107000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_633fc122-820e-435b-8911-5ba776feeb05"
      unitRef="U_USD">1399000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_f8e27881-0a32-47cf-9cd9-91b0b6d9b7ac"
      unitRef="U_USD">-867000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <tcrt:IncreaseDecreaseInOperatingDeposits
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_a8565d9a-d8b8-48f4-aa40-035b6b802560"
      unitRef="U_USD">42000</tcrt:IncreaseDecreaseInOperatingDeposits>
    <tcrt:IncreaseDecreaseInOperatingDeposits
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_5c29e0d3-f8b6-437e-9ba0-1a6330b5ac46"
      unitRef="U_USD">0</tcrt:IncreaseDecreaseInOperatingDeposits>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_5390603f-b3b9-4b00-a07b-11cc1e929004"
      unitRef="U_USD">-500000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_77770c7f-ab7c-42c8-b736-ddb4ea1c2d71"
      unitRef="U_USD">-131000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_de21a915-01b6-4e4d-8d93-26644ef34100"
      unitRef="U_USD">-773000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_84aa0b19-24b1-42f5-81e2-2fcd45f33d27"
      unitRef="U_USD">-25000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_8ddb3592-f1a4-4f38-aae4-83e16aaa0414"
      unitRef="U_USD">-3989000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_99d58e8f-0949-4af9-8e4f-4bd6b36ccfe7"
      unitRef="U_USD">-668000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <tcrt:IncreaseDecreaseInLeaseLiabilities
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_0dce7925-635e-4b44-8a30-4d4d1a4b92a4"
      unitRef="U_USD">-610000</tcrt:IncreaseDecreaseInLeaseLiabilities>
    <tcrt:IncreaseDecreaseInLeaseLiabilities
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_af727150-f285-42e7-b041-10f91b153003"
      unitRef="U_USD">-570000</tcrt:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_6175a2d2-fd17-4995-a7b1-e7e423e91c35"
      unitRef="U_USD">-28000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_d577a245-ec6f-4154-8154-e5e5c5ca6283"
      unitRef="U_USD">28000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_7f2604be-9c41-409b-9c96-84a367197acb"
      unitRef="U_USD">-30142000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_3b934134-e3e6-4f56-a260-19d8288c8249"
      unitRef="U_USD">-29232000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_82ed1822-5f93-46c5-8fdb-0b92fc63f710"
      unitRef="U_USD">197000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_a0dea074-87b1-4014-8b39-43f0bde22e90"
      unitRef="U_USD">216000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_b07be922-b088-4885-9558-4e57d8e7ed56"
      unitRef="U_USD">1543000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_e17ddb73-2ac7-4cb2-a6f0-70147ee23c02"
      unitRef="U_USD">23000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_4fd05f90-882a-42d1-b911-72a2f6b1d83b"
      unitRef="U_USD">1346000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_288e84b3-7fc6-481e-b918-e9933f9c5ae6"
      unitRef="U_USD">-193000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_16637ba1-22fc-4aa0-84a0-b5ab2798702a"
      unitRef="U_USD">92000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_aad7f459-9536-4a7c-a8c3-418532b61ba3"
      unitRef="U_USD">14724000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_ce706446-2c8e-41a4-8933-5bb892c95b96"
      unitRef="U_USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_ad725eb2-3d54-4ad9-a05b-aef619a25831"
      unitRef="U_USD">21000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_3ab5fa21-45cc-4d3c-864c-cdad193ddb16"
      unitRef="U_USD">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_20a2079c-2bb0-4382-963a-bc71278d0487"
      unitRef="U_USD">45000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_aff94808-33d3-4325-82b3-33f6cb4454a8"
      unitRef="U_USD">18105000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_aff920d9-951c-44a1-8a0a-25d3435a7f09"
      unitRef="U_USD">8333000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_bf92f3b1-cf1b-49b2-8a6a-dce503d0569a"
      unitRef="U_USD">125000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_6ef40dc7-b137-497d-90d1-5b9d4a488eaf"
      unitRef="U_USD">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_41a4fa94-6430-43fd-9454-6e0820525cb8"
      unitRef="U_USD">-18138000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_b6f5b409-d552-4138-8dfe-fcc371242772"
      unitRef="U_USD">6367000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_61df6c7e-395c-488e-a9ae-0798fa3c177a"
      unitRef="U_USD">-46934000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_d7d7a346-46e1-416c-83aa-12b22f237174"
      unitRef="U_USD">-23058000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_6248aa83-66cb-4941-84db-9b16b89f9121"
      unitRef="U_USD">52996000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_9e81976f-0dda-4005-94a7-17763001d331"
      decimals="-3"
      id="F_81351239-3623-4377-9440-d616bcbaf985"
      unitRef="U_USD">76054000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_221e9209-e738-4157-bd8c-bc401a78ba1b"
      unitRef="U_USD">6062000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_7af67d65-eb83-46d1-9ec8-c3de2d4acc73"
      unitRef="U_USD">52996000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_bf4a75f9-d17d-45ac-9c93-bdb8a470237f"
      unitRef="U_USD">2063000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_4781dc10-6c36-467c-9d4f-20bf0f8e4110"
      unitRef="U_USD">2171000</us-gaap:InterestPaidNet>
    <tcrt:ReductionInRightOfUseAssetsForModificationAndTermination
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_f738340f-d051-414a-b003-790001ada227"
      unitRef="U_USD">1839000</tcrt:ReductionInRightOfUseAssetsForModificationAndTermination>
    <tcrt:ReductionInRightOfUseAssetsForModificationAndTermination
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_81435723-cc7d-459a-85c1-b794762cd832"
      unitRef="U_USD">1790000</tcrt:ReductionInRightOfUseAssetsForModificationAndTermination>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_cf9e86c7-edba-4daa-8ee7-d7cc2bd6a4b8"
      unitRef="U_USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_154e892b-6320-46de-a6df-fdb61536ed95"
      unitRef="U_USD">91000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_3a0f95e0-c307-42f5-9c8b-cec4e85557a7">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Alaunos Therapeutics, Inc., which is referred to herein as &#x201c;Alaunos,&#x201d; or the &#x201c;Company,&#x201d; is a clinical-stage oncology-focused cell therapy company that was historically involved in the development of adoptive TCR therapies, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. On January 25, 2022, the Company changed its corporate name from ZIOPHARM Oncology, Inc. to Alaunos Therapeutics, Inc. The Company was working to leverage its proprietary, non-viral &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; gene transfer platform and its novel cancer mutation hotspot TCR library to design and manufacture personalized cell therapies that target neoantigens arising from common tumor-related mutations in key oncogenic genes, including &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;KRAS&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;TP53 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;EGFR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s operations to date have consisted primarily of conducting research and development and raising capital to fund those efforts.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,012,522&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;shares of common stock outstanding and an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,918,297&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock reserved for issuance pursuant to outstanding stock options and warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 14, 2023, the Company announced a strategic reprioritization of its business and wind down of its TCR-T Library Phase 1/2 Trial. In connection with the reprioritization, the Company has significantly reduced its workforce and continues working to reduce costs in order to extend its cash runway. The Company continues to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. The Company has engaged Cantor Fitzgerald &amp;amp; Co., or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cantor&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, to act as strategic advisor for this process.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company follows the guidance of Accounting Standards Codification, or ASC, Topic 205-40, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Presentation of Financial Statements - Going Concern&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has operated at a loss since its inception in 2003 and has no recurring revenue from operations.&#x202f;The Company anticipates that losses will continue for the foreseeable future. As of December 31, 2023, the Company had approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x202f;million of cash and cash equivalents. The Company&#x2019;s accumulated deficit at December 31, 2023 was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;915.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x202f;million.&#x202f;Given its current development plans and cash management efforts, the Company anticipates cash resources will be sufficient to fund operations into the third quarter of 2024.&#x202f;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company continues to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. The Company&#x2019;s ability to continue operations after its current cash resources are exhausted depends on future events, including its ability to obtain additional financing or to achieve profitable operations, as to which no assurances can be given, nor are within the Company's control. If adequate additional funds are not available when required, or if the Company is unsuccessful in entering into partnership agreements for further development of its product candidates, management may need to curtail its development efforts and planned operations to conserve cash until sufficient additional capital is raised. There can be no assurances that such a plan would be successful.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements, and substantial doubt as to the Company's ability to continue as a going concern exists. This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has elected to make a reclassification in the presentation of the cash flow to show non-cash changes in right-of-use assets and lease liabilities related to modifications and terminations as non-cash for the year ended December 31, 2022 in order to conform presentation to the December 31, 2023 disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0fb6425a-bd51-4ef2-a4fc-01fe4f515d0b"
      decimals="INF"
      id="F_3e4b43ad-9841-4ef6-b0d6-e6d912c601cd"
      unitRef="U_shares">16012522</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0fb6425a-bd51-4ef2-a4fc-01fe4f515d0b"
      decimals="INF"
      id="F_92b14dea-f4ac-46ac-93b5-df01a01cabb1"
      unitRef="U_shares">1918297</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <tcrt:StrategicAdvisorName
      contextRef="C_018d6e8c-001c-45fa-97e4-4efe0b2a752b"
      id="F_3cbb77a9-e6f1-47b6-a57b-ec142d7b2591">Cantor</tcrt:StrategicAdvisorName>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-5"
      id="F_8aac8710-c1b9-4938-9437-78497cf0313c"
      unitRef="U_USD">6100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-5"
      id="F_155dd0a0-71d7-4a96-91f5-bb402b7356b6"
      unitRef="U_USD">-915800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <tcrt:FinancingArrangementsDisclosureTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_5fe9a89f-dc70-495e-91b0-44789b36a77a">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financings&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2021 Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 6, 2021, the Company entered into a Loan and Security Agreement, or the Loan and Security Agreement, with Silicon Valley Bank and affiliates of Silicon Valley Bank, or collectively, SVB. The Loan and Security Agreement provided for an initial term loan of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million funded at the closing, or the Term A Tranche, with an additional tranche of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million available if certain funding and clinical milestones were met by August 31, 2022, or the Term B Tranche.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective December 28, 2021, the Company, entered into an amendment to the Loan and Security Agreement, or the First Amendment. The First Amendment extended the interest-only period through August 31, 2022. The First Amendment also eliminated the Term B Tranche, which remained unfunded, leaving only the Term A Tranche, or the SVB Facility. Under the amended Loan and Security Agreement, the SVB Facility was to mature on August 1, 2023. On May 1, 2023, the Company repaid its outstanding debt obligations under the amended Loan and Security Agreement in their entirety.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Refer to Note 4, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for further discussion of the Loan and Security Agreement and the First Amendment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2022 Equity Distribution Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 12, 2022, the Company entered into an Equity Distribution Agreement, or the Equity Distribution Agreement, with Piper Sandler &amp;amp; Co., or Piper Sandler, pursuant to which the Company can offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million through Piper Sandler as its sales agent in an "at the market offering." Piper Sandler will receive a commission of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the gross proceeds of any common stock sold under the Equity Distribution Agreement. During the years ended December 31, 2023 and 2022, there have been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; sales of the Company's common stock under the Equity Distribution Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2022 Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On November 29, 2022, the Company entered into an underwriting agreement, or the Underwriting Agreement, with Cantor Fitzgerald &amp;amp; Co., or the Underwriter, as the sole underwriter, relating to the issuance and sale in an underwritten offering, or the Offering, of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,615,248&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, or the Firm Shares, of the Company&#x2019;s common stock to the Underwriter at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.2865&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The net proceeds to the Company from the Offering were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (before accounting for the partial exercise of the Underwriter's option as described below) after deducting underwriting discounts and commissions and offering expenses payable by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the terms of the Underwriting Agreement, the Company granted the Underwriter an option, exercisable for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;30 days&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, to purchase up to an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;242,287&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, which we refer to, together with the Firm Shares, as the Shares, at the same price per share as the Firm Shares. On January 5, 2023, the Underwriter partially exercised its option to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,420&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;</tcrt:FinancingArrangementsDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_c513888a-3b48-4024-a189-900f74620507"
      decimals="-5"
      id="F_d7cc6f69-3473-4476-8db2-180b283f34d3"
      unitRef="U_USD">25000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_d63de51f-7fcb-4cee-816b-0f40bc587e2e"
      decimals="-5"
      id="F_630365e8-46d8-4e3a-b466-3147a6ddec5c"
      unitRef="U_USD">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_178ac7cd-5b14-4544-b80c-336bc2dd52d9"
      decimals="-5"
      id="F_26e4348f-80fb-4235-95a3-88904579417a"
      unitRef="U_USD">50000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <tcrt:PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock
      contextRef="C_178ac7cd-5b14-4544-b80c-336bc2dd52d9"
      decimals="3"
      id="F_89ff1fde-529c-4255-ac57-dbe8c3990b6e"
      unitRef="U_pure">0.03</tcrt:PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock>
    <tcrt:StockOfferedDuringPeriodShares
      contextRef="C_c34e2ea2-6bfb-4c2d-919a-3fb69b17bab3"
      decimals="INF"
      id="F_7d85b550-41b8-446c-acde-35bff44bac7b"
      unitRef="U_shares">0</tcrt:StockOfferedDuringPeriodShares>
    <tcrt:StockOfferedDuringPeriodShares
      contextRef="C_a0e9f476-c0cc-4b3e-b34e-81e4371b4b81"
      decimals="INF"
      id="F_8512b420-fde3-4d98-8625-57db33ed72a6"
      unitRef="U_shares">0</tcrt:StockOfferedDuringPeriodShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b2c1287b-cb3c-456e-a570-1593261f684d"
      decimals="0"
      id="F_1c986885-1988-4d7d-bb9e-0e5bc44f50b5"
      unitRef="U_shares">1615248</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <tcrt:UnderwriterParOrStatedValuePerShare
      contextRef="C_d276298c-740b-42ff-98cb-ed95e869f300"
      decimals="4"
      id="F_97c92761-a7d7-4366-ba9f-7d4c06045013"
      unitRef="U_USDollarShare">9.2865</tcrt:UnderwriterParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_8d3c500a-8039-4aa4-9783-2c2376933de5"
      decimals="-5"
      id="F_9e9d988e-322d-4024-9a8b-e204bd25620e"
      unitRef="U_USD">14700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <tcrt:ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings
      contextRef="C_b2c1287b-cb3c-456e-a570-1593261f684d"
      id="F_2a3ba876-063b-4f13-a319-0bedaf38a879">30 days</tcrt:ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings>
    <tcrt:NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase
      contextRef="C_6804cc66-48f9-4973-9521-76cf1de8e41d"
      decimals="0"
      id="F_86cd6d04-d2b4-49e9-a964-85a498c2cf10"
      unitRef="U_shares">242287</tcrt:NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase>
    <tcrt:StockOfferedDuringPeriodShares
      contextRef="C_9b52611a-b9c3-4f92-b8bb-c439f1b299fc"
      decimals="0"
      id="F_28183e36-4a0a-47c4-8b6e-a7f26f6455b9"
      unitRef="U_shares">14420</tcrt:StockOfferedDuringPeriodShares>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_d0c11f10-1c9c-4037-91da-3c9bc2c84437">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s most significant estimates and judgments used in the preparation of the financial statements are:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Clinical trial expenses and other research and development expenses;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Collaboration agreements;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value measurements of stock-based compensation; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents consist primarily of demand deposit accounts, certificates of deposit and deposits in short-term U.S. treasury money market mutual funds. Cash equivalents are stated at cost, which approximates fair market value.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to expense while the costs of significant improvements are capitalized. Depreciation and amortization is calculated on a straight-line basis using the following periods, which represent the estimated useful lives of the assets:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:54.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:26.68%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Office and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_fa18b81e-dc37-4248-8153-57693071a98f;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Life of the lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Costs, including certain design, construction and installation costs related to assets that are under construction and are in the process of being readied for their intended use, are recorded as construction in progress and are not depreciated until such time as the subject asset is placed in service. Repairs and maintenance that do not extend the useful life of the asset are expensed as incurred. Upon sale, retirement or other disposition of these assets, the costs and related accumulated depreciation are removed from the respective accounts and any gain or loss on the disposition is included in the statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assessments of long-lived assets and the remaining useful lives of such long-lived assets are reviewed for impairment whenever a triggering event occurs or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An asset, or group of assets, is considered to be impaired when the undiscounted estimated net cash flows expected to be generated by the asset, or group of assets, are less than its carrying amount. The impairment recognized is the amount by which the carrying amount exceeds the fair market value of the impaired asset, or group of assets, based on the present value of the expected future cash flows associated with the use of the asset.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Operating Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the Company&#x2019;s chief operating decision maker, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company assesses whether warrants issued require accounting as derivatives. The Company determined that the warrants were (1) indexed to the Company&#x2019;s own stock and (2) classified in stockholders&#x2019; equity in accordance with Financial Accounting Standards Board, or FASB, ASC Topic 815, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. As such, the Company has concluded the warrants meet the scope exception for determining whether the instruments require accounting as derivatives and should be classified in stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&#x2014;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of December 31, 2023 and 2022 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The cash equivalents represent demand deposit accounts and deposits in a short-term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset. There have been no changes to the valuation methods during the years ended December 31, 2023 and 2022. The Company had no financial assets or liabilities that were classified as Level 2 or Level 3 during the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair value of non-financial instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company evaluates assets for impairment whenever events or changes in circumstances indicate that indicators of impairment exist. In those evaluations, the Company compares estimated future undiscounted cash flows generated by each asset (or asset group) to the carrying value of the asset (or asset group) to determine if an impairment charge is required. If the undiscounted cash flows test fails, the Company estimates the fair value of the asset (or asset group) to determine the impairment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Following the Company&#x2019;s announced strategic reprioritization on August 14, 2023, the Company determined that changes in the intended use of certain property and equipment represented an indicator of impairment, resulting in an impairment charge of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which was primarily related to leasehold improvements of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and lab equipment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, the Company determined certain prepaid expense balances to be impaired given the Company&#x2019;s strategic reprioritization, and therefore, has recorded an impairment charge of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million related to prepaid expenses and other current assets, which is recorded in research and development expenses within the statement of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On November 9, 2023, the Company executed an agreement to sell laboratory equipment for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and recognized a gain on disposal of equipment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand, which is recorded in other income in the statement of operations&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition from Collaboration Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue for the year ended December 31, 2023 consisted of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand and for the year ended December 31, 2022 consisted of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. For the years ended December 31, 2023 and 2022, the Company recognized revenue through its Collaboration Agreement with Solasia Pharma K.K. primarily due to the achievement of milestones, as further described in Note 9, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Commitments and Contingencies.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company primarily generates revenue through collaboration arrangements with strategic partners for the development and commercialization of product candidates. The Company recognizes revenue in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers, or &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ASC 606. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods and/or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and/or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes collaboration revenue under certain of the Company&#x2019;s license or collaboration agreements that are within the scope of ASC 606. The Company&#x2019;s contracts with customers typically include promises related to licenses to intellectual property, research and development services and options to purchase additional goods and/or services. If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Contracts that include an option to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer&#x2019;s election.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The terms of the Company&#x2019;s arrangements with customers typically include the payment of one or more of the following:(i) non-refundable, up-front payment, (ii) development, regulatory and commercial milestone payments, (iii) future options and (iv) royalties on net sales of licensed products. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the most likely amount method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company reevaluates the probability of achievement of each milestone and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company allocates the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contract to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require the use of judgment to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenue, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As part of the process of preparing the Company's financial statements, the Company is required to estimate its accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with its personnel and third-party vendors to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the services when the Company has not yet been invoiced or otherwise notified of the actual costs. The majority of the Company's service providers invoice the Company in arrears for services performed, on a predetermined schedule or when contractual milestones are met; however, a few require advanced payments. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known to it at that time. Examples of estimated accrued research and development expenses include fees paid to:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;clinical research organizations, or CROs, in connection with performing research services on its behalf and clinical trials;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;investigative sites or other providers in connection with clinical trials;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;vendors in connection with preclinical and clinical development activities; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;vendors related to product manufacturing, development, and distribution of preclinical and clinical supplies.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company bases its expenses related to preclinical studies and clinical trials on its estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct and manage clinical trials on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company's vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed, enrollment of patients, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low in any particular period.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. The Company evaluates the realizability of its deferred tax assets and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions using a &#x201c;more-likely-than-not&#x201d; threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates this tax position on an annual basis. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense (Refer to Note 12, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting for Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation cost is measured at the grant date based on the estimated fair value of the award and is recognized as expense over the employee&#x2019;s requisite service period. Stock-based compensation expense is based on the number of awards ultimately expected to vest and is reduced for forfeitures as they occur. Consistent with prior years, the Company uses the Black-Scholes option pricing model, which requires estimates of the expected term option holders will retain their options before exercising them and the estimated volatility of the Company&#x2019;s common stock price over the expected term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognized the full impact of its share-based employee payment plans in the statements of operations for each of the years ended December 31, 2023 and 2022 and did not capitalize any such costs on the balance sheets. The Company recognized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of compensation expense related to stock options &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for the year ended December 31, 2023 and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of compensation expense related to stock options &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for the year ended December 31, 2022. The Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of compensation expense related to restricted stock for&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; the year ended December 31, 2023 and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for the year ended December 31, 2022 (refer to Note 13, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Option Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;). The total compensation expense relating to vesting of stock options and restricted stock awards for the year ended December 31, 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2022. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents share-based compensation expense included in the Company&#x2019;s statements of operations:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:64.713%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.643%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:15.523%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. The estimated weighted-average fair value of stock options granted to employees in the year ended December 31, 2023 was approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.58&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;per share and was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.54&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company&#x2019;s historical experience. The risk-free interest rate is based on a U.S. treasury note with a maturity similar to the option award&#x2019;s expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The Company calculated expected term using the simplified method described in SEC Staff Accounting Bulletin, or SAB, No. 107 and No. 110 as it continues to meet the requirements promulgated in SAB No. 110.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The assumptions for volatility, expected life, dividend yield and risk-free interest rate are presented in the table below:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.173%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.443%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
          &lt;td style="width:16.143%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.51&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.63&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected life in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.06&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89.69&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;112.12&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74.49&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 31, 2024, the Company filed a Second Amended and Restated Certificate of Incorporation (the &#x201c;Charter Amendment&#x201d;) with the Secretary of State of the State of Delaware in order to effect a reverse stock split of the Company&#x2019;s common stock at a ratio of 1-for-15 (the &#x201c;Reverse Split&#x201d;). The Charter Amendment decreased the number of authorized shares of common stock from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;520,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,666,667&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Charter Amendment does not affect the par value of the Company&#x2019;s common stock or change the number of authorized shares or par value of the Company&#x2019;s preferred stock. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Charter Amendment became effective on January 31, 2024 at 5:00 p.m. Eastern Time, at which time every 15 shares of the Company&#x2019;s issued and outstanding common stock automatically combined and converted into 1 share of common stock.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;No fractional shares were issued in connection with the Reverse Split. Stockholders of record who would otherwise have been entitled to receive fractional shares as a result of the Reverse Split received a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing sales price per share of the common stock (as adjusted for the Reverse Split) on The Nasdaq Capital Market on January 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p id="bkmk_220" style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All share and per share amounts of common stock, options, warrants, and restricted stock in the accompanying financial statements and notes thereto have been retroactively adjusted for all periods presented to reflect the Reverse Split as if it had occurred at the beginning of the earliest period presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company&#x2019;s common stock during the applicable period, unless their effect on net loss per share is antidilutive. The effect of computing diluted net loss per common share was antidilutive for any potentially issuable shares of common stock from the conversion of stock options, unvested restricted stock and warrants and, as such, have been excluded from the calculation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The computation of basic and diluted net loss per share consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,995,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,475,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Certain shares related to some of the Company&#x2019;s outstanding common stock options, unvested restricted stock and warrants have not been included in the computation of diluted net loss per share for the years ended December 31, 2023 and 2022 as the result would be antidilutive. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Such potential common shares on December 31, 2023 and 2022 consist of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;465,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;693,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,452,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,528,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,918,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,284,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued Accounting Standards Update, or ASU, 2016-13, Financial Instruments: Credit Losses (Topic 326) as clarified in ASU 2019-04, ASU 2019-05 and ASU 2020-02. The objective of this standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than-temporary impairments on investment securities are recorded. The Company adopted ASU 2016-13 effective January 1, 2023, with no material impact upon adoption.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances the disclosures required for operating segments in the Company's annual and interim financial statements. ASU 2023-07 is effective retrospectively for fiscal years beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this standard.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for the Company prospectively to all annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this standard.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_55f57150-f25e-407f-9a5b-764c21f3c24d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_b3410640-f30e-45b9-802e-138cb2f17035">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s most significant estimates and judgments used in the preparation of the financial statements are:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Clinical trial expenses and other research and development expenses;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Collaboration agreements;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value measurements of stock-based compensation; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_4e9a4da4-ff16-4852-8111-6b4bba64fde3">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents consist primarily of demand deposit accounts, certificates of deposit and deposits in short-term U.S. treasury money market mutual funds. Cash equivalents are stated at cost, which approximates fair market value.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_fe6fabe2-74ee-4be9-8c24-6ede6eed4e52">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_9626ccae-6e52-4e9f-9082-b5426b851e40">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to expense while the costs of significant improvements are capitalized. Depreciation and amortization is calculated on a straight-line basis using the following periods, which represent the estimated useful lives of the assets:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:54.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:26.68%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Office and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&#xfeff;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_fa18b81e-dc37-4248-8153-57693071a98f;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Life of the lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Costs, including certain design, construction and installation costs related to assets that are under construction and are in the process of being readied for their intended use, are recorded as construction in progress and are not depreciated until such time as the subject asset is placed in service. Repairs and maintenance that do not extend the useful life of the asset are expensed as incurred. Upon sale, retirement or other disposition of these assets, the costs and related accumulated depreciation are removed from the respective accounts and any gain or loss on the disposition is included in the statements of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_ae07e329-a5b4-4996-9101-5c81cefa338b"
      id="F_9bdcb5de-fc56-40d7-bf5c-033b1ef8f2cc">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_59b1d649-d101-49bf-a3c7-bd6b2abc3d7d"
      id="F_f036f18f-7662-42c3-bdad-7c12c67ef643">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0d7a6c39-7681-4ca3-99fb-8b12b128396b"
      id="F_1b9190a4-fc10-4738-884a-d9b58d14f9c1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_05e7bddb-cf01-43a9-95b3-c481b4685c0c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assessments of long-lived assets and the remaining useful lives of such long-lived assets are reviewed for impairment whenever a triggering event occurs or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An asset, or group of assets, is considered to be impaired when the undiscounted estimated net cash flows expected to be generated by the asset, or group of assets, are less than its carrying amount. The impairment recognized is the amount by which the carrying amount exceeds the fair market value of the impaired asset, or group of assets, based on the present value of the expected future cash flows associated with the use of the asset.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_7c19be71-7a9d-4032-bbb4-70be8e322455">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Operating Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the Company&#x2019;s chief operating decision maker, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <tcrt:WarrantsPolicyTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_690fffcd-4e61-41d5-8d53-63dbe6d93c4a">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company assesses whether warrants issued require accounting as derivatives. The Company determined that the warrants were (1) indexed to the Company&#x2019;s own stock and (2) classified in stockholders&#x2019; equity in accordance with Financial Accounting Standards Board, or FASB, ASC Topic 815, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. As such, the Company has concluded the warrants meet the scope exception for determining whether the instruments require accounting as derivatives and should be classified in stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;</tcrt:WarrantsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_8414510a-5d8a-4ac8-855c-b21209234e6d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&#x2014;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of December 31, 2023 and 2022 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The cash equivalents represent demand deposit accounts and deposits in a short-term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset. There have been no changes to the valuation methods during the years ended December 31, 2023 and 2022. The Company had no financial assets or liabilities that were classified as Level 2 or Level 3 during the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair value of non-financial instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company evaluates assets for impairment whenever events or changes in circumstances indicate that indicators of impairment exist. In those evaluations, the Company compares estimated future undiscounted cash flows generated by each asset (or asset group) to the carrying value of the asset (or asset group) to determine if an impairment charge is required. If the undiscounted cash flows test fails, the Company estimates the fair value of the asset (or asset group) to determine the impairment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Following the Company&#x2019;s announced strategic reprioritization on August 14, 2023, the Company determined that changes in the intended use of certain property and equipment represented an indicator of impairment, resulting in an impairment charge of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which was primarily related to leasehold improvements of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and lab equipment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, the Company determined certain prepaid expense balances to be impaired given the Company&#x2019;s strategic reprioritization, and therefore, has recorded an impairment charge of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million related to prepaid expenses and other current assets, which is recorded in research and development expenses within the statement of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On November 9, 2023, the Company executed an agreement to sell laboratory equipment for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and recognized a gain on disposal of equipment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand, which is recorded in other income in the statement of operations&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_4d7dfef4-7428-4c62-8e8d-a6d2bf7d63b2">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of December 31, 2023 and 2022 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d20f89b1-a277-46ad-a886-0783d93e0131"
      decimals="-3"
      id="F_94d5cd61-b6f8-485c-87d5-d1ff7c9d1609"
      unitRef="U_USD">5744000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_6ee1d3ea-fecf-43a4-b0be-9cca9bc302be"
      decimals="-3"
      id="F_bce979fc-cef6-4236-ad85-273f0baad847"
      unitRef="U_USD">5744000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d5b52643-6d79-400f-8b1d-031a3c875379"
      decimals="-3"
      id="F_0eaad22e-bca5-4bf0-81ee-458f5e2c7638"
      unitRef="U_USD">38058000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b4d53f28-56a7-404b-af45-6335e67f7941"
      decimals="-3"
      id="F_4f6643f4-b025-46c9-88f7-78ba54497f56"
      unitRef="U_USD">38058000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="C_018d6e8c-001c-45fa-97e4-4efe0b2a752b"
      decimals="-5"
      id="F_75864bf6-fbe7-4373-9d92-5f229f8a7a8e"
      unitRef="U_USD">4800000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_f1be53cd-8ca0-4fbc-8225-e0b9cea77dc9"
      decimals="-5"
      id="F_de2f47b1-b8e8-4c6b-82e2-03affc0def88"
      unitRef="U_USD">3800000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_aec61900-53b4-4857-87b4-484cc2b801ce"
      decimals="-5"
      id="F_cf0f34fd-3bcf-4924-8b7d-c3ba0777ed98"
      unitRef="U_USD">1000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_ffb8b599-3fe6-43c2-9fb2-30c91dd8802b"
      decimals="-5"
      id="F_3c62849a-d5a0-4004-b4c4-941db49c4eca"
      unitRef="U_USD">200000</us-gaap:AssetImpairmentCharges>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_b1dfdf14-86ec-4861-a350-a0829f3f94bb"
      decimals="-5"
      id="F_e3cfdbac-fffa-42ad-991c-e6ef93fb803a"
      unitRef="U_USD">1500000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_b1dfdf14-86ec-4861-a350-a0829f3f94bb"
      decimals="-3"
      id="F_e104cd13-9496-45d8-b527-c6b206978d50"
      unitRef="U_USD">3000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_275979c4-bf1b-410b-934c-6d3da77c35eb">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition from Collaboration Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue for the year ended December 31, 2023 consisted of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand and for the year ended December 31, 2022 consisted of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. For the years ended December 31, 2023 and 2022, the Company recognized revenue through its Collaboration Agreement with Solasia Pharma K.K. primarily due to the achievement of milestones, as further described in Note 9, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Commitments and Contingencies.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company primarily generates revenue through collaboration arrangements with strategic partners for the development and commercialization of product candidates. The Company recognizes revenue in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers, or &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ASC 606. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods and/or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and/or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes collaboration revenue under certain of the Company&#x2019;s license or collaboration agreements that are within the scope of ASC 606. The Company&#x2019;s contracts with customers typically include promises related to licenses to intellectual property, research and development services and options to purchase additional goods and/or services. If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Contracts that include an option to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer&#x2019;s election.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The terms of the Company&#x2019;s arrangements with customers typically include the payment of one or more of the following:(i) non-refundable, up-front payment, (ii) development, regulatory and commercial milestone payments, (iii) future options and (iv) royalties on net sales of licensed products. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the most likely amount method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company reevaluates the probability of achievement of each milestone and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company allocates the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contract to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require the use of judgment to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenue, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_0f5f01fc-1a36-40b9-8786-ba66a246d6f2"
      unitRef="U_USD">5000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-5"
      id="F_5415a93c-6936-461d-afb1-96edeeda9c92"
      unitRef="U_USD">2900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_54a0fc6c-4d20-42af-b89a-7adb2982d152">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As part of the process of preparing the Company's financial statements, the Company is required to estimate its accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with its personnel and third-party vendors to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the services when the Company has not yet been invoiced or otherwise notified of the actual costs. The majority of the Company's service providers invoice the Company in arrears for services performed, on a predetermined schedule or when contractual milestones are met; however, a few require advanced payments. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known to it at that time. Examples of estimated accrued research and development expenses include fees paid to:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;clinical research organizations, or CROs, in connection with performing research services on its behalf and clinical trials;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;investigative sites or other providers in connection with clinical trials;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;vendors in connection with preclinical and clinical development activities; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;vendors related to product manufacturing, development, and distribution of preclinical and clinical supplies.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company bases its expenses related to preclinical studies and clinical trials on its estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct and manage clinical trials on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company's vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed, enrollment of patients, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low in any particular period.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_a5b3b18c-6a30-4139-ad06-319520af78e4">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. The Company evaluates the realizability of its deferred tax assets and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions using a &#x201c;more-likely-than-not&#x201d; threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates this tax position on an annual basis. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense (Refer to Note 12, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_18e7c8e5-08d8-4a79-94b6-29da4f31e53b">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting for Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation cost is measured at the grant date based on the estimated fair value of the award and is recognized as expense over the employee&#x2019;s requisite service period. Stock-based compensation expense is based on the number of awards ultimately expected to vest and is reduced for forfeitures as they occur. Consistent with prior years, the Company uses the Black-Scholes option pricing model, which requires estimates of the expected term option holders will retain their options before exercising them and the estimated volatility of the Company&#x2019;s common stock price over the expected term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognized the full impact of its share-based employee payment plans in the statements of operations for each of the years ended December 31, 2023 and 2022 and did not capitalize any such costs on the balance sheets. The Company recognized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of compensation expense related to stock options &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for the year ended December 31, 2023 and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of compensation expense related to stock options &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for the year ended December 31, 2022. The Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of compensation expense related to restricted stock for&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; the year ended December 31, 2023 and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for the year ended December 31, 2022 (refer to Note 13, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Option Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;). The total compensation expense relating to vesting of stock options and restricted stock awards for the year ended December 31, 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2022. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents share-based compensation expense included in the Company&#x2019;s statements of operations:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:64.713%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.643%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:15.523%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. The estimated weighted-average fair value of stock options granted to employees in the year ended December 31, 2023 was approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.58&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;per share and was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.54&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company&#x2019;s historical experience. The risk-free interest rate is based on a U.S. treasury note with a maturity similar to the option award&#x2019;s expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The Company calculated expected term using the simplified method described in SEC Staff Accounting Bulletin, or SAB, No. 107 and No. 110 as it continues to meet the requirements promulgated in SAB No. 110.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The assumptions for volatility, expected life, dividend yield and risk-free interest rate are presented in the table below:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.173%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.443%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
          &lt;td style="width:16.143%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.51&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.63&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected life in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.06&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89.69&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;112.12&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74.49&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 31, 2024, the Company filed a Second Amended and Restated Certificate of Incorporation (the &#x201c;Charter Amendment&#x201d;) with the Secretary of State of the State of Delaware in order to effect a reverse stock split of the Company&#x2019;s common stock at a ratio of 1-for-15 (the &#x201c;Reverse Split&#x201d;). The Charter Amendment decreased the number of authorized shares of common stock from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;520,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,666,667&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Charter Amendment does not affect the par value of the Company&#x2019;s common stock or change the number of authorized shares or par value of the Company&#x2019;s preferred stock. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Charter Amendment became effective on January 31, 2024 at 5:00 p.m. Eastern Time, at which time every 15 shares of the Company&#x2019;s issued and outstanding common stock automatically combined and converted into 1 share of common stock.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;No fractional shares were issued in connection with the Reverse Split. Stockholders of record who would otherwise have been entitled to receive fractional shares as a result of the Reverse Split received a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing sales price per share of the common stock (as adjusted for the Reverse Split) on The Nasdaq Capital Market on January 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p id="bkmk_220" style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All share and per share amounts of common stock, options, warrants, and restricted stock in the accompanying financial statements and notes thereto have been retroactively adjusted for all periods presented to reflect the Reverse Split as if it had occurred at the beginning of the earliest period presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensation
      contextRef="C_47de4d35-3a62-44ad-a1e3-078eb736401e"
      decimals="-5"
      id="F_f5c625fa-adad-4eb6-b3ff-606286977591"
      unitRef="U_USD">2500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_66a9005c-fc69-4b3a-83be-3826cef87dcb"
      decimals="-5"
      id="F_767c8412-f591-44f9-bd3d-880702f54ed2"
      unitRef="U_USD">3000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_b3feb1b1-0ac3-4b26-ba91-a5e0df500c8d"
      decimals="-5"
      id="F_1c428618-1b98-435e-8644-d8b43f2c8f4b"
      unitRef="U_USD">300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_d601659b-5678-4e9a-8c2e-09453abc5b8d"
      decimals="-5"
      id="F_9d31c007-98d3-49ce-aa79-fc4fc96be661"
      unitRef="U_USD">500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_df6734c9-10ba-4183-bed0-db726b38f022"
      decimals="-5"
      id="F_91b43b6a-783a-4334-9f3c-3fceaa100b20"
      unitRef="U_USD">2800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_cc7acd0c-a196-474b-904e-2422719555e7"
      decimals="-5"
      id="F_5d44fc3d-7c90-48fa-879d-ee833de489f7"
      unitRef="U_USD">3500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_87fdc4d5-9852-4981-be5d-e0b87b27fb31">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents share-based compensation expense included in the Company&#x2019;s statements of operations:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:64.713%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.643%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:15.523%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="C_2d8ef632-f188-499c-855f-f56d87eeb09c"
      decimals="-3"
      id="F_515dc6da-4b0b-4691-a8d8-1a4972a875f3"
      unitRef="U_USD">439000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_60aa9216-7e7f-400b-9d0d-65567c8ce942"
      decimals="-3"
      id="F_0fe670f6-0d14-4d8b-a404-94032e8f388a"
      unitRef="U_USD">868000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_a0517427-ae4d-43a0-9947-ed007458a817"
      decimals="-3"
      id="F_cb825339-34b4-490c-9bfc-e4e4a8b0b339"
      unitRef="U_USD">2361000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_86d41d2a-3fa1-4e8f-a00d-faeb00c9cc56"
      decimals="-3"
      id="F_e5049425-8859-433e-b210-3f0a2075599b"
      unitRef="U_USD">2660000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_02c2006c-bfd5-4eb7-bb25-06c49e9347b2"
      unitRef="U_USD">2800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_b903f96f-ebc0-4c37-aa6e-875bab5948c2"
      unitRef="U_USD">3528000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="2"
      id="F_531babb8-9499-4898-a051-b01e929f582d"
      unitRef="U_USDollarShare">5.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="2"
      id="F_820ce1a7-0715-42c7-b7e0-3903dfcd4193"
      unitRef="U_USDollarShare">11.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_614c2781-2006-402a-9e08-98e2874f6993">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The assumptions for volatility, expected life, dividend yield and risk-free interest rate are presented in the table below:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.173%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.443%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
          &lt;td style="width:16.143%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.51&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.63&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected life in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.06&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89.69&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;112.12&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74.49&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="4"
      id="F_639eed61-d510-42e1-a42a-517b7b31e8a6"
      unitRef="U_pure">0.0351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="4"
      id="F_b508de13-8792-4c8a-a32b-5049edcf89e2"
      unitRef="U_pure">0.0401</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="4"
      id="F_6c6d0a2a-fc1e-4182-bc05-7e0557fbad26"
      unitRef="U_pure">0.0163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="4"
      id="F_ae222a16-b882-4b36-b104-fb73d63aea68"
      unitRef="U_pure">0.0421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_c08c022b-51fd-407b-9baa-ebc8ead77d26"
      id="F_ed1eef18-91b0-47bf-8d52-ccb0e6779c50">P5Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_d22c7a01-1ee3-4ae9-b8e5-5302459c17aa"
      id="F_ce566634-79a8-405d-96d2-624379010254">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_614aa634-42cc-4d32-8a9a-8b4df7e3a7b4"
      id="F_ed004503-5340-4e50-bd8b-0074139c4412">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_38467bd2-81f8-405d-9362-d3b8371c7945"
      id="F_065fe0c4-7c48-41d8-a5b3-9bb6062ea924">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="4"
      id="F_d2f29327-1d3e-4de4-b75a-967f40e8aacc"
      unitRef="U_pure">0.8969</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="4"
      id="F_a9b60cce-a0d6-4cbd-99bf-1dc30d9275a3"
      unitRef="U_pure">1.1212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="4"
      id="F_10e0dcba-5c4d-46c4-a9ad-3b3b385183f1"
      unitRef="U_pure">0.7449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="4"
      id="F_fd62d006-94b4-4671-8398-1f2609b1b7de"
      unitRef="U_pure">0.8875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <tcrt:PreStockSplitSharesAuthorized
      contextRef="C_1a75d2a0-9d24-4504-a3dc-2dac5fdd0e65"
      decimals="INF"
      id="F_92c59b7f-df53-44b3-9c87-1d4591792963"
      unitRef="U_shares">520000000</tcrt:PreStockSplitSharesAuthorized>
    <tcrt:PostStockSplitSharesAuthorized
      contextRef="C_1a75d2a0-9d24-4504-a3dc-2dac5fdd0e65"
      decimals="INF"
      id="F_4a4a0905-e911-4214-ba70-710c3c6e3cc4"
      unitRef="U_shares">34666667</tcrt:PostStockSplitSharesAuthorized>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_8c63ac11-1fe7-4822-9cb9-1e975eedf1b6"
      id="F_b48bafbd-aeea-4a83-b97e-302cd621f330">The Charter Amendment became effective on January 31, 2024 at 5:00 p.m. Eastern Time, at which time every 15 shares of the Company&#x2019;s issued and outstanding common stock automatically combined and converted into 1 share of common stock.</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_cddaa5f4-aead-4071-8da5-f3ba53177542">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company&#x2019;s common stock during the applicable period, unless their effect on net loss per share is antidilutive. The effect of computing diluted net loss per common share was antidilutive for any potentially issuable shares of common stock from the conversion of stock options, unvested restricted stock and warrants and, as such, have been excluded from the calculation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The computation of basic and diluted net loss per share consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,995,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,475,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Certain shares related to some of the Company&#x2019;s outstanding common stock options, unvested restricted stock and warrants have not been included in the computation of diluted net loss per share for the years ended December 31, 2023 and 2022 as the result would be antidilutive. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Such potential common shares on December 31, 2023 and 2022 consist of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;465,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;693,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,452,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,528,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,918,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,284,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_ff8e5c82-8933-4923-aac2-dc31ff7558b8">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company&#x2019;s common stock during the applicable period, unless their effect on net loss per share is antidilutive. The effect of computing diluted net loss per common share was antidilutive for any potentially issuable shares of common stock from the conversion of stock options, unvested restricted stock and warrants and, as such, have been excluded from the calculation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The computation of basic and diluted net loss per share consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,995,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,475,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_d3ee0ee7-23f4-447b-ba42-5951d3813488"
      unitRef="U_USD">-35140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_9338b24d-9519-4c11-8163-b2ef35a9286c"
      unitRef="U_USD">-37730000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="0"
      id="F_ab06097a-e952-47fe-a7e9-e1f2e492400e"
      unitRef="U_shares">15995323</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="0"
      id="F_a6bb691b-a1cf-426e-847a-fd08787bf53c"
      unitRef="U_shares">15995323</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="0"
      id="F_ae86b235-2c64-4b71-a99c-3d8403738e04"
      unitRef="U_shares">14475354</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="0"
      id="F_bf01d427-02d8-46c9-ad36-898c407dfdab"
      unitRef="U_shares">14475354</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="2"
      id="F_915291ca-64e7-4b63-8e92-38edc57f4cd6"
      unitRef="U_USDollarShare">-2.2</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="2"
      id="F_bc65e511-b865-48d7-97fa-218411eb8354"
      unitRef="U_USDollarShare">-2.2</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="2"
      id="F_2f1d5f48-8cf1-4087-88b2-f65796d7d40a"
      unitRef="U_USDollarShare">-2.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="2"
      id="F_2055e1eb-8227-4cf1-87ef-f1df171b4268"
      unitRef="U_USDollarShare">-2.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_e88792c3-3c40-4cc4-abac-7b2bba9d15e8">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Such potential common shares on December 31, 2023 and 2022 consist of the following:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;465,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;693,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,452,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,528,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,918,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,284,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4104f83e-9d9d-42d3-ba02-e04dc9b2ed5f"
      decimals="0"
      id="F_8dc406dc-3393-4605-bcf0-2cba12847668"
      unitRef="U_shares">465898</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0a9aab26-46d9-488c-b695-2646b51f35c2"
      decimals="0"
      id="F_c7f9b236-b4e2-4968-8b1c-514ee6a7c9ea"
      unitRef="U_shares">693909</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5a00674d-0901-4260-8a18-828129c14592"
      decimals="0"
      id="F_0df0f2db-0b54-4ae4-9e32-11ce324bc3b2"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9251b0d7-fe5b-457f-a984-b77be81cbbed"
      decimals="0"
      id="F_f92dad80-186c-422b-8619-d509597908f9"
      unitRef="U_shares">62604</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ab6d30fd-d037-4c8b-a225-3af57f8a921c"
      decimals="0"
      id="F_d8212927-696f-4c30-a764-a80b79af487f"
      unitRef="U_shares">1452399</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9372d727-0118-429b-87d8-c76963744d6d"
      decimals="0"
      id="F_ab5ff1f9-166b-4c34-bea7-a4ff049f5759"
      unitRef="U_shares">1528156</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="0"
      id="F_68087b1e-f3e2-4928-8e00-894ee07d6408"
      unitRef="U_shares">1918297</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="0"
      id="F_8efe0f17-f224-4043-96e9-93f55e9a29e4"
      unitRef="U_shares">2284669</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_9e0827b2-d323-49d0-b81e-ca03dca1b2c4">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued Accounting Standards Update, or ASU, 2016-13, Financial Instruments: Credit Losses (Topic 326) as clarified in ASU 2019-04, ASU 2019-05 and ASU 2020-02. The objective of this standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than-temporary impairments on investment securities are recorded. The Company adopted ASU 2016-13 effective January 1, 2023, with no material impact upon adoption.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances the disclosures required for operating segments in the Company's annual and interim financial statements. ASU 2023-07 is effective retrospectively for fiscal years beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this standard.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for the Company prospectively to all annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this standard.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_f433ffa9-4880-4bab-b9e2-55e72e40aca6">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. Debt&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; debt obligations outstanding at December 31, 2023. The carrying values of the Company's debt obligation at December 31, 2022 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unamortized discount on Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: long-term debt, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 6, 2021, the Company entered into the Loan and Security Agreement with SVB. The Loan and Security Agreement provided for the funding of the Term A Tranche at the closing, with the Term B Tranche available if certain funding and clinical milestones were met by August 31, 2022. The SVB Facility and related obligations under the Loan and Security Agreement were secured by substantially all of the Company's&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;properties, rights and assets, except for its intellectual property (which was subject to a negative pledge under the Loan and Security Agreement). In addition, the Loan and Security Agreement contained customary representations, warranties, events of default and covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On December 28, 2021, the Company entered into the First Amendment to the Loan and Security Agreement. The First Amendment eliminated the unfunded Term B Tranche, among other things. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The SVB Facility bore interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and (b) the current published U.S. prime rate, plus a margin of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All outstanding obligations under the amended Loan and Security Agreement were due and payable on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;August 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. In connection with the payment of all of the Company's outstanding obligations, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the Company also owed SVB &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the original principal amounts borrowed as a final payment, or the Final Payment. Effective March 30, 2023, the Company entered into a Third Amendment to the Loan and Security Agreement, or the Third Amendment. Under the terms of the Third Amendment, the Company was no longer required to maintain all of its operating accounts, depository accounts and excess cash with SVB or one of its affiliates, and was instead only required to maintain a single operating or depository account at Silicon Valley Bank. The Third Amendment also modified the cash collateralization requirement, such that the Company was required to cash collateralize the entire sum of the outstanding principal amount of the SVB Facility, plus an amount equal to the Final Payment, which amount was to be reduced commensurate with each regularly scheduled monthly payment of principal and interest on the SVB Facility.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On May 1, 2023, the Company paid SVB an amount equal to the entire outstanding principal amount under the SVB Facility, all accrued and unpaid interest and the Final Payment. In accordance with the First Amendment, the payment was subject to a prepayment premium of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; During the year ended December 31, 2023, the Company recorded the remaining amounts associated with the Final Payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and the prepayment premium of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as interest expense within the statement of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with its entry into the Loan and Security Agreement in August 2021, the Company issued to SVB warrants to purchase (i) up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,856&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, in the aggregate, and (ii) up to an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,856&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, in the aggregate, in the event the Company achieved certain clinical milestones, in each case at an exercise price per share of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with its entry into the First Amendment in December 2021, the Company amended and restated the warrants issued to SVB. As amended and restated, the warrants are for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,308&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company's common stock, in the aggregate, with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, or the SVB Warrants. The SVB Warrants expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;August 6, 2031&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The issuance costs for the Loan and Security Agreement, including the First Amendment, were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and primarily related to the SVB Warrants, which were amortized into interest expense over the term of the loan. Interest expense, including the amortization of issuance costs, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2023 and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_ea9db2c3-1969-44fd-ba72-4e4b2d4744f4">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; debt obligations outstanding at December 31, 2023. The carrying values of the Company's debt obligation at December 31, 2022 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unamortized discount on Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: long-term debt, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_a8ce865e-2a59-4efd-9635-db723186bf11"
      unitRef="U_USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_e64be0f6-91d9-4db7-86b4-e80514f8c958"
      decimals="-3"
      id="F_66aeae9f-93bf-4e4e-adf3-fe0a36d11045"
      unitRef="U_USD">17395000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_e64be0f6-91d9-4db7-86b4-e80514f8c958"
      decimals="-3"
      id="F_67606748-0aa0-452a-bdbd-42c445461b97"
      unitRef="U_USD">630000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_fe8a2cab-4833-4574-bcb6-3eb3f19f27fe"
      unitRef="U_USD">16765000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_c5450736-e7ab-474e-b750-61f78ffcb68e"
      unitRef="U_USD">16765000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_9754e075-fb64-4200-95ce-751e89b9345d"
      unitRef="U_USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="C_b4ef7ff5-bba3-4349-98dd-d7df9d126723"
      id="F_00915b95-be63-48ce-b1df-d5cbd594744d">The SVB Facility bore interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) 7.75% and (b) the current published U.S. prime rate, plus a margin of 4.5%.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_36cd6252-28b4-4775-b0f9-58a9b230b1c3"
      decimals="4"
      id="F_38847a84-ff57-4b52-a69d-1be25a17ab5f"
      unitRef="U_pure">0.0775</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_70ef5a8d-4cca-4f80-ae99-5f24fedd40fc"
      decimals="3"
      id="F_33312005-1ea7-4236-b610-d39888ad6a02"
      unitRef="U_pure">0.045</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="C_b4ef7ff5-bba3-4349-98dd-d7df9d126723"
      id="F_80515573-ae88-4ff7-abf9-47b76caefbad">2023-08-01</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms
      contextRef="C_5d7932fa-9451-44de-93c6-0aeabfb182de"
      id="F_088be771-7077-4a5e-9de1-897069dfb287">the Company also owed SVB 5.75% of the original principal amounts borrowed as a final payment, or the Final Payment. Effective March 30, 2023, the Company entered into a Third Amendment to the Loan and Security Agreement, or the Third Amendment. Under the terms of the Third Amendment, the Company was no longer required to maintain all of its operating accounts, depository accounts and excess cash with SVB or one of its affiliates, and was instead only required to maintain a single operating or depository account at Silicon Valley Bank. The Third Amendment also modified the cash collateralization requirement, such that the Company was required to cash collateralize the entire sum of the outstanding principal amount of the SVB Facility, plus an amount equal to the Final Payment, which amount was to be reduced commensurate with each regularly scheduled monthly payment of principal and interest on the SVB Facility.On May 1, 2023, the Company paid SVB an amount equal to the entire outstanding principal amount under the SVB Facility, all accrued and unpaid interest and the Final Payment. In accordance with the First Amendment, the payment was subject to a prepayment premium of 2.00%.</us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms>
    <tcrt:PercentageOfOriginalPrincipalDueAsAFinalPayment
      contextRef="C_36cd6252-28b4-4775-b0f9-58a9b230b1c3"
      decimals="4"
      id="F_0b36667f-ffad-4f1a-95fb-0c04b8408c2f"
      unitRef="U_pure">0.0575</tcrt:PercentageOfOriginalPrincipalDueAsAFinalPayment>
    <tcrt:PercentageOfPrepaymentsPremium
      contextRef="C_f075a278-5164-4d2a-9bd2-198370833aca"
      decimals="4"
      id="F_41026c6e-4956-4500-a440-b8be322bea70"
      unitRef="U_pure">0.02</tcrt:PercentageOfPrepaymentsPremium>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="C_b4ef7ff5-bba3-4349-98dd-d7df9d126723"
      decimals="-5"
      id="F_44edd090-c163-4346-9e98-4358479f0e57"
      unitRef="U_USD">500000</us-gaap:ExtinguishmentOfDebtAmount>
    <tcrt:AmountOfPrepaymentsPremium
      contextRef="C_b4ef7ff5-bba3-4349-98dd-d7df9d126723"
      decimals="-5"
      id="F_dc477a7a-a61a-476e-a5c2-2de4d686cd9d"
      unitRef="U_USD">100000</tcrt:AmountOfPrepaymentsPremium>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_7076c57a-eac4-4967-be0d-548e7041b7f8"
      decimals="INF"
      id="F_c7843618-781d-4771-bd89-53b39a50ff98"
      unitRef="U_shares">28856</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <tcrt:AdditionalNumberOfWarrantsIssued
      contextRef="C_7076c57a-eac4-4967-be0d-548e7041b7f8"
      decimals="INF"
      id="F_f01ad276-45ba-475a-9ba2-0be6438b3bd5"
      unitRef="U_shares">28856</tcrt:AdditionalNumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_7076c57a-eac4-4967-be0d-548e7041b7f8"
      decimals="2"
      id="F_197d6a5b-e21c-4531-bd43-f103fdfcbf07"
      unitRef="U_USDollarShare">33.3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="C_0a5a10cc-553a-4c9b-9781-bb8cb6a5dd9b"
      decimals="INF"
      id="F_469b306c-168b-4ee7-9cd5-59fbe65eb1ba"
      unitRef="U_shares">43308</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_42fcfea8-a421-4581-aa9a-f10b12c3fff7"
      decimals="2"
      id="F_8cc81055-b5ac-4ac3-8947-6cd33b78a0be"
      unitRef="U_USDollarShare">17.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcrt:WarrantsExpirationDate
      contextRef="C_0a5a10cc-553a-4c9b-9781-bb8cb6a5dd9b"
      id="F_16529a74-6784-463a-8385-2dd23bbc0e49">2031-08-06</tcrt:WarrantsExpirationDate>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="C_bb295f58-cf1f-496d-99a4-62856a01fdf4"
      decimals="-5"
      id="F_949723f6-f74c-437c-b15b-333ea4c2d86f"
      unitRef="U_USD">1200000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:InterestExpenseDebt
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-5"
      id="F_fbbea518-0261-409e-b6e4-a51e67edaf56"
      unitRef="U_USD">1900000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-5"
      id="F_7f1602b7-fe87-4c1e-9705-5ae80271d020"
      unitRef="U_USD">3200000</us-gaap:InterestExpenseDebt>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_54d01e53-53e4-4165-924c-e55ccc1684e8">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;5.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net, consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.213%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Office and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation expense for the year ended December 31, 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2022. During the year ended December 31, 2023, the Company impaired property and equipment by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Refer to Note 3, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, for further details.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_e9fae5cd-acec-4d10-b87c-5934a25b20b2">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net, consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.213%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Office and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ae07e329-a5b4-4996-9101-5c81cefa338b"
      decimals="-3"
      id="F_5bda8718-96a8-4b22-8c4a-891fb99d147c"
      unitRef="U_USD">15000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c03e3f83-0461-4bff-a6ec-c8e8f6eae256"
      decimals="-3"
      id="F_8f8e6492-5846-4a98-b424-b5fb0b617fb8"
      unitRef="U_USD">2183000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_59b1d649-d101-49bf-a3c7-bd6b2abc3d7d"
      decimals="-3"
      id="F_5cfb3842-1ad3-43ca-a160-7b465674bef1"
      unitRef="U_USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_63da8372-4842-42f7-846e-29d35b96baad"
      decimals="-3"
      id="F_a6e71f24-458b-4150-b0ea-57a3b6d67d01"
      unitRef="U_USD">1291000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_53b2cce5-dd6d-4584-81a2-934fca6f36e1"
      decimals="-3"
      id="F_accd9a7f-6749-41b1-8a48-42e54f1a585d"
      unitRef="U_USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1eb9814e-4de9-413f-980e-56701e4ada9c"
      decimals="-3"
      id="F_0df60c81-1541-4b81-9be6-9197e79589a6"
      unitRef="U_USD">9561000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0d7a6c39-7681-4ca3-99fb-8b12b128396b"
      decimals="-3"
      id="F_c74a7d9c-e457-4754-bfc7-80c15555ca9f"
      unitRef="U_USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8437c692-33c1-493a-b928-11fb26d089fe"
      decimals="-3"
      id="F_2967a6c4-7637-494d-94d0-972562ede83b"
      unitRef="U_USD">5232000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_b02084f4-0a4c-4200-a4a6-93b2903c9a18"
      unitRef="U_USD">15000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_f988f6b1-5574-43a1-8ab1-b9bb8eb509db"
      unitRef="U_USD">18267000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_7279ba97-269e-48ae-b1af-1ebe45701193"
      unitRef="U_USD">13000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_20ad6d81-e7b2-42b7-86f6-87c78ec56175"
      unitRef="U_USD">9807000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_89ea558e-7391-4b4a-91ed-8a2fabceea74"
      unitRef="U_USD">2000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_aa9746c6-89f4-4d8a-b567-3ee470c6ded3"
      unitRef="U_USD">8460000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-5"
      id="F_036c76db-c852-42b0-9d76-0bad20cbd1a3"
      unitRef="U_USD">2300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-5"
      id="F_847a1955-9a6e-425e-8f74-e474a79dbc62"
      unitRef="U_USD">2800000</us-gaap:Depreciation>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_61732725-ae5b-416f-8f67-a2ab46a40cc5"
      decimals="-5"
      id="F_12be8c6f-e92a-4493-a4fb-75dca9ecd834"
      unitRef="U_USD">4800000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_ee0bf0c7-33aa-4d64-ba1e-d9fb87b3ade7">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;6.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Clinical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employee compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Preclinical services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Manufacturing services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other consulting services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_cdec8af5-273f-45b0-95d3-6639fea597ea">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Clinical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employee compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Preclinical services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Manufacturing services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other consulting services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <tcrt:AccruedClinicalExpensesCurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_25f409bf-4d25-44f0-a827-ffbab1cba529"
      unitRef="U_USD">568000</tcrt:AccruedClinicalExpensesCurrent>
    <tcrt:AccruedClinicalExpensesCurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_1daf1ca7-40be-4d97-8670-6586899af628"
      unitRef="U_USD">2200000</tcrt:AccruedClinicalExpensesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_3ae5374b-9f32-4218-bbb3-30fc8fca5821"
      unitRef="U_USD">43000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_e5c11288-efdb-40bf-96be-c01ae9bf8f01"
      unitRef="U_USD">1160000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_1aae791b-c060-402c-a7db-efa5d59801ee"
      unitRef="U_USD">717000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_4839e19d-a568-4b8e-8300-84f448446e6c"
      unitRef="U_USD">534000</us-gaap:AccruedProfessionalFeesCurrent>
    <tcrt:AccruedPreclinicalServicesCurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_e930e229-12e8-4797-b135-0fd23c980a7b"
      unitRef="U_USD">0</tcrt:AccruedPreclinicalServicesCurrent>
    <tcrt:AccruedPreclinicalServicesCurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_bae8d8a1-cdf8-47a9-9f72-6d3334c12338"
      unitRef="U_USD">198000</tcrt:AccruedPreclinicalServicesCurrent>
    <tcrt:AccruedManufacturingCostsCurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_d5ea0a61-c9e9-43e8-b342-31bbda1ab403"
      unitRef="U_USD">12000</tcrt:AccruedManufacturingCostsCurrent>
    <tcrt:AccruedManufacturingCostsCurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_29594e79-d3e3-4692-be71-7e9cd274091a"
      unitRef="U_USD">1177000</tcrt:AccruedManufacturingCostsCurrent>
    <tcrt:AccruedConsultingFeesCurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_421987d2-9311-4712-b303-78178fcc47bd"
      unitRef="U_USD">0</tcrt:AccruedConsultingFeesCurrent>
    <tcrt:AccruedConsultingFeesCurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_42475661-4d8f-4c12-b14e-a919ad850903"
      unitRef="U_USD">16000</tcrt:AccruedConsultingFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_335ff904-2ac2-4c04-9078-fe29f2686d1f"
      unitRef="U_USD">0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_e31ae0da-0c2b-4bd3-8157-3d3bf2ac8a4d"
      unitRef="U_USD">169000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_7f01a9d9-e35e-4f72-9338-b6ff28de548f"
      unitRef="U_USD">1340000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_18c88f8d-d1dc-4dd9-9562-e611fee0016f"
      unitRef="U_USD">5454000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_78a79fea-8202-4ef2-abb5-da32b097d0f4">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;7.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Related Party Transactions&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Joint Venture with TriArm Therapeutics/Eden BioCell&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On December 18, 2018, the Company and TriArm Therapeutics, Ltd., or TriArm, launched Eden BioCell, Ltd., or Eden BioCell, as a joint venture to lead commercialization of the Company&#x2019;s &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-generated CAR-T therapies in the People&#x2019;s Republic of China (including Macau and Hong Kong), Taiwan and Korea. The Company licensed to Eden BioCell the rights in Greater China for its third-generation Sleeping Beauty-generated CAR-T therapies targeting the CD19 antigen. Eden BioCell is owned equally by the Company and TriArm and the parties share decision-making authority. TriArm contributed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to Eden BioCell and has committed up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to this joint venture. TriArm also managed all clinical development in the territory pursuant to a master services agreement between TriArm and Eden BioCell. James Huang was the founder and serves as managing partner of Panacea Venture, which is an investor in TriArm. Mr. Huang was the Chair of the Company's board of directors until September 22, 2023 and had been a director since July 2020. He also serves as a member of Eden BioCell&#x2019;s board of directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2021, TriArm and Alaunos mutually agreed to dissolve the Eden BioCell joint venture. The joint venture agreement has been terminated and the Eden BioCell entity has been dissolved as of July 2023. Refer to Note 15, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Joint Venture&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, for further details.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Collaboration with Dune Lake Capital&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2023, the Company entered into a consulting agreement with Dune Lake Capital, LLC, or Dune Lake Capital, which was founded by Dale Curtis Hogue, Jr., the Company's interim Chief Executive Officer. During the year ended December 31, 2023, the Company recorded expenses of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand for consulting services performed by Dune Lake Capital with respect to the period from January 2023 to August 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="C_01c537c5-d7da-43b7-9828-3dd4fac7a6b1"
      decimals="-5"
      id="F_f96dd304-45b0-490c-939d-4a7598d90d32"
      unitRef="U_USD">10000000</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <tcrt:AdditionalLoansCommitted
      contextRef="C_c83e3ba4-ff7f-49bc-b367-c3a48773a81c"
      decimals="-5"
      id="F_7ee63367-801f-492b-8489-cbe0f023fb66"
      unitRef="U_USD">25000000</tcrt:AdditionalLoansCommitted>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="C_fec7df81-6165-4556-94da-9ce5e0afffd4"
      decimals="-3"
      id="F_1c24c4aa-136a-43a8-9f8c-8d94f2a8a816"
      unitRef="U_USD">37000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_7f73cc1d-8706-47b6-9812-6fbd987857ed">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;8.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In April 2022, the Company modified its real estate lease agreement executed on December 15, 2020 with MD Anderson for office space in Houston, Texas, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;which reduced the Company's leased space from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,111&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,228&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet. As a result, the associated lease liability and right-of-use asset were remeasured to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million based on revised lease payments. A gain of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was recorded on the lease modification during the year ended December 31, 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2022, the Company executed an agreement to sub-sublease &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,772&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of subleased office space in Boston. For the year ended December 31, 2023, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand in lease income, and for the year ended December 31, 2022, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in lease income. Lease income is classified within other income on the statement of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;April 19, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company terminated its office lease in Boston, Massachusetts, which was set to expire on August 31, 2026. In connection with the termination, the Company also assigned to the landlord its sub-sublease of the Boston office space, which had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;a term expiring on June 30, 2025 with an option to extend through &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;July 31, 2026&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Termination costs for the Boston office lease were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. A gain of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was recorded on the lease termination during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2023, in accordance with the lease agreement executed on December 15, 2020, the Company notified MD Anderson, as landlord, of its intention to terminate office space of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,228&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet in Houston, Texas. As a result, the associated lease liability and right-of-use asset were remeasured to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand, reflecting the revised lease payments and term end date of November 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On November 1, 2023, the Company and MD Anderson, as landlord, agreed to mutually terminate the leases dated October 15, 2019 and April 7, 2020, which represented office space totaling &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,037&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet, effective November 15, 2023. As a result, the Company agreed to make a final payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to the landlord. A gain of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was recorded on the lease termination during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p id="bkmk_231" style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.493%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.839%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.915%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.839%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.914%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in operating lease costs for the year-ended December 31, 2023. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognize new operating lease assets obtained in exchange for operating lease liabilities for the year-ended December 31, 2023. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t have any leases, other than a short-term lease, as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <tcrt:OperatingLeaseArea
      contextRef="C_41ccee47-b234-4941-b8eb-978d9f5b2e42"
      decimals="INF"
      id="F_f1444f76-8f2a-46b4-8333-927d82ff0cb8"
      unitRef="U_sqft">18111</tcrt:OperatingLeaseArea>
    <tcrt:OperatingLeaseArea
      contextRef="C_aa3c307b-d3f5-4b67-b1f6-1018ba02f672"
      decimals="INF"
      id="F_aaf2d64f-0e4f-433f-a8cd-d195e8926385"
      unitRef="U_sqft">3228</tcrt:OperatingLeaseArea>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_aa3c307b-d3f5-4b67-b1f6-1018ba02f672"
      decimals="-5"
      id="F_c8fc9c35-f964-4356-9882-76b51a7dc4b1"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <tcrt:GainLossOnModificationOfLease
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-5"
      id="F_9ca563f9-02ec-4473-ac24-627e0702085d"
      unitRef="U_USD">100000</tcrt:GainLossOnModificationOfLease>
    <tcrt:SubleaseArea
      contextRef="C_112e62be-1071-454a-9093-81a7c718e165"
      decimals="0"
      id="F_11fc1bec-4b64-4bcf-b24e-14c34b5e0c57"
      unitRef="U_sqft">4772</tcrt:SubleaseArea>
    <us-gaap:LeaseIncome
      contextRef="C_9f6ea145-3408-4127-8187-484ad479069b"
      decimals="-3"
      id="F_e7bcaf91-342b-4c0c-b2e1-3bb352a8761e"
      unitRef="U_USD">43000</us-gaap:LeaseIncome>
    <us-gaap:LeaseIncome
      contextRef="C_95d872d4-ff79-4993-afa4-1fc260f3a843"
      decimals="-5"
      id="F_1f390000-62e7-4bdf-8082-49990cc5aa8c"
      unitRef="U_USD">100000</us-gaap:LeaseIncome>
    <tcrt:LeaseTerminationDate
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_f52ebf41-a794-49ad-a782-5faf5565adca">2023-04-19</tcrt:LeaseTerminationDate>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_759b438f-e084-415a-bd3e-33a77795c829"
      id="F_d3b063b6-47eb-43df-ae72-c96c7c502a34">a term expiring on June 30, 2025 with an option to extend through July 31, 2026</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <tcrt:SubleaseTermCommencedEndDateAmendment
      contextRef="C_759b438f-e084-415a-bd3e-33a77795c829"
      id="F_c1812c93-2671-4598-a2a5-1546d7e70253">2026-07-31</tcrt:SubleaseTermCommencedEndDateAmendment>
    <tcrt:TerminationCosts
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-5"
      id="F_78bc9ea9-c3fb-49c4-a9b7-dabae183b80f"
      unitRef="U_USD">200000</tcrt:TerminationCosts>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="C_31df6cae-3411-4d1e-afda-0b2df9d5828c"
      decimals="-5"
      id="F_f7a1992e-9b70-4f21-a414-bae29c51d087"
      unitRef="U_USD">200000</us-gaap:GainLossOnTerminationOfLease>
    <tcrt:OperatingLeaseArea
      contextRef="C_a5f0ce97-7e26-409e-8300-d1a1644a54a8"
      decimals="0"
      id="F_cdfba2a6-11c1-48fc-8056-0e6277427878"
      unitRef="U_sqft">3228</tcrt:OperatingLeaseArea>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_a5f0ce97-7e26-409e-8300-d1a1644a54a8"
      decimals="-3"
      id="F_bec7e99a-4d97-4916-bdf5-61b3bb0e544e"
      unitRef="U_USD">19000</us-gaap:OperatingLeaseRightOfUseAsset>
    <tcrt:OperatingLeaseArea
      contextRef="C_c30dcdbc-ca80-4f40-8509-a02802f4927d"
      decimals="0"
      id="F_51052de3-21bd-4175-9752-c556394c0ecc"
      unitRef="U_sqft">14037</tcrt:OperatingLeaseArea>
    <us-gaap:OperatingLeasePayments
      contextRef="C_5192514c-c4a7-4570-99f5-e8a967b213de"
      decimals="-5"
      id="F_3837987a-77dc-4921-b7bf-cb46fb23280c"
      unitRef="U_USD">100000</us-gaap:OperatingLeasePayments>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="C_0b32ddd3-7ce4-4f74-9808-a45ab5d03ffd"
      decimals="-5"
      id="F_43074f09-eba4-4df8-8a49-68c9831897d6"
      unitRef="U_USD">100000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_ae71dfb2-212e-473d-a067-e1829a5b9d9b">&lt;p id="bkmk_231" style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.493%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.839%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.915%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.839%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.914%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_38427c69-5b8d-43e8-84bf-9ca32bb39bc1"
      unitRef="U_USD">428000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_a5043313-85a5-4f9b-b7ca-eda5d95a5e0b"
      unitRef="U_USD">756000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_09a2b4f7-4c22-46a8-be53-adafd97a0158"
      unitRef="U_USD">428000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_ce7efc7d-23a1-4a71-a787-6d3cd5305c24"
      unitRef="U_USD">756000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      id="F_edc1ca29-d7a0-4ab2-bad2-aa458d85c900">P4Y1M17D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="2"
      id="F_ff822e01-f4d4-4514-8121-284e13c2a51b"
      unitRef="U_pure">0</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="4"
      id="F_5fa335db-0c51-42db-b34a-1df63193cc63"
      unitRef="U_pure">0.0826</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-5"
      id="F_17d7c030-e17e-4764-a268-188b1efd83ad"
      unitRef="U_USD">400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="0"
      id="F_3a0a7b2b-28ab-4d2b-951c-e1fb26fa1c31"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="0"
      id="F_9eeec2c1-3e84-4b4d-9309-bb7f4e0d9f2a"
      unitRef="U_USD">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_8d279e3a-cef3-49b2-b120-09a04de48714">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;9.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.667%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Exclusive License Agreement with Precigen&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On October 5, 2018, the Company entered into an exclusive license agreement, or License Agreement, with PGEN Therapeutics, or PGEN, a wholly owned subsidiary of Precigen Inc., or Precigen, which was formerly known as Intrexon Corporation. Except where the context otherwise requires, the Company refers to PGEN and Precigen together as Precigen. Pursuant to the terms of the License Agreement, the Company had exclusive, worldwide rights to research, develop and commercialize (i) TCR products designed for neoantigens for the treatment of cancer, (ii) products utilizing Precigen&#x2019;s RheoSwitch&#xae; gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (iii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the License and Collaboration Agreement effective March 27, 2015 between the Company, Precigen and ARES TRADING S.A., a subsidiary of Merck KGaA, as assigned by Precigen to PGEN. Under the License Agreement, the Company also had exclusive, worldwide rights for certain patents relating to the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company was responsible for all aspects of the research, development and commercialization and was required to use commercially reasonable efforts to develop certain products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In consideration of the licenses and other rights granted by Precigen, the Company was required to pay Precigen an annual license fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, reimburse Precigen for certain historical costs, pay Precigen milestones up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for each exclusively licensed program upon the achievement of certain milestones, and pay Precigen tiered royalties up to a maximum royalty amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in the aggregate. The Company was also obligated to pay Precigen &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of any sublicensing income received relating to the licensed products. The Company was responsible for all development costs associated with each of the licensed products. For the years ended December 31, 2023 and 2022, the Company paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in annual license fees under this agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Precigen was obligated to pay the Company royalties up to a maximum royalty amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; royalty amounts were incurred during the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 3, 2023, the Company entered into the Amended and Restated Exclusive License Agreement with Precigen, or the A&amp;amp;R License Agreement, which restated and amended the License Agreement in full. Under the A&amp;amp;R License Agreement, the Company still has exclusive, worldwide rights to research, develop and commercialize TCR products designed for neoantigens or driver mutations for the treatment of cancer and non-exclusive rights to use non-driver mutation TCRs. The Company further maintains its exclusive, worldwide rights for certain patents relating to the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company remains solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. The (i) products utilizing Precigen&#x2019;s RheoSwitch&#xae; gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (ii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the License and Collaboration Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;effective &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 27, 2015 between the Company, Precigen and ARES TRADING S.A., a subsidiary of Merck KGaA, as assigned by Precigen to PGEN are no longer exclusively licensed to the Company. The Company is no longer obligated to use commercially reasonable efforts for the exclusively licensed products. The A&amp;amp;R License Agreement further eliminates any royalty or milestone obligations to Precigen, with an annual license fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand due on the anniversary of the A&amp;amp;R License Agreement effective date. Precigen is no longer obligated to pay the Company royalties on the net sales derived from the sale of Precigen's CAR products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;License Agreement and 2015 Research and Development Agreement &#x2014;The University of Texas MD Anderson Cancer Center&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 13, 2015&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company, together with Precigen, entered into a license agreement, or the MD Anderson License with MD Anderson (which Precigen subsequently assigned to PGEN). Pursuant to the MD Anderson License, the Company, together with Precigen, holds an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR T-cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells, and TCRs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 17, 2015, the Company, Precigen and MD Anderson entered into the 2015 R&amp;amp;D Agreement to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. The rights and obligations of Precigen under the 2015 R&amp;amp;D Agreement were assigned to the Company pursuant to the Fourth Amendment to 2015 R&amp;amp;D Agreement which was entered into on September 19, 2019 (the &#x201c;Fourth Amendment&#x201d;) with an effective date of October 5, 2018. The activities under the 2015 R&amp;amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As provided under the MD Anderson License, the Company provided funding for research and development activities in support of the research programs under the 2015 R&amp;amp;D Agreement for a period of three years and in an amount of no less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and no greater than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million per year. On November 14, 2017, the Company entered into an amendment to the 2015 R&amp;amp;D Agreement, extending its term until April 15, 2021. In connection with the execution of the 2019 R&amp;amp;D Agreement described below, on October 22, 2019, the Company amended the 2015 R&amp;amp;D Agreement to extend the term of the 2015 R&amp;amp;D Agreement until December 31, 2026 and to allow cash resources on hand at MD Anderson under the 2015 R&amp;amp;D Agreement to be used for development costs under the 2019 Research and Development Agreement, or the 2019 R&amp;amp;D Agreement, which the Company entered into on October 22, 2019, with MD Anderson, pursuant to which the Company agreed to collaborate with respect to the TCR program. For the year ended December 31, 2023 the Company incurred clinical expenses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from MD Anderson related to the 2015 R&amp;amp;D Agreement, and did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t incur clinical costs from MD Anderson related to the 2015 R&amp;amp;D Agreement for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term of the MD Anderson License, the Company, together with Precigen, shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if the Company and Precigen are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if the Company and Precigen are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by the Company and Precigen, if such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both the Company and Precigen and may be terminated by the mutual written agreement of the Company, Precigen, and MD Anderson.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2019 Research and Development Agreement&#x2014;The University of Texas MD Anderson Cancer Center&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the 2019 R&amp;amp;D Agreement, the Company and MD Anderson will, among other things, collaborate on programs to expand the Company's TCR library and conduct clinical trials. The activities under the 2019 R&amp;amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company will own all inventions and intellectual property developed under the 2019 R&amp;amp;D Agreement and the Company will retain all rights to all intellectual property, patentable or not, for oncology products manufactured using non-viral gene transfer technologies under the 2019 R&amp;amp;D Agreement, including the Company's&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Sleeping Beauty&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; technology. The Company has granted MD Anderson an exclusive license for such intellectual property to develop and commercialize autologous TCR products manufactured using viral gene transfer technologies and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;any products outside the field of oncology and a non-exclusive license for allogenic TCR products manufactured using viral-based technologies.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the 2019 R&amp;amp;D Agreement, the Company agreed, beginning on January 1, 2021, to reimburse MD Anderson up to a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for development costs under the 2019 R&amp;amp;D Agreement, after the funds from the 2015 R&amp;amp;D Agreement are exhausted. In addition, the Company will pay MD Anderson royalties on net sales of its TCR products. The Company is required to make performance-based payments upon the successful completion of clinical and regulatory benchmarks relating to its TCR products. The aggregate potential benchmark payments are $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, of which only $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million will be due prior to the first marketing approval of the Company's TCR products. The royalty rates and benchmark payments owed to MD Anderson may be reduced upon the occurrence of certain events. The Company also agreed to sell its TCR products to MD Anderson at preferential prices and will sell the Company's TCR products in Texas exclusively to MD Anderson for a limited period of time following the first commercial sale of the Company's TCR products. For the years ended December 31, 2023 and 2022, the Company incurred clinical expenses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from MD Anderson related to the 2019 R&amp;amp;D Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2019 R&amp;amp;D Agreement will terminate on December 31, 2026 and either party may terminate the 2019 R&amp;amp;D Agreement following written notice of a material breach. The 2019 R&amp;amp;D Agreement also contains customary provisions related to indemnification obligations, confidentiality and other matters.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the execution of the 2019 R&amp;amp;D Agreement, on October 22, 2019, the Company issued MD Anderson a warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;222,222&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company's common stock, which is referred to as the MD Anderson Warrant. The MD Anderson Warrant has an initial exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.015&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, expires on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and vests upon the occurrence of certain clinical milestones. As of December 31, 2023, the milestones have not been met.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;License Agreement with the NCI&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On May 28, 2019, the Company entered into a patent license agreement, or the Patent License, with the NCI. Pursuant to the Patent License, the Company held an exclusive, worldwide license to certain intellectual property to develop and commercialize patient-derived (autologous), peripheral blood T-cell therapy products engineered by transposon-mediated gene transfer to express TCRs reactive to mutated &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;KRAS, TP53&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;EGFR &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;neoantigens. In addition, pursuant to the Patent License, the Company held an exclusive, worldwide license to certain intellectual property for manufacturing technologies to develop and commercialize autologous, peripheral blood T-cell therapy products engineered by non-viral gene transfer to express TCRs, as well as a non-exclusive, worldwide license to certain additional manufacturing technologies. On May 29, 2019, January 8, 2020, September 28, 2020, April 16, 2021, May 4, 2021 and August 13, 2021 the Company amended the Patent License to expand its TCR library to include additional TCRs reactive to mutated &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;KRAS &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;TP53 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;neoantigens licensed from the NCI.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The terms of the Patent License required the Company to pay the NCI minimum annual royalties in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which amount would be reduced to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million once the aggregate minimum annual royalties paid by the Company equaled $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company was also required to make performance-based payments upon successful completion of clinical and regulatory benchmarks relating to the licensed products. Of such payments, the aggregate potential benchmark payments were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, of which aggregate payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million would be due only after marketing approval in the United States or in Europe, Japan, Australia, China or India. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The first benchmark payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was paid during the year ended December 31, 2022 upon the initiation of the Company's TCR-T Library Phase 1/2 Trial, which was a qualifying Phase 1 clinical trial under the terms of the Patent License.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, the Company was required to pay the NCI one-time benchmark payments following aggregate net sales of licensed products at certain aggregate net sales ranging from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion. The aggregate potential amount of these benchmark payments was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company was also required to pay the NCI royalties on net sales of products covered by the Patent License at rates in the low to mid-single digits depending upon the technology included in a licensed product. To the extent the Company entered into a sublicensing agreement relating to a licensed product, the Company would be required to pay the NCI a percentage of all consideration received from a sublicensee, which percentage would decrease based on the stage of development of the licensed product at the time of the sublicense.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Patent License was to expire upon expiration of the last patent contained in the licensed patent rights, unless terminated earlier. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The NCI could terminate or modify the Patent License in the event of a material breach, including if the Company did not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The Company could terminate the Patent License, or any portion thereof, in the Company's sole discretion at any time upon &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; days&#x2019; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;written notice to the NCI. In addition, the NCI had the right to: (i) require the Company to sublicense the rights to the product candidates covered by the Patent License upon certain conditions, including if the Company was not reasonably satisfying required health and safety needs and (ii) terminate or modify the Patent License, including if the Company was not satisfying requirements for public use as specified by federal regulations. On October 27, 2023, the Company provided the NCI the requisite notice of its intent to terminate the Patent&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;License, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;effective December 26, 2023. The Company discovered multiple proprietary TCRs targeting driver mutations through its hunTR TCR discovery platform, including many of the same &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;KRAS &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;TP53 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;mutations licensed from the NCI.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the year ended December 31, 2023 the Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of expenses and incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of expenses for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cooperative Research and Development Agreement (CRADA) with the NCI&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 9, 2017, the Company entered into a Cooperative Research and Development Agreement, or the CRADA, with the NCI. The purpose of this collaboration was to advance a personalized TCR-T approach for the treatment of solid tumors. Using the Company's &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; technology, the NCI would analyze a patient&#x2019;s own cancer cells, identify their unique neoantigens and TCRs reactive against those neoantigens and then use the Company's &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; technology to transpose one or more TCRs into T cells for re-infusion. Research conducted under the CRADA was under the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI, in collaboration with the Company's researchers.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company was responsible for providing the NCI with the test materials necessary for them to conduct their studies, and eventually, clinical trials pursuant to the CRADA. Inventions, data and materials discovered or produced in connection with performance of the research plan under the CRADA would have remained the sole property of the party who produced the discovery. The parties would have jointly owned all inventions jointly discovered under the research plan. The owner of any invention under the CRADA would have made the decision to file a patent covering the invention, or in the case of a jointly owned invention, the Company would have the first opportunity to file a patent covering the invention. If the Company failed to provide timely notice of its decision to the NCI or decided not to file a patent covering the joint invention, the NCI had the right to make the filing. For any invention solely owned by the NCI or jointly made by the NCI and the Company for which a patent application was filed, the U.S. Public Health service granted the Company an exclusive option to elect an exclusive or non-exclusive commercialization license. For inventions owned solely by the NCI or jointly owned by the NCI and the Company, which were licensed according to the terms described above, the Company agreed to grant to the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world. The Company was also required to grant the U.S. government a non-exclusive, non-transferable, irrevocable and paid up license to practice the invention or have the invention practiced on its behalf throughout the world for any of the Company's solely owned inventions. The agreement could be terminated by any of the parties upon 60 days' prior written consent.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2019, the Company extended the CRADA with the NCI until January 9, 2022, committing an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to this program; however, for the third and fourth quarters of 2021, the Company was not required to make payments toward the program as agreed with the NCI. In March 2022, the Company entered into an amendment to the CRADA that is retroactive, effective January 9, 2022 to extend the term of the CRADA until January 9, 2023. In June 2022, the Company entered into the Fourth Amendment to the CRADA, or the CRADA Fourth Amendment, which, among other things, extended the term of the CRADA until January 9, 2025. In connection with the CRADA Fourth Amendment, the Company agreed to contribute $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million per year, payable on a quarterly basis, beginning in the first quarter of 2023. The Company recorded expenses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2023, compared to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 14, 2023, the Company announced that it had provided the requisite notice to terminate the CRADA, pursuant to its terms, effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 13, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, in light of the Company&#x2019;s exploration of strategic alternatives.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Patent and Technology License Agreement&#x2014;The University of Texas MD Anderson Cancer Center and the Texas A&amp;amp;M University System&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 24, 2004, the Company entered into a patent and technology license agreement with MD Anderson and the Texas A&amp;amp;M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes darinaparsin.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the terms of the agreement, the Company may be required to make additional payments to the Licensors upon achievement of certain milestones in varying amounts which, on a cumulative basis could total up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. In addition, the Licensors are entitled to receive royalty payments on sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances. During the year ended December 31, 2023, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t incur any milestone expenses under this agreement, and the Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand in royalty expenses on sales under this agreement during the year ended December 31, 2023. During the year ended December 31, 2022, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;was incurred as a one-time milestone payment under&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;terms of the agreement, and the Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand in royalty expenses on sales under this agreement during the year ended December 31, 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Collaboration Agreement with Solasia Pharma K.K.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia Pharma K. K., or Solasia, which was amended on July 31, 2014 to include an exclusive worldwide license and amended on October 14, 2021 to revise certain payment schedule details, or, as so amended, the Solasia License and Collaboration Agreement. Pursuant to the Solasia License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms and related organic arsenic molecules, in all indications for human use.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As consideration for the license, the Company is eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenue generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company&#x2019;s licensors, as defined in the Solasia License and Collaboration Agreement, will receive a portion of all milestone and royalty payments made by Solasia to the Company in accordance with the terms of the Solasia License and Collaboration Agreement with the licensors, as described above.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2022, Solasia announced that darinaparsin had been approved from relapsed or refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare in Japan. During the year ended December 31, 2023, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t earn collaboration revenue and earned $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand in royalty revenues on net sales under the Solasia License and Collaboration Agreement. During the year ended December 31, 2022, the Company earned $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of collaboration revenue under the Solasia License and Collaboration Agreement primarily related to Solasia's achievement of certain sales-based milestones in Japan, and did not earn royalty revenues on net sales under the agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;KBI Biopharma Litigation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 17, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;KBI Biopharma&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, Inc., or KBI, filed a complaint against the Company in the District Court of Harris County, Texas, 165th Judicial District, asserting breach of an Amended and Restated Master Services Agreement between the Company and KBI relating to the development of an autologous gene modified T-cell therapy product, or the KBI Agreement. KBI was primarily seeking unspecified monetary damages in excess of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. On May 1, 2023, the Company filed an answer generally denying all of KBI&#x2019;s allegations and asserting affirmative and other defenses as well as counterclaims for breach of the KBI Agreement and conversion. On October 20, 2023, the Company entered into an agreement with KBI to settle all claims asserted by KBI against the Company and the Company's counterclaims against KBI at issue in the litigation for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <tcrt:AnnualLicenseFees
      contextRef="C_56dcfc15-8dde-431d-a7db-bbfed94629e4"
      decimals="-5"
      id="F_5e2c512f-579a-4a77-bec8-bbc1a72b21c9"
      unitRef="U_USD">100000</tcrt:AnnualLicenseFees>
    <tcrt:MaximumAmountOfAdditionalMilestonesPayable
      contextRef="C_56dcfc15-8dde-431d-a7db-bbfed94629e4"
      decimals="-5"
      id="F_5e7c9cce-f7fd-40cc-9136-8fcce3c00971"
      unitRef="U_USD">52500000</tcrt:MaximumAmountOfAdditionalMilestonesPayable>
    <tcrt:MaximumAmountOfRoyaltyPayable
      contextRef="C_b07e679c-ee37-4ba5-b372-9bfc376e0ba0"
      decimals="-5"
      id="F_e3d5aef3-7616-48c0-89b8-1a434256c162"
      unitRef="U_USD">100000000</tcrt:MaximumAmountOfRoyaltyPayable>
    <tcrt:PercentageOfSubLicensingIncomePayableToRelatedParty
      contextRef="C_b07e679c-ee37-4ba5-b372-9bfc376e0ba0"
      decimals="2"
      id="F_75d6462d-e4b0-4f6d-9512-45d77a859483"
      unitRef="U_pure">0.20</tcrt:PercentageOfSubLicensingIncomePayableToRelatedParty>
    <tcrt:AnnualLicenseFees
      contextRef="C_5f261627-186d-4c4c-9a00-ee68ecc9a86c"
      decimals="-5"
      id="F_7a60ae98-d676-4b6b-9404-4b611e826ec1"
      unitRef="U_USD">100000</tcrt:AnnualLicenseFees>
    <tcrt:AnnualLicenseFees
      contextRef="C_8a40112e-a10a-439d-a924-dded53c33f05"
      decimals="-5"
      id="F_44306530-9eb6-4e2e-959f-17d04835ca61"
      unitRef="U_USD">100000</tcrt:AnnualLicenseFees>
    <tcrt:MaximumRoyaltyAmount
      contextRef="C_9eeb8156-fd64-4f9c-a68b-13acb840c000"
      decimals="-5"
      id="F_98bb3a2f-7c9b-4142-9c55-2ab1b5250eff"
      unitRef="U_USD">100000000</tcrt:MaximumRoyaltyAmount>
    <us-gaap:RoyaltyExpense
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_89687c62-2515-4501-9aec-e33a96ab40fa"
      unitRef="U_USD">0</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_078c23b6-e159-4a59-8a52-5c05a43f652c"
      unitRef="U_USD">0</us-gaap:RoyaltyExpense>
    <tcrt:AnnualLicenseFees
      contextRef="C_dada01c2-0448-4544-80b7-17e67bdfc890"
      decimals="-3"
      id="F_8401a7a4-2fee-4464-9e95-fd5011493c5c"
      unitRef="U_USD">75000</tcrt:AnnualLicenseFees>
    <tcrt:LicenseAgreementCommencingDate
      contextRef="C_4c598769-068f-4e4c-b4a0-a1504cfbdf40"
      id="F_c1cca0ac-cd39-4525-9274-c0f11a1812bd">2015-01-13</tcrt:LicenseAgreementCommencingDate>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_61083e15-726c-43c1-8169-eca505a1dd5c"
      decimals="-5"
      id="F_cfdefe25-8674-46bd-9a0f-734147dacddd"
      unitRef="U_USD">15000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_9bebd57d-5315-4cfa-aa91-69cf64124596"
      decimals="-5"
      id="F_0e1a55eb-6dc9-43b7-a6da-117224b10df2"
      unitRef="U_USD">20000000</us-gaap:ResearchAndDevelopmentExpense>
    <tcrt:ClinicalExpenses
      contextRef="C_7dad8626-c247-4cc6-80b0-0ea99635780c"
      decimals="-5"
      id="F_4efc3e77-8f89-49d3-9263-657f13a7529c"
      unitRef="U_USD">100000</tcrt:ClinicalExpenses>
    <tcrt:ClinicalExpenses
      contextRef="C_82b0d417-0325-416b-9745-26ad2cfd0d65"
      decimals="-6"
      id="F_c35b29ea-d9d2-4733-a253-fec6056ab122"
      unitRef="U_USD">0</tcrt:ClinicalExpenses>
    <tcrt:AggregateAmountPotentiallyReimburseableAmount
      contextRef="C_46848514-696b-4f06-9e6b-d4096db50827"
      decimals="-5"
      id="F_c9661da2-601d-4f19-84d1-c5f4fde2a99c"
      unitRef="U_USD">20000000</tcrt:AggregateAmountPotentiallyReimburseableAmount>
    <tcrt:AggregatePotentialBenchmarkPayments
      contextRef="C_46848514-696b-4f06-9e6b-d4096db50827"
      decimals="-5"
      id="F_866cfc9a-8360-4935-85e0-bc61767bd17d"
      unitRef="U_USD">36500000</tcrt:AggregatePotentialBenchmarkPayments>
    <tcrt:AccrualsPriorToFirstMarketingApproval
      contextRef="C_46848514-696b-4f06-9e6b-d4096db50827"
      decimals="-5"
      id="F_8b6a34d7-e2f9-444b-9a73-e6148510a33d"
      unitRef="U_USD">3000000</tcrt:AccrualsPriorToFirstMarketingApproval>
    <tcrt:ClinicalExpenses
      contextRef="C_db1f1c30-f159-463f-bb42-52af80ab87ba"
      decimals="-5"
      id="F_396d8b43-5ec5-42ef-80fa-500a8e6eec0a"
      unitRef="U_USD">800000</tcrt:ClinicalExpenses>
    <tcrt:ClinicalExpenses
      contextRef="C_afef85da-f505-4cb3-8378-c367deebf43d"
      decimals="-5"
      id="F_9c4d1d5b-3610-42b3-aeba-703167aee121"
      unitRef="U_USD">800000</tcrt:ClinicalExpenses>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_37060ce3-beaa-4b5d-8b6b-3b25f9e47087"
      decimals="INF"
      id="F_1ce16746-bb97-4e60-83df-1fd518672e1a"
      unitRef="U_shares">222222</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_37060ce3-beaa-4b5d-8b6b-3b25f9e47087"
      decimals="INF"
      id="F_c9f91e8a-3dc8-45d6-96d7-fe6f61b1ea68"
      unitRef="U_USDollarShare">0.015</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_37060ce3-beaa-4b5d-8b6b-3b25f9e47087"
      id="F_6c9a4053-38c1-48a5-842b-3d55fb07f31f">2026-12-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <tcrt:MinimumRoyaltiesAmountPayable
      contextRef="C_d4b60ecf-6d80-4fa1-b071-1864dd9c10b1"
      decimals="-5"
      id="F_aeb4016a-0b15-40a3-ac34-95ff98b7ca22"
      unitRef="U_USD">300000</tcrt:MinimumRoyaltiesAmountPayable>
    <tcrt:RoyaltiesAmountPayableThereafter
      contextRef="C_d4b60ecf-6d80-4fa1-b071-1864dd9c10b1"
      decimals="-5"
      id="F_7e48108f-09ef-4a01-9a7c-840b7806448f"
      unitRef="U_USD">100000</tcrt:RoyaltiesAmountPayableThereafter>
    <tcrt:AggregateMinimumAnnualRoyaltiesPaid
      contextRef="C_d4b60ecf-6d80-4fa1-b071-1864dd9c10b1"
      decimals="-5"
      id="F_656b94bc-894d-4854-82aa-1e512c2bc3e6"
      unitRef="U_USD">1500000</tcrt:AggregateMinimumAnnualRoyaltiesPaid>
    <tcrt:AggregateBenchmarkPaymentsPayable
      contextRef="C_d86720e4-1c24-43a1-bbdc-09b83278c5c5"
      decimals="-5"
      id="F_9059c92f-88c0-4da3-b908-98793ac7128f"
      unitRef="U_USD">4300000</tcrt:AggregateBenchmarkPaymentsPayable>
    <tcrt:AggregateBenchmarkPaymentsPayable
      contextRef="C_bcbf392a-4dba-4a84-ab43-3ee5a35cd906"
      decimals="-5"
      id="F_90b582b7-647d-4fc4-9ef7-db742e934aa5"
      unitRef="U_USD">3000000</tcrt:AggregateBenchmarkPaymentsPayable>
    <tcrt:DescriptionOfFirstBenchmarkPayable
      contextRef="C_c84cbaaa-b7b5-4569-80f5-59327bf2d4e3"
      id="F_35b2dd21-b98a-4226-bfff-b7d4c4c99212">The first benchmark payment of $0.1 million was paid during the year ended December 31, 2022 upon the initiation of the Company's TCR-T Library Phase 1/2 Trial, which was a qualifying Phase 1 clinical trial under the terms of the Patent License.</tcrt:DescriptionOfFirstBenchmarkPayable>
    <tcrt:InitialBenchmarkPaymentDue
      contextRef="C_919b08ce-ab39-4642-b52f-67c2d4317819"
      decimals="-5"
      id="F_c5d084c2-51e0-4afb-9cf4-97f0c1e98d67"
      unitRef="U_USD">100000</tcrt:InitialBenchmarkPaymentDue>
    <tcrt:MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable
      contextRef="C_8e377f39-2755-46fa-ab15-461adb70dd68"
      decimals="-5"
      id="F_fb9b104b-d154-452d-87f5-ec9b68f0ba7c"
      unitRef="U_USD">250000000</tcrt:MinimumSalesRevenueOnWhichBenchmarkPaymentsPayable>
    <tcrt:MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable
      contextRef="C_8e377f39-2755-46fa-ab15-461adb70dd68"
      decimals="-8"
      id="F_aed05913-549e-401a-8c61-ad56ebdfd6bd"
      unitRef="U_USD">1000000000</tcrt:MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable>
    <tcrt:PotentialBenchmarkPaymentsPayable
      contextRef="C_3bcbadbe-09aa-42ba-8a38-e52fd3a5ad82"
      decimals="-5"
      id="F_eaec5b49-4802-4911-916a-125b732425ff"
      unitRef="U_USD">12000000</tcrt:PotentialBenchmarkPaymentsPayable>
    <tcrt:DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones
      contextRef="C_c84cbaaa-b7b5-4569-80f5-59327bf2d4e3"
      id="F_b1d81f66-90f1-42a2-a99d-ab7880eed21d">The NCI could terminate or modify the Patent License in the event of a material breach, including if the Company did not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event.</tcrt:DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones>
    <tcrt:AgreementTerminationNoticePeriod
      contextRef="C_c84cbaaa-b7b5-4569-80f5-59327bf2d4e3"
      id="F_7d817de8-2e78-457f-896d-eae0a828e873">P60D</tcrt:AgreementTerminationNoticePeriod>
    <tcrt:LicenseExpense
      contextRef="C_271f0dcf-64b5-4fbf-a9a4-9481a9d78720"
      decimals="-5"
      id="F_fcfc080a-cc5d-4f87-b058-2475a6a83658"
      unitRef="U_USD">400000</tcrt:LicenseExpense>
    <tcrt:LicenseExpense
      contextRef="C_9e105059-91f4-41fa-bb01-cb0f4ed0fb32"
      decimals="-5"
      id="F_6aea52ee-122d-4b90-aed5-85b157417ece"
      unitRef="U_USD">700000</tcrt:LicenseExpense>
    <tcrt:ObligationsDueUnderContract
      contextRef="C_c2285624-3869-463c-86d8-22c65f4a4ba3"
      decimals="-5"
      id="F_68da5da6-aede-47f4-96d0-bae64412a102"
      unitRef="U_USD">5000000</tcrt:ObligationsDueUnderContract>
    <tcrt:ContributionPayableOnPerAnnumBasis
      contextRef="C_1b0fea0c-fa5c-4f28-a5af-abd1ad3285a6"
      decimals="-5"
      id="F_18244394-58ca-4c17-9005-f716efb12d3b"
      unitRef="U_USD">1000000</tcrt:ContributionPayableOnPerAnnumBasis>
    <tcrt:AnnualExpenseIncurred
      contextRef="C_1b0fea0c-fa5c-4f28-a5af-abd1ad3285a6"
      decimals="-5"
      id="F_41af8d00-9e29-4f5e-87ff-d905054b2940"
      unitRef="U_USD">500000</tcrt:AnnualExpenseIncurred>
    <tcrt:AnnualExpenseIncurred
      contextRef="C_ed3ce84b-d7e9-4796-87f3-b1cbfed8bb7c"
      decimals="-6"
      id="F_c1cbb805-c18c-4079-965d-2a63e2bf18d1"
      unitRef="U_USD">0</tcrt:AnnualExpenseIncurred>
    <tcrt:AgreementTerminationDate
      contextRef="C_c6b3f307-9aef-450c-9206-261565a5306c"
      id="F_8fd0d596-094a-4b8c-8347-00aa4077e45a">2023-10-13</tcrt:AgreementTerminationDate>
    <tcrt:MilestonePaymentsMaximumAmount
      contextRef="C_bef1fda7-f827-43a9-a2e5-5a8bc3c58ab2"
      decimals="-5"
      id="F_174b5644-71c5-4f4d-acba-6338ae77dd17"
      unitRef="U_USD">4500000</tcrt:MilestonePaymentsMaximumAmount>
    <tcrt:PaymentUnderLicenseAgreement
      contextRef="C_d5a914c9-36ee-47c1-b8f0-1cd50fd2cc9e"
      decimals="-6"
      id="F_b2ff508c-2489-4b95-89ba-dc00e68b47a7"
      unitRef="U_USD">0</tcrt:PaymentUnderLicenseAgreement>
    <tcrt:PaymentUnderLicenseAgreement
      contextRef="C_d5a914c9-36ee-47c1-b8f0-1cd50fd2cc9e"
      decimals="-3"
      id="F_75db513a-219b-429b-91d5-5475e9d21e76"
      unitRef="U_USD">1000</tcrt:PaymentUnderLicenseAgreement>
    <tcrt:MilestonePayment
      contextRef="C_4e1408a8-5e0e-4b89-8b8c-917a420bac4c"
      decimals="-5"
      id="F_057850b7-a43d-4de1-a745-7c7334200f4a"
      unitRef="U_USD">2500000</tcrt:MilestonePayment>
    <tcrt:PaymentUnderLicenseAgreement
      contextRef="C_c3c26aba-b1fb-4834-9c5e-b8e01a5ecc3e"
      decimals="-3"
      id="F_d9955d8c-f5ea-4b27-aeb5-16c98978037b"
      unitRef="U_USD">2000</tcrt:PaymentUnderLicenseAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a62dc996-32ea-430d-9357-c8af5aff9a7c"
      decimals="-3"
      id="F_f7657f58-d203-46f5-8a18-c3e684075d91"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8d19272f-497c-47f6-a99d-591f9130da04"
      decimals="-3"
      id="F_84beb26d-4f37-4fd5-87ca-75feac7901be"
      unitRef="U_USD">5000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_1270a725-670c-4033-b553-4b1ffa03336d"
      decimals="-5"
      id="F_98b6e073-c47f-4b46-85b5-16ab7ad5d6a4"
      unitRef="U_USD">2900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LossContingencyNameOfPlaintiff
      contextRef="C_5b40d2d6-501d-4e7d-8b78-1a53bdaa393a"
      id="F_4b88dc6b-3942-4b0c-999d-ff04a7634a60">KBI Biopharma</us-gaap:LossContingencyNameOfPlaintiff>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="C_5b40d2d6-501d-4e7d-8b78-1a53bdaa393a"
      decimals="-5"
      id="F_224165f3-c2c3-4be0-8bf6-bd624b694b4c"
      unitRef="U_USD">3200000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LitigationSettlementExpense
      contextRef="C_97c705ca-f124-47df-ba05-d7327601d771"
      decimals="-5"
      id="F_c4c39402-b05c-4b67-b885-1ac0903c5a9e"
      unitRef="U_USD">1000000</us-gaap:LitigationSettlementExpense>
    <tcrt:WarrantTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_97d9cf1c-7a6e-4b81-8766-4e5e2c792fe4">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;10.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the Company&#x2019;s November 2018 private placement that provided net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, the Company issued warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,262,626&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, which became exercisable six months after the closing of the private placement, or the November 2018 Warrants. The November 2018 Warrants had an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and have a five-year term. The fair value of the November 2018 Warrants was estimated at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million using a Black-Scholes model with the following assumptions: expected volatility of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, risk free interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, expected life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; dividends.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 26, 2019 and September 12, 2019, the Company entered into agreements with existing investors whereby the investors exercised the November 2018 Warrants for an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,186,869&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. Proceeds from the warrant exercise after deducting placement agent fees and other related expenses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company issued participating investors new warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,186,869&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; additional shares of common stock (the "2019 Warrants") as consideration for the warrant holders to exercise their November 2018 Warrants. The 2019 Warrants will expire on the fifth anniversary of the initial exercise date and have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The 2019 Warrants were valued using a Black-Scholes valuation model and resulted in a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million non-cash charge in the Company&#x2019;s statement of operations in 2019.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On October 22, 2019, the Company entered into the 2019 R&amp;amp;D Agreement with MD Anderson. In connection with the execution of the 2019 R&amp;amp;D Agreement, the Company issued the MD Anderson Warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;222,222&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock. The MD Anderson Warrant has an initial exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.015&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and grant date fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The MD Anderson Warrant expires on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and vests upon the occurrence of certain clinical milestones. The Company will recognize expense on the MD Anderson Warrant in the same manner as if the Company paid cash for services to be rendered. For the years ended December 31, 2023 and 2022, the Company did not recognize any expense related to the MD Anderson Warrant as the clinical milestones have not been achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 6, 2021, the Company entered into the Loan and Security Agreement with SVB. Refer to Note 4, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. In connection with the Loan and Security Agreement, the Company issued SVB warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,856&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;33.30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. The warrants have a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; life and were fully vested upon issuance. The fair value of the warrants was estimated at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million using a Black-Scholes model with the following assumptions: expected volatility of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, risk free interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, expected life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; dividends. On December 28, 2021, the Company entered into the First Amendment, as described in Note 4, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;in connection with which, the original warrants issued to SVB were amended and restated. As amended and restated, the SVB Warrants are for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,308&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, in the aggregate, with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;17.40&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. The SVB Warrants expire on August 6, 2031 and were fully vested upon issuance. As of December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;none&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the SVB Warrants have been exercised.&lt;/span&gt;&lt;/p&gt;</tcrt:WarrantTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_03dd637f-957e-4172-9001-e07d902c6e28"
      decimals="-5"
      id="F_bc1ddb5d-5c61-4077-be67-e20657464987"
      unitRef="U_USD">47100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_4bade1a4-e2fe-4751-93c1-f31838539841"
      decimals="0"
      id="F_f51c5fd3-a66c-4ac6-b3d4-f7a8c2f96e3c"
      unitRef="U_shares">1262626</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_4bade1a4-e2fe-4751-93c1-f31838539841"
      decimals="2"
      id="F_b50a59c9-8a8f-4ad9-ac5d-b32184fc8e97"
      unitRef="U_USDollarShare">45.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcrt:FairValueOfWarrants
      contextRef="C_532e995e-0f74-4893-864c-58c3f779b2e8"
      decimals="-5"
      id="F_44300fa8-499f-43d8-bdb3-e54d1cc93413"
      unitRef="U_USD">18400000</tcrt:FairValueOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_532e995e-0f74-4893-864c-58c3f779b2e8"
      decimals="2"
      id="F_861bfd46-fa44-4f57-b5d6-853bc27b4b9f"
      unitRef="U_pure">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_532e995e-0f74-4893-864c-58c3f779b2e8"
      decimals="4"
      id="F_7e569f53-6a73-4c1a-932d-7ff2cef5fb60"
      unitRef="U_pure">0.0299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_532e995e-0f74-4893-864c-58c3f779b2e8"
      id="F_40fbedc4-c435-49b0-b813-42a7393873fe">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:Dividends
      contextRef="C_532e995e-0f74-4893-864c-58c3f779b2e8"
      decimals="-3"
      id="F_6c491cef-b9f1-4db3-ad23-93fb4c2283cc"
      unitRef="U_USD">0</us-gaap:Dividends>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_f2dfc65a-f1b4-4bd3-ae8f-235fa879ba0d"
      decimals="0"
      id="F_cc8f971f-2089-428f-920d-dbcdc1d908a5"
      unitRef="U_shares">1186869</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_f2dfc65a-f1b4-4bd3-ae8f-235fa879ba0d"
      decimals="2"
      id="F_3dea688b-26ad-48f7-a22a-219c0d4c2566"
      unitRef="U_USDollarShare">45.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcrt:PlacementAgentFeesAndOtherRelatedExpenses
      contextRef="C_6eff864f-3158-4523-99bb-a0cf8c94ad47"
      decimals="-5"
      id="F_2e3a253c-ab9d-4fee-b696-adefcee10117"
      unitRef="U_USD">1100000</tcrt:PlacementAgentFeesAndOtherRelatedExpenses>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_c4120da5-aa3b-4ae8-8a1f-b0df2ff0da10"
      decimals="-5"
      id="F_04f05df7-6c6d-40fe-8435-7cdea016ac25"
      unitRef="U_USD">52500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_220d9373-ebbf-48e2-9ada-0496f791e56e"
      decimals="0"
      id="F_17cbe2d8-9841-486d-903b-e93364d75ea6"
      unitRef="U_shares">1186869</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_220d9373-ebbf-48e2-9ada-0496f791e56e"
      decimals="2"
      id="F_8fba17ff-1ccd-4fdc-a0fb-cb7b4944da40"
      unitRef="U_USDollarShare">105</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcrt:NonOperatingIncomeExpenseInducementOfWarrants
      contextRef="C_6240eae2-8099-486d-9b0b-6163532f0ff8"
      decimals="-5"
      id="F_abbe0462-2b2f-471b-8dc5-ba242f390447"
      unitRef="U_USD">60800000</tcrt:NonOperatingIncomeExpenseInducementOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_c3fc31a6-03ef-43cc-97ab-fa4366fe7871"
      decimals="INF"
      id="F_b9ab38b0-3bd4-4a89-97b9-6a3c4c94dff1"
      unitRef="U_shares">222222</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_c3fc31a6-03ef-43cc-97ab-fa4366fe7871"
      decimals="3"
      id="F_fbe09c5c-2a46-4949-a822-aa5b699d20c5"
      unitRef="U_USDollarShare">0.015</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcrt:FairValueOfWarrants
      contextRef="C_6e982006-943b-4fee-97ab-42236865abf4"
      decimals="-5"
      id="F_0603f136-4afc-4d91-aab0-40ccb35eebf4"
      unitRef="U_USD">14500000</tcrt:FairValueOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_c3fc31a6-03ef-43cc-97ab-fa4366fe7871"
      id="F_2f044e3c-a6e8-40b3-bc6b-b86c07b9399f">2026-12-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="C_db650e42-fee8-4d18-8c55-3c11a3ece9bc"
      decimals="0"
      id="F_96f52267-5558-4422-a49b-02124f7f5c3b"
      unitRef="U_shares">28856</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:CommonStockCallOrExerciseFeatures
      contextRef="C_c1da526c-ca16-481e-9bc7-b20e2797d243"
      id="F_8274197e-35af-482d-9c46-8cedb5db661e">33.30</us-gaap:CommonStockCallOrExerciseFeatures>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_db650e42-fee8-4d18-8c55-3c11a3ece9bc"
      id="F_0242dfeb-4a26-400f-8f61-8fd44696656c">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <tcrt:FairValueOfWarrants
      contextRef="C_5d722990-44ad-48ec-bab6-e38f76af3769"
      decimals="-5"
      id="F_7eb98951-941d-4234-89ec-93fed6c44ab0"
      unitRef="U_USD">800000</tcrt:FairValueOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_5d722990-44ad-48ec-bab6-e38f76af3769"
      decimals="2"
      id="F_23318e7b-f660-47df-aa71-d8baab14cf5a"
      unitRef="U_pure">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_5d722990-44ad-48ec-bab6-e38f76af3769"
      decimals="4"
      id="F_22bede1d-bd95-43ce-96bd-3a01ecbac9ac"
      unitRef="U_pure">0.0131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_5d722990-44ad-48ec-bab6-e38f76af3769"
      id="F_6746e362-644c-4065-8326-d13915d8fb77">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:Dividends
      contextRef="C_5d722990-44ad-48ec-bab6-e38f76af3769"
      decimals="-3"
      id="F_c4faf58a-9b21-4848-bb66-6aa911207ff7"
      unitRef="U_USD">0</us-gaap:Dividends>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_9eb8bb51-2ecf-42fc-9df9-3543c2498b7b"
      decimals="0"
      id="F_d4d02a07-ad43-4c36-8159-4784d59147e2"
      unitRef="U_shares">43308</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:CommonStockCallOrExerciseFeatures
      contextRef="C_ec1d55bd-1201-4107-bcad-9c39a5fd6ee6"
      id="F_64c85b7f-9c38-49d2-b4c4-15227b7726bd">17.40</us-gaap:CommonStockCallOrExerciseFeatures>
    <tcrt:ClassOfWarrantOrRightWarrantsExercised
      contextRef="C_7c575269-28b3-45c2-9022-f2fac466229a"
      decimals="0"
      id="F_840fc5b9-5afa-43b5-944f-60757acac016"
      unitRef="U_shares">0</tcrt:ClassOfWarrantOrRightWarrantsExercised>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_a5085f8d-a2d3-4678-85a0-4f2658f6d4a7">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;11.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restructuring&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 14, 2023, the Company announced a strategic reprioritization of its business and wind down of its TCR-T Library Phase 1/2 Trial. In connection with the reprioritization, the Company reduced its workforce during the third and fourth quarters of 2023. Concurrently, the Company began considering certain strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. During the year ended December 31, 2023, the Company recorded termination benefits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, recorded in restructuring costs within the statement of operations. The termination benefits were fully paid as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-5"
      id="F_0bb52f69-28ac-4d7d-bb24-d9e80ddd5f03"
      unitRef="U_USD">1300000</us-gaap:SeveranceCosts1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_8fa5c478-4d5a-4f5a-98f3-4beb59eac23c">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;12.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There is no provision for income taxes because the Company has incurred operating losses since inception. The reported amounts of income tax expense for the years ended December 31, 2023 and 2022 differ from the amounts that would result from applying domestic federal statutory tax rates to pretax losses primarily because of the changes in the valuation allowance. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s deferred tax assets at December 31, 2023 and 2022 are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.923%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.923%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;148,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;171,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Start-up and pre-clinical studies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized acquisition costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;211,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;237,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;211,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. At December 31, 2023, the Company has aggregate net operating loss carryforwards for federal tax purposes of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;704.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, of which approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;341.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million expire at various dates through December 31, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2037 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;363.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million can be carried forward indefinitely. The Company is reducing its approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;497.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of state net operating loss carryforwards to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as these state net operating loss carryforwards all related to Massachusetts filings and, as of December 31, 2023 the Company no longer had any employees or property in Massachusetts and, as a result, the Company will no longer have income tax nexus in Massachusetts or an income tax filing obligation after the year ended December 31, 2023. Additionally, the Company has approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of federal and state research and development credits at December 31, 2023, expiring in varying amounts through &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2043&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which may be available to reduce future taxes. The Company has reduced its Massachusetts credits carryforward to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has provided a valuation allowance for the full amount of its net deferred tax assets since it is more likely than not that these future benefits will not be realized. However, these deferred tax assets may be available to offset future income tax liabilities and expenses. The valuation allowance decreased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in 2023 due primarily to the reduction of Massachusetts net operating loss carryforwards and Massachusetts research and development credits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes using the federal statutory income tax rate differ from the Company&#x2019;s effective tax rate primarily due to non-deductible expenses related to the Company&#x2019;s issuance of warrants along with the change in the valuation allowance on deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of income tax expense (benefit) at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.360000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal income tax at statutory rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income tax, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development true-up&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal/state rate change&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company adopted ASC 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting for Uncertain Tax Positions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; on January 1, 2007. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements in accordance with FASB Statement No. 109, &#x201c;Accounting for Income Taxes.&#x201d; ASC 740 prescribes a recognition threshold and measurement of a tax position taken or expected to be taken in a tax return. The Company did not establish any additional reserves for uncertain tax liabilities upon adoption of ASC 740. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; adjustments to its uncertain tax positions in the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has not recognized any interest and penalties in the statements of operations because of the Company&#x2019;s net operating losses and tax credits that are available to be carried forward. When necessary, the Company will account for interest and penalties related to uncertain tax positions as part of its provision for federal and state income taxes. The Company does not expect the amounts of unrecognized benefits will change significantly within the next twelve months.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is currently open to audit under the statute of limitations by the Internal Revenue Service and state jurisdictions for the years ended December 31, 1999 through 2023 to the extent net operating losses continue to be carried forward to 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Beginning in 2022, the Tax Cuts and Jobs Act of 2017, or the Tax Act, eliminated the option to deduct research and development expenditures immediately in the year incurred and requires taxpayers to capitalize and amortize them over five years pursuant to IRC Section 174. The mandatory capitalization requirement had no impact to the overall deferred tax assets due to the Company's loss position and full valuation allowance.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_1ff4cdb3-cc97-413a-ab56-4dcf28a782ed">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s deferred tax assets at December 31, 2023 and 2022 are as follows:&lt;/span&gt;&lt;p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.923%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.923%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;148,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;171,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Start-up and pre-clinical studies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized acquisition costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;211,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;237,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;211,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;236,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_aa962916-6cb2-4999-a20e-f437893b37c2"
      unitRef="U_USD">148009000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_080ffe87-7077-4552-846c-37129cc3dbb7"
      unitRef="U_USD">171070000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <tcrt:DeferredTaxAssetsStartUpAndPreClinicalStudies
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_0bfae520-1289-4095-9e01-ba02de9e3798"
      unitRef="U_USD">13754000</tcrt:DeferredTaxAssetsStartUpAndPreClinicalStudies>
    <tcrt:DeferredTaxAssetsStartUpAndPreClinicalStudies
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_1054c29f-e158-413f-ba75-fa3f6fb4412c"
      unitRef="U_USD">17204000</tcrt:DeferredTaxAssetsStartUpAndPreClinicalStudies>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_8703552e-5e00-46dd-bf77-5a68ffd9b302"
      unitRef="U_USD">39838000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_c41166c2-b506-49ed-98fc-d20004c02667"
      unitRef="U_USD">40116000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_a6c31848-7325-485a-b8c5-91d8394d8b6e"
      unitRef="U_USD">681000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_d8c85ef9-6077-43ee-8798-e863c5792ea0"
      unitRef="U_USD">698000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <tcrt:DeferredTaxAssetsCapitalizedAcquisitionCosts
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_7c3ec787-e090-4c8c-881a-2890bccb687b"
      unitRef="U_USD">1570000</tcrt:DeferredTaxAssetsCapitalizedAcquisitionCosts>
    <tcrt:DeferredTaxAssetsCapitalizedAcquisitionCosts
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_9091cb0f-6334-408f-8503-21d86d25d836"
      unitRef="U_USD">2180000</tcrt:DeferredTaxAssetsCapitalizedAcquisitionCosts>
    <tcrt:DeferredTaxAssetsLeaseLiability
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_f328c3da-22a6-4e3e-a6c6-b138629c6c42"
      unitRef="U_USD">0</tcrt:DeferredTaxAssetsLeaseLiability>
    <tcrt:DeferredTaxAssetsLeaseLiability
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_80fa05dc-2854-4ce5-8343-d1b6ebc435ad"
      unitRef="U_USD">618000</tcrt:DeferredTaxAssetsLeaseLiability>
    <tcrt:DeferredTaxAssetsDepreciation
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_af20ce3a-5501-46aa-95c7-b9f92dc874a1"
      unitRef="U_USD">1000</tcrt:DeferredTaxAssetsDepreciation>
    <tcrt:DeferredTaxAssetsDepreciation
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_6b215203-9e68-4970-ae18-8306f95842f0"
      unitRef="U_USD">239000</tcrt:DeferredTaxAssetsDepreciation>
    <tcrt:DeferredTaxAssetsResearchExpensesCapitalized
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_6489c932-9cfa-4752-9107-c3055926b4e3"
      unitRef="U_USD">7176000</tcrt:DeferredTaxAssetsResearchExpensesCapitalized>
    <tcrt:DeferredTaxAssetsResearchExpensesCapitalized
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_cc9defed-f50f-483d-9b49-35152244b3e9"
      unitRef="U_USD">5156000</tcrt:DeferredTaxAssetsResearchExpensesCapitalized>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_68431c4c-0720-48de-bf4c-ff81406303b4"
      unitRef="U_USD">2000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_a0d70218-9baf-4e7b-bc6a-13d667dd3710"
      unitRef="U_USD">27000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_2c855339-db1a-4488-9b92-d2c219d272e9"
      unitRef="U_USD">211031000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_7b55cc2c-b99e-453b-a9b9-abdb24f7700c"
      unitRef="U_USD">237308000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_3d91eb4d-bb11-4bbb-af34-af0599823267"
      unitRef="U_USD">211031000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_ff6ee13f-520c-48b6-8adc-30b97bc5b653"
      unitRef="U_USD">236827000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_90786b30-7cb1-4cad-ae09-575a420b60e1"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_cdad5b20-84ae-42e6-8b9a-f780307db7d5"
      unitRef="U_USD">481000</us-gaap:DeferredTaxAssetsNet>
    <tcrt:DeferredTaxLiabilityRightOfUseAsset
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_6eff5e4c-8f9b-436d-a704-f5daa5c364a0"
      unitRef="U_USD">0</tcrt:DeferredTaxLiabilityRightOfUseAsset>
    <tcrt:DeferredTaxLiabilityRightOfUseAsset
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_01d97356-10d0-48a0-985d-c34dd2d6747b"
      unitRef="U_USD">481000</tcrt:DeferredTaxLiabilityRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_05006676-09ca-4584-a3b1-375ac5c6466e"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_aeeb343b-bc21-4012-a072-e512a06cf9b8"
      unitRef="U_USD">481000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_818b1f1e-f3ce-4544-b618-1f4a01f15662"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="-3"
      id="F_4ed6d1cf-9e89-4e01-aa35-6ddf18a2fcd3"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_941cd6f3-5783-415e-b2da-d758935f04dc"
      decimals="-5"
      id="F_7e535fa6-da43-41fe-8b7d-a5aba6affe0d"
      unitRef="U_USD">704900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_d5434f85-d96c-496b-8794-5fd3bbc24ce8"
      decimals="-5"
      id="F_05dd8a38-4104-4c72-bfa9-af3f446c0ac3"
      unitRef="U_USD">341700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <tcrt:OperatingLossCarryforwardsExpirationDatesState
      contextRef="C_c44e0959-6f71-4672-bea1-d6bc634b6ad9"
      id="F_f761efe8-7d38-4b8d-b20b-920b9eb84e4f">2037</tcrt:OperatingLossCarryforwardsExpirationDatesState>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-5"
      id="F_4784b88a-c464-4e84-97a9-82347ad84c00"
      unitRef="U_USD">363200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_5f040735-cf7c-45e8-b576-fbda049ff33e"
      decimals="-5"
      id="F_84caa237-019b-42f3-9c26-54d76bb428be"
      unitRef="U_USD">497900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_e0870a39-743c-4197-a2bf-d7b68c1a75eb"
      decimals="-3"
      id="F_9e97b2ab-f345-4901-9716-b8a84dbae578"
      unitRef="U_USD">0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_25fd3671-b6ec-42c5-a84d-f3bb943d4679"
      decimals="-5"
      id="F_f0cb3cab-acd6-4aee-87f6-b0d4adff88cf"
      unitRef="U_USD">39800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <tcrt:OperatingLossCarryforwardsResearchExpirationDates
      contextRef="C_2e188d5a-6779-4f0e-aeb1-22f1285c7349"
      id="F_b991c6cb-3309-44f0-a5d1-894155fa1a38">2043</tcrt:OperatingLossCarryforwardsResearchExpirationDates>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_f3fb2508-894b-4dee-ad07-e5523a67bd11"
      unitRef="U_USD">0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-5"
      id="F_0887cc76-ee99-4a49-ad5b-3ae5f18477ad"
      unitRef="U_USD">-25800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_de951ad6-4258-4753-807b-8ce68311ba8a">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of income tax expense (benefit) at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.360000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal income tax at statutory rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income tax, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development true-up&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal/state rate change&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="2"
      id="F_fbfe4132-186a-4e5d-9f42-7ca900035f7e"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="2"
      id="F_0e9265f6-29e1-499f-a893-c69486044239"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="2"
      id="F_9e4df151-9158-4030-bcba-f309e2c45d8b"
      unitRef="U_pure">-0.92</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="2"
      id="F_216a2cc0-6687-4f46-b133-afc2d23b03e3"
      unitRef="U_pure">0.03</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="2"
      id="F_1a00034d-b644-45ce-9b15-2a5d7e170801"
      unitRef="U_pure">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="2"
      id="F_0ab3e13b-a6f9-41db-89a0-5b7be1811aa9"
      unitRef="U_pure">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="2"
      id="F_029faeaf-5370-48f8-84bf-80eb8ce79692"
      unitRef="U_pure">-0.01</tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp>
    <tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="2"
      id="F_293822d0-8f7a-49e4-8f60-14d3777520fc"
      unitRef="U_pure">-0.02</tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="2"
      id="F_a1bb0a67-95a9-4437-9639-dfab9758a6b9"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="2"
      id="F_8dd75218-bd78-4950-a218-2241504d8412"
      unitRef="U_pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="2"
      id="F_3f026270-2100-4bb0-99e8-8646d5b23357"
      unitRef="U_pure">-0.03</tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange>
    <tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="2"
      id="F_21721ae4-c555-493e-a1aa-f43738fe42d3"
      unitRef="U_pure">-0.05</tcrt:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="2"
      id="F_ede46d50-be0b-4ffd-bd78-de621d1eafc7"
      unitRef="U_pure">0.73</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="2"
      id="F_4d5730a0-9dc1-45e7-9250-998ece1e9fd6"
      unitRef="U_pure">-0.18</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="2"
      id="F_f517ead0-9a47-4427-b773-04397e8f0ac7"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="2"
      id="F_b2690e5d-fb5b-43c3-a7b6-9efa67276f39"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-6"
      id="F_f4068645-0b51-4a1d-b7c2-fd6db7653e59"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-6"
      id="F_4ee307a0-4b24-4928-aaba-acafbc239c54"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_033b2a15-9955-4192-9e4a-f643df1f3580">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;13.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock Option Plan&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company adopted the 2012 Equity Incentive Plan, or the 2012 Plan, in May 2012. Including subsequent increases, the Company had reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;933,333&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares for issuance. On December 31, 2023, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,728&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares reserved for issuance and no shares available for future grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company adopted the 2020 Equity Incentive Plan, or the 2020 Plan, in June 2020. The Company reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,400,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares for issuance plus a carryover of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,085&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares from the 2012 Plan for a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,471,085&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, returning shares from the 2012 Plan are available for issuance under the 2020 Plan. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400,167&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares reserved for issuance and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,302,411&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares available for future grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock options generally vest ratably in either quarterly or annual installments over three or four years, commencing on the first anniversary of the grant date and have contractual terms of ten years. Stock options to directors generally vest ratably over one or two years and have contractual terms of ten years. Stock options are valued using the Black-Scholes option pricing model and compensation is recognized based on such fair value over the period of vesting on a straight-line basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; proceeds from option exercises during the year ended December 31, 2023 as compared to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand during the year ended December 31, 2022. The intrinsic value of these options amounted to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock option activity under the Company's stock options plans for the years ending December 31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;(in thousands, except share and per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted- Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted- Average Contractual Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;711,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;313,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;328,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;693,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;259,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;487,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;465,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.81&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercisable, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;415,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.64&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options available for future grant, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,302,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On December 31, 2023, total unrecognized compensation costs related to non-vested stock options outstanding amounted to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.53&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the year ended December 31, 2023 the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t issue&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;shares of restricted stock and issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,667&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in the year ended December 31, 2022 to directors. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; repurchases by the Company for the year ended December 31, 2023. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the year ended December 31, 2022, the Company repurchased &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,250&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share to cover payroll taxes for one employee exercise, which is in accordance with the original terms of the award.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of the status of restricted stock as of December 31, 2023 and 2022 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, there was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; unrecognized stock-based compensation expense related to non-vested restricted stock arrangements.&lt;/span&gt;&lt;/p&gt;</tcrt:StockOptionsAndRestrictedStockAwardsTextBlockTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0982ca17-65ec-46e2-b808-c94e4aa0b3df"
      decimals="0"
      id="F_1eac0463-3094-4de2-83ef-2784f320e26e"
      unitRef="U_shares">933333</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1a51d51e-d3d6-455b-ac86-ce8e857d2093"
      decimals="0"
      id="F_b58997cc-fa95-4894-a68f-4c93265cc177"
      unitRef="U_shares">65728</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_12319f01-0ffd-4415-8d9c-445e79250b84"
      decimals="0"
      id="F_c55faf3d-1795-4e07-8cc9-25a6d233fe88"
      unitRef="U_shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_d4a1c311-3a9e-4881-9787-deb17fe41e97"
      decimals="0"
      id="F_92a0b922-84b0-45b0-91f4-94e17ae84219"
      unitRef="U_shares">71085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_12319f01-0ffd-4415-8d9c-445e79250b84"
      decimals="0"
      id="F_342d803c-bcca-478b-9f59-c637f3d0f6c3"
      unitRef="U_shares">1471085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_c5e88f0f-cfd7-41a4-bf45-de43957559af"
      decimals="0"
      id="F_0a2dbb44-5063-4e1e-bf3d-bdee6de4a3c8"
      unitRef="U_shares">400167</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="0"
      id="F_88e12f30-26f1-4004-9f54-b3402b39c2fd"
      unitRef="U_shares">1302411</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-3"
      id="F_b90791b1-2d16-4918-b7b3-4aa8e51b6a18"
      unitRef="U_USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_3033177d-6aea-4b14-946c-e2c7da0ddbd3"
      unitRef="U_USD">21000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-3"
      id="F_372ecb99-2389-49ba-9421-cf15d25da45c"
      unitRef="U_USD">26000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_b88c21a1-b584-4f92-9a09-0ed4a047244e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock option activity under the Company's stock options plans for the years ending December 31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;(in thousands, except share and per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted- Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted- Average Contractual Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;711,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;313,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;328,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;693,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;259,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;487,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;465,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.81&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercisable, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;415,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.64&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options available for future grant, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,302,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_9e81976f-0dda-4005-94a7-17763001d331"
      decimals="0"
      id="F_508b5950-0a0b-490a-9406-4bf4e6c0292d"
      unitRef="U_shares">711058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_9e81976f-0dda-4005-94a7-17763001d331"
      decimals="2"
      id="F_0fde087f-930c-47d8-9783-400fc31af37f"
      unitRef="U_USDollarShare">43.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="0"
      id="F_8b13e483-fc0f-4618-a5cd-51e27b32c068"
      unitRef="U_shares">313167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="2"
      id="F_8fcdf489-cea2-4000-a864-bc29e48ee603"
      unitRef="U_USDollarShare">16.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="0"
      id="F_4a6e4df7-fd32-4916-a85d-61fd9c9652f3"
      unitRef="U_shares">1750</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="2"
      id="F_52878e53-6fca-4700-a5e4-a4701fcf0e38"
      unitRef="U_USDollarShare">12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="0"
      id="F_5832b686-1ee7-430a-8ef1-5850b80a9d2d"
      unitRef="U_shares">328566</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="2"
      id="F_281ac761-fecc-4627-9226-61eebbbd63fd"
      unitRef="U_USDollarShare">50.1</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="0"
      id="F_96384b31-bcff-4c6a-afb1-a15c5929d742"
      unitRef="U_shares">693909</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_00cfa7b8-8106-4392-b55d-bf6ad7d81305"
      decimals="2"
      id="F_58a16e8e-3b4b-40f4-89be-2e2d4f3d31ed"
      unitRef="U_USDollarShare">27.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="0"
      id="F_e56e3da1-4f72-498f-8c8a-37a022198ba7"
      unitRef="U_shares">259122</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="2"
      id="F_c9845eca-6190-4a01-8289-be5342c478c6"
      unitRef="U_USDollarShare">7.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="0"
      id="F_441608b5-fb44-46db-bd22-b5e27c5abc8c"
      unitRef="U_shares">487133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="2"
      id="F_253504ff-7ed5-4158-99bb-174075692a3d"
      unitRef="U_USDollarShare">17.7</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="0"
      id="F_d0fd2b02-290e-490b-bde0-08db40a0f33e"
      unitRef="U_shares">465898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="2"
      id="F_bbf8ee5e-4ad4-44e7-8181-26207371b3f7"
      unitRef="U_USDollarShare">26.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_3a6ed2db-e851-44d0-8114-9aae8af99eab">P7Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_75c2ec62-aa58-42d8-92f1-07bb23defd7c"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="0"
      id="F_2ee13ece-e2a6-491b-b3d0-de6ad743944b"
      unitRef="U_shares">415376</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="2"
      id="F_b8e4ad67-2c86-4960-b6de-bf06d747985c"
      unitRef="U_USDollarShare">28.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_46475b01-6a45-4e51-a4d6-eaa9521aff08">P7Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="-3"
      id="F_315eee6d-5b35-4f06-97c7-862f62ba8c69"
      unitRef="U_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_4764432d-361f-42c3-b4d4-131225ea696e"
      decimals="0"
      id="F_5517e9eb-f60a-4b9d-b4f6-b010cb3d4d85"
      unitRef="U_shares">1302411</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_5d5825d4-3830-441a-87c7-7eaf314a9d2c"
      decimals="-5"
      id="F_36ec86d5-a02b-406f-abfb-a1570098deeb"
      unitRef="U_USD">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_11b50a8f-e3f7-4d6b-85de-985e603d9114"
      id="F_f6997428-43f5-4f23-9bfd-67a5c8d38733">P1Y6M10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_ae242319-1a7e-447c-b3ec-f37cbc585f56"
      decimals="0"
      id="F_1ac736cb-dca7-47d5-beef-3f21033d0efc"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_c56bef7f-3b74-416e-b3f9-37e431049ea5"
      decimals="0"
      id="F_c6606cdb-00b2-4624-b6fe-dc1d412ff82e"
      unitRef="U_shares">18667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_ae242319-1a7e-447c-b3ec-f37cbc585f56"
      decimals="0"
      id="F_a945c44d-d016-4a2b-bb29-b127da843c15"
      unitRef="U_shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_c56bef7f-3b74-416e-b3f9-37e431049ea5"
      decimals="0"
      id="F_0c68331d-897c-4a03-ad07-01fe19f562ba"
      unitRef="U_shares">1250</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:SharePrice
      contextRef="C_f95291d4-e96b-46f8-b36c-1c199e1f5e39"
      decimals="2"
      id="F_75a9e43a-205e-4edf-906e-e9f702b0dc5a"
      unitRef="U_USDollarShare">36.15</us-gaap:SharePrice>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_ce0c1c0f-756d-4d71-9dc5-b65c1fa65b4a">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of the status of restricted stock as of December 31, 2023 and 2022 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_cd40fe04-39eb-4618-9e08-4ccfc8585a11"
      decimals="0"
      id="F_4ccc935f-7170-4e98-923d-38012d904a80"
      unitRef="U_shares">79905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_cd40fe04-39eb-4618-9e08-4ccfc8585a11"
      decimals="2"
      id="F_7862f059-966f-412f-99b5-076963a0d55e"
      unitRef="U_USDollarShare">31.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_63369074-a4f7-4fe2-8674-f1c4a1a3245e"
      decimals="0"
      id="F_b83d9da5-bf25-452a-af00-a9d5fd549c55"
      unitRef="U_shares">18667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_63369074-a4f7-4fe2-8674-f1c4a1a3245e"
      decimals="2"
      id="F_f88d1f70-64ec-494c-9fe3-1734d53d5465"
      unitRef="U_USDollarShare">12.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_63369074-a4f7-4fe2-8674-f1c4a1a3245e"
      decimals="0"
      id="F_05f9aa35-ad77-4786-91ce-5013f1f1c86f"
      unitRef="U_shares">20441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_63369074-a4f7-4fe2-8674-f1c4a1a3245e"
      decimals="2"
      id="F_e4df8c41-17ea-4809-9b4a-6170839111ef"
      unitRef="U_USDollarShare">34.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_63369074-a4f7-4fe2-8674-f1c4a1a3245e"
      decimals="0"
      id="F_8c6cae1a-3fa6-4038-b905-c4d031fb9236"
      unitRef="U_shares">15527</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_63369074-a4f7-4fe2-8674-f1c4a1a3245e"
      decimals="2"
      id="F_4df4c0f4-ae5c-46a5-b59e-d6752d77fae3"
      unitRef="U_USDollarShare">47.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_3c4cb663-e0ce-4562-a60a-f57ab1bd16cb"
      decimals="0"
      id="F_8a36c485-cda8-42eb-863d-5fcba97875bb"
      unitRef="U_shares">62604</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_3c4cb663-e0ce-4562-a60a-f57ab1bd16cb"
      decimals="2"
      id="F_f24d15c5-bdb0-497a-beff-285b0c120e0e"
      unitRef="U_USDollarShare">21.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_6dbf0481-cdd5-4b3c-8af0-560dbff890e7"
      decimals="0"
      id="F_b6ec5998-98c7-4e67-b095-6bb1b31953d8"
      unitRef="U_shares">33322</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_6dbf0481-cdd5-4b3c-8af0-560dbff890e7"
      decimals="2"
      id="F_2ada6e08-e1ff-4e8a-9bda-04fb70ac7da1"
      unitRef="U_USDollarShare">17.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_6dbf0481-cdd5-4b3c-8af0-560dbff890e7"
      decimals="0"
      id="F_474944b5-66cc-4e8f-a5eb-56876ce4f6ca"
      unitRef="U_shares">29282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_6dbf0481-cdd5-4b3c-8af0-560dbff890e7"
      decimals="2"
      id="F_07f285cc-1a33-405f-8df1-45699afc1ded"
      unitRef="U_USDollarShare">24.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_f8995cf5-f0d5-4e4e-99fc-41441a44780e"
      decimals="0"
      id="F_b4258ea1-8c89-45f7-9946-b57653e31a09"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_f8995cf5-f0d5-4e4e-99fc-41441a44780e"
      decimals="0"
      id="F_4f1e9f89-8a10-4392-a357-41564271b235"
      unitRef="U_USDollarShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_f8995cf5-f0d5-4e4e-99fc-41441a44780e"
      decimals="0"
      id="F_e1e602d6-193c-4f9c-806c-2861940507a1"
      unitRef="U_USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_3d4c77a7-baea-4752-8bb5-5dc27d43a222">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;14.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Employee Benefit Plan&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company sponsors a qualified 401(k) retirement plan under which employees are allowed to contribute certain percentages of their pay, up to the maximum allowed under Section 401(k) of the IRC, or the 401(k) Plan. The Company may make contributions to the 401(k) Plan at its discretion. The Company contributed approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to the 401(k) Plan during the year ended December 31, 2023 and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      decimals="-5"
      id="F_d403e80e-4d28-497e-b174-3cffd94b9916"
      unitRef="U_USD">200000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="C_ca613479-d043-416d-8cb2-0957fc2d9f3c"
      decimals="-5"
      id="F_4bd64422-4f18-4595-b947-a3191bbf03ef"
      unitRef="U_USD">500000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_d64042ff-ef4a-4b62-8191-ae24d08a2335">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;15.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Joint Venture&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On December 18, 2018, the Company entered into a Framework Agreement with TriArm whereby the parties agreed to launch Eden BioCell, to lead clinical development and commercialization of certain &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-generated CAR-T therapies as set forth in a separate license agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 3, 2019, Eden BioCell was incorporated in Hong Kong as a private company. Eden BioCell, the Company and TriArm entered into a Share Subscription Agreement on January 23, 2019, where the Company and TriArm agreed to contribute certain intellectual property, services and cash (only with respect to TriArm) to Eden BioCell to subscribe for a certain number of newly issued ordinary shares in the share capital of Eden BioCell.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The closing of the transaction occurred on July 5, 2019. The Framework Agreement and Share Subscription Agreements were each respectively amended to be effective as of this date. Upon consummation of the joint venture, Eden BioCell and the Company also entered into a license agreement, pursuant to which the Company licensed the rights to Eden BioCell for third generation &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-generated CAR-T therapies targeting the CD19 antigen for the territory of China (including Macau and Hong Kong), Taiwan and Korea. TriArm and the Company each received a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% equity interest in the joint venture in exchange for their contributions to Eden BioCell.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determined that Eden BioCell was considered a variable interest entity, or VIE, and concluded that it was not the primary beneficiary of the VIE as it did not have the power to direct the activities of the VIE. As a result, the Company accounted for the equity interest in Eden BioCell under the equity method of accounting as it had the ability to exercise significant influence.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2021, TriArm and the Company mutually agreed to dissolve the joint venture, which has now been terminated. The Eden BioCell entity has been dissolved as of July 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_c4e43b9c-1c1a-4ee7-8310-f49b0b04362e"
      decimals="2"
      id="F_e211d675-3d39-4990-88bf-16f137825b28"
      unitRef="U_pure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_05605a3c-4399-47be-99a9-52abcb18dab3"
      id="F_fe504b48-a48b-4de5-8e4e-48c731286d1f">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;16.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Subsequent Events&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company evaluated all events and transactions that occurred after the balance sheet date through the date of this Annual Report on Form 10-K. Other than as described in the notes to the financial statements, the Company did not have any material subsequent events that impacted its financial statements or disclosures aside from the following.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 20, 2024, the Board of Directors appointed Dale Curtis Hogue, Jr. as Interim Chief Executive Officer of the Company, effective immediately. On January 21, 2024, the Company entered into an employment agreement with Mr. Hogue, under which he will receive an annual base salary of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;250&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand. Mr. Hogue was awarded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock of the Company with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 15, 2024, Michael Wong gave notice of his resignation as Vice President, Finance, effective February 23, 2024. On February 22, 2024, the Company and Ferdinand Groenewald entered into a consulting agreement, or the Consulting Agreement, effective February 22, 2024, pursuant to which Mr. Groenewald will lead accounting and financial reporting activities of the Company. Mr. Groenewald will serve as the Company&#x2019;s Vice President, Finance. The Consulting Agreement will continue indefinitely until terminated by either party upon &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;30 days&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2019; advance notice. The Consulting Agreement provides for compensation at a fixed rate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand per month and reimbursement by the Company for any usual and customary business expenses incurred by Mr. Groenewald in connection with performing services pursuant to the Consulting Agreement. In addition, the Consulting Agreement provides for the Company to indemnify Mr. Groenewald on terms customary for officers.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="C_8d0c8320-b169-4c12-9015-18779c3f403e"
      decimals="-3"
      id="F_0cda8272-277f-478d-8f5c-400d1ddfed59"
      unitRef="U_USD">250000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_8d0c8320-b169-4c12-9015-18779c3f403e"
      decimals="0"
      id="F_82ab4648-0d23-40a8-9f7e-ba97dbae7b8b"
      unitRef="U_shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_8d0c8320-b169-4c12-9015-18779c3f403e"
      decimals="2"
      id="F_d0801d18-2e7b-4383-8b1f-8a767e82f0c6"
      unitRef="U_USDollarShare">1.8</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <tcrt:AdvanceNoticePeriodForTerminationAgreement
      contextRef="C_2a4b610b-874a-4c4c-a87e-050473791707"
      id="F_1a598809-9f7a-4e27-a9d4-3a9770bb20b2">P30D</tcrt:AdvanceNoticePeriodForTerminationAgreement>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="C_c5399d8c-4124-42b7-a6a2-756bfbee1738"
      decimals="-3"
      id="F_dc9b5349-f125-4b7f-b674-49009cfd1ebf"
      unitRef="U_USD">15000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
